network unknown {
}
variable Fault {
  type discrete [ 76 ] { AIDS early, AILD, ALIP, Cat scratch disease, Dermatopathic laden, Florid follic hyperp, GLH hyaline vascular, GLH plasma cell, Granulomatous laden, Histiocytosis x, Infectious mono, Leprosy-lepromatous, Lymphangiographic, Mantle zone hyperpla, Necrotizing Kikuchi, Necrotiz non-Kikuchi, Rheumatoid arthritis, Sarcoidosis, SHML, Sinus histiocytosis, Syphilis, Toxoplasmosis, Tuberculosis, Viral NOS, Whipple's disease, L&H nodular HD, L&H diffuse HD, Nodular sclerosis HD, Cellular phase NSHD, Syncytial NSHD, Mixed cellularity HD, Interfollicular HD, Diffuse fibrosis HD, Reticular-type HD, Small cleaved fol, Mixed fol, Large cell fol, Small noncleaved fol, Small lymphocytic, Plasmacytoid lyctic, Mantle zone lymphoma, Small cleaved dif, Mixed FCC dif, Large cell dif, B-immunoblastic, T-immunob mixed, AILD-like T-cell lym, Japanese ATL, Lymphoblastic, Small noncleaved dif, True histiocytic, Ki-1 LC anaplas T, Multiple myeloma, Mycosis fungoides, AML, Hairy cell leukemia, Carcinoma, Melanoma, EM plasmacytoma, Kaposi's sarcoma, Mast-cell disease, AIDS involutionary, T-immunob large, Monocytoid B-cell, Nasopharyngeal CA, Seminoma, SLE, Mycobact histiocytos, Mast-cell hyperplas, LGV, Histoplasmosis, Coccidioidomycosis, CMV, Brucellosis, Ki-1 LC anaplas B, Intermed lymphocytic };
}
variable ACID {
  type discrete [ 2 ] { Negative, Positive };
}
variable F_CSA {
  type discrete [ 3 ] { No follicles, Absent, Present };
}
variable F_ISL {
  type discrete [ 3 ] { No follicles, Absent, Present };
}
variable F_POL {
  type discrete [ 3 ] { No follicles, Absent, Present };
}
variable F_RPBV {
  type discrete [ 4 ] { No follicles, None, One, More than one };
}
variable BH_LANG {
  type discrete [ 4 ] { Absent, Slight, Moderate, Marked };
}
variable BH_FOAM {
  type discrete [ 5 ] { Absent, Rare, Focal, Multifocal, Extensive };
}
variable BH_NOS {
  type discrete [ 3 ] { Absent to slight [<5pc], Moderate [5-50pc], Marked [>50pc] };
}
variable BH_SS {
  type discrete [ 5 ] { Absent, Rare, Focal SS pattern, Multifocal SS pattern, Extensive SS pattern };
}
variable CA {
  type discrete [ 2 ] { Absent, Present };
}
variable SR {
  type discrete [ 5 ] { Absent [0], Rare [1-3], Present [4-15], Many [16-50], Striking [>50] };
}
variable DVS {
  type discrete [ 2 ] { Absent, Present };
}
variable EMPERI {
  type discrete [ 3 ] { Absent [0], Present [1-2], Prominent [>2] };
}
variable MA_EOSIN {
  type discrete [ 2 ] { Absent, Present };
}
variable EMM {
  type discrete [ 2 ] { Absent, Present };
}
variable EOSIN {
  type discrete [ 3 ] { Absent, Present, Prominent };
}
variable EHC {
  type discrete [ 3 ] { Absent [0pc], Present [<5pc], Prominent [>5pc] };
}
variable EHC_ENC {
  type discrete [ 4 ] { No epithelial clusters/no follicles, Absent [no], Some, Many };
}
variable EH_NC {
  type discrete [ 3 ] { Absent [0pc], Present [<5pc], Prominent [>5pc] };
}
variable ECCC {
  type discrete [ 4 ] { Absent [0pc], Rare [1-10pc], Present [11-50pc], Many [51-70pc] };
}
variable FCB {
  type discrete [ 3 ] { Absent, Present, Prominent };
}
variable FCB_NOD {
  type discrete [ 3 ] { No collagenous bands, Absent, Present };
}
variable FIBROS {
  type discrete [ 2 ] { Absent, Present };
}
variable FITE {
  type discrete [ 2 ] { Negative, Positive };
}
variable FBODY {
  type discrete [ 3 ] { Absent [0], Present [1-5], Prominent [>5] };
}
variable GENE_TC {
  type discrete [ 2 ] { Absent, Present };
}
variable HAIRY {
  type discrete [ 2 ] { Absent, Present };
}
variable HTLV_I {
  type discrete [ 2 ] { Negative, Positive };
}
variable HIV {
  type discrete [ 2 ] { Negative, Positive };
}
variable INTFOL {
  type discrete [ 3 ] { No expansion, Mild-moderate expansion, Unif mrkd expan/no follicles };
}
variable ICLC {
  type discrete [ 2 ] { Absent, Present };
}
variable KARYO {
  type discrete [ 3 ] { Absent, Present, Prominent };
}
variable L_and_H {
  type discrete [ 5 ] { Absent [0], Rare [1-5], Few [6-25], Many [26-100], Striking [>100] };
}
variable LH_NOD {
  type discrete [ 2 ] { Absent, Present };
}
variable LACUN {
  type discrete [ 6 ] { Absent [0], Rare [1-5], Few [6-25], Many [26 - 100], Striking [>100], Sheets [>50pc of section] };
}
variable LANG {
  type discrete [ 3 ] { Absent [0], Present [1-5], Prominent [>5] };
}
variable LEUK {
  type discrete [ 2 ] { Absent, Present };
}
variable LLC_CY {
  type discrete [ 4 ] { No LLCs, Scanty, Moderate-abundant clear, Moderate-abundant deep };
}
variable LLC_NS {
  type discrete [ 6 ] { No LLCs, Multilobated [some], Cerebriform/Mulberry [some], Convoluted [some], Irregular [most], Round/slightly irregular [most] };
}
variable LLC {
  type discrete [ 5 ] { Absent [0pc], Sparse [<10pc], Moderate [11-50pc], Numerous [51-90pc], Striking [>90pc] };
}
variable F_POPU {
  type discrete [ 5 ] { No follicles, >80pc 6-12u, >50pc 13-20u with nucleoli, >50pc >20u with nucleoli, Other };
}
variable MAST {
  type discrete [ 3 ] { Absent [0], Present [1-50], Prominent [>50] };
}
variable MLC {
  type discrete [ 5 ] { Absent [0pc], Sparse [<10pc], Moderate [11-50pc], Numerous [51-90pc], Striking [>90pc] };
}
variable MELANOMA {
  type discrete [ 2 ] { Absent, Present };
}
variable MF10HP {
  type discrete [ 4 ] { 0-5, 6-15, 16-50, >50 };
}
variable MLC_CY {
  type discrete [ 4 ] { No MLCs, Scanty, Moderate-abundant clear, Moderate-abundant deep };
}
variable MLC_NS {
  type discrete [ 5 ] { No MLCs, Cerebriform [some], Convoluted [some], Irregular [most], Round/slightly irregular [most] };
}
variable MLC_NI {
  type discrete [ 5 ] { No MLCs, Absent to rare, Large central, Peripheral, Other };
}
variable MCC {
  type discrete [ 4 ] { Absent [0pc], Present [<5pc], Prominent [5-50pc], Confluence [>50pc] };
}
variable MONO {
  type discrete [ 4 ] { Absent [0], Rare [1-2], Present [3-20], Many [>20] };
}
variable MOT_HIST {
  type discrete [ 4 ] { Absent, Focal [nonextensive], Multifocal [nonextensive], Extensive };
}
variable MOT_LLC {
  type discrete [ 4 ] { No mottling, Focal [nonextensive], Multifocal [nonextensive], Extensive };
}
variable MUMMY {
  type discrete [ 4 ] { Absent [0], Rare [1-2], Present [3-20], Many [>20] };
}
variable NECR {
  type discrete [ 4 ] { Absent, Focal [nonextensive], Multifocal [nonextensive], Extensive };
}
variable MA_NEUT {
  type discrete [ 2 ] { Absent, Present };
}
variable NEUTRO {
  type discrete [ 3 ] { Absent, Present, Prominent };
}
variable PAS {
  type discrete [ 2 ] { No, Yes };
}
variable PI {
  type discrete [ 3 ] { Absent, Present, Prominent };
}
variable PLASMA {
  type discrete [ 6 ] { Absent [0pc], Few [<5pc], Moderate [6-20pc], Marked [21-50pc], Striking [51-90pc], Sheets [>90pc] };
}
variable PC_TP {
  type discrete [ 6 ] { No plasma cells, Mature, Immature, Blastic, Pleomorphic, Mixed };
}
variable PLEO {
  type discrete [ 5 ] { Absent [0], Rare [1-5], Few [6-25], Many [26-100], Striking [>100] };
}
variable PFP {
  type discrete [ 2 ] { Absent, Present };
}
variable PTGC_NOD {
  type discrete [ 2 ] { Absent, Present };
}
variable RD_BOD {
  type discrete [ 2 ] { Absent, Present };
}
variable SARCOMA {
  type discrete [ 2 ] { Absent, Present };
}
variable SCHAUM {
  type discrete [ 2 ] { Absent, Present };
}
variable S_RING {
  type discrete [ 2 ] { Absent, Present };
}
variable SLC_CY {
  type discrete [ 4 ] { No SLCs, Scanty, Moderate-abundant clear, Moderate-abundant deep };
}
variable SLC_NS {
  type discrete [ 5 ] { No SLCs, Cerebriform [some], Convoluted [some], Moderate-mark irregular [most], Round/slightly irregular [most] };
}
variable SLC {
  type discrete [ 5 ] { Absent [0pc], Sparse [1-10pc], Moderate [11-50pc], Numerous [51-90pc], Striking [>90pc] };
}
variable SINUSES {
  type discrete [ 4 ] { Distended, Patent, Part-greatly obliterated, Completely obliterated };
}
variable VASC_C {
  type discrete [ 2 ] { Absent, Present };
}
variable VASC_NS {
  type discrete [ 5 ] { Absent, Slight, Moderate, Marked, Pronounced };
}
variable VASC_S {
  type discrete [ 2 ] { Absent, Present };
}
variable F_HEM {
  type discrete [ 3 ] { No follicles, Absent, Present };
}
variable TAB {
  type discrete [ 2 ] { Absent, Present };
}
variable CT {
  type discrete [ 4 ] { Absent, Slight [<10], Moderate [10-20], Marked [>20] };
}
variable GENE_IG {
  type discrete [ 2 ] { Absent, Present };
}
variable HIV_ST {
  type discrete [ 3 ] { Negative, Positive/Asymptomatic, Positive/Symptomatic };
}
variable MLC_LLC {
  type discrete [ 2 ] { No, Yes };
}
variable LLC_NI {
  type discrete [ 5 ] { No LLCs, Absent to rare, Large central, Peripheral, Other };
}
variable SLC_CS {
  type discrete [ 5 ] { No SLCs, Clumped, Vesicular, Fine and delicate, Plasmacytoid };
}
variable LLC_ID {
  type discrete [ 4 ] { No LLCs, Other, Large cleaved, Large noncleaved };
}
variable FOLLICLE {
  type discrete [ 5 ] { Absent [0pc], 1-25pc, 25-75pc, 75-90pc, >90pc };
}
variable F_DEN {
  type discrete [ 5 ] { No follicles, Back to back, Closely packed, Separated, Far apart };
}
variable F_SS {
  type discrete [ 5 ] { No follicles, Absent [0], Slight [1-15], Moderate [16-30], Marked [>30] };
}
variable F_MZSTAT {
  type discrete [ 5 ] { No follicles/no mantle zones, Mantle zones absent in most follicles, Most incompletely surround follicles, Most completely surround fol not thick, Most thick [>10 lymphocytes] };
}
variable F_MZCM {
  type discrete [ 3 ] { No follicles/no mantle zones, Absent, Present };
}
variable F_DEF {
  type discrete [ 4 ] { No follicles, Almost all well defined, Both well and poor defined, Almost all poor defined };
}
variable F_MITO {
  type discrete [ 4 ] { No follicles, 0-20, 21-50, >50 };
}
variable F_MZ {
  type discrete [ 3 ] { No follicles, Absent, Present };
}
variable F_CIO {
  type discrete [ 4 ] { No follicles, Most similar, Some similar, None similar };
}
variable LLC_KL {
  type discrete [ 4 ] { No LLCs, Neither positive, Monoclonal, Polyclonal };
}
variable PLAS_KL {
  type discrete [ 4 ] { No plasma cells, Polyclonal, Monoclonal, Neither positive };
}
variable FCC_KL {
  type discrete [ 4 ] { No follicles, Polyclonal, Monoclonal, Neither positive };
}
variable MZL_KL {
  type discrete [ 4 ] { No mantle zones, Polyclonal, Monoclonal, Neither positive };
}
variable SR_LEU {
  type discrete [ 5 ] { No classic SRs, Both -, Leu-M1+ CLA-, Leu-M1- CLA+, Both + };
}
variable LAC_LEU {
  type discrete [ 5 ] { No Lacunar SRs, Both -, Leu-M1+ CLA-, Leu-M1- CLA+, Both+ };
}
variable PLEO_LEU {
  type discrete [ 5 ] { No pleomorphic SRs, Both -, Leu-M1+ CLA-, Leu-M1- CLA+, Both + };
}
variable MONO_LEU {
  type discrete [ 5 ] { No mononuclear SRs, Both -, Leu-M1+ CLA-, Leu-M1- CLA+, Both + };
}
variable LH_LEU {
  type discrete [ 5 ] { No L&H SRs, Both -, Leu-M1+ CLA-, Leu-M1- CLA+, Both + };
}
variable CA_KER {
  type discrete [ 2 ] { Negative, Positive };
}
variable MLC_LEU9 {
  type discrete [ 3 ] { No MLCs, Negative, Positive };
}
variable MLC_TDT {
  type discrete [ 3 ] { No MLCs, Negative, Positive };
}
variable CA_CHROM {
  type discrete [ 2 ] { Negative, Positive };
}
variable UCHL_1 {
  type discrete [ 2 ] { Negative, Positive };
}
variable KI_AB {
  type discrete [ 2 ] { Negative, Positive };
}
variable L_26 {
  type discrete [ 2 ] { Negative, Positive };
}
variable BER_H2 {
  type discrete [ 2 ] { Negative, Positive };
}
variable SEMINOMA {
  type discrete [ 2 ] { Absent, Present };
}
variable AGE {
  type discrete [ 4 ] { 0-20, 21-30, 31-70, >70 };
}
variable LYMPHADE {
  type discrete [ 2 ] { Localized [stage 1 or 2], Generalized [stage 3 or 4] };
}
variable MED_MASS {
  type discrete [ 2 ] { Absent, Present };
}
variable HMB45 {
  type discrete [ 2 ] { Negative, Positive };
}
variable MLC_LYZ {
  type discrete [ 3 ] { No MLCs, Negative, Positive };
}
variable MLC_I {
  type discrete [ 2 ] { Absent [no], Present [yes] };
}
variable LLC_I {
  type discrete [ 2 ] { Absent [no], Present [yes] };
}
variable LIPID {
  type discrete [ 2 ] { Absent to few, Prominent };
}
variable HX_LA {
  type discrete [ 2 ] { Absent, Present };
}
variable HEMATOX {
  type discrete [ 2 ] { Absent, Present };
}
variable CMV {
  type discrete [ 2 ] { Absent, Present };
}
variable BRUCELLA {
  type discrete [ 2 ] { No, Yes };
}
variable COCCIDIA {
  type discrete [ 2 ] { Absent, Present };
}
variable HISTOPLA {
  type discrete [ 2 ] { Absent, Present };
}
variable LGV {
  type discrete [ 2 ] { No, Yes };
}
variable VDRL {
  type discrete [ 2 ] { No, Yes };
}
variable PLASCY_T {
  type discrete [ 3 ] { Absent, Present, Prominent };
}
variable TB {
  type discrete [ 3 ] { Absent, Present, Prominent };
}
variable MELANIN {
  type discrete [ 3 ] { Absent to normal, Present, Prominent };
}
variable MC_SL_NS {
  type discrete [ 5 ] { No follicles/no mantle zones, Round, Slightly irregular, Moderately irregular, Markedly irregular };
}
variable FMZ_FUS {
  type discrete [ 4 ] { No thick mantle zones, No nodules no fusion, Nodules but no fusion, Fusion with or without nodules };
}
variable BH_NOS_L {
  type discrete [ 4 ] { No NOS benign histiocytes, Mainly interfollicular, Mainly sinusoidal, Both interfollicular and sinusoidal };
}
variable SLC_NI {
  type discrete [ 5 ] { No SLCs, None identifiable, 1 or more peripheral small, 1 central medium to large, Other };
}
variable HYALIN {
  type discrete [ 3 ] { Absent, Present, Prominent };
}
probability ( Fault ) {
  table  20.00,   1.50,   5.00,   5.00,  25.00,  25.00,   5.00,   5.00,  15.00,   4.00,   2.00,   2.00,   5.00,  12.50,   8.00,  12.80,   2.00,   2.00,   3.00,  20.00,   2.00,   5.00,   4.00,  15.00,   0.50,  15.00,   2.50,  90.00,   8.00,   8.00,  70.00,   5.00,   3.00,   3.00, 110.00,  55.00,  20.00,   5.00,  40.00,   8.00,  10.00,   5.00,   6.00, 110.00,  20.00,  20.00,  12.00,   2.00,  10.00,  80.00,   1.00,  15.00,   2.00,   3.00,   5.00,   0.10,  20.00,   8.00,   5.00,   8.00,   2.00,  20.00,  25.00,  20.00,   5.00,   2.00,   2.00,   2.00,   2.00,   2.00,   2.00,   2.00,   5.00,   0.25,   4.00,   8.00;
}
probability ( ACID | TB ) {
  (Absent) 1.0, 0.0;
  (Present) 0.1, 0.9;
  (Prominent) 0.0, 1.0;
}
probability ( F_CSA | Fault, FOLLICLE ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0;
  (AIDS early, 1-25pc) 0.0, 0.9, 0.1;
  (AILD, 1-25pc) 0.0, 0.3, 0.7;
  (ALIP, 1-25pc) 0.0, 0.9, 0.1;
  (Cat scratch disease, 1-25pc) 0.0, 0.9, 0.1;
  (Dermatopathic laden, 1-25pc) 0.0, 0.9, 0.1;
  (Florid follic hyperp, 1-25pc) 0.0, 0.9, 0.1;
  (GLH hyaline vascular, 1-25pc) 0.0, 0.0, 1.0;
  (GLH plasma cell, 1-25pc) 0.0, 0.9, 0.1;
  (Granulomatous laden, 1-25pc) 0.0, 0.9, 0.1;
  (Histiocytosis x, 1-25pc) 0.0, 0.9, 0.1;
  (Infectious mono, 1-25pc) 0.0, 0.9, 0.1;
  (Leprosy-lepromatous, 1-25pc) 0.0, 0.9, 0.1;
  (Lymphangiographic, 1-25pc) 0.0, 0.9, 0.1;
  (Mantle zone hyperpla, 1-25pc) 0.0, 0.2, 0.8;
  (Necrotizing Kikuchi, 1-25pc) 0.0, 0.9, 0.1;
  (Necrotiz non-Kikuchi, 1-25pc) 0.0, 0.9, 0.1;
  (Rheumatoid arthritis, 1-25pc) 0.0, 0.9, 0.1;
  (Sarcoidosis, 1-25pc) 0.0, 0.9, 0.1;
  (SHML, 1-25pc) 0.0, 0.9, 0.1;
  (Sinus histiocytosis, 1-25pc) 0.0, 0.9, 0.1;
  (Syphilis, 1-25pc) 0.0, 0.9, 0.1;
  (Toxoplasmosis, 1-25pc) 0.0, 0.9, 0.1;
  (Tuberculosis, 1-25pc) 0.0, 0.9, 0.1;
  (Viral NOS, 1-25pc) 0.0, 0.9, 0.1;
  (Whipple's disease, 1-25pc) 0.0, 0.9, 0.1;
  (L&H nodular HD, 1-25pc) 0.0, 0.9, 0.1;
  (L&H diffuse HD, 1-25pc) 0.0, 0.9, 0.1;
  (Nodular sclerosis HD, 1-25pc) 0.0, 0.9, 0.1;
  (Cellular phase NSHD, 1-25pc) 0.0, 0.9, 0.1;
  (Syncytial NSHD, 1-25pc) 0.0, 0.9, 0.1;
  (Mixed cellularity HD, 1-25pc) 0.0, 0.9, 0.1;
  (Interfollicular HD, 1-25pc) 0.0, 0.9, 0.1;
  (Diffuse fibrosis HD, 1-25pc) 0.0, 0.9, 0.1;
  (Reticular-type HD, 1-25pc) 0.0, 0.9, 0.1;
  (Small cleaved fol, 1-25pc) 0.000, 0.999, 0.001;
  (Mixed fol, 1-25pc) 0.000, 0.999, 0.001;
  (Large cell fol, 1-25pc) 0.000, 0.999, 0.001;
  (Small noncleaved fol, 1-25pc) 0.000, 0.999, 0.001;
  (Small lymphocytic, 1-25pc) 0.0, 0.9, 0.1;
  (Plasmacytoid lyctic, 1-25pc) 0.0, 0.9, 0.1;
  (Mantle zone lymphoma, 1-25pc) 0.0, 0.1, 0.9;
  (Small cleaved dif, 1-25pc) 0.0, 0.9, 0.1;
  (Mixed FCC dif, 1-25pc) 0.0, 0.9, 0.1;
  (Large cell dif, 1-25pc) 0.0, 0.9, 0.1;
  (B-immunoblastic, 1-25pc) 0.0, 0.9, 0.1;
  (T-immunob mixed, 1-25pc) 0.0, 0.9, 0.1;
  (AILD-like T-cell lym, 1-25pc) 0.0, 0.3, 0.7;
  (Japanese ATL, 1-25pc) 0.0, 0.9, 0.1;
  (Lymphoblastic, 1-25pc) 0.0, 0.9, 0.1;
  (Small noncleaved dif, 1-25pc) 0.0, 0.9, 0.1;
  (True histiocytic, 1-25pc) 0.0, 0.9, 0.1;
  (Ki-1 LC anaplas T, 1-25pc) 0.0, 0.9, 0.1;
  (Multiple myeloma, 1-25pc) 0.0, 0.9, 0.1;
  (Mycosis fungoides, 1-25pc) 0.0, 0.9, 0.1;
  (AML, 1-25pc) 0.0, 0.9, 0.1;
  (Hairy cell leukemia, 1-25pc) 0.0, 0.9, 0.1;
  (Carcinoma, 1-25pc) 0.0, 0.9, 0.1;
  (Melanoma, 1-25pc) 0.0, 0.9, 0.1;
  (EM plasmacytoma, 1-25pc) 0.0, 0.9, 0.1;
  (Kaposi's sarcoma, 1-25pc) 0.0, 0.8, 0.2;
  (Mast-cell disease, 1-25pc) 0.0, 0.9, 0.1;
  (AIDS involutionary, 1-25pc) 0.0, 0.1, 0.9;
  (T-immunob large, 1-25pc) 0.0, 0.9, 0.1;
  (Monocytoid B-cell, 1-25pc) 0.0, 0.9, 0.1;
  (Nasopharyngeal CA, 1-25pc) 0.0, 0.9, 0.1;
  (Seminoma, 1-25pc) 0.0, 0.9, 0.1;
  (SLE, 1-25pc) 0.0, 0.9, 0.1;
  (Mycobact histiocytos, 1-25pc) 0.0, 0.8, 0.2;
  (Mast-cell hyperplas, 1-25pc) 0.0, 0.9, 0.1;
  (LGV, 1-25pc) 0.0, 0.9, 0.1;
  (Histoplasmosis, 1-25pc) 0.0, 0.8, 0.2;
  (Coccidioidomycosis, 1-25pc) 0.0, 0.8, 0.2;
  (CMV, 1-25pc) 0.0, 0.8, 0.2;
  (Brucellosis, 1-25pc) 0.0, 0.9, 0.1;
  (Ki-1 LC anaplas B, 1-25pc) 0.0, 0.9, 0.1;
  (Intermed lymphocytic, 1-25pc) 0.0, 0.1, 0.9;
  (AIDS early, 25-75pc) 0.0, 0.9, 0.1;
  (AILD, 25-75pc) 0.0, 0.3, 0.7;
  (ALIP, 25-75pc) 0.0, 0.9, 0.1;
  (Cat scratch disease, 25-75pc) 0.0, 0.9, 0.1;
  (Dermatopathic laden, 25-75pc) 0.0, 0.9, 0.1;
  (Florid follic hyperp, 25-75pc) 0.0, 0.9, 0.1;
  (GLH hyaline vascular, 25-75pc) 0.0, 0.0, 1.0;
  (GLH plasma cell, 25-75pc) 0.0, 0.9, 0.1;
  (Granulomatous laden, 25-75pc) 0.0, 0.9, 0.1;
  (Histiocytosis x, 25-75pc) 0.0, 0.9, 0.1;
  (Infectious mono, 25-75pc) 0.0, 0.9, 0.1;
  (Leprosy-lepromatous, 25-75pc) 0.0, 0.9, 0.1;
  (Lymphangiographic, 25-75pc) 0.0, 0.9, 0.1;
  (Mantle zone hyperpla, 25-75pc) 0.0, 0.2, 0.8;
  (Necrotizing Kikuchi, 25-75pc) 0.0, 0.9, 0.1;
  (Necrotiz non-Kikuchi, 25-75pc) 0.0, 0.9, 0.1;
  (Rheumatoid arthritis, 25-75pc) 0.0, 0.9, 0.1;
  (Sarcoidosis, 25-75pc) 0.0, 0.9, 0.1;
  (SHML, 25-75pc) 0.0, 0.9, 0.1;
  (Sinus histiocytosis, 25-75pc) 0.0, 0.9, 0.1;
  (Syphilis, 25-75pc) 0.0, 0.9, 0.1;
  (Toxoplasmosis, 25-75pc) 0.0, 0.9, 0.1;
  (Tuberculosis, 25-75pc) 0.0, 0.9, 0.1;
  (Viral NOS, 25-75pc) 0.0, 0.9, 0.1;
  (Whipple's disease, 25-75pc) 0.0, 0.9, 0.1;
  (L&H nodular HD, 25-75pc) 0.0, 0.9, 0.1;
  (L&H diffuse HD, 25-75pc) 0.0, 0.9, 0.1;
  (Nodular sclerosis HD, 25-75pc) 0.0, 0.9, 0.1;
  (Cellular phase NSHD, 25-75pc) 0.0, 0.9, 0.1;
  (Syncytial NSHD, 25-75pc) 0.0, 0.9, 0.1;
  (Mixed cellularity HD, 25-75pc) 0.0, 0.9, 0.1;
  (Interfollicular HD, 25-75pc) 0.0, 0.9, 0.1;
  (Diffuse fibrosis HD, 25-75pc) 0.0, 0.9, 0.1;
  (Reticular-type HD, 25-75pc) 0.0, 0.9, 0.1;
  (Small cleaved fol, 25-75pc) 0.000, 0.999, 0.001;
  (Mixed fol, 25-75pc) 0.000, 0.999, 0.001;
  (Large cell fol, 25-75pc) 0.000, 0.999, 0.001;
  (Small noncleaved fol, 25-75pc) 0.000, 0.999, 0.001;
  (Small lymphocytic, 25-75pc) 0.0, 0.9, 0.1;
  (Plasmacytoid lyctic, 25-75pc) 0.0, 0.9, 0.1;
  (Mantle zone lymphoma, 25-75pc) 0.0, 0.1, 0.9;
  (Small cleaved dif, 25-75pc) 0.0, 0.9, 0.1;
  (Mixed FCC dif, 25-75pc) 0.0, 0.9, 0.1;
  (Large cell dif, 25-75pc) 0.0, 0.9, 0.1;
  (B-immunoblastic, 25-75pc) 0.0, 0.9, 0.1;
  (T-immunob mixed, 25-75pc) 0.0, 0.9, 0.1;
  (AILD-like T-cell lym, 25-75pc) 0.0, 0.3, 0.7;
  (Japanese ATL, 25-75pc) 0.0, 0.9, 0.1;
  (Lymphoblastic, 25-75pc) 0.0, 0.9, 0.1;
  (Small noncleaved dif, 25-75pc) 0.0, 0.9, 0.1;
  (True histiocytic, 25-75pc) 0.0, 0.9, 0.1;
  (Ki-1 LC anaplas T, 25-75pc) 0.0, 0.9, 0.1;
  (Multiple myeloma, 25-75pc) 0.0, 0.9, 0.1;
  (Mycosis fungoides, 25-75pc) 0.0, 0.9, 0.1;
  (AML, 25-75pc) 0.0, 0.9, 0.1;
  (Hairy cell leukemia, 25-75pc) 0.0, 0.9, 0.1;
  (Carcinoma, 25-75pc) 0.0, 0.9, 0.1;
  (Melanoma, 25-75pc) 0.0, 0.9, 0.1;
  (EM plasmacytoma, 25-75pc) 0.0, 0.9, 0.1;
  (Kaposi's sarcoma, 25-75pc) 0.0, 0.8, 0.2;
  (Mast-cell disease, 25-75pc) 0.0, 0.9, 0.1;
  (AIDS involutionary, 25-75pc) 0.0, 0.1, 0.9;
  (T-immunob large, 25-75pc) 0.0, 0.9, 0.1;
  (Monocytoid B-cell, 25-75pc) 0.0, 0.9, 0.1;
  (Nasopharyngeal CA, 25-75pc) 0.0, 0.9, 0.1;
  (Seminoma, 25-75pc) 0.0, 0.9, 0.1;
  (SLE, 25-75pc) 0.0, 0.9, 0.1;
  (Mycobact histiocytos, 25-75pc) 0.0, 0.8, 0.2;
  (Mast-cell hyperplas, 25-75pc) 0.0, 0.9, 0.1;
  (LGV, 25-75pc) 0.0, 0.9, 0.1;
  (Histoplasmosis, 25-75pc) 0.0, 0.8, 0.2;
  (Coccidioidomycosis, 25-75pc) 0.0, 0.8, 0.2;
  (CMV, 25-75pc) 0.0, 0.8, 0.2;
  (Brucellosis, 25-75pc) 0.0, 0.9, 0.1;
  (Ki-1 LC anaplas B, 25-75pc) 0.0, 0.9, 0.1;
  (Intermed lymphocytic, 25-75pc) 0.0, 0.1, 0.9;
  (AIDS early, 75-90pc) 0.0, 0.9, 0.1;
  (AILD, 75-90pc) 0.0, 0.3, 0.7;
  (ALIP, 75-90pc) 0.0, 0.9, 0.1;
  (Cat scratch disease, 75-90pc) 0.0, 0.9, 0.1;
  (Dermatopathic laden, 75-90pc) 0.0, 0.9, 0.1;
  (Florid follic hyperp, 75-90pc) 0.0, 0.9, 0.1;
  (GLH hyaline vascular, 75-90pc) 0.0, 0.0, 1.0;
  (GLH plasma cell, 75-90pc) 0.0, 0.9, 0.1;
  (Granulomatous laden, 75-90pc) 0.0, 0.9, 0.1;
  (Histiocytosis x, 75-90pc) 0.0, 0.9, 0.1;
  (Infectious mono, 75-90pc) 0.0, 0.9, 0.1;
  (Leprosy-lepromatous, 75-90pc) 0.0, 0.9, 0.1;
  (Lymphangiographic, 75-90pc) 0.0, 0.9, 0.1;
  (Mantle zone hyperpla, 75-90pc) 0.0, 0.2, 0.8;
  (Necrotizing Kikuchi, 75-90pc) 0.0, 0.9, 0.1;
  (Necrotiz non-Kikuchi, 75-90pc) 0.0, 0.9, 0.1;
  (Rheumatoid arthritis, 75-90pc) 0.0, 0.9, 0.1;
  (Sarcoidosis, 75-90pc) 0.0, 0.9, 0.1;
  (SHML, 75-90pc) 0.0, 0.9, 0.1;
  (Sinus histiocytosis, 75-90pc) 0.0, 0.9, 0.1;
  (Syphilis, 75-90pc) 0.0, 0.9, 0.1;
  (Toxoplasmosis, 75-90pc) 0.0, 0.9, 0.1;
  (Tuberculosis, 75-90pc) 0.0, 0.9, 0.1;
  (Viral NOS, 75-90pc) 0.0, 0.9, 0.1;
  (Whipple's disease, 75-90pc) 0.0, 0.9, 0.1;
  (L&H nodular HD, 75-90pc) 0.0, 0.9, 0.1;
  (L&H diffuse HD, 75-90pc) 0.0, 0.9, 0.1;
  (Nodular sclerosis HD, 75-90pc) 0.0, 0.9, 0.1;
  (Cellular phase NSHD, 75-90pc) 0.0, 0.9, 0.1;
  (Syncytial NSHD, 75-90pc) 0.0, 0.9, 0.1;
  (Mixed cellularity HD, 75-90pc) 0.0, 0.9, 0.1;
  (Interfollicular HD, 75-90pc) 0.0, 0.9, 0.1;
  (Diffuse fibrosis HD, 75-90pc) 0.0, 0.9, 0.1;
  (Reticular-type HD, 75-90pc) 0.0, 0.9, 0.1;
  (Small cleaved fol, 75-90pc) 0.000, 0.999, 0.001;
  (Mixed fol, 75-90pc) 0.000, 0.999, 0.001;
  (Large cell fol, 75-90pc) 0.000, 0.999, 0.001;
  (Small noncleaved fol, 75-90pc) 0.000, 0.999, 0.001;
  (Small lymphocytic, 75-90pc) 0.0, 0.9, 0.1;
  (Plasmacytoid lyctic, 75-90pc) 0.0, 0.9, 0.1;
  (Mantle zone lymphoma, 75-90pc) 0.0, 0.1, 0.9;
  (Small cleaved dif, 75-90pc) 0.0, 0.9, 0.1;
  (Mixed FCC dif, 75-90pc) 0.0, 0.9, 0.1;
  (Large cell dif, 75-90pc) 0.0, 0.9, 0.1;
  (B-immunoblastic, 75-90pc) 0.0, 0.9, 0.1;
  (T-immunob mixed, 75-90pc) 0.0, 0.9, 0.1;
  (AILD-like T-cell lym, 75-90pc) 0.0, 0.3, 0.7;
  (Japanese ATL, 75-90pc) 0.0, 0.9, 0.1;
  (Lymphoblastic, 75-90pc) 0.0, 0.9, 0.1;
  (Small noncleaved dif, 75-90pc) 0.0, 0.9, 0.1;
  (True histiocytic, 75-90pc) 0.0, 0.9, 0.1;
  (Ki-1 LC anaplas T, 75-90pc) 0.0, 0.9, 0.1;
  (Multiple myeloma, 75-90pc) 0.0, 0.9, 0.1;
  (Mycosis fungoides, 75-90pc) 0.0, 0.9, 0.1;
  (AML, 75-90pc) 0.0, 0.9, 0.1;
  (Hairy cell leukemia, 75-90pc) 0.0, 0.9, 0.1;
  (Carcinoma, 75-90pc) 0.0, 0.9, 0.1;
  (Melanoma, 75-90pc) 0.0, 0.9, 0.1;
  (EM plasmacytoma, 75-90pc) 0.0, 0.9, 0.1;
  (Kaposi's sarcoma, 75-90pc) 0.0, 0.8, 0.2;
  (Mast-cell disease, 75-90pc) 0.0, 0.9, 0.1;
  (AIDS involutionary, 75-90pc) 0.0, 0.1, 0.9;
  (T-immunob large, 75-90pc) 0.0, 0.9, 0.1;
  (Monocytoid B-cell, 75-90pc) 0.0, 0.9, 0.1;
  (Nasopharyngeal CA, 75-90pc) 0.0, 0.9, 0.1;
  (Seminoma, 75-90pc) 0.0, 0.9, 0.1;
  (SLE, 75-90pc) 0.0, 0.9, 0.1;
  (Mycobact histiocytos, 75-90pc) 0.0, 0.8, 0.2;
  (Mast-cell hyperplas, 75-90pc) 0.0, 0.9, 0.1;
  (LGV, 75-90pc) 0.0, 0.9, 0.1;
  (Histoplasmosis, 75-90pc) 0.0, 0.8, 0.2;
  (Coccidioidomycosis, 75-90pc) 0.0, 0.8, 0.2;
  (CMV, 75-90pc) 0.0, 0.8, 0.2;
  (Brucellosis, 75-90pc) 0.0, 0.9, 0.1;
  (Ki-1 LC anaplas B, 75-90pc) 0.0, 0.9, 0.1;
  (Intermed lymphocytic, 75-90pc) 0.0, 0.1, 0.9;
  (AIDS early, >90pc) 0.0, 0.9, 0.1;
  (AILD, >90pc) 0.0, 0.3, 0.7;
  (ALIP, >90pc) 0.0, 0.9, 0.1;
  (Cat scratch disease, >90pc) 0.0, 0.9, 0.1;
  (Dermatopathic laden, >90pc) 0.0, 0.9, 0.1;
  (Florid follic hyperp, >90pc) 0.0, 0.9, 0.1;
  (GLH hyaline vascular, >90pc) 0.0, 0.0, 1.0;
  (GLH plasma cell, >90pc) 0.0, 0.9, 0.1;
  (Granulomatous laden, >90pc) 0.0, 0.9, 0.1;
  (Histiocytosis x, >90pc) 0.0, 0.9, 0.1;
  (Infectious mono, >90pc) 0.0, 0.9, 0.1;
  (Leprosy-lepromatous, >90pc) 0.0, 0.9, 0.1;
  (Lymphangiographic, >90pc) 0.0, 0.9, 0.1;
  (Mantle zone hyperpla, >90pc) 0.0, 0.2, 0.8;
  (Necrotizing Kikuchi, >90pc) 0.0, 0.9, 0.1;
  (Necrotiz non-Kikuchi, >90pc) 0.0, 0.9, 0.1;
  (Rheumatoid arthritis, >90pc) 0.0, 0.9, 0.1;
  (Sarcoidosis, >90pc) 0.0, 0.9, 0.1;
  (SHML, >90pc) 0.0, 0.9, 0.1;
  (Sinus histiocytosis, >90pc) 0.0, 0.9, 0.1;
  (Syphilis, >90pc) 0.0, 0.9, 0.1;
  (Toxoplasmosis, >90pc) 0.0, 0.9, 0.1;
  (Tuberculosis, >90pc) 0.0, 0.9, 0.1;
  (Viral NOS, >90pc) 0.0, 0.9, 0.1;
  (Whipple's disease, >90pc) 0.0, 0.9, 0.1;
  (L&H nodular HD, >90pc) 0.0, 0.9, 0.1;
  (L&H diffuse HD, >90pc) 0.0, 0.9, 0.1;
  (Nodular sclerosis HD, >90pc) 0.0, 0.9, 0.1;
  (Cellular phase NSHD, >90pc) 0.0, 0.9, 0.1;
  (Syncytial NSHD, >90pc) 0.0, 0.9, 0.1;
  (Mixed cellularity HD, >90pc) 0.0, 0.9, 0.1;
  (Interfollicular HD, >90pc) 0.0, 0.9, 0.1;
  (Diffuse fibrosis HD, >90pc) 0.0, 0.9, 0.1;
  (Reticular-type HD, >90pc) 0.0, 0.9, 0.1;
  (Small cleaved fol, >90pc) 0.000, 0.999, 0.001;
  (Mixed fol, >90pc) 0.000, 0.999, 0.001;
  (Large cell fol, >90pc) 0.000, 0.999, 0.001;
  (Small noncleaved fol, >90pc) 0.000, 0.999, 0.001;
  (Small lymphocytic, >90pc) 0.0, 0.9, 0.1;
  (Plasmacytoid lyctic, >90pc) 0.0, 0.9, 0.1;
  (Mantle zone lymphoma, >90pc) 0.0, 0.1, 0.9;
  (Small cleaved dif, >90pc) 0.0, 0.9, 0.1;
  (Mixed FCC dif, >90pc) 0.0, 0.9, 0.1;
  (Large cell dif, >90pc) 0.0, 0.9, 0.1;
  (B-immunoblastic, >90pc) 0.0, 0.9, 0.1;
  (T-immunob mixed, >90pc) 0.0, 0.9, 0.1;
  (AILD-like T-cell lym, >90pc) 0.0, 0.3, 0.7;
  (Japanese ATL, >90pc) 0.0, 0.9, 0.1;
  (Lymphoblastic, >90pc) 0.0, 0.9, 0.1;
  (Small noncleaved dif, >90pc) 0.0, 0.9, 0.1;
  (True histiocytic, >90pc) 0.0, 0.9, 0.1;
  (Ki-1 LC anaplas T, >90pc) 0.0, 0.9, 0.1;
  (Multiple myeloma, >90pc) 0.0, 0.9, 0.1;
  (Mycosis fungoides, >90pc) 0.0, 0.9, 0.1;
  (AML, >90pc) 0.0, 0.9, 0.1;
  (Hairy cell leukemia, >90pc) 0.0, 0.9, 0.1;
  (Carcinoma, >90pc) 0.0, 0.9, 0.1;
  (Melanoma, >90pc) 0.0, 0.9, 0.1;
  (EM plasmacytoma, >90pc) 0.0, 0.9, 0.1;
  (Kaposi's sarcoma, >90pc) 0.0, 0.8, 0.2;
  (Mast-cell disease, >90pc) 0.0, 0.9, 0.1;
  (AIDS involutionary, >90pc) 0.0, 0.1, 0.9;
  (T-immunob large, >90pc) 0.0, 0.9, 0.1;
  (Monocytoid B-cell, >90pc) 0.0, 0.9, 0.1;
  (Nasopharyngeal CA, >90pc) 0.0, 0.9, 0.1;
  (Seminoma, >90pc) 0.0, 0.9, 0.1;
  (SLE, >90pc) 0.0, 0.9, 0.1;
  (Mycobact histiocytos, >90pc) 0.0, 0.8, 0.2;
  (Mast-cell hyperplas, >90pc) 0.0, 0.9, 0.1;
  (LGV, >90pc) 0.0, 0.9, 0.1;
  (Histoplasmosis, >90pc) 0.0, 0.8, 0.2;
  (Coccidioidomycosis, >90pc) 0.0, 0.8, 0.2;
  (CMV, >90pc) 0.0, 0.8, 0.2;
  (Brucellosis, >90pc) 0.0, 0.9, 0.1;
  (Ki-1 LC anaplas B, >90pc) 0.0, 0.9, 0.1;
  (Intermed lymphocytic, >90pc) 0.0, 0.1, 0.9;
}
probability ( F_ISL | Fault, F_HEM ) {
  (AIDS early, No follicles) 1.0, 0.0, 0.0;
  (AILD, No follicles) 1.0, 0.0, 0.0;
  (ALIP, No follicles) 1.0, 0.0, 0.0;
  (Cat scratch disease, No follicles) 1.0, 0.0, 0.0;
  (Dermatopathic laden, No follicles) 1.0, 0.0, 0.0;
  (Florid follic hyperp, No follicles) 1.0, 0.0, 0.0;
  (GLH hyaline vascular, No follicles) 1.0, 0.0, 0.0;
  (GLH plasma cell, No follicles) 1.0, 0.0, 0.0;
  (Granulomatous laden, No follicles) 1.0, 0.0, 0.0;
  (Histiocytosis x, No follicles) 1.0, 0.0, 0.0;
  (Infectious mono, No follicles) 1.0, 0.0, 0.0;
  (Leprosy-lepromatous, No follicles) 1.0, 0.0, 0.0;
  (Lymphangiographic, No follicles) 1.0, 0.0, 0.0;
  (Mantle zone hyperpla, No follicles) 1.0, 0.0, 0.0;
  (Necrotizing Kikuchi, No follicles) 1.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, No follicles) 1.0, 0.0, 0.0;
  (Rheumatoid arthritis, No follicles) 1.0, 0.0, 0.0;
  (Sarcoidosis, No follicles) 1.0, 0.0, 0.0;
  (SHML, No follicles) 1.0, 0.0, 0.0;
  (Sinus histiocytosis, No follicles) 1.0, 0.0, 0.0;
  (Syphilis, No follicles) 1.0, 0.0, 0.0;
  (Toxoplasmosis, No follicles) 1.0, 0.0, 0.0;
  (Tuberculosis, No follicles) 1.0, 0.0, 0.0;
  (Viral NOS, No follicles) 1.0, 0.0, 0.0;
  (Whipple's disease, No follicles) 1.0, 0.0, 0.0;
  (L&H nodular HD, No follicles) 1.0, 0.0, 0.0;
  (L&H diffuse HD, No follicles) 1.0, 0.0, 0.0;
  (Nodular sclerosis HD, No follicles) 1.0, 0.0, 0.0;
  (Cellular phase NSHD, No follicles) 1.0, 0.0, 0.0;
  (Syncytial NSHD, No follicles) 1.0, 0.0, 0.0;
  (Mixed cellularity HD, No follicles) 1.0, 0.0, 0.0;
  (Interfollicular HD, No follicles) 1.0, 0.0, 0.0;
  (Diffuse fibrosis HD, No follicles) 1.0, 0.0, 0.0;
  (Reticular-type HD, No follicles) 1.0, 0.0, 0.0;
  (Small cleaved fol, No follicles) 1.0, 0.0, 0.0;
  (Mixed fol, No follicles) 1.0, 0.0, 0.0;
  (Large cell fol, No follicles) 1.0, 0.0, 0.0;
  (Small noncleaved fol, No follicles) 1.0, 0.0, 0.0;
  (Small lymphocytic, No follicles) 1.0, 0.0, 0.0;
  (Plasmacytoid lyctic, No follicles) 1.0, 0.0, 0.0;
  (Mantle zone lymphoma, No follicles) 1.0, 0.0, 0.0;
  (Small cleaved dif, No follicles) 1.0, 0.0, 0.0;
  (Mixed FCC dif, No follicles) 1.0, 0.0, 0.0;
  (Large cell dif, No follicles) 1.0, 0.0, 0.0;
  (B-immunoblastic, No follicles) 1.0, 0.0, 0.0;
  (T-immunob mixed, No follicles) 1.0, 0.0, 0.0;
  (AILD-like T-cell lym, No follicles) 1.0, 0.0, 0.0;
  (Japanese ATL, No follicles) 1.0, 0.0, 0.0;
  (Lymphoblastic, No follicles) 1.0, 0.0, 0.0;
  (Small noncleaved dif, No follicles) 1.0, 0.0, 0.0;
  (True histiocytic, No follicles) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, No follicles) 1.0, 0.0, 0.0;
  (Multiple myeloma, No follicles) 1.0, 0.0, 0.0;
  (Mycosis fungoides, No follicles) 1.0, 0.0, 0.0;
  (AML, No follicles) 1.0, 0.0, 0.0;
  (Hairy cell leukemia, No follicles) 1.0, 0.0, 0.0;
  (Carcinoma, No follicles) 1.0, 0.0, 0.0;
  (Melanoma, No follicles) 1.0, 0.0, 0.0;
  (EM plasmacytoma, No follicles) 1.0, 0.0, 0.0;
  (Kaposi's sarcoma, No follicles) 1.0, 0.0, 0.0;
  (Mast-cell disease, No follicles) 1.0, 0.0, 0.0;
  (AIDS involutionary, No follicles) 1.0, 0.0, 0.0;
  (T-immunob large, No follicles) 1.0, 0.0, 0.0;
  (Monocytoid B-cell, No follicles) 1.0, 0.0, 0.0;
  (Nasopharyngeal CA, No follicles) 1.0, 0.0, 0.0;
  (Seminoma, No follicles) 1.0, 0.0, 0.0;
  (SLE, No follicles) 1.0, 0.0, 0.0;
  (Mycobact histiocytos, No follicles) 1.0, 0.0, 0.0;
  (Mast-cell hyperplas, No follicles) 1.0, 0.0, 0.0;
  (LGV, No follicles) 1.0, 0.0, 0.0;
  (Histoplasmosis, No follicles) 1.0, 0.0, 0.0;
  (Coccidioidomycosis, No follicles) 1.0, 0.0, 0.0;
  (CMV, No follicles) 1.0, 0.0, 0.0;
  (Brucellosis, No follicles) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, No follicles) 1.0, 0.0, 0.0;
  (Intermed lymphocytic, No follicles) 1.0, 0.0, 0.0;
  (AIDS early, Absent) 0.0, 0.8, 0.2;
  (AILD, Absent) 0.00, 0.99, 0.01;
  (ALIP, Absent) 0.00, 0.99, 0.01;
  (Cat scratch disease, Absent) 0.00, 0.99, 0.01;
  (Dermatopathic laden, Absent) 0.00, 0.99, 0.01;
  (Florid follic hyperp, Absent) 0.00, 0.95, 0.05;
  (GLH hyaline vascular, Absent) 0.00, 0.99, 0.01;
  (GLH plasma cell, Absent) 0.00, 0.99, 0.01;
  (Granulomatous laden, Absent) 0.00, 0.99, 0.01;
  (Histiocytosis x, Absent) 0.00, 0.99, 0.01;
  (Infectious mono, Absent) 0.00, 0.99, 0.01;
  (Leprosy-lepromatous, Absent) 0.00, 0.99, 0.01;
  (Lymphangiographic, Absent) 0.00, 0.99, 0.01;
  (Mantle zone hyperpla, Absent) 0.00, 0.99, 0.01;
  (Necrotizing Kikuchi, Absent) 0.00, 0.99, 0.01;
  (Necrotiz non-Kikuchi, Absent) 0.00, 0.99, 0.01;
  (Rheumatoid arthritis, Absent) 0.00, 0.99, 0.01;
  (Sarcoidosis, Absent) 0.00, 0.99, 0.01;
  (SHML, Absent) 0.00, 0.99, 0.01;
  (Sinus histiocytosis, Absent) 0.00, 0.99, 0.01;
  (Syphilis, Absent) 0.00, 0.99, 0.01;
  (Toxoplasmosis, Absent) 0.00, 0.99, 0.01;
  (Tuberculosis, Absent) 0.00, 0.99, 0.01;
  (Viral NOS, Absent) 0.00, 0.99, 0.01;
  (Whipple's disease, Absent) 0.00, 0.99, 0.01;
  (L&H nodular HD, Absent) 0.00, 0.99, 0.01;
  (L&H diffuse HD, Absent) 0.00, 0.99, 0.01;
  (Nodular sclerosis HD, Absent) 0.00, 0.99, 0.01;
  (Cellular phase NSHD, Absent) 0.00, 0.99, 0.01;
  (Syncytial NSHD, Absent) 0.00, 0.99, 0.01;
  (Mixed cellularity HD, Absent) 0.00, 0.99, 0.01;
  (Interfollicular HD, Absent) 0.00, 0.99, 0.01;
  (Diffuse fibrosis HD, Absent) 0.00, 0.99, 0.01;
  (Reticular-type HD, Absent) 0.00, 0.99, 0.01;
  (Small cleaved fol, Absent) 0.00, 0.99, 0.01;
  (Mixed fol, Absent) 0.00, 0.99, 0.01;
  (Large cell fol, Absent) 0.00, 0.99, 0.01;
  (Small noncleaved fol, Absent) 0.00, 0.99, 0.01;
  (Small lymphocytic, Absent) 0.00, 0.99, 0.01;
  (Plasmacytoid lyctic, Absent) 0.00, 0.99, 0.01;
  (Mantle zone lymphoma, Absent) 0.00, 0.99, 0.01;
  (Small cleaved dif, Absent) 0.00, 0.99, 0.01;
  (Mixed FCC dif, Absent) 0.00, 0.99, 0.01;
  (Large cell dif, Absent) 0.00, 0.99, 0.01;
  (B-immunoblastic, Absent) 0.00, 0.99, 0.01;
  (T-immunob mixed, Absent) 0.00, 0.99, 0.01;
  (AILD-like T-cell lym, Absent) 0.00, 0.99, 0.01;
  (Japanese ATL, Absent) 0.00, 0.99, 0.01;
  (Lymphoblastic, Absent) 0.00, 0.99, 0.01;
  (Small noncleaved dif, Absent) 0.00, 0.99, 0.01;
  (True histiocytic, Absent) 0.00, 0.99, 0.01;
  (Ki-1 LC anaplas T, Absent) 0.00, 0.99, 0.01;
  (Multiple myeloma, Absent) 0.00, 0.99, 0.01;
  (Mycosis fungoides, Absent) 0.00, 0.99, 0.01;
  (AML, Absent) 0.00, 0.99, 0.01;
  (Hairy cell leukemia, Absent) 0.00, 0.99, 0.01;
  (Carcinoma, Absent) 0.00, 0.99, 0.01;
  (Melanoma, Absent) 0.00, 0.99, 0.01;
  (EM plasmacytoma, Absent) 0.00, 0.99, 0.01;
  (Kaposi's sarcoma, Absent) 0.00, 0.99, 0.01;
  (Mast-cell disease, Absent) 0.00, 0.99, 0.01;
  (AIDS involutionary, Absent) 0.0, 0.9, 0.1;
  (T-immunob large, Absent) 0.00, 0.99, 0.01;
  (Monocytoid B-cell, Absent) 0.00, 0.99, 0.01;
  (Nasopharyngeal CA, Absent) 0.00, 0.99, 0.01;
  (Seminoma, Absent) 0.00, 0.99, 0.01;
  (SLE, Absent) 0.00, 0.99, 0.01;
  (Mycobact histiocytos, Absent) 0.00, 0.95, 0.05;
  (Mast-cell hyperplas, Absent) 0.00, 0.99, 0.01;
  (LGV, Absent) 0.00, 0.99, 0.01;
  (Histoplasmosis, Absent) 0.00, 0.95, 0.05;
  (Coccidioidomycosis, Absent) 0.00, 0.95, 0.05;
  (CMV, Absent) 0.00, 0.95, 0.05;
  (Brucellosis, Absent) 0.00, 0.99, 0.01;
  (Ki-1 LC anaplas B, Absent) 0.00, 0.99, 0.01;
  (Intermed lymphocytic, Absent) 0.00, 0.99, 0.01;
  (AIDS early, Present) 0.0, 0.7, 0.3;
  (AILD, Present) 0.00, 0.99, 0.01;
  (ALIP, Present) 0.00, 0.99, 0.01;
  (Cat scratch disease, Present) 0.00, 0.99, 0.01;
  (Dermatopathic laden, Present) 0.00, 0.99, 0.01;
  (Florid follic hyperp, Present) 0.0, 0.9, 0.1;
  (GLH hyaline vascular, Present) 0.00, 0.99, 0.01;
  (GLH plasma cell, Present) 0.00, 0.99, 0.01;
  (Granulomatous laden, Present) 0.00, 0.99, 0.01;
  (Histiocytosis x, Present) 0.00, 0.99, 0.01;
  (Infectious mono, Present) 0.00, 0.99, 0.01;
  (Leprosy-lepromatous, Present) 0.00, 0.99, 0.01;
  (Lymphangiographic, Present) 0.00, 0.99, 0.01;
  (Mantle zone hyperpla, Present) 0.00, 0.99, 0.01;
  (Necrotizing Kikuchi, Present) 0.00, 0.99, 0.01;
  (Necrotiz non-Kikuchi, Present) 0.00, 0.99, 0.01;
  (Rheumatoid arthritis, Present) 0.00, 0.99, 0.01;
  (Sarcoidosis, Present) 0.00, 0.99, 0.01;
  (SHML, Present) 0.00, 0.99, 0.01;
  (Sinus histiocytosis, Present) 0.00, 0.99, 0.01;
  (Syphilis, Present) 0.00, 0.99, 0.01;
  (Toxoplasmosis, Present) 0.00, 0.99, 0.01;
  (Tuberculosis, Present) 0.00, 0.99, 0.01;
  (Viral NOS, Present) 0.00, 0.99, 0.01;
  (Whipple's disease, Present) 0.00, 0.99, 0.01;
  (L&H nodular HD, Present) 0.00, 0.99, 0.01;
  (L&H diffuse HD, Present) 0.00, 0.99, 0.01;
  (Nodular sclerosis HD, Present) 0.00, 0.99, 0.01;
  (Cellular phase NSHD, Present) 0.00, 0.99, 0.01;
  (Syncytial NSHD, Present) 0.00, 0.99, 0.01;
  (Mixed cellularity HD, Present) 0.00, 0.99, 0.01;
  (Interfollicular HD, Present) 0.00, 0.99, 0.01;
  (Diffuse fibrosis HD, Present) 0.00, 0.99, 0.01;
  (Reticular-type HD, Present) 0.00, 0.99, 0.01;
  (Small cleaved fol, Present) 0.00, 0.99, 0.01;
  (Mixed fol, Present) 0.00, 0.99, 0.01;
  (Large cell fol, Present) 0.00, 0.99, 0.01;
  (Small noncleaved fol, Present) 0.00, 0.99, 0.01;
  (Small lymphocytic, Present) 0.00, 0.99, 0.01;
  (Plasmacytoid lyctic, Present) 0.00, 0.99, 0.01;
  (Mantle zone lymphoma, Present) 0.00, 0.99, 0.01;
  (Small cleaved dif, Present) 0.00, 0.99, 0.01;
  (Mixed FCC dif, Present) 0.00, 0.99, 0.01;
  (Large cell dif, Present) 0.00, 0.99, 0.01;
  (B-immunoblastic, Present) 0.00, 0.99, 0.01;
  (T-immunob mixed, Present) 0.00, 0.99, 0.01;
  (AILD-like T-cell lym, Present) 0.00, 0.99, 0.01;
  (Japanese ATL, Present) 0.00, 0.99, 0.01;
  (Lymphoblastic, Present) 0.00, 0.99, 0.01;
  (Small noncleaved dif, Present) 0.00, 0.99, 0.01;
  (True histiocytic, Present) 0.00, 0.99, 0.01;
  (Ki-1 LC anaplas T, Present) 0.00, 0.99, 0.01;
  (Multiple myeloma, Present) 0.00, 0.99, 0.01;
  (Mycosis fungoides, Present) 0.00, 0.99, 0.01;
  (AML, Present) 0.00, 0.99, 0.01;
  (Hairy cell leukemia, Present) 0.00, 0.99, 0.01;
  (Carcinoma, Present) 0.00, 0.99, 0.01;
  (Melanoma, Present) 0.00, 0.99, 0.01;
  (EM plasmacytoma, Present) 0.00, 0.99, 0.01;
  (Kaposi's sarcoma, Present) 0.00, 0.99, 0.01;
  (Mast-cell disease, Present) 0.00, 0.99, 0.01;
  (AIDS involutionary, Present) 0.00, 0.85, 0.15;
  (T-immunob large, Present) 0.00, 0.99, 0.01;
  (Monocytoid B-cell, Present) 0.00, 0.99, 0.01;
  (Nasopharyngeal CA, Present) 0.00, 0.99, 0.01;
  (Seminoma, Present) 0.00, 0.99, 0.01;
  (SLE, Present) 0.00, 0.99, 0.01;
  (Mycobact histiocytos, Present) 0.0, 0.9, 0.1;
  (Mast-cell hyperplas, Present) 0.00, 0.99, 0.01;
  (LGV, Present) 0.00, 0.99, 0.01;
  (Histoplasmosis, Present) 0.0, 0.9, 0.1;
  (Coccidioidomycosis, Present) 0.0, 0.9, 0.1;
  (CMV, Present) 0.0, 0.9, 0.1;
  (Brucellosis, Present) 0.00, 0.99, 0.01;
  (Ki-1 LC anaplas B, Present) 0.00, 0.99, 0.01;
  (Intermed lymphocytic, Present) 0.00, 0.99, 0.01;
}
probability ( F_POL | Fault, FOLLICLE ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0;
  (AIDS early, 1-25pc) 0.00, 0.05, 0.95;
  (AILD, 1-25pc) 0.00, 0.99, 0.01;
  (ALIP, 1-25pc) 0.00, 0.98, 0.02;
  (Cat scratch disease, 1-25pc) 0.0, 0.9, 0.1;
  (Dermatopathic laden, 1-25pc) 0.00, 0.95, 0.05;
  (Florid follic hyperp, 1-25pc) 0.0, 0.8, 0.2;
  (GLH hyaline vascular, 1-25pc) 0.00, 0.99, 0.01;
  (GLH plasma cell, 1-25pc) 0.0, 0.8, 0.2;
  (Granulomatous laden, 1-25pc) 0.00, 0.95, 0.05;
  (Histiocytosis x, 1-25pc) 0.00, 0.98, 0.02;
  (Infectious mono, 1-25pc) 0.0, 0.9, 0.1;
  (Leprosy-lepromatous, 1-25pc) 0.00, 0.98, 0.02;
  (Lymphangiographic, 1-25pc) 0.00, 0.98, 0.02;
  (Mantle zone hyperpla, 1-25pc) 0.00, 0.98, 0.02;
  (Necrotizing Kikuchi, 1-25pc) 0.0, 0.9, 0.1;
  (Necrotiz non-Kikuchi, 1-25pc) 0.0, 0.9, 0.1;
  (Rheumatoid arthritis, 1-25pc) 0.0, 0.8, 0.2;
  (Sarcoidosis, 1-25pc) 0.00, 0.98, 0.02;
  (SHML, 1-25pc) 0.00, 0.98, 0.02;
  (Sinus histiocytosis, 1-25pc) 0.00, 0.98, 0.02;
  (Syphilis, 1-25pc) 0.00, 0.95, 0.05;
  (Toxoplasmosis, 1-25pc) 0.00, 0.95, 0.05;
  (Tuberculosis, 1-25pc) 0.00, 0.98, 0.02;
  (Viral NOS, 1-25pc) 0.0, 0.9, 0.1;
  (Whipple's disease, 1-25pc) 0.00, 0.98, 0.02;
  (L&H nodular HD, 1-25pc) 0.00, 0.98, 0.02;
  (L&H diffuse HD, 1-25pc) 0.00, 0.98, 0.02;
  (Nodular sclerosis HD, 1-25pc) 0.00, 0.98, 0.02;
  (Cellular phase NSHD, 1-25pc) 0.00, 0.99, 0.01;
  (Syncytial NSHD, 1-25pc) 0.00, 0.99, 0.01;
  (Mixed cellularity HD, 1-25pc) 0.00, 0.99, 0.01;
  (Interfollicular HD, 1-25pc) 0.00, 0.98, 0.02;
  (Diffuse fibrosis HD, 1-25pc) 0.00, 0.98, 0.02;
  (Reticular-type HD, 1-25pc) 0.00, 0.98, 0.02;
  (Small cleaved fol, 1-25pc) 0.0, 1.0, 0.0;
  (Mixed fol, 1-25pc) 0.0, 1.0, 0.0;
  (Large cell fol, 1-25pc) 0.0, 1.0, 0.0;
  (Small noncleaved fol, 1-25pc) 0.0, 1.0, 0.0;
  (Small lymphocytic, 1-25pc) 0.00, 0.99, 0.01;
  (Plasmacytoid lyctic, 1-25pc) 0.00, 0.99, 0.01;
  (Mantle zone lymphoma, 1-25pc) 0.00, 0.98, 0.02;
  (Small cleaved dif, 1-25pc) 0.00, 0.99, 0.01;
  (Mixed FCC dif, 1-25pc) 0.00, 0.99, 0.01;
  (Large cell dif, 1-25pc) 0.00, 0.99, 0.01;
  (B-immunoblastic, 1-25pc) 0.00, 0.99, 0.01;
  (T-immunob mixed, 1-25pc) 0.00, 0.99, 0.01;
  (AILD-like T-cell lym, 1-25pc) 0.00, 0.99, 0.01;
  (Japanese ATL, 1-25pc) 0.00, 0.99, 0.01;
  (Lymphoblastic, 1-25pc) 0.00, 0.99, 0.01;
  (Small noncleaved dif, 1-25pc) 0.00, 0.99, 0.01;
  (True histiocytic, 1-25pc) 0.00, 0.99, 0.01;
  (Ki-1 LC anaplas T, 1-25pc) 0.00, 0.99, 0.01;
  (Multiple myeloma, 1-25pc) 0.00, 0.98, 0.02;
  (Mycosis fungoides, 1-25pc) 0.00, 0.98, 0.02;
  (AML, 1-25pc) 0.00, 0.98, 0.02;
  (Hairy cell leukemia, 1-25pc) 0.00, 0.98, 0.02;
  (Carcinoma, 1-25pc) 0.00, 0.98, 0.02;
  (Melanoma, 1-25pc) 0.00, 0.98, 0.02;
  (EM plasmacytoma, 1-25pc) 0.00, 0.99, 0.01;
  (Kaposi's sarcoma, 1-25pc) 0.0, 0.8, 0.2;
  (Mast-cell disease, 1-25pc) 0.00, 0.99, 0.01;
  (AIDS involutionary, 1-25pc) 0.0, 0.9, 0.1;
  (T-immunob large, 1-25pc) 0.00, 0.99, 0.01;
  (Monocytoid B-cell, 1-25pc) 0.0, 0.9, 0.1;
  (Nasopharyngeal CA, 1-25pc) 0.00, 0.98, 0.02;
  (Seminoma, 1-25pc) 0.00, 0.98, 0.02;
  (SLE, 1-25pc) 0.0, 0.9, 0.1;
  (Mycobact histiocytos, 1-25pc) 0.00, 0.95, 0.05;
  (Mast-cell hyperplas, 1-25pc) 0.00, 0.95, 0.05;
  (LGV, 1-25pc) 0.00, 0.95, 0.05;
  (Histoplasmosis, 1-25pc) 0.00, 0.95, 0.05;
  (Coccidioidomycosis, 1-25pc) 0.00, 0.95, 0.05;
  (CMV, 1-25pc) 0.00, 0.95, 0.05;
  (Brucellosis, 1-25pc) 0.00, 0.95, 0.05;
  (Ki-1 LC anaplas B, 1-25pc) 0.00, 0.99, 0.01;
  (Intermed lymphocytic, 1-25pc) 0.00, 0.98, 0.02;
  (AIDS early, 25-75pc) 0.00, 0.05, 0.95;
  (AILD, 25-75pc) 0.00, 0.99, 0.01;
  (ALIP, 25-75pc) 0.00, 0.98, 0.02;
  (Cat scratch disease, 25-75pc) 0.0, 0.9, 0.1;
  (Dermatopathic laden, 25-75pc) 0.00, 0.95, 0.05;
  (Florid follic hyperp, 25-75pc) 0.0, 0.8, 0.2;
  (GLH hyaline vascular, 25-75pc) 0.00, 0.99, 0.01;
  (GLH plasma cell, 25-75pc) 0.0, 0.8, 0.2;
  (Granulomatous laden, 25-75pc) 0.00, 0.95, 0.05;
  (Histiocytosis x, 25-75pc) 0.00, 0.98, 0.02;
  (Infectious mono, 25-75pc) 0.0, 0.9, 0.1;
  (Leprosy-lepromatous, 25-75pc) 0.00, 0.98, 0.02;
  (Lymphangiographic, 25-75pc) 0.00, 0.98, 0.02;
  (Mantle zone hyperpla, 25-75pc) 0.00, 0.98, 0.02;
  (Necrotizing Kikuchi, 25-75pc) 0.0, 0.9, 0.1;
  (Necrotiz non-Kikuchi, 25-75pc) 0.0, 0.9, 0.1;
  (Rheumatoid arthritis, 25-75pc) 0.0, 0.8, 0.2;
  (Sarcoidosis, 25-75pc) 0.00, 0.98, 0.02;
  (SHML, 25-75pc) 0.00, 0.98, 0.02;
  (Sinus histiocytosis, 25-75pc) 0.00, 0.98, 0.02;
  (Syphilis, 25-75pc) 0.00, 0.95, 0.05;
  (Toxoplasmosis, 25-75pc) 0.00, 0.95, 0.05;
  (Tuberculosis, 25-75pc) 0.00, 0.98, 0.02;
  (Viral NOS, 25-75pc) 0.0, 0.9, 0.1;
  (Whipple's disease, 25-75pc) 0.00, 0.98, 0.02;
  (L&H nodular HD, 25-75pc) 0.00, 0.98, 0.02;
  (L&H diffuse HD, 25-75pc) 0.00, 0.98, 0.02;
  (Nodular sclerosis HD, 25-75pc) 0.00, 0.98, 0.02;
  (Cellular phase NSHD, 25-75pc) 0.00, 0.99, 0.01;
  (Syncytial NSHD, 25-75pc) 0.00, 0.99, 0.01;
  (Mixed cellularity HD, 25-75pc) 0.00, 0.99, 0.01;
  (Interfollicular HD, 25-75pc) 0.00, 0.98, 0.02;
  (Diffuse fibrosis HD, 25-75pc) 0.00, 0.98, 0.02;
  (Reticular-type HD, 25-75pc) 0.00, 0.98, 0.02;
  (Small cleaved fol, 25-75pc) 0.0, 1.0, 0.0;
  (Mixed fol, 25-75pc) 0.0, 1.0, 0.0;
  (Large cell fol, 25-75pc) 0.0, 1.0, 0.0;
  (Small noncleaved fol, 25-75pc) 0.0, 1.0, 0.0;
  (Small lymphocytic, 25-75pc) 0.00, 0.99, 0.01;
  (Plasmacytoid lyctic, 25-75pc) 0.00, 0.99, 0.01;
  (Mantle zone lymphoma, 25-75pc) 0.00, 0.98, 0.02;
  (Small cleaved dif, 25-75pc) 0.00, 0.99, 0.01;
  (Mixed FCC dif, 25-75pc) 0.00, 0.99, 0.01;
  (Large cell dif, 25-75pc) 0.00, 0.99, 0.01;
  (B-immunoblastic, 25-75pc) 0.00, 0.99, 0.01;
  (T-immunob mixed, 25-75pc) 0.00, 0.99, 0.01;
  (AILD-like T-cell lym, 25-75pc) 0.00, 0.99, 0.01;
  (Japanese ATL, 25-75pc) 0.00, 0.99, 0.01;
  (Lymphoblastic, 25-75pc) 0.00, 0.99, 0.01;
  (Small noncleaved dif, 25-75pc) 0.00, 0.99, 0.01;
  (True histiocytic, 25-75pc) 0.00, 0.99, 0.01;
  (Ki-1 LC anaplas T, 25-75pc) 0.00, 0.99, 0.01;
  (Multiple myeloma, 25-75pc) 0.00, 0.98, 0.02;
  (Mycosis fungoides, 25-75pc) 0.00, 0.98, 0.02;
  (AML, 25-75pc) 0.00, 0.98, 0.02;
  (Hairy cell leukemia, 25-75pc) 0.00, 0.98, 0.02;
  (Carcinoma, 25-75pc) 0.00, 0.98, 0.02;
  (Melanoma, 25-75pc) 0.00, 0.98, 0.02;
  (EM plasmacytoma, 25-75pc) 0.00, 0.99, 0.01;
  (Kaposi's sarcoma, 25-75pc) 0.0, 0.8, 0.2;
  (Mast-cell disease, 25-75pc) 0.00, 0.99, 0.01;
  (AIDS involutionary, 25-75pc) 0.0, 0.9, 0.1;
  (T-immunob large, 25-75pc) 0.00, 0.99, 0.01;
  (Monocytoid B-cell, 25-75pc) 0.0, 0.9, 0.1;
  (Nasopharyngeal CA, 25-75pc) 0.00, 0.98, 0.02;
  (Seminoma, 25-75pc) 0.00, 0.98, 0.02;
  (SLE, 25-75pc) 0.0, 0.9, 0.1;
  (Mycobact histiocytos, 25-75pc) 0.00, 0.95, 0.05;
  (Mast-cell hyperplas, 25-75pc) 0.00, 0.95, 0.05;
  (LGV, 25-75pc) 0.00, 0.95, 0.05;
  (Histoplasmosis, 25-75pc) 0.00, 0.95, 0.05;
  (Coccidioidomycosis, 25-75pc) 0.00, 0.95, 0.05;
  (CMV, 25-75pc) 0.00, 0.95, 0.05;
  (Brucellosis, 25-75pc) 0.00, 0.95, 0.05;
  (Ki-1 LC anaplas B, 25-75pc) 0.00, 0.99, 0.01;
  (Intermed lymphocytic, 25-75pc) 0.00, 0.98, 0.02;
  (AIDS early, 75-90pc) 0.00, 0.05, 0.95;
  (AILD, 75-90pc) 0.00, 0.99, 0.01;
  (ALIP, 75-90pc) 0.00, 0.98, 0.02;
  (Cat scratch disease, 75-90pc) 0.0, 0.9, 0.1;
  (Dermatopathic laden, 75-90pc) 0.00, 0.95, 0.05;
  (Florid follic hyperp, 75-90pc) 0.0, 0.8, 0.2;
  (GLH hyaline vascular, 75-90pc) 0.00, 0.99, 0.01;
  (GLH plasma cell, 75-90pc) 0.0, 0.8, 0.2;
  (Granulomatous laden, 75-90pc) 0.00, 0.95, 0.05;
  (Histiocytosis x, 75-90pc) 0.00, 0.98, 0.02;
  (Infectious mono, 75-90pc) 0.0, 0.9, 0.1;
  (Leprosy-lepromatous, 75-90pc) 0.00, 0.98, 0.02;
  (Lymphangiographic, 75-90pc) 0.00, 0.98, 0.02;
  (Mantle zone hyperpla, 75-90pc) 0.00, 0.98, 0.02;
  (Necrotizing Kikuchi, 75-90pc) 0.0, 0.9, 0.1;
  (Necrotiz non-Kikuchi, 75-90pc) 0.0, 0.9, 0.1;
  (Rheumatoid arthritis, 75-90pc) 0.0, 0.8, 0.2;
  (Sarcoidosis, 75-90pc) 0.00, 0.98, 0.02;
  (SHML, 75-90pc) 0.00, 0.98, 0.02;
  (Sinus histiocytosis, 75-90pc) 0.00, 0.98, 0.02;
  (Syphilis, 75-90pc) 0.00, 0.95, 0.05;
  (Toxoplasmosis, 75-90pc) 0.00, 0.95, 0.05;
  (Tuberculosis, 75-90pc) 0.00, 0.98, 0.02;
  (Viral NOS, 75-90pc) 0.0, 0.9, 0.1;
  (Whipple's disease, 75-90pc) 0.00, 0.98, 0.02;
  (L&H nodular HD, 75-90pc) 0.00, 0.98, 0.02;
  (L&H diffuse HD, 75-90pc) 0.00, 0.98, 0.02;
  (Nodular sclerosis HD, 75-90pc) 0.00, 0.98, 0.02;
  (Cellular phase NSHD, 75-90pc) 0.00, 0.99, 0.01;
  (Syncytial NSHD, 75-90pc) 0.00, 0.99, 0.01;
  (Mixed cellularity HD, 75-90pc) 0.00, 0.99, 0.01;
  (Interfollicular HD, 75-90pc) 0.00, 0.98, 0.02;
  (Diffuse fibrosis HD, 75-90pc) 0.00, 0.98, 0.02;
  (Reticular-type HD, 75-90pc) 0.00, 0.98, 0.02;
  (Small cleaved fol, 75-90pc) 0.0, 1.0, 0.0;
  (Mixed fol, 75-90pc) 0.0, 1.0, 0.0;
  (Large cell fol, 75-90pc) 0.0, 1.0, 0.0;
  (Small noncleaved fol, 75-90pc) 0.0, 1.0, 0.0;
  (Small lymphocytic, 75-90pc) 0.00, 0.99, 0.01;
  (Plasmacytoid lyctic, 75-90pc) 0.00, 0.99, 0.01;
  (Mantle zone lymphoma, 75-90pc) 0.00, 0.98, 0.02;
  (Small cleaved dif, 75-90pc) 0.00, 0.99, 0.01;
  (Mixed FCC dif, 75-90pc) 0.00, 0.99, 0.01;
  (Large cell dif, 75-90pc) 0.00, 0.99, 0.01;
  (B-immunoblastic, 75-90pc) 0.00, 0.99, 0.01;
  (T-immunob mixed, 75-90pc) 0.00, 0.99, 0.01;
  (AILD-like T-cell lym, 75-90pc) 0.00, 0.99, 0.01;
  (Japanese ATL, 75-90pc) 0.00, 0.99, 0.01;
  (Lymphoblastic, 75-90pc) 0.00, 0.99, 0.01;
  (Small noncleaved dif, 75-90pc) 0.00, 0.99, 0.01;
  (True histiocytic, 75-90pc) 0.00, 0.99, 0.01;
  (Ki-1 LC anaplas T, 75-90pc) 0.00, 0.99, 0.01;
  (Multiple myeloma, 75-90pc) 0.00, 0.98, 0.02;
  (Mycosis fungoides, 75-90pc) 0.00, 0.98, 0.02;
  (AML, 75-90pc) 0.00, 0.98, 0.02;
  (Hairy cell leukemia, 75-90pc) 0.00, 0.98, 0.02;
  (Carcinoma, 75-90pc) 0.00, 0.98, 0.02;
  (Melanoma, 75-90pc) 0.00, 0.98, 0.02;
  (EM plasmacytoma, 75-90pc) 0.00, 0.99, 0.01;
  (Kaposi's sarcoma, 75-90pc) 0.0, 0.8, 0.2;
  (Mast-cell disease, 75-90pc) 0.00, 0.99, 0.01;
  (AIDS involutionary, 75-90pc) 0.0, 0.9, 0.1;
  (T-immunob large, 75-90pc) 0.00, 0.99, 0.01;
  (Monocytoid B-cell, 75-90pc) 0.0, 0.9, 0.1;
  (Nasopharyngeal CA, 75-90pc) 0.00, 0.98, 0.02;
  (Seminoma, 75-90pc) 0.00, 0.98, 0.02;
  (SLE, 75-90pc) 0.0, 0.9, 0.1;
  (Mycobact histiocytos, 75-90pc) 0.00, 0.95, 0.05;
  (Mast-cell hyperplas, 75-90pc) 0.00, 0.95, 0.05;
  (LGV, 75-90pc) 0.00, 0.95, 0.05;
  (Histoplasmosis, 75-90pc) 0.00, 0.95, 0.05;
  (Coccidioidomycosis, 75-90pc) 0.00, 0.95, 0.05;
  (CMV, 75-90pc) 0.00, 0.95, 0.05;
  (Brucellosis, 75-90pc) 0.00, 0.95, 0.05;
  (Ki-1 LC anaplas B, 75-90pc) 0.00, 0.99, 0.01;
  (Intermed lymphocytic, 75-90pc) 0.00, 0.98, 0.02;
  (AIDS early, >90pc) 0.00, 0.05, 0.95;
  (AILD, >90pc) 0.00, 0.99, 0.01;
  (ALIP, >90pc) 0.00, 0.98, 0.02;
  (Cat scratch disease, >90pc) 0.0, 0.9, 0.1;
  (Dermatopathic laden, >90pc) 0.00, 0.95, 0.05;
  (Florid follic hyperp, >90pc) 0.0, 0.8, 0.2;
  (GLH hyaline vascular, >90pc) 0.00, 0.99, 0.01;
  (GLH plasma cell, >90pc) 0.0, 0.8, 0.2;
  (Granulomatous laden, >90pc) 0.00, 0.95, 0.05;
  (Histiocytosis x, >90pc) 0.00, 0.98, 0.02;
  (Infectious mono, >90pc) 0.0, 0.9, 0.1;
  (Leprosy-lepromatous, >90pc) 0.00, 0.98, 0.02;
  (Lymphangiographic, >90pc) 0.00, 0.98, 0.02;
  (Mantle zone hyperpla, >90pc) 0.00, 0.98, 0.02;
  (Necrotizing Kikuchi, >90pc) 0.0, 0.9, 0.1;
  (Necrotiz non-Kikuchi, >90pc) 0.0, 0.9, 0.1;
  (Rheumatoid arthritis, >90pc) 0.0, 0.8, 0.2;
  (Sarcoidosis, >90pc) 0.00, 0.98, 0.02;
  (SHML, >90pc) 0.00, 0.98, 0.02;
  (Sinus histiocytosis, >90pc) 0.00, 0.98, 0.02;
  (Syphilis, >90pc) 0.00, 0.95, 0.05;
  (Toxoplasmosis, >90pc) 0.00, 0.95, 0.05;
  (Tuberculosis, >90pc) 0.00, 0.98, 0.02;
  (Viral NOS, >90pc) 0.0, 0.9, 0.1;
  (Whipple's disease, >90pc) 0.00, 0.98, 0.02;
  (L&H nodular HD, >90pc) 0.00, 0.98, 0.02;
  (L&H diffuse HD, >90pc) 0.00, 0.98, 0.02;
  (Nodular sclerosis HD, >90pc) 0.00, 0.98, 0.02;
  (Cellular phase NSHD, >90pc) 0.00, 0.99, 0.01;
  (Syncytial NSHD, >90pc) 0.00, 0.99, 0.01;
  (Mixed cellularity HD, >90pc) 0.00, 0.99, 0.01;
  (Interfollicular HD, >90pc) 0.00, 0.98, 0.02;
  (Diffuse fibrosis HD, >90pc) 0.00, 0.98, 0.02;
  (Reticular-type HD, >90pc) 0.00, 0.98, 0.02;
  (Small cleaved fol, >90pc) 0.0, 1.0, 0.0;
  (Mixed fol, >90pc) 0.0, 1.0, 0.0;
  (Large cell fol, >90pc) 0.0, 1.0, 0.0;
  (Small noncleaved fol, >90pc) 0.0, 1.0, 0.0;
  (Small lymphocytic, >90pc) 0.00, 0.99, 0.01;
  (Plasmacytoid lyctic, >90pc) 0.00, 0.99, 0.01;
  (Mantle zone lymphoma, >90pc) 0.00, 0.98, 0.02;
  (Small cleaved dif, >90pc) 0.00, 0.99, 0.01;
  (Mixed FCC dif, >90pc) 0.00, 0.99, 0.01;
  (Large cell dif, >90pc) 0.00, 0.99, 0.01;
  (B-immunoblastic, >90pc) 0.00, 0.99, 0.01;
  (T-immunob mixed, >90pc) 0.00, 0.99, 0.01;
  (AILD-like T-cell lym, >90pc) 0.00, 0.99, 0.01;
  (Japanese ATL, >90pc) 0.00, 0.99, 0.01;
  (Lymphoblastic, >90pc) 0.00, 0.99, 0.01;
  (Small noncleaved dif, >90pc) 0.00, 0.99, 0.01;
  (True histiocytic, >90pc) 0.00, 0.99, 0.01;
  (Ki-1 LC anaplas T, >90pc) 0.00, 0.99, 0.01;
  (Multiple myeloma, >90pc) 0.00, 0.98, 0.02;
  (Mycosis fungoides, >90pc) 0.00, 0.98, 0.02;
  (AML, >90pc) 0.00, 0.98, 0.02;
  (Hairy cell leukemia, >90pc) 0.00, 0.98, 0.02;
  (Carcinoma, >90pc) 0.00, 0.98, 0.02;
  (Melanoma, >90pc) 0.00, 0.98, 0.02;
  (EM plasmacytoma, >90pc) 0.00, 0.99, 0.01;
  (Kaposi's sarcoma, >90pc) 0.0, 0.8, 0.2;
  (Mast-cell disease, >90pc) 0.00, 0.99, 0.01;
  (AIDS involutionary, >90pc) 0.0, 0.9, 0.1;
  (T-immunob large, >90pc) 0.00, 0.99, 0.01;
  (Monocytoid B-cell, >90pc) 0.0, 0.9, 0.1;
  (Nasopharyngeal CA, >90pc) 0.00, 0.98, 0.02;
  (Seminoma, >90pc) 0.00, 0.98, 0.02;
  (SLE, >90pc) 0.0, 0.9, 0.1;
  (Mycobact histiocytos, >90pc) 0.00, 0.95, 0.05;
  (Mast-cell hyperplas, >90pc) 0.00, 0.95, 0.05;
  (LGV, >90pc) 0.00, 0.95, 0.05;
  (Histoplasmosis, >90pc) 0.00, 0.95, 0.05;
  (Coccidioidomycosis, >90pc) 0.00, 0.95, 0.05;
  (CMV, >90pc) 0.00, 0.95, 0.05;
  (Brucellosis, >90pc) 0.00, 0.95, 0.05;
  (Ki-1 LC anaplas B, >90pc) 0.00, 0.99, 0.01;
  (Intermed lymphocytic, >90pc) 0.00, 0.98, 0.02;
}
probability ( F_RPBV | Fault, F_CSA ) {
  (AIDS early, No follicles) 1.0, 0.0, 0.0, 0.0;
  (AILD, No follicles) 1.0, 0.0, 0.0, 0.0;
  (ALIP, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, No follicles) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, No follicles) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, No follicles) 1.0, 0.0, 0.0, 0.0;
  (SHML, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, No follicles) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, No follicles) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, No follicles) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, No follicles) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, No follicles) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, No follicles) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, No follicles) 1.0, 0.0, 0.0, 0.0;
  (AML, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, No follicles) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, No follicles) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, No follicles) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, No follicles) 1.0, 0.0, 0.0, 0.0;
  (SLE, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, No follicles) 1.0, 0.0, 0.0, 0.0;
  (LGV, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, No follicles) 1.0, 0.0, 0.0, 0.0;
  (CMV, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, No follicles) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, Absent) 0.000, 0.989, 0.010, 0.001;
  (AILD, Absent) 0.000, 0.989, 0.010, 0.001;
  (ALIP, Absent) 0.000, 0.989, 0.010, 0.001;
  (Cat scratch disease, Absent) 0.000, 0.989, 0.010, 0.001;
  (Dermatopathic laden, Absent) 0.000, 0.989, 0.010, 0.001;
  (Florid follic hyperp, Absent) 0.000, 0.989, 0.010, 0.001;
  (GLH hyaline vascular, Absent) 0.00000, 0.00001, 0.02000, 0.97999;
  (GLH plasma cell, Absent) 0.000, 0.988, 0.010, 0.002;
  (Granulomatous laden, Absent) 0.000, 0.989, 0.010, 0.001;
  (Histiocytosis x, Absent) 0.000, 0.989, 0.010, 0.001;
  (Infectious mono, Absent) 0.000, 0.989, 0.010, 0.001;
  (Leprosy-lepromatous, Absent) 0.000, 0.989, 0.010, 0.001;
  (Lymphangiographic, Absent) 0.000, 0.989, 0.010, 0.001;
  (Mantle zone hyperpla, Absent) 0.000, 0.989, 0.010, 0.001;
  (Necrotizing Kikuchi, Absent) 0.000, 0.989, 0.010, 0.001;
  (Necrotiz non-Kikuchi, Absent) 0.000, 0.989, 0.010, 0.001;
  (Rheumatoid arthritis, Absent) 0.000, 0.989, 0.010, 0.001;
  (Sarcoidosis, Absent) 0.000, 0.989, 0.010, 0.001;
  (SHML, Absent) 0.000, 0.989, 0.010, 0.001;
  (Sinus histiocytosis, Absent) 0.000, 0.989, 0.010, 0.001;
  (Syphilis, Absent) 0.000, 0.989, 0.010, 0.001;
  (Toxoplasmosis, Absent) 0.000, 0.989, 0.010, 0.001;
  (Tuberculosis, Absent) 0.000, 0.989, 0.010, 0.001;
  (Viral NOS, Absent) 0.000, 0.989, 0.010, 0.001;
  (Whipple's disease, Absent) 0.000, 0.989, 0.010, 0.001;
  (L&H nodular HD, Absent) 0.000, 0.989, 0.010, 0.001;
  (L&H diffuse HD, Absent) 0.000, 0.989, 0.010, 0.001;
  (Nodular sclerosis HD, Absent) 0.000, 0.989, 0.010, 0.001;
  (Cellular phase NSHD, Absent) 0.000, 0.989, 0.010, 0.001;
  (Syncytial NSHD, Absent) 0.000, 0.989, 0.010, 0.001;
  (Mixed cellularity HD, Absent) 0.000, 0.989, 0.010, 0.001;
  (Interfollicular HD, Absent) 0.000, 0.989, 0.010, 0.001;
  (Diffuse fibrosis HD, Absent) 0.000, 0.989, 0.010, 0.001;
  (Reticular-type HD, Absent) 0.000, 0.989, 0.010, 0.001;
  (Small cleaved fol, Absent) 0.0000, 0.9998, 0.0001, 0.0001;
  (Mixed fol, Absent) 0.0000, 0.9998, 0.0001, 0.0001;
  (Large cell fol, Absent) 0.0000, 0.9998, 0.0001, 0.0001;
  (Small noncleaved fol, Absent) 0.0000, 0.9998, 0.0001, 0.0001;
  (Small lymphocytic, Absent) 0.000, 0.989, 0.010, 0.001;
  (Plasmacytoid lyctic, Absent) 0.000, 0.989, 0.010, 0.001;
  (Mantle zone lymphoma, Absent) 0.000, 0.989, 0.010, 0.001;
  (Small cleaved dif, Absent) 0.000, 0.989, 0.010, 0.001;
  (Mixed FCC dif, Absent) 0.000, 0.989, 0.010, 0.001;
  (Large cell dif, Absent) 0.000, 0.989, 0.010, 0.001;
  (B-immunoblastic, Absent) 0.000, 0.989, 0.010, 0.001;
  (T-immunob mixed, Absent) 0.000, 0.989, 0.010, 0.001;
  (AILD-like T-cell lym, Absent) 0.000, 0.989, 0.010, 0.001;
  (Japanese ATL, Absent) 0.000, 0.989, 0.010, 0.001;
  (Lymphoblastic, Absent) 0.000, 0.989, 0.010, 0.001;
  (Small noncleaved dif, Absent) 0.000, 0.989, 0.010, 0.001;
  (True histiocytic, Absent) 0.000, 0.989, 0.010, 0.001;
  (Ki-1 LC anaplas T, Absent) 0.000, 0.989, 0.010, 0.001;
  (Multiple myeloma, Absent) 0.000, 0.989, 0.010, 0.001;
  (Mycosis fungoides, Absent) 0.000, 0.989, 0.010, 0.001;
  (AML, Absent) 0.000, 0.989, 0.010, 0.001;
  (Hairy cell leukemia, Absent) 0.000, 0.989, 0.010, 0.001;
  (Carcinoma, Absent) 0.000, 0.989, 0.010, 0.001;
  (Melanoma, Absent) 0.000, 0.989, 0.010, 0.001;
  (EM plasmacytoma, Absent) 0.000, 0.989, 0.010, 0.001;
  (Kaposi's sarcoma, Absent) 0.000, 0.988, 0.010, 0.002;
  (Mast-cell disease, Absent) 0.000, 0.989, 0.010, 0.001;
  (AIDS involutionary, Absent) 0.000, 0.988, 0.010, 0.002;
  (T-immunob large, Absent) 0.000, 0.989, 0.010, 0.001;
  (Monocytoid B-cell, Absent) 0.0000, 0.9989, 0.0010, 0.0001;
  (Nasopharyngeal CA, Absent) 0.000, 0.989, 0.010, 0.001;
  (Seminoma, Absent) 0.000, 0.989, 0.010, 0.001;
  (SLE, Absent) 0.000, 0.989, 0.010, 0.001;
  (Mycobact histiocytos, Absent) 0.000, 0.988, 0.010, 0.002;
  (Mast-cell hyperplas, Absent) 0.000, 0.989, 0.010, 0.001;
  (LGV, Absent) 0.000, 0.989, 0.010, 0.001;
  (Histoplasmosis, Absent) 0.000, 0.988, 0.010, 0.002;
  (Coccidioidomycosis, Absent) 0.000, 0.988, 0.010, 0.002;
  (CMV, Absent) 0.000, 0.988, 0.010, 0.002;
  (Brucellosis, Absent) 0.000, 0.989, 0.010, 0.001;
  (Ki-1 LC anaplas B, Absent) 0.000, 0.989, 0.010, 0.001;
  (Intermed lymphocytic, Absent) 0.000, 0.989, 0.010, 0.001;
  (AIDS early, Present) 0.000, 0.989, 0.010, 0.001;
  (AILD, Present) 0.000, 0.989, 0.010, 0.001;
  (ALIP, Present) 0.000, 0.989, 0.010, 0.001;
  (Cat scratch disease, Present) 0.000, 0.989, 0.010, 0.001;
  (Dermatopathic laden, Present) 0.000, 0.989, 0.010, 0.001;
  (Florid follic hyperp, Present) 0.000, 0.989, 0.010, 0.001;
  (GLH hyaline vascular, Present) 0.00000, 0.00001, 0.02000, 0.97999;
  (GLH plasma cell, Present) 0.000, 0.988, 0.010, 0.002;
  (Granulomatous laden, Present) 0.000, 0.989, 0.010, 0.001;
  (Histiocytosis x, Present) 0.000, 0.989, 0.010, 0.001;
  (Infectious mono, Present) 0.000, 0.989, 0.010, 0.001;
  (Leprosy-lepromatous, Present) 0.000, 0.989, 0.010, 0.001;
  (Lymphangiographic, Present) 0.000, 0.989, 0.010, 0.001;
  (Mantle zone hyperpla, Present) 0.000, 0.989, 0.010, 0.001;
  (Necrotizing Kikuchi, Present) 0.000, 0.989, 0.010, 0.001;
  (Necrotiz non-Kikuchi, Present) 0.000, 0.989, 0.010, 0.001;
  (Rheumatoid arthritis, Present) 0.000, 0.989, 0.010, 0.001;
  (Sarcoidosis, Present) 0.000, 0.989, 0.010, 0.001;
  (SHML, Present) 0.000, 0.989, 0.010, 0.001;
  (Sinus histiocytosis, Present) 0.000, 0.989, 0.010, 0.001;
  (Syphilis, Present) 0.000, 0.989, 0.010, 0.001;
  (Toxoplasmosis, Present) 0.000, 0.989, 0.010, 0.001;
  (Tuberculosis, Present) 0.000, 0.989, 0.010, 0.001;
  (Viral NOS, Present) 0.000, 0.989, 0.010, 0.001;
  (Whipple's disease, Present) 0.000, 0.989, 0.010, 0.001;
  (L&H nodular HD, Present) 0.000, 0.989, 0.010, 0.001;
  (L&H diffuse HD, Present) 0.000, 0.989, 0.010, 0.001;
  (Nodular sclerosis HD, Present) 0.000, 0.989, 0.010, 0.001;
  (Cellular phase NSHD, Present) 0.000, 0.989, 0.010, 0.001;
  (Syncytial NSHD, Present) 0.000, 0.989, 0.010, 0.001;
  (Mixed cellularity HD, Present) 0.000, 0.989, 0.010, 0.001;
  (Interfollicular HD, Present) 0.000, 0.989, 0.010, 0.001;
  (Diffuse fibrosis HD, Present) 0.000, 0.989, 0.010, 0.001;
  (Reticular-type HD, Present) 0.000, 0.989, 0.010, 0.001;
  (Small cleaved fol, Present) 0.0000, 0.9998, 0.0001, 0.0001;
  (Mixed fol, Present) 0.0000, 0.9998, 0.0001, 0.0001;
  (Large cell fol, Present) 0.0000, 0.9998, 0.0001, 0.0001;
  (Small noncleaved fol, Present) 0.0000, 0.9998, 0.0001, 0.0001;
  (Small lymphocytic, Present) 0.000, 0.989, 0.010, 0.001;
  (Plasmacytoid lyctic, Present) 0.000, 0.989, 0.010, 0.001;
  (Mantle zone lymphoma, Present) 0.000, 0.989, 0.010, 0.001;
  (Small cleaved dif, Present) 0.000, 0.989, 0.010, 0.001;
  (Mixed FCC dif, Present) 0.000, 0.989, 0.010, 0.001;
  (Large cell dif, Present) 0.000, 0.989, 0.010, 0.001;
  (B-immunoblastic, Present) 0.000, 0.989, 0.010, 0.001;
  (T-immunob mixed, Present) 0.000, 0.989, 0.010, 0.001;
  (AILD-like T-cell lym, Present) 0.000, 0.989, 0.010, 0.001;
  (Japanese ATL, Present) 0.000, 0.989, 0.010, 0.001;
  (Lymphoblastic, Present) 0.000, 0.989, 0.010, 0.001;
  (Small noncleaved dif, Present) 0.000, 0.989, 0.010, 0.001;
  (True histiocytic, Present) 0.000, 0.989, 0.010, 0.001;
  (Ki-1 LC anaplas T, Present) 0.000, 0.989, 0.010, 0.001;
  (Multiple myeloma, Present) 0.000, 0.989, 0.010, 0.001;
  (Mycosis fungoides, Present) 0.000, 0.989, 0.010, 0.001;
  (AML, Present) 0.000, 0.989, 0.010, 0.001;
  (Hairy cell leukemia, Present) 0.000, 0.989, 0.010, 0.001;
  (Carcinoma, Present) 0.000, 0.989, 0.010, 0.001;
  (Melanoma, Present) 0.000, 0.989, 0.010, 0.001;
  (EM plasmacytoma, Present) 0.000, 0.989, 0.010, 0.001;
  (Kaposi's sarcoma, Present) 0.000, 0.988, 0.010, 0.002;
  (Mast-cell disease, Present) 0.000, 0.989, 0.010, 0.001;
  (AIDS involutionary, Present) 0.000, 0.988, 0.010, 0.002;
  (T-immunob large, Present) 0.000, 0.989, 0.010, 0.001;
  (Monocytoid B-cell, Present) 0.0000, 0.9989, 0.0010, 0.0001;
  (Nasopharyngeal CA, Present) 0.000, 0.989, 0.010, 0.001;
  (Seminoma, Present) 0.000, 0.989, 0.010, 0.001;
  (SLE, Present) 0.000, 0.989, 0.010, 0.001;
  (Mycobact histiocytos, Present) 0.000, 0.988, 0.010, 0.002;
  (Mast-cell hyperplas, Present) 0.000, 0.989, 0.010, 0.001;
  (LGV, Present) 0.000, 0.989, 0.010, 0.001;
  (Histoplasmosis, Present) 0.000, 0.988, 0.010, 0.002;
  (Coccidioidomycosis, Present) 0.000, 0.988, 0.010, 0.002;
  (CMV, Present) 0.000, 0.988, 0.010, 0.002;
  (Brucellosis, Present) 0.000, 0.989, 0.010, 0.001;
  (Ki-1 LC anaplas B, Present) 0.000, 0.989, 0.010, 0.001;
  (Intermed lymphocytic, Present) 0.000, 0.989, 0.010, 0.001;
}
probability ( BH_LANG | Fault ) {
  (AIDS early) 0.989, 0.010, 0.001, 0.000;
  (AILD) 0.989, 0.010, 0.001, 0.000;
  (ALIP) 0.989, 0.010, 0.001, 0.000;
  (Cat scratch disease) 0.989, 0.010, 0.001, 0.000;
  (Dermatopathic laden) 0.83, 0.02, 0.10, 0.05;
  (Florid follic hyperp) 0.989, 0.010, 0.001, 0.000;
  (GLH hyaline vascular) 0.989, 0.010, 0.001, 0.000;
  (GLH plasma cell) 0.989, 0.010, 0.001, 0.000;
  (Granulomatous laden) 0.989, 0.010, 0.001, 0.000;
  (Histiocytosis x) 0.00, 0.00, 0.05, 0.95;
  (Infectious mono) 0.989, 0.010, 0.001, 0.000;
  (Leprosy-lepromatous) 0.989, 0.010, 0.001, 0.000;
  (Lymphangiographic) 0.989, 0.010, 0.001, 0.000;
  (Mantle zone hyperpla) 0.989, 0.010, 0.001, 0.000;
  (Necrotizing Kikuchi) 0.989, 0.010, 0.001, 0.000;
  (Necrotiz non-Kikuchi) 0.989, 0.010, 0.001, 0.000;
  (Rheumatoid arthritis) 0.989, 0.010, 0.001, 0.000;
  (Sarcoidosis) 0.989, 0.010, 0.001, 0.000;
  (SHML) 0.989, 0.010, 0.001, 0.000;
  (Sinus histiocytosis) 0.989, 0.010, 0.001, 0.000;
  (Syphilis) 0.989, 0.010, 0.001, 0.000;
  (Toxoplasmosis) 0.989, 0.010, 0.001, 0.000;
  (Tuberculosis) 0.989, 0.010, 0.001, 0.000;
  (Viral NOS) 0.989, 0.010, 0.001, 0.000;
  (Whipple's disease) 0.989, 0.010, 0.001, 0.000;
  (L&H nodular HD) 0.989, 0.010, 0.001, 0.000;
  (L&H diffuse HD) 0.989, 0.010, 0.001, 0.000;
  (Nodular sclerosis HD) 0.989, 0.010, 0.001, 0.000;
  (Cellular phase NSHD) 0.989, 0.010, 0.001, 0.000;
  (Syncytial NSHD) 0.989, 0.010, 0.001, 0.000;
  (Mixed cellularity HD) 0.989, 0.010, 0.001, 0.000;
  (Interfollicular HD) 0.989, 0.010, 0.001, 0.000;
  (Diffuse fibrosis HD) 0.989, 0.010, 0.001, 0.000;
  (Reticular-type HD) 0.989, 0.010, 0.001, 0.000;
  (Small cleaved fol) 0.989, 0.010, 0.001, 0.000;
  (Mixed fol) 0.989, 0.010, 0.001, 0.000;
  (Large cell fol) 0.989, 0.010, 0.001, 0.000;
  (Small noncleaved fol) 0.989, 0.010, 0.001, 0.000;
  (Small lymphocytic) 0.989, 0.010, 0.001, 0.000;
  (Plasmacytoid lyctic) 0.989, 0.010, 0.001, 0.000;
  (Mantle zone lymphoma) 0.989, 0.010, 0.001, 0.000;
  (Small cleaved dif) 0.989, 0.010, 0.001, 0.000;
  (Mixed FCC dif) 0.989, 0.010, 0.001, 0.000;
  (Large cell dif) 0.989, 0.010, 0.001, 0.000;
  (B-immunoblastic) 0.989, 0.010, 0.001, 0.000;
  (T-immunob mixed) 0.989, 0.010, 0.001, 0.000;
  (AILD-like T-cell lym) 0.989, 0.010, 0.001, 0.000;
  (Japanese ATL) 0.989, 0.010, 0.001, 0.000;
  (Lymphoblastic) 0.989, 0.010, 0.001, 0.000;
  (Small noncleaved dif) 0.989, 0.010, 0.001, 0.000;
  (True histiocytic) 0.989, 0.010, 0.001, 0.000;
  (Ki-1 LC anaplas T) 0.989, 0.010, 0.001, 0.000;
  (Multiple myeloma) 0.989, 0.010, 0.001, 0.000;
  (Mycosis fungoides) 0.989, 0.010, 0.001, 0.000;
  (AML) 0.989, 0.010, 0.001, 0.000;
  (Hairy cell leukemia) 0.989, 0.010, 0.001, 0.000;
  (Carcinoma) 0.989, 0.010, 0.001, 0.000;
  (Melanoma) 0.989, 0.010, 0.001, 0.000;
  (EM plasmacytoma) 0.989, 0.010, 0.001, 0.000;
  (Kaposi's sarcoma) 0.989, 0.010, 0.001, 0.000;
  (Mast-cell disease) 0.989, 0.010, 0.001, 0.000;
  (AIDS involutionary) 0.989, 0.010, 0.001, 0.000;
  (T-immunob large) 0.989, 0.010, 0.001, 0.000;
  (Monocytoid B-cell) 0.989, 0.010, 0.001, 0.000;
  (Nasopharyngeal CA) 0.989, 0.010, 0.001, 0.000;
  (Seminoma) 0.989, 0.010, 0.001, 0.000;
  (SLE) 0.989, 0.010, 0.001, 0.000;
  (Mycobact histiocytos) 0.989, 0.010, 0.001, 0.000;
  (Mast-cell hyperplas) 0.989, 0.010, 0.001, 0.000;
  (LGV) 0.989, 0.010, 0.001, 0.000;
  (Histoplasmosis) 0.989, 0.010, 0.001, 0.000;
  (Coccidioidomycosis) 0.989, 0.010, 0.001, 0.000;
  (CMV) 0.989, 0.010, 0.001, 0.000;
  (Brucellosis) 0.989, 0.010, 0.001, 0.000;
  (Ki-1 LC anaplas B) 0.989, 0.010, 0.001, 0.000;
  (Intermed lymphocytic) 0.989, 0.010, 0.001, 0.000;
}
probability ( BH_FOAM | Fault ) {
  (AIDS early) 0.979020979, 0.019980020, 0.000999001, 0.000000000, 0.000000000;
  (AILD) 0.979020979, 0.019980020, 0.000999001, 0.000000000, 0.000000000;
  (ALIP) 0.979020979, 0.019980020, 0.000999001, 0.000000000, 0.000000000;
  (Cat scratch disease) 0.979020979, 0.019980020, 0.000999001, 0.000000000, 0.000000000;
  (Dermatopathic laden) 0.28, 0.40, 0.20, 0.10, 0.02;
  (Florid follic hyperp) 0.979020979, 0.019980020, 0.000999001, 0.000000000, 0.000000000;
  (GLH hyaline vascular) 0.979020979, 0.019980020, 0.000999001, 0.000000000, 0.000000000;
  (GLH plasma cell) 0.979020979, 0.019980020, 0.000999001, 0.000000000, 0.000000000;
  (Granulomatous laden) 0.699300699, 0.199800200, 0.099900100, 0.000999001, 0.000000000;
  (Histiocytosis x) 0.979020979, 0.019980020, 0.000999001, 0.000000000, 0.000000000;
  (Infectious mono) 0.979020979, 0.019980020, 0.000999001, 0.000000000, 0.000000000;
  (Leprosy-lepromatous) 0.01, 0.54, 0.25, 0.15, 0.05;
  (Lymphangiographic) 0.00, 0.01, 0.09, 0.60, 0.30;
  (Mantle zone hyperpla) 0.979020979, 0.019980020, 0.000999001, 0.000000000, 0.000000000;
  (Necrotizing Kikuchi) 0.4899, 0.4000, 0.1000, 0.0100, 0.0001;
  (Necrotiz non-Kikuchi) 0.4899, 0.4000, 0.1000, 0.0100, 0.0001;
  (Rheumatoid arthritis) 0.979020979, 0.019980020, 0.000999001, 0.000000000, 0.000000000;
  (Sarcoidosis) 0.979020979, 0.019980020, 0.000999001, 0.000000000, 0.000000000;
  (SHML) 0.979020979, 0.019980020, 0.000999001, 0.000000000, 0.000000000;
  (Sinus histiocytosis) 0.969, 0.020, 0.010, 0.001, 0.000;
  (Syphilis) 0.979020979, 0.019980020, 0.000999001, 0.000000000, 0.000000000;
  (Toxoplasmosis) 0.979020979, 0.019980020, 0.000999001, 0.000000000, 0.000000000;
  (Tuberculosis) 0.899100899, 0.089910090, 0.009990010, 0.000999001, 0.000000000;
  (Viral NOS) 0.979020979, 0.019980020, 0.000999001, 0.000000000, 0.000000000;
  (Whipple's disease) 0.00, 0.01, 0.09, 0.60, 0.30;
  (L&H nodular HD) 0.95, 0.01, 0.01, 0.02, 0.01;
  (L&H diffuse HD) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Nodular sclerosis HD) 0.94, 0.03, 0.02, 0.01, 0.00;
  (Cellular phase NSHD) 0.94, 0.03, 0.02, 0.01, 0.00;
  (Syncytial NSHD) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Mixed cellularity HD) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Interfollicular HD) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Diffuse fibrosis HD) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Reticular-type HD) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Small cleaved fol) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Mixed fol) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Large cell fol) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Small noncleaved fol) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Small lymphocytic) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Plasmacytoid lyctic) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Mantle zone lymphoma) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Small cleaved dif) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Mixed FCC dif) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Large cell dif) 0.95, 0.01, 0.01, 0.02, 0.01;
  (B-immunoblastic) 0.95, 0.01, 0.01, 0.02, 0.01;
  (T-immunob mixed) 0.95, 0.01, 0.01, 0.02, 0.01;
  (AILD-like T-cell lym) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Japanese ATL) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Lymphoblastic) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Small noncleaved dif) 0.95, 0.01, 0.01, 0.02, 0.01;
  (True histiocytic) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Ki-1 LC anaplas T) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Multiple myeloma) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Mycosis fungoides) 0.95, 0.01, 0.01, 0.02, 0.01;
  (AML) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Hairy cell leukemia) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Carcinoma) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Melanoma) 0.95, 0.01, 0.01, 0.02, 0.01;
  (EM plasmacytoma) 0.979020979, 0.019980020, 0.000999001, 0.000000000, 0.000000000;
  (Kaposi's sarcoma) 0.979020979, 0.019980020, 0.000999001, 0.000000000, 0.000000000;
  (Mast-cell disease) 0.979020979, 0.019980020, 0.000999001, 0.000000000, 0.000000000;
  (AIDS involutionary) 0.4899, 0.4000, 0.1000, 0.0100, 0.0001;
  (T-immunob large) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Monocytoid B-cell) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Nasopharyngeal CA) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Seminoma) 0.95, 0.01, 0.01, 0.02, 0.01;
  (SLE) 0.979020979, 0.019980020, 0.000999001, 0.000000000, 0.000000000;
  (Mycobact histiocytos) 0.20, 0.45, 0.20, 0.10, 0.05;
  (Mast-cell hyperplas) 0.979020979, 0.019980020, 0.000999001, 0.000000000, 0.000000000;
  (LGV) 0.979020979, 0.019980020, 0.000999001, 0.000000000, 0.000000000;
  (Histoplasmosis) 0.8999, 0.0500, 0.0300, 0.0200, 0.0001;
  (Coccidioidomycosis) 0.8999, 0.0500, 0.0300, 0.0200, 0.0001;
  (CMV) 0.8999, 0.0500, 0.0300, 0.0200, 0.0001;
  (Brucellosis) 0.979020979, 0.019980020, 0.000999001, 0.000000000, 0.000000000;
  (Ki-1 LC anaplas B) 0.95, 0.01, 0.01, 0.02, 0.01;
  (Intermed lymphocytic) 0.95, 0.01, 0.01, 0.02, 0.01;
}
probability ( BH_NOS | Fault, NECR ) {
  (AIDS early, Absent) 0.99, 0.01, 0.00;
  (AILD, Absent) 0.95, 0.05, 0.00;
  (ALIP, Absent) 0.95, 0.05, 0.00;
  (Cat scratch disease, Absent) 0.70, 0.25, 0.05;
  (Dermatopathic laden, Absent) 0.91, 0.05, 0.04;
  (Florid follic hyperp, Absent) 0.99, 0.01, 0.00;
  (GLH hyaline vascular, Absent) 0.99, 0.01, 0.00;
  (GLH plasma cell, Absent) 0.99, 0.01, 0.00;
  (Granulomatous laden, Absent) 0.45, 0.50, 0.05;
  (Histiocytosis x, Absent) 0.99, 0.01, 0.00;
  (Infectious mono, Absent) 0.9, 0.1, 0.0;
  (Leprosy-lepromatous, Absent) 0.01, 0.74, 0.25;
  (Lymphangiographic, Absent) 0.75, 0.25, 0.00;
  (Mantle zone hyperpla, Absent) 0.99, 0.01, 0.00;
  (Necrotizing Kikuchi, Absent) 0.02, 0.93, 0.05;
  (Necrotiz non-Kikuchi, Absent) 0.3333333, 0.3333333, 0.3333333;
  (Rheumatoid arthritis, Absent) 0.99, 0.01, 0.00;
  (Sarcoidosis, Absent) 0.99, 0.01, 0.00;
  (SHML, Absent) 0.0, 0.1, 0.9;
  (Sinus histiocytosis, Absent) 0.0, 0.8, 0.2;
  (Syphilis, Absent) 0.79, 0.20, 0.01;
  (Toxoplasmosis, Absent) 0.99, 0.01, 0.00;
  (Tuberculosis, Absent) 0.899, 0.100, 0.001;
  (Viral NOS, Absent) 0.9, 0.1, 0.0;
  (Whipple's disease, Absent) 0.75, 0.25, 0.00;
  (L&H nodular HD, Absent) 0.99, 0.01, 0.00;
  (L&H diffuse HD, Absent) 0.99, 0.01, 0.00;
  (Nodular sclerosis HD, Absent) 0.99, 0.01, 0.00;
  (Cellular phase NSHD, Absent) 0.99, 0.01, 0.00;
  (Syncytial NSHD, Absent) 0.99, 0.01, 0.00;
  (Mixed cellularity HD, Absent) 0.99, 0.01, 0.00;
  (Interfollicular HD, Absent) 0.99, 0.01, 0.00;
  (Diffuse fibrosis HD, Absent) 0.99, 0.01, 0.00;
  (Reticular-type HD, Absent) 0.99, 0.01, 0.00;
  (Small cleaved fol, Absent) 0.99, 0.01, 0.00;
  (Mixed fol, Absent) 0.99, 0.01, 0.00;
  (Large cell fol, Absent) 0.99, 0.01, 0.00;
  (Small noncleaved fol, Absent) 0.99, 0.01, 0.00;
  (Small lymphocytic, Absent) 0.99, 0.01, 0.00;
  (Plasmacytoid lyctic, Absent) 0.99, 0.01, 0.00;
  (Mantle zone lymphoma, Absent) 0.99, 0.01, 0.00;
  (Small cleaved dif, Absent) 0.99, 0.01, 0.00;
  (Mixed FCC dif, Absent) 0.94, 0.05, 0.01;
  (Large cell dif, Absent) 0.99, 0.01, 0.00;
  (B-immunoblastic, Absent) 0.99, 0.01, 0.00;
  (T-immunob mixed, Absent) 0.76, 0.20, 0.04;
  (AILD-like T-cell lym, Absent) 0.95, 0.05, 0.00;
  (Japanese ATL, Absent) 0.95, 0.05, 0.00;
  (Lymphoblastic, Absent) 0.99, 0.01, 0.00;
  (Small noncleaved dif, Absent) 0.99, 0.01, 0.00;
  (True histiocytic, Absent) 0.99, 0.01, 0.00;
  (Ki-1 LC anaplas T, Absent) 0.99, 0.01, 0.00;
  (Multiple myeloma, Absent) 0.99, 0.01, 0.00;
  (Mycosis fungoides, Absent) 0.99, 0.01, 0.00;
  (AML, Absent) 0.99, 0.01, 0.00;
  (Hairy cell leukemia, Absent) 0.99, 0.01, 0.00;
  (Carcinoma, Absent) 0.99, 0.01, 0.00;
  (Melanoma, Absent) 0.95, 0.05, 0.00;
  (EM plasmacytoma, Absent) 0.99, 0.01, 0.00;
  (Kaposi's sarcoma, Absent) 0.95, 0.05, 0.00;
  (Mast-cell disease, Absent) 0.99, 0.01, 0.00;
  (AIDS involutionary, Absent) 0.9, 0.1, 0.0;
  (T-immunob large, Absent) 0.985, 0.010, 0.005;
  (Monocytoid B-cell, Absent) 0.99, 0.01, 0.00;
  (Nasopharyngeal CA, Absent) 0.99, 0.01, 0.00;
  (Seminoma, Absent) 0.99, 0.01, 0.00;
  (SLE, Absent) 0.95, 0.05, 0.00;
  (Mycobact histiocytos, Absent) 0.0, 0.1, 0.9;
  (Mast-cell hyperplas, Absent) 0.99, 0.01, 0.00;
  (LGV, Absent) 0.70, 0.25, 0.05;
  (Histoplasmosis, Absent) 0.70, 0.25, 0.05;
  (Coccidioidomycosis, Absent) 0.70, 0.25, 0.05;
  (CMV, Absent) 0.95, 0.05, 0.00;
  (Brucellosis, Absent) 0.99, 0.01, 0.00;
  (Ki-1 LC anaplas B, Absent) 0.99, 0.01, 0.00;
  (Intermed lymphocytic, Absent) 0.99, 0.01, 0.00;
  (AIDS early, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (AILD, Focal [nonextensive]) 0.93, 0.07, 0.00;
  (ALIP, Focal [nonextensive]) 0.93, 0.07, 0.00;
  (Cat scratch disease, Focal [nonextensive]) 0.68, 0.27, 0.05;
  (Dermatopathic laden, Focal [nonextensive]) 0.89, 0.07, 0.04;
  (Florid follic hyperp, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (GLH hyaline vascular, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (GLH plasma cell, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Granulomatous laden, Focal [nonextensive]) 0.43, 0.52, 0.05;
  (Histiocytosis x, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Infectious mono, Focal [nonextensive]) 0.85, 0.15, 0.00;
  (Leprosy-lepromatous, Focal [nonextensive]) 0.01, 0.74, 0.25;
  (Lymphangiographic, Focal [nonextensive]) 0.7, 0.3, 0.0;
  (Mantle zone hyperpla, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Necrotizing Kikuchi, Focal [nonextensive]) 0.02, 0.93, 0.05;
  (Necrotiz non-Kikuchi, Focal [nonextensive]) 0.03, 0.96, 0.01;
  (Rheumatoid arthritis, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Sarcoidosis, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (SHML, Focal [nonextensive]) 0.0, 0.1, 0.9;
  (Sinus histiocytosis, Focal [nonextensive]) 0.0, 0.8, 0.2;
  (Syphilis, Focal [nonextensive]) 0.77, 0.22, 0.01;
  (Toxoplasmosis, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Tuberculosis, Focal [nonextensive]) 0.879, 0.120, 0.001;
  (Viral NOS, Focal [nonextensive]) 0.85, 0.15, 0.00;
  (Whipple's disease, Focal [nonextensive]) 0.7, 0.3, 0.0;
  (L&H nodular HD, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (L&H diffuse HD, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Nodular sclerosis HD, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Cellular phase NSHD, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Syncytial NSHD, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Mixed cellularity HD, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Interfollicular HD, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Diffuse fibrosis HD, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Reticular-type HD, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Small cleaved fol, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Mixed fol, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Large cell fol, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Small noncleaved fol, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Small lymphocytic, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Plasmacytoid lyctic, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Mantle zone lymphoma, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Small cleaved dif, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Mixed FCC dif, Focal [nonextensive]) 0.92, 0.07, 0.01;
  (Large cell dif, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (B-immunoblastic, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (T-immunob mixed, Focal [nonextensive]) 0.74, 0.22, 0.04;
  (AILD-like T-cell lym, Focal [nonextensive]) 0.93, 0.07, 0.00;
  (Japanese ATL, Focal [nonextensive]) 0.93, 0.07, 0.00;
  (Lymphoblastic, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Small noncleaved dif, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (True histiocytic, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Ki-1 LC anaplas T, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Multiple myeloma, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Mycosis fungoides, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (AML, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Hairy cell leukemia, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Carcinoma, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Melanoma, Focal [nonextensive]) 0.93, 0.07, 0.00;
  (EM plasmacytoma, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Kaposi's sarcoma, Focal [nonextensive]) 0.93, 0.07, 0.00;
  (Mast-cell disease, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (AIDS involutionary, Focal [nonextensive]) 0.85, 0.15, 0.00;
  (T-immunob large, Focal [nonextensive]) 0.965, 0.030, 0.005;
  (Monocytoid B-cell, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Nasopharyngeal CA, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Seminoma, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (SLE, Focal [nonextensive]) 0.93, 0.07, 0.00;
  (Mycobact histiocytos, Focal [nonextensive]) 0.0, 0.1, 0.9;
  (Mast-cell hyperplas, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (LGV, Focal [nonextensive]) 0.68, 0.27, 0.05;
  (Histoplasmosis, Focal [nonextensive]) 0.68, 0.27, 0.05;
  (Coccidioidomycosis, Focal [nonextensive]) 0.68, 0.27, 0.05;
  (CMV, Focal [nonextensive]) 0.93, 0.07, 0.00;
  (Brucellosis, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Ki-1 LC anaplas B, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (Intermed lymphocytic, Focal [nonextensive]) 0.97, 0.03, 0.00;
  (AIDS early, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (AILD, Multifocal [nonextensive]) 0.91, 0.09, 0.00;
  (ALIP, Multifocal [nonextensive]) 0.91, 0.09, 0.00;
  (Cat scratch disease, Multifocal [nonextensive]) 0.66, 0.29, 0.05;
  (Dermatopathic laden, Multifocal [nonextensive]) 0.87, 0.09, 0.04;
  (Florid follic hyperp, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (GLH hyaline vascular, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (GLH plasma cell, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Granulomatous laden, Multifocal [nonextensive]) 0.41, 0.54, 0.05;
  (Histiocytosis x, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Infectious mono, Multifocal [nonextensive]) 0.85, 0.15, 0.00;
  (Leprosy-lepromatous, Multifocal [nonextensive]) 0.01, 0.74, 0.25;
  (Lymphangiographic, Multifocal [nonextensive]) 0.7, 0.3, 0.0;
  (Mantle zone hyperpla, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Necrotizing Kikuchi, Multifocal [nonextensive]) 0.02, 0.93, 0.05;
  (Necrotiz non-Kikuchi, Multifocal [nonextensive]) 0.03, 0.96, 0.01;
  (Rheumatoid arthritis, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Sarcoidosis, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (SHML, Multifocal [nonextensive]) 0.0, 0.1, 0.9;
  (Sinus histiocytosis, Multifocal [nonextensive]) 0.0, 0.8, 0.2;
  (Syphilis, Multifocal [nonextensive]) 0.75, 0.24, 0.01;
  (Toxoplasmosis, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Tuberculosis, Multifocal [nonextensive]) 0.859, 0.140, 0.001;
  (Viral NOS, Multifocal [nonextensive]) 0.85, 0.15, 0.00;
  (Whipple's disease, Multifocal [nonextensive]) 0.7, 0.3, 0.0;
  (L&H nodular HD, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (L&H diffuse HD, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Nodular sclerosis HD, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Cellular phase NSHD, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Syncytial NSHD, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Mixed cellularity HD, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Interfollicular HD, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Diffuse fibrosis HD, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Reticular-type HD, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Small cleaved fol, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Mixed fol, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Large cell fol, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Small noncleaved fol, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Small lymphocytic, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Plasmacytoid lyctic, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Mantle zone lymphoma, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Small cleaved dif, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Mixed FCC dif, Multifocal [nonextensive]) 0.90, 0.09, 0.01;
  (Large cell dif, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (B-immunoblastic, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (T-immunob mixed, Multifocal [nonextensive]) 0.72, 0.24, 0.04;
  (AILD-like T-cell lym, Multifocal [nonextensive]) 0.91, 0.09, 0.00;
  (Japanese ATL, Multifocal [nonextensive]) 0.91, 0.09, 0.00;
  (Lymphoblastic, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Small noncleaved dif, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (True histiocytic, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Ki-1 LC anaplas T, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Multiple myeloma, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Mycosis fungoides, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (AML, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Hairy cell leukemia, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Carcinoma, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Melanoma, Multifocal [nonextensive]) 0.91, 0.09, 0.00;
  (EM plasmacytoma, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Kaposi's sarcoma, Multifocal [nonextensive]) 0.91, 0.09, 0.00;
  (Mast-cell disease, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (AIDS involutionary, Multifocal [nonextensive]) 0.85, 0.15, 0.00;
  (T-immunob large, Multifocal [nonextensive]) 0.925, 0.070, 0.005;
  (Monocytoid B-cell, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Nasopharyngeal CA, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Seminoma, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (SLE, Multifocal [nonextensive]) 0.91, 0.09, 0.00;
  (Mycobact histiocytos, Multifocal [nonextensive]) 0.0, 0.1, 0.9;
  (Mast-cell hyperplas, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (LGV, Multifocal [nonextensive]) 0.66, 0.29, 0.05;
  (Histoplasmosis, Multifocal [nonextensive]) 0.66, 0.29, 0.05;
  (Coccidioidomycosis, Multifocal [nonextensive]) 0.66, 0.29, 0.05;
  (CMV, Multifocal [nonextensive]) 0.91, 0.09, 0.00;
  (Brucellosis, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Ki-1 LC anaplas B, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (Intermed lymphocytic, Multifocal [nonextensive]) 0.95, 0.05, 0.00;
  (AIDS early, Extensive) 0.95, 0.05, 0.00;
  (AILD, Extensive) 0.91, 0.09, 0.00;
  (ALIP, Extensive) 0.91, 0.09, 0.00;
  (Cat scratch disease, Extensive) 0.66, 0.29, 0.05;
  (Dermatopathic laden, Extensive) 0.87, 0.09, 0.04;
  (Florid follic hyperp, Extensive) 0.95, 0.05, 0.00;
  (GLH hyaline vascular, Extensive) 0.95, 0.05, 0.00;
  (GLH plasma cell, Extensive) 0.95, 0.05, 0.00;
  (Granulomatous laden, Extensive) 0.41, 0.54, 0.05;
  (Histiocytosis x, Extensive) 0.95, 0.05, 0.00;
  (Infectious mono, Extensive) 0.85, 0.15, 0.00;
  (Leprosy-lepromatous, Extensive) 0.01, 0.74, 0.25;
  (Lymphangiographic, Extensive) 0.7, 0.3, 0.0;
  (Mantle zone hyperpla, Extensive) 0.95, 0.05, 0.00;
  (Necrotizing Kikuchi, Extensive) 0.02, 0.93, 0.05;
  (Necrotiz non-Kikuchi, Extensive) 0.03, 0.96, 0.01;
  (Rheumatoid arthritis, Extensive) 0.95, 0.05, 0.00;
  (Sarcoidosis, Extensive) 0.95, 0.05, 0.00;
  (SHML, Extensive) 0.0, 0.1, 0.9;
  (Sinus histiocytosis, Extensive) 0.0, 0.8, 0.2;
  (Syphilis, Extensive) 0.75, 0.24, 0.01;
  (Toxoplasmosis, Extensive) 0.95, 0.05, 0.00;
  (Tuberculosis, Extensive) 0.859, 0.140, 0.001;
  (Viral NOS, Extensive) 0.85, 0.15, 0.00;
  (Whipple's disease, Extensive) 0.7, 0.3, 0.0;
  (L&H nodular HD, Extensive) 0.95, 0.05, 0.00;
  (L&H diffuse HD, Extensive) 0.95, 0.05, 0.00;
  (Nodular sclerosis HD, Extensive) 0.95, 0.05, 0.00;
  (Cellular phase NSHD, Extensive) 0.95, 0.05, 0.00;
  (Syncytial NSHD, Extensive) 0.95, 0.05, 0.00;
  (Mixed cellularity HD, Extensive) 0.95, 0.05, 0.00;
  (Interfollicular HD, Extensive) 0.95, 0.05, 0.00;
  (Diffuse fibrosis HD, Extensive) 0.95, 0.05, 0.00;
  (Reticular-type HD, Extensive) 0.95, 0.05, 0.00;
  (Small cleaved fol, Extensive) 0.95, 0.05, 0.00;
  (Mixed fol, Extensive) 0.95, 0.05, 0.00;
  (Large cell fol, Extensive) 0.95, 0.05, 0.00;
  (Small noncleaved fol, Extensive) 0.95, 0.05, 0.00;
  (Small lymphocytic, Extensive) 0.95, 0.05, 0.00;
  (Plasmacytoid lyctic, Extensive) 0.95, 0.05, 0.00;
  (Mantle zone lymphoma, Extensive) 0.95, 0.05, 0.00;
  (Small cleaved dif, Extensive) 0.95, 0.05, 0.00;
  (Mixed FCC dif, Extensive) 0.90, 0.09, 0.01;
  (Large cell dif, Extensive) 0.95, 0.05, 0.00;
  (B-immunoblastic, Extensive) 0.95, 0.05, 0.00;
  (T-immunob mixed, Extensive) 0.72, 0.24, 0.04;
  (AILD-like T-cell lym, Extensive) 0.91, 0.09, 0.00;
  (Japanese ATL, Extensive) 0.91, 0.09, 0.00;
  (Lymphoblastic, Extensive) 0.95, 0.05, 0.00;
  (Small noncleaved dif, Extensive) 0.95, 0.05, 0.00;
  (True histiocytic, Extensive) 0.95, 0.05, 0.00;
  (Ki-1 LC anaplas T, Extensive) 0.95, 0.05, 0.00;
  (Multiple myeloma, Extensive) 0.95, 0.05, 0.00;
  (Mycosis fungoides, Extensive) 0.95, 0.05, 0.00;
  (AML, Extensive) 0.95, 0.05, 0.00;
  (Hairy cell leukemia, Extensive) 0.95, 0.05, 0.00;
  (Carcinoma, Extensive) 0.95, 0.05, 0.00;
  (Melanoma, Extensive) 0.91, 0.09, 0.00;
  (EM plasmacytoma, Extensive) 0.95, 0.05, 0.00;
  (Kaposi's sarcoma, Extensive) 0.91, 0.09, 0.00;
  (Mast-cell disease, Extensive) 0.95, 0.05, 0.00;
  (AIDS involutionary, Extensive) 0.85, 0.15, 0.00;
  (T-immunob large, Extensive) 0.925, 0.070, 0.005;
  (Monocytoid B-cell, Extensive) 0.95, 0.05, 0.00;
  (Nasopharyngeal CA, Extensive) 0.95, 0.05, 0.00;
  (Seminoma, Extensive) 0.95, 0.05, 0.00;
  (SLE, Extensive) 0.91, 0.09, 0.00;
  (Mycobact histiocytos, Extensive) 0.0, 0.1, 0.9;
  (Mast-cell hyperplas, Extensive) 0.95, 0.05, 0.00;
  (LGV, Extensive) 0.66, 0.29, 0.05;
  (Histoplasmosis, Extensive) 0.66, 0.29, 0.05;
  (Coccidioidomycosis, Extensive) 0.66, 0.29, 0.05;
  (CMV, Extensive) 0.91, 0.09, 0.00;
  (Brucellosis, Extensive) 0.95, 0.05, 0.00;
  (Ki-1 LC anaplas B, Extensive) 0.95, 0.05, 0.00;
  (Intermed lymphocytic, Extensive) 0.95, 0.05, 0.00;
}
probability ( BH_SS | Fault ) {
  (AIDS early) 0.900, 0.099, 0.001, 0.000, 0.000;
  (AILD) 0.694, 0.300, 0.005, 0.001, 0.000;
  (ALIP) 0.694, 0.300, 0.005, 0.001, 0.000;
  (Cat scratch disease) 0.739, 0.250, 0.010, 0.001, 0.000;
  (Dermatopathic laden) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Florid follic hyperp) 0.900, 0.099, 0.001, 0.000, 0.000;
  (GLH hyaline vascular) 0.900, 0.099, 0.001, 0.000, 0.000;
  (GLH plasma cell) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Granulomatous laden) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Histiocytosis x) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Infectious mono) 0.689, 0.250, 0.050, 0.010, 0.001;
  (Leprosy-lepromatous) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Lymphangiographic) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Mantle zone hyperpla) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Necrotizing Kikuchi) 0.739, 0.250, 0.010, 0.001, 0.000;
  (Necrotiz non-Kikuchi) 0.739, 0.250, 0.010, 0.001, 0.000;
  (Rheumatoid arthritis) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Sarcoidosis) 0.900, 0.099, 0.001, 0.000, 0.000;
  (SHML) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Sinus histiocytosis) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Syphilis) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Toxoplasmosis) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Tuberculosis) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Viral NOS) 0.739, 0.250, 0.010, 0.001, 0.000;
  (Whipple's disease) 0.900, 0.099, 0.001, 0.000, 0.000;
  (L&H nodular HD) 0.900, 0.099, 0.001, 0.000, 0.000;
  (L&H diffuse HD) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Nodular sclerosis HD) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Cellular phase NSHD) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Syncytial NSHD) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Mixed cellularity HD) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Interfollicular HD) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Diffuse fibrosis HD) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Reticular-type HD) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Small cleaved fol) 0.889, 0.100, 0.010, 0.001, 0.000;
  (Mixed fol) 0.889, 0.100, 0.010, 0.001, 0.000;
  (Large cell fol) 0.919, 0.050, 0.020, 0.010, 0.001;
  (Small noncleaved fol) 0.919, 0.050, 0.020, 0.010, 0.001;
  (Small lymphocytic) 0.694, 0.300, 0.005, 0.001, 0.000;
  (Plasmacytoid lyctic) 0.694, 0.300, 0.005, 0.001, 0.000;
  (Mantle zone lymphoma) 0.900, 0.095, 0.005, 0.000, 0.000;
  (Small cleaved dif) 0.874, 0.070, 0.050, 0.005, 0.001;
  (Mixed FCC dif) 0.88, 0.05, 0.04, 0.02, 0.01;
  (Large cell dif) 0.65, 0.15, 0.10, 0.05, 0.05;
  (B-immunoblastic) 0.59, 0.15, 0.12, 0.07, 0.07;
  (T-immunob mixed) 0.68, 0.10, 0.10, 0.07, 0.05;
  (AILD-like T-cell lym) 0.694, 0.300, 0.005, 0.001, 0.000;
  (Japanese ATL) 0.68, 0.10, 0.10, 0.07, 0.05;
  (Lymphoblastic) 0.70, 0.05, 0.05, 0.10, 0.10;
  (Small noncleaved dif) 0.000999001, 0.009990010, 0.049950050, 0.199800200, 0.739260739;
  (True histiocytic) 0.68, 0.10, 0.10, 0.07, 0.05;
  (Ki-1 LC anaplas T) 0.80, 0.10, 0.05, 0.03, 0.02;
  (Multiple myeloma) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Mycosis fungoides) 0.900, 0.099, 0.001, 0.000, 0.000;
  (AML) 0.68, 0.10, 0.10, 0.07, 0.05;
  (Hairy cell leukemia) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Carcinoma) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Melanoma) 0.900, 0.099, 0.001, 0.000, 0.000;
  (EM plasmacytoma) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Kaposi's sarcoma) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Mast-cell disease) 0.900, 0.099, 0.001, 0.000, 0.000;
  (AIDS involutionary) 0.900, 0.099, 0.001, 0.000, 0.000;
  (T-immunob large) 0.68, 0.10, 0.10, 0.07, 0.05;
  (Monocytoid B-cell) 0.694, 0.300, 0.005, 0.001, 0.000;
  (Nasopharyngeal CA) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Seminoma) 0.900, 0.099, 0.001, 0.000, 0.000;
  (SLE) 0.689, 0.250, 0.050, 0.010, 0.001;
  (Mycobact histiocytos) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Mast-cell hyperplas) 0.900, 0.099, 0.001, 0.000, 0.000;
  (LGV) 0.739, 0.250, 0.010, 0.001, 0.000;
  (Histoplasmosis) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Coccidioidomycosis) 0.900, 0.099, 0.001, 0.000, 0.000;
  (CMV) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Brucellosis) 0.900, 0.099, 0.001, 0.000, 0.000;
  (Ki-1 LC anaplas B) 0.80, 0.10, 0.05, 0.03, 0.02;
  (Intermed lymphocytic) 0.89, 0.10, 0.01, 0.00, 0.00;
}
probability ( CA | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 1.0, 0.0;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 1.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 1.0, 0.0;
  (L&H diffuse HD) 1.0, 0.0;
  (Nodular sclerosis HD) 1.0, 0.0;
  (Cellular phase NSHD) 1.0, 0.0;
  (Syncytial NSHD) 1.0, 0.0;
  (Mixed cellularity HD) 1.0, 0.0;
  (Interfollicular HD) 1.0, 0.0;
  (Diffuse fibrosis HD) 1.0, 0.0;
  (Reticular-type HD) 1.0, 0.0;
  (Small cleaved fol) 1.0, 0.0;
  (Mixed fol) 1.0, 0.0;
  (Large cell fol) 1.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0;
  (Small lymphocytic) 1.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0;
  (Small cleaved dif) 1.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0;
  (Large cell dif) 1.0, 0.0;
  (B-immunoblastic) 1.0, 0.0;
  (T-immunob mixed) 1.0, 0.0;
  (AILD-like T-cell lym) 1.0, 0.0;
  (Japanese ATL) 1.0, 0.0;
  (Lymphoblastic) 1.0, 0.0;
  (Small noncleaved dif) 1.0, 0.0;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 1.0, 0.0;
  (Multiple myeloma) 1.0, 0.0;
  (Mycosis fungoides) 1.0, 0.0;
  (AML) 1.0, 0.0;
  (Hairy cell leukemia) 1.0, 0.0;
  (Carcinoma) 0.0, 1.0;
  (Melanoma) 1.0, 0.0;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0;
  (Mast-cell disease) 1.0, 0.0;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 1.0, 0.0;
  (Monocytoid B-cell) 1.0, 0.0;
  (Nasopharyngeal CA) 0.0, 1.0;
  (Seminoma) 1.0, 0.0;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 1.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0;
}
probability ( SR | Fault, MONO ) {
  (AIDS early, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0]) 0.999, 0.001, 0.000, 0.000, 0.000;
  (ALIP, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0]) 0.99, 0.01, 0.00, 0.00, 0.00;
  (Leprosy-lepromatous, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0]) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Whipple's disease, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0]) 0.95, 0.05, 0.00, 0.00, 0.00;
  (L&H diffuse HD, Absent [0]) 0.95, 0.05, 0.00, 0.00, 0.00;
  (Nodular sclerosis HD, Absent [0]) 0.000, 0.020, 0.825, 0.150, 0.005;
  (Cellular phase NSHD, Absent [0]) 0.000, 0.020, 0.825, 0.150, 0.005;
  (Syncytial NSHD, Absent [0]) 0.00, 0.01, 0.59, 0.35, 0.05;
  (Mixed cellularity HD, Absent [0]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Interfollicular HD, Absent [0]) 0.00, 0.30, 0.65, 0.05, 0.00;
  (Diffuse fibrosis HD, Absent [0]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Reticular-type HD, Absent [0]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small cleaved fol, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0]) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Plasmacytoid lyctic, Absent [0]) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Mantle zone lymphoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0]) 0.99, 0.01, 0.00, 0.00, 0.00;
  (Large cell dif, Absent [0]) 0.9799, 0.0100, 0.0100, 0.0001, 0.0000;
  (B-immunoblastic, Absent [0]) 0.9749, 0.0200, 0.0050, 0.0001, 0.0000;
  (T-immunob mixed, Absent [0]) 0.99, 0.01, 0.00, 0.00, 0.00;
  (AILD-like T-cell lym, Absent [0]) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Japanese ATL, Absent [0]) 0.94, 0.03, 0.02, 0.01, 0.00;
  (Lymphoblastic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0]) 0.9799, 0.0100, 0.0100, 0.0001, 0.0000;
  (Ki-1 LC anaplas T, Absent [0]) 0.9699, 0.0200, 0.0100, 0.0001, 0.0000;
  (Multiple myeloma, Absent [0]) 0.9699, 0.0200, 0.0100, 0.0001, 0.0000;
  (Mycosis fungoides, Absent [0]) 0.989, 0.010, 0.001, 0.000, 0.000;
  (AML, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0]) 0.969, 0.020, 0.010, 0.001, 0.000;
  (Melanoma, Absent [0]) 0.969, 0.020, 0.010, 0.001, 0.000;
  (EM plasmacytoma, Absent [0]) 0.979, 0.020, 0.001, 0.000, 0.000;
  (Kaposi's sarcoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0]) 0.9799, 0.0100, 0.0100, 0.0001, 0.0000;
  (Monocytoid B-cell, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0]) 0.969, 0.020, 0.010, 0.001, 0.000;
  (Seminoma, Absent [0]) 0.999, 0.001, 0.000, 0.000, 0.000;
  (SLE, Absent [0]) 0.99, 0.01, 0.00, 0.00, 0.00;
  (Mycobact histiocytos, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0]) 0.979, 0.020, 0.001, 0.000, 0.000;
  (Brucellosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0]) 0.9699, 0.0200, 0.0100, 0.0001, 0.0000;
  (Intermed lymphocytic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS early, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD, Rare [1-2]) 0.999, 0.001, 0.000, 0.000, 0.000;
  (ALIP, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Infectious mono, Rare [1-2]) 0.99, 0.01, 0.00, 0.00, 0.00;
  (Leprosy-lepromatous, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SHML, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syphilis, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Viral NOS, Rare [1-2]) 0.995002998, 0.004997002, 0.000000000, 0.000000000, 0.000000000;
  (Whipple's disease, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Rare [1-2]) 0.0, 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Rare [1-2]) 0.0, 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Rare [1-2]) 0.000, 0.020, 0.825, 0.150, 0.005;
  (Cellular phase NSHD, Rare [1-2]) 0.000, 0.020, 0.825, 0.150, 0.005;
  (Syncytial NSHD, Rare [1-2]) 0.00, 0.01, 0.59, 0.35, 0.05;
  (Mixed cellularity HD, Rare [1-2]) 0.0, 0.0, 0.8, 0.2, 0.0;
  (Interfollicular HD, Rare [1-2]) 0.00, 0.30, 0.65, 0.05, 0.00;
  (Diffuse fibrosis HD, Rare [1-2]) 0.00, 0.02, 0.62, 0.35, 0.01;
  (Reticular-type HD, Rare [1-2]) 0.00, 0.00, 0.01, 0.59, 0.40;
  (Small cleaved fol, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed fol, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell fol, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Rare [1-2]) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Plasmacytoid lyctic, Rare [1-2]) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Mantle zone lymphoma, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Rare [1-2]) 0.99, 0.01, 0.00, 0.00, 0.00;
  (Large cell dif, Rare [1-2]) 0.9889, 0.0100, 0.0010, 0.0001, 0.0000;
  (B-immunoblastic, Rare [1-2]) 0.9749, 0.0200, 0.0050, 0.0001, 0.0000;
  (T-immunob mixed, Rare [1-2]) 0.99, 0.01, 0.00, 0.00, 0.00;
  (AILD-like T-cell lym, Rare [1-2]) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Japanese ATL, Rare [1-2]) 0.92, 0.05, 0.02, 0.01, 0.00;
  (Lymphoblastic, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (True histiocytic, Rare [1-2]) 0.9889, 0.0100, 0.0010, 0.0001, 0.0000;
  (Ki-1 LC anaplas T, Rare [1-2]) 0.9699, 0.0200, 0.0100, 0.0001, 0.0000;
  (Multiple myeloma, Rare [1-2]) 0.9699, 0.0200, 0.0100, 0.0001, 0.0000;
  (Mycosis fungoides, Rare [1-2]) 0.989, 0.010, 0.001, 0.000, 0.000;
  (AML, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Carcinoma, Rare [1-2]) 0.97, 0.02, 0.01, 0.00, 0.00;
  (Melanoma, Rare [1-2]) 0.97, 0.02, 0.01, 0.00, 0.00;
  (EM plasmacytoma, Rare [1-2]) 0.979, 0.020, 0.001, 0.000, 0.000;
  (Kaposi's sarcoma, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob large, Rare [1-2]) 0.9889, 0.0100, 0.0010, 0.0001, 0.0000;
  (Monocytoid B-cell, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Rare [1-2]) 0.97, 0.02, 0.01, 0.00, 0.00;
  (Seminoma, Rare [1-2]) 0.999, 0.001, 0.000, 0.000, 0.000;
  (SLE, Rare [1-2]) 0.99, 0.01, 0.00, 0.00, 0.00;
  (Mycobact histiocytos, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (LGV, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (CMV, Rare [1-2]) 0.969, 0.030, 0.001, 0.000, 0.000;
  (Brucellosis, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Rare [1-2]) 0.9699, 0.0200, 0.0100, 0.0001, 0.0000;
  (Intermed lymphocytic, Rare [1-2]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS early, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (AILD, Present [3-20]) 0.9979, 0.0020, 0.0001, 0.0000, 0.0000;
  (ALIP, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Cat scratch disease, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Dermatopathic laden, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Florid follic hyperp, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (GLH hyaline vascular, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (GLH plasma cell, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Granulomatous laden, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Histiocytosis x, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Infectious mono, Present [3-20]) 0.98, 0.02, 0.00, 0.00, 0.00;
  (Leprosy-lepromatous, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Lymphangiographic, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mantle zone hyperpla, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Necrotizing Kikuchi, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Necrotiz non-Kikuchi, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Rheumatoid arthritis, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Sarcoidosis, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (SHML, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Sinus histiocytosis, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Syphilis, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Toxoplasmosis, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Tuberculosis, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Viral NOS, Present [3-20]) 0.995, 0.005, 0.000, 0.000, 0.000;
  (Whipple's disease, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (L&H nodular HD, Present [3-20]) 0.0, 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Present [3-20]) 0.0, 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Present [3-20]) 0.00, 0.01, 0.76, 0.22, 0.01;
  (Cellular phase NSHD, Present [3-20]) 0.00, 0.01, 0.76, 0.22, 0.01;
  (Syncytial NSHD, Present [3-20]) 0.00, 0.01, 0.29, 0.60, 0.10;
  (Mixed cellularity HD, Present [3-20]) 0.0, 0.0, 0.7, 0.3, 0.0;
  (Interfollicular HD, Present [3-20]) 0.00, 0.30, 0.63, 0.07, 0.00;
  (Diffuse fibrosis HD, Present [3-20]) 0.00, 0.02, 0.62, 0.35, 0.01;
  (Reticular-type HD, Present [3-20]) 0.00, 0.00, 0.01, 0.40, 0.59;
  (Small cleaved fol, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mixed fol, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Large cell fol, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small noncleaved fol, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small lymphocytic, Present [3-20]) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Plasmacytoid lyctic, Present [3-20]) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Mantle zone lymphoma, Present [3-20]) 0.9999, 0.0001, 0.0000, 0.0000, 0.0000;
  (Small cleaved dif, Present [3-20]) 0.9999, 0.0001, 0.0000, 0.0000, 0.0000;
  (Mixed FCC dif, Present [3-20]) 0.99, 0.01, 0.00, 0.00, 0.00;
  (Large cell dif, Present [3-20]) 0.9889, 0.0100, 0.0010, 0.0001, 0.0000;
  (B-immunoblastic, Present [3-20]) 0.9699, 0.0200, 0.0100, 0.0001, 0.0000;
  (T-immunob mixed, Present [3-20]) 0.99, 0.01, 0.00, 0.00, 0.00;
  (AILD-like T-cell lym, Present [3-20]) 0.9979, 0.0020, 0.0001, 0.0000, 0.0000;
  (Japanese ATL, Present [3-20]) 0.92, 0.05, 0.02, 0.01, 0.00;
  (Lymphoblastic, Present [3-20]) 0.9999, 0.0001, 0.0000, 0.0000, 0.0000;
  (Small noncleaved dif, Present [3-20]) 0.9999, 0.0001, 0.0000, 0.0000, 0.0000;
  (True histiocytic, Present [3-20]) 0.9889, 0.0100, 0.0010, 0.0001, 0.0000;
  (Ki-1 LC anaplas T, Present [3-20]) 0.9699, 0.0200, 0.0100, 0.0001, 0.0000;
  (Multiple myeloma, Present [3-20]) 0.9699, 0.0200, 0.0100, 0.0001, 0.0000;
  (Mycosis fungoides, Present [3-20]) 0.989, 0.010, 0.001, 0.000, 0.000;
  (AML, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Hairy cell leukemia, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Carcinoma, Present [3-20]) 0.96, 0.01, 0.02, 0.01, 0.00;
  (Melanoma, Present [3-20]) 0.96, 0.01, 0.02, 0.01, 0.00;
  (EM plasmacytoma, Present [3-20]) 0.969, 0.030, 0.001, 0.000, 0.000;
  (Kaposi's sarcoma, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mast-cell disease, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (AIDS involutionary, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (T-immunob large, Present [3-20]) 0.9889, 0.0100, 0.0010, 0.0001, 0.0000;
  (Monocytoid B-cell, Present [3-20]) 0.9999, 0.0001, 0.0000, 0.0000, 0.0000;
  (Nasopharyngeal CA, Present [3-20]) 0.96, 0.01, 0.02, 0.01, 0.00;
  (Seminoma, Present [3-20]) 0.998, 0.002, 0.000, 0.000, 0.000;
  (SLE, Present [3-20]) 0.98, 0.02, 0.00, 0.00, 0.00;
  (Mycobact histiocytos, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mast-cell hyperplas, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (LGV, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Histoplasmosis, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Coccidioidomycosis, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (CMV, Present [3-20]) 0.959, 0.040, 0.001, 0.000, 0.000;
  (Brucellosis, Present [3-20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Ki-1 LC anaplas B, Present [3-20]) 0.9699, 0.0200, 0.0100, 0.0001, 0.0000;
  (Intermed lymphocytic, Present [3-20]) 0.9999, 0.0001, 0.0000, 0.0000, 0.0000;
  (AIDS early, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (AILD, Many [>20]) 0.989, 0.010, 0.001, 0.000, 0.000;
  (ALIP, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Cat scratch disease, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Dermatopathic laden, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Florid follic hyperp, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (GLH hyaline vascular, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (GLH plasma cell, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Granulomatous laden, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Histiocytosis x, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Infectious mono, Many [>20]) 0.98, 0.02, 0.00, 0.00, 0.00;
  (Leprosy-lepromatous, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Lymphangiographic, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mantle zone hyperpla, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Necrotizing Kikuchi, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Necrotiz non-Kikuchi, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Rheumatoid arthritis, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Sarcoidosis, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (SHML, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Sinus histiocytosis, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Syphilis, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Toxoplasmosis, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Tuberculosis, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Viral NOS, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Whipple's disease, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (L&H nodular HD, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (L&H diffuse HD, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Nodular sclerosis HD, Many [>20]) 0.00, 0.01, 0.68, 0.30, 0.01;
  (Cellular phase NSHD, Many [>20]) 0.00, 0.01, 0.68, 0.30, 0.01;
  (Syncytial NSHD, Many [>20]) 0.00, 0.01, 0.24, 0.65, 0.10;
  (Mixed cellularity HD, Many [>20]) 0.00, 0.01, 0.59, 0.40, 0.00;
  (Interfollicular HD, Many [>20]) 0.00, 0.01, 0.69, 0.30, 0.00;
  (Diffuse fibrosis HD, Many [>20]) 0.00, 0.00, 0.53, 0.45, 0.02;
  (Reticular-type HD, Many [>20]) 0.00, 0.00, 0.01, 0.25, 0.74;
  (Small cleaved fol, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mixed fol, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Large cell fol, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small noncleaved fol, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small lymphocytic, Many [>20]) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Plasmacytoid lyctic, Many [>20]) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Mantle zone lymphoma, Many [>20]) 0.9999, 0.0001, 0.0000, 0.0000, 0.0000;
  (Small cleaved dif, Many [>20]) 0.9999, 0.0001, 0.0000, 0.0000, 0.0000;
  (Mixed FCC dif, Many [>20]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell dif, Many [>20]) 0.9889, 0.0100, 0.0010, 0.0001, 0.0000;
  (B-immunoblastic, Many [>20]) 0.9699, 0.0200, 0.0100, 0.0001, 0.0000;
  (T-immunob mixed, Many [>20]) 0.9889, 0.0100, 0.0010, 0.0001, 0.0000;
  (AILD-like T-cell lym, Many [>20]) 0.989, 0.010, 0.001, 0.000, 0.000;
  (Japanese ATL, Many [>20]) 0.92, 0.05, 0.02, 0.01, 0.00;
  (Lymphoblastic, Many [>20]) 0.9999, 0.0001, 0.0000, 0.0000, 0.0000;
  (Small noncleaved dif, Many [>20]) 0.9999, 0.0001, 0.0000, 0.0000, 0.0000;
  (True histiocytic, Many [>20]) 0.9889, 0.0100, 0.0010, 0.0001, 0.0000;
  (Ki-1 LC anaplas T, Many [>20]) 0.9699, 0.0200, 0.0100, 0.0001, 0.0000;
  (Multiple myeloma, Many [>20]) 0.9699, 0.0200, 0.0100, 0.0001, 0.0000;
  (Mycosis fungoides, Many [>20]) 0.98, 0.02, 0.00, 0.00, 0.00;
  (AML, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Hairy cell leukemia, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Carcinoma, Many [>20]) 0.94, 0.03, 0.02, 0.01, 0.00;
  (Melanoma, Many [>20]) 0.94, 0.03, 0.02, 0.01, 0.00;
  (EM plasmacytoma, Many [>20]) 0.95, 0.04, 0.01, 0.00, 0.00;
  (Kaposi's sarcoma, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mast-cell disease, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (AIDS involutionary, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (T-immunob large, Many [>20]) 0.9889, 0.0100, 0.0010, 0.0001, 0.0000;
  (Monocytoid B-cell, Many [>20]) 0.9999, 0.0001, 0.0000, 0.0000, 0.0000;
  (Nasopharyngeal CA, Many [>20]) 0.96, 0.02, 0.01, 0.01, 0.00;
  (Seminoma, Many [>20]) 0.998, 0.002, 0.000, 0.000, 0.000;
  (SLE, Many [>20]) 0.98, 0.02, 0.00, 0.00, 0.00;
  (Mycobact histiocytos, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mast-cell hyperplas, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (LGV, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Histoplasmosis, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Coccidioidomycosis, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (CMV, Many [>20]) 0.949, 0.050, 0.001, 0.000, 0.000;
  (Brucellosis, Many [>20]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Ki-1 LC anaplas B, Many [>20]) 0.9699, 0.0200, 0.0100, 0.0001, 0.0000;
  (Intermed lymphocytic, Many [>20]) 0.9999, 0.0001, 0.0000, 0.0000, 0.0000;
}
probability ( DVS | Fault ) {
  (AIDS early) 0.99999, 0.00001;
  (AILD) 0.99999, 0.00001;
  (ALIP) 0.99999, 0.00001;
  (Cat scratch disease) 0.99999, 0.00001;
  (Dermatopathic laden) 0.99999, 0.00001;
  (Florid follic hyperp) 0.99999, 0.00001;
  (GLH hyaline vascular) 0.99999, 0.00001;
  (GLH plasma cell) 0.99999, 0.00001;
  (Granulomatous laden) 0.99999, 0.00001;
  (Histiocytosis x) 0.99999, 0.00001;
  (Infectious mono) 0.99999, 0.00001;
  (Leprosy-lepromatous) 0.99999, 0.00001;
  (Lymphangiographic) 0.99999, 0.00001;
  (Mantle zone hyperpla) 0.99999, 0.00001;
  (Necrotizing Kikuchi) 0.99999, 0.00001;
  (Necrotiz non-Kikuchi) 0.99999, 0.00001;
  (Rheumatoid arthritis) 0.99999, 0.00001;
  (Sarcoidosis) 0.99999, 0.00001;
  (SHML) 0.99999, 0.00001;
  (Sinus histiocytosis) 0.99999, 0.00001;
  (Syphilis) 0.99999, 0.00001;
  (Toxoplasmosis) 0.99999, 0.00001;
  (Tuberculosis) 0.99999, 0.00001;
  (Viral NOS) 0.99999, 0.00001;
  (Whipple's disease) 0.99999, 0.00001;
  (L&H nodular HD) 0.99999, 0.00001;
  (L&H diffuse HD) 0.99999, 0.00001;
  (Nodular sclerosis HD) 0.99999, 0.00001;
  (Cellular phase NSHD) 0.99999, 0.00001;
  (Syncytial NSHD) 0.99999, 0.00001;
  (Mixed cellularity HD) 0.99999, 0.00001;
  (Interfollicular HD) 0.99999, 0.00001;
  (Diffuse fibrosis HD) 0.99999, 0.00001;
  (Reticular-type HD) 0.99999, 0.00001;
  (Small cleaved fol) 0.99999, 0.00001;
  (Mixed fol) 0.99999, 0.00001;
  (Large cell fol) 0.99999, 0.00001;
  (Small noncleaved fol) 0.99999, 0.00001;
  (Small lymphocytic) 0.99999, 0.00001;
  (Plasmacytoid lyctic) 0.99999, 0.00001;
  (Mantle zone lymphoma) 0.99999, 0.00001;
  (Small cleaved dif) 0.99999, 0.00001;
  (Mixed FCC dif) 0.99999, 0.00001;
  (Large cell dif) 0.99999, 0.00001;
  (B-immunoblastic) 0.99999, 0.00001;
  (T-immunob mixed) 0.99999, 0.00001;
  (AILD-like T-cell lym) 0.99999, 0.00001;
  (Japanese ATL) 0.99999, 0.00001;
  (Lymphoblastic) 0.99999, 0.00001;
  (Small noncleaved dif) 0.99999, 0.00001;
  (True histiocytic) 0.99999, 0.00001;
  (Ki-1 LC anaplas T) 0.99999, 0.00001;
  (Multiple myeloma) 0.99999, 0.00001;
  (Mycosis fungoides) 0.99999, 0.00001;
  (AML) 0.99999, 0.00001;
  (Hairy cell leukemia) 0.25, 0.75;
  (Carcinoma) 0.99999, 0.00001;
  (Melanoma) 0.99999, 0.00001;
  (EM plasmacytoma) 0.99999, 0.00001;
  (Kaposi's sarcoma) 0.99, 0.01;
  (Mast-cell disease) 0.99999, 0.00001;
  (AIDS involutionary) 0.99999, 0.00001;
  (T-immunob large) 0.99999, 0.00001;
  (Monocytoid B-cell) 0.99999, 0.00001;
  (Nasopharyngeal CA) 0.99999, 0.00001;
  (Seminoma) 0.99999, 0.00001;
  (SLE) 0.99999, 0.00001;
  (Mycobact histiocytos) 0.99999, 0.00001;
  (Mast-cell hyperplas) 0.99999, 0.00001;
  (LGV) 0.99999, 0.00001;
  (Histoplasmosis) 0.99999, 0.00001;
  (Coccidioidomycosis) 0.99999, 0.00001;
  (CMV) 0.99999, 0.00001;
  (Brucellosis) 0.99999, 0.00001;
  (Ki-1 LC anaplas B) 0.99999, 0.00001;
  (Intermed lymphocytic) 0.99999, 0.00001;
}
probability ( EMPERI | Fault, BH_NOS ) {
  (AIDS early, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (AILD, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (ALIP, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Cat scratch disease, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Dermatopathic laden, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Florid follic hyperp, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (GLH plasma cell, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Granulomatous laden, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Histiocytosis x, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Infectious mono, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Lymphangiographic, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Sarcoidosis, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (SHML, Absent to slight [<5pc]) 0.5, 0.4, 0.1;
  (Sinus histiocytosis, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Syphilis, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Toxoplasmosis, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Tuberculosis, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Viral NOS, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Whipple's disease, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (L&H nodular HD, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (L&H diffuse HD, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Syncytial NSHD, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Interfollicular HD, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Reticular-type HD, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Small cleaved fol, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Mixed fol, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Large cell fol, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Small noncleaved fol, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Small lymphocytic, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Small cleaved dif, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Mixed FCC dif, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Large cell dif, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (B-immunoblastic, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (T-immunob mixed, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Japanese ATL, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Lymphoblastic, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Small noncleaved dif, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (True histiocytic, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Multiple myeloma, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Mycosis fungoides, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (AML, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Carcinoma, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Melanoma, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (EM plasmacytoma, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Mast-cell disease, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (AIDS involutionary, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (T-immunob large, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Seminoma, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (SLE, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (LGV, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Histoplasmosis, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (CMV, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Brucellosis, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent to slight [<5pc]) 1.0, 0.0, 0.0;
  (AIDS early, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (AILD, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (ALIP, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Cat scratch disease, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Dermatopathic laden, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Florid follic hyperp, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (GLH hyaline vascular, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (GLH plasma cell, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Granulomatous laden, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Histiocytosis x, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Infectious mono, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Leprosy-lepromatous, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Lymphangiographic, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Mantle zone hyperpla, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Necrotizing Kikuchi, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Necrotiz non-Kikuchi, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Rheumatoid arthritis, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Sarcoidosis, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (SHML, Moderate [5-50pc]) 9.99990e-06, 4.99995e-01, 4.99995e-01;
  (Sinus histiocytosis, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Syphilis, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Toxoplasmosis, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Tuberculosis, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Viral NOS, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Whipple's disease, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (L&H nodular HD, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (L&H diffuse HD, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Nodular sclerosis HD, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Cellular phase NSHD, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Syncytial NSHD, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Mixed cellularity HD, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Interfollicular HD, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Diffuse fibrosis HD, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Reticular-type HD, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Small cleaved fol, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Mixed fol, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Large cell fol, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Small noncleaved fol, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Small lymphocytic, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Plasmacytoid lyctic, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Mantle zone lymphoma, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Small cleaved dif, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Mixed FCC dif, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Large cell dif, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (B-immunoblastic, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (T-immunob mixed, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (AILD-like T-cell lym, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Japanese ATL, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Lymphoblastic, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Small noncleaved dif, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (True histiocytic, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Ki-1 LC anaplas T, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Multiple myeloma, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Mycosis fungoides, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (AML, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Hairy cell leukemia, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Carcinoma, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Melanoma, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (EM plasmacytoma, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Kaposi's sarcoma, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Mast-cell disease, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (AIDS involutionary, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (T-immunob large, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Monocytoid B-cell, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Nasopharyngeal CA, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Seminoma, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (SLE, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Mycobact histiocytos, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Mast-cell hyperplas, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (LGV, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Histoplasmosis, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Coccidioidomycosis, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (CMV, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Brucellosis, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Ki-1 LC anaplas B, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (Intermed lymphocytic, Moderate [5-50pc]) 9.9999e-01, 9.9999e-06, 0.0000e+00;
  (AIDS early, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (AILD, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (ALIP, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Cat scratch disease, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Dermatopathic laden, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Florid follic hyperp, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (GLH hyaline vascular, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (GLH plasma cell, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Granulomatous laden, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Histiocytosis x, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Infectious mono, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Leprosy-lepromatous, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Lymphangiographic, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Mantle zone hyperpla, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Necrotizing Kikuchi, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Necrotiz non-Kikuchi, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Rheumatoid arthritis, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Sarcoidosis, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (SHML, Marked [>50pc]) 0.0, 0.3, 0.7;
  (Sinus histiocytosis, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Syphilis, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Toxoplasmosis, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Tuberculosis, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Viral NOS, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Whipple's disease, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (L&H nodular HD, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (L&H diffuse HD, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Nodular sclerosis HD, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Cellular phase NSHD, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Syncytial NSHD, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Mixed cellularity HD, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Interfollicular HD, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Diffuse fibrosis HD, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Reticular-type HD, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Small cleaved fol, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Mixed fol, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Large cell fol, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Small noncleaved fol, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Small lymphocytic, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Plasmacytoid lyctic, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Mantle zone lymphoma, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Small cleaved dif, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Mixed FCC dif, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Large cell dif, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (B-immunoblastic, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (T-immunob mixed, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (AILD-like T-cell lym, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Japanese ATL, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Lymphoblastic, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Small noncleaved dif, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (True histiocytic, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Ki-1 LC anaplas T, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Multiple myeloma, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Mycosis fungoides, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (AML, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Hairy cell leukemia, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Carcinoma, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Melanoma, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (EM plasmacytoma, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Kaposi's sarcoma, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Mast-cell disease, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (AIDS involutionary, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (T-immunob large, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Monocytoid B-cell, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Nasopharyngeal CA, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Seminoma, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (SLE, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Mycobact histiocytos, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Mast-cell hyperplas, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (LGV, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Histoplasmosis, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Coccidioidomycosis, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (CMV, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Brucellosis, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Ki-1 LC anaplas B, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
  (Intermed lymphocytic, Marked [>50pc]) 9.999e-01, 9.999e-05, 0.000e+00;
}
probability ( MA_EOSIN | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 0.9999, 0.0001;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 0.9999, 0.0001;
  (Histiocytosis x) 0.6, 0.4;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 0.9999, 0.0001;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 1.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 1.0, 0.0;
  (L&H diffuse HD) 1.0, 0.0;
  (Nodular sclerosis HD) 0.99, 0.01;
  (Cellular phase NSHD) 0.99, 0.01;
  (Syncytial NSHD) 0.99, 0.01;
  (Mixed cellularity HD) 0.99, 0.01;
  (Interfollicular HD) 0.99, 0.01;
  (Diffuse fibrosis HD) 1.0, 0.0;
  (Reticular-type HD) 1.0, 0.0;
  (Small cleaved fol) 1.0, 0.0;
  (Mixed fol) 1.0, 0.0;
  (Large cell fol) 1.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0;
  (Small lymphocytic) 1.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0;
  (Small cleaved dif) 1.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0;
  (Large cell dif) 1.0, 0.0;
  (B-immunoblastic) 1.0, 0.0;
  (T-immunob mixed) 1.0, 0.0;
  (AILD-like T-cell lym) 1.0, 0.0;
  (Japanese ATL) 1.0, 0.0;
  (Lymphoblastic) 1.0, 0.0;
  (Small noncleaved dif) 1.0, 0.0;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 1.0, 0.0;
  (Multiple myeloma) 1.0, 0.0;
  (Mycosis fungoides) 1.0, 0.0;
  (AML) 1.0, 0.0;
  (Hairy cell leukemia) 1.0, 0.0;
  (Carcinoma) 1.0, 0.0;
  (Melanoma) 1.0, 0.0;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0;
  (Mast-cell disease) 0.9999, 0.0001;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 1.0, 0.0;
  (Monocytoid B-cell) 1.0, 0.0;
  (Nasopharyngeal CA) 0.99, 0.01;
  (Seminoma) 1.0, 0.0;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 0.9999, 0.0001;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 1.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0;
}
probability ( EMM | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 1.0, 0.0;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 1.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 1.0, 0.0;
  (L&H diffuse HD) 1.0, 0.0;
  (Nodular sclerosis HD) 1.0, 0.0;
  (Cellular phase NSHD) 1.0, 0.0;
  (Syncytial NSHD) 1.0, 0.0;
  (Mixed cellularity HD) 1.0, 0.0;
  (Interfollicular HD) 1.0, 0.0;
  (Diffuse fibrosis HD) 1.0, 0.0;
  (Reticular-type HD) 1.0, 0.0;
  (Small cleaved fol) 1.0, 0.0;
  (Mixed fol) 1.0, 0.0;
  (Large cell fol) 1.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0;
  (Small lymphocytic) 1.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0;
  (Small cleaved dif) 1.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0;
  (Large cell dif) 1.0, 0.0;
  (B-immunoblastic) 1.0, 0.0;
  (T-immunob mixed) 1.0, 0.0;
  (AILD-like T-cell lym) 1.0, 0.0;
  (Japanese ATL) 1.0, 0.0;
  (Lymphoblastic) 1.0, 0.0;
  (Small noncleaved dif) 1.0, 0.0;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 1.0, 0.0;
  (Multiple myeloma) 1.0, 0.0;
  (Mycosis fungoides) 1.0, 0.0;
  (AML) 0.5, 0.5;
  (Hairy cell leukemia) 1.0, 0.0;
  (Carcinoma) 1.0, 0.0;
  (Melanoma) 1.0, 0.0;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0;
  (Mast-cell disease) 1.0, 0.0;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 1.0, 0.0;
  (Monocytoid B-cell) 1.0, 0.0;
  (Nasopharyngeal CA) 1.0, 0.0;
  (Seminoma) 1.0, 0.0;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 1.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0;
}
probability ( EOSIN | Fault, EMM ) {
  (AIDS early, Absent) 0.599, 0.400, 0.001;
  (AILD, Absent) 0.20, 0.75, 0.05;
  (ALIP, Absent) 0.20, 0.75, 0.05;
  (Cat scratch disease, Absent) 0.05, 0.90, 0.05;
  (Dermatopathic laden, Absent) 0.15, 0.83, 0.02;
  (Florid follic hyperp, Absent) 0.599, 0.400, 0.001;
  (GLH hyaline vascular, Absent) 0.599, 0.400, 0.001;
  (GLH plasma cell, Absent) 0.599, 0.400, 0.001;
  (Granulomatous laden, Absent) 0.05, 0.90, 0.05;
  (Histiocytosis x, Absent) 0.01, 0.20, 0.79;
  (Infectious mono, Absent) 0.15, 0.83, 0.02;
  (Leprosy-lepromatous, Absent) 0.599, 0.400, 0.001;
  (Lymphangiographic, Absent) 0.599, 0.400, 0.001;
  (Mantle zone hyperpla, Absent) 0.599, 0.400, 0.001;
  (Necrotizing Kikuchi, Absent) 0.9799, 0.0200, 0.0001;
  (Necrotiz non-Kikuchi, Absent) 0.05, 0.90, 0.05;
  (Rheumatoid arthritis, Absent) 0.599, 0.400, 0.001;
  (Sarcoidosis, Absent) 0.599, 0.400, 0.001;
  (SHML, Absent) 0.599, 0.400, 0.001;
  (Sinus histiocytosis, Absent) 0.599, 0.400, 0.001;
  (Syphilis, Absent) 0.15, 0.83, 0.02;
  (Toxoplasmosis, Absent) 0.599, 0.400, 0.001;
  (Tuberculosis, Absent) 0.599, 0.400, 0.001;
  (Viral NOS, Absent) 0.15, 0.83, 0.02;
  (Whipple's disease, Absent) 0.599, 0.400, 0.001;
  (L&H nodular HD, Absent) 0.599, 0.400, 0.001;
  (L&H diffuse HD, Absent) 0.599, 0.400, 0.001;
  (Nodular sclerosis HD, Absent) 0.10, 0.75, 0.15;
  (Cellular phase NSHD, Absent) 0.10, 0.75, 0.15;
  (Syncytial NSHD, Absent) 0.10, 0.75, 0.15;
  (Mixed cellularity HD, Absent) 0.10, 0.75, 0.15;
  (Interfollicular HD, Absent) 0.10, 0.75, 0.15;
  (Diffuse fibrosis HD, Absent) 0.599, 0.400, 0.001;
  (Reticular-type HD, Absent) 0.599, 0.400, 0.001;
  (Small cleaved fol, Absent) 0.599, 0.400, 0.001;
  (Mixed fol, Absent) 0.599, 0.400, 0.001;
  (Large cell fol, Absent) 0.599, 0.400, 0.001;
  (Small noncleaved fol, Absent) 0.599, 0.400, 0.001;
  (Small lymphocytic, Absent) 0.599, 0.400, 0.001;
  (Plasmacytoid lyctic, Absent) 0.599, 0.400, 0.001;
  (Mantle zone lymphoma, Absent) 0.599, 0.400, 0.001;
  (Small cleaved dif, Absent) 0.599, 0.400, 0.001;
  (Mixed FCC dif, Absent) 0.599, 0.400, 0.001;
  (Large cell dif, Absent) 0.599, 0.400, 0.001;
  (B-immunoblastic, Absent) 0.599, 0.400, 0.001;
  (T-immunob mixed, Absent) 0.35, 0.63, 0.02;
  (AILD-like T-cell lym, Absent) 0.20, 0.75, 0.05;
  (Japanese ATL, Absent) 0.599, 0.400, 0.001;
  (Lymphoblastic, Absent) 0.599, 0.400, 0.001;
  (Small noncleaved dif, Absent) 0.599, 0.400, 0.001;
  (True histiocytic, Absent) 0.599, 0.400, 0.001;
  (Ki-1 LC anaplas T, Absent) 0.599, 0.400, 0.001;
  (Multiple myeloma, Absent) 0.599, 0.400, 0.001;
  (Mycosis fungoides, Absent) 0.599, 0.400, 0.001;
  (AML, Absent) 0.94990501, 0.04999500, 0.00009999;
  (Hairy cell leukemia, Absent) 0.599, 0.400, 0.001;
  (Carcinoma, Absent) 0.599, 0.400, 0.001;
  (Melanoma, Absent) 0.599, 0.400, 0.001;
  (EM plasmacytoma, Absent) 0.599, 0.400, 0.001;
  (Kaposi's sarcoma, Absent) 0.599, 0.400, 0.001;
  (Mast-cell disease, Absent) 0.05, 0.90, 0.05;
  (AIDS involutionary, Absent) 0.599, 0.400, 0.001;
  (T-immunob large, Absent) 0.35, 0.63, 0.02;
  (Monocytoid B-cell, Absent) 0.599, 0.400, 0.001;
  (Nasopharyngeal CA, Absent) 0.10, 0.75, 0.15;
  (Seminoma, Absent) 0.599, 0.400, 0.001;
  (SLE, Absent) 0.15, 0.83, 0.02;
  (Mycobact histiocytos, Absent) 0.599, 0.400, 0.001;
  (Mast-cell hyperplas, Absent) 0.05, 0.90, 0.05;
  (LGV, Absent) 0.599, 0.400, 0.001;
  (Histoplasmosis, Absent) 0.599, 0.400, 0.001;
  (Coccidioidomycosis, Absent) 0.599, 0.400, 0.001;
  (CMV, Absent) 0.599, 0.400, 0.001;
  (Brucellosis, Absent) 0.599, 0.400, 0.001;
  (Ki-1 LC anaplas B, Absent) 0.599, 0.400, 0.001;
  (Intermed lymphocytic, Absent) 0.599, 0.400, 0.001;
  (AIDS early, Present) 0.3333333, 0.3333333, 0.3333333;
  (AILD, Present) 0.3333333, 0.3333333, 0.3333333;
  (ALIP, Present) 0.3333333, 0.3333333, 0.3333333;
  (Cat scratch disease, Present) 0.3333333, 0.3333333, 0.3333333;
  (Dermatopathic laden, Present) 0.3333333, 0.3333333, 0.3333333;
  (Florid follic hyperp, Present) 0.3333333, 0.3333333, 0.3333333;
  (GLH hyaline vascular, Present) 0.3333333, 0.3333333, 0.3333333;
  (GLH plasma cell, Present) 0.3333333, 0.3333333, 0.3333333;
  (Granulomatous laden, Present) 0.3333333, 0.3333333, 0.3333333;
  (Histiocytosis x, Present) 0.3333333, 0.3333333, 0.3333333;
  (Infectious mono, Present) 0.3333333, 0.3333333, 0.3333333;
  (Leprosy-lepromatous, Present) 0.3333333, 0.3333333, 0.3333333;
  (Lymphangiographic, Present) 0.3333333, 0.3333333, 0.3333333;
  (Mantle zone hyperpla, Present) 0.3333333, 0.3333333, 0.3333333;
  (Necrotizing Kikuchi, Present) 0.3333333, 0.3333333, 0.3333333;
  (Necrotiz non-Kikuchi, Present) 0.3333333, 0.3333333, 0.3333333;
  (Rheumatoid arthritis, Present) 0.3333333, 0.3333333, 0.3333333;
  (Sarcoidosis, Present) 0.3333333, 0.3333333, 0.3333333;
  (SHML, Present) 0.3333333, 0.3333333, 0.3333333;
  (Sinus histiocytosis, Present) 0.3333333, 0.3333333, 0.3333333;
  (Syphilis, Present) 0.3333333, 0.3333333, 0.3333333;
  (Toxoplasmosis, Present) 0.3333333, 0.3333333, 0.3333333;
  (Tuberculosis, Present) 0.3333333, 0.3333333, 0.3333333;
  (Viral NOS, Present) 0.3333333, 0.3333333, 0.3333333;
  (Whipple's disease, Present) 0.3333333, 0.3333333, 0.3333333;
  (L&H nodular HD, Present) 0.3333333, 0.3333333, 0.3333333;
  (L&H diffuse HD, Present) 0.3333333, 0.3333333, 0.3333333;
  (Nodular sclerosis HD, Present) 0.3333333, 0.3333333, 0.3333333;
  (Cellular phase NSHD, Present) 0.3333333, 0.3333333, 0.3333333;
  (Syncytial NSHD, Present) 0.3333333, 0.3333333, 0.3333333;
  (Mixed cellularity HD, Present) 0.3333333, 0.3333333, 0.3333333;
  (Interfollicular HD, Present) 0.3333333, 0.3333333, 0.3333333;
  (Diffuse fibrosis HD, Present) 0.3333333, 0.3333333, 0.3333333;
  (Reticular-type HD, Present) 0.3333333, 0.3333333, 0.3333333;
  (Small cleaved fol, Present) 0.3333333, 0.3333333, 0.3333333;
  (Mixed fol, Present) 0.3333333, 0.3333333, 0.3333333;
  (Large cell fol, Present) 0.3333333, 0.3333333, 0.3333333;
  (Small noncleaved fol, Present) 0.3333333, 0.3333333, 0.3333333;
  (Small lymphocytic, Present) 0.3333333, 0.3333333, 0.3333333;
  (Plasmacytoid lyctic, Present) 0.3333333, 0.3333333, 0.3333333;
  (Mantle zone lymphoma, Present) 0.3333333, 0.3333333, 0.3333333;
  (Small cleaved dif, Present) 0.3333333, 0.3333333, 0.3333333;
  (Mixed FCC dif, Present) 0.3333333, 0.3333333, 0.3333333;
  (Large cell dif, Present) 0.3333333, 0.3333333, 0.3333333;
  (B-immunoblastic, Present) 0.3333333, 0.3333333, 0.3333333;
  (T-immunob mixed, Present) 0.3333333, 0.3333333, 0.3333333;
  (AILD-like T-cell lym, Present) 0.3333333, 0.3333333, 0.3333333;
  (Japanese ATL, Present) 0.3333333, 0.3333333, 0.3333333;
  (Lymphoblastic, Present) 0.3333333, 0.3333333, 0.3333333;
  (Small noncleaved dif, Present) 0.3333333, 0.3333333, 0.3333333;
  (True histiocytic, Present) 0.3333333, 0.3333333, 0.3333333;
  (Ki-1 LC anaplas T, Present) 0.3333333, 0.3333333, 0.3333333;
  (Multiple myeloma, Present) 0.3333333, 0.3333333, 0.3333333;
  (Mycosis fungoides, Present) 0.3333333, 0.3333333, 0.3333333;
  (AML, Present) 0.01, 0.89, 0.10;
  (Hairy cell leukemia, Present) 0.3333333, 0.3333333, 0.3333333;
  (Carcinoma, Present) 0.3333333, 0.3333333, 0.3333333;
  (Melanoma, Present) 0.3333333, 0.3333333, 0.3333333;
  (EM plasmacytoma, Present) 0.3333333, 0.3333333, 0.3333333;
  (Kaposi's sarcoma, Present) 0.3333333, 0.3333333, 0.3333333;
  (Mast-cell disease, Present) 0.3333333, 0.3333333, 0.3333333;
  (AIDS involutionary, Present) 0.3333333, 0.3333333, 0.3333333;
  (T-immunob large, Present) 0.3333333, 0.3333333, 0.3333333;
  (Monocytoid B-cell, Present) 0.3333333, 0.3333333, 0.3333333;
  (Nasopharyngeal CA, Present) 0.3333333, 0.3333333, 0.3333333;
  (Seminoma, Present) 0.3333333, 0.3333333, 0.3333333;
  (SLE, Present) 0.3333333, 0.3333333, 0.3333333;
  (Mycobact histiocytos, Present) 0.3333333, 0.3333333, 0.3333333;
  (Mast-cell hyperplas, Present) 0.3333333, 0.3333333, 0.3333333;
  (LGV, Present) 0.3333333, 0.3333333, 0.3333333;
  (Histoplasmosis, Present) 0.3333333, 0.3333333, 0.3333333;
  (Coccidioidomycosis, Present) 0.3333333, 0.3333333, 0.3333333;
  (CMV, Present) 0.3333333, 0.3333333, 0.3333333;
  (Brucellosis, Present) 0.3333333, 0.3333333, 0.3333333;
  (Ki-1 LC anaplas B, Present) 0.3333333, 0.3333333, 0.3333333;
  (Intermed lymphocytic, Present) 0.3333333, 0.3333333, 0.3333333;
}
probability ( EHC | Fault ) {
  (AIDS early) 0.98, 0.02, 0.00;
  (AILD) 0.88, 0.10, 0.02;
  (ALIP) 0.98, 0.02, 0.00;
  (Cat scratch disease) 0.3, 0.6, 0.1;
  (Dermatopathic laden) 0.79, 0.20, 0.01;
  (Florid follic hyperp) 0.98, 0.02, 0.00;
  (GLH hyaline vascular) 0.98, 0.02, 0.00;
  (GLH plasma cell) 0.98, 0.02, 0.00;
  (Granulomatous laden) 0.0, 0.7, 0.3;
  (Histiocytosis x) 0.98, 0.02, 0.00;
  (Infectious mono) 0.25, 0.70, 0.05;
  (Leprosy-lepromatous) 0.02, 0.88, 0.10;
  (Lymphangiographic) 0.01, 0.79, 0.20;
  (Mantle zone hyperpla) 0.98, 0.02, 0.00;
  (Necrotizing Kikuchi) 0.945, 0.050, 0.005;
  (Necrotiz non-Kikuchi) 0.50, 0.45, 0.05;
  (Rheumatoid arthritis) 0.98, 0.02, 0.00;
  (Sarcoidosis) 0.0, 0.0, 1.0;
  (SHML) 0.98, 0.02, 0.00;
  (Sinus histiocytosis) 0.98, 0.02, 0.00;
  (Syphilis) 0.0, 0.7, 0.3;
  (Toxoplasmosis) 0.0, 0.6, 0.4;
  (Tuberculosis) 0.02, 0.88, 0.10;
  (Viral NOS) 0.25, 0.70, 0.05;
  (Whipple's disease) 0.01, 0.79, 0.20;
  (L&H nodular HD) 0.25, 0.45, 0.30;
  (L&H diffuse HD) 0.25, 0.45, 0.30;
  (Nodular sclerosis HD) 0.950, 0.049, 0.001;
  (Cellular phase NSHD) 0.950, 0.049, 0.001;
  (Syncytial NSHD) 0.950, 0.049, 0.001;
  (Mixed cellularity HD) 0.2, 0.3, 0.5;
  (Interfollicular HD) 0.3, 0.6, 0.1;
  (Diffuse fibrosis HD) 0.98, 0.02, 0.00;
  (Reticular-type HD) 0.98, 0.02, 0.00;
  (Small cleaved fol) 0.98, 0.02, 0.00;
  (Mixed fol) 0.98, 0.02, 0.00;
  (Large cell fol) 0.98, 0.02, 0.00;
  (Small noncleaved fol) 0.98, 0.02, 0.00;
  (Small lymphocytic) 0.98, 0.02, 0.00;
  (Plasmacytoid lyctic) 0.98, 0.02, 0.00;
  (Mantle zone lymphoma) 0.98, 0.02, 0.00;
  (Small cleaved dif) 0.98, 0.02, 0.00;
  (Mixed FCC dif) 0.88, 0.10, 0.02;
  (Large cell dif) 0.975, 0.020, 0.005;
  (B-immunoblastic) 0.98, 0.02, 0.00;
  (T-immunob mixed) 0.88, 0.10, 0.02;
  (AILD-like T-cell lym) 0.89, 0.10, 0.01;
  (Japanese ATL) 0.91, 0.08, 0.01;
  (Lymphoblastic) 0.98, 0.02, 0.00;
  (Small noncleaved dif) 0.98, 0.02, 0.00;
  (True histiocytic) 0.975, 0.020, 0.005;
  (Ki-1 LC anaplas T) 0.98, 0.02, 0.00;
  (Multiple myeloma) 0.98, 0.02, 0.00;
  (Mycosis fungoides) 0.91, 0.08, 0.01;
  (AML) 0.98, 0.02, 0.00;
  (Hairy cell leukemia) 0.98, 0.02, 0.00;
  (Carcinoma) 0.98, 0.02, 0.00;
  (Melanoma) 0.98, 0.02, 0.00;
  (EM plasmacytoma) 0.98, 0.02, 0.00;
  (Kaposi's sarcoma) 0.98, 0.02, 0.00;
  (Mast-cell disease) 0.3, 0.6, 0.1;
  (AIDS involutionary) 0.3, 0.6, 0.1;
  (T-immunob large) 0.91, 0.08, 0.01;
  (Monocytoid B-cell) 0.975, 0.020, 0.005;
  (Nasopharyngeal CA) 0.98, 0.02, 0.00;
  (Seminoma) 0.5, 0.2, 0.3;
  (SLE) 0.25, 0.70, 0.05;
  (Mycobact histiocytos) 0.65, 0.34, 0.01;
  (Mast-cell hyperplas) 0.3, 0.6, 0.1;
  (LGV) 0.65, 0.34, 0.01;
  (Histoplasmosis) 0.3, 0.6, 0.1;
  (Coccidioidomycosis) 0.3, 0.6, 0.1;
  (CMV) 0.3, 0.6, 0.1;
  (Brucellosis) 0.0, 0.6, 0.4;
  (Ki-1 LC anaplas B) 0.98, 0.02, 0.00;
  (Intermed lymphocytic) 0.98, 0.02, 0.00;
}
probability ( EHC_ENC | Fault, FOLLICLE, EHC ) {
  (AIDS early, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AML, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc], Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (ALIP, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SHML, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AML, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SLE, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (LGV, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (CMV, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, 1-25pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (ALIP, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SHML, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AML, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SLE, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (LGV, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (CMV, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, 25-75pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (ALIP, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SHML, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AML, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SLE, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (LGV, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (CMV, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, 75-90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (ALIP, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SHML, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AML, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SLE, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (LGV, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (CMV, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, >90pc, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (AML, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc], Present [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (AILD, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (ALIP, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Cat scratch disease, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Dermatopathic laden, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Florid follic hyperp, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (GLH hyaline vascular, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (GLH plasma cell, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Granulomatous laden, 1-25pc, Present [<5pc]) 0.00, 0.95, 0.05, 0.00;
  (Histiocytosis x, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Infectious mono, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Leprosy-lepromatous, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Lymphangiographic, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mantle zone hyperpla, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Necrotizing Kikuchi, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Necrotiz non-Kikuchi, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Rheumatoid arthritis, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Sarcoidosis, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (SHML, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Sinus histiocytosis, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Syphilis, 1-25pc, Present [<5pc]) 0.00, 0.95, 0.05, 0.00;
  (Toxoplasmosis, 1-25pc, Present [<5pc]) 0.0, 0.0, 0.8, 0.2;
  (Tuberculosis, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Viral NOS, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Whipple's disease, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (L&H nodular HD, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (L&H diffuse HD, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Nodular sclerosis HD, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Cellular phase NSHD, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Syncytial NSHD, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mixed cellularity HD, 1-25pc, Present [<5pc]) 0.00, 0.99, 0.01, 0.00;
  (Interfollicular HD, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Diffuse fibrosis HD, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Reticular-type HD, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Small cleaved fol, 1-25pc, Present [<5pc]) 0.0, 1.0, 0.0, 0.0;
  (Mixed fol, 1-25pc, Present [<5pc]) 0.0, 1.0, 0.0, 0.0;
  (Large cell fol, 1-25pc, Present [<5pc]) 0.0, 1.0, 0.0, 0.0;
  (Small noncleaved fol, 1-25pc, Present [<5pc]) 0.0, 1.0, 0.0, 0.0;
  (Small lymphocytic, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Plasmacytoid lyctic, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Mantle zone lymphoma, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Small cleaved dif, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Mixed FCC dif, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Large cell dif, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (B-immunoblastic, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (T-immunob mixed, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (AILD-like T-cell lym, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Japanese ATL, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Lymphoblastic, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Small noncleaved dif, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (True histiocytic, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Ki-1 LC anaplas T, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Multiple myeloma, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Mycosis fungoides, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (AML, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Hairy cell leukemia, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Carcinoma, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Melanoma, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (EM plasmacytoma, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Kaposi's sarcoma, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Mast-cell disease, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (AIDS involutionary, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (T-immunob large, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Monocytoid B-cell, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Nasopharyngeal CA, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Seminoma, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (SLE, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mycobact histiocytos, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mast-cell hyperplas, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (LGV, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Histoplasmosis, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Coccidioidomycosis, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (CMV, 1-25pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Brucellosis, 1-25pc, Present [<5pc]) 0.0, 0.0, 0.8, 0.2;
  (Ki-1 LC anaplas B, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Intermed lymphocytic, 1-25pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (AIDS early, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (AILD, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (ALIP, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Cat scratch disease, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Dermatopathic laden, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Florid follic hyperp, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (GLH hyaline vascular, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (GLH plasma cell, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Granulomatous laden, 25-75pc, Present [<5pc]) 0.00, 0.95, 0.05, 0.00;
  (Histiocytosis x, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Infectious mono, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Leprosy-lepromatous, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Lymphangiographic, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mantle zone hyperpla, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Necrotizing Kikuchi, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Necrotiz non-Kikuchi, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Rheumatoid arthritis, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Sarcoidosis, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (SHML, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Sinus histiocytosis, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Syphilis, 25-75pc, Present [<5pc]) 0.00, 0.95, 0.05, 0.00;
  (Toxoplasmosis, 25-75pc, Present [<5pc]) 0.0, 0.0, 0.8, 0.2;
  (Tuberculosis, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Viral NOS, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Whipple's disease, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (L&H nodular HD, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (L&H diffuse HD, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Nodular sclerosis HD, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Cellular phase NSHD, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Syncytial NSHD, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mixed cellularity HD, 25-75pc, Present [<5pc]) 0.00, 0.99, 0.01, 0.00;
  (Interfollicular HD, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Diffuse fibrosis HD, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Reticular-type HD, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Small cleaved fol, 25-75pc, Present [<5pc]) 0.0, 1.0, 0.0, 0.0;
  (Mixed fol, 25-75pc, Present [<5pc]) 0.0, 1.0, 0.0, 0.0;
  (Large cell fol, 25-75pc, Present [<5pc]) 0.0, 1.0, 0.0, 0.0;
  (Small noncleaved fol, 25-75pc, Present [<5pc]) 0.0, 1.0, 0.0, 0.0;
  (Small lymphocytic, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Plasmacytoid lyctic, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Mantle zone lymphoma, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Small cleaved dif, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Mixed FCC dif, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Large cell dif, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (B-immunoblastic, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (T-immunob mixed, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (AILD-like T-cell lym, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Japanese ATL, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Lymphoblastic, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Small noncleaved dif, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (True histiocytic, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Ki-1 LC anaplas T, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Multiple myeloma, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Mycosis fungoides, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (AML, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Hairy cell leukemia, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Carcinoma, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Melanoma, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (EM plasmacytoma, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Kaposi's sarcoma, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Mast-cell disease, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (AIDS involutionary, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (T-immunob large, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Monocytoid B-cell, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Nasopharyngeal CA, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Seminoma, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (SLE, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mycobact histiocytos, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mast-cell hyperplas, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (LGV, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Histoplasmosis, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Coccidioidomycosis, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (CMV, 25-75pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Brucellosis, 25-75pc, Present [<5pc]) 0.0, 0.0, 0.8, 0.2;
  (Ki-1 LC anaplas B, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Intermed lymphocytic, 25-75pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (AIDS early, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (AILD, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (ALIP, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Cat scratch disease, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Dermatopathic laden, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Florid follic hyperp, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (GLH hyaline vascular, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (GLH plasma cell, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Granulomatous laden, 75-90pc, Present [<5pc]) 0.00, 0.95, 0.05, 0.00;
  (Histiocytosis x, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Infectious mono, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Leprosy-lepromatous, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Lymphangiographic, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mantle zone hyperpla, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Necrotizing Kikuchi, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Necrotiz non-Kikuchi, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Rheumatoid arthritis, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Sarcoidosis, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (SHML, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Sinus histiocytosis, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Syphilis, 75-90pc, Present [<5pc]) 0.00, 0.95, 0.05, 0.00;
  (Toxoplasmosis, 75-90pc, Present [<5pc]) 0.0, 0.0, 0.8, 0.2;
  (Tuberculosis, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Viral NOS, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Whipple's disease, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (L&H nodular HD, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (L&H diffuse HD, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Nodular sclerosis HD, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Cellular phase NSHD, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Syncytial NSHD, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mixed cellularity HD, 75-90pc, Present [<5pc]) 0.00, 0.99, 0.01, 0.00;
  (Interfollicular HD, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Diffuse fibrosis HD, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Reticular-type HD, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Small cleaved fol, 75-90pc, Present [<5pc]) 0.0, 1.0, 0.0, 0.0;
  (Mixed fol, 75-90pc, Present [<5pc]) 0.0, 1.0, 0.0, 0.0;
  (Large cell fol, 75-90pc, Present [<5pc]) 0.0, 1.0, 0.0, 0.0;
  (Small noncleaved fol, 75-90pc, Present [<5pc]) 0.0, 1.0, 0.0, 0.0;
  (Small lymphocytic, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Plasmacytoid lyctic, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Mantle zone lymphoma, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Small cleaved dif, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Mixed FCC dif, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Large cell dif, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (B-immunoblastic, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (T-immunob mixed, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (AILD-like T-cell lym, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Japanese ATL, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Lymphoblastic, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Small noncleaved dif, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (True histiocytic, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Ki-1 LC anaplas T, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Multiple myeloma, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Mycosis fungoides, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (AML, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Hairy cell leukemia, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Carcinoma, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Melanoma, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (EM plasmacytoma, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Kaposi's sarcoma, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Mast-cell disease, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (AIDS involutionary, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (T-immunob large, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Monocytoid B-cell, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Nasopharyngeal CA, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Seminoma, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (SLE, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mycobact histiocytos, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mast-cell hyperplas, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (LGV, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Histoplasmosis, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Coccidioidomycosis, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (CMV, 75-90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Brucellosis, 75-90pc, Present [<5pc]) 0.0, 0.0, 0.8, 0.2;
  (Ki-1 LC anaplas B, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Intermed lymphocytic, 75-90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (AIDS early, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (AILD, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (ALIP, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Cat scratch disease, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Dermatopathic laden, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Florid follic hyperp, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (GLH hyaline vascular, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (GLH plasma cell, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Granulomatous laden, >90pc, Present [<5pc]) 0.00, 0.95, 0.05, 0.00;
  (Histiocytosis x, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Infectious mono, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Leprosy-lepromatous, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Lymphangiographic, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mantle zone hyperpla, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Necrotizing Kikuchi, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Necrotiz non-Kikuchi, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Rheumatoid arthritis, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Sarcoidosis, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (SHML, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Sinus histiocytosis, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Syphilis, >90pc, Present [<5pc]) 0.00, 0.95, 0.05, 0.00;
  (Toxoplasmosis, >90pc, Present [<5pc]) 0.0, 0.0, 0.8, 0.2;
  (Tuberculosis, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Viral NOS, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Whipple's disease, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (L&H nodular HD, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (L&H diffuse HD, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Nodular sclerosis HD, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Cellular phase NSHD, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Syncytial NSHD, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mixed cellularity HD, >90pc, Present [<5pc]) 0.00, 0.99, 0.01, 0.00;
  (Interfollicular HD, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Diffuse fibrosis HD, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Reticular-type HD, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Small cleaved fol, >90pc, Present [<5pc]) 0.0, 1.0, 0.0, 0.0;
  (Mixed fol, >90pc, Present [<5pc]) 0.0, 1.0, 0.0, 0.0;
  (Large cell fol, >90pc, Present [<5pc]) 0.0, 1.0, 0.0, 0.0;
  (Small noncleaved fol, >90pc, Present [<5pc]) 0.0, 1.0, 0.0, 0.0;
  (Small lymphocytic, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Plasmacytoid lyctic, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Mantle zone lymphoma, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Small cleaved dif, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Mixed FCC dif, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Large cell dif, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (B-immunoblastic, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (T-immunob mixed, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (AILD-like T-cell lym, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Japanese ATL, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Lymphoblastic, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Small noncleaved dif, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (True histiocytic, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Ki-1 LC anaplas T, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Multiple myeloma, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Mycosis fungoides, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (AML, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Hairy cell leukemia, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Carcinoma, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Melanoma, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (EM plasmacytoma, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Kaposi's sarcoma, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Mast-cell disease, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (AIDS involutionary, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (T-immunob large, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Monocytoid B-cell, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Nasopharyngeal CA, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Seminoma, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (SLE, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mycobact histiocytos, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mast-cell hyperplas, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (LGV, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Histoplasmosis, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Coccidioidomycosis, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (CMV, >90pc, Present [<5pc]) 0.000, 0.999, 0.001, 0.000;
  (Brucellosis, >90pc, Present [<5pc]) 0.0, 0.0, 0.8, 0.2;
  (Ki-1 LC anaplas B, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (Intermed lymphocytic, >90pc, Present [<5pc]) 0.0000, 0.9999, 0.0001, 0.0000;
  (AIDS early, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (AML, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc], Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (AILD, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (ALIP, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, 1-25pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Dermatopathic laden, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Florid follic hyperp, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, 1-25pc, Prominent [>5pc]) 0.000, 0.849, 0.150, 0.001;
  (Histiocytosis x, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, 1-25pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Leprosy-lepromatous, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Lymphangiographic, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mantle zone hyperpla, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Necrotiz non-Kikuchi, 1-25pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Rheumatoid arthritis, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (SHML, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, 1-25pc, Prominent [>5pc]) 0.000, 0.849, 0.150, 0.001;
  (Toxoplasmosis, 1-25pc, Prominent [>5pc]) 0.0, 0.0, 0.4, 0.6;
  (Tuberculosis, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Viral NOS, 1-25pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Whipple's disease, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (L&H nodular HD, 1-25pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (L&H diffuse HD, 1-25pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Nodular sclerosis HD, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Cellular phase NSHD, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Syncytial NSHD, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mixed cellularity HD, 1-25pc, Prominent [>5pc]) 0.00, 0.98, 0.02, 0.00;
  (Interfollicular HD, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Diffuse fibrosis HD, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (AILD-like T-cell lym, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Japanese ATL, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (AML, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (AIDS involutionary, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (T-immunob large, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Nasopharyngeal CA, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Seminoma, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (SLE, 1-25pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Mycobact histiocytos, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mast-cell hyperplas, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (LGV, 1-25pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Histoplasmosis, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Coccidioidomycosis, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (CMV, 1-25pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Brucellosis, 1-25pc, Prominent [>5pc]) 0.0, 0.0, 0.4, 0.6;
  (Ki-1 LC anaplas B, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, 1-25pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (AILD, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (ALIP, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, 25-75pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Dermatopathic laden, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Florid follic hyperp, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, 25-75pc, Prominent [>5pc]) 0.000, 0.849, 0.150, 0.001;
  (Histiocytosis x, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, 25-75pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Leprosy-lepromatous, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Lymphangiographic, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mantle zone hyperpla, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Necrotiz non-Kikuchi, 25-75pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Rheumatoid arthritis, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (SHML, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, 25-75pc, Prominent [>5pc]) 0.000, 0.849, 0.150, 0.001;
  (Toxoplasmosis, 25-75pc, Prominent [>5pc]) 0.0, 0.0, 0.4, 0.6;
  (Tuberculosis, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Viral NOS, 25-75pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Whipple's disease, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (L&H nodular HD, 25-75pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (L&H diffuse HD, 25-75pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Nodular sclerosis HD, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Cellular phase NSHD, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Syncytial NSHD, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mixed cellularity HD, 25-75pc, Prominent [>5pc]) 0.00, 0.98, 0.02, 0.00;
  (Interfollicular HD, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Diffuse fibrosis HD, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (AILD-like T-cell lym, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Japanese ATL, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (AML, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (AIDS involutionary, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (T-immunob large, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Nasopharyngeal CA, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Seminoma, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (SLE, 25-75pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Mycobact histiocytos, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mast-cell hyperplas, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (LGV, 25-75pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Histoplasmosis, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Coccidioidomycosis, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (CMV, 25-75pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Brucellosis, 25-75pc, Prominent [>5pc]) 0.0, 0.0, 0.4, 0.6;
  (Ki-1 LC anaplas B, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, 25-75pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (AILD, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (ALIP, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, 75-90pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Dermatopathic laden, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Florid follic hyperp, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, 75-90pc, Prominent [>5pc]) 0.000, 0.849, 0.150, 0.001;
  (Histiocytosis x, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, 75-90pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Leprosy-lepromatous, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Lymphangiographic, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mantle zone hyperpla, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Necrotiz non-Kikuchi, 75-90pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Rheumatoid arthritis, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (SHML, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, 75-90pc, Prominent [>5pc]) 0.000, 0.849, 0.150, 0.001;
  (Toxoplasmosis, 75-90pc, Prominent [>5pc]) 0.0, 0.0, 0.4, 0.6;
  (Tuberculosis, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Viral NOS, 75-90pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Whipple's disease, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (L&H nodular HD, 75-90pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (L&H diffuse HD, 75-90pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Nodular sclerosis HD, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Cellular phase NSHD, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Syncytial NSHD, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mixed cellularity HD, 75-90pc, Prominent [>5pc]) 0.00, 0.98, 0.02, 0.00;
  (Interfollicular HD, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Diffuse fibrosis HD, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (AILD-like T-cell lym, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Japanese ATL, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (AML, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (AIDS involutionary, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (T-immunob large, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Nasopharyngeal CA, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Seminoma, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (SLE, 75-90pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Mycobact histiocytos, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mast-cell hyperplas, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (LGV, 75-90pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Histoplasmosis, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Coccidioidomycosis, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (CMV, 75-90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Brucellosis, 75-90pc, Prominent [>5pc]) 0.0, 0.0, 0.4, 0.6;
  (Ki-1 LC anaplas B, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, 75-90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (AILD, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (ALIP, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, >90pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Dermatopathic laden, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Florid follic hyperp, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, >90pc, Prominent [>5pc]) 0.000, 0.849, 0.150, 0.001;
  (Histiocytosis x, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, >90pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Leprosy-lepromatous, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Lymphangiographic, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mantle zone hyperpla, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Necrotiz non-Kikuchi, >90pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Rheumatoid arthritis, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (SHML, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, >90pc, Prominent [>5pc]) 0.000, 0.849, 0.150, 0.001;
  (Toxoplasmosis, >90pc, Prominent [>5pc]) 0.0, 0.0, 0.4, 0.6;
  (Tuberculosis, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Viral NOS, >90pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Whipple's disease, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (L&H nodular HD, >90pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (L&H diffuse HD, >90pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Nodular sclerosis HD, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Cellular phase NSHD, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Syncytial NSHD, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mixed cellularity HD, >90pc, Prominent [>5pc]) 0.00, 0.98, 0.02, 0.00;
  (Interfollicular HD, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Diffuse fibrosis HD, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (AILD-like T-cell lym, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Japanese ATL, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (AML, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (AIDS involutionary, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (T-immunob large, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Nasopharyngeal CA, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Seminoma, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (SLE, >90pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Mycobact histiocytos, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Mast-cell hyperplas, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (LGV, >90pc, Prominent [>5pc]) 0.000, 0.995, 0.005, 0.000;
  (Histoplasmosis, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Coccidioidomycosis, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (CMV, >90pc, Prominent [>5pc]) 0.000, 0.999, 0.001, 0.000;
  (Brucellosis, >90pc, Prominent [>5pc]) 0.0, 0.0, 0.4, 0.6;
  (Ki-1 LC anaplas B, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, >90pc, Prominent [>5pc]) 1.0, 0.0, 0.0, 0.0;
}
probability ( EH_NC | Fault ) {
  (AIDS early) 0.9, 0.1, 0.0;
  (AILD) 0.80, 0.15, 0.05;
  (ALIP) 0.8999, 0.1000, 0.0001;
  (Cat scratch disease) 0.1, 0.8, 0.1;
  (Dermatopathic laden) 0.05, 0.80, 0.15;
  (Florid follic hyperp) 0.8999, 0.1000, 0.0001;
  (GLH hyaline vascular) 0.8999, 0.1000, 0.0001;
  (GLH plasma cell) 0.8999, 0.1000, 0.0001;
  (Granulomatous laden) 0.1, 0.8, 0.1;
  (Histiocytosis x) 0.8999, 0.1000, 0.0001;
  (Infectious mono) 0.899, 0.100, 0.001;
  (Leprosy-lepromatous) 0.05, 0.85, 0.10;
  (Lymphangiographic) 0.01, 0.80, 0.19;
  (Mantle zone hyperpla) 0.8999, 0.1000, 0.0001;
  (Necrotizing Kikuchi) 0.89, 0.10, 0.01;
  (Necrotiz non-Kikuchi) 0.05, 0.90, 0.05;
  (Rheumatoid arthritis) 0.8999, 0.1000, 0.0001;
  (Sarcoidosis) 0.8999, 0.1000, 0.0001;
  (SHML) 0.8999, 0.1000, 0.0001;
  (Sinus histiocytosis) 0.8999, 0.1000, 0.0001;
  (Syphilis) 0.1, 0.8, 0.1;
  (Toxoplasmosis) 0.899, 0.100, 0.001;
  (Tuberculosis) 0.05, 0.85, 0.10;
  (Viral NOS) 0.899, 0.100, 0.001;
  (Whipple's disease) 0.01, 0.80, 0.19;
  (L&H nodular HD) 0.02, 0.70, 0.28;
  (L&H diffuse HD) 0.02, 0.70, 0.28;
  (Nodular sclerosis HD) 0.799, 0.200, 0.001;
  (Cellular phase NSHD) 0.799, 0.200, 0.001;
  (Syncytial NSHD) 0.799, 0.200, 0.001;
  (Mixed cellularity HD) 0.30, 0.69, 0.01;
  (Interfollicular HD) 0.20, 0.79, 0.01;
  (Diffuse fibrosis HD) 0.8999, 0.1000, 0.0001;
  (Reticular-type HD) 0.8999, 0.1000, 0.0001;
  (Small cleaved fol) 0.8999, 0.1000, 0.0001;
  (Mixed fol) 0.8999, 0.1000, 0.0001;
  (Large cell fol) 0.8999, 0.1000, 0.0001;
  (Small noncleaved fol) 0.8999, 0.1000, 0.0001;
  (Small lymphocytic) 0.949, 0.050, 0.001;
  (Plasmacytoid lyctic) 0.949, 0.050, 0.001;
  (Mantle zone lymphoma) 0.8999, 0.1000, 0.0001;
  (Small cleaved dif) 0.949, 0.050, 0.001;
  (Mixed FCC dif) 0.75, 0.20, 0.05;
  (Large cell dif) 0.949, 0.050, 0.001;
  (B-immunoblastic) 0.949, 0.050, 0.001;
  (T-immunob mixed) 0.5, 0.4, 0.1;
  (AILD-like T-cell lym) 0.80, 0.15, 0.05;
  (Japanese ATL) 0.949, 0.050, 0.001;
  (Lymphoblastic) 0.949, 0.050, 0.001;
  (Small noncleaved dif) 0.949, 0.050, 0.001;
  (True histiocytic) 0.949, 0.050, 0.001;
  (Ki-1 LC anaplas T) 0.949, 0.050, 0.001;
  (Multiple myeloma) 0.8999, 0.1000, 0.0001;
  (Mycosis fungoides) 0.05, 0.80, 0.15;
  (AML) 0.8999, 0.1000, 0.0001;
  (Hairy cell leukemia) 0.8999, 0.1000, 0.0001;
  (Carcinoma) 0.8999, 0.1000, 0.0001;
  (Melanoma) 0.8999, 0.1000, 0.0001;
  (EM plasmacytoma) 0.8999, 0.1000, 0.0001;
  (Kaposi's sarcoma) 0.30, 0.69, 0.01;
  (Mast-cell disease) 0.20, 0.79, 0.01;
  (AIDS involutionary) 0.10, 0.88, 0.02;
  (T-immunob large) 0.68, 0.30, 0.02;
  (Monocytoid B-cell) 0.87, 0.10, 0.03;
  (Nasopharyngeal CA) 0.8999, 0.1000, 0.0001;
  (Seminoma) 0.79, 0.20, 0.01;
  (SLE) 0.899, 0.100, 0.001;
  (Mycobact histiocytos) 0.01, 0.79, 0.20;
  (Mast-cell hyperplas) 0.20, 0.79, 0.01;
  (LGV) 0.1, 0.8, 0.1;
  (Histoplasmosis) 0.1, 0.8, 0.1;
  (Coccidioidomycosis) 0.1, 0.8, 0.1;
  (CMV) 0.1, 0.8, 0.1;
  (Brucellosis) 0.899, 0.100, 0.001;
  (Ki-1 LC anaplas B) 0.949, 0.050, 0.001;
  (Intermed lymphocytic) 0.8999, 0.1000, 0.0001;
}
probability ( ECCC | Fault, LLC_I, MLC_I ) {
  (AIDS early, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (AILD, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [no], Absent [no]) 0.25, 0.25, 0.25, 0.25;
  (Leprosy-lepromatous, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (SHML, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [no], Absent [no]) 0.25, 0.25, 0.25, 0.25;
  (Whipple's disease, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [no], Absent [no]) 0.25, 0.25, 0.25, 0.25;
  (B-immunoblastic, Absent [no], Absent [no]) 0.25, 0.25, 0.25, 0.25;
  (T-immunob mixed, Absent [no], Absent [no]) 0.25, 0.25, 0.25, 0.25;
  (AILD-like T-cell lym, Absent [no], Absent [no]) 0.25, 0.25, 0.25, 0.25;
  (Japanese ATL, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [no], Absent [no]) 0.25, 0.25, 0.25, 0.25;
  (Ki-1 LC anaplas T, Absent [no], Absent [no]) 0.25, 0.25, 0.25, 0.25;
  (Multiple myeloma, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (AML, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [no], Absent [no]) 0.25, 0.25, 0.25, 0.25;
  (Monocytoid B-cell, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (SLE, Absent [no], Absent [no]) 0.25, 0.25, 0.25, 0.25;
  (Mycobact histiocytos, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (LGV, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (CMV, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [no], Absent [no]) 0.25, 0.25, 0.25, 0.25;
  (Intermed lymphocytic, Absent [no], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (AILD, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (ALIP, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Present [yes], Absent [no]) 0.999, 0.001, 0.000, 0.000;
  (Dermatopathic laden, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, Present [yes], Absent [no]) 0.999, 0.001, 0.000, 0.000;
  (Leprosy-lepromatous, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Present [yes], Absent [no]) 0.999, 0.001, 0.000, 0.000;
  (Necrotiz non-Kikuchi, Present [yes], Absent [no]) 0.999, 0.001, 0.000, 0.000;
  (Rheumatoid arthritis, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (SHML, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, Present [yes], Absent [no]) 0.999, 0.001, 0.000, 0.000;
  (Whipple's disease, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Present [yes], Absent [no]) 0.999, 0.001, 0.000, 0.000;
  (Cellular phase NSHD, Present [yes], Absent [no]) 0.999, 0.001, 0.000, 0.000;
  (Syncytial NSHD, Present [yes], Absent [no]) 0.999, 0.001, 0.000, 0.000;
  (Mixed cellularity HD, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, Present [yes], Absent [no]) 0.98, 0.02, 0.00, 0.00;
  (B-immunoblastic, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Present [yes], Absent [no]) 0.96, 0.02, 0.01, 0.01;
  (AILD-like T-cell lym, Present [yes], Absent [no]) 0.00, 0.05, 0.50, 0.45;
  (Japanese ATL, Present [yes], Absent [no]) 0.97, 0.02, 0.01, 0.00;
  (Lymphoblastic, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Present [yes], Absent [no]) 0.25, 0.25, 0.25, 0.25;
  (True histiocytic, Present [yes], Absent [no]) 0.97, 0.02, 0.01, 0.00;
  (Ki-1 LC anaplas T, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (AML, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, Present [yes], Absent [no]) 0.999, 0.001, 0.000, 0.000;
  (Melanoma, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, Present [yes], Absent [no]) 0.96, 0.02, 0.01, 0.01;
  (Monocytoid B-cell, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Present [yes], Absent [no]) 0.999, 0.001, 0.000, 0.000;
  (Seminoma, Present [yes], Absent [no]) 0.999, 0.001, 0.000, 0.000;
  (SLE, Present [yes], Absent [no]) 0.999, 0.001, 0.000, 0.000;
  (Mycobact histiocytos, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (LGV, Present [yes], Absent [no]) 0.999, 0.001, 0.000, 0.000;
  (Histoplasmosis, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (CMV, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Present [yes], Absent [no]) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (AILD, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [no], Present [yes]) 0.25, 0.25, 0.25, 0.25;
  (Leprosy-lepromatous, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (SHML, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [no], Present [yes]) 0.25, 0.25, 0.25, 0.25;
  (Whipple's disease, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [no], Present [yes]) 0.25, 0.25, 0.25, 0.25;
  (B-immunoblastic, Absent [no], Present [yes]) 0.25, 0.25, 0.25, 0.25;
  (T-immunob mixed, Absent [no], Present [yes]) 0.25, 0.25, 0.25, 0.25;
  (AILD-like T-cell lym, Absent [no], Present [yes]) 0.25, 0.25, 0.25, 0.25;
  (Japanese ATL, Absent [no], Present [yes]) 0.98, 0.01, 0.01, 0.00;
  (Lymphoblastic, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [no], Present [yes]) 0.25, 0.25, 0.25, 0.25;
  (Ki-1 LC anaplas T, Absent [no], Present [yes]) 0.25, 0.25, 0.25, 0.25;
  (Multiple myeloma, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (AML, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [no], Present [yes]) 0.97, 0.02, 0.01, 0.00;
  (Carcinoma, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [no], Present [yes]) 0.97, 0.02, 0.01, 0.00;
  (AIDS involutionary, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [no], Present [yes]) 0.25, 0.25, 0.25, 0.25;
  (Monocytoid B-cell, Absent [no], Present [yes]) 0.97, 0.02, 0.01, 0.00;
  (Nasopharyngeal CA, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (SLE, Absent [no], Present [yes]) 0.25, 0.25, 0.25, 0.25;
  (Mycobact histiocytos, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [no], Present [yes]) 0.97, 0.02, 0.01, 0.00;
  (LGV, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (CMV, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [no], Present [yes]) 0.25, 0.25, 0.25, 0.25;
  (Intermed lymphocytic, Absent [no], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (AILD, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (ALIP, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Present [yes], Present [yes]) 0.995, 0.005, 0.000, 0.000;
  (Dermatopathic laden, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, Present [yes], Present [yes]) 0.995, 0.005, 0.000, 0.000;
  (Leprosy-lepromatous, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Present [yes], Present [yes]) 0.995, 0.005, 0.000, 0.000;
  (Necrotiz non-Kikuchi, Present [yes], Present [yes]) 0.995, 0.005, 0.000, 0.000;
  (Rheumatoid arthritis, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (SHML, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, Present [yes], Present [yes]) 0.995, 0.005, 0.000, 0.000;
  (Whipple's disease, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Present [yes], Present [yes]) 0.9995, 0.0005, 0.0000, 0.0000;
  (Cellular phase NSHD, Present [yes], Present [yes]) 0.9995, 0.0005, 0.0000, 0.0000;
  (Syncytial NSHD, Present [yes], Present [yes]) 0.9995, 0.0005, 0.0000, 0.0000;
  (Mixed cellularity HD, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, Present [yes], Present [yes]) 0.98, 0.02, 0.00, 0.00;
  (B-immunoblastic, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Present [yes], Present [yes]) 0.96, 0.02, 0.01, 0.01;
  (AILD-like T-cell lym, Present [yes], Present [yes]) 0.00, 0.05, 0.45, 0.50;
  (Japanese ATL, Present [yes], Present [yes]) 0.98, 0.01, 0.01, 0.00;
  (Lymphoblastic, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, Present [yes], Present [yes]) 0.97, 0.02, 0.01, 0.00;
  (Ki-1 LC anaplas T, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (AML, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Present [yes], Present [yes]) 0.97, 0.02, 0.01, 0.00;
  (Carcinoma, Present [yes], Present [yes]) 0.998, 0.001, 0.001, 0.000;
  (Melanoma, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Present [yes], Present [yes]) 0.97, 0.02, 0.01, 0.00;
  (AIDS involutionary, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, Present [yes], Present [yes]) 0.94, 0.04, 0.01, 0.01;
  (Monocytoid B-cell, Present [yes], Present [yes]) 0.97, 0.02, 0.01, 0.00;
  (Nasopharyngeal CA, Present [yes], Present [yes]) 0.998, 0.001, 0.001, 0.000;
  (Seminoma, Present [yes], Present [yes]) 0.998, 0.001, 0.001, 0.000;
  (SLE, Present [yes], Present [yes]) 0.995, 0.005, 0.000, 0.000;
  (Mycobact histiocytos, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Present [yes], Present [yes]) 0.97, 0.02, 0.01, 0.00;
  (LGV, Present [yes], Present [yes]) 0.995, 0.005, 0.000, 0.000;
  (Histoplasmosis, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (CMV, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Present [yes], Present [yes]) 1.0, 0.0, 0.0, 0.0;
}
probability ( FCB | Fault, CT ) {
  (AIDS early, Absent) 0.94, 0.05, 0.01;
  (AILD, Absent) 0.80, 0.15, 0.05;
  (ALIP, Absent) 0.94, 0.05, 0.01;
  (Cat scratch disease, Absent) 0.94, 0.05, 0.01;
  (Dermatopathic laden, Absent) 0.94, 0.05, 0.01;
  (Florid follic hyperp, Absent) 0.94, 0.05, 0.01;
  (GLH hyaline vascular, Absent) 0.01, 0.64, 0.35;
  (GLH plasma cell, Absent) 0.94, 0.05, 0.01;
  (Granulomatous laden, Absent) 0.78, 0.15, 0.07;
  (Histiocytosis x, Absent) 0.94, 0.05, 0.01;
  (Infectious mono, Absent) 0.94, 0.05, 0.01;
  (Leprosy-lepromatous, Absent) 0.94, 0.05, 0.01;
  (Lymphangiographic, Absent) 0.94, 0.05, 0.01;
  (Mantle zone hyperpla, Absent) 0.94, 0.05, 0.01;
  (Necrotizing Kikuchi, Absent) 0.94, 0.05, 0.01;
  (Necrotiz non-Kikuchi, Absent) 0.94, 0.05, 0.01;
  (Rheumatoid arthritis, Absent) 0.78, 0.15, 0.07;
  (Sarcoidosis, Absent) 0.84, 0.15, 0.01;
  (SHML, Absent) 0.01, 0.94, 0.05;
  (Sinus histiocytosis, Absent) 0.94, 0.05, 0.01;
  (Syphilis, Absent) 0.78, 0.15, 0.07;
  (Toxoplasmosis, Absent) 0.94, 0.05, 0.01;
  (Tuberculosis, Absent) 0.78, 0.15, 0.07;
  (Viral NOS, Absent) 0.94, 0.05, 0.01;
  (Whipple's disease, Absent) 0.94, 0.05, 0.01;
  (L&H nodular HD, Absent) 0.94, 0.05, 0.01;
  (L&H diffuse HD, Absent) 0.94, 0.05, 0.01;
  (Nodular sclerosis HD, Absent) 0.0, 0.8, 0.2;
  (Cellular phase NSHD, Absent) 0.949, 0.050, 0.001;
  (Syncytial NSHD, Absent) 0.00, 0.96, 0.04;
  (Mixed cellularity HD, Absent) 0.97, 0.02, 0.01;
  (Interfollicular HD, Absent) 0.94, 0.05, 0.01;
  (Diffuse fibrosis HD, Absent) 0.1, 0.7, 0.2;
  (Reticular-type HD, Absent) 0.94, 0.05, 0.01;
  (Small cleaved fol, Absent) 0.94, 0.05, 0.01;
  (Mixed fol, Absent) 0.94, 0.05, 0.01;
  (Large cell fol, Absent) 0.94, 0.05, 0.01;
  (Small noncleaved fol, Absent) 0.94, 0.05, 0.01;
  (Small lymphocytic, Absent) 0.94, 0.05, 0.01;
  (Plasmacytoid lyctic, Absent) 0.94, 0.05, 0.01;
  (Mantle zone lymphoma, Absent) 0.94, 0.05, 0.01;
  (Small cleaved dif, Absent) 0.80, 0.15, 0.05;
  (Mixed FCC dif, Absent) 0.80, 0.15, 0.05;
  (Large cell dif, Absent) 0.80, 0.15, 0.05;
  (B-immunoblastic, Absent) 0.94, 0.05, 0.01;
  (T-immunob mixed, Absent) 0.55, 0.40, 0.05;
  (AILD-like T-cell lym, Absent) 0.80, 0.15, 0.05;
  (Japanese ATL, Absent) 0.94, 0.05, 0.01;
  (Lymphoblastic, Absent) 0.94, 0.05, 0.01;
  (Small noncleaved dif, Absent) 0.94, 0.05, 0.01;
  (True histiocytic, Absent) 0.94, 0.05, 0.01;
  (Ki-1 LC anaplas T, Absent) 0.94, 0.05, 0.01;
  (Multiple myeloma, Absent) 0.94, 0.05, 0.01;
  (Mycosis fungoides, Absent) 0.94, 0.05, 0.01;
  (AML, Absent) 0.94, 0.05, 0.01;
  (Hairy cell leukemia, Absent) 0.94, 0.05, 0.01;
  (Carcinoma, Absent) 0.94, 0.05, 0.01;
  (Melanoma, Absent) 0.94, 0.05, 0.01;
  (EM plasmacytoma, Absent) 0.94, 0.05, 0.01;
  (Kaposi's sarcoma, Absent) 0.94, 0.05, 0.01;
  (Mast-cell disease, Absent) 0.1, 0.8, 0.1;
  (AIDS involutionary, Absent) 0.94, 0.05, 0.01;
  (T-immunob large, Absent) 0.80, 0.15, 0.05;
  (Monocytoid B-cell, Absent) 0.94, 0.05, 0.01;
  (Nasopharyngeal CA, Absent) 0.0, 0.8, 0.2;
  (Seminoma, Absent) 0.94, 0.05, 0.01;
  (SLE, Absent) 0.94, 0.05, 0.01;
  (Mycobact histiocytos, Absent) 0.94, 0.05, 0.01;
  (Mast-cell hyperplas, Absent) 0.94, 0.05, 0.01;
  (LGV, Absent) 0.94, 0.05, 0.01;
  (Histoplasmosis, Absent) 0.94, 0.05, 0.01;
  (Coccidioidomycosis, Absent) 0.94, 0.05, 0.01;
  (CMV, Absent) 0.94, 0.05, 0.01;
  (Brucellosis, Absent) 0.94, 0.05, 0.01;
  (Ki-1 LC anaplas B, Absent) 0.94, 0.05, 0.01;
  (Intermed lymphocytic, Absent) 0.94, 0.05, 0.01;
  (AIDS early, Slight [<10]) 0.94, 0.05, 0.01;
  (AILD, Slight [<10]) 0.80, 0.15, 0.05;
  (ALIP, Slight [<10]) 0.94, 0.05, 0.01;
  (Cat scratch disease, Slight [<10]) 0.94, 0.05, 0.01;
  (Dermatopathic laden, Slight [<10]) 0.94, 0.05, 0.01;
  (Florid follic hyperp, Slight [<10]) 0.94, 0.05, 0.01;
  (GLH hyaline vascular, Slight [<10]) 0.01, 0.64, 0.35;
  (GLH plasma cell, Slight [<10]) 0.94, 0.05, 0.01;
  (Granulomatous laden, Slight [<10]) 0.78, 0.15, 0.07;
  (Histiocytosis x, Slight [<10]) 0.94, 0.05, 0.01;
  (Infectious mono, Slight [<10]) 0.94, 0.05, 0.01;
  (Leprosy-lepromatous, Slight [<10]) 0.94, 0.05, 0.01;
  (Lymphangiographic, Slight [<10]) 0.94, 0.05, 0.01;
  (Mantle zone hyperpla, Slight [<10]) 0.94, 0.05, 0.01;
  (Necrotizing Kikuchi, Slight [<10]) 0.94, 0.05, 0.01;
  (Necrotiz non-Kikuchi, Slight [<10]) 0.94, 0.05, 0.01;
  (Rheumatoid arthritis, Slight [<10]) 0.78, 0.15, 0.07;
  (Sarcoidosis, Slight [<10]) 0.84, 0.15, 0.01;
  (SHML, Slight [<10]) 0.01, 0.89, 0.10;
  (Sinus histiocytosis, Slight [<10]) 0.94, 0.05, 0.01;
  (Syphilis, Slight [<10]) 0.78, 0.15, 0.07;
  (Toxoplasmosis, Slight [<10]) 0.94, 0.05, 0.01;
  (Tuberculosis, Slight [<10]) 0.78, 0.15, 0.07;
  (Viral NOS, Slight [<10]) 0.94, 0.05, 0.01;
  (Whipple's disease, Slight [<10]) 0.94, 0.05, 0.01;
  (L&H nodular HD, Slight [<10]) 0.94, 0.05, 0.01;
  (L&H diffuse HD, Slight [<10]) 0.94, 0.05, 0.01;
  (Nodular sclerosis HD, Slight [<10]) 0.0, 0.7, 0.3;
  (Cellular phase NSHD, Slight [<10]) 0.95, 0.05, 0.00;
  (Syncytial NSHD, Slight [<10]) 0.00, 0.85, 0.15;
  (Mixed cellularity HD, Slight [<10]) 0.975, 0.020, 0.005;
  (Interfollicular HD, Slight [<10]) 0.94, 0.05, 0.01;
  (Diffuse fibrosis HD, Slight [<10]) 0.1, 0.7, 0.2;
  (Reticular-type HD, Slight [<10]) 0.94, 0.05, 0.01;
  (Small cleaved fol, Slight [<10]) 0.94, 0.05, 0.01;
  (Mixed fol, Slight [<10]) 0.94, 0.05, 0.01;
  (Large cell fol, Slight [<10]) 0.94, 0.05, 0.01;
  (Small noncleaved fol, Slight [<10]) 0.94, 0.05, 0.01;
  (Small lymphocytic, Slight [<10]) 0.94, 0.05, 0.01;
  (Plasmacytoid lyctic, Slight [<10]) 0.94, 0.05, 0.01;
  (Mantle zone lymphoma, Slight [<10]) 0.94, 0.05, 0.01;
  (Small cleaved dif, Slight [<10]) 0.80, 0.15, 0.05;
  (Mixed FCC dif, Slight [<10]) 0.80, 0.15, 0.05;
  (Large cell dif, Slight [<10]) 0.80, 0.15, 0.05;
  (B-immunoblastic, Slight [<10]) 0.94, 0.05, 0.01;
  (T-immunob mixed, Slight [<10]) 0.55, 0.40, 0.05;
  (AILD-like T-cell lym, Slight [<10]) 0.80, 0.15, 0.05;
  (Japanese ATL, Slight [<10]) 0.94, 0.05, 0.01;
  (Lymphoblastic, Slight [<10]) 0.94, 0.05, 0.01;
  (Small noncleaved dif, Slight [<10]) 0.94, 0.05, 0.01;
  (True histiocytic, Slight [<10]) 0.94, 0.05, 0.01;
  (Ki-1 LC anaplas T, Slight [<10]) 0.94, 0.05, 0.01;
  (Multiple myeloma, Slight [<10]) 0.94, 0.05, 0.01;
  (Mycosis fungoides, Slight [<10]) 0.94, 0.05, 0.01;
  (AML, Slight [<10]) 0.94, 0.05, 0.01;
  (Hairy cell leukemia, Slight [<10]) 0.94, 0.05, 0.01;
  (Carcinoma, Slight [<10]) 0.94, 0.05, 0.01;
  (Melanoma, Slight [<10]) 0.94, 0.05, 0.01;
  (EM plasmacytoma, Slight [<10]) 0.94, 0.05, 0.01;
  (Kaposi's sarcoma, Slight [<10]) 0.94, 0.05, 0.01;
  (Mast-cell disease, Slight [<10]) 0.1, 0.8, 0.1;
  (AIDS involutionary, Slight [<10]) 0.94, 0.05, 0.01;
  (T-immunob large, Slight [<10]) 0.80, 0.15, 0.05;
  (Monocytoid B-cell, Slight [<10]) 0.94, 0.05, 0.01;
  (Nasopharyngeal CA, Slight [<10]) 0.0, 0.7, 0.3;
  (Seminoma, Slight [<10]) 0.94, 0.05, 0.01;
  (SLE, Slight [<10]) 0.94, 0.05, 0.01;
  (Mycobact histiocytos, Slight [<10]) 0.94, 0.05, 0.01;
  (Mast-cell hyperplas, Slight [<10]) 0.94, 0.05, 0.01;
  (LGV, Slight [<10]) 0.94, 0.05, 0.01;
  (Histoplasmosis, Slight [<10]) 0.94, 0.05, 0.01;
  (Coccidioidomycosis, Slight [<10]) 0.94, 0.05, 0.01;
  (CMV, Slight [<10]) 0.94, 0.05, 0.01;
  (Brucellosis, Slight [<10]) 0.94, 0.05, 0.01;
  (Ki-1 LC anaplas B, Slight [<10]) 0.94, 0.05, 0.01;
  (Intermed lymphocytic, Slight [<10]) 0.94, 0.05, 0.01;
  (AIDS early, Moderate [10-20]) 0.90, 0.08, 0.02;
  (AILD, Moderate [10-20]) 0.80, 0.15, 0.05;
  (ALIP, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Cat scratch disease, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Dermatopathic laden, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Florid follic hyperp, Moderate [10-20]) 0.90, 0.08, 0.02;
  (GLH hyaline vascular, Moderate [10-20]) 0.01, 0.64, 0.35;
  (GLH plasma cell, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Granulomatous laden, Moderate [10-20]) 0.40, 0.45, 0.15;
  (Histiocytosis x, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Infectious mono, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Leprosy-lepromatous, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Lymphangiographic, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Mantle zone hyperpla, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Necrotizing Kikuchi, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Necrotiz non-Kikuchi, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Rheumatoid arthritis, Moderate [10-20]) 0.40, 0.45, 0.15;
  (Sarcoidosis, Moderate [10-20]) 0.80, 0.18, 0.02;
  (SHML, Moderate [10-20]) 0.01, 0.94, 0.05;
  (Sinus histiocytosis, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Syphilis, Moderate [10-20]) 0.40, 0.45, 0.15;
  (Toxoplasmosis, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Tuberculosis, Moderate [10-20]) 0.40, 0.45, 0.15;
  (Viral NOS, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Whipple's disease, Moderate [10-20]) 0.90, 0.08, 0.02;
  (L&H nodular HD, Moderate [10-20]) 0.90, 0.08, 0.02;
  (L&H diffuse HD, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Nodular sclerosis HD, Moderate [10-20]) 0.0, 0.8, 0.2;
  (Cellular phase NSHD, Moderate [10-20]) 0.95, 0.05, 0.00;
  (Syncytial NSHD, Moderate [10-20]) 0.00, 0.94, 0.06;
  (Mixed cellularity HD, Moderate [10-20]) 0.94, 0.05, 0.01;
  (Interfollicular HD, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Diffuse fibrosis HD, Moderate [10-20]) 0.1, 0.7, 0.2;
  (Reticular-type HD, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Small cleaved fol, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Mixed fol, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Large cell fol, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Small noncleaved fol, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Small lymphocytic, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Plasmacytoid lyctic, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Mantle zone lymphoma, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Small cleaved dif, Moderate [10-20]) 0.80, 0.15, 0.05;
  (Mixed FCC dif, Moderate [10-20]) 0.80, 0.15, 0.05;
  (Large cell dif, Moderate [10-20]) 0.80, 0.15, 0.05;
  (B-immunoblastic, Moderate [10-20]) 0.90, 0.08, 0.02;
  (T-immunob mixed, Moderate [10-20]) 0.48, 0.45, 0.07;
  (AILD-like T-cell lym, Moderate [10-20]) 0.80, 0.15, 0.05;
  (Japanese ATL, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Lymphoblastic, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Small noncleaved dif, Moderate [10-20]) 0.90, 0.08, 0.02;
  (True histiocytic, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Ki-1 LC anaplas T, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Multiple myeloma, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Mycosis fungoides, Moderate [10-20]) 0.90, 0.08, 0.02;
  (AML, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Hairy cell leukemia, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Carcinoma, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Melanoma, Moderate [10-20]) 0.90, 0.08, 0.02;
  (EM plasmacytoma, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Kaposi's sarcoma, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Mast-cell disease, Moderate [10-20]) 0.1, 0.8, 0.1;
  (AIDS involutionary, Moderate [10-20]) 0.90, 0.08, 0.02;
  (T-immunob large, Moderate [10-20]) 0.80, 0.15, 0.05;
  (Monocytoid B-cell, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Nasopharyngeal CA, Moderate [10-20]) 0.0, 0.8, 0.2;
  (Seminoma, Moderate [10-20]) 0.90, 0.08, 0.02;
  (SLE, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Mycobact histiocytos, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Mast-cell hyperplas, Moderate [10-20]) 0.90, 0.08, 0.02;
  (LGV, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Histoplasmosis, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Coccidioidomycosis, Moderate [10-20]) 0.90, 0.08, 0.02;
  (CMV, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Brucellosis, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Ki-1 LC anaplas B, Moderate [10-20]) 0.90, 0.08, 0.02;
  (Intermed lymphocytic, Moderate [10-20]) 0.90, 0.08, 0.02;
  (AIDS early, Marked [>20]) 0.90, 0.08, 0.02;
  (AILD, Marked [>20]) 0.80, 0.15, 0.05;
  (ALIP, Marked [>20]) 0.90, 0.08, 0.02;
  (Cat scratch disease, Marked [>20]) 0.90, 0.08, 0.02;
  (Dermatopathic laden, Marked [>20]) 0.90, 0.08, 0.02;
  (Florid follic hyperp, Marked [>20]) 0.90, 0.08, 0.02;
  (GLH hyaline vascular, Marked [>20]) 0.01, 0.64, 0.35;
  (GLH plasma cell, Marked [>20]) 0.90, 0.08, 0.02;
  (Granulomatous laden, Marked [>20]) 0.40, 0.45, 0.15;
  (Histiocytosis x, Marked [>20]) 0.90, 0.08, 0.02;
  (Infectious mono, Marked [>20]) 0.90, 0.08, 0.02;
  (Leprosy-lepromatous, Marked [>20]) 0.90, 0.08, 0.02;
  (Lymphangiographic, Marked [>20]) 0.90, 0.08, 0.02;
  (Mantle zone hyperpla, Marked [>20]) 0.90, 0.08, 0.02;
  (Necrotizing Kikuchi, Marked [>20]) 0.90, 0.08, 0.02;
  (Necrotiz non-Kikuchi, Marked [>20]) 0.90, 0.08, 0.02;
  (Rheumatoid arthritis, Marked [>20]) 0.40, 0.45, 0.15;
  (Sarcoidosis, Marked [>20]) 0.80, 0.18, 0.02;
  (SHML, Marked [>20]) 0.01, 0.94, 0.05;
  (Sinus histiocytosis, Marked [>20]) 0.90, 0.08, 0.02;
  (Syphilis, Marked [>20]) 0.40, 0.45, 0.15;
  (Toxoplasmosis, Marked [>20]) 0.90, 0.08, 0.02;
  (Tuberculosis, Marked [>20]) 0.40, 0.45, 0.15;
  (Viral NOS, Marked [>20]) 0.90, 0.08, 0.02;
  (Whipple's disease, Marked [>20]) 0.90, 0.08, 0.02;
  (L&H nodular HD, Marked [>20]) 0.90, 0.08, 0.02;
  (L&H diffuse HD, Marked [>20]) 0.90, 0.08, 0.02;
  (Nodular sclerosis HD, Marked [>20]) 0.0, 0.8, 0.2;
  (Cellular phase NSHD, Marked [>20]) 0.95, 0.05, 0.00;
  (Syncytial NSHD, Marked [>20]) 0.00, 0.94, 0.06;
  (Mixed cellularity HD, Marked [>20]) 0.94, 0.05, 0.01;
  (Interfollicular HD, Marked [>20]) 0.90, 0.08, 0.02;
  (Diffuse fibrosis HD, Marked [>20]) 0.1, 0.7, 0.2;
  (Reticular-type HD, Marked [>20]) 0.90, 0.08, 0.02;
  (Small cleaved fol, Marked [>20]) 0.90, 0.08, 0.02;
  (Mixed fol, Marked [>20]) 0.90, 0.08, 0.02;
  (Large cell fol, Marked [>20]) 0.90, 0.08, 0.02;
  (Small noncleaved fol, Marked [>20]) 0.90, 0.08, 0.02;
  (Small lymphocytic, Marked [>20]) 0.90, 0.08, 0.02;
  (Plasmacytoid lyctic, Marked [>20]) 0.90, 0.08, 0.02;
  (Mantle zone lymphoma, Marked [>20]) 0.90, 0.08, 0.02;
  (Small cleaved dif, Marked [>20]) 0.80, 0.15, 0.05;
  (Mixed FCC dif, Marked [>20]) 0.80, 0.15, 0.05;
  (Large cell dif, Marked [>20]) 0.80, 0.15, 0.05;
  (B-immunoblastic, Marked [>20]) 0.90, 0.08, 0.02;
  (T-immunob mixed, Marked [>20]) 0.48, 0.45, 0.07;
  (AILD-like T-cell lym, Marked [>20]) 0.80, 0.15, 0.05;
  (Japanese ATL, Marked [>20]) 0.90, 0.08, 0.02;
  (Lymphoblastic, Marked [>20]) 0.90, 0.08, 0.02;
  (Small noncleaved dif, Marked [>20]) 0.90, 0.08, 0.02;
  (True histiocytic, Marked [>20]) 0.90, 0.08, 0.02;
  (Ki-1 LC anaplas T, Marked [>20]) 0.90, 0.08, 0.02;
  (Multiple myeloma, Marked [>20]) 0.90, 0.08, 0.02;
  (Mycosis fungoides, Marked [>20]) 0.90, 0.08, 0.02;
  (AML, Marked [>20]) 0.90, 0.08, 0.02;
  (Hairy cell leukemia, Marked [>20]) 0.90, 0.08, 0.02;
  (Carcinoma, Marked [>20]) 0.90, 0.08, 0.02;
  (Melanoma, Marked [>20]) 0.90, 0.08, 0.02;
  (EM plasmacytoma, Marked [>20]) 0.90, 0.08, 0.02;
  (Kaposi's sarcoma, Marked [>20]) 0.90, 0.08, 0.02;
  (Mast-cell disease, Marked [>20]) 0.1, 0.8, 0.1;
  (AIDS involutionary, Marked [>20]) 0.90, 0.08, 0.02;
  (T-immunob large, Marked [>20]) 0.80, 0.15, 0.05;
  (Monocytoid B-cell, Marked [>20]) 0.90, 0.08, 0.02;
  (Nasopharyngeal CA, Marked [>20]) 0.0, 0.8, 0.2;
  (Seminoma, Marked [>20]) 0.90, 0.08, 0.02;
  (SLE, Marked [>20]) 0.90, 0.08, 0.02;
  (Mycobact histiocytos, Marked [>20]) 0.90, 0.08, 0.02;
  (Mast-cell hyperplas, Marked [>20]) 0.90, 0.08, 0.02;
  (LGV, Marked [>20]) 0.90, 0.08, 0.02;
  (Histoplasmosis, Marked [>20]) 0.90, 0.08, 0.02;
  (Coccidioidomycosis, Marked [>20]) 0.90, 0.08, 0.02;
  (CMV, Marked [>20]) 0.90, 0.08, 0.02;
  (Brucellosis, Marked [>20]) 0.90, 0.08, 0.02;
  (Ki-1 LC anaplas B, Marked [>20]) 0.90, 0.08, 0.02;
  (Intermed lymphocytic, Marked [>20]) 0.90, 0.08, 0.02;
}
probability ( FCB_NOD | Fault, FCB ) {
  (AIDS early, Absent) 1.0, 0.0, 0.0;
  (AILD, Absent) 1.0, 0.0, 0.0;
  (ALIP, Absent) 1.0, 0.0, 0.0;
  (Cat scratch disease, Absent) 1.0, 0.0, 0.0;
  (Dermatopathic laden, Absent) 1.0, 0.0, 0.0;
  (Florid follic hyperp, Absent) 1.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent) 1.0, 0.0, 0.0;
  (GLH plasma cell, Absent) 1.0, 0.0, 0.0;
  (Granulomatous laden, Absent) 1.0, 0.0, 0.0;
  (Histiocytosis x, Absent) 1.0, 0.0, 0.0;
  (Infectious mono, Absent) 1.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent) 1.0, 0.0, 0.0;
  (Lymphangiographic, Absent) 1.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent) 1.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent) 1.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent) 1.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent) 1.0, 0.0, 0.0;
  (Sarcoidosis, Absent) 1.0, 0.0, 0.0;
  (SHML, Absent) 1.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent) 1.0, 0.0, 0.0;
  (Syphilis, Absent) 1.0, 0.0, 0.0;
  (Toxoplasmosis, Absent) 1.0, 0.0, 0.0;
  (Tuberculosis, Absent) 1.0, 0.0, 0.0;
  (Viral NOS, Absent) 1.0, 0.0, 0.0;
  (Whipple's disease, Absent) 1.0, 0.0, 0.0;
  (L&H nodular HD, Absent) 1.0, 0.0, 0.0;
  (L&H diffuse HD, Absent) 1.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent) 1.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent) 1.0, 0.0, 0.0;
  (Syncytial NSHD, Absent) 1.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent) 1.0, 0.0, 0.0;
  (Interfollicular HD, Absent) 1.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent) 1.0, 0.0, 0.0;
  (Reticular-type HD, Absent) 1.0, 0.0, 0.0;
  (Small cleaved fol, Absent) 1.0, 0.0, 0.0;
  (Mixed fol, Absent) 1.0, 0.0, 0.0;
  (Large cell fol, Absent) 1.0, 0.0, 0.0;
  (Small noncleaved fol, Absent) 1.0, 0.0, 0.0;
  (Small lymphocytic, Absent) 1.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent) 1.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent) 1.0, 0.0, 0.0;
  (Small cleaved dif, Absent) 1.0, 0.0, 0.0;
  (Mixed FCC dif, Absent) 1.0, 0.0, 0.0;
  (Large cell dif, Absent) 1.0, 0.0, 0.0;
  (B-immunoblastic, Absent) 1.0, 0.0, 0.0;
  (T-immunob mixed, Absent) 1.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent) 1.0, 0.0, 0.0;
  (Japanese ATL, Absent) 1.0, 0.0, 0.0;
  (Lymphoblastic, Absent) 1.0, 0.0, 0.0;
  (Small noncleaved dif, Absent) 1.0, 0.0, 0.0;
  (True histiocytic, Absent) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent) 1.0, 0.0, 0.0;
  (Multiple myeloma, Absent) 1.0, 0.0, 0.0;
  (Mycosis fungoides, Absent) 1.0, 0.0, 0.0;
  (AML, Absent) 1.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent) 1.0, 0.0, 0.0;
  (Carcinoma, Absent) 1.0, 0.0, 0.0;
  (Melanoma, Absent) 1.0, 0.0, 0.0;
  (EM plasmacytoma, Absent) 1.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent) 1.0, 0.0, 0.0;
  (Mast-cell disease, Absent) 1.0, 0.0, 0.0;
  (AIDS involutionary, Absent) 1.0, 0.0, 0.0;
  (T-immunob large, Absent) 1.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent) 1.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent) 1.0, 0.0, 0.0;
  (Seminoma, Absent) 1.0, 0.0, 0.0;
  (SLE, Absent) 1.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent) 1.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent) 1.0, 0.0, 0.0;
  (LGV, Absent) 1.0, 0.0, 0.0;
  (Histoplasmosis, Absent) 1.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent) 1.0, 0.0, 0.0;
  (CMV, Absent) 1.0, 0.0, 0.0;
  (Brucellosis, Absent) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent) 1.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent) 1.0, 0.0, 0.0;
  (AIDS early, Present) 0.000, 0.995, 0.005;
  (AILD, Present) 0.000, 0.995, 0.005;
  (ALIP, Present) 0.000, 0.995, 0.005;
  (Cat scratch disease, Present) 0.000, 0.995, 0.005;
  (Dermatopathic laden, Present) 0.000, 0.995, 0.005;
  (Florid follic hyperp, Present) 0.000, 0.995, 0.005;
  (GLH hyaline vascular, Present) 0.00, 0.95, 0.05;
  (GLH plasma cell, Present) 0.000, 0.995, 0.005;
  (Granulomatous laden, Present) 0.00, 0.98, 0.02;
  (Histiocytosis x, Present) 0.000, 0.995, 0.005;
  (Infectious mono, Present) 0.000, 0.995, 0.005;
  (Leprosy-lepromatous, Present) 0.000, 0.995, 0.005;
  (Lymphangiographic, Present) 0.000, 0.995, 0.005;
  (Mantle zone hyperpla, Present) 0.000, 0.995, 0.005;
  (Necrotizing Kikuchi, Present) 0.000, 0.995, 0.005;
  (Necrotiz non-Kikuchi, Present) 0.000, 0.995, 0.005;
  (Rheumatoid arthritis, Present) 0.00, 0.98, 0.02;
  (Sarcoidosis, Present) 0.000, 0.995, 0.005;
  (SHML, Present) 0.00, 0.95, 0.05;
  (Sinus histiocytosis, Present) 0.000, 0.995, 0.005;
  (Syphilis, Present) 0.00, 0.98, 0.02;
  (Toxoplasmosis, Present) 0.000, 0.995, 0.005;
  (Tuberculosis, Present) 0.00, 0.98, 0.02;
  (Viral NOS, Present) 0.000, 0.995, 0.005;
  (Whipple's disease, Present) 0.000, 0.995, 0.005;
  (L&H nodular HD, Present) 0.000, 0.995, 0.005;
  (L&H diffuse HD, Present) 0.000, 0.995, 0.005;
  (Nodular sclerosis HD, Present) 0.0, 0.0, 1.0;
  (Cellular phase NSHD, Present) 0.0, 1.0, 0.0;
  (Syncytial NSHD, Present) 0.0, 0.0, 1.0;
  (Mixed cellularity HD, Present) 0.00, 0.99, 0.01;
  (Interfollicular HD, Present) 0.000, 0.995, 0.005;
  (Diffuse fibrosis HD, Present) 0.0, 0.9, 0.1;
  (Reticular-type HD, Present) 0.000, 0.995, 0.005;
  (Small cleaved fol, Present) 0.000, 0.995, 0.005;
  (Mixed fol, Present) 0.000, 0.995, 0.005;
  (Large cell fol, Present) 0.000, 0.995, 0.005;
  (Small noncleaved fol, Present) 0.000, 0.995, 0.005;
  (Small lymphocytic, Present) 0.000, 0.995, 0.005;
  (Plasmacytoid lyctic, Present) 0.000, 0.995, 0.005;
  (Mantle zone lymphoma, Present) 0.000, 0.995, 0.005;
  (Small cleaved dif, Present) 0.0, 0.9, 0.1;
  (Mixed FCC dif, Present) 0.0, 0.9, 0.1;
  (Large cell dif, Present) 0.0, 0.9, 0.1;
  (B-immunoblastic, Present) 0.000, 0.995, 0.005;
  (T-immunob mixed, Present) 0.0, 0.9, 0.1;
  (AILD-like T-cell lym, Present) 0.00, 0.97, 0.03;
  (Japanese ATL, Present) 0.000, 0.995, 0.005;
  (Lymphoblastic, Present) 0.000, 0.995, 0.005;
  (Small noncleaved dif, Present) 0.000, 0.995, 0.005;
  (True histiocytic, Present) 0.000, 0.995, 0.005;
  (Ki-1 LC anaplas T, Present) 0.000, 0.995, 0.005;
  (Multiple myeloma, Present) 0.000, 0.995, 0.005;
  (Mycosis fungoides, Present) 0.000, 0.995, 0.005;
  (AML, Present) 0.000, 0.995, 0.005;
  (Hairy cell leukemia, Present) 0.000, 0.995, 0.005;
  (Carcinoma, Present) 0.000, 0.995, 0.005;
  (Melanoma, Present) 0.000, 0.995, 0.005;
  (EM plasmacytoma, Present) 0.000, 0.995, 0.005;
  (Kaposi's sarcoma, Present) 0.000, 0.995, 0.005;
  (Mast-cell disease, Present) 0.00, 0.95, 0.05;
  (AIDS involutionary, Present) 0.000, 0.995, 0.005;
  (T-immunob large, Present) 0.00, 0.97, 0.03;
  (Monocytoid B-cell, Present) 0.000, 0.995, 0.005;
  (Nasopharyngeal CA, Present) 0.0, 0.0, 1.0;
  (Seminoma, Present) 0.000, 0.995, 0.005;
  (SLE, Present) 0.000, 0.995, 0.005;
  (Mycobact histiocytos, Present) 0.000, 0.995, 0.005;
  (Mast-cell hyperplas, Present) 0.000, 0.995, 0.005;
  (LGV, Present) 0.000, 0.995, 0.005;
  (Histoplasmosis, Present) 0.000, 0.995, 0.005;
  (Coccidioidomycosis, Present) 0.000, 0.995, 0.005;
  (CMV, Present) 0.000, 0.995, 0.005;
  (Brucellosis, Present) 0.000, 0.995, 0.005;
  (Ki-1 LC anaplas B, Present) 0.000, 0.995, 0.005;
  (Intermed lymphocytic, Present) 0.000, 0.995, 0.005;
  (AIDS early, Prominent) 0.00, 0.99, 0.01;
  (AILD, Prominent) 0.00, 0.99, 0.01;
  (ALIP, Prominent) 0.00, 0.99, 0.01;
  (Cat scratch disease, Prominent) 0.00, 0.99, 0.01;
  (Dermatopathic laden, Prominent) 0.00, 0.99, 0.01;
  (Florid follic hyperp, Prominent) 0.00, 0.99, 0.01;
  (GLH hyaline vascular, Prominent) 0.0, 0.8, 0.2;
  (GLH plasma cell, Prominent) 0.00, 0.99, 0.01;
  (Granulomatous laden, Prominent) 0.00, 0.95, 0.05;
  (Histiocytosis x, Prominent) 0.00, 0.99, 0.01;
  (Infectious mono, Prominent) 0.00, 0.99, 0.01;
  (Leprosy-lepromatous, Prominent) 0.00, 0.99, 0.01;
  (Lymphangiographic, Prominent) 0.00, 0.99, 0.01;
  (Mantle zone hyperpla, Prominent) 0.00, 0.99, 0.01;
  (Necrotizing Kikuchi, Prominent) 0.00, 0.99, 0.01;
  (Necrotiz non-Kikuchi, Prominent) 0.00, 0.99, 0.01;
  (Rheumatoid arthritis, Prominent) 0.00, 0.95, 0.05;
  (Sarcoidosis, Prominent) 0.00, 0.99, 0.01;
  (SHML, Prominent) 0.0, 0.9, 0.1;
  (Sinus histiocytosis, Prominent) 0.00, 0.99, 0.01;
  (Syphilis, Prominent) 0.00, 0.95, 0.05;
  (Toxoplasmosis, Prominent) 0.00, 0.99, 0.01;
  (Tuberculosis, Prominent) 0.00, 0.95, 0.05;
  (Viral NOS, Prominent) 0.00, 0.99, 0.01;
  (Whipple's disease, Prominent) 0.00, 0.99, 0.01;
  (L&H nodular HD, Prominent) 0.00, 0.99, 0.01;
  (L&H diffuse HD, Prominent) 0.00, 0.99, 0.01;
  (Nodular sclerosis HD, Prominent) 0.0, 0.0, 1.0;
  (Cellular phase NSHD, Prominent) 0.0, 1.0, 0.0;
  (Syncytial NSHD, Prominent) 0.0, 0.0, 1.0;
  (Mixed cellularity HD, Prominent) 0.00, 0.98, 0.02;
  (Interfollicular HD, Prominent) 0.00, 0.99, 0.01;
  (Diffuse fibrosis HD, Prominent) 0.0, 0.8, 0.2;
  (Reticular-type HD, Prominent) 0.00, 0.99, 0.01;
  (Small cleaved fol, Prominent) 0.00, 0.99, 0.01;
  (Mixed fol, Prominent) 0.00, 0.99, 0.01;
  (Large cell fol, Prominent) 0.00, 0.99, 0.01;
  (Small noncleaved fol, Prominent) 0.00, 0.99, 0.01;
  (Small lymphocytic, Prominent) 0.00, 0.99, 0.01;
  (Plasmacytoid lyctic, Prominent) 0.00, 0.99, 0.01;
  (Mantle zone lymphoma, Prominent) 0.00, 0.99, 0.01;
  (Small cleaved dif, Prominent) 0.0, 0.9, 0.1;
  (Mixed FCC dif, Prominent) 0.0, 0.9, 0.1;
  (Large cell dif, Prominent) 0.0, 0.9, 0.1;
  (B-immunoblastic, Prominent) 0.00, 0.99, 0.01;
  (T-immunob mixed, Prominent) 0.0, 0.9, 0.1;
  (AILD-like T-cell lym, Prominent) 0.0, 0.9, 0.1;
  (Japanese ATL, Prominent) 0.00, 0.99, 0.01;
  (Lymphoblastic, Prominent) 0.00, 0.99, 0.01;
  (Small noncleaved dif, Prominent) 0.00, 0.99, 0.01;
  (True histiocytic, Prominent) 0.00, 0.99, 0.01;
  (Ki-1 LC anaplas T, Prominent) 0.00, 0.99, 0.01;
  (Multiple myeloma, Prominent) 0.00, 0.99, 0.01;
  (Mycosis fungoides, Prominent) 0.00, 0.99, 0.01;
  (AML, Prominent) 0.00, 0.99, 0.01;
  (Hairy cell leukemia, Prominent) 0.00, 0.99, 0.01;
  (Carcinoma, Prominent) 0.00, 0.99, 0.01;
  (Melanoma, Prominent) 0.00, 0.99, 0.01;
  (EM plasmacytoma, Prominent) 0.00, 0.99, 0.01;
  (Kaposi's sarcoma, Prominent) 0.00, 0.99, 0.01;
  (Mast-cell disease, Prominent) 0.0, 0.9, 0.1;
  (AIDS involutionary, Prominent) 0.00, 0.99, 0.01;
  (T-immunob large, Prominent) 0.00, 0.95, 0.05;
  (Monocytoid B-cell, Prominent) 0.00, 0.99, 0.01;
  (Nasopharyngeal CA, Prominent) 0.0, 0.0, 1.0;
  (Seminoma, Prominent) 0.00, 0.99, 0.01;
  (SLE, Prominent) 0.00, 0.99, 0.01;
  (Mycobact histiocytos, Prominent) 0.00, 0.99, 0.01;
  (Mast-cell hyperplas, Prominent) 0.00, 0.99, 0.01;
  (LGV, Prominent) 0.00, 0.99, 0.01;
  (Histoplasmosis, Prominent) 0.00, 0.99, 0.01;
  (Coccidioidomycosis, Prominent) 0.00, 0.99, 0.01;
  (CMV, Prominent) 0.00, 0.99, 0.01;
  (Brucellosis, Prominent) 0.00, 0.99, 0.01;
  (Ki-1 LC anaplas B, Prominent) 0.00, 0.99, 0.01;
  (Intermed lymphocytic, Prominent) 0.00, 0.99, 0.01;
}
probability ( FIBROS | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 0.95, 0.05;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 0.95, 0.05;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 0.99, 0.01;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 1.0, 0.0;
  (L&H diffuse HD) 1.0, 0.0;
  (Nodular sclerosis HD) 0.95, 0.05;
  (Cellular phase NSHD) 1.0, 0.0;
  (Syncytial NSHD) 1.0, 0.0;
  (Mixed cellularity HD) 0.999, 0.001;
  (Interfollicular HD) 1.0, 0.0;
  (Diffuse fibrosis HD) 0.0, 1.0;
  (Reticular-type HD) 0.999, 0.001;
  (Small cleaved fol) 1.0, 0.0;
  (Mixed fol) 1.0, 0.0;
  (Large cell fol) 1.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0;
  (Small lymphocytic) 1.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0;
  (Small cleaved dif) 1.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0;
  (Large cell dif) 1.0, 0.0;
  (B-immunoblastic) 1.0, 0.0;
  (T-immunob mixed) 1.0, 0.0;
  (AILD-like T-cell lym) 1.0, 0.0;
  (Japanese ATL) 1.0, 0.0;
  (Lymphoblastic) 1.0, 0.0;
  (Small noncleaved dif) 1.0, 0.0;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 1.0, 0.0;
  (Multiple myeloma) 1.0, 0.0;
  (Mycosis fungoides) 1.0, 0.0;
  (AML) 1.0, 0.0;
  (Hairy cell leukemia) 1.0, 0.0;
  (Carcinoma) 1.0, 0.0;
  (Melanoma) 1.0, 0.0;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 0.95, 0.05;
  (Mast-cell disease) 0.8, 0.2;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 1.0, 0.0;
  (Monocytoid B-cell) 1.0, 0.0;
  (Nasopharyngeal CA) 0.999, 0.001;
  (Seminoma) 1.0, 0.0;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 0.9, 0.1;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 1.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0;
}
probability ( FITE | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 1.0, 0.0;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 0.01, 0.99;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 1.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 1.0, 0.0;
  (L&H diffuse HD) 1.0, 0.0;
  (Nodular sclerosis HD) 1.0, 0.0;
  (Cellular phase NSHD) 1.0, 0.0;
  (Syncytial NSHD) 1.0, 0.0;
  (Mixed cellularity HD) 1.0, 0.0;
  (Interfollicular HD) 1.0, 0.0;
  (Diffuse fibrosis HD) 1.0, 0.0;
  (Reticular-type HD) 1.0, 0.0;
  (Small cleaved fol) 1.0, 0.0;
  (Mixed fol) 1.0, 0.0;
  (Large cell fol) 1.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0;
  (Small lymphocytic) 1.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0;
  (Small cleaved dif) 1.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0;
  (Large cell dif) 1.0, 0.0;
  (B-immunoblastic) 1.0, 0.0;
  (T-immunob mixed) 1.0, 0.0;
  (AILD-like T-cell lym) 1.0, 0.0;
  (Japanese ATL) 1.0, 0.0;
  (Lymphoblastic) 1.0, 0.0;
  (Small noncleaved dif) 1.0, 0.0;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 1.0, 0.0;
  (Multiple myeloma) 1.0, 0.0;
  (Mycosis fungoides) 1.0, 0.0;
  (AML) 1.0, 0.0;
  (Hairy cell leukemia) 1.0, 0.0;
  (Carcinoma) 1.0, 0.0;
  (Melanoma) 1.0, 0.0;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0;
  (Mast-cell disease) 1.0, 0.0;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 1.0, 0.0;
  (Monocytoid B-cell) 1.0, 0.0;
  (Nasopharyngeal CA) 1.0, 0.0;
  (Seminoma) 1.0, 0.0;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 1.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0;
}
probability ( FBODY | Fault ) {
  (AIDS early) 0.999, 0.001, 0.000;
  (AILD) 0.99, 0.01, 0.00;
  (ALIP) 0.999, 0.001, 0.000;
  (Cat scratch disease) 0.88, 0.10, 0.02;
  (Dermatopathic laden) 0.999, 0.001, 0.000;
  (Florid follic hyperp) 0.999, 0.001, 0.000;
  (GLH hyaline vascular) 0.999, 0.001, 0.000;
  (GLH plasma cell) 0.999, 0.001, 0.000;
  (Granulomatous laden) 0.40, 0.35, 0.25;
  (Histiocytosis x) 0.93, 0.05, 0.02;
  (Infectious mono) 0.999, 0.001, 0.000;
  (Leprosy-lepromatous) 0.87, 0.10, 0.03;
  (Lymphangiographic) 0.01, 0.29, 0.70;
  (Mantle zone hyperpla) 0.999, 0.001, 0.000;
  (Necrotizing Kikuchi) 0.999, 0.001, 0.000;
  (Necrotiz non-Kikuchi) 0.94, 0.05, 0.01;
  (Rheumatoid arthritis) 0.999, 0.001, 0.000;
  (Sarcoidosis) 0.90, 0.09, 0.01;
  (SHML) 0.999, 0.001, 0.000;
  (Sinus histiocytosis) 0.999, 0.001, 0.000;
  (Syphilis) 0.88, 0.10, 0.02;
  (Toxoplasmosis) 0.999, 0.001, 0.000;
  (Tuberculosis) 0.87, 0.10, 0.03;
  (Viral NOS) 0.999, 0.001, 0.000;
  (Whipple's disease) 0.01, 0.29, 0.70;
  (L&H nodular HD) 0.999, 0.001, 0.000;
  (L&H diffuse HD) 0.999, 0.001, 0.000;
  (Nodular sclerosis HD) 0.999, 0.001, 0.000;
  (Cellular phase NSHD) 0.999, 0.001, 0.000;
  (Syncytial NSHD) 0.999, 0.001, 0.000;
  (Mixed cellularity HD) 0.95, 0.04, 0.01;
  (Interfollicular HD) 0.999, 0.001, 0.000;
  (Diffuse fibrosis HD) 0.999, 0.001, 0.000;
  (Reticular-type HD) 0.999, 0.001, 0.000;
  (Small cleaved fol) 0.999, 0.001, 0.000;
  (Mixed fol) 0.999, 0.001, 0.000;
  (Large cell fol) 0.999, 0.001, 0.000;
  (Small noncleaved fol) 0.999, 0.001, 0.000;
  (Small lymphocytic) 0.999, 0.001, 0.000;
  (Plasmacytoid lyctic) 0.999, 0.001, 0.000;
  (Mantle zone lymphoma) 0.999, 0.001, 0.000;
  (Small cleaved dif) 0.999, 0.001, 0.000;
  (Mixed FCC dif) 0.999, 0.001, 0.000;
  (Large cell dif) 0.999, 0.001, 0.000;
  (B-immunoblastic) 0.999, 0.001, 0.000;
  (T-immunob mixed) 0.999, 0.001, 0.000;
  (AILD-like T-cell lym) 0.99, 0.01, 0.00;
  (Japanese ATL) 0.999, 0.001, 0.000;
  (Lymphoblastic) 0.999, 0.001, 0.000;
  (Small noncleaved dif) 0.999, 0.001, 0.000;
  (True histiocytic) 0.999, 0.001, 0.000;
  (Ki-1 LC anaplas T) 0.999, 0.001, 0.000;
  (Multiple myeloma) 0.999, 0.001, 0.000;
  (Mycosis fungoides) 0.999, 0.001, 0.000;
  (AML) 0.999, 0.001, 0.000;
  (Hairy cell leukemia) 0.999, 0.001, 0.000;
  (Carcinoma) 0.999, 0.001, 0.000;
  (Melanoma) 0.999, 0.001, 0.000;
  (EM plasmacytoma) 0.999, 0.001, 0.000;
  (Kaposi's sarcoma) 0.999, 0.001, 0.000;
  (Mast-cell disease) 0.97, 0.02, 0.01;
  (AIDS involutionary) 0.999, 0.001, 0.000;
  (T-immunob large) 0.999, 0.001, 0.000;
  (Monocytoid B-cell) 0.999, 0.001, 0.000;
  (Nasopharyngeal CA) 0.999, 0.001, 0.000;
  (Seminoma) 0.999, 0.001, 0.000;
  (SLE) 0.999, 0.001, 0.000;
  (Mycobact histiocytos) 0.88, 0.10, 0.02;
  (Mast-cell hyperplas) 0.97, 0.02, 0.01;
  (LGV) 0.88, 0.10, 0.02;
  (Histoplasmosis) 0.88, 0.10, 0.02;
  (Coccidioidomycosis) 0.88, 0.10, 0.02;
  (CMV) 0.88, 0.10, 0.02;
  (Brucellosis) 0.999, 0.001, 0.000;
  (Ki-1 LC anaplas B) 0.999, 0.001, 0.000;
  (Intermed lymphocytic) 0.999, 0.001, 0.000;
}
probability ( GENE_TC | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 0.4, 0.6;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 1.0, 0.0;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 1.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 1.0, 0.0;
  (L&H diffuse HD) 0.95, 0.05;
  (Nodular sclerosis HD) 0.95, 0.05;
  (Cellular phase NSHD) 0.95, 0.05;
  (Syncytial NSHD) 0.95, 0.05;
  (Mixed cellularity HD) 0.95, 0.05;
  (Interfollicular HD) 0.95, 0.05;
  (Diffuse fibrosis HD) 0.95, 0.05;
  (Reticular-type HD) 0.95, 0.05;
  (Small cleaved fol) 1.0, 0.0;
  (Mixed fol) 1.0, 0.0;
  (Large cell fol) 1.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0;
  (Small lymphocytic) 1.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0;
  (Small cleaved dif) 1.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0;
  (Large cell dif) 1.0, 0.0;
  (B-immunoblastic) 1.0, 0.0;
  (T-immunob mixed) 0.0, 1.0;
  (AILD-like T-cell lym) 0.0, 1.0;
  (Japanese ATL) 0.0, 1.0;
  (Lymphoblastic) 0.0, 1.0;
  (Small noncleaved dif) 1.0, 0.0;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 0.0, 1.0;
  (Multiple myeloma) 1.0, 0.0;
  (Mycosis fungoides) 0.0, 1.0;
  (AML) 1.0, 0.0;
  (Hairy cell leukemia) 1.0, 0.0;
  (Carcinoma) 1.0, 0.0;
  (Melanoma) 1.0, 0.0;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0;
  (Mast-cell disease) 1.0, 0.0;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 0.0, 1.0;
  (Monocytoid B-cell) 1.0, 0.0;
  (Nasopharyngeal CA) 1.0, 0.0;
  (Seminoma) 1.0, 0.0;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 1.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0;
}
probability ( HAIRY | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 1.0, 0.0;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 1.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 1.0, 0.0;
  (L&H diffuse HD) 1.0, 0.0;
  (Nodular sclerosis HD) 1.0, 0.0;
  (Cellular phase NSHD) 1.0, 0.0;
  (Syncytial NSHD) 1.0, 0.0;
  (Mixed cellularity HD) 1.0, 0.0;
  (Interfollicular HD) 1.0, 0.0;
  (Diffuse fibrosis HD) 1.0, 0.0;
  (Reticular-type HD) 1.0, 0.0;
  (Small cleaved fol) 1.0, 0.0;
  (Mixed fol) 1.0, 0.0;
  (Large cell fol) 1.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0;
  (Small lymphocytic) 1.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0;
  (Small cleaved dif) 1.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0;
  (Large cell dif) 1.0, 0.0;
  (B-immunoblastic) 1.0, 0.0;
  (T-immunob mixed) 1.0, 0.0;
  (AILD-like T-cell lym) 1.0, 0.0;
  (Japanese ATL) 1.0, 0.0;
  (Lymphoblastic) 1.0, 0.0;
  (Small noncleaved dif) 1.0, 0.0;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 1.0, 0.0;
  (Multiple myeloma) 1.0, 0.0;
  (Mycosis fungoides) 1.0, 0.0;
  (AML) 1.0, 0.0;
  (Hairy cell leukemia) 0.0, 1.0;
  (Carcinoma) 1.0, 0.0;
  (Melanoma) 1.0, 0.0;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0;
  (Mast-cell disease) 1.0, 0.0;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 1.0, 0.0;
  (Monocytoid B-cell) 1.0, 0.0;
  (Nasopharyngeal CA) 1.0, 0.0;
  (Seminoma) 1.0, 0.0;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 1.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0;
}
probability ( HTLV_I | Fault ) {
  (AIDS early) 0.999, 0.001;
  (AILD) 0.999, 0.001;
  (ALIP) 0.999, 0.001;
  (Cat scratch disease) 0.999, 0.001;
  (Dermatopathic laden) 0.999, 0.001;
  (Florid follic hyperp) 0.999, 0.001;
  (GLH hyaline vascular) 0.999, 0.001;
  (GLH plasma cell) 0.999, 0.001;
  (Granulomatous laden) 0.999, 0.001;
  (Histiocytosis x) 0.999, 0.001;
  (Infectious mono) 0.999, 0.001;
  (Leprosy-lepromatous) 0.999, 0.001;
  (Lymphangiographic) 0.999, 0.001;
  (Mantle zone hyperpla) 0.999, 0.001;
  (Necrotizing Kikuchi) 0.999, 0.001;
  (Necrotiz non-Kikuchi) 0.999, 0.001;
  (Rheumatoid arthritis) 0.999, 0.001;
  (Sarcoidosis) 0.999, 0.001;
  (SHML) 0.999, 0.001;
  (Sinus histiocytosis) 0.999, 0.001;
  (Syphilis) 0.999, 0.001;
  (Toxoplasmosis) 0.999, 0.001;
  (Tuberculosis) 0.999, 0.001;
  (Viral NOS) 0.999, 0.001;
  (Whipple's disease) 0.999, 0.001;
  (L&H nodular HD) 0.999, 0.001;
  (L&H diffuse HD) 0.999, 0.001;
  (Nodular sclerosis HD) 0.999, 0.001;
  (Cellular phase NSHD) 0.999, 0.001;
  (Syncytial NSHD) 0.999, 0.001;
  (Mixed cellularity HD) 0.999, 0.001;
  (Interfollicular HD) 0.999, 0.001;
  (Diffuse fibrosis HD) 0.999, 0.001;
  (Reticular-type HD) 0.999, 0.001;
  (Small cleaved fol) 0.999, 0.001;
  (Mixed fol) 0.999, 0.001;
  (Large cell fol) 0.999, 0.001;
  (Small noncleaved fol) 0.999, 0.001;
  (Small lymphocytic) 0.999, 0.001;
  (Plasmacytoid lyctic) 0.999, 0.001;
  (Mantle zone lymphoma) 0.999, 0.001;
  (Small cleaved dif) 0.999, 0.001;
  (Mixed FCC dif) 0.999, 0.001;
  (Large cell dif) 0.999, 0.001;
  (B-immunoblastic) 0.999, 0.001;
  (T-immunob mixed) 0.999, 0.001;
  (AILD-like T-cell lym) 0.999, 0.001;
  (Japanese ATL) 0.001, 0.999;
  (Lymphoblastic) 0.999, 0.001;
  (Small noncleaved dif) 0.999, 0.001;
  (True histiocytic) 0.999, 0.001;
  (Ki-1 LC anaplas T) 0.999, 0.001;
  (Multiple myeloma) 0.999, 0.001;
  (Mycosis fungoides) 0.999, 0.001;
  (AML) 0.999, 0.001;
  (Hairy cell leukemia) 0.999, 0.001;
  (Carcinoma) 0.999, 0.001;
  (Melanoma) 0.999, 0.001;
  (EM plasmacytoma) 0.999, 0.001;
  (Kaposi's sarcoma) 0.999, 0.001;
  (Mast-cell disease) 0.999, 0.001;
  (AIDS involutionary) 0.999, 0.001;
  (T-immunob large) 0.999, 0.001;
  (Monocytoid B-cell) 0.999, 0.001;
  (Nasopharyngeal CA) 0.999, 0.001;
  (Seminoma) 0.999, 0.001;
  (SLE) 0.999, 0.001;
  (Mycobact histiocytos) 0.999, 0.001;
  (Mast-cell hyperplas) 0.999, 0.001;
  (LGV) 0.999, 0.001;
  (Histoplasmosis) 0.999, 0.001;
  (Coccidioidomycosis) 0.999, 0.001;
  (CMV) 0.999, 0.001;
  (Brucellosis) 0.999, 0.001;
  (Ki-1 LC anaplas B) 0.999, 0.001;
  (Intermed lymphocytic) 0.999, 0.001;
}
probability ( HIV | HIV_ST ) {
  (Negative) 0.9999, 0.0001;
  (Positive/Asymptomatic) 0.0001, 0.9999;
  (Positive/Symptomatic) 0.0001, 0.9999;
}
probability ( INTFOL | Fault, FOLLICLE ) {
  (AIDS early, Absent [0pc]) 0.0, 0.0, 1.0;
  (AILD, Absent [0pc]) 0.0, 0.0, 1.0;
  (ALIP, Absent [0pc]) 0.0, 0.0, 1.0;
  (Cat scratch disease, Absent [0pc]) 0.0, 0.0, 1.0;
  (Dermatopathic laden, Absent [0pc]) 0.0, 0.0, 1.0;
  (Florid follic hyperp, Absent [0pc]) 0.0, 0.0, 1.0;
  (GLH hyaline vascular, Absent [0pc]) 0.0, 0.0, 1.0;
  (GLH plasma cell, Absent [0pc]) 0.0, 0.0, 1.0;
  (Granulomatous laden, Absent [0pc]) 0.0, 0.0, 1.0;
  (Histiocytosis x, Absent [0pc]) 0.0, 0.0, 1.0;
  (Infectious mono, Absent [0pc]) 0.0, 0.0, 1.0;
  (Leprosy-lepromatous, Absent [0pc]) 0.0, 0.0, 1.0;
  (Lymphangiographic, Absent [0pc]) 0.0, 0.0, 1.0;
  (Mantle zone hyperpla, Absent [0pc]) 0.0, 0.0, 1.0;
  (Necrotizing Kikuchi, Absent [0pc]) 0.0, 0.0, 1.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 0.0, 0.0, 1.0;
  (Rheumatoid arthritis, Absent [0pc]) 0.0, 0.0, 1.0;
  (Sarcoidosis, Absent [0pc]) 0.0, 0.0, 1.0;
  (SHML, Absent [0pc]) 0.0, 0.0, 1.0;
  (Sinus histiocytosis, Absent [0pc]) 0.0, 0.0, 1.0;
  (Syphilis, Absent [0pc]) 0.0, 0.0, 1.0;
  (Toxoplasmosis, Absent [0pc]) 0.0, 0.0, 1.0;
  (Tuberculosis, Absent [0pc]) 0.0, 0.0, 1.0;
  (Viral NOS, Absent [0pc]) 0.0, 0.0, 1.0;
  (Whipple's disease, Absent [0pc]) 0.0, 0.0, 1.0;
  (L&H nodular HD, Absent [0pc]) 0.0, 0.0, 1.0;
  (L&H diffuse HD, Absent [0pc]) 0.0, 0.0, 1.0;
  (Nodular sclerosis HD, Absent [0pc]) 0.0, 0.0, 1.0;
  (Cellular phase NSHD, Absent [0pc]) 0.0, 0.0, 1.0;
  (Syncytial NSHD, Absent [0pc]) 0.0, 0.0, 1.0;
  (Mixed cellularity HD, Absent [0pc]) 0.0, 0.0, 1.0;
  (Interfollicular HD, Absent [0pc]) 0.0, 0.0, 1.0;
  (Diffuse fibrosis HD, Absent [0pc]) 0.0, 0.0, 1.0;
  (Reticular-type HD, Absent [0pc]) 0.0, 0.0, 1.0;
  (Small cleaved fol, Absent [0pc]) 0.0, 0.0, 1.0;
  (Mixed fol, Absent [0pc]) 0.0, 0.0, 1.0;
  (Large cell fol, Absent [0pc]) 0.0, 0.0, 1.0;
  (Small noncleaved fol, Absent [0pc]) 0.0, 0.0, 1.0;
  (Small lymphocytic, Absent [0pc]) 0.0, 0.0, 1.0;
  (Plasmacytoid lyctic, Absent [0pc]) 0.0, 0.0, 1.0;
  (Mantle zone lymphoma, Absent [0pc]) 0.0, 0.0, 1.0;
  (Small cleaved dif, Absent [0pc]) 0.0, 0.0, 1.0;
  (Mixed FCC dif, Absent [0pc]) 0.0, 0.0, 1.0;
  (Large cell dif, Absent [0pc]) 0.0, 0.0, 1.0;
  (B-immunoblastic, Absent [0pc]) 0.0, 0.0, 1.0;
  (T-immunob mixed, Absent [0pc]) 0.0, 0.0, 1.0;
  (AILD-like T-cell lym, Absent [0pc]) 0.0, 0.0, 1.0;
  (Japanese ATL, Absent [0pc]) 0.0, 0.0, 1.0;
  (Lymphoblastic, Absent [0pc]) 0.0, 0.0, 1.0;
  (Small noncleaved dif, Absent [0pc]) 0.0, 0.0, 1.0;
  (True histiocytic, Absent [0pc]) 0.0, 0.0, 1.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 0.0, 0.0, 1.0;
  (Multiple myeloma, Absent [0pc]) 0.0, 0.0, 1.0;
  (Mycosis fungoides, Absent [0pc]) 0.0, 0.0, 1.0;
  (AML, Absent [0pc]) 0.0, 0.0, 1.0;
  (Hairy cell leukemia, Absent [0pc]) 0.0, 0.0, 1.0;
  (Carcinoma, Absent [0pc]) 0.0, 0.0, 1.0;
  (Melanoma, Absent [0pc]) 0.0, 0.0, 1.0;
  (EM plasmacytoma, Absent [0pc]) 0.0, 0.0, 1.0;
  (Kaposi's sarcoma, Absent [0pc]) 0.0, 0.0, 1.0;
  (Mast-cell disease, Absent [0pc]) 0.0, 0.0, 1.0;
  (AIDS involutionary, Absent [0pc]) 0.0, 0.0, 1.0;
  (T-immunob large, Absent [0pc]) 0.0, 0.0, 1.0;
  (Monocytoid B-cell, Absent [0pc]) 0.0, 0.0, 1.0;
  (Nasopharyngeal CA, Absent [0pc]) 0.0, 0.0, 1.0;
  (Seminoma, Absent [0pc]) 0.0, 0.0, 1.0;
  (SLE, Absent [0pc]) 0.0, 0.0, 1.0;
  (Mycobact histiocytos, Absent [0pc]) 0.0, 0.0, 1.0;
  (Mast-cell hyperplas, Absent [0pc]) 0.0, 0.0, 1.0;
  (LGV, Absent [0pc]) 0.0, 0.0, 1.0;
  (Histoplasmosis, Absent [0pc]) 0.0, 0.0, 1.0;
  (Coccidioidomycosis, Absent [0pc]) 0.0, 0.0, 1.0;
  (CMV, Absent [0pc]) 0.0, 0.0, 1.0;
  (Brucellosis, Absent [0pc]) 0.0, 0.0, 1.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 0.0, 0.0, 1.0;
  (Intermed lymphocytic, Absent [0pc]) 0.0, 0.0, 1.0;
  (AIDS early, 1-25pc) 0.3333333, 0.3333333, 0.3333333;
  (AILD, 1-25pc) 0.0, 0.0, 1.0;
  (ALIP, 1-25pc) 0.0, 0.0, 1.0;
  (Cat scratch disease, 1-25pc) 0.01, 0.74, 0.25;
  (Dermatopathic laden, 1-25pc) 0.01, 0.84, 0.15;
  (Florid follic hyperp, 1-25pc) 0.3333333, 0.3333333, 0.3333333;
  (GLH hyaline vascular, 1-25pc) 0.01, 0.84, 0.15;
  (GLH plasma cell, 1-25pc) 0.01, 0.84, 0.15;
  (Granulomatous laden, 1-25pc) 0.01, 0.74, 0.25;
  (Histiocytosis x, 1-25pc) 0.02, 0.78, 0.20;
  (Infectious mono, 1-25pc) 0.05, 0.65, 0.30;
  (Leprosy-lepromatous, 1-25pc) 0.02, 0.68, 0.30;
  (Lymphangiographic, 1-25pc) 0.01, 0.59, 0.40;
  (Mantle zone hyperpla, 1-25pc) 0.9, 0.1, 0.0;
  (Necrotizing Kikuchi, 1-25pc) 0.01, 0.74, 0.25;
  (Necrotiz non-Kikuchi, 1-25pc) 0.01, 0.74, 0.25;
  (Rheumatoid arthritis, 1-25pc) 0.01, 0.84, 0.15;
  (Sarcoidosis, 1-25pc) 0.02, 0.68, 0.30;
  (SHML, 1-25pc) 0.969, 0.030, 0.001;
  (Sinus histiocytosis, 1-25pc) 0.969, 0.030, 0.001;
  (Syphilis, 1-25pc) 0.01, 0.84, 0.15;
  (Toxoplasmosis, 1-25pc) 0.01, 0.84, 0.15;
  (Tuberculosis, 1-25pc) 0.02, 0.68, 0.30;
  (Viral NOS, 1-25pc) 0.05, 0.65, 0.30;
  (Whipple's disease, 1-25pc) 0.01, 0.59, 0.40;
  (L&H nodular HD, 1-25pc) 0.05, 0.05, 0.90;
  (L&H diffuse HD, 1-25pc) 0.05, 0.05, 0.90;
  (Nodular sclerosis HD, 1-25pc) 0.01, 0.31, 0.68;
  (Cellular phase NSHD, 1-25pc) 0.01, 0.31, 0.68;
  (Syncytial NSHD, 1-25pc) 0.01, 0.31, 0.68;
  (Mixed cellularity HD, 1-25pc) 0.01, 0.31, 0.68;
  (Interfollicular HD, 1-25pc) 0.1, 0.4, 0.5;
  (Diffuse fibrosis HD, 1-25pc) 0.00, 0.01, 0.99;
  (Reticular-type HD, 1-25pc) 0.00, 0.01, 0.99;
  (Small cleaved fol, 1-25pc) 0.45, 0.10, 0.45;
  (Mixed fol, 1-25pc) 0.45, 0.10, 0.45;
  (Large cell fol, 1-25pc) 0.45, 0.10, 0.45;
  (Small noncleaved fol, 1-25pc) 0.45, 0.10, 0.45;
  (Small lymphocytic, 1-25pc) 0.00, 0.06, 0.94;
  (Plasmacytoid lyctic, 1-25pc) 0.00, 0.06, 0.94;
  (Mantle zone lymphoma, 1-25pc) 0.01, 0.05, 0.94;
  (Small cleaved dif, 1-25pc) 0.00, 0.02, 0.98;
  (Mixed FCC dif, 1-25pc) 0.00, 0.02, 0.98;
  (Large cell dif, 1-25pc) 0.00, 0.02, 0.98;
  (B-immunoblastic, 1-25pc) 0.00, 0.02, 0.98;
  (T-immunob mixed, 1-25pc) 0.00, 0.02, 0.98;
  (AILD-like T-cell lym, 1-25pc) 0.00, 0.02, 0.98;
  (Japanese ATL, 1-25pc) 0.00, 0.02, 0.98;
  (Lymphoblastic, 1-25pc) 0.00, 0.03, 0.97;
  (Small noncleaved dif, 1-25pc) 0.00, 0.02, 0.98;
  (True histiocytic, 1-25pc) 0.00, 0.02, 0.98;
  (Ki-1 LC anaplas T, 1-25pc) 0.001, 0.200, 0.799;
  (Multiple myeloma, 1-25pc) 0.45, 0.10, 0.45;
  (Mycosis fungoides, 1-25pc) 0.45, 0.10, 0.45;
  (AML, 1-25pc) 0.45, 0.10, 0.45;
  (Hairy cell leukemia, 1-25pc) 0.45, 0.10, 0.45;
  (Carcinoma, 1-25pc) 0.45, 0.10, 0.45;
  (Melanoma, 1-25pc) 0.45, 0.10, 0.45;
  (EM plasmacytoma, 1-25pc) 0.0, 0.1, 0.9;
  (Kaposi's sarcoma, 1-25pc) 0.2, 0.4, 0.4;
  (Mast-cell disease, 1-25pc) 0.0, 0.3, 0.7;
  (AIDS involutionary, 1-25pc) 0.01, 0.84, 0.15;
  (T-immunob large, 1-25pc) 0.00, 0.02, 0.98;
  (Monocytoid B-cell, 1-25pc) 0.00, 0.05, 0.95;
  (Nasopharyngeal CA, 1-25pc) 0.45, 0.10, 0.45;
  (Seminoma, 1-25pc) 0.45, 0.10, 0.45;
  (SLE, 1-25pc) 0.05, 0.65, 0.30;
  (Mycobact histiocytos, 1-25pc) 0.01, 0.84, 0.15;
  (Mast-cell hyperplas, 1-25pc) 0.01, 0.84, 0.15;
  (LGV, 1-25pc) 0.01, 0.74, 0.25;
  (Histoplasmosis, 1-25pc) 0.01, 0.84, 0.15;
  (Coccidioidomycosis, 1-25pc) 0.01, 0.84, 0.15;
  (CMV, 1-25pc) 0.01, 0.84, 0.15;
  (Brucellosis, 1-25pc) 0.01, 0.84, 0.15;
  (Ki-1 LC anaplas B, 1-25pc) 0.001, 0.200, 0.799;
  (Intermed lymphocytic, 1-25pc) 0.01, 0.03, 0.96;
  (AIDS early, 25-75pc) 0.60, 0.39, 0.01;
  (AILD, 25-75pc) 0.3333333, 0.3333333, 0.3333333;
  (ALIP, 25-75pc) 0.3333333, 0.3333333, 0.3333333;
  (Cat scratch disease, 25-75pc) 0.50, 0.49, 0.01;
  (Dermatopathic laden, 25-75pc) 0.50, 0.49, 0.01;
  (Florid follic hyperp, 25-75pc) 0.60, 0.39, 0.01;
  (GLH hyaline vascular, 25-75pc) 0.50, 0.49, 0.01;
  (GLH plasma cell, 25-75pc) 0.50, 0.49, 0.01;
  (Granulomatous laden, 25-75pc) 0.50, 0.49, 0.01;
  (Histiocytosis x, 25-75pc) 0.50, 0.49, 0.01;
  (Infectious mono, 25-75pc) 0.15, 0.75, 0.10;
  (Leprosy-lepromatous, 25-75pc) 0.10, 0.75, 0.15;
  (Lymphangiographic, 25-75pc) 0.50, 0.49, 0.01;
  (Mantle zone hyperpla, 25-75pc) 0.95, 0.05, 0.00;
  (Necrotizing Kikuchi, 25-75pc) 0.50, 0.49, 0.01;
  (Necrotiz non-Kikuchi, 25-75pc) 0.50, 0.49, 0.01;
  (Rheumatoid arthritis, 25-75pc) 0.50, 0.49, 0.01;
  (Sarcoidosis, 25-75pc) 0.10, 0.75, 0.15;
  (SHML, 25-75pc) 0.990, 0.009, 0.001;
  (Sinus histiocytosis, 25-75pc) 0.990, 0.009, 0.001;
  (Syphilis, 25-75pc) 0.50, 0.49, 0.01;
  (Toxoplasmosis, 25-75pc) 0.50, 0.49, 0.01;
  (Tuberculosis, 25-75pc) 0.10, 0.75, 0.15;
  (Viral NOS, 25-75pc) 0.15, 0.75, 0.10;
  (Whipple's disease, 25-75pc) 0.50, 0.49, 0.01;
  (L&H nodular HD, 25-75pc) 0.3333333, 0.3333333, 0.3333333;
  (L&H diffuse HD, 25-75pc) 0.3333333, 0.3333333, 0.3333333;
  (Nodular sclerosis HD, 25-75pc) 0.01, 0.31, 0.68;
  (Cellular phase NSHD, 25-75pc) 0.01, 0.31, 0.68;
  (Syncytial NSHD, 25-75pc) 0.01, 0.31, 0.68;
  (Mixed cellularity HD, 25-75pc) 0.01, 0.31, 0.68;
  (Interfollicular HD, 25-75pc) 0.1, 0.4, 0.5;
  (Diffuse fibrosis HD, 25-75pc) 0.3333333, 0.3333333, 0.3333333;
  (Reticular-type HD, 25-75pc) 0.3333333, 0.3333333, 0.3333333;
  (Small cleaved fol, 25-75pc) 0.50, 0.05, 0.45;
  (Mixed fol, 25-75pc) 0.50, 0.05, 0.45;
  (Large cell fol, 25-75pc) 0.50, 0.05, 0.45;
  (Small noncleaved fol, 25-75pc) 0.50, 0.05, 0.45;
  (Small lymphocytic, 25-75pc) 0.00, 0.06, 0.94;
  (Plasmacytoid lyctic, 25-75pc) 0.00, 0.06, 0.94;
  (Mantle zone lymphoma, 25-75pc) 0.25, 0.25, 0.50;
  (Small cleaved dif, 25-75pc) 0.3333333, 0.3333333, 0.3333333;
  (Mixed FCC dif, 25-75pc) 0.3333333, 0.3333333, 0.3333333;
  (Large cell dif, 25-75pc) 0.3333333, 0.3333333, 0.3333333;
  (B-immunoblastic, 25-75pc) 0.3333333, 0.3333333, 0.3333333;
  (T-immunob mixed, 25-75pc) 0.3333333, 0.3333333, 0.3333333;
  (AILD-like T-cell lym, 25-75pc) 0.3333333, 0.3333333, 0.3333333;
  (Japanese ATL, 25-75pc) 0.3333333, 0.3333333, 0.3333333;
  (Lymphoblastic, 25-75pc) 0.00, 0.03, 0.97;
  (Small noncleaved dif, 25-75pc) 0.3333333, 0.3333333, 0.3333333;
  (True histiocytic, 25-75pc) 0.3333333, 0.3333333, 0.3333333;
  (Ki-1 LC anaplas T, 25-75pc) 0.01, 0.25, 0.74;
  (Multiple myeloma, 25-75pc) 0.55, 0.10, 0.35;
  (Mycosis fungoides, 25-75pc) 0.55, 0.10, 0.35;
  (AML, 25-75pc) 0.55, 0.10, 0.35;
  (Hairy cell leukemia, 25-75pc) 0.55, 0.10, 0.35;
  (Carcinoma, 25-75pc) 0.55, 0.10, 0.35;
  (Melanoma, 25-75pc) 0.55, 0.10, 0.35;
  (EM plasmacytoma, 25-75pc) 0.01, 0.40, 0.59;
  (Kaposi's sarcoma, 25-75pc) 0.4, 0.4, 0.2;
  (Mast-cell disease, 25-75pc) 0.05, 0.45, 0.50;
  (AIDS involutionary, 25-75pc) 0.50, 0.49, 0.01;
  (T-immunob large, 25-75pc) 0.3333333, 0.3333333, 0.3333333;
  (Monocytoid B-cell, 25-75pc) 0.01, 0.10, 0.89;
  (Nasopharyngeal CA, 25-75pc) 0.55, 0.10, 0.35;
  (Seminoma, 25-75pc) 0.55, 0.10, 0.35;
  (SLE, 25-75pc) 0.15, 0.75, 0.10;
  (Mycobact histiocytos, 25-75pc) 0.50, 0.49, 0.01;
  (Mast-cell hyperplas, 25-75pc) 0.50, 0.49, 0.01;
  (LGV, 25-75pc) 0.50, 0.49, 0.01;
  (Histoplasmosis, 25-75pc) 0.50, 0.49, 0.01;
  (Coccidioidomycosis, 25-75pc) 0.50, 0.49, 0.01;
  (CMV, 25-75pc) 0.50, 0.49, 0.01;
  (Brucellosis, 25-75pc) 0.50, 0.49, 0.01;
  (Ki-1 LC anaplas B, 25-75pc) 0.01, 0.25, 0.74;
  (Intermed lymphocytic, 25-75pc) 0.3333333, 0.3333333, 0.3333333;
  (AIDS early, 75-90pc) 0.99, 0.01, 0.00;
  (AILD, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (ALIP, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Cat scratch disease, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Dermatopathic laden, 75-90pc) 0.95, 0.05, 0.00;
  (Florid follic hyperp, 75-90pc) 0.99, 0.01, 0.00;
  (GLH hyaline vascular, 75-90pc) 0.95, 0.05, 0.00;
  (GLH plasma cell, 75-90pc) 0.95, 0.05, 0.00;
  (Granulomatous laden, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Histiocytosis x, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Infectious mono, 75-90pc) 0.95, 0.05, 0.00;
  (Leprosy-lepromatous, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Lymphangiographic, 75-90pc) 0.95, 0.05, 0.00;
  (Mantle zone hyperpla, 75-90pc) 0.99, 0.01, 0.00;
  (Necrotizing Kikuchi, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Necrotiz non-Kikuchi, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Rheumatoid arthritis, 75-90pc) 0.95, 0.05, 0.00;
  (Sarcoidosis, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (SHML, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Sinus histiocytosis, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Syphilis, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Toxoplasmosis, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Tuberculosis, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Viral NOS, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Whipple's disease, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (L&H nodular HD, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (L&H diffuse HD, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Nodular sclerosis HD, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Cellular phase NSHD, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Syncytial NSHD, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Mixed cellularity HD, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Interfollicular HD, 75-90pc) 0.95, 0.05, 0.00;
  (Diffuse fibrosis HD, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Reticular-type HD, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Small cleaved fol, 75-90pc) 0.99, 0.01, 0.00;
  (Mixed fol, 75-90pc) 0.99, 0.01, 0.00;
  (Large cell fol, 75-90pc) 0.99, 0.01, 0.00;
  (Small noncleaved fol, 75-90pc) 0.99, 0.01, 0.00;
  (Small lymphocytic, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Plasmacytoid lyctic, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Mantle zone lymphoma, 75-90pc) 0.75, 0.20, 0.05;
  (Small cleaved dif, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Mixed FCC dif, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Large cell dif, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (B-immunoblastic, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (T-immunob mixed, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (AILD-like T-cell lym, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Japanese ATL, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Lymphoblastic, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Small noncleaved dif, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (True histiocytic, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Ki-1 LC anaplas T, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Multiple myeloma, 75-90pc) 0.99, 0.01, 0.00;
  (Mycosis fungoides, 75-90pc) 0.99, 0.01, 0.00;
  (AML, 75-90pc) 0.99, 0.01, 0.00;
  (Hairy cell leukemia, 75-90pc) 0.99, 0.01, 0.00;
  (Carcinoma, 75-90pc) 0.99, 0.01, 0.00;
  (Melanoma, 75-90pc) 0.99, 0.01, 0.00;
  (EM plasmacytoma, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Kaposi's sarcoma, 75-90pc) 0.95, 0.05, 0.00;
  (Mast-cell disease, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (AIDS involutionary, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (T-immunob large, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Monocytoid B-cell, 75-90pc) 0.95, 0.05, 0.00;
  (Nasopharyngeal CA, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Seminoma, 75-90pc) 0.99, 0.01, 0.00;
  (SLE, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Mycobact histiocytos, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Mast-cell hyperplas, 75-90pc) 0.95, 0.05, 0.00;
  (LGV, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Histoplasmosis, 75-90pc) 0.95, 0.05, 0.00;
  (Coccidioidomycosis, 75-90pc) 0.95, 0.05, 0.00;
  (CMV, 75-90pc) 0.95, 0.05, 0.00;
  (Brucellosis, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Ki-1 LC anaplas B, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (Intermed lymphocytic, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (AIDS early, >90pc) 0.999, 0.001, 0.000;
  (AILD, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (ALIP, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Cat scratch disease, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Dermatopathic laden, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Florid follic hyperp, >90pc) 0.999, 0.001, 0.000;
  (GLH hyaline vascular, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (GLH plasma cell, >90pc) 0.999, 0.001, 0.000;
  (Granulomatous laden, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Histiocytosis x, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Infectious mono, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Leprosy-lepromatous, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Lymphangiographic, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Mantle zone hyperpla, >90pc) 0.999, 0.001, 0.000;
  (Necrotizing Kikuchi, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Necrotiz non-Kikuchi, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Rheumatoid arthritis, >90pc) 0.999, 0.001, 0.000;
  (Sarcoidosis, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (SHML, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Sinus histiocytosis, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Syphilis, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Toxoplasmosis, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Tuberculosis, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Viral NOS, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Whipple's disease, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (L&H nodular HD, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (L&H diffuse HD, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Nodular sclerosis HD, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Cellular phase NSHD, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Syncytial NSHD, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Mixed cellularity HD, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Interfollicular HD, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Diffuse fibrosis HD, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Reticular-type HD, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Small cleaved fol, >90pc) 0.999, 0.001, 0.000;
  (Mixed fol, >90pc) 0.999, 0.001, 0.000;
  (Large cell fol, >90pc) 0.999, 0.001, 0.000;
  (Small noncleaved fol, >90pc) 0.999, 0.001, 0.000;
  (Small lymphocytic, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Plasmacytoid lyctic, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Mantle zone lymphoma, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Small cleaved dif, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Mixed FCC dif, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Large cell dif, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (B-immunoblastic, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (T-immunob mixed, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (AILD-like T-cell lym, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Japanese ATL, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Lymphoblastic, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Small noncleaved dif, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (True histiocytic, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Ki-1 LC anaplas T, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Multiple myeloma, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Mycosis fungoides, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (AML, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Hairy cell leukemia, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Carcinoma, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Melanoma, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (EM plasmacytoma, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Kaposi's sarcoma, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Mast-cell disease, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (AIDS involutionary, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (T-immunob large, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Monocytoid B-cell, >90pc) 0.999, 0.001, 0.000;
  (Nasopharyngeal CA, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Seminoma, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (SLE, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Mycobact histiocytos, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Mast-cell hyperplas, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (LGV, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Histoplasmosis, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Coccidioidomycosis, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (CMV, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Brucellosis, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Ki-1 LC anaplas B, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Intermed lymphocytic, >90pc) 0.3333333, 0.3333333, 0.3333333;
}
probability ( ICLC | Fault, ECCC, LLC_I, MLC_I ) {
  (AIDS early, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (AILD, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (ALIP, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Cat scratch disease, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Dermatopathic laden, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Florid follic hyperp, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (GLH hyaline vascular, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (GLH plasma cell, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Granulomatous laden, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Histiocytosis x, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Infectious mono, Absent [0pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Leprosy-lepromatous, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Lymphangiographic, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Sarcoidosis, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (SHML, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Sinus histiocytosis, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Syphilis, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Toxoplasmosis, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Tuberculosis, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Viral NOS, Absent [0pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Whipple's disease, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (L&H nodular HD, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (L&H diffuse HD, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Cellular phase NSHD, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Syncytial NSHD, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Mixed cellularity HD, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Interfollicular HD, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Reticular-type HD, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Small cleaved fol, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Mixed fol, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Large cell fol, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Small noncleaved fol, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Small lymphocytic, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Small cleaved dif, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Mixed FCC dif, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Large cell dif, Absent [0pc], Absent [no], Absent [no]) 0.5, 0.5;
  (B-immunoblastic, Absent [0pc], Absent [no], Absent [no]) 0.5, 0.5;
  (T-immunob mixed, Absent [0pc], Absent [no], Absent [no]) 0.5, 0.5;
  (AILD-like T-cell lym, Absent [0pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Japanese ATL, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Lymphoblastic, Absent [0pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Small noncleaved dif, Absent [0pc], Absent [no], Absent [no]) 0.5, 0.5;
  (True histiocytic, Absent [0pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Ki-1 LC anaplas T, Absent [0pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Multiple myeloma, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Mycosis fungoides, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (AML, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Hairy cell leukemia, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Carcinoma, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Melanoma, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (EM plasmacytoma, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Mast-cell disease, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (AIDS involutionary, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (T-immunob large, Absent [0pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Monocytoid B-cell, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Seminoma, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (SLE, Absent [0pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mycobact histiocytos, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (LGV, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Histoplasmosis, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Coccidioidomycosis, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (CMV, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Brucellosis, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Intermed lymphocytic, Absent [0pc], Absent [no], Absent [no]) 1.0, 0.0;
  (AIDS early, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (AILD, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (ALIP, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Cat scratch disease, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Dermatopathic laden, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Florid follic hyperp, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (GLH hyaline vascular, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (GLH plasma cell, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Granulomatous laden, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Histiocytosis x, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Infectious mono, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Leprosy-lepromatous, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Lymphangiographic, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mantle zone hyperpla, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Necrotizing Kikuchi, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Necrotiz non-Kikuchi, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Rheumatoid arthritis, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Sarcoidosis, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (SHML, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Sinus histiocytosis, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Syphilis, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Toxoplasmosis, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Tuberculosis, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Viral NOS, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Whipple's disease, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (L&H nodular HD, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (L&H diffuse HD, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Nodular sclerosis HD, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Cellular phase NSHD, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Syncytial NSHD, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mixed cellularity HD, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Interfollicular HD, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Diffuse fibrosis HD, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Reticular-type HD, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Small cleaved fol, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mixed fol, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Large cell fol, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Small noncleaved fol, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Small lymphocytic, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Plasmacytoid lyctic, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mantle zone lymphoma, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Small cleaved dif, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mixed FCC dif, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Large cell dif, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (B-immunoblastic, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (T-immunob mixed, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (AILD-like T-cell lym, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Japanese ATL, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Lymphoblastic, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Small noncleaved dif, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (True histiocytic, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Ki-1 LC anaplas T, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Multiple myeloma, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mycosis fungoides, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (AML, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Hairy cell leukemia, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Carcinoma, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Melanoma, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (EM plasmacytoma, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Kaposi's sarcoma, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mast-cell disease, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (AIDS involutionary, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (T-immunob large, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Monocytoid B-cell, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Nasopharyngeal CA, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Seminoma, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (SLE, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mycobact histiocytos, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mast-cell hyperplas, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (LGV, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Histoplasmosis, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Coccidioidomycosis, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (CMV, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Brucellosis, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Ki-1 LC anaplas B, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Intermed lymphocytic, Rare [1-10pc], Absent [no], Absent [no]) 0.5, 0.5;
  (AIDS early, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (AILD, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (ALIP, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Cat scratch disease, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Dermatopathic laden, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Florid follic hyperp, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (GLH hyaline vascular, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (GLH plasma cell, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Granulomatous laden, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Histiocytosis x, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Infectious mono, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Leprosy-lepromatous, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Lymphangiographic, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mantle zone hyperpla, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Necrotizing Kikuchi, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Necrotiz non-Kikuchi, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Rheumatoid arthritis, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Sarcoidosis, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (SHML, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Sinus histiocytosis, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Syphilis, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Toxoplasmosis, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Tuberculosis, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Viral NOS, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Whipple's disease, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (L&H nodular HD, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (L&H diffuse HD, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Nodular sclerosis HD, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Cellular phase NSHD, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Syncytial NSHD, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mixed cellularity HD, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Interfollicular HD, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Diffuse fibrosis HD, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Reticular-type HD, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Small cleaved fol, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mixed fol, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Large cell fol, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Small noncleaved fol, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Small lymphocytic, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Plasmacytoid lyctic, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mantle zone lymphoma, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Small cleaved dif, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mixed FCC dif, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Large cell dif, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (B-immunoblastic, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (T-immunob mixed, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (AILD-like T-cell lym, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Japanese ATL, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Lymphoblastic, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Small noncleaved dif, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (True histiocytic, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Ki-1 LC anaplas T, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Multiple myeloma, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mycosis fungoides, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (AML, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Hairy cell leukemia, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Carcinoma, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Melanoma, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (EM plasmacytoma, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Kaposi's sarcoma, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mast-cell disease, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (AIDS involutionary, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (T-immunob large, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Monocytoid B-cell, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Nasopharyngeal CA, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Seminoma, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (SLE, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mycobact histiocytos, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mast-cell hyperplas, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (LGV, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Histoplasmosis, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Coccidioidomycosis, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (CMV, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Brucellosis, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Ki-1 LC anaplas B, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Intermed lymphocytic, Present [11-50pc], Absent [no], Absent [no]) 0.5, 0.5;
  (AIDS early, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (AILD, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (ALIP, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Cat scratch disease, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Dermatopathic laden, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Florid follic hyperp, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (GLH hyaline vascular, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (GLH plasma cell, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Granulomatous laden, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Histiocytosis x, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Infectious mono, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Leprosy-lepromatous, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Lymphangiographic, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mantle zone hyperpla, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Necrotizing Kikuchi, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Necrotiz non-Kikuchi, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Rheumatoid arthritis, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Sarcoidosis, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (SHML, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Sinus histiocytosis, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Syphilis, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Toxoplasmosis, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Tuberculosis, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Viral NOS, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Whipple's disease, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (L&H nodular HD, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (L&H diffuse HD, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Nodular sclerosis HD, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Cellular phase NSHD, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Syncytial NSHD, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mixed cellularity HD, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Interfollicular HD, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Diffuse fibrosis HD, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Reticular-type HD, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Small cleaved fol, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mixed fol, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Large cell fol, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Small noncleaved fol, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Small lymphocytic, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Plasmacytoid lyctic, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mantle zone lymphoma, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Small cleaved dif, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mixed FCC dif, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Large cell dif, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (B-immunoblastic, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (T-immunob mixed, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (AILD-like T-cell lym, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Japanese ATL, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Lymphoblastic, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Small noncleaved dif, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (True histiocytic, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Ki-1 LC anaplas T, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Multiple myeloma, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mycosis fungoides, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (AML, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Hairy cell leukemia, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Carcinoma, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Melanoma, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (EM plasmacytoma, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Kaposi's sarcoma, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mast-cell disease, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (AIDS involutionary, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (T-immunob large, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Monocytoid B-cell, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Nasopharyngeal CA, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Seminoma, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (SLE, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mycobact histiocytos, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Mast-cell hyperplas, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (LGV, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Histoplasmosis, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Coccidioidomycosis, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (CMV, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Brucellosis, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Ki-1 LC anaplas B, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (Intermed lymphocytic, Many [51-70pc], Absent [no], Absent [no]) 0.5, 0.5;
  (AIDS early, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (AILD, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (ALIP, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Cat scratch disease, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Dermatopathic laden, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Florid follic hyperp, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (GLH hyaline vascular, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (GLH plasma cell, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Granulomatous laden, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Histiocytosis x, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Infectious mono, Absent [0pc], Present [yes], Absent [no]) 0.99, 0.01;
  (Leprosy-lepromatous, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Lymphangiographic, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Mantle zone hyperpla, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Necrotizing Kikuchi, Absent [0pc], Present [yes], Absent [no]) 0.99, 0.01;
  (Necrotiz non-Kikuchi, Absent [0pc], Present [yes], Absent [no]) 0.99, 0.01;
  (Rheumatoid arthritis, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Sarcoidosis, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (SHML, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Sinus histiocytosis, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Syphilis, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Toxoplasmosis, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Tuberculosis, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Viral NOS, Absent [0pc], Present [yes], Absent [no]) 0.99, 0.01;
  (Whipple's disease, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (L&H nodular HD, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (L&H diffuse HD, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Nodular sclerosis HD, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Cellular phase NSHD, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Syncytial NSHD, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Mixed cellularity HD, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Interfollicular HD, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Diffuse fibrosis HD, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Reticular-type HD, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Small cleaved fol, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Mixed fol, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Large cell fol, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Small noncleaved fol, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Small lymphocytic, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Plasmacytoid lyctic, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Mantle zone lymphoma, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Small cleaved dif, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Mixed FCC dif, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Large cell dif, Absent [0pc], Present [yes], Absent [no]) 0.99, 0.01;
  (B-immunoblastic, Absent [0pc], Present [yes], Absent [no]) 0.99, 0.01;
  (T-immunob mixed, Absent [0pc], Present [yes], Absent [no]) 0.99, 0.01;
  (AILD-like T-cell lym, Absent [0pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Japanese ATL, Absent [0pc], Present [yes], Absent [no]) 0.99, 0.01;
  (Lymphoblastic, Absent [0pc], Present [yes], Absent [no]) 0.99, 0.01;
  (Small noncleaved dif, Absent [0pc], Present [yes], Absent [no]) 0.5, 0.5;
  (True histiocytic, Absent [0pc], Present [yes], Absent [no]) 0.99, 0.01;
  (Ki-1 LC anaplas T, Absent [0pc], Present [yes], Absent [no]) 0.7, 0.3;
  (Multiple myeloma, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Mycosis fungoides, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (AML, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Hairy cell leukemia, Absent [0pc], Present [yes], Absent [no]) 0.99, 0.01;
  (Carcinoma, Absent [0pc], Present [yes], Absent [no]) 0.9, 0.1;
  (Melanoma, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (EM plasmacytoma, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Kaposi's sarcoma, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Mast-cell disease, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (AIDS involutionary, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (T-immunob large, Absent [0pc], Present [yes], Absent [no]) 0.99, 0.01;
  (Monocytoid B-cell, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Nasopharyngeal CA, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Seminoma, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (SLE, Absent [0pc], Present [yes], Absent [no]) 0.99, 0.01;
  (Mycobact histiocytos, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Mast-cell hyperplas, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (LGV, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Histoplasmosis, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Coccidioidomycosis, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (CMV, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Brucellosis, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (Ki-1 LC anaplas B, Absent [0pc], Present [yes], Absent [no]) 0.7, 0.3;
  (Intermed lymphocytic, Absent [0pc], Present [yes], Absent [no]) 0.9999, 0.0001;
  (AIDS early, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (AILD, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (ALIP, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Cat scratch disease, Rare [1-10pc], Present [yes], Absent [no]) 0.99, 0.01;
  (Dermatopathic laden, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Florid follic hyperp, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (GLH hyaline vascular, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (GLH plasma cell, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Granulomatous laden, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Histiocytosis x, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Infectious mono, Rare [1-10pc], Present [yes], Absent [no]) 0.99, 0.01;
  (Leprosy-lepromatous, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Lymphangiographic, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mantle zone hyperpla, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Necrotizing Kikuchi, Rare [1-10pc], Present [yes], Absent [no]) 0.99, 0.01;
  (Necrotiz non-Kikuchi, Rare [1-10pc], Present [yes], Absent [no]) 0.99, 0.01;
  (Rheumatoid arthritis, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Sarcoidosis, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (SHML, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Sinus histiocytosis, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Syphilis, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Toxoplasmosis, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Tuberculosis, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Viral NOS, Rare [1-10pc], Present [yes], Absent [no]) 0.99, 0.01;
  (Whipple's disease, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (L&H nodular HD, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (L&H diffuse HD, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Nodular sclerosis HD, Rare [1-10pc], Present [yes], Absent [no]) 0.999, 0.001;
  (Cellular phase NSHD, Rare [1-10pc], Present [yes], Absent [no]) 0.999, 0.001;
  (Syncytial NSHD, Rare [1-10pc], Present [yes], Absent [no]) 0.999, 0.001;
  (Mixed cellularity HD, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Interfollicular HD, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Diffuse fibrosis HD, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Reticular-type HD, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Small cleaved fol, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mixed fol, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Large cell fol, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Small noncleaved fol, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Small lymphocytic, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Plasmacytoid lyctic, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mantle zone lymphoma, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Small cleaved dif, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mixed FCC dif, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Large cell dif, Rare [1-10pc], Present [yes], Absent [no]) 0.995, 0.005;
  (B-immunoblastic, Rare [1-10pc], Present [yes], Absent [no]) 0.99, 0.01;
  (T-immunob mixed, Rare [1-10pc], Present [yes], Absent [no]) 0.99, 0.01;
  (AILD-like T-cell lym, Rare [1-10pc], Present [yes], Absent [no]) 0.9, 0.1;
  (Japanese ATL, Rare [1-10pc], Present [yes], Absent [no]) 0.99, 0.01;
  (Lymphoblastic, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Small noncleaved dif, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (True histiocytic, Rare [1-10pc], Present [yes], Absent [no]) 0.99, 0.01;
  (Ki-1 LC anaplas T, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Multiple myeloma, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mycosis fungoides, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (AML, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Hairy cell leukemia, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Carcinoma, Rare [1-10pc], Present [yes], Absent [no]) 0.999, 0.001;
  (Melanoma, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (EM plasmacytoma, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Kaposi's sarcoma, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mast-cell disease, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (AIDS involutionary, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (T-immunob large, Rare [1-10pc], Present [yes], Absent [no]) 0.99, 0.01;
  (Monocytoid B-cell, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Nasopharyngeal CA, Rare [1-10pc], Present [yes], Absent [no]) 0.999, 0.001;
  (Seminoma, Rare [1-10pc], Present [yes], Absent [no]) 0.999, 0.001;
  (SLE, Rare [1-10pc], Present [yes], Absent [no]) 0.99, 0.01;
  (Mycobact histiocytos, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mast-cell hyperplas, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (LGV, Rare [1-10pc], Present [yes], Absent [no]) 0.99, 0.01;
  (Histoplasmosis, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Coccidioidomycosis, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (CMV, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Brucellosis, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Ki-1 LC anaplas B, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Intermed lymphocytic, Rare [1-10pc], Present [yes], Absent [no]) 0.5, 0.5;
  (AIDS early, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (AILD, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (ALIP, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Cat scratch disease, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Dermatopathic laden, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Florid follic hyperp, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (GLH hyaline vascular, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (GLH plasma cell, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Granulomatous laden, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Histiocytosis x, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Infectious mono, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Leprosy-lepromatous, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Lymphangiographic, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mantle zone hyperpla, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Necrotizing Kikuchi, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Necrotiz non-Kikuchi, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Rheumatoid arthritis, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Sarcoidosis, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (SHML, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Sinus histiocytosis, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Syphilis, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Toxoplasmosis, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Tuberculosis, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Viral NOS, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Whipple's disease, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (L&H nodular HD, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (L&H diffuse HD, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Nodular sclerosis HD, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Cellular phase NSHD, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Syncytial NSHD, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mixed cellularity HD, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Interfollicular HD, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Diffuse fibrosis HD, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Reticular-type HD, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Small cleaved fol, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mixed fol, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Large cell fol, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Small noncleaved fol, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Small lymphocytic, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Plasmacytoid lyctic, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mantle zone lymphoma, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Small cleaved dif, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mixed FCC dif, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Large cell dif, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (B-immunoblastic, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (T-immunob mixed, Present [11-50pc], Present [yes], Absent [no]) 0.98, 0.02;
  (AILD-like T-cell lym, Present [11-50pc], Present [yes], Absent [no]) 0.8, 0.2;
  (Japanese ATL, Present [11-50pc], Present [yes], Absent [no]) 0.98, 0.02;
  (Lymphoblastic, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Small noncleaved dif, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (True histiocytic, Present [11-50pc], Present [yes], Absent [no]) 0.98, 0.02;
  (Ki-1 LC anaplas T, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Multiple myeloma, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mycosis fungoides, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (AML, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Hairy cell leukemia, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Carcinoma, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Melanoma, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (EM plasmacytoma, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Kaposi's sarcoma, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mast-cell disease, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (AIDS involutionary, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (T-immunob large, Present [11-50pc], Present [yes], Absent [no]) 0.98, 0.02;
  (Monocytoid B-cell, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Nasopharyngeal CA, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Seminoma, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (SLE, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mycobact histiocytos, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mast-cell hyperplas, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (LGV, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Histoplasmosis, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Coccidioidomycosis, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (CMV, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Brucellosis, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Ki-1 LC anaplas B, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Intermed lymphocytic, Present [11-50pc], Present [yes], Absent [no]) 0.5, 0.5;
  (AIDS early, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (AILD, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (ALIP, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Cat scratch disease, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Dermatopathic laden, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Florid follic hyperp, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (GLH hyaline vascular, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (GLH plasma cell, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Granulomatous laden, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Histiocytosis x, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Infectious mono, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Leprosy-lepromatous, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Lymphangiographic, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mantle zone hyperpla, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Necrotizing Kikuchi, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Necrotiz non-Kikuchi, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Rheumatoid arthritis, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Sarcoidosis, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (SHML, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Sinus histiocytosis, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Syphilis, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Toxoplasmosis, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Tuberculosis, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Viral NOS, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Whipple's disease, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (L&H nodular HD, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (L&H diffuse HD, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Nodular sclerosis HD, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Cellular phase NSHD, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Syncytial NSHD, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mixed cellularity HD, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Interfollicular HD, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Diffuse fibrosis HD, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Reticular-type HD, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Small cleaved fol, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mixed fol, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Large cell fol, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Small noncleaved fol, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Small lymphocytic, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Plasmacytoid lyctic, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mantle zone lymphoma, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Small cleaved dif, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mixed FCC dif, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Large cell dif, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (B-immunoblastic, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (T-immunob mixed, Many [51-70pc], Present [yes], Absent [no]) 0.99, 0.01;
  (AILD-like T-cell lym, Many [51-70pc], Present [yes], Absent [no]) 0.3, 0.7;
  (Japanese ATL, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Lymphoblastic, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Small noncleaved dif, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (True histiocytic, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Ki-1 LC anaplas T, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Multiple myeloma, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mycosis fungoides, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (AML, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Hairy cell leukemia, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Carcinoma, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Melanoma, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (EM plasmacytoma, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Kaposi's sarcoma, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mast-cell disease, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (AIDS involutionary, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (T-immunob large, Many [51-70pc], Present [yes], Absent [no]) 0.99, 0.01;
  (Monocytoid B-cell, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Nasopharyngeal CA, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Seminoma, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (SLE, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mycobact histiocytos, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Mast-cell hyperplas, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (LGV, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Histoplasmosis, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Coccidioidomycosis, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (CMV, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Brucellosis, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Ki-1 LC anaplas B, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (Intermed lymphocytic, Many [51-70pc], Present [yes], Absent [no]) 0.5, 0.5;
  (AIDS early, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (AILD, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (ALIP, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Cat scratch disease, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Dermatopathic laden, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Florid follic hyperp, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (GLH hyaline vascular, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (GLH plasma cell, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Granulomatous laden, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Histiocytosis x, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Infectious mono, Absent [0pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Leprosy-lepromatous, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Lymphangiographic, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Sarcoidosis, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (SHML, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Sinus histiocytosis, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Syphilis, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Toxoplasmosis, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Tuberculosis, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Viral NOS, Absent [0pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Whipple's disease, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (L&H nodular HD, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (L&H diffuse HD, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Cellular phase NSHD, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Syncytial NSHD, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Mixed cellularity HD, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Interfollicular HD, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Reticular-type HD, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Small cleaved fol, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Mixed fol, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Large cell fol, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Small noncleaved fol, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Small lymphocytic, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Small cleaved dif, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Mixed FCC dif, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Large cell dif, Absent [0pc], Absent [no], Present [yes]) 0.5, 0.5;
  (B-immunoblastic, Absent [0pc], Absent [no], Present [yes]) 0.5, 0.5;
  (T-immunob mixed, Absent [0pc], Absent [no], Present [yes]) 0.5, 0.5;
  (AILD-like T-cell lym, Absent [0pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Japanese ATL, Absent [0pc], Absent [no], Present [yes]) 0.999, 0.001;
  (Lymphoblastic, Absent [0pc], Absent [no], Present [yes]) 0.99, 0.01;
  (Small noncleaved dif, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (True histiocytic, Absent [0pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Ki-1 LC anaplas T, Absent [0pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Multiple myeloma, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Mycosis fungoides, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (AML, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Hairy cell leukemia, Absent [0pc], Absent [no], Present [yes]) 0.999, 0.001;
  (Carcinoma, Absent [0pc], Absent [no], Present [yes]) 0.999, 0.001;
  (Melanoma, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (EM plasmacytoma, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Mast-cell disease, Absent [0pc], Absent [no], Present [yes]) 0.999, 0.001;
  (AIDS involutionary, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (T-immunob large, Absent [0pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Monocytoid B-cell, Absent [0pc], Absent [no], Present [yes]) 0.999, 0.001;
  (Nasopharyngeal CA, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Seminoma, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (SLE, Absent [0pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mycobact histiocytos, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc], Absent [no], Present [yes]) 0.999, 0.001;
  (LGV, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Histoplasmosis, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Coccidioidomycosis, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (CMV, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Brucellosis, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Intermed lymphocytic, Absent [0pc], Absent [no], Present [yes]) 1.0, 0.0;
  (AIDS early, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (AILD, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (ALIP, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Cat scratch disease, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Dermatopathic laden, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Florid follic hyperp, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (GLH hyaline vascular, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (GLH plasma cell, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Granulomatous laden, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Histiocytosis x, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Infectious mono, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Leprosy-lepromatous, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Lymphangiographic, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mantle zone hyperpla, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Necrotizing Kikuchi, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Necrotiz non-Kikuchi, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Rheumatoid arthritis, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Sarcoidosis, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (SHML, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Sinus histiocytosis, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Syphilis, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Toxoplasmosis, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Tuberculosis, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Viral NOS, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Whipple's disease, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (L&H nodular HD, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (L&H diffuse HD, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Nodular sclerosis HD, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Cellular phase NSHD, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Syncytial NSHD, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mixed cellularity HD, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Interfollicular HD, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Diffuse fibrosis HD, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Reticular-type HD, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Small cleaved fol, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mixed fol, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Large cell fol, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Small noncleaved fol, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Small lymphocytic, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Plasmacytoid lyctic, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mantle zone lymphoma, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Small cleaved dif, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mixed FCC dif, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Large cell dif, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (B-immunoblastic, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (T-immunob mixed, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (AILD-like T-cell lym, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Japanese ATL, Rare [1-10pc], Absent [no], Present [yes]) 0.999, 0.001;
  (Lymphoblastic, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Small noncleaved dif, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (True histiocytic, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Ki-1 LC anaplas T, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Multiple myeloma, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mycosis fungoides, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (AML, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Hairy cell leukemia, Rare [1-10pc], Absent [no], Present [yes]) 0.99, 0.01;
  (Carcinoma, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Melanoma, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (EM plasmacytoma, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Kaposi's sarcoma, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mast-cell disease, Rare [1-10pc], Absent [no], Present [yes]) 0.999, 0.001;
  (AIDS involutionary, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (T-immunob large, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Monocytoid B-cell, Rare [1-10pc], Absent [no], Present [yes]) 0.999, 0.001;
  (Nasopharyngeal CA, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Seminoma, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (SLE, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mycobact histiocytos, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mast-cell hyperplas, Rare [1-10pc], Absent [no], Present [yes]) 0.999, 0.001;
  (LGV, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Histoplasmosis, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Coccidioidomycosis, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (CMV, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Brucellosis, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Ki-1 LC anaplas B, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Intermed lymphocytic, Rare [1-10pc], Absent [no], Present [yes]) 0.5, 0.5;
  (AIDS early, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (AILD, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (ALIP, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Cat scratch disease, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Dermatopathic laden, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Florid follic hyperp, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (GLH hyaline vascular, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (GLH plasma cell, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Granulomatous laden, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Histiocytosis x, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Infectious mono, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Leprosy-lepromatous, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Lymphangiographic, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mantle zone hyperpla, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Necrotizing Kikuchi, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Necrotiz non-Kikuchi, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Rheumatoid arthritis, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Sarcoidosis, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (SHML, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Sinus histiocytosis, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Syphilis, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Toxoplasmosis, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Tuberculosis, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Viral NOS, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Whipple's disease, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (L&H nodular HD, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (L&H diffuse HD, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Nodular sclerosis HD, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Cellular phase NSHD, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Syncytial NSHD, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mixed cellularity HD, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Interfollicular HD, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Diffuse fibrosis HD, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Reticular-type HD, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Small cleaved fol, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mixed fol, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Large cell fol, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Small noncleaved fol, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Small lymphocytic, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Plasmacytoid lyctic, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mantle zone lymphoma, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Small cleaved dif, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mixed FCC dif, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Large cell dif, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (B-immunoblastic, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (T-immunob mixed, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (AILD-like T-cell lym, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Japanese ATL, Present [11-50pc], Absent [no], Present [yes]) 0.99, 0.01;
  (Lymphoblastic, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Small noncleaved dif, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (True histiocytic, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Ki-1 LC anaplas T, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Multiple myeloma, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mycosis fungoides, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (AML, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Hairy cell leukemia, Present [11-50pc], Absent [no], Present [yes]) 0.99, 0.01;
  (Carcinoma, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Melanoma, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (EM plasmacytoma, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Kaposi's sarcoma, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mast-cell disease, Present [11-50pc], Absent [no], Present [yes]) 0.999, 0.001;
  (AIDS involutionary, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (T-immunob large, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Monocytoid B-cell, Present [11-50pc], Absent [no], Present [yes]) 0.999, 0.001;
  (Nasopharyngeal CA, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Seminoma, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (SLE, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mycobact histiocytos, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mast-cell hyperplas, Present [11-50pc], Absent [no], Present [yes]) 0.999, 0.001;
  (LGV, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Histoplasmosis, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Coccidioidomycosis, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (CMV, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Brucellosis, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Ki-1 LC anaplas B, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Intermed lymphocytic, Present [11-50pc], Absent [no], Present [yes]) 0.5, 0.5;
  (AIDS early, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (AILD, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (ALIP, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Cat scratch disease, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Dermatopathic laden, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Florid follic hyperp, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (GLH hyaline vascular, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (GLH plasma cell, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Granulomatous laden, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Histiocytosis x, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Infectious mono, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Leprosy-lepromatous, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Lymphangiographic, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mantle zone hyperpla, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Necrotizing Kikuchi, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Necrotiz non-Kikuchi, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Rheumatoid arthritis, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Sarcoidosis, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (SHML, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Sinus histiocytosis, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Syphilis, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Toxoplasmosis, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Tuberculosis, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Viral NOS, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Whipple's disease, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (L&H nodular HD, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (L&H diffuse HD, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Nodular sclerosis HD, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Cellular phase NSHD, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Syncytial NSHD, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mixed cellularity HD, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Interfollicular HD, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Diffuse fibrosis HD, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Reticular-type HD, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Small cleaved fol, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mixed fol, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Large cell fol, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Small noncleaved fol, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Small lymphocytic, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Plasmacytoid lyctic, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mantle zone lymphoma, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Small cleaved dif, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mixed FCC dif, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Large cell dif, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (B-immunoblastic, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (T-immunob mixed, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (AILD-like T-cell lym, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Japanese ATL, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Lymphoblastic, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Small noncleaved dif, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (True histiocytic, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Ki-1 LC anaplas T, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Multiple myeloma, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mycosis fungoides, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (AML, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Hairy cell leukemia, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Carcinoma, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Melanoma, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (EM plasmacytoma, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Kaposi's sarcoma, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mast-cell disease, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (AIDS involutionary, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (T-immunob large, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Monocytoid B-cell, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Nasopharyngeal CA, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Seminoma, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (SLE, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mycobact histiocytos, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Mast-cell hyperplas, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (LGV, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Histoplasmosis, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Coccidioidomycosis, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (CMV, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Brucellosis, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Ki-1 LC anaplas B, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (Intermed lymphocytic, Many [51-70pc], Absent [no], Present [yes]) 0.5, 0.5;
  (AIDS early, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (AILD, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (ALIP, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Cat scratch disease, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Dermatopathic laden, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Florid follic hyperp, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (GLH hyaline vascular, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (GLH plasma cell, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Granulomatous laden, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Histiocytosis x, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Infectious mono, Absent [0pc], Present [yes], Present [yes]) 0.98, 0.02;
  (Leprosy-lepromatous, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Lymphangiographic, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Mantle zone hyperpla, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Necrotizing Kikuchi, Absent [0pc], Present [yes], Present [yes]) 0.98, 0.02;
  (Necrotiz non-Kikuchi, Absent [0pc], Present [yes], Present [yes]) 0.98, 0.02;
  (Rheumatoid arthritis, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Sarcoidosis, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (SHML, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Sinus histiocytosis, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Syphilis, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Toxoplasmosis, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Tuberculosis, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Viral NOS, Absent [0pc], Present [yes], Present [yes]) 0.98, 0.02;
  (Whipple's disease, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (L&H nodular HD, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (L&H diffuse HD, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Nodular sclerosis HD, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Cellular phase NSHD, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Syncytial NSHD, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Mixed cellularity HD, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Interfollicular HD, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Diffuse fibrosis HD, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Reticular-type HD, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Small cleaved fol, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Mixed fol, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Large cell fol, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Small noncleaved fol, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Small lymphocytic, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Plasmacytoid lyctic, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Mantle zone lymphoma, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Small cleaved dif, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Mixed FCC dif, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Large cell dif, Absent [0pc], Present [yes], Present [yes]) 0.99, 0.01;
  (B-immunoblastic, Absent [0pc], Present [yes], Present [yes]) 0.99, 0.01;
  (T-immunob mixed, Absent [0pc], Present [yes], Present [yes]) 0.99, 0.01;
  (AILD-like T-cell lym, Absent [0pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Japanese ATL, Absent [0pc], Present [yes], Present [yes]) 0.99, 0.01;
  (Lymphoblastic, Absent [0pc], Present [yes], Present [yes]) 0.95, 0.05;
  (Small noncleaved dif, Absent [0pc], Present [yes], Present [yes]) 0.99, 0.01;
  (True histiocytic, Absent [0pc], Present [yes], Present [yes]) 0.99, 0.01;
  (Ki-1 LC anaplas T, Absent [0pc], Present [yes], Present [yes]) 0.7, 0.3;
  (Multiple myeloma, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Mycosis fungoides, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (AML, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Hairy cell leukemia, Absent [0pc], Present [yes], Present [yes]) 0.99, 0.01;
  (Carcinoma, Absent [0pc], Present [yes], Present [yes]) 0.9, 0.1;
  (Melanoma, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (EM plasmacytoma, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Kaposi's sarcoma, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Mast-cell disease, Absent [0pc], Present [yes], Present [yes]) 0.999, 0.001;
  (AIDS involutionary, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (T-immunob large, Absent [0pc], Present [yes], Present [yes]) 0.99, 0.01;
  (Monocytoid B-cell, Absent [0pc], Present [yes], Present [yes]) 0.999, 0.001;
  (Nasopharyngeal CA, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Seminoma, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (SLE, Absent [0pc], Present [yes], Present [yes]) 0.98, 0.02;
  (Mycobact histiocytos, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Mast-cell hyperplas, Absent [0pc], Present [yes], Present [yes]) 0.999, 0.001;
  (LGV, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Histoplasmosis, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Coccidioidomycosis, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (CMV, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Brucellosis, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (Ki-1 LC anaplas B, Absent [0pc], Present [yes], Present [yes]) 0.7, 0.3;
  (Intermed lymphocytic, Absent [0pc], Present [yes], Present [yes]) 0.9999, 0.0001;
  (AIDS early, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (AILD, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (ALIP, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Cat scratch disease, Rare [1-10pc], Present [yes], Present [yes]) 0.99, 0.01;
  (Dermatopathic laden, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Florid follic hyperp, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (GLH hyaline vascular, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (GLH plasma cell, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Granulomatous laden, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Histiocytosis x, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Infectious mono, Rare [1-10pc], Present [yes], Present [yes]) 0.98, 0.02;
  (Leprosy-lepromatous, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Lymphangiographic, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mantle zone hyperpla, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Necrotizing Kikuchi, Rare [1-10pc], Present [yes], Present [yes]) 0.98, 0.02;
  (Necrotiz non-Kikuchi, Rare [1-10pc], Present [yes], Present [yes]) 0.98, 0.02;
  (Rheumatoid arthritis, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Sarcoidosis, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (SHML, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Sinus histiocytosis, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Syphilis, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Toxoplasmosis, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Tuberculosis, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Viral NOS, Rare [1-10pc], Present [yes], Present [yes]) 0.98, 0.02;
  (Whipple's disease, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (L&H nodular HD, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (L&H diffuse HD, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Nodular sclerosis HD, Rare [1-10pc], Present [yes], Present [yes]) 0.99, 0.01;
  (Cellular phase NSHD, Rare [1-10pc], Present [yes], Present [yes]) 0.99, 0.01;
  (Syncytial NSHD, Rare [1-10pc], Present [yes], Present [yes]) 0.99, 0.01;
  (Mixed cellularity HD, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Interfollicular HD, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Diffuse fibrosis HD, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Reticular-type HD, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Small cleaved fol, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mixed fol, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Large cell fol, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Small noncleaved fol, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Small lymphocytic, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Plasmacytoid lyctic, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mantle zone lymphoma, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Small cleaved dif, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mixed FCC dif, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Large cell dif, Rare [1-10pc], Present [yes], Present [yes]) 0.99, 0.01;
  (B-immunoblastic, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (T-immunob mixed, Rare [1-10pc], Present [yes], Present [yes]) 0.99, 0.01;
  (AILD-like T-cell lym, Rare [1-10pc], Present [yes], Present [yes]) 0.9, 0.1;
  (Japanese ATL, Rare [1-10pc], Present [yes], Present [yes]) 0.96, 0.04;
  (Lymphoblastic, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Small noncleaved dif, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (True histiocytic, Rare [1-10pc], Present [yes], Present [yes]) 0.97, 0.03;
  (Ki-1 LC anaplas T, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Multiple myeloma, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mycosis fungoides, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (AML, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Hairy cell leukemia, Rare [1-10pc], Present [yes], Present [yes]) 0.99, 0.01;
  (Carcinoma, Rare [1-10pc], Present [yes], Present [yes]) 0.999, 0.001;
  (Melanoma, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (EM plasmacytoma, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Kaposi's sarcoma, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mast-cell disease, Rare [1-10pc], Present [yes], Present [yes]) 0.999, 0.001;
  (AIDS involutionary, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (T-immunob large, Rare [1-10pc], Present [yes], Present [yes]) 0.97, 0.03;
  (Monocytoid B-cell, Rare [1-10pc], Present [yes], Present [yes]) 0.999, 0.001;
  (Nasopharyngeal CA, Rare [1-10pc], Present [yes], Present [yes]) 0.999, 0.001;
  (Seminoma, Rare [1-10pc], Present [yes], Present [yes]) 0.999, 0.001;
  (SLE, Rare [1-10pc], Present [yes], Present [yes]) 0.98, 0.02;
  (Mycobact histiocytos, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mast-cell hyperplas, Rare [1-10pc], Present [yes], Present [yes]) 0.999, 0.001;
  (LGV, Rare [1-10pc], Present [yes], Present [yes]) 0.99, 0.01;
  (Histoplasmosis, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Coccidioidomycosis, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (CMV, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Brucellosis, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Ki-1 LC anaplas B, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Intermed lymphocytic, Rare [1-10pc], Present [yes], Present [yes]) 0.5, 0.5;
  (AIDS early, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (AILD, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (ALIP, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Cat scratch disease, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Dermatopathic laden, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Florid follic hyperp, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (GLH hyaline vascular, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (GLH plasma cell, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Granulomatous laden, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Histiocytosis x, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Infectious mono, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Leprosy-lepromatous, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Lymphangiographic, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mantle zone hyperpla, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Necrotizing Kikuchi, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Necrotiz non-Kikuchi, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Rheumatoid arthritis, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Sarcoidosis, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (SHML, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Sinus histiocytosis, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Syphilis, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Toxoplasmosis, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Tuberculosis, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Viral NOS, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Whipple's disease, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (L&H nodular HD, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (L&H diffuse HD, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Nodular sclerosis HD, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Cellular phase NSHD, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Syncytial NSHD, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mixed cellularity HD, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Interfollicular HD, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Diffuse fibrosis HD, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Reticular-type HD, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Small cleaved fol, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mixed fol, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Large cell fol, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Small noncleaved fol, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Small lymphocytic, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Plasmacytoid lyctic, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mantle zone lymphoma, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Small cleaved dif, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mixed FCC dif, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Large cell dif, Present [11-50pc], Present [yes], Present [yes]) 0.99, 0.01;
  (B-immunoblastic, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (T-immunob mixed, Present [11-50pc], Present [yes], Present [yes]) 0.98, 0.02;
  (AILD-like T-cell lym, Present [11-50pc], Present [yes], Present [yes]) 0.8, 0.2;
  (Japanese ATL, Present [11-50pc], Present [yes], Present [yes]) 0.98, 0.02;
  (Lymphoblastic, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Small noncleaved dif, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (True histiocytic, Present [11-50pc], Present [yes], Present [yes]) 0.98, 0.02;
  (Ki-1 LC anaplas T, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Multiple myeloma, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mycosis fungoides, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (AML, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Hairy cell leukemia, Present [11-50pc], Present [yes], Present [yes]) 0.99, 0.01;
  (Carcinoma, Present [11-50pc], Present [yes], Present [yes]) 0.999, 0.001;
  (Melanoma, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (EM plasmacytoma, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Kaposi's sarcoma, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mast-cell disease, Present [11-50pc], Present [yes], Present [yes]) 0.999, 0.001;
  (AIDS involutionary, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (T-immunob large, Present [11-50pc], Present [yes], Present [yes]) 0.98, 0.02;
  (Monocytoid B-cell, Present [11-50pc], Present [yes], Present [yes]) 0.999, 0.001;
  (Nasopharyngeal CA, Present [11-50pc], Present [yes], Present [yes]) 0.999, 0.001;
  (Seminoma, Present [11-50pc], Present [yes], Present [yes]) 0.999, 0.001;
  (SLE, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mycobact histiocytos, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mast-cell hyperplas, Present [11-50pc], Present [yes], Present [yes]) 0.999, 0.001;
  (LGV, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Histoplasmosis, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Coccidioidomycosis, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (CMV, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Brucellosis, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Ki-1 LC anaplas B, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Intermed lymphocytic, Present [11-50pc], Present [yes], Present [yes]) 0.5, 0.5;
  (AIDS early, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (AILD, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (ALIP, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Cat scratch disease, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Dermatopathic laden, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Florid follic hyperp, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (GLH hyaline vascular, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (GLH plasma cell, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Granulomatous laden, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Histiocytosis x, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Infectious mono, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Leprosy-lepromatous, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Lymphangiographic, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mantle zone hyperpla, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Necrotizing Kikuchi, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Necrotiz non-Kikuchi, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Rheumatoid arthritis, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Sarcoidosis, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (SHML, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Sinus histiocytosis, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Syphilis, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Toxoplasmosis, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Tuberculosis, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Viral NOS, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Whipple's disease, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (L&H nodular HD, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (L&H diffuse HD, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Nodular sclerosis HD, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Cellular phase NSHD, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Syncytial NSHD, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mixed cellularity HD, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Interfollicular HD, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Diffuse fibrosis HD, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Reticular-type HD, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Small cleaved fol, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mixed fol, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Large cell fol, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Small noncleaved fol, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Small lymphocytic, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Plasmacytoid lyctic, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mantle zone lymphoma, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Small cleaved dif, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mixed FCC dif, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Large cell dif, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (B-immunoblastic, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (T-immunob mixed, Many [51-70pc], Present [yes], Present [yes]) 0.9, 0.1;
  (AILD-like T-cell lym, Many [51-70pc], Present [yes], Present [yes]) 0.3, 0.7;
  (Japanese ATL, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Lymphoblastic, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Small noncleaved dif, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (True histiocytic, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Ki-1 LC anaplas T, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Multiple myeloma, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mycosis fungoides, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (AML, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Hairy cell leukemia, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Carcinoma, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Melanoma, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (EM plasmacytoma, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Kaposi's sarcoma, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mast-cell disease, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (AIDS involutionary, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (T-immunob large, Many [51-70pc], Present [yes], Present [yes]) 0.98, 0.02;
  (Monocytoid B-cell, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Nasopharyngeal CA, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Seminoma, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (SLE, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mycobact histiocytos, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Mast-cell hyperplas, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (LGV, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Histoplasmosis, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Coccidioidomycosis, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (CMV, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Brucellosis, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Ki-1 LC anaplas B, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
  (Intermed lymphocytic, Many [51-70pc], Present [yes], Present [yes]) 0.5, 0.5;
}
probability ( KARYO | Fault, NECR ) {
  (AIDS early, Absent) 0.999, 0.001, 0.000;
  (AILD, Absent) 0.999, 0.001, 0.000;
  (ALIP, Absent) 0.999, 0.001, 0.000;
  (Cat scratch disease, Absent) 0.38, 0.60, 0.02;
  (Dermatopathic laden, Absent) 0.999, 0.001, 0.000;
  (Florid follic hyperp, Absent) 0.999, 0.001, 0.000;
  (GLH hyaline vascular, Absent) 0.999, 0.001, 0.000;
  (GLH plasma cell, Absent) 0.999, 0.001, 0.000;
  (Granulomatous laden, Absent) 0.89, 0.10, 0.01;
  (Histiocytosis x, Absent) 0.9999, 0.0001, 0.0000;
  (Infectious mono, Absent) 0.95, 0.05, 0.00;
  (Leprosy-lepromatous, Absent) 0.89, 0.10, 0.01;
  (Lymphangiographic, Absent) 0.999, 0.001, 0.000;
  (Mantle zone hyperpla, Absent) 0.999, 0.001, 0.000;
  (Necrotizing Kikuchi, Absent) 0.38, 0.60, 0.02;
  (Necrotiz non-Kikuchi, Absent) 0.38, 0.60, 0.02;
  (Rheumatoid arthritis, Absent) 0.999, 0.001, 0.000;
  (Sarcoidosis, Absent) 0.999, 0.001, 0.000;
  (SHML, Absent) 0.999, 0.001, 0.000;
  (Sinus histiocytosis, Absent) 0.999, 0.001, 0.000;
  (Syphilis, Absent) 0.999, 0.001, 0.000;
  (Toxoplasmosis, Absent) 0.999, 0.001, 0.000;
  (Tuberculosis, Absent) 0.89, 0.10, 0.01;
  (Viral NOS, Absent) 0.95, 0.05, 0.00;
  (Whipple's disease, Absent) 0.999, 0.001, 0.000;
  (L&H nodular HD, Absent) 0.999, 0.001, 0.000;
  (L&H diffuse HD, Absent) 0.999, 0.001, 0.000;
  (Nodular sclerosis HD, Absent) 0.95, 0.05, 0.00;
  (Cellular phase NSHD, Absent) 0.95, 0.05, 0.00;
  (Syncytial NSHD, Absent) 0.95, 0.05, 0.00;
  (Mixed cellularity HD, Absent) 0.95, 0.05, 0.00;
  (Interfollicular HD, Absent) 0.95, 0.05, 0.00;
  (Diffuse fibrosis HD, Absent) 0.999, 0.001, 0.000;
  (Reticular-type HD, Absent) 0.999, 0.001, 0.000;
  (Small cleaved fol, Absent) 0.999, 0.001, 0.000;
  (Mixed fol, Absent) 0.999, 0.001, 0.000;
  (Large cell fol, Absent) 0.999, 0.001, 0.000;
  (Small noncleaved fol, Absent) 0.999, 0.001, 0.000;
  (Small lymphocytic, Absent) 0.999, 0.001, 0.000;
  (Plasmacytoid lyctic, Absent) 0.999, 0.001, 0.000;
  (Mantle zone lymphoma, Absent) 0.999, 0.001, 0.000;
  (Small cleaved dif, Absent) 0.999, 0.001, 0.000;
  (Mixed FCC dif, Absent) 0.999, 0.001, 0.000;
  (Large cell dif, Absent) 0.999, 0.001, 0.000;
  (B-immunoblastic, Absent) 0.999, 0.001, 0.000;
  (T-immunob mixed, Absent) 0.999, 0.001, 0.000;
  (AILD-like T-cell lym, Absent) 0.999, 0.001, 0.000;
  (Japanese ATL, Absent) 0.999, 0.001, 0.000;
  (Lymphoblastic, Absent) 0.999, 0.001, 0.000;
  (Small noncleaved dif, Absent) 0.80, 0.19, 0.01;
  (True histiocytic, Absent) 0.999, 0.001, 0.000;
  (Ki-1 LC anaplas T, Absent) 0.999, 0.001, 0.000;
  (Multiple myeloma, Absent) 0.999, 0.001, 0.000;
  (Mycosis fungoides, Absent) 0.999, 0.001, 0.000;
  (AML, Absent) 0.999, 0.001, 0.000;
  (Hairy cell leukemia, Absent) 0.999, 0.001, 0.000;
  (Carcinoma, Absent) 0.999, 0.001, 0.000;
  (Melanoma, Absent) 0.999, 0.001, 0.000;
  (EM plasmacytoma, Absent) 0.999, 0.001, 0.000;
  (Kaposi's sarcoma, Absent) 0.999, 0.001, 0.000;
  (Mast-cell disease, Absent) 0.95, 0.05, 0.00;
  (AIDS involutionary, Absent) 0.999, 0.001, 0.000;
  (T-immunob large, Absent) 0.999, 0.001, 0.000;
  (Monocytoid B-cell, Absent) 0.999, 0.001, 0.000;
  (Nasopharyngeal CA, Absent) 0.95, 0.05, 0.00;
  (Seminoma, Absent) 0.999, 0.001, 0.000;
  (SLE, Absent) 0.999, 0.001, 0.000;
  (Mycobact histiocytos, Absent) 0.999, 0.001, 0.000;
  (Mast-cell hyperplas, Absent) 0.95, 0.05, 0.00;
  (LGV, Absent) 0.38, 0.60, 0.02;
  (Histoplasmosis, Absent) 0.999, 0.001, 0.000;
  (Coccidioidomycosis, Absent) 0.999, 0.001, 0.000;
  (CMV, Absent) 0.999, 0.001, 0.000;
  (Brucellosis, Absent) 0.999, 0.001, 0.000;
  (Ki-1 LC anaplas B, Absent) 0.999, 0.001, 0.000;
  (Intermed lymphocytic, Absent) 0.999, 0.001, 0.000;
  (AIDS early, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (AILD, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (ALIP, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Cat scratch disease, Focal [nonextensive]) 0.25, 0.60, 0.15;
  (Dermatopathic laden, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Florid follic hyperp, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (GLH hyaline vascular, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (GLH plasma cell, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Granulomatous laden, Focal [nonextensive]) 0.5, 0.4, 0.1;
  (Histiocytosis x, Focal [nonextensive]) 0.97, 0.02, 0.01;
  (Infectious mono, Focal [nonextensive]) 0.95, 0.04, 0.01;
  (Leprosy-lepromatous, Focal [nonextensive]) 0.88, 0.10, 0.02;
  (Lymphangiographic, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Mantle zone hyperpla, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Necrotizing Kikuchi, Focal [nonextensive]) 0.25, 0.60, 0.15;
  (Necrotiz non-Kikuchi, Focal [nonextensive]) 0.25, 0.60, 0.15;
  (Rheumatoid arthritis, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Sarcoidosis, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (SHML, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Sinus histiocytosis, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Syphilis, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Toxoplasmosis, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Tuberculosis, Focal [nonextensive]) 0.88, 0.10, 0.02;
  (Viral NOS, Focal [nonextensive]) 0.95, 0.04, 0.01;
  (Whipple's disease, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (L&H nodular HD, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (L&H diffuse HD, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Nodular sclerosis HD, Focal [nonextensive]) 0.89, 0.10, 0.01;
  (Cellular phase NSHD, Focal [nonextensive]) 0.89, 0.10, 0.01;
  (Syncytial NSHD, Focal [nonextensive]) 0.89, 0.10, 0.01;
  (Mixed cellularity HD, Focal [nonextensive]) 0.89, 0.10, 0.01;
  (Interfollicular HD, Focal [nonextensive]) 0.89, 0.10, 0.01;
  (Diffuse fibrosis HD, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Reticular-type HD, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Small cleaved fol, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Mixed fol, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Large cell fol, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Small noncleaved fol, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Small lymphocytic, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Plasmacytoid lyctic, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Mantle zone lymphoma, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Small cleaved dif, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Mixed FCC dif, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Large cell dif, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (B-immunoblastic, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (T-immunob mixed, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (AILD-like T-cell lym, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Japanese ATL, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Lymphoblastic, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Small noncleaved dif, Focal [nonextensive]) 0.80, 0.18, 0.02;
  (True histiocytic, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Ki-1 LC anaplas T, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Multiple myeloma, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Mycosis fungoides, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (AML, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Hairy cell leukemia, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Carcinoma, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Melanoma, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (EM plasmacytoma, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Kaposi's sarcoma, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Mast-cell disease, Focal [nonextensive]) 0.89, 0.10, 0.01;
  (AIDS involutionary, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (T-immunob large, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Monocytoid B-cell, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Nasopharyngeal CA, Focal [nonextensive]) 0.89, 0.10, 0.01;
  (Seminoma, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (SLE, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Mycobact histiocytos, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Mast-cell hyperplas, Focal [nonextensive]) 0.89, 0.10, 0.01;
  (LGV, Focal [nonextensive]) 0.25, 0.60, 0.15;
  (Histoplasmosis, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Coccidioidomycosis, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (CMV, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Brucellosis, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Ki-1 LC anaplas B, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (Intermed lymphocytic, Focal [nonextensive]) 0.90, 0.09, 0.01;
  (AIDS early, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (AILD, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (ALIP, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Cat scratch disease, Multifocal [nonextensive]) 0.01, 0.74, 0.25;
  (Dermatopathic laden, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Florid follic hyperp, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (GLH hyaline vascular, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (GLH plasma cell, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Granulomatous laden, Multifocal [nonextensive]) 0.01, 0.79, 0.20;
  (Histiocytosis x, Multifocal [nonextensive]) 0.93, 0.05, 0.02;
  (Infectious mono, Multifocal [nonextensive]) 0.01, 0.90, 0.09;
  (Leprosy-lepromatous, Multifocal [nonextensive]) 0.85, 0.12, 0.03;
  (Lymphangiographic, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Mantle zone hyperpla, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Necrotizing Kikuchi, Multifocal [nonextensive]) 0.01, 0.74, 0.25;
  (Necrotiz non-Kikuchi, Multifocal [nonextensive]) 0.01, 0.74, 0.25;
  (Rheumatoid arthritis, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Sarcoidosis, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (SHML, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Sinus histiocytosis, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Syphilis, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Toxoplasmosis, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Tuberculosis, Multifocal [nonextensive]) 0.85, 0.12, 0.03;
  (Viral NOS, Multifocal [nonextensive]) 0.01, 0.90, 0.09;
  (Whipple's disease, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (L&H nodular HD, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (L&H diffuse HD, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Nodular sclerosis HD, Multifocal [nonextensive]) 0.86, 0.12, 0.02;
  (Cellular phase NSHD, Multifocal [nonextensive]) 0.86, 0.12, 0.02;
  (Syncytial NSHD, Multifocal [nonextensive]) 0.86, 0.12, 0.02;
  (Mixed cellularity HD, Multifocal [nonextensive]) 0.86, 0.12, 0.02;
  (Interfollicular HD, Multifocal [nonextensive]) 0.86, 0.12, 0.02;
  (Diffuse fibrosis HD, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Reticular-type HD, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Small cleaved fol, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Mixed fol, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Large cell fol, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Small noncleaved fol, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Small lymphocytic, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Plasmacytoid lyctic, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Mantle zone lymphoma, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Small cleaved dif, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Mixed FCC dif, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Large cell dif, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (B-immunoblastic, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (T-immunob mixed, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (AILD-like T-cell lym, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Japanese ATL, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Lymphoblastic, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Small noncleaved dif, Multifocal [nonextensive]) 0.75, 0.20, 0.05;
  (True histiocytic, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Ki-1 LC anaplas T, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Multiple myeloma, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Mycosis fungoides, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (AML, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Hairy cell leukemia, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Carcinoma, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Melanoma, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (EM plasmacytoma, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Kaposi's sarcoma, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Mast-cell disease, Multifocal [nonextensive]) 0.86, 0.12, 0.02;
  (AIDS involutionary, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (T-immunob large, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Monocytoid B-cell, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Nasopharyngeal CA, Multifocal [nonextensive]) 0.86, 0.12, 0.02;
  (Seminoma, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (SLE, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Mycobact histiocytos, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Mast-cell hyperplas, Multifocal [nonextensive]) 0.86, 0.12, 0.02;
  (LGV, Multifocal [nonextensive]) 0.01, 0.74, 0.25;
  (Histoplasmosis, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Coccidioidomycosis, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (CMV, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Brucellosis, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Ki-1 LC anaplas B, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (Intermed lymphocytic, Multifocal [nonextensive]) 0.80, 0.18, 0.02;
  (AIDS early, Extensive) 0.75, 0.20, 0.05;
  (AILD, Extensive) 0.75, 0.20, 0.05;
  (ALIP, Extensive) 0.75, 0.20, 0.05;
  (Cat scratch disease, Extensive) 0.01, 0.49, 0.50;
  (Dermatopathic laden, Extensive) 0.75, 0.20, 0.05;
  (Florid follic hyperp, Extensive) 0.75, 0.20, 0.05;
  (GLH hyaline vascular, Extensive) 0.75, 0.20, 0.05;
  (GLH plasma cell, Extensive) 0.75, 0.20, 0.05;
  (Granulomatous laden, Extensive) 0.05, 0.70, 0.25;
  (Histiocytosis x, Extensive) 0.89, 0.08, 0.03;
  (Infectious mono, Extensive) 0.05, 0.75, 0.20;
  (Leprosy-lepromatous, Extensive) 0.50, 0.45, 0.05;
  (Lymphangiographic, Extensive) 0.75, 0.20, 0.05;
  (Mantle zone hyperpla, Extensive) 0.75, 0.20, 0.05;
  (Necrotizing Kikuchi, Extensive) 0.01, 0.49, 0.50;
  (Necrotiz non-Kikuchi, Extensive) 0.01, 0.49, 0.50;
  (Rheumatoid arthritis, Extensive) 0.75, 0.20, 0.05;
  (Sarcoidosis, Extensive) 0.75, 0.20, 0.05;
  (SHML, Extensive) 0.75, 0.20, 0.05;
  (Sinus histiocytosis, Extensive) 0.75, 0.20, 0.05;
  (Syphilis, Extensive) 0.75, 0.20, 0.05;
  (Toxoplasmosis, Extensive) 0.75, 0.20, 0.05;
  (Tuberculosis, Extensive) 0.50, 0.45, 0.05;
  (Viral NOS, Extensive) 0.05, 0.75, 0.20;
  (Whipple's disease, Extensive) 0.75, 0.20, 0.05;
  (L&H nodular HD, Extensive) 0.75, 0.20, 0.05;
  (L&H diffuse HD, Extensive) 0.75, 0.20, 0.05;
  (Nodular sclerosis HD, Extensive) 0.55, 0.40, 0.05;
  (Cellular phase NSHD, Extensive) 0.55, 0.40, 0.05;
  (Syncytial NSHD, Extensive) 0.55, 0.40, 0.05;
  (Mixed cellularity HD, Extensive) 0.55, 0.40, 0.05;
  (Interfollicular HD, Extensive) 0.55, 0.40, 0.05;
  (Diffuse fibrosis HD, Extensive) 0.75, 0.20, 0.05;
  (Reticular-type HD, Extensive) 0.75, 0.20, 0.05;
  (Small cleaved fol, Extensive) 0.75, 0.20, 0.05;
  (Mixed fol, Extensive) 0.75, 0.20, 0.05;
  (Large cell fol, Extensive) 0.75, 0.20, 0.05;
  (Small noncleaved fol, Extensive) 0.75, 0.20, 0.05;
  (Small lymphocytic, Extensive) 0.75, 0.20, 0.05;
  (Plasmacytoid lyctic, Extensive) 0.75, 0.20, 0.05;
  (Mantle zone lymphoma, Extensive) 0.75, 0.20, 0.05;
  (Small cleaved dif, Extensive) 0.75, 0.20, 0.05;
  (Mixed FCC dif, Extensive) 0.75, 0.20, 0.05;
  (Large cell dif, Extensive) 0.75, 0.20, 0.05;
  (B-immunoblastic, Extensive) 0.75, 0.20, 0.05;
  (T-immunob mixed, Extensive) 0.75, 0.20, 0.05;
  (AILD-like T-cell lym, Extensive) 0.75, 0.20, 0.05;
  (Japanese ATL, Extensive) 0.75, 0.20, 0.05;
  (Lymphoblastic, Extensive) 0.75, 0.20, 0.05;
  (Small noncleaved dif, Extensive) 0.25, 0.60, 0.15;
  (True histiocytic, Extensive) 0.75, 0.20, 0.05;
  (Ki-1 LC anaplas T, Extensive) 0.75, 0.20, 0.05;
  (Multiple myeloma, Extensive) 0.75, 0.20, 0.05;
  (Mycosis fungoides, Extensive) 0.75, 0.20, 0.05;
  (AML, Extensive) 0.75, 0.20, 0.05;
  (Hairy cell leukemia, Extensive) 0.75, 0.20, 0.05;
  (Carcinoma, Extensive) 0.75, 0.20, 0.05;
  (Melanoma, Extensive) 0.75, 0.20, 0.05;
  (EM plasmacytoma, Extensive) 0.75, 0.20, 0.05;
  (Kaposi's sarcoma, Extensive) 0.75, 0.20, 0.05;
  (Mast-cell disease, Extensive) 0.55, 0.40, 0.05;
  (AIDS involutionary, Extensive) 0.75, 0.20, 0.05;
  (T-immunob large, Extensive) 0.75, 0.20, 0.05;
  (Monocytoid B-cell, Extensive) 0.75, 0.20, 0.05;
  (Nasopharyngeal CA, Extensive) 0.55, 0.40, 0.05;
  (Seminoma, Extensive) 0.75, 0.20, 0.05;
  (SLE, Extensive) 0.75, 0.20, 0.05;
  (Mycobact histiocytos, Extensive) 0.75, 0.20, 0.05;
  (Mast-cell hyperplas, Extensive) 0.55, 0.40, 0.05;
  (LGV, Extensive) 0.01, 0.49, 0.50;
  (Histoplasmosis, Extensive) 0.75, 0.20, 0.05;
  (Coccidioidomycosis, Extensive) 0.75, 0.20, 0.05;
  (CMV, Extensive) 0.75, 0.20, 0.05;
  (Brucellosis, Extensive) 0.75, 0.20, 0.05;
  (Ki-1 LC anaplas B, Extensive) 0.75, 0.20, 0.05;
  (Intermed lymphocytic, Extensive) 0.75, 0.20, 0.05;
}
probability ( L_and_H | Fault, LH_NOD ) {
  (AIDS early, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (AILD, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (ALIP, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Cat scratch disease, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Dermatopathic laden, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Florid follic hyperp, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (GLH hyaline vascular, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (GLH plasma cell, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Granulomatous laden, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Histiocytosis x, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Infectious mono, Absent) 0.99, 0.01, 0.00, 0.00, 0.00;
  (Leprosy-lepromatous, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Lymphangiographic, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Mantle zone hyperpla, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Necrotizing Kikuchi, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Necrotiz non-Kikuchi, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Rheumatoid arthritis, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Sarcoidosis, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (SHML, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Sinus histiocytosis, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Syphilis, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Toxoplasmosis, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Tuberculosis, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Viral NOS, Absent) 0.99, 0.01, 0.00, 0.00, 0.00;
  (Whipple's disease, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (L&H nodular HD, Absent) 0.2, 0.2, 0.2, 0.2, 0.2;
  (L&H diffuse HD, Absent) 0.00, 0.01, 0.20, 0.69, 0.10;
  (Nodular sclerosis HD, Absent) 0.95, 0.04, 0.01, 0.00, 0.00;
  (Cellular phase NSHD, Absent) 0.95, 0.04, 0.01, 0.00, 0.00;
  (Syncytial NSHD, Absent) 0.95, 0.04, 0.01, 0.00, 0.00;
  (Mixed cellularity HD, Absent) 0.95, 0.04, 0.01, 0.00, 0.00;
  (Interfollicular HD, Absent) 0.95, 0.04, 0.01, 0.00, 0.00;
  (Diffuse fibrosis HD, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Mixed fol, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Large cell fol, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Small noncleaved fol, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Small lymphocytic, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Plasmacytoid lyctic, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Mantle zone lymphoma, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Small cleaved dif, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Mixed FCC dif, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Large cell dif, Absent) 0.9889, 0.0100, 0.0010, 0.0001, 0.0000;
  (B-immunoblastic, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (T-immunob mixed, Absent) 0.9889, 0.0100, 0.0010, 0.0001, 0.0000;
  (AILD-like T-cell lym, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent) 0.9889, 0.0100, 0.0010, 0.0001, 0.0000;
  (Lymphoblastic, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Small noncleaved dif, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (True histiocytic, Absent) 0.9889, 0.0100, 0.0010, 0.0001, 0.0000;
  (Ki-1 LC anaplas T, Absent) 0.9889, 0.0100, 0.0010, 0.0001, 0.0000;
  (Multiple myeloma, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Mycosis fungoides, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (AML, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Hairy cell leukemia, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Carcinoma, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Melanoma, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (EM plasmacytoma, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Kaposi's sarcoma, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Mast-cell disease, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (AIDS involutionary, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (T-immunob large, Absent) 0.9889, 0.0100, 0.0010, 0.0001, 0.0000;
  (Monocytoid B-cell, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Nasopharyngeal CA, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Seminoma, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (SLE, Absent) 0.99, 0.01, 0.00, 0.00, 0.00;
  (Mycobact histiocytos, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Mast-cell hyperplas, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (LGV, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Histoplasmosis, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Coccidioidomycosis, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (CMV, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Brucellosis, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Ki-1 LC anaplas B, Absent) 0.9889, 0.0100, 0.0010, 0.0001, 0.0000;
  (Intermed lymphocytic, Absent) 0.999, 0.001, 0.000, 0.000, 0.000;
  (AIDS early, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (AILD, Present) 1.0, 0.0, 0.0, 0.0, 0.0;
  (ALIP, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Cat scratch disease, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Dermatopathic laden, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Florid follic hyperp, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (GLH hyaline vascular, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (GLH plasma cell, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Granulomatous laden, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Histiocytosis x, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Infectious mono, Present) 0.99, 0.01, 0.00, 0.00, 0.00;
  (Leprosy-lepromatous, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Lymphangiographic, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Mantle zone hyperpla, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Necrotizing Kikuchi, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Necrotiz non-Kikuchi, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Rheumatoid arthritis, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Sarcoidosis, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (SHML, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Sinus histiocytosis, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Syphilis, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Toxoplasmosis, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Tuberculosis, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Viral NOS, Present) 0.99, 0.01, 0.00, 0.00, 0.00;
  (Whipple's disease, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (L&H nodular HD, Present) 0.00, 0.01, 0.20, 0.69, 0.10;
  (L&H diffuse HD, Present) 0.00, 0.01, 0.20, 0.69, 0.10;
  (Nodular sclerosis HD, Present) 0.849, 0.100, 0.050, 0.001, 0.000;
  (Cellular phase NSHD, Present) 0.95, 0.04, 0.01, 0.00, 0.00;
  (Syncytial NSHD, Present) 0.95, 0.04, 0.01, 0.00, 0.00;
  (Mixed cellularity HD, Present) 0.849, 0.100, 0.050, 0.001, 0.000;
  (Interfollicular HD, Present) 0.95, 0.04, 0.01, 0.00, 0.00;
  (Diffuse fibrosis HD, Present) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Present) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Mixed fol, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Large cell fol, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Small noncleaved fol, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Small lymphocytic, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Plasmacytoid lyctic, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Mantle zone lymphoma, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Small cleaved dif, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Mixed FCC dif, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Large cell dif, Present) 0.9889, 0.0100, 0.0010, 0.0001, 0.0000;
  (B-immunoblastic, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (T-immunob mixed, Present) 0.9889, 0.0100, 0.0010, 0.0001, 0.0000;
  (AILD-like T-cell lym, Present) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Present) 0.9889, 0.0100, 0.0010, 0.0001, 0.0000;
  (Lymphoblastic, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Small noncleaved dif, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (True histiocytic, Present) 0.9889, 0.0100, 0.0010, 0.0001, 0.0000;
  (Ki-1 LC anaplas T, Present) 0.9889, 0.0100, 0.0010, 0.0001, 0.0000;
  (Multiple myeloma, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Mycosis fungoides, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (AML, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Hairy cell leukemia, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Carcinoma, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Melanoma, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (EM plasmacytoma, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Kaposi's sarcoma, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Mast-cell disease, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (AIDS involutionary, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (T-immunob large, Present) 0.9889, 0.0100, 0.0010, 0.0001, 0.0000;
  (Monocytoid B-cell, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Nasopharyngeal CA, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Seminoma, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (SLE, Present) 0.99, 0.01, 0.00, 0.00, 0.00;
  (Mycobact histiocytos, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Mast-cell hyperplas, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (LGV, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Histoplasmosis, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Coccidioidomycosis, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (CMV, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Brucellosis, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Ki-1 LC anaplas B, Present) 0.9889, 0.0100, 0.0010, 0.0001, 0.0000;
  (Intermed lymphocytic, Present) 0.999, 0.001, 0.000, 0.000, 0.000;
}
probability ( LH_NOD | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 1.0, 0.0;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 1.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 0.0, 1.0;
  (L&H diffuse HD) 1.0, 0.0;
  (Nodular sclerosis HD) 0.995, 0.005;
  (Cellular phase NSHD) 1.0, 0.0;
  (Syncytial NSHD) 1.0, 0.0;
  (Mixed cellularity HD) 0.995, 0.005;
  (Interfollicular HD) 1.0, 0.0;
  (Diffuse fibrosis HD) 1.0, 0.0;
  (Reticular-type HD) 1.0, 0.0;
  (Small cleaved fol) 1.0, 0.0;
  (Mixed fol) 1.0, 0.0;
  (Large cell fol) 1.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0;
  (Small lymphocytic) 1.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0;
  (Small cleaved dif) 1.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0;
  (Large cell dif) 1.0, 0.0;
  (B-immunoblastic) 1.0, 0.0;
  (T-immunob mixed) 1.0, 0.0;
  (AILD-like T-cell lym) 1.0, 0.0;
  (Japanese ATL) 1.0, 0.0;
  (Lymphoblastic) 1.0, 0.0;
  (Small noncleaved dif) 1.0, 0.0;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 1.0, 0.0;
  (Multiple myeloma) 1.0, 0.0;
  (Mycosis fungoides) 1.0, 0.0;
  (AML) 1.0, 0.0;
  (Hairy cell leukemia) 1.0, 0.0;
  (Carcinoma) 1.0, 0.0;
  (Melanoma) 1.0, 0.0;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0;
  (Mast-cell disease) 1.0, 0.0;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 1.0, 0.0;
  (Monocytoid B-cell) 1.0, 0.0;
  (Nasopharyngeal CA) 1.0, 0.0;
  (Seminoma) 1.0, 0.0;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 1.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0;
}
probability ( LACUN | Fault ) {
  (AIDS early) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (AILD) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (ALIP) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Cat scratch disease) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Dermatopathic laden) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Florid follic hyperp) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (GLH hyaline vascular) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (GLH plasma cell) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Granulomatous laden) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Histiocytosis x) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Infectious mono) 0.99, 0.01, 0.00, 0.00, 0.00, 0.00;
  (Leprosy-lepromatous) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Lymphangiographic) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Mantle zone hyperpla) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Necrotizing Kikuchi) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Necrotiz non-Kikuchi) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Rheumatoid arthritis) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Sarcoidosis) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (SHML) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Sinus histiocytosis) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Syphilis) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Toxoplasmosis) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Tuberculosis) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Viral NOS) 0.99, 0.01, 0.00, 0.00, 0.00, 0.00;
  (Whipple's disease) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (L&H nodular HD) 0.94, 0.05, 0.01, 0.00, 0.00, 0.00;
  (L&H diffuse HD) 0.94, 0.05, 0.01, 0.00, 0.00, 0.00;
  (Nodular sclerosis HD) 0.00, 0.01, 0.40, 0.58, 0.01, 0.00;
  (Cellular phase NSHD) 0.00, 0.01, 0.40, 0.58, 0.01, 0.00;
  (Syncytial NSHD) 0.0, 0.0, 0.0, 0.0, 0.2, 0.8;
  (Mixed cellularity HD) 0.989, 0.010, 0.001, 0.000, 0.000, 0.000;
  (Interfollicular HD) 0.989, 0.010, 0.001, 0.000, 0.000, 0.000;
  (Diffuse fibrosis HD) 0.90, 0.09, 0.01, 0.00, 0.00, 0.00;
  (Reticular-type HD) 0.90, 0.09, 0.01, 0.00, 0.00, 0.00;
  (Small cleaved fol) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Mixed fol) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Large cell fol) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Small noncleaved fol) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Small lymphocytic) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Plasmacytoid lyctic) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Mantle zone lymphoma) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Small cleaved dif) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Mixed FCC dif) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Large cell dif) 0.8389, 0.1000, 0.0500, 0.0100, 0.0010, 0.0001;
  (B-immunoblastic) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (T-immunob mixed) 0.84, 0.10, 0.05, 0.01, 0.00, 0.00;
  (AILD-like T-cell lym) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Japanese ATL) 0.84, 0.10, 0.05, 0.01, 0.00, 0.00;
  (Lymphoblastic) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Small noncleaved dif) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (True histiocytic) 0.8389, 0.1000, 0.0500, 0.0100, 0.0010, 0.0001;
  (Ki-1 LC anaplas T) 0.8389, 0.1000, 0.0500, 0.0100, 0.0010, 0.0001;
  (Multiple myeloma) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Mycosis fungoides) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (AML) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Hairy cell leukemia) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Carcinoma) 0.919, 0.050, 0.020, 0.010, 0.001, 0.000;
  (Melanoma) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (EM plasmacytoma) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Kaposi's sarcoma) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Mast-cell disease) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (AIDS involutionary) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (T-immunob large) 0.8389, 0.1000, 0.0500, 0.0100, 0.0010, 0.0001;
  (Monocytoid B-cell) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Nasopharyngeal CA) 0.919, 0.050, 0.020, 0.010, 0.001, 0.000;
  (Seminoma) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (SLE) 0.99, 0.01, 0.00, 0.00, 0.00, 0.00;
  (Mycobact histiocytos) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Mast-cell hyperplas) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (LGV) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Histoplasmosis) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Coccidioidomycosis) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (CMV) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Brucellosis) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
  (Ki-1 LC anaplas B) 0.8389, 0.1000, 0.0500, 0.0100, 0.0010, 0.0001;
  (Intermed lymphocytic) 0.999, 0.001, 0.000, 0.000, 0.000, 0.000;
}
probability ( LANG | Fault ) {
  (AIDS early) 0.9999, 0.0001, 0.0000;
  (AILD) 0.999, 0.001, 0.000;
  (ALIP) 0.9999, 0.0001, 0.0000;
  (Cat scratch disease) 0.80, 0.17, 0.03;
  (Dermatopathic laden) 0.9999, 0.0001, 0.0000;
  (Florid follic hyperp) 0.9999, 0.0001, 0.0000;
  (GLH hyaline vascular) 0.9999, 0.0001, 0.0000;
  (GLH plasma cell) 0.9999, 0.0001, 0.0000;
  (Granulomatous laden) 0.80, 0.15, 0.05;
  (Histiocytosis x) 0.9999, 0.0001, 0.0000;
  (Infectious mono) 0.9999, 0.0001, 0.0000;
  (Leprosy-lepromatous) 0.4, 0.5, 0.1;
  (Lymphangiographic) 0.70, 0.25, 0.05;
  (Mantle zone hyperpla) 0.9999, 0.0001, 0.0000;
  (Necrotizing Kikuchi) 0.9999, 0.0001, 0.0000;
  (Necrotiz non-Kikuchi) 0.97, 0.02, 0.01;
  (Rheumatoid arthritis) 0.9999, 0.0001, 0.0000;
  (Sarcoidosis) 0.90, 0.09, 0.01;
  (SHML) 0.9999, 0.0001, 0.0000;
  (Sinus histiocytosis) 0.9999, 0.0001, 0.0000;
  (Syphilis) 0.97, 0.02, 0.01;
  (Toxoplasmosis) 0.9999, 0.0001, 0.0000;
  (Tuberculosis) 0.05, 0.60, 0.35;
  (Viral NOS) 0.9999, 0.0001, 0.0000;
  (Whipple's disease) 0.70, 0.25, 0.05;
  (L&H nodular HD) 0.9999, 0.0001, 0.0000;
  (L&H diffuse HD) 0.9999, 0.0001, 0.0000;
  (Nodular sclerosis HD) 0.9999, 0.0001, 0.0000;
  (Cellular phase NSHD) 0.9999, 0.0001, 0.0000;
  (Syncytial NSHD) 0.9999, 0.0001, 0.0000;
  (Mixed cellularity HD) 0.975, 0.020, 0.005;
  (Interfollicular HD) 0.9999, 0.0001, 0.0000;
  (Diffuse fibrosis HD) 0.9999, 0.0001, 0.0000;
  (Reticular-type HD) 0.9999, 0.0001, 0.0000;
  (Small cleaved fol) 0.9999, 0.0001, 0.0000;
  (Mixed fol) 0.9999, 0.0001, 0.0000;
  (Large cell fol) 0.9999, 0.0001, 0.0000;
  (Small noncleaved fol) 0.9999, 0.0001, 0.0000;
  (Small lymphocytic) 0.9999, 0.0001, 0.0000;
  (Plasmacytoid lyctic) 0.9999, 0.0001, 0.0000;
  (Mantle zone lymphoma) 0.9999, 0.0001, 0.0000;
  (Small cleaved dif) 0.9999, 0.0001, 0.0000;
  (Mixed FCC dif) 0.9999, 0.0001, 0.0000;
  (Large cell dif) 0.9999, 0.0001, 0.0000;
  (B-immunoblastic) 0.9999, 0.0001, 0.0000;
  (T-immunob mixed) 0.9999, 0.0001, 0.0000;
  (AILD-like T-cell lym) 0.999, 0.001, 0.000;
  (Japanese ATL) 0.9999, 0.0001, 0.0000;
  (Lymphoblastic) 0.9999, 0.0001, 0.0000;
  (Small noncleaved dif) 0.9999, 0.0001, 0.0000;
  (True histiocytic) 0.9999, 0.0001, 0.0000;
  (Ki-1 LC anaplas T) 0.9999, 0.0001, 0.0000;
  (Multiple myeloma) 0.9999, 0.0001, 0.0000;
  (Mycosis fungoides) 0.9999, 0.0001, 0.0000;
  (AML) 0.9999, 0.0001, 0.0000;
  (Hairy cell leukemia) 0.9999, 0.0001, 0.0000;
  (Carcinoma) 0.9999, 0.0001, 0.0000;
  (Melanoma) 0.9999, 0.0001, 0.0000;
  (EM plasmacytoma) 0.9999, 0.0001, 0.0000;
  (Kaposi's sarcoma) 0.9999, 0.0001, 0.0000;
  (Mast-cell disease) 0.9999, 0.0001, 0.0000;
  (AIDS involutionary) 0.9999, 0.0001, 0.0000;
  (T-immunob large) 0.9999, 0.0001, 0.0000;
  (Monocytoid B-cell) 0.9999, 0.0001, 0.0000;
  (Nasopharyngeal CA) 0.9999, 0.0001, 0.0000;
  (Seminoma) 0.9999, 0.0001, 0.0000;
  (SLE) 0.9999, 0.0001, 0.0000;
  (Mycobact histiocytos) 0.90, 0.08, 0.02;
  (Mast-cell hyperplas) 0.9999, 0.0001, 0.0000;
  (LGV) 0.80, 0.17, 0.03;
  (Histoplasmosis) 0.80, 0.15, 0.05;
  (Coccidioidomycosis) 0.80, 0.15, 0.05;
  (CMV) 0.80, 0.15, 0.05;
  (Brucellosis) 0.9999, 0.0001, 0.0000;
  (Ki-1 LC anaplas B) 0.9999, 0.0001, 0.0000;
  (Intermed lymphocytic) 0.9999, 0.0001, 0.0000;
}
probability ( LEUK | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 1.0, 0.0;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 1.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 1.0, 0.0;
  (L&H diffuse HD) 1.0, 0.0;
  (Nodular sclerosis HD) 1.0, 0.0;
  (Cellular phase NSHD) 1.0, 0.0;
  (Syncytial NSHD) 1.0, 0.0;
  (Mixed cellularity HD) 1.0, 0.0;
  (Interfollicular HD) 1.0, 0.0;
  (Diffuse fibrosis HD) 1.0, 0.0;
  (Reticular-type HD) 1.0, 0.0;
  (Small cleaved fol) 1.0, 0.0;
  (Mixed fol) 1.0, 0.0;
  (Large cell fol) 1.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0;
  (Small lymphocytic) 1.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0;
  (Small cleaved dif) 1.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0;
  (Large cell dif) 1.0, 0.0;
  (B-immunoblastic) 1.0, 0.0;
  (T-immunob mixed) 1.0, 0.0;
  (AILD-like T-cell lym) 1.0, 0.0;
  (Japanese ATL) 1.0, 0.0;
  (Lymphoblastic) 1.0, 0.0;
  (Small noncleaved dif) 1.0, 0.0;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 1.0, 0.0;
  (Multiple myeloma) 1.0, 0.0;
  (Mycosis fungoides) 1.0, 0.0;
  (AML) 0.0, 1.0;
  (Hairy cell leukemia) 0.1, 0.9;
  (Carcinoma) 1.0, 0.0;
  (Melanoma) 1.0, 0.0;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0;
  (Mast-cell disease) 1.0, 0.0;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 1.0, 0.0;
  (Monocytoid B-cell) 1.0, 0.0;
  (Nasopharyngeal CA) 1.0, 0.0;
  (Seminoma) 1.0, 0.0;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 1.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0;
}
probability ( LLC_CY | Fault, LLC_ID ) {
  (AIDS early, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (AILD, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (ALIP, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (SHML, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (AML, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (SLE, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (LGV, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (CMV, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, Other) 0.0, 0.6, 0.2, 0.2;
  (AILD, Other) 0.0, 0.6, 0.2, 0.2;
  (ALIP, Other) 0.0, 0.6, 0.2, 0.2;
  (Cat scratch disease, Other) 0.00, 0.70, 0.15, 0.15;
  (Dermatopathic laden, Other) 0.0, 0.6, 0.2, 0.2;
  (Florid follic hyperp, Other) 0.0, 0.6, 0.2, 0.2;
  (GLH hyaline vascular, Other) 0.0, 0.6, 0.2, 0.2;
  (GLH plasma cell, Other) 0.00, 0.70, 0.15, 0.15;
  (Granulomatous laden, Other) 0.00, 0.70, 0.15, 0.15;
  (Histiocytosis x, Other) 0.0, 0.6, 0.2, 0.2;
  (Infectious mono, Other) 0.00, 0.70, 0.15, 0.15;
  (Leprosy-lepromatous, Other) 0.0, 0.6, 0.2, 0.2;
  (Lymphangiographic, Other) 0.0, 0.6, 0.2, 0.2;
  (Mantle zone hyperpla, Other) 0.0, 0.6, 0.2, 0.2;
  (Necrotizing Kikuchi, Other) 0.00, 0.70, 0.15, 0.15;
  (Necrotiz non-Kikuchi, Other) 0.00, 0.70, 0.15, 0.15;
  (Rheumatoid arthritis, Other) 0.0, 0.6, 0.2, 0.2;
  (Sarcoidosis, Other) 0.0, 0.6, 0.2, 0.2;
  (SHML, Other) 0.0, 0.6, 0.2, 0.2;
  (Sinus histiocytosis, Other) 0.0, 0.6, 0.2, 0.2;
  (Syphilis, Other) 0.0, 0.6, 0.2, 0.2;
  (Toxoplasmosis, Other) 0.0, 0.6, 0.2, 0.2;
  (Tuberculosis, Other) 0.0, 0.6, 0.2, 0.2;
  (Viral NOS, Other) 0.00, 0.70, 0.15, 0.15;
  (Whipple's disease, Other) 0.0, 0.6, 0.2, 0.2;
  (L&H nodular HD, Other) 0.00, 0.80, 0.19, 0.01;
  (L&H diffuse HD, Other) 0.00, 0.80, 0.19, 0.01;
  (Nodular sclerosis HD, Other) 0.00, 0.80, 0.19, 0.01;
  (Cellular phase NSHD, Other) 0.00, 0.80, 0.19, 0.01;
  (Syncytial NSHD, Other) 0.00, 0.80, 0.19, 0.01;
  (Mixed cellularity HD, Other) 0.00, 0.80, 0.19, 0.01;
  (Interfollicular HD, Other) 0.00, 0.80, 0.19, 0.01;
  (Diffuse fibrosis HD, Other) 0.00, 0.80, 0.19, 0.01;
  (Reticular-type HD, Other) 0.00, 0.80, 0.19, 0.01;
  (Small cleaved fol, Other) 0.000, 0.975, 0.020, 0.005;
  (Mixed fol, Other) 0.00, 0.96, 0.03, 0.01;
  (Large cell fol, Other) 0.00, 0.94, 0.05, 0.01;
  (Small noncleaved fol, Other) 0.00, 0.96, 0.03, 0.01;
  (Small lymphocytic, Other) 0.00, 0.79, 0.20, 0.01;
  (Plasmacytoid lyctic, Other) 0.00, 0.89, 0.01, 0.10;
  (Mantle zone lymphoma, Other) 0.0, 0.6, 0.2, 0.2;
  (Small cleaved dif, Other) 0.000, 0.975, 0.020, 0.005;
  (Mixed FCC dif, Other) 0.00, 0.96, 0.03, 0.01;
  (Large cell dif, Other) 0.00, 0.94, 0.05, 0.01;
  (B-immunoblastic, Other) 0.0, 0.2, 0.0, 0.8;
  (T-immunob mixed, Other) 0.00, 0.50, 0.48, 0.02;
  (AILD-like T-cell lym, Other) 0.0, 0.1, 0.8, 0.1;
  (Japanese ATL, Other) 0.00, 0.50, 0.25, 0.25;
  (Lymphoblastic, Other) 0.0, 1.0, 0.0, 0.0;
  (Small noncleaved dif, Other) 0.00, 0.96, 0.03, 0.01;
  (True histiocytic, Other) 0.00, 0.01, 0.90, 0.09;
  (Ki-1 LC anaplas T, Other) 0.0, 0.2, 0.2, 0.6;
  (Multiple myeloma, Other) 0.0, 0.2, 0.0, 0.8;
  (Mycosis fungoides, Other) 0.00, 0.55, 0.40, 0.05;
  (AML, Other) 0.00, 0.98, 0.01, 0.01;
  (Hairy cell leukemia, Other) 0.0, 0.7, 0.3, 0.0;
  (Carcinoma, Other) 0.00, 0.30, 0.52, 0.18;
  (Melanoma, Other) 0.00, 0.10, 0.01, 0.89;
  (EM plasmacytoma, Other) 0.0, 0.3, 0.0, 0.7;
  (Kaposi's sarcoma, Other) 0.0, 0.6, 0.2, 0.2;
  (Mast-cell disease, Other) 0.00, 0.70, 0.28, 0.02;
  (AIDS involutionary, Other) 0.0, 0.6, 0.2, 0.2;
  (T-immunob large, Other) 0.00, 0.40, 0.58, 0.02;
  (Monocytoid B-cell, Other) 0.00, 0.50, 0.45, 0.05;
  (Nasopharyngeal CA, Other) 0.00, 0.30, 0.52, 0.18;
  (Seminoma, Other) 0.00, 0.02, 0.80, 0.18;
  (SLE, Other) 0.00, 0.70, 0.15, 0.15;
  (Mycobact histiocytos, Other) 0.0, 0.6, 0.2, 0.2;
  (Mast-cell hyperplas, Other) 0.00, 0.70, 0.28, 0.02;
  (LGV, Other) 0.00, 0.70, 0.15, 0.15;
  (Histoplasmosis, Other) 0.0, 0.6, 0.2, 0.2;
  (Coccidioidomycosis, Other) 0.0, 0.6, 0.2, 0.2;
  (CMV, Other) 0.0, 0.6, 0.2, 0.2;
  (Brucellosis, Other) 0.0, 0.6, 0.2, 0.2;
  (Ki-1 LC anaplas B, Other) 0.0, 0.2, 0.2, 0.6;
  (Intermed lymphocytic, Other) 0.0, 0.6, 0.2, 0.2;
  (AIDS early, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (AILD, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (ALIP, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Cat scratch disease, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Dermatopathic laden, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Florid follic hyperp, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (GLH hyaline vascular, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (GLH plasma cell, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Granulomatous laden, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Histiocytosis x, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Infectious mono, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Leprosy-lepromatous, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Lymphangiographic, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Mantle zone hyperpla, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Necrotizing Kikuchi, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Necrotiz non-Kikuchi, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Rheumatoid arthritis, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Sarcoidosis, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (SHML, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Sinus histiocytosis, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Syphilis, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Toxoplasmosis, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Tuberculosis, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Viral NOS, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Whipple's disease, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (L&H nodular HD, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (L&H diffuse HD, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Nodular sclerosis HD, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Cellular phase NSHD, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Syncytial NSHD, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Mixed cellularity HD, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Interfollicular HD, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Diffuse fibrosis HD, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Reticular-type HD, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Small cleaved fol, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Mixed fol, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Large cell fol, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Small noncleaved fol, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Small lymphocytic, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Plasmacytoid lyctic, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Mantle zone lymphoma, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Small cleaved dif, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Mixed FCC dif, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Large cell dif, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (B-immunoblastic, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (T-immunob mixed, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (AILD-like T-cell lym, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Japanese ATL, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Lymphoblastic, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Small noncleaved dif, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (True histiocytic, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Ki-1 LC anaplas T, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Multiple myeloma, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Mycosis fungoides, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (AML, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Hairy cell leukemia, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Carcinoma, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Melanoma, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (EM plasmacytoma, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Kaposi's sarcoma, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Mast-cell disease, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (AIDS involutionary, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (T-immunob large, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Monocytoid B-cell, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Nasopharyngeal CA, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Seminoma, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (SLE, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Mycobact histiocytos, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Mast-cell hyperplas, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (LGV, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Histoplasmosis, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Coccidioidomycosis, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (CMV, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Brucellosis, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Ki-1 LC anaplas B, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (Intermed lymphocytic, Large cleaved) 0.000, 0.998, 0.001, 0.001;
  (AIDS early, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (AILD, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (ALIP, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Cat scratch disease, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Dermatopathic laden, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Florid follic hyperp, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (GLH hyaline vascular, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (GLH plasma cell, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Granulomatous laden, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Histiocytosis x, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Infectious mono, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Leprosy-lepromatous, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Lymphangiographic, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Mantle zone hyperpla, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Necrotizing Kikuchi, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Necrotiz non-Kikuchi, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Rheumatoid arthritis, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Sarcoidosis, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (SHML, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Sinus histiocytosis, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Syphilis, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Toxoplasmosis, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Tuberculosis, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Viral NOS, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Whipple's disease, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (L&H nodular HD, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (L&H diffuse HD, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Nodular sclerosis HD, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Cellular phase NSHD, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Syncytial NSHD, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Mixed cellularity HD, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Interfollicular HD, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Diffuse fibrosis HD, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Reticular-type HD, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Small cleaved fol, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Mixed fol, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Large cell fol, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Small noncleaved fol, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Small lymphocytic, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Plasmacytoid lyctic, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Mantle zone lymphoma, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Small cleaved dif, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Mixed FCC dif, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Large cell dif, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (B-immunoblastic, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (T-immunob mixed, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (AILD-like T-cell lym, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Japanese ATL, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Lymphoblastic, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Small noncleaved dif, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (True histiocytic, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Ki-1 LC anaplas T, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Multiple myeloma, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Mycosis fungoides, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (AML, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Hairy cell leukemia, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Carcinoma, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Melanoma, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (EM plasmacytoma, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Kaposi's sarcoma, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Mast-cell disease, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (AIDS involutionary, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (T-immunob large, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Monocytoid B-cell, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Nasopharyngeal CA, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Seminoma, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (SLE, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Mycobact histiocytos, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Mast-cell hyperplas, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (LGV, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Histoplasmosis, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Coccidioidomycosis, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (CMV, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Brucellosis, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Ki-1 LC anaplas B, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
  (Intermed lymphocytic, Large noncleaved) 0.000, 0.990, 0.005, 0.005;
}
probability ( LLC_NS | Fault, LLC_ID ) {
  (AIDS early, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (AILD, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (ALIP, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Infectious mono, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (SHML, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Syphilis, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Tuberculosis, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Viral NOS, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Whipple's disease, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed fol, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell fol, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell dif, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Japanese ATL, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (True histiocytic, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (AML, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Carcinoma, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Melanoma, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob large, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Seminoma, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (SLE, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (LGV, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (CMV, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Brucellosis, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS early, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (AILD, Other) 0.00, 0.00, 0.00, 0.00, 0.05, 0.95;
  (ALIP, Other) 0.00, 0.00, 0.00, 0.00, 0.02, 0.98;
  (Cat scratch disease, Other) 0.00, 0.00, 0.00, 0.00, 0.02, 0.98;
  (Dermatopathic laden, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Florid follic hyperp, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (GLH hyaline vascular, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (GLH plasma cell, Other) 0.00, 0.00, 0.00, 0.00, 0.02, 0.98;
  (Granulomatous laden, Other) 0.00, 0.00, 0.00, 0.00, 0.02, 0.98;
  (Histiocytosis x, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Infectious mono, Other) 0.00, 0.00, 0.00, 0.00, 0.02, 0.98;
  (Leprosy-lepromatous, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Lymphangiographic, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mantle zone hyperpla, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Necrotizing Kikuchi, Other) 0.00, 0.00, 0.00, 0.00, 0.02, 0.98;
  (Necrotiz non-Kikuchi, Other) 0.00, 0.00, 0.00, 0.00, 0.02, 0.98;
  (Rheumatoid arthritis, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Sarcoidosis, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (SHML, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Sinus histiocytosis, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Syphilis, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Toxoplasmosis, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Tuberculosis, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Viral NOS, Other) 0.00, 0.00, 0.00, 0.00, 0.02, 0.98;
  (Whipple's disease, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (L&H nodular HD, Other) 0.00, 0.01, 0.00, 0.00, 0.09, 0.90;
  (L&H diffuse HD, Other) 0.00, 0.01, 0.00, 0.00, 0.09, 0.90;
  (Nodular sclerosis HD, Other) 0.00, 0.01, 0.00, 0.00, 0.09, 0.90;
  (Cellular phase NSHD, Other) 0.00, 0.01, 0.00, 0.00, 0.09, 0.90;
  (Syncytial NSHD, Other) 0.00, 0.01, 0.00, 0.00, 0.09, 0.90;
  (Mixed cellularity HD, Other) 0.00, 0.01, 0.00, 0.00, 0.09, 0.90;
  (Interfollicular HD, Other) 0.00, 0.01, 0.00, 0.00, 0.09, 0.90;
  (Diffuse fibrosis HD, Other) 0.00, 0.01, 0.00, 0.00, 0.09, 0.90;
  (Reticular-type HD, Other) 0.00, 0.01, 0.00, 0.00, 0.09, 0.90;
  (Small cleaved fol, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mixed fol, Other) 0.00, 0.03, 0.00, 0.01, 0.15, 0.81;
  (Large cell fol, Other) 0.00, 0.03, 0.00, 0.01, 0.15, 0.81;
  (Small noncleaved fol, Other) 0.000, 0.001, 0.000, 0.010, 0.100, 0.889;
  (Small lymphocytic, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Plasmacytoid lyctic, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mantle zone lymphoma, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Small cleaved dif, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mixed FCC dif, Other) 0.00, 0.03, 0.00, 0.01, 0.15, 0.81;
  (Large cell dif, Other) 0.00, 0.03, 0.00, 0.01, 0.15, 0.81;
  (B-immunoblastic, Other) 0.000, 0.010, 0.000, 0.005, 0.050, 0.935;
  (T-immunob mixed, Other) 0.000, 0.030, 0.001, 0.010, 0.150, 0.809;
  (AILD-like T-cell lym, Other) 0.00, 0.00, 0.00, 0.00, 0.05, 0.95;
  (Japanese ATL, Other) 0.00, 0.10, 0.20, 0.25, 0.42, 0.03;
  (Lymphoblastic, Other) 0.00, 0.01, 0.01, 0.01, 0.10, 0.87;
  (Small noncleaved dif, Other) 0.000, 0.001, 0.000, 0.010, 0.100, 0.889;
  (True histiocytic, Other) 0.000, 0.030, 0.001, 0.010, 0.150, 0.809;
  (Ki-1 LC anaplas T, Other) 0.000, 0.010, 0.000, 0.005, 0.050, 0.935;
  (Multiple myeloma, Other) 0.000, 0.010, 0.000, 0.005, 0.050, 0.935;
  (Mycosis fungoides, Other) 0.000, 0.005, 0.250, 0.100, 0.200, 0.445;
  (AML, Other) 0.00, 0.03, 0.00, 0.01, 0.15, 0.81;
  (Hairy cell leukemia, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Carcinoma, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Melanoma, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (EM plasmacytoma, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Kaposi's sarcoma, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mast-cell disease, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (AIDS involutionary, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (T-immunob large, Other) 0.000, 0.030, 0.001, 0.010, 0.150, 0.809;
  (Monocytoid B-cell, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Nasopharyngeal CA, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Seminoma, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (SLE, Other) 0.00, 0.00, 0.00, 0.00, 0.02, 0.98;
  (Mycobact histiocytos, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mast-cell hyperplas, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (LGV, Other) 0.00, 0.00, 0.00, 0.00, 0.02, 0.98;
  (Histoplasmosis, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Coccidioidomycosis, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (CMV, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Brucellosis, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Ki-1 LC anaplas B, Other) 0.000, 0.010, 0.000, 0.005, 0.050, 0.935;
  (Intermed lymphocytic, Other) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (AIDS early, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (AILD, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (ALIP, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Cat scratch disease, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Dermatopathic laden, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Florid follic hyperp, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (GLH hyaline vascular, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (GLH plasma cell, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Granulomatous laden, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Histiocytosis x, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Infectious mono, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Leprosy-lepromatous, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Lymphangiographic, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Mantle zone hyperpla, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Necrotizing Kikuchi, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Necrotiz non-Kikuchi, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Rheumatoid arthritis, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Sarcoidosis, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (SHML, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Sinus histiocytosis, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Syphilis, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Toxoplasmosis, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Tuberculosis, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Viral NOS, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Whipple's disease, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (L&H nodular HD, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (L&H diffuse HD, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Nodular sclerosis HD, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Cellular phase NSHD, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Syncytial NSHD, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Mixed cellularity HD, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Interfollicular HD, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Diffuse fibrosis HD, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Reticular-type HD, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Small cleaved fol, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Mixed fol, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Large cell fol, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Small noncleaved fol, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Small lymphocytic, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Plasmacytoid lyctic, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Mantle zone lymphoma, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Small cleaved dif, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Mixed FCC dif, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Large cell dif, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (B-immunoblastic, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (T-immunob mixed, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (AILD-like T-cell lym, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Japanese ATL, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Lymphoblastic, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Small noncleaved dif, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (True histiocytic, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Ki-1 LC anaplas T, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Multiple myeloma, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Mycosis fungoides, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (AML, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Hairy cell leukemia, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Carcinoma, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Melanoma, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (EM plasmacytoma, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Kaposi's sarcoma, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Mast-cell disease, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (AIDS involutionary, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (T-immunob large, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Monocytoid B-cell, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Nasopharyngeal CA, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Seminoma, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (SLE, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Mycobact histiocytos, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Mast-cell hyperplas, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (LGV, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Histoplasmosis, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Coccidioidomycosis, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (CMV, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Brucellosis, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Ki-1 LC anaplas B, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (Intermed lymphocytic, Large cleaved) 0.00, 0.00, 0.00, 0.00, 0.99, 0.01;
  (AIDS early, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (AILD, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (ALIP, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Cat scratch disease, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Dermatopathic laden, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Florid follic hyperp, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (GLH hyaline vascular, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (GLH plasma cell, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Granulomatous laden, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Histiocytosis x, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Infectious mono, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Leprosy-lepromatous, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Lymphangiographic, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mantle zone hyperpla, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Necrotizing Kikuchi, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Necrotiz non-Kikuchi, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Rheumatoid arthritis, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Sarcoidosis, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (SHML, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Sinus histiocytosis, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Syphilis, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Toxoplasmosis, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Tuberculosis, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Viral NOS, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Whipple's disease, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (L&H nodular HD, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (L&H diffuse HD, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Nodular sclerosis HD, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Cellular phase NSHD, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Syncytial NSHD, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mixed cellularity HD, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Interfollicular HD, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Diffuse fibrosis HD, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Reticular-type HD, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Small cleaved fol, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mixed fol, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Large cell fol, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Small noncleaved fol, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Small lymphocytic, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Plasmacytoid lyctic, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mantle zone lymphoma, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Small cleaved dif, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mixed FCC dif, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Large cell dif, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (B-immunoblastic, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (T-immunob mixed, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (AILD-like T-cell lym, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Japanese ATL, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Lymphoblastic, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Small noncleaved dif, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (True histiocytic, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Ki-1 LC anaplas T, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Multiple myeloma, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mycosis fungoides, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (AML, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Hairy cell leukemia, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Carcinoma, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Melanoma, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (EM plasmacytoma, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Kaposi's sarcoma, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mast-cell disease, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (AIDS involutionary, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (T-immunob large, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Monocytoid B-cell, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Nasopharyngeal CA, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Seminoma, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (SLE, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mycobact histiocytos, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mast-cell hyperplas, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (LGV, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Histoplasmosis, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Coccidioidomycosis, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (CMV, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Brucellosis, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Ki-1 LC anaplas B, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
  (Intermed lymphocytic, Large noncleaved) 0.00, 0.00, 0.00, 0.00, 0.01, 0.99;
}
probability ( LLC | Fault ) {
  (AIDS early) 0.94, 0.05, 0.01, 0.00, 0.00;
  (AILD) 0.0, 0.3, 0.7, 0.0, 0.0;
  (ALIP) 0.0, 0.8, 0.2, 0.0, 0.0;
  (Cat scratch disease) 0.20, 0.79, 0.01, 0.00, 0.00;
  (Dermatopathic laden) 0.30, 0.69, 0.01, 0.00, 0.00;
  (Florid follic hyperp) 0.94, 0.05, 0.01, 0.00, 0.00;
  (GLH hyaline vascular) 0.30, 0.69, 0.01, 0.00, 0.00;
  (GLH plasma cell) 0.30, 0.69, 0.01, 0.00, 0.00;
  (Granulomatous laden) 0.30, 0.69, 0.01, 0.00, 0.00;
  (Histiocytosis x) 0.985, 0.010, 0.005, 0.000, 0.000;
  (Infectious mono) 0.00000, 0.69999, 0.29000, 0.01000, 0.00001;
  (Leprosy-lepromatous) 0.985, 0.010, 0.005, 0.000, 0.000;
  (Lymphangiographic) 0.985, 0.010, 0.005, 0.000, 0.000;
  (Mantle zone hyperpla) 0.985, 0.010, 0.005, 0.000, 0.000;
  (Necrotizing Kikuchi) 0.1, 0.6, 0.3, 0.0, 0.0;
  (Necrotiz non-Kikuchi) 0.25, 0.70, 0.05, 0.00, 0.00;
  (Rheumatoid arthritis) 0.94, 0.05, 0.01, 0.00, 0.00;
  (Sarcoidosis) 0.985, 0.010, 0.005, 0.000, 0.000;
  (SHML) 0.985, 0.010, 0.005, 0.000, 0.000;
  (Sinus histiocytosis) 0.985, 0.010, 0.005, 0.000, 0.000;
  (Syphilis) 0.94, 0.05, 0.01, 0.00, 0.00;
  (Toxoplasmosis) 0.94, 0.05, 0.01, 0.00, 0.00;
  (Tuberculosis) 0.985, 0.010, 0.005, 0.000, 0.000;
  (Viral NOS) 0.0000, 0.7999, 0.2000, 0.0001, 0.0000;
  (Whipple's disease) 0.985, 0.010, 0.005, 0.000, 0.000;
  (L&H nodular HD) 0.300, 0.686, 0.014, 0.000, 0.000;
  (L&H diffuse HD) 0.300, 0.686, 0.014, 0.000, 0.000;
  (Nodular sclerosis HD) 0.300, 0.686, 0.014, 0.000, 0.000;
  (Cellular phase NSHD) 0.300, 0.686, 0.014, 0.000, 0.000;
  (Syncytial NSHD) 0.300, 0.686, 0.014, 0.000, 0.000;
  (Mixed cellularity HD) 0.300, 0.686, 0.014, 0.000, 0.000;
  (Interfollicular HD) 0.300, 0.686, 0.014, 0.000, 0.000;
  (Diffuse fibrosis HD) 0.300, 0.686, 0.014, 0.000, 0.000;
  (Reticular-type HD) 0.300, 0.686, 0.014, 0.000, 0.000;
  (Small cleaved fol) 0.98, 0.02, 0.00, 0.00, 0.00;
  (Mixed fol) 0.80, 0.15, 0.05, 0.00, 0.00;
  (Large cell fol) 0.0500, 0.2375, 0.2375, 0.2375, 0.2375;
  (Small noncleaved fol) 0.66, 0.30, 0.04, 0.00, 0.00;
  (Small lymphocytic) 0.0500, 0.9025, 0.0475, 0.0000, 0.0000;
  (Plasmacytoid lyctic) 0.900, 0.095, 0.005, 0.000, 0.000;
  (Mantle zone lymphoma) 0.99, 0.01, 0.00, 0.00, 0.00;
  (Small cleaved dif) 0.99, 0.01, 0.00, 0.00, 0.00;
  (Mixed FCC dif) 0.00, 0.65, 0.35, 0.00, 0.00;
  (Large cell dif) 0.00, 0.00, 0.02, 0.23, 0.75;
  (B-immunoblastic) 0.00, 0.00, 0.01, 0.24, 0.75;
  (T-immunob mixed) 0.0, 0.3, 0.7, 0.0, 0.0;
  (AILD-like T-cell lym) 0.00, 0.25, 0.70, 0.05, 0.00;
  (Japanese ATL) 0.01, 0.02, 0.22, 0.15, 0.60;
  (Lymphoblastic) 0.99, 0.01, 0.00, 0.00, 0.00;
  (Small noncleaved dif) 0.66, 0.30, 0.04, 0.00, 0.00;
  (True histiocytic) 0.00, 0.00, 0.01, 0.14, 0.85;
  (Ki-1 LC anaplas T) 0.00, 0.00, 0.05, 0.60, 0.35;
  (Multiple myeloma) 0.0, 0.0, 0.1, 0.8, 0.1;
  (Mycosis fungoides) 0.399, 0.280, 0.300, 0.020, 0.001;
  (AML) 0.3, 0.1, 0.1, 0.2, 0.3;
  (Hairy cell leukemia) 0.985, 0.010, 0.005, 0.000, 0.000;
  (Carcinoma) 0.996, 0.001, 0.001, 0.001, 0.001;
  (Melanoma) 0.996, 0.001, 0.001, 0.001, 0.001;
  (EM plasmacytoma) 0.94, 0.05, 0.01, 0.00, 0.00;
  (Kaposi's sarcoma) 0.985, 0.010, 0.005, 0.000, 0.000;
  (Mast-cell disease) 0.985, 0.010, 0.005, 0.000, 0.000;
  (AIDS involutionary) 0.79, 0.20, 0.01, 0.00, 0.00;
  (T-immunob large) 0.00, 0.00, 0.02, 0.48, 0.50;
  (Monocytoid B-cell) 0.010, 0.189, 0.800, 0.001, 0.000;
  (Nasopharyngeal CA) 0.996, 0.001, 0.001, 0.001, 0.001;
  (Seminoma) 0.996, 0.001, 0.001, 0.001, 0.001;
  (SLE) 0.00000, 0.69999, 0.29000, 0.01000, 0.00001;
  (Mycobact histiocytos) 0.985, 0.010, 0.005, 0.000, 0.000;
  (Mast-cell hyperplas) 0.985, 0.010, 0.005, 0.000, 0.000;
  (LGV) 0.20, 0.79, 0.01, 0.00, 0.00;
  (Histoplasmosis) 0.985, 0.010, 0.005, 0.000, 0.000;
  (Coccidioidomycosis) 0.985, 0.010, 0.005, 0.000, 0.000;
  (CMV) 0.985, 0.010, 0.005, 0.000, 0.000;
  (Brucellosis) 0.94, 0.05, 0.01, 0.00, 0.00;
  (Ki-1 LC anaplas B) 0.00, 0.00, 0.05, 0.60, 0.35;
  (Intermed lymphocytic) 0.99, 0.01, 0.00, 0.00, 0.00;
}
probability ( F_POPU | Fault, FOLLICLE ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS early, 1-25pc) 0.00, 0.02, 0.01, 0.03, 0.94;
  (AILD, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (ALIP, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Cat scratch disease, 1-25pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Dermatopathic laden, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Florid follic hyperp, 1-25pc) 0.00, 0.02, 0.01, 0.03, 0.94;
  (GLH hyaline vascular, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (GLH plasma cell, 1-25pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Granulomatous laden, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Histiocytosis x, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Infectious mono, 1-25pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Leprosy-lepromatous, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Lymphangiographic, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mantle zone hyperpla, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Necrotizing Kikuchi, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Necrotiz non-Kikuchi, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Rheumatoid arthritis, 1-25pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Sarcoidosis, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (SHML, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Sinus histiocytosis, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Syphilis, 1-25pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Toxoplasmosis, 1-25pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Tuberculosis, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Viral NOS, 1-25pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Whipple's disease, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (L&H nodular HD, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (L&H diffuse HD, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Nodular sclerosis HD, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Cellular phase NSHD, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Syncytial NSHD, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mixed cellularity HD, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Interfollicular HD, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Diffuse fibrosis HD, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Reticular-type HD, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Small cleaved fol, 1-25pc) 0.0, 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, 1-25pc) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Large cell fol, 1-25pc) 0.00, 0.00, 0.00, 0.95, 0.05;
  (Small noncleaved fol, 1-25pc) 0.0, 0.0, 1.0, 0.0, 0.0;
  (Small lymphocytic, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Plasmacytoid lyctic, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mantle zone lymphoma, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Small cleaved dif, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mixed FCC dif, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Large cell dif, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (B-immunoblastic, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (T-immunob mixed, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (AILD-like T-cell lym, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Japanese ATL, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Lymphoblastic, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Small noncleaved dif, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (True histiocytic, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Ki-1 LC anaplas T, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Multiple myeloma, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mycosis fungoides, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (AML, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Hairy cell leukemia, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Carcinoma, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Melanoma, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (EM plasmacytoma, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Kaposi's sarcoma, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mast-cell disease, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (AIDS involutionary, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (T-immunob large, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Monocytoid B-cell, 1-25pc) 0.000, 0.400, 0.001, 0.001, 0.598;
  (Nasopharyngeal CA, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Seminoma, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (SLE, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mycobact histiocytos, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mast-cell hyperplas, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (LGV, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Histoplasmosis, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Coccidioidomycosis, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (CMV, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Brucellosis, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Ki-1 LC anaplas B, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Intermed lymphocytic, 1-25pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (AIDS early, 25-75pc) 0.00, 0.02, 0.01, 0.03, 0.94;
  (AILD, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (ALIP, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Cat scratch disease, 25-75pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Dermatopathic laden, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Florid follic hyperp, 25-75pc) 0.00, 0.02, 0.01, 0.03, 0.94;
  (GLH hyaline vascular, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (GLH plasma cell, 25-75pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Granulomatous laden, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Histiocytosis x, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Infectious mono, 25-75pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Leprosy-lepromatous, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Lymphangiographic, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mantle zone hyperpla, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Necrotizing Kikuchi, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Necrotiz non-Kikuchi, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Rheumatoid arthritis, 25-75pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Sarcoidosis, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (SHML, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Sinus histiocytosis, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Syphilis, 25-75pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Toxoplasmosis, 25-75pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Tuberculosis, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Viral NOS, 25-75pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Whipple's disease, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (L&H nodular HD, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (L&H diffuse HD, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Nodular sclerosis HD, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Cellular phase NSHD, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Syncytial NSHD, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mixed cellularity HD, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Interfollicular HD, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Diffuse fibrosis HD, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Reticular-type HD, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Small cleaved fol, 25-75pc) 0.0, 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, 25-75pc) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Large cell fol, 25-75pc) 0.00, 0.00, 0.00, 0.95, 0.05;
  (Small noncleaved fol, 25-75pc) 0.0, 0.0, 1.0, 0.0, 0.0;
  (Small lymphocytic, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Plasmacytoid lyctic, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mantle zone lymphoma, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Small cleaved dif, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mixed FCC dif, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Large cell dif, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (B-immunoblastic, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (T-immunob mixed, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (AILD-like T-cell lym, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Japanese ATL, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Lymphoblastic, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Small noncleaved dif, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (True histiocytic, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Ki-1 LC anaplas T, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Multiple myeloma, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mycosis fungoides, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (AML, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Hairy cell leukemia, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Carcinoma, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Melanoma, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (EM plasmacytoma, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Kaposi's sarcoma, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mast-cell disease, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (AIDS involutionary, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (T-immunob large, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Monocytoid B-cell, 25-75pc) 0.000, 0.400, 0.001, 0.001, 0.598;
  (Nasopharyngeal CA, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Seminoma, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (SLE, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mycobact histiocytos, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mast-cell hyperplas, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (LGV, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Histoplasmosis, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Coccidioidomycosis, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (CMV, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Brucellosis, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Ki-1 LC anaplas B, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Intermed lymphocytic, 25-75pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (AIDS early, 75-90pc) 0.00, 0.02, 0.01, 0.03, 0.94;
  (AILD, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (ALIP, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Cat scratch disease, 75-90pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Dermatopathic laden, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Florid follic hyperp, 75-90pc) 0.00, 0.02, 0.01, 0.03, 0.94;
  (GLH hyaline vascular, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (GLH plasma cell, 75-90pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Granulomatous laden, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Histiocytosis x, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Infectious mono, 75-90pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Leprosy-lepromatous, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Lymphangiographic, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mantle zone hyperpla, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Necrotizing Kikuchi, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Necrotiz non-Kikuchi, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Rheumatoid arthritis, 75-90pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Sarcoidosis, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (SHML, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Sinus histiocytosis, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Syphilis, 75-90pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Toxoplasmosis, 75-90pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Tuberculosis, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Viral NOS, 75-90pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Whipple's disease, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (L&H nodular HD, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (L&H diffuse HD, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Nodular sclerosis HD, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Cellular phase NSHD, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Syncytial NSHD, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mixed cellularity HD, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Interfollicular HD, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Diffuse fibrosis HD, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Reticular-type HD, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Small cleaved fol, 75-90pc) 0.0, 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, 75-90pc) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Large cell fol, 75-90pc) 0.00, 0.00, 0.00, 0.95, 0.05;
  (Small noncleaved fol, 75-90pc) 0.0, 0.0, 1.0, 0.0, 0.0;
  (Small lymphocytic, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Plasmacytoid lyctic, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mantle zone lymphoma, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Small cleaved dif, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mixed FCC dif, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Large cell dif, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (B-immunoblastic, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (T-immunob mixed, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (AILD-like T-cell lym, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Japanese ATL, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Lymphoblastic, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Small noncleaved dif, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (True histiocytic, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Ki-1 LC anaplas T, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Multiple myeloma, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mycosis fungoides, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (AML, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Hairy cell leukemia, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Carcinoma, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Melanoma, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (EM plasmacytoma, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Kaposi's sarcoma, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mast-cell disease, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (AIDS involutionary, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (T-immunob large, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Monocytoid B-cell, 75-90pc) 0.000, 0.400, 0.001, 0.001, 0.598;
  (Nasopharyngeal CA, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Seminoma, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (SLE, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mycobact histiocytos, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mast-cell hyperplas, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (LGV, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Histoplasmosis, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Coccidioidomycosis, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (CMV, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Brucellosis, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Ki-1 LC anaplas B, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Intermed lymphocytic, 75-90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (AIDS early, >90pc) 0.00, 0.02, 0.01, 0.03, 0.94;
  (AILD, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (ALIP, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Cat scratch disease, >90pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Dermatopathic laden, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Florid follic hyperp, >90pc) 0.00, 0.02, 0.01, 0.03, 0.94;
  (GLH hyaline vascular, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (GLH plasma cell, >90pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Granulomatous laden, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Histiocytosis x, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Infectious mono, >90pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Leprosy-lepromatous, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Lymphangiographic, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mantle zone hyperpla, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Necrotizing Kikuchi, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Necrotiz non-Kikuchi, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Rheumatoid arthritis, >90pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Sarcoidosis, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (SHML, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Sinus histiocytosis, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Syphilis, >90pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Toxoplasmosis, >90pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Tuberculosis, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Viral NOS, >90pc) 0.000, 0.100, 0.001, 0.001, 0.898;
  (Whipple's disease, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (L&H nodular HD, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (L&H diffuse HD, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Nodular sclerosis HD, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Cellular phase NSHD, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Syncytial NSHD, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mixed cellularity HD, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Interfollicular HD, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Diffuse fibrosis HD, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Reticular-type HD, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Small cleaved fol, >90pc) 0.0, 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, >90pc) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Large cell fol, >90pc) 0.00, 0.00, 0.00, 0.95, 0.05;
  (Small noncleaved fol, >90pc) 0.0, 0.0, 1.0, 0.0, 0.0;
  (Small lymphocytic, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Plasmacytoid lyctic, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mantle zone lymphoma, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Small cleaved dif, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mixed FCC dif, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Large cell dif, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (B-immunoblastic, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (T-immunob mixed, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (AILD-like T-cell lym, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Japanese ATL, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Lymphoblastic, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Small noncleaved dif, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (True histiocytic, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Ki-1 LC anaplas T, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Multiple myeloma, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mycosis fungoides, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (AML, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Hairy cell leukemia, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Carcinoma, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Melanoma, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (EM plasmacytoma, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Kaposi's sarcoma, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mast-cell disease, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (AIDS involutionary, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (T-immunob large, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Monocytoid B-cell, >90pc) 0.000, 0.400, 0.001, 0.001, 0.598;
  (Nasopharyngeal CA, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Seminoma, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (SLE, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mycobact histiocytos, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Mast-cell hyperplas, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (LGV, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Histoplasmosis, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Coccidioidomycosis, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (CMV, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Brucellosis, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Ki-1 LC anaplas B, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
  (Intermed lymphocytic, >90pc) 0.000, 0.200, 0.001, 0.001, 0.798;
}
probability ( MAST | Fault ) {
  (AIDS early) 0.9, 0.1, 0.0;
  (AILD) 0.9, 0.1, 0.0;
  (ALIP) 0.9, 0.1, 0.0;
  (Cat scratch disease) 0.9, 0.1, 0.0;
  (Dermatopathic laden) 0.9, 0.1, 0.0;
  (Florid follic hyperp) 0.9, 0.1, 0.0;
  (GLH hyaline vascular) 0.9, 0.1, 0.0;
  (GLH plasma cell) 0.9, 0.1, 0.0;
  (Granulomatous laden) 0.9, 0.1, 0.0;
  (Histiocytosis x) 0.9, 0.1, 0.0;
  (Infectious mono) 0.9, 0.1, 0.0;
  (Leprosy-lepromatous) 0.9, 0.1, 0.0;
  (Lymphangiographic) 0.9, 0.1, 0.0;
  (Mantle zone hyperpla) 0.9, 0.1, 0.0;
  (Necrotizing Kikuchi) 0.9, 0.1, 0.0;
  (Necrotiz non-Kikuchi) 0.9, 0.1, 0.0;
  (Rheumatoid arthritis) 0.9, 0.1, 0.0;
  (Sarcoidosis) 0.9, 0.1, 0.0;
  (SHML) 0.9, 0.1, 0.0;
  (Sinus histiocytosis) 0.9, 0.1, 0.0;
  (Syphilis) 0.9, 0.1, 0.0;
  (Toxoplasmosis) 0.9, 0.1, 0.0;
  (Tuberculosis) 0.9, 0.1, 0.0;
  (Viral NOS) 0.9, 0.1, 0.0;
  (Whipple's disease) 0.9, 0.1, 0.0;
  (L&H nodular HD) 0.9, 0.1, 0.0;
  (L&H diffuse HD) 0.9, 0.1, 0.0;
  (Nodular sclerosis HD) 0.9, 0.1, 0.0;
  (Cellular phase NSHD) 0.9, 0.1, 0.0;
  (Syncytial NSHD) 0.9, 0.1, 0.0;
  (Mixed cellularity HD) 0.9, 0.1, 0.0;
  (Interfollicular HD) 0.9, 0.1, 0.0;
  (Diffuse fibrosis HD) 0.9, 0.1, 0.0;
  (Reticular-type HD) 0.9, 0.1, 0.0;
  (Small cleaved fol) 0.9, 0.1, 0.0;
  (Mixed fol) 0.9, 0.1, 0.0;
  (Large cell fol) 0.9, 0.1, 0.0;
  (Small noncleaved fol) 0.9, 0.1, 0.0;
  (Small lymphocytic) 0.9, 0.1, 0.0;
  (Plasmacytoid lyctic) 0.9, 0.1, 0.0;
  (Mantle zone lymphoma) 0.9, 0.1, 0.0;
  (Small cleaved dif) 0.9, 0.1, 0.0;
  (Mixed FCC dif) 0.9, 0.1, 0.0;
  (Large cell dif) 0.9, 0.1, 0.0;
  (B-immunoblastic) 0.9, 0.1, 0.0;
  (T-immunob mixed) 0.9, 0.1, 0.0;
  (AILD-like T-cell lym) 0.9, 0.1, 0.0;
  (Japanese ATL) 0.9, 0.1, 0.0;
  (Lymphoblastic) 0.9, 0.1, 0.0;
  (Small noncleaved dif) 0.9, 0.1, 0.0;
  (True histiocytic) 0.9, 0.1, 0.0;
  (Ki-1 LC anaplas T) 0.9, 0.1, 0.0;
  (Multiple myeloma) 0.9, 0.1, 0.0;
  (Mycosis fungoides) 0.9, 0.1, 0.0;
  (AML) 0.9, 0.1, 0.0;
  (Hairy cell leukemia) 0.9, 0.1, 0.0;
  (Carcinoma) 0.9, 0.1, 0.0;
  (Melanoma) 0.9, 0.1, 0.0;
  (EM plasmacytoma) 0.9, 0.1, 0.0;
  (Kaposi's sarcoma) 0.9, 0.1, 0.0;
  (Mast-cell disease) 0.0, 0.3, 0.7;
  (AIDS involutionary) 0.9, 0.1, 0.0;
  (T-immunob large) 0.9, 0.1, 0.0;
  (Monocytoid B-cell) 0.9, 0.1, 0.0;
  (Nasopharyngeal CA) 0.9, 0.1, 0.0;
  (Seminoma) 0.9, 0.1, 0.0;
  (SLE) 0.9, 0.1, 0.0;
  (Mycobact histiocytos) 0.9, 0.1, 0.0;
  (Mast-cell hyperplas) 0.0, 0.9, 0.1;
  (LGV) 0.9, 0.1, 0.0;
  (Histoplasmosis) 0.9, 0.1, 0.0;
  (Coccidioidomycosis) 0.9, 0.1, 0.0;
  (CMV) 0.9, 0.1, 0.0;
  (Brucellosis) 0.9, 0.1, 0.0;
  (Ki-1 LC anaplas B) 0.9, 0.1, 0.0;
  (Intermed lymphocytic) 0.9, 0.1, 0.0;
}
probability ( MLC | Fault ) {
  (AIDS early) 0.79, 0.20, 0.01, 0.00, 0.00;
  (AILD) 0.01, 0.79, 0.20, 0.00, 0.00;
  (ALIP) 0.01, 0.94, 0.05, 0.00, 0.00;
  (Cat scratch disease) 0.25, 0.70, 0.05, 0.00, 0.00;
  (Dermatopathic laden) 0.79, 0.20, 0.01, 0.00, 0.00;
  (Florid follic hyperp) 0.60, 0.39, 0.01, 0.00, 0.00;
  (GLH hyaline vascular) 0.79, 0.20, 0.01, 0.00, 0.00;
  (GLH plasma cell) 0.25, 0.65, 0.10, 0.00, 0.00;
  (Granulomatous laden) 0.25, 0.65, 0.10, 0.00, 0.00;
  (Histiocytosis x) 0.79, 0.20, 0.01, 0.00, 0.00;
  (Infectious mono) 0.010, 0.693, 0.297, 0.000, 0.000;
  (Leprosy-lepromatous) 0.79, 0.20, 0.01, 0.00, 0.00;
  (Lymphangiographic) 0.79, 0.20, 0.01, 0.00, 0.00;
  (Mantle zone hyperpla) 0.79, 0.20, 0.01, 0.00, 0.00;
  (Necrotizing Kikuchi) 0.25, 0.65, 0.10, 0.00, 0.00;
  (Necrotiz non-Kikuchi) 0.25, 0.65, 0.10, 0.00, 0.00;
  (Rheumatoid arthritis) 0.60, 0.39, 0.01, 0.00, 0.00;
  (Sarcoidosis) 0.79, 0.20, 0.01, 0.00, 0.00;
  (SHML) 0.79, 0.20, 0.01, 0.00, 0.00;
  (Sinus histiocytosis) 0.79, 0.20, 0.01, 0.00, 0.00;
  (Syphilis) 0.60, 0.39, 0.01, 0.00, 0.00;
  (Toxoplasmosis) 0.60, 0.39, 0.01, 0.00, 0.00;
  (Tuberculosis) 0.79, 0.20, 0.01, 0.00, 0.00;
  (Viral NOS) 0.010, 0.693, 0.297, 0.000, 0.000;
  (Whipple's disease) 0.79, 0.20, 0.01, 0.00, 0.00;
  (L&H nodular HD) 0.20, 0.76, 0.04, 0.00, 0.00;
  (L&H diffuse HD) 0.20, 0.76, 0.04, 0.00, 0.00;
  (Nodular sclerosis HD) 0.20, 0.76, 0.04, 0.00, 0.00;
  (Cellular phase NSHD) 0.20, 0.76, 0.04, 0.00, 0.00;
  (Syncytial NSHD) 0.20, 0.76, 0.04, 0.00, 0.00;
  (Mixed cellularity HD) 0.20, 0.76, 0.04, 0.00, 0.00;
  (Interfollicular HD) 0.20, 0.76, 0.04, 0.00, 0.00;
  (Diffuse fibrosis HD) 0.20, 0.76, 0.04, 0.00, 0.00;
  (Reticular-type HD) 0.20, 0.76, 0.04, 0.00, 0.00;
  (Small cleaved fol) 0.50, 0.49, 0.01, 0.00, 0.00;
  (Mixed fol) 0.30, 0.69, 0.01, 0.00, 0.00;
  (Large cell fol) 0.10, 0.85, 0.05, 0.00, 0.00;
  (Small noncleaved fol) 0.05, 0.10, 0.15, 0.40, 0.30;
  (Small lymphocytic) 0.10, 0.83, 0.07, 0.00, 0.00;
  (Plasmacytoid lyctic) 0.84, 0.15, 0.01, 0.00, 0.00;
  (Mantle zone lymphoma) 0.95, 0.05, 0.00, 0.00, 0.00;
  (Small cleaved dif) 0.95, 0.05, 0.00, 0.00, 0.00;
  (Mixed FCC dif) 0.10, 0.65, 0.25, 0.00, 0.00;
  (Large cell dif) 0.1, 0.7, 0.2, 0.0, 0.0;
  (B-immunoblastic) 0.80, 0.19, 0.01, 0.00, 0.00;
  (T-immunob mixed) 0.10, 0.65, 0.25, 0.00, 0.00;
  (AILD-like T-cell lym) 0.01, 0.84, 0.15, 0.00, 0.00;
  (Japanese ATL) 0.100, 0.805, 0.090, 0.005, 0.000;
  (Lymphoblastic) 0.00, 0.00, 0.01, 0.19, 0.80;
  (Small noncleaved dif) 0.00, 0.00, 0.01, 0.05, 0.94;
  (True histiocytic) 0.9500, 0.0475, 0.0025, 0.0000, 0.0000;
  (Ki-1 LC anaplas T) 0.949, 0.050, 0.001, 0.000, 0.000;
  (Multiple myeloma) 0.300, 0.665, 0.035, 0.000, 0.000;
  (Mycosis fungoides) 0.010, 0.100, 0.855, 0.030, 0.005;
  (AML) 0.25, 0.10, 0.45, 0.10, 0.10;
  (Hairy cell leukemia) 0.05, 0.85, 0.10, 0.00, 0.00;
  (Carcinoma) 0.79, 0.20, 0.01, 0.00, 0.00;
  (Melanoma) 0.79, 0.20, 0.01, 0.00, 0.00;
  (EM plasmacytoma) 0.200, 0.792, 0.008, 0.000, 0.000;
  (Kaposi's sarcoma) 0.79, 0.20, 0.01, 0.00, 0.00;
  (Mast-cell disease) 0.55, 0.40, 0.05, 0.00, 0.00;
  (AIDS involutionary) 0.79, 0.20, 0.01, 0.00, 0.00;
  (T-immunob large) 0.1, 0.8, 0.1, 0.0, 0.0;
  (Monocytoid B-cell) 0.65000, 0.24999, 0.10000, 0.00001, 0.00000;
  (Nasopharyngeal CA) 0.79, 0.20, 0.01, 0.00, 0.00;
  (Seminoma) 0.79, 0.20, 0.01, 0.00, 0.00;
  (SLE) 0.010, 0.693, 0.297, 0.000, 0.000;
  (Mycobact histiocytos) 0.79, 0.20, 0.01, 0.00, 0.00;
  (Mast-cell hyperplas) 0.60, 0.36, 0.04, 0.00, 0.00;
  (LGV) 0.25, 0.70, 0.05, 0.00, 0.00;
  (Histoplasmosis) 0.79, 0.20, 0.01, 0.00, 0.00;
  (Coccidioidomycosis) 0.79, 0.20, 0.01, 0.00, 0.00;
  (CMV) 0.79, 0.20, 0.01, 0.00, 0.00;
  (Brucellosis) 0.79, 0.20, 0.01, 0.00, 0.00;
  (Ki-1 LC anaplas B) 0.949, 0.050, 0.001, 0.000, 0.000;
  (Intermed lymphocytic) 0.95, 0.05, 0.00, 0.00, 0.00;
}
probability ( MELANOMA | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 1.0, 0.0;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 1.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 1.0, 0.0;
  (L&H diffuse HD) 1.0, 0.0;
  (Nodular sclerosis HD) 1.0, 0.0;
  (Cellular phase NSHD) 1.0, 0.0;
  (Syncytial NSHD) 1.0, 0.0;
  (Mixed cellularity HD) 1.0, 0.0;
  (Interfollicular HD) 1.0, 0.0;
  (Diffuse fibrosis HD) 1.0, 0.0;
  (Reticular-type HD) 1.0, 0.0;
  (Small cleaved fol) 1.0, 0.0;
  (Mixed fol) 1.0, 0.0;
  (Large cell fol) 1.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0;
  (Small lymphocytic) 1.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0;
  (Small cleaved dif) 1.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0;
  (Large cell dif) 1.0, 0.0;
  (B-immunoblastic) 1.0, 0.0;
  (T-immunob mixed) 1.0, 0.0;
  (AILD-like T-cell lym) 1.0, 0.0;
  (Japanese ATL) 1.0, 0.0;
  (Lymphoblastic) 1.0, 0.0;
  (Small noncleaved dif) 1.0, 0.0;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 1.0, 0.0;
  (Multiple myeloma) 1.0, 0.0;
  (Mycosis fungoides) 1.0, 0.0;
  (AML) 1.0, 0.0;
  (Hairy cell leukemia) 1.0, 0.0;
  (Carcinoma) 1.0, 0.0;
  (Melanoma) 0.0, 1.0;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0;
  (Mast-cell disease) 1.0, 0.0;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 1.0, 0.0;
  (Monocytoid B-cell) 1.0, 0.0;
  (Nasopharyngeal CA) 1.0, 0.0;
  (Seminoma) 1.0, 0.0;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 1.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0;
}
probability ( MF10HP | Fault ) {
  (AIDS early) 0.899, 0.100, 0.001, 0.000;
  (AILD) 0.00, 0.01, 0.89, 0.10;
  (ALIP) 0.00, 0.05, 0.93, 0.02;
  (Cat scratch disease) 0.899, 0.100, 0.001, 0.000;
  (Dermatopathic laden) 0.899, 0.100, 0.001, 0.000;
  (Florid follic hyperp) 0.899, 0.100, 0.001, 0.000;
  (GLH hyaline vascular) 0.899, 0.100, 0.001, 0.000;
  (GLH plasma cell) 0.899, 0.100, 0.001, 0.000;
  (Granulomatous laden) 0.899, 0.100, 0.001, 0.000;
  (Histiocytosis x) 0.899, 0.100, 0.001, 0.000;
  (Infectious mono) 0.05, 0.65, 0.29, 0.01;
  (Leprosy-lepromatous) 0.899, 0.100, 0.001, 0.000;
  (Lymphangiographic) 0.899, 0.100, 0.001, 0.000;
  (Mantle zone hyperpla) 0.899, 0.100, 0.001, 0.000;
  (Necrotizing Kikuchi) 0.0010, 0.7000, 0.2989, 0.0001;
  (Necrotiz non-Kikuchi) 0.0010, 0.7000, 0.2989, 0.0001;
  (Rheumatoid arthritis) 0.899, 0.100, 0.001, 0.000;
  (Sarcoidosis) 0.899, 0.100, 0.001, 0.000;
  (SHML) 0.899, 0.100, 0.001, 0.000;
  (Sinus histiocytosis) 0.899, 0.100, 0.001, 0.000;
  (Syphilis) 0.899, 0.100, 0.001, 0.000;
  (Toxoplasmosis) 0.899, 0.100, 0.001, 0.000;
  (Tuberculosis) 0.899, 0.100, 0.001, 0.000;
  (Viral NOS) 0.05, 0.65, 0.29, 0.01;
  (Whipple's disease) 0.899, 0.100, 0.001, 0.000;
  (L&H nodular HD) 0.02, 0.50, 0.47, 0.01;
  (L&H diffuse HD) 0.02, 0.50, 0.47, 0.01;
  (Nodular sclerosis HD) 0.02, 0.50, 0.47, 0.01;
  (Cellular phase NSHD) 0.02, 0.50, 0.47, 0.01;
  (Syncytial NSHD) 0.02, 0.50, 0.47, 0.01;
  (Mixed cellularity HD) 0.02, 0.50, 0.47, 0.01;
  (Interfollicular HD) 0.02, 0.50, 0.47, 0.01;
  (Diffuse fibrosis HD) 0.0, 0.4, 0.5, 0.1;
  (Reticular-type HD) 0.0, 0.4, 0.5, 0.1;
  (Small cleaved fol) 0.2000, 0.6999, 0.1000, 0.0001;
  (Mixed fol) 0.2000, 0.6999, 0.1000, 0.0001;
  (Large cell fol) 0.10, 0.35, 0.43, 0.12;
  (Small noncleaved fol) 0.10, 0.35, 0.43, 0.12;
  (Small lymphocytic) 0.3000, 0.6000, 0.0999, 0.0001;
  (Plasmacytoid lyctic) 0.3000, 0.6000, 0.0999, 0.0001;
  (Mantle zone lymphoma) 0.100, 0.700, 0.199, 0.001;
  (Small cleaved dif) 0.00, 0.05, 0.85, 0.10;
  (Mixed FCC dif) 0.000, 0.005, 0.745, 0.250;
  (Large cell dif) 0.000, 0.001, 0.200, 0.799;
  (B-immunoblastic) 0.000, 0.001, 0.200, 0.799;
  (T-immunob mixed) 0.000, 0.005, 0.450, 0.545;
  (AILD-like T-cell lym) 0.000, 0.005, 0.795, 0.200;
  (Japanese ATL) 0.000, 0.001, 0.200, 0.799;
  (Lymphoblastic) 0.000, 0.001, 0.020, 0.979;
  (Small noncleaved dif) 0.000, 0.001, 0.020, 0.979;
  (True histiocytic) 0.000, 0.001, 0.200, 0.799;
  (Ki-1 LC anaplas T) 0.000, 0.001, 0.200, 0.799;
  (Multiple myeloma) 0.000, 0.001, 0.200, 0.799;
  (Mycosis fungoides) 0.005, 0.295, 0.650, 0.050;
  (AML) 0.00, 0.05, 0.40, 0.55;
  (Hairy cell leukemia) 0.799, 0.200, 0.001, 0.000;
  (Carcinoma) 0.0, 0.3, 0.6, 0.1;
  (Melanoma) 0.0, 0.3, 0.6, 0.1;
  (EM plasmacytoma) 0.01, 0.40, 0.58, 0.01;
  (Kaposi's sarcoma) 0.01, 0.40, 0.58, 0.01;
  (Mast-cell disease) 0.20, 0.75, 0.04, 0.01;
  (AIDS involutionary) 0.899, 0.100, 0.001, 0.000;
  (T-immunob large) 0.000, 0.001, 0.200, 0.799;
  (Monocytoid B-cell) 0.00, 0.01, 0.94, 0.05;
  (Nasopharyngeal CA) 0.00, 0.55, 0.40, 0.05;
  (Seminoma) 0.0, 0.3, 0.6, 0.1;
  (SLE) 0.05, 0.65, 0.29, 0.01;
  (Mycobact histiocytos) 0.899, 0.100, 0.001, 0.000;
  (Mast-cell hyperplas) 0.899, 0.100, 0.001, 0.000;
  (LGV) 0.899, 0.100, 0.001, 0.000;
  (Histoplasmosis) 0.899, 0.100, 0.001, 0.000;
  (Coccidioidomycosis) 0.899, 0.100, 0.001, 0.000;
  (CMV) 0.899, 0.100, 0.001, 0.000;
  (Brucellosis) 0.899, 0.100, 0.001, 0.000;
  (Ki-1 LC anaplas B) 0.000, 0.001, 0.200, 0.799;
  (Intermed lymphocytic) 0.050, 0.595, 0.350, 0.005;
}
probability ( MLC_CY | Fault, MLC ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (AILD, Sparse [<10pc]) 0.0, 0.8, 0.1, 0.1;
  (ALIP, Sparse [<10pc]) 0.0, 0.8, 0.1, 0.1;
  (Cat scratch disease, Sparse [<10pc]) 0.0, 0.8, 0.1, 0.1;
  (Dermatopathic laden, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (Florid follic hyperp, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (GLH hyaline vascular, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (GLH plasma cell, Sparse [<10pc]) 0.0, 0.8, 0.1, 0.1;
  (Granulomatous laden, Sparse [<10pc]) 0.0, 0.8, 0.1, 0.1;
  (Histiocytosis x, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (Infectious mono, Sparse [<10pc]) 0.0, 0.8, 0.1, 0.1;
  (Leprosy-lepromatous, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (Lymphangiographic, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (Mantle zone hyperpla, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (Necrotizing Kikuchi, Sparse [<10pc]) 0.0, 0.8, 0.1, 0.1;
  (Necrotiz non-Kikuchi, Sparse [<10pc]) 0.0, 0.8, 0.1, 0.1;
  (Rheumatoid arthritis, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (Sarcoidosis, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (SHML, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (Sinus histiocytosis, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (Syphilis, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (Toxoplasmosis, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (Tuberculosis, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (Viral NOS, Sparse [<10pc]) 0.0, 0.8, 0.1, 0.1;
  (Whipple's disease, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (L&H nodular HD, Sparse [<10pc]) 0.0, 0.8, 0.2, 0.0;
  (L&H diffuse HD, Sparse [<10pc]) 0.0, 0.8, 0.2, 0.0;
  (Nodular sclerosis HD, Sparse [<10pc]) 0.0, 0.8, 0.2, 0.0;
  (Cellular phase NSHD, Sparse [<10pc]) 0.0, 0.8, 0.2, 0.0;
  (Syncytial NSHD, Sparse [<10pc]) 0.0, 0.8, 0.2, 0.0;
  (Mixed cellularity HD, Sparse [<10pc]) 0.0, 0.8, 0.2, 0.0;
  (Interfollicular HD, Sparse [<10pc]) 0.0, 0.8, 0.2, 0.0;
  (Diffuse fibrosis HD, Sparse [<10pc]) 0.0, 0.8, 0.2, 0.0;
  (Reticular-type HD, Sparse [<10pc]) 0.0, 0.8, 0.2, 0.0;
  (Small cleaved fol, Sparse [<10pc]) 0.00, 0.98, 0.01, 0.01;
  (Mixed fol, Sparse [<10pc]) 0.00, 0.98, 0.01, 0.01;
  (Large cell fol, Sparse [<10pc]) 0.00, 0.98, 0.01, 0.01;
  (Small noncleaved fol, Sparse [<10pc]) 0.00, 0.98, 0.01, 0.01;
  (Small lymphocytic, Sparse [<10pc]) 0.00, 0.79, 0.20, 0.01;
  (Plasmacytoid lyctic, Sparse [<10pc]) 0.00, 0.89, 0.01, 0.10;
  (Mantle zone lymphoma, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (Small cleaved dif, Sparse [<10pc]) 0.00, 0.98, 0.01, 0.01;
  (Mixed FCC dif, Sparse [<10pc]) 0.00, 0.98, 0.01, 0.01;
  (Large cell dif, Sparse [<10pc]) 0.00, 0.98, 0.01, 0.01;
  (B-immunoblastic, Sparse [<10pc]) 0.0, 0.7, 0.0, 0.3;
  (T-immunob mixed, Sparse [<10pc]) 0.00, 0.50, 0.48, 0.02;
  (AILD-like T-cell lym, Sparse [<10pc]) 0.00, 0.02, 0.97, 0.01;
  (Japanese ATL, Sparse [<10pc]) 0.00, 0.70, 0.15, 0.15;
  (Lymphoblastic, Sparse [<10pc]) 0.0, 1.0, 0.0, 0.0;
  (Small noncleaved dif, Sparse [<10pc]) 0.00, 0.98, 0.01, 0.01;
  (True histiocytic, Sparse [<10pc]) 0.00, 0.60, 0.35, 0.05;
  (Ki-1 LC anaplas T, Sparse [<10pc]) 0.0, 0.4, 0.4, 0.2;
  (Multiple myeloma, Sparse [<10pc]) 0.0, 0.7, 0.0, 0.3;
  (Mycosis fungoides, Sparse [<10pc]) 0.0, 0.8, 0.1, 0.1;
  (AML, Sparse [<10pc]) 0.000000000, 0.988900101, 0.001009082, 0.010090817;
  (Hairy cell leukemia, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (Carcinoma, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (Melanoma, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (EM plasmacytoma, Sparse [<10pc]) 0.0, 0.6, 0.0, 0.4;
  (Kaposi's sarcoma, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (Mast-cell disease, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (AIDS involutionary, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (T-immunob large, Sparse [<10pc]) 0.00, 0.50, 0.45, 0.05;
  (Monocytoid B-cell, Sparse [<10pc]) 0.00, 0.20, 0.78, 0.02;
  (Nasopharyngeal CA, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (Seminoma, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (SLE, Sparse [<10pc]) 0.0, 0.8, 0.1, 0.1;
  (Mycobact histiocytos, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (Mast-cell hyperplas, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (LGV, Sparse [<10pc]) 0.0, 0.8, 0.1, 0.1;
  (Histoplasmosis, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (Coccidioidomycosis, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (CMV, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (Brucellosis, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (Ki-1 LC anaplas B, Sparse [<10pc]) 0.0, 0.4, 0.4, 0.2;
  (Intermed lymphocytic, Sparse [<10pc]) 0.00, 0.90, 0.05, 0.05;
  (AIDS early, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (AILD, Moderate [11-50pc]) 0.0, 0.8, 0.1, 0.1;
  (ALIP, Moderate [11-50pc]) 0.0, 0.8, 0.1, 0.1;
  (Cat scratch disease, Moderate [11-50pc]) 0.0, 0.8, 0.1, 0.1;
  (Dermatopathic laden, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (Florid follic hyperp, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (GLH hyaline vascular, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (GLH plasma cell, Moderate [11-50pc]) 0.0, 0.8, 0.1, 0.1;
  (Granulomatous laden, Moderate [11-50pc]) 0.0, 0.8, 0.1, 0.1;
  (Histiocytosis x, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (Infectious mono, Moderate [11-50pc]) 0.0, 0.8, 0.1, 0.1;
  (Leprosy-lepromatous, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (Lymphangiographic, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (Mantle zone hyperpla, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (Necrotizing Kikuchi, Moderate [11-50pc]) 0.0, 0.8, 0.1, 0.1;
  (Necrotiz non-Kikuchi, Moderate [11-50pc]) 0.0, 0.8, 0.1, 0.1;
  (Rheumatoid arthritis, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (Sarcoidosis, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (SHML, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (Sinus histiocytosis, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (Syphilis, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (Toxoplasmosis, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (Tuberculosis, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (Viral NOS, Moderate [11-50pc]) 0.0, 0.8, 0.1, 0.1;
  (Whipple's disease, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (L&H nodular HD, Moderate [11-50pc]) 0.0, 0.8, 0.2, 0.0;
  (L&H diffuse HD, Moderate [11-50pc]) 0.0, 0.8, 0.2, 0.0;
  (Nodular sclerosis HD, Moderate [11-50pc]) 0.0, 0.8, 0.2, 0.0;
  (Cellular phase NSHD, Moderate [11-50pc]) 0.0, 0.8, 0.2, 0.0;
  (Syncytial NSHD, Moderate [11-50pc]) 0.0, 0.8, 0.2, 0.0;
  (Mixed cellularity HD, Moderate [11-50pc]) 0.0, 0.8, 0.2, 0.0;
  (Interfollicular HD, Moderate [11-50pc]) 0.0, 0.8, 0.2, 0.0;
  (Diffuse fibrosis HD, Moderate [11-50pc]) 0.0, 0.8, 0.2, 0.0;
  (Reticular-type HD, Moderate [11-50pc]) 0.0, 0.8, 0.2, 0.0;
  (Small cleaved fol, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01;
  (Mixed fol, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01;
  (Large cell fol, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01;
  (Small noncleaved fol, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01;
  (Small lymphocytic, Moderate [11-50pc]) 0.00, 0.79, 0.20, 0.01;
  (Plasmacytoid lyctic, Moderate [11-50pc]) 0.00, 0.89, 0.01, 0.10;
  (Mantle zone lymphoma, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (Small cleaved dif, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01;
  (Mixed FCC dif, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01;
  (Large cell dif, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01;
  (B-immunoblastic, Moderate [11-50pc]) 0.0, 0.7, 0.0, 0.3;
  (T-immunob mixed, Moderate [11-50pc]) 0.00, 0.50, 0.48, 0.02;
  (AILD-like T-cell lym, Moderate [11-50pc]) 0.00, 0.02, 0.97, 0.01;
  (Japanese ATL, Moderate [11-50pc]) 0.00, 0.70, 0.15, 0.15;
  (Lymphoblastic, Moderate [11-50pc]) 0.0, 1.0, 0.0, 0.0;
  (Small noncleaved dif, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01;
  (True histiocytic, Moderate [11-50pc]) 0.00, 0.60, 0.35, 0.05;
  (Ki-1 LC anaplas T, Moderate [11-50pc]) 0.0, 0.4, 0.4, 0.2;
  (Multiple myeloma, Moderate [11-50pc]) 0.0, 0.7, 0.0, 0.3;
  (Mycosis fungoides, Moderate [11-50pc]) 0.0, 0.8, 0.1, 0.1;
  (AML, Moderate [11-50pc]) 0.000000000, 0.988900101, 0.001009082, 0.010090817;
  (Hairy cell leukemia, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (Carcinoma, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (Melanoma, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (EM plasmacytoma, Moderate [11-50pc]) 0.0, 0.6, 0.0, 0.4;
  (Kaposi's sarcoma, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (Mast-cell disease, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (AIDS involutionary, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (T-immunob large, Moderate [11-50pc]) 0.00, 0.50, 0.45, 0.05;
  (Monocytoid B-cell, Moderate [11-50pc]) 0.00, 0.20, 0.78, 0.02;
  (Nasopharyngeal CA, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (Seminoma, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (SLE, Moderate [11-50pc]) 0.0, 0.8, 0.1, 0.1;
  (Mycobact histiocytos, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (Mast-cell hyperplas, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (LGV, Moderate [11-50pc]) 0.0, 0.8, 0.1, 0.1;
  (Histoplasmosis, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (Coccidioidomycosis, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (CMV, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (Brucellosis, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (Ki-1 LC anaplas B, Moderate [11-50pc]) 0.0, 0.4, 0.4, 0.2;
  (Intermed lymphocytic, Moderate [11-50pc]) 0.00, 0.90, 0.05, 0.05;
  (AIDS early, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (AILD, Numerous [51-90pc]) 0.0, 0.8, 0.1, 0.1;
  (ALIP, Numerous [51-90pc]) 0.0, 0.8, 0.1, 0.1;
  (Cat scratch disease, Numerous [51-90pc]) 0.0, 0.8, 0.1, 0.1;
  (Dermatopathic laden, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (Florid follic hyperp, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (GLH hyaline vascular, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (GLH plasma cell, Numerous [51-90pc]) 0.0, 0.8, 0.1, 0.1;
  (Granulomatous laden, Numerous [51-90pc]) 0.0, 0.8, 0.1, 0.1;
  (Histiocytosis x, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (Infectious mono, Numerous [51-90pc]) 0.0, 0.8, 0.1, 0.1;
  (Leprosy-lepromatous, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (Lymphangiographic, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (Mantle zone hyperpla, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (Necrotizing Kikuchi, Numerous [51-90pc]) 0.0, 0.8, 0.1, 0.1;
  (Necrotiz non-Kikuchi, Numerous [51-90pc]) 0.0, 0.8, 0.1, 0.1;
  (Rheumatoid arthritis, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (Sarcoidosis, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (SHML, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (Sinus histiocytosis, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (Syphilis, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (Toxoplasmosis, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (Tuberculosis, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (Viral NOS, Numerous [51-90pc]) 0.0, 0.8, 0.1, 0.1;
  (Whipple's disease, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (L&H nodular HD, Numerous [51-90pc]) 0.0, 0.8, 0.2, 0.0;
  (L&H diffuse HD, Numerous [51-90pc]) 0.0, 0.8, 0.2, 0.0;
  (Nodular sclerosis HD, Numerous [51-90pc]) 0.0, 0.8, 0.2, 0.0;
  (Cellular phase NSHD, Numerous [51-90pc]) 0.0, 0.8, 0.2, 0.0;
  (Syncytial NSHD, Numerous [51-90pc]) 0.0, 0.8, 0.2, 0.0;
  (Mixed cellularity HD, Numerous [51-90pc]) 0.0, 0.8, 0.2, 0.0;
  (Interfollicular HD, Numerous [51-90pc]) 0.0, 0.8, 0.2, 0.0;
  (Diffuse fibrosis HD, Numerous [51-90pc]) 0.0, 0.8, 0.2, 0.0;
  (Reticular-type HD, Numerous [51-90pc]) 0.0, 0.8, 0.2, 0.0;
  (Small cleaved fol, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01;
  (Mixed fol, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01;
  (Large cell fol, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01;
  (Small noncleaved fol, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01;
  (Small lymphocytic, Numerous [51-90pc]) 0.00, 0.79, 0.20, 0.01;
  (Plasmacytoid lyctic, Numerous [51-90pc]) 0.00, 0.89, 0.01, 0.10;
  (Mantle zone lymphoma, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (Small cleaved dif, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01;
  (Mixed FCC dif, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01;
  (Large cell dif, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01;
  (B-immunoblastic, Numerous [51-90pc]) 0.0, 0.7, 0.0, 0.3;
  (T-immunob mixed, Numerous [51-90pc]) 0.00, 0.50, 0.48, 0.02;
  (AILD-like T-cell lym, Numerous [51-90pc]) 0.00, 0.02, 0.97, 0.01;
  (Japanese ATL, Numerous [51-90pc]) 0.00, 0.70, 0.15, 0.15;
  (Lymphoblastic, Numerous [51-90pc]) 0.0, 1.0, 0.0, 0.0;
  (Small noncleaved dif, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01;
  (True histiocytic, Numerous [51-90pc]) 0.00, 0.60, 0.35, 0.05;
  (Ki-1 LC anaplas T, Numerous [51-90pc]) 0.0, 0.4, 0.4, 0.2;
  (Multiple myeloma, Numerous [51-90pc]) 0.0, 0.7, 0.0, 0.3;
  (Mycosis fungoides, Numerous [51-90pc]) 0.0, 0.8, 0.1, 0.1;
  (AML, Numerous [51-90pc]) 0.000000000, 0.988900101, 0.001009082, 0.010090817;
  (Hairy cell leukemia, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (Carcinoma, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (Melanoma, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (EM plasmacytoma, Numerous [51-90pc]) 0.0, 0.6, 0.0, 0.4;
  (Kaposi's sarcoma, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (Mast-cell disease, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (AIDS involutionary, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (T-immunob large, Numerous [51-90pc]) 0.00, 0.50, 0.45, 0.05;
  (Monocytoid B-cell, Numerous [51-90pc]) 0.00, 0.20, 0.78, 0.02;
  (Nasopharyngeal CA, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (Seminoma, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (SLE, Numerous [51-90pc]) 0.0, 0.8, 0.1, 0.1;
  (Mycobact histiocytos, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (Mast-cell hyperplas, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (LGV, Numerous [51-90pc]) 0.0, 0.8, 0.1, 0.1;
  (Histoplasmosis, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (Coccidioidomycosis, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (CMV, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (Brucellosis, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (Ki-1 LC anaplas B, Numerous [51-90pc]) 0.0, 0.4, 0.4, 0.2;
  (Intermed lymphocytic, Numerous [51-90pc]) 0.00, 0.90, 0.05, 0.05;
  (AIDS early, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (AILD, Striking [>90pc]) 0.0, 0.8, 0.1, 0.1;
  (ALIP, Striking [>90pc]) 0.0, 0.8, 0.1, 0.1;
  (Cat scratch disease, Striking [>90pc]) 0.0, 0.8, 0.1, 0.1;
  (Dermatopathic laden, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (Florid follic hyperp, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (GLH hyaline vascular, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (GLH plasma cell, Striking [>90pc]) 0.0, 0.8, 0.1, 0.1;
  (Granulomatous laden, Striking [>90pc]) 0.0, 0.8, 0.1, 0.1;
  (Histiocytosis x, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (Infectious mono, Striking [>90pc]) 0.0, 0.8, 0.1, 0.1;
  (Leprosy-lepromatous, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (Lymphangiographic, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (Mantle zone hyperpla, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (Necrotizing Kikuchi, Striking [>90pc]) 0.0, 0.8, 0.1, 0.1;
  (Necrotiz non-Kikuchi, Striking [>90pc]) 0.0, 0.8, 0.1, 0.1;
  (Rheumatoid arthritis, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (Sarcoidosis, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (SHML, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (Sinus histiocytosis, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (Syphilis, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (Toxoplasmosis, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (Tuberculosis, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (Viral NOS, Striking [>90pc]) 0.0, 0.8, 0.1, 0.1;
  (Whipple's disease, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (L&H nodular HD, Striking [>90pc]) 0.0, 0.8, 0.2, 0.0;
  (L&H diffuse HD, Striking [>90pc]) 0.0, 0.8, 0.2, 0.0;
  (Nodular sclerosis HD, Striking [>90pc]) 0.0, 0.8, 0.2, 0.0;
  (Cellular phase NSHD, Striking [>90pc]) 0.0, 0.8, 0.2, 0.0;
  (Syncytial NSHD, Striking [>90pc]) 0.0, 0.8, 0.2, 0.0;
  (Mixed cellularity HD, Striking [>90pc]) 0.0, 0.8, 0.2, 0.0;
  (Interfollicular HD, Striking [>90pc]) 0.0, 0.8, 0.2, 0.0;
  (Diffuse fibrosis HD, Striking [>90pc]) 0.0, 0.8, 0.2, 0.0;
  (Reticular-type HD, Striking [>90pc]) 0.0, 0.8, 0.2, 0.0;
  (Small cleaved fol, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01;
  (Mixed fol, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01;
  (Large cell fol, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01;
  (Small noncleaved fol, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01;
  (Small lymphocytic, Striking [>90pc]) 0.00, 0.79, 0.20, 0.01;
  (Plasmacytoid lyctic, Striking [>90pc]) 0.00, 0.89, 0.01, 0.10;
  (Mantle zone lymphoma, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (Small cleaved dif, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01;
  (Mixed FCC dif, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01;
  (Large cell dif, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01;
  (B-immunoblastic, Striking [>90pc]) 0.0, 0.7, 0.0, 0.3;
  (T-immunob mixed, Striking [>90pc]) 0.00, 0.50, 0.48, 0.02;
  (AILD-like T-cell lym, Striking [>90pc]) 0.00, 0.02, 0.97, 0.01;
  (Japanese ATL, Striking [>90pc]) 0.00, 0.70, 0.15, 0.15;
  (Lymphoblastic, Striking [>90pc]) 0.0, 1.0, 0.0, 0.0;
  (Small noncleaved dif, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01;
  (True histiocytic, Striking [>90pc]) 0.00, 0.60, 0.35, 0.05;
  (Ki-1 LC anaplas T, Striking [>90pc]) 0.0, 0.4, 0.4, 0.2;
  (Multiple myeloma, Striking [>90pc]) 0.0, 0.7, 0.0, 0.3;
  (Mycosis fungoides, Striking [>90pc]) 0.0, 0.8, 0.1, 0.1;
  (AML, Striking [>90pc]) 0.000000000, 0.988900101, 0.001009082, 0.010090817;
  (Hairy cell leukemia, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (Carcinoma, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (Melanoma, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (EM plasmacytoma, Striking [>90pc]) 0.0, 0.6, 0.0, 0.4;
  (Kaposi's sarcoma, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (Mast-cell disease, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (AIDS involutionary, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (T-immunob large, Striking [>90pc]) 0.00, 0.50, 0.45, 0.05;
  (Monocytoid B-cell, Striking [>90pc]) 0.00, 0.20, 0.78, 0.02;
  (Nasopharyngeal CA, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (Seminoma, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (SLE, Striking [>90pc]) 0.0, 0.8, 0.1, 0.1;
  (Mycobact histiocytos, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (Mast-cell hyperplas, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (LGV, Striking [>90pc]) 0.0, 0.8, 0.1, 0.1;
  (Histoplasmosis, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (Coccidioidomycosis, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (CMV, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (Brucellosis, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
  (Ki-1 LC anaplas B, Striking [>90pc]) 0.0, 0.4, 0.4, 0.2;
  (Intermed lymphocytic, Striking [>90pc]) 0.00, 0.90, 0.05, 0.05;
}
probability ( MLC_NS | Fault, MLC ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS early, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (AILD, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.05, 0.95;
  (ALIP, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Cat scratch disease, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Dermatopathic laden, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Florid follic hyperp, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (GLH hyaline vascular, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (GLH plasma cell, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Granulomatous laden, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Histiocytosis x, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Infectious mono, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Leprosy-lepromatous, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Lymphangiographic, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mantle zone hyperpla, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Necrotizing Kikuchi, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Necrotiz non-Kikuchi, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Rheumatoid arthritis, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Sarcoidosis, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (SHML, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Sinus histiocytosis, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Syphilis, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Toxoplasmosis, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Tuberculosis, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Viral NOS, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Whipple's disease, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (L&H nodular HD, Sparse [<10pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (L&H diffuse HD, Sparse [<10pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Nodular sclerosis HD, Sparse [<10pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Cellular phase NSHD, Sparse [<10pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Syncytial NSHD, Sparse [<10pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Mixed cellularity HD, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Interfollicular HD, Sparse [<10pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Diffuse fibrosis HD, Sparse [<10pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Reticular-type HD, Sparse [<10pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Small cleaved fol, Sparse [<10pc]) 0.000, 0.000, 0.001, 0.050, 0.949;
  (Mixed fol, Sparse [<10pc]) 0.000, 0.000, 0.001, 0.050, 0.949;
  (Large cell fol, Sparse [<10pc]) 0.000, 0.000, 0.001, 0.050, 0.949;
  (Small noncleaved fol, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Small lymphocytic, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Plasmacytoid lyctic, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mantle zone lymphoma, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Small cleaved dif, Sparse [<10pc]) 0.000, 0.000, 0.001, 0.050, 0.949;
  (Mixed FCC dif, Sparse [<10pc]) 0.00, 0.00, 0.01, 0.45, 0.54;
  (Large cell dif, Sparse [<10pc]) 0.00, 0.00, 0.01, 0.45, 0.54;
  (B-immunoblastic, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (T-immunob mixed, Sparse [<10pc]) 0.0000, 0.0001, 0.0100, 0.4500, 0.5399;
  (AILD-like T-cell lym, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Japanese ATL, Sparse [<10pc]) 0.00, 0.20, 0.29, 0.50, 0.01;
  (Lymphoblastic, Sparse [<10pc]) 0.000, 0.001, 0.250, 0.600, 0.149;
  (Small noncleaved dif, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (True histiocytic, Sparse [<10pc]) 0.0000, 0.0001, 0.0100, 0.4500, 0.5399;
  (Ki-1 LC anaplas T, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Multiple myeloma, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mycosis fungoides, Sparse [<10pc]) 0.00, 0.60, 0.35, 0.05, 0.00;
  (AML, Sparse [<10pc]) 0.00, 0.00, 0.01, 0.04, 0.95;
  (Hairy cell leukemia, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Carcinoma, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Melanoma, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (EM plasmacytoma, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Kaposi's sarcoma, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mast-cell disease, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (AIDS involutionary, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (T-immunob large, Sparse [<10pc]) 0.0000, 0.0001, 0.0100, 0.4500, 0.5399;
  (Monocytoid B-cell, Sparse [<10pc]) 0.000, 0.000, 0.001, 0.149, 0.850;
  (Nasopharyngeal CA, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Seminoma, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (SLE, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mycobact histiocytos, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mast-cell hyperplas, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (LGV, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Histoplasmosis, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Coccidioidomycosis, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (CMV, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Brucellosis, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Ki-1 LC anaplas B, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Intermed lymphocytic, Sparse [<10pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (AIDS early, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (AILD, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.05, 0.95;
  (ALIP, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Cat scratch disease, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Dermatopathic laden, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Florid follic hyperp, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (GLH hyaline vascular, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (GLH plasma cell, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Granulomatous laden, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Histiocytosis x, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Infectious mono, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Leprosy-lepromatous, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Lymphangiographic, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mantle zone hyperpla, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Necrotizing Kikuchi, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Necrotiz non-Kikuchi, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Rheumatoid arthritis, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Sarcoidosis, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (SHML, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Sinus histiocytosis, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Syphilis, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Toxoplasmosis, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Tuberculosis, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Viral NOS, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Whipple's disease, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (L&H nodular HD, Moderate [11-50pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (L&H diffuse HD, Moderate [11-50pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Nodular sclerosis HD, Moderate [11-50pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Cellular phase NSHD, Moderate [11-50pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Syncytial NSHD, Moderate [11-50pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Mixed cellularity HD, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Interfollicular HD, Moderate [11-50pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Diffuse fibrosis HD, Moderate [11-50pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Reticular-type HD, Moderate [11-50pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Small cleaved fol, Moderate [11-50pc]) 0.000, 0.000, 0.001, 0.050, 0.949;
  (Mixed fol, Moderate [11-50pc]) 0.000, 0.000, 0.001, 0.050, 0.949;
  (Large cell fol, Moderate [11-50pc]) 0.000, 0.000, 0.001, 0.050, 0.949;
  (Small noncleaved fol, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Small lymphocytic, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Plasmacytoid lyctic, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mantle zone lymphoma, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Small cleaved dif, Moderate [11-50pc]) 0.000, 0.000, 0.001, 0.050, 0.949;
  (Mixed FCC dif, Moderate [11-50pc]) 0.00, 0.00, 0.01, 0.45, 0.54;
  (Large cell dif, Moderate [11-50pc]) 0.00, 0.00, 0.01, 0.45, 0.54;
  (B-immunoblastic, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (T-immunob mixed, Moderate [11-50pc]) 0.0000, 0.0001, 0.0100, 0.4500, 0.5399;
  (AILD-like T-cell lym, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Japanese ATL, Moderate [11-50pc]) 0.00, 0.20, 0.29, 0.50, 0.01;
  (Lymphoblastic, Moderate [11-50pc]) 0.000, 0.001, 0.250, 0.600, 0.149;
  (Small noncleaved dif, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (True histiocytic, Moderate [11-50pc]) 0.0000, 0.0001, 0.0100, 0.4500, 0.5399;
  (Ki-1 LC anaplas T, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Multiple myeloma, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mycosis fungoides, Moderate [11-50pc]) 0.00, 0.60, 0.35, 0.05, 0.00;
  (AML, Moderate [11-50pc]) 0.00, 0.00, 0.01, 0.04, 0.95;
  (Hairy cell leukemia, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Carcinoma, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Melanoma, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (EM plasmacytoma, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Kaposi's sarcoma, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mast-cell disease, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (AIDS involutionary, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (T-immunob large, Moderate [11-50pc]) 0.0000, 0.0001, 0.0100, 0.4500, 0.5399;
  (Monocytoid B-cell, Moderate [11-50pc]) 0.000, 0.000, 0.001, 0.149, 0.850;
  (Nasopharyngeal CA, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Seminoma, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (SLE, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mycobact histiocytos, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mast-cell hyperplas, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (LGV, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Histoplasmosis, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Coccidioidomycosis, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (CMV, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Brucellosis, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Ki-1 LC anaplas B, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Intermed lymphocytic, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (AIDS early, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (AILD, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.05, 0.95;
  (ALIP, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Cat scratch disease, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Dermatopathic laden, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Florid follic hyperp, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (GLH hyaline vascular, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (GLH plasma cell, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Granulomatous laden, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Histiocytosis x, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Infectious mono, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Leprosy-lepromatous, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Lymphangiographic, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mantle zone hyperpla, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Necrotizing Kikuchi, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Necrotiz non-Kikuchi, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Rheumatoid arthritis, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Sarcoidosis, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (SHML, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Sinus histiocytosis, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Syphilis, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Toxoplasmosis, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Tuberculosis, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Viral NOS, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Whipple's disease, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (L&H nodular HD, Numerous [51-90pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (L&H diffuse HD, Numerous [51-90pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Nodular sclerosis HD, Numerous [51-90pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Cellular phase NSHD, Numerous [51-90pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Syncytial NSHD, Numerous [51-90pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Mixed cellularity HD, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Interfollicular HD, Numerous [51-90pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Diffuse fibrosis HD, Numerous [51-90pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Reticular-type HD, Numerous [51-90pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Small cleaved fol, Numerous [51-90pc]) 0.000, 0.000, 0.001, 0.050, 0.949;
  (Mixed fol, Numerous [51-90pc]) 0.000, 0.000, 0.001, 0.050, 0.949;
  (Large cell fol, Numerous [51-90pc]) 0.000, 0.000, 0.001, 0.050, 0.949;
  (Small noncleaved fol, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Small lymphocytic, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Plasmacytoid lyctic, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mantle zone lymphoma, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Small cleaved dif, Numerous [51-90pc]) 0.000, 0.000, 0.001, 0.050, 0.949;
  (Mixed FCC dif, Numerous [51-90pc]) 0.00, 0.00, 0.01, 0.45, 0.54;
  (Large cell dif, Numerous [51-90pc]) 0.00, 0.00, 0.01, 0.45, 0.54;
  (B-immunoblastic, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (T-immunob mixed, Numerous [51-90pc]) 0.0000, 0.0001, 0.0100, 0.4500, 0.5399;
  (AILD-like T-cell lym, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Japanese ATL, Numerous [51-90pc]) 0.00, 0.20, 0.29, 0.50, 0.01;
  (Lymphoblastic, Numerous [51-90pc]) 0.000, 0.001, 0.250, 0.600, 0.149;
  (Small noncleaved dif, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (True histiocytic, Numerous [51-90pc]) 0.0000, 0.0001, 0.0100, 0.4500, 0.5399;
  (Ki-1 LC anaplas T, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Multiple myeloma, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mycosis fungoides, Numerous [51-90pc]) 0.00, 0.60, 0.35, 0.05, 0.00;
  (AML, Numerous [51-90pc]) 0.00, 0.00, 0.01, 0.04, 0.95;
  (Hairy cell leukemia, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Carcinoma, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Melanoma, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (EM plasmacytoma, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Kaposi's sarcoma, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mast-cell disease, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (AIDS involutionary, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (T-immunob large, Numerous [51-90pc]) 0.0000, 0.0001, 0.0100, 0.4500, 0.5399;
  (Monocytoid B-cell, Numerous [51-90pc]) 0.000, 0.000, 0.001, 0.149, 0.850;
  (Nasopharyngeal CA, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Seminoma, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (SLE, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mycobact histiocytos, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mast-cell hyperplas, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (LGV, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Histoplasmosis, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Coccidioidomycosis, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (CMV, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Brucellosis, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Ki-1 LC anaplas B, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Intermed lymphocytic, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (AIDS early, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (AILD, Striking [>90pc]) 0.00, 0.00, 0.00, 0.05, 0.95;
  (ALIP, Striking [>90pc]) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Cat scratch disease, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Dermatopathic laden, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Florid follic hyperp, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (GLH hyaline vascular, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (GLH plasma cell, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Granulomatous laden, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Histiocytosis x, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Infectious mono, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Leprosy-lepromatous, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Lymphangiographic, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mantle zone hyperpla, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Necrotizing Kikuchi, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Necrotiz non-Kikuchi, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Rheumatoid arthritis, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Sarcoidosis, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (SHML, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Sinus histiocytosis, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Syphilis, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Toxoplasmosis, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Tuberculosis, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Viral NOS, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Whipple's disease, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (L&H nodular HD, Striking [>90pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (L&H diffuse HD, Striking [>90pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Nodular sclerosis HD, Striking [>90pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Cellular phase NSHD, Striking [>90pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Syncytial NSHD, Striking [>90pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Mixed cellularity HD, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Interfollicular HD, Striking [>90pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Diffuse fibrosis HD, Striking [>90pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Reticular-type HD, Striking [>90pc]) 0.000, 0.000, 0.001, 0.020, 0.979;
  (Small cleaved fol, Striking [>90pc]) 0.000, 0.000, 0.001, 0.050, 0.949;
  (Mixed fol, Striking [>90pc]) 0.000, 0.000, 0.001, 0.050, 0.949;
  (Large cell fol, Striking [>90pc]) 0.000, 0.000, 0.001, 0.050, 0.949;
  (Small noncleaved fol, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Small lymphocytic, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Plasmacytoid lyctic, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mantle zone lymphoma, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Small cleaved dif, Striking [>90pc]) 0.000, 0.000, 0.001, 0.050, 0.949;
  (Mixed FCC dif, Striking [>90pc]) 0.00, 0.00, 0.01, 0.45, 0.54;
  (Large cell dif, Striking [>90pc]) 0.00, 0.00, 0.01, 0.45, 0.54;
  (B-immunoblastic, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (T-immunob mixed, Striking [>90pc]) 0.0000, 0.0001, 0.0100, 0.4500, 0.5399;
  (AILD-like T-cell lym, Striking [>90pc]) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Japanese ATL, Striking [>90pc]) 0.00, 0.20, 0.29, 0.50, 0.01;
  (Lymphoblastic, Striking [>90pc]) 0.000, 0.001, 0.250, 0.600, 0.149;
  (Small noncleaved dif, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (True histiocytic, Striking [>90pc]) 0.0000, 0.0001, 0.0100, 0.4500, 0.5399;
  (Ki-1 LC anaplas T, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Multiple myeloma, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mycosis fungoides, Striking [>90pc]) 0.00, 0.60, 0.35, 0.05, 0.00;
  (AML, Striking [>90pc]) 0.00, 0.00, 0.01, 0.04, 0.95;
  (Hairy cell leukemia, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Carcinoma, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Melanoma, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (EM plasmacytoma, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Kaposi's sarcoma, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mast-cell disease, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (AIDS involutionary, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (T-immunob large, Striking [>90pc]) 0.0000, 0.0001, 0.0100, 0.4500, 0.5399;
  (Monocytoid B-cell, Striking [>90pc]) 0.000, 0.000, 0.001, 0.149, 0.850;
  (Nasopharyngeal CA, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Seminoma, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (SLE, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mycobact histiocytos, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Mast-cell hyperplas, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (LGV, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Histoplasmosis, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Coccidioidomycosis, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (CMV, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Brucellosis, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Ki-1 LC anaplas B, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
  (Intermed lymphocytic, Striking [>90pc]) 0.00, 0.00, 0.00, 0.01, 0.99;
}
probability ( MLC_NI | Fault, MLC ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS early, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (AILD, Sparse [<10pc]) 0.000, 0.051, 0.739, 0.200, 0.010;
  (ALIP, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Cat scratch disease, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Dermatopathic laden, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Florid follic hyperp, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (GLH hyaline vascular, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (GLH plasma cell, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Granulomatous laden, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Histiocytosis x, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Infectious mono, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Leprosy-lepromatous, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Lymphangiographic, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Mantle zone hyperpla, Sparse [<10pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Necrotizing Kikuchi, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Necrotiz non-Kikuchi, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Rheumatoid arthritis, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Sarcoidosis, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (SHML, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Sinus histiocytosis, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Syphilis, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Toxoplasmosis, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Tuberculosis, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Viral NOS, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Whipple's disease, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (L&H nodular HD, Sparse [<10pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (L&H diffuse HD, Sparse [<10pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Nodular sclerosis HD, Sparse [<10pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Cellular phase NSHD, Sparse [<10pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Syncytial NSHD, Sparse [<10pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Mixed cellularity HD, Sparse [<10pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Interfollicular HD, Sparse [<10pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Diffuse fibrosis HD, Sparse [<10pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Reticular-type HD, Sparse [<10pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Small cleaved fol, Sparse [<10pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Mixed fol, Sparse [<10pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Large cell fol, Sparse [<10pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Small noncleaved fol, Sparse [<10pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Small lymphocytic, Sparse [<10pc]) 0.00, 0.01, 0.96, 0.02, 0.01;
  (Plasmacytoid lyctic, Sparse [<10pc]) 0.00, 0.01, 0.96, 0.02, 0.01;
  (Mantle zone lymphoma, Sparse [<10pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Small cleaved dif, Sparse [<10pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Mixed FCC dif, Sparse [<10pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Large cell dif, Sparse [<10pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (B-immunoblastic, Sparse [<10pc]) 0.00, 0.01, 0.93, 0.05, 0.01;
  (T-immunob mixed, Sparse [<10pc]) 0.000, 0.051, 0.739, 0.200, 0.010;
  (AILD-like T-cell lym, Sparse [<10pc]) 0.000, 0.051, 0.739, 0.200, 0.010;
  (Japanese ATL, Sparse [<10pc]) 0.00, 0.10, 0.59, 0.30, 0.01;
  (Lymphoblastic, Sparse [<10pc]) 0.00, 0.97, 0.00, 0.02, 0.01;
  (Small noncleaved dif, Sparse [<10pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (True histiocytic, Sparse [<10pc]) 0.000, 0.051, 0.739, 0.200, 0.010;
  (Ki-1 LC anaplas T, Sparse [<10pc]) 0.00, 0.04, 0.76, 0.19, 0.01;
  (Multiple myeloma, Sparse [<10pc]) 0.00, 0.01, 0.93, 0.05, 0.01;
  (Mycosis fungoides, Sparse [<10pc]) 0.00, 0.44, 0.25, 0.30, 0.01;
  (AML, Sparse [<10pc]) 0.00, 0.10, 0.35, 0.54, 0.01;
  (Hairy cell leukemia, Sparse [<10pc]) 0.00, 0.30, 0.30, 0.39, 0.01;
  (Carcinoma, Sparse [<10pc]) 0.00, 0.05, 0.40, 0.54, 0.01;
  (Melanoma, Sparse [<10pc]) 0.00, 0.05, 0.40, 0.54, 0.01;
  (EM plasmacytoma, Sparse [<10pc]) 0.00, 0.01, 0.96, 0.02, 0.01;
  (Kaposi's sarcoma, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Mast-cell disease, Sparse [<10pc]) 0.00, 0.30, 0.30, 0.39, 0.01;
  (AIDS involutionary, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (T-immunob large, Sparse [<10pc]) 0.000, 0.051, 0.739, 0.200, 0.010;
  (Monocytoid B-cell, Sparse [<10pc]) 0.00, 0.30, 0.30, 0.39, 0.01;
  (Nasopharyngeal CA, Sparse [<10pc]) 0.00, 0.05, 0.40, 0.54, 0.01;
  (Seminoma, Sparse [<10pc]) 0.00, 0.05, 0.40, 0.54, 0.01;
  (SLE, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Mycobact histiocytos, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Mast-cell hyperplas, Sparse [<10pc]) 0.00, 0.30, 0.30, 0.39, 0.01;
  (LGV, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Histoplasmosis, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Coccidioidomycosis, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (CMV, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Brucellosis, Sparse [<10pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Ki-1 LC anaplas B, Sparse [<10pc]) 0.00, 0.04, 0.76, 0.19, 0.01;
  (Intermed lymphocytic, Sparse [<10pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (AIDS early, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (AILD, Moderate [11-50pc]) 0.000, 0.051, 0.739, 0.200, 0.010;
  (ALIP, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Cat scratch disease, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Dermatopathic laden, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Florid follic hyperp, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (GLH hyaline vascular, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (GLH plasma cell, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Granulomatous laden, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Histiocytosis x, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Infectious mono, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Leprosy-lepromatous, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Lymphangiographic, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Mantle zone hyperpla, Moderate [11-50pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Necrotizing Kikuchi, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Necrotiz non-Kikuchi, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Rheumatoid arthritis, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Sarcoidosis, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (SHML, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Sinus histiocytosis, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Syphilis, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Toxoplasmosis, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Tuberculosis, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Viral NOS, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Whipple's disease, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (L&H nodular HD, Moderate [11-50pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (L&H diffuse HD, Moderate [11-50pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Nodular sclerosis HD, Moderate [11-50pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Cellular phase NSHD, Moderate [11-50pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Syncytial NSHD, Moderate [11-50pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Mixed cellularity HD, Moderate [11-50pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Interfollicular HD, Moderate [11-50pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Diffuse fibrosis HD, Moderate [11-50pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Reticular-type HD, Moderate [11-50pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Small cleaved fol, Moderate [11-50pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Mixed fol, Moderate [11-50pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Large cell fol, Moderate [11-50pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Small noncleaved fol, Moderate [11-50pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Small lymphocytic, Moderate [11-50pc]) 0.00, 0.01, 0.96, 0.02, 0.01;
  (Plasmacytoid lyctic, Moderate [11-50pc]) 0.00, 0.01, 0.96, 0.02, 0.01;
  (Mantle zone lymphoma, Moderate [11-50pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Small cleaved dif, Moderate [11-50pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Mixed FCC dif, Moderate [11-50pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Large cell dif, Moderate [11-50pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (B-immunoblastic, Moderate [11-50pc]) 0.00, 0.01, 0.93, 0.05, 0.01;
  (T-immunob mixed, Moderate [11-50pc]) 0.000, 0.051, 0.739, 0.200, 0.010;
  (AILD-like T-cell lym, Moderate [11-50pc]) 0.000, 0.051, 0.739, 0.200, 0.010;
  (Japanese ATL, Moderate [11-50pc]) 0.00, 0.10, 0.59, 0.30, 0.01;
  (Lymphoblastic, Moderate [11-50pc]) 0.00, 0.97, 0.00, 0.02, 0.01;
  (Small noncleaved dif, Moderate [11-50pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (True histiocytic, Moderate [11-50pc]) 0.000, 0.051, 0.739, 0.200, 0.010;
  (Ki-1 LC anaplas T, Moderate [11-50pc]) 0.00, 0.04, 0.76, 0.19, 0.01;
  (Multiple myeloma, Moderate [11-50pc]) 0.00, 0.01, 0.93, 0.05, 0.01;
  (Mycosis fungoides, Moderate [11-50pc]) 0.00, 0.44, 0.25, 0.30, 0.01;
  (AML, Moderate [11-50pc]) 0.00, 0.10, 0.35, 0.54, 0.01;
  (Hairy cell leukemia, Moderate [11-50pc]) 0.00, 0.30, 0.30, 0.39, 0.01;
  (Carcinoma, Moderate [11-50pc]) 0.00, 0.05, 0.40, 0.54, 0.01;
  (Melanoma, Moderate [11-50pc]) 0.00, 0.05, 0.40, 0.54, 0.01;
  (EM plasmacytoma, Moderate [11-50pc]) 0.00, 0.01, 0.96, 0.02, 0.01;
  (Kaposi's sarcoma, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Mast-cell disease, Moderate [11-50pc]) 0.00, 0.30, 0.30, 0.39, 0.01;
  (AIDS involutionary, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (T-immunob large, Moderate [11-50pc]) 0.000, 0.051, 0.739, 0.200, 0.010;
  (Monocytoid B-cell, Moderate [11-50pc]) 0.00, 0.30, 0.30, 0.39, 0.01;
  (Nasopharyngeal CA, Moderate [11-50pc]) 0.00, 0.05, 0.40, 0.54, 0.01;
  (Seminoma, Moderate [11-50pc]) 0.00, 0.05, 0.40, 0.54, 0.01;
  (SLE, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Mycobact histiocytos, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Mast-cell hyperplas, Moderate [11-50pc]) 0.00, 0.30, 0.30, 0.39, 0.01;
  (LGV, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Histoplasmosis, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Coccidioidomycosis, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (CMV, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Brucellosis, Moderate [11-50pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Ki-1 LC anaplas B, Moderate [11-50pc]) 0.00, 0.04, 0.76, 0.19, 0.01;
  (Intermed lymphocytic, Moderate [11-50pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (AIDS early, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (AILD, Numerous [51-90pc]) 0.000, 0.051, 0.739, 0.200, 0.010;
  (ALIP, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Cat scratch disease, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Dermatopathic laden, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Florid follic hyperp, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (GLH hyaline vascular, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (GLH plasma cell, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Granulomatous laden, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Histiocytosis x, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Infectious mono, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Leprosy-lepromatous, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Lymphangiographic, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Mantle zone hyperpla, Numerous [51-90pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Necrotizing Kikuchi, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Necrotiz non-Kikuchi, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Rheumatoid arthritis, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Sarcoidosis, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (SHML, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Sinus histiocytosis, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Syphilis, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Toxoplasmosis, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Tuberculosis, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Viral NOS, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Whipple's disease, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (L&H nodular HD, Numerous [51-90pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (L&H diffuse HD, Numerous [51-90pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Nodular sclerosis HD, Numerous [51-90pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Cellular phase NSHD, Numerous [51-90pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Syncytial NSHD, Numerous [51-90pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Mixed cellularity HD, Numerous [51-90pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Interfollicular HD, Numerous [51-90pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Diffuse fibrosis HD, Numerous [51-90pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Reticular-type HD, Numerous [51-90pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Small cleaved fol, Numerous [51-90pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Mixed fol, Numerous [51-90pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Large cell fol, Numerous [51-90pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Small noncleaved fol, Numerous [51-90pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Small lymphocytic, Numerous [51-90pc]) 0.00, 0.01, 0.96, 0.02, 0.01;
  (Plasmacytoid lyctic, Numerous [51-90pc]) 0.00, 0.01, 0.96, 0.02, 0.01;
  (Mantle zone lymphoma, Numerous [51-90pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Small cleaved dif, Numerous [51-90pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Mixed FCC dif, Numerous [51-90pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Large cell dif, Numerous [51-90pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (B-immunoblastic, Numerous [51-90pc]) 0.00, 0.01, 0.93, 0.05, 0.01;
  (T-immunob mixed, Numerous [51-90pc]) 0.000, 0.051, 0.739, 0.200, 0.010;
  (AILD-like T-cell lym, Numerous [51-90pc]) 0.000, 0.051, 0.739, 0.200, 0.010;
  (Japanese ATL, Numerous [51-90pc]) 0.00, 0.10, 0.59, 0.30, 0.01;
  (Lymphoblastic, Numerous [51-90pc]) 0.00, 0.97, 0.00, 0.02, 0.01;
  (Small noncleaved dif, Numerous [51-90pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (True histiocytic, Numerous [51-90pc]) 0.000, 0.051, 0.739, 0.200, 0.010;
  (Ki-1 LC anaplas T, Numerous [51-90pc]) 0.00, 0.04, 0.76, 0.19, 0.01;
  (Multiple myeloma, Numerous [51-90pc]) 0.00, 0.01, 0.93, 0.05, 0.01;
  (Mycosis fungoides, Numerous [51-90pc]) 0.00, 0.44, 0.25, 0.30, 0.01;
  (AML, Numerous [51-90pc]) 0.00, 0.10, 0.35, 0.54, 0.01;
  (Hairy cell leukemia, Numerous [51-90pc]) 0.00, 0.30, 0.30, 0.39, 0.01;
  (Carcinoma, Numerous [51-90pc]) 0.00, 0.05, 0.40, 0.54, 0.01;
  (Melanoma, Numerous [51-90pc]) 0.00, 0.05, 0.40, 0.54, 0.01;
  (EM plasmacytoma, Numerous [51-90pc]) 0.00, 0.01, 0.96, 0.02, 0.01;
  (Kaposi's sarcoma, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Mast-cell disease, Numerous [51-90pc]) 0.00, 0.30, 0.30, 0.39, 0.01;
  (AIDS involutionary, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (T-immunob large, Numerous [51-90pc]) 0.000, 0.051, 0.739, 0.200, 0.010;
  (Monocytoid B-cell, Numerous [51-90pc]) 0.00, 0.30, 0.30, 0.39, 0.01;
  (Nasopharyngeal CA, Numerous [51-90pc]) 0.00, 0.05, 0.40, 0.54, 0.01;
  (Seminoma, Numerous [51-90pc]) 0.00, 0.05, 0.40, 0.54, 0.01;
  (SLE, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Mycobact histiocytos, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Mast-cell hyperplas, Numerous [51-90pc]) 0.00, 0.30, 0.30, 0.39, 0.01;
  (LGV, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Histoplasmosis, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Coccidioidomycosis, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (CMV, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Brucellosis, Numerous [51-90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Ki-1 LC anaplas B, Numerous [51-90pc]) 0.00, 0.04, 0.76, 0.19, 0.01;
  (Intermed lymphocytic, Numerous [51-90pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (AIDS early, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (AILD, Striking [>90pc]) 0.000, 0.051, 0.739, 0.200, 0.010;
  (ALIP, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Cat scratch disease, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Dermatopathic laden, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Florid follic hyperp, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (GLH hyaline vascular, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (GLH plasma cell, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Granulomatous laden, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Histiocytosis x, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Infectious mono, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Leprosy-lepromatous, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Lymphangiographic, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Mantle zone hyperpla, Striking [>90pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Necrotizing Kikuchi, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Necrotiz non-Kikuchi, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Rheumatoid arthritis, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Sarcoidosis, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (SHML, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Sinus histiocytosis, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Syphilis, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Toxoplasmosis, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Tuberculosis, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Viral NOS, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Whipple's disease, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (L&H nodular HD, Striking [>90pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (L&H diffuse HD, Striking [>90pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Nodular sclerosis HD, Striking [>90pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Cellular phase NSHD, Striking [>90pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Syncytial NSHD, Striking [>90pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Mixed cellularity HD, Striking [>90pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Interfollicular HD, Striking [>90pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Diffuse fibrosis HD, Striking [>90pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Reticular-type HD, Striking [>90pc]) 0.00, 0.15, 0.25, 0.59, 0.01;
  (Small cleaved fol, Striking [>90pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Mixed fol, Striking [>90pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Large cell fol, Striking [>90pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Small noncleaved fol, Striking [>90pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Small lymphocytic, Striking [>90pc]) 0.00, 0.01, 0.96, 0.02, 0.01;
  (Plasmacytoid lyctic, Striking [>90pc]) 0.00, 0.01, 0.96, 0.02, 0.01;
  (Mantle zone lymphoma, Striking [>90pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Small cleaved dif, Striking [>90pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Mixed FCC dif, Striking [>90pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (Large cell dif, Striking [>90pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (B-immunoblastic, Striking [>90pc]) 0.00, 0.01, 0.93, 0.05, 0.01;
  (T-immunob mixed, Striking [>90pc]) 0.000, 0.051, 0.739, 0.200, 0.010;
  (AILD-like T-cell lym, Striking [>90pc]) 0.000, 0.051, 0.739, 0.200, 0.010;
  (Japanese ATL, Striking [>90pc]) 0.00, 0.10, 0.59, 0.30, 0.01;
  (Lymphoblastic, Striking [>90pc]) 0.00, 0.97, 0.00, 0.02, 0.01;
  (Small noncleaved dif, Striking [>90pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
  (True histiocytic, Striking [>90pc]) 0.000, 0.051, 0.739, 0.200, 0.010;
  (Ki-1 LC anaplas T, Striking [>90pc]) 0.00, 0.04, 0.76, 0.19, 0.01;
  (Multiple myeloma, Striking [>90pc]) 0.00, 0.01, 0.93, 0.05, 0.01;
  (Mycosis fungoides, Striking [>90pc]) 0.00, 0.44, 0.25, 0.30, 0.01;
  (AML, Striking [>90pc]) 0.00, 0.10, 0.35, 0.54, 0.01;
  (Hairy cell leukemia, Striking [>90pc]) 0.00, 0.30, 0.30, 0.39, 0.01;
  (Carcinoma, Striking [>90pc]) 0.00, 0.05, 0.40, 0.54, 0.01;
  (Melanoma, Striking [>90pc]) 0.00, 0.05, 0.40, 0.54, 0.01;
  (EM plasmacytoma, Striking [>90pc]) 0.00, 0.01, 0.96, 0.02, 0.01;
  (Kaposi's sarcoma, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Mast-cell disease, Striking [>90pc]) 0.00, 0.30, 0.30, 0.39, 0.01;
  (AIDS involutionary, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (T-immunob large, Striking [>90pc]) 0.000, 0.051, 0.739, 0.200, 0.010;
  (Monocytoid B-cell, Striking [>90pc]) 0.00, 0.30, 0.30, 0.39, 0.01;
  (Nasopharyngeal CA, Striking [>90pc]) 0.00, 0.05, 0.40, 0.54, 0.01;
  (Seminoma, Striking [>90pc]) 0.00, 0.05, 0.40, 0.54, 0.01;
  (SLE, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Mycobact histiocytos, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Mast-cell hyperplas, Striking [>90pc]) 0.00, 0.30, 0.30, 0.39, 0.01;
  (LGV, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Histoplasmosis, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Coccidioidomycosis, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (CMV, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Brucellosis, Striking [>90pc]) 0.00, 0.10, 0.40, 0.49, 0.01;
  (Ki-1 LC anaplas B, Striking [>90pc]) 0.00, 0.04, 0.76, 0.19, 0.01;
  (Intermed lymphocytic, Striking [>90pc]) 0.00, 0.05, 0.01, 0.93, 0.01;
}
probability ( MCC | Fault ) {
  (AIDS early) 0.05, 0.85, 0.10, 0.00;
  (AILD) 0.99999, 0.00001, 0.00000, 0.00000;
  (ALIP) 0.99999, 0.00001, 0.00000, 0.00000;
  (Cat scratch disease) 0.94, 0.05, 0.01, 0.00;
  (Dermatopathic laden) 0.99999, 0.00001, 0.00000, 0.00000;
  (Florid follic hyperp) 0.96, 0.03, 0.01, 0.00;
  (GLH hyaline vascular) 0.99999, 0.00001, 0.00000, 0.00000;
  (GLH plasma cell) 0.99999, 0.00001, 0.00000, 0.00000;
  (Granulomatous laden) 0.97, 0.02, 0.01, 0.00;
  (Histiocytosis x) 0.99999, 0.00001, 0.00000, 0.00000;
  (Infectious mono) 0.25, 0.70, 0.05, 0.00;
  (Leprosy-lepromatous) 0.99999, 0.00001, 0.00000, 0.00000;
  (Lymphangiographic) 0.99999, 0.00001, 0.00000, 0.00000;
  (Mantle zone hyperpla) 0.99999, 0.00001, 0.00000, 0.00000;
  (Necrotizing Kikuchi) 0.97, 0.02, 0.01, 0.00;
  (Necrotiz non-Kikuchi) 0.97, 0.02, 0.01, 0.00;
  (Rheumatoid arthritis) 0.99999, 0.00001, 0.00000, 0.00000;
  (Sarcoidosis) 0.99999, 0.00001, 0.00000, 0.00000;
  (SHML) 0.99999, 0.00001, 0.00000, 0.00000;
  (Sinus histiocytosis) 0.99999, 0.00001, 0.00000, 0.00000;
  (Syphilis) 0.94, 0.05, 0.01, 0.00;
  (Toxoplasmosis) 0.0, 0.6, 0.4, 0.0;
  (Tuberculosis) 0.99999, 0.00001, 0.00000, 0.00000;
  (Viral NOS) 0.25, 0.70, 0.05, 0.00;
  (Whipple's disease) 0.99999, 0.00001, 0.00000, 0.00000;
  (L&H nodular HD) 0.999, 0.001, 0.000, 0.000;
  (L&H diffuse HD) 0.999, 0.001, 0.000, 0.000;
  (Nodular sclerosis HD) 0.97, 0.02, 0.01, 0.00;
  (Cellular phase NSHD) 0.97, 0.02, 0.01, 0.00;
  (Syncytial NSHD) 0.999, 0.001, 0.000, 0.000;
  (Mixed cellularity HD) 0.97, 0.02, 0.01, 0.00;
  (Interfollicular HD) 0.97, 0.02, 0.01, 0.00;
  (Diffuse fibrosis HD) 0.999, 0.001, 0.000, 0.000;
  (Reticular-type HD) 0.999, 0.001, 0.000, 0.000;
  (Small cleaved fol) 0.91, 0.04, 0.03, 0.02;
  (Mixed fol) 0.91, 0.04, 0.03, 0.02;
  (Large cell fol) 0.91, 0.04, 0.03, 0.02;
  (Small noncleaved fol) 0.91, 0.04, 0.03, 0.02;
  (Small lymphocytic) 0.91, 0.04, 0.03, 0.02;
  (Plasmacytoid lyctic) 0.91, 0.04, 0.03, 0.02;
  (Mantle zone lymphoma) 0.91, 0.04, 0.03, 0.02;
  (Small cleaved dif) 0.984, 0.010, 0.001, 0.005;
  (Mixed FCC dif) 0.984, 0.010, 0.001, 0.005;
  (Large cell dif) 0.984, 0.010, 0.001, 0.005;
  (B-immunoblastic) 0.99999, 0.00001, 0.00000, 0.00000;
  (T-immunob mixed) 0.99999, 0.00001, 0.00000, 0.00000;
  (AILD-like T-cell lym) 0.99999, 0.00001, 0.00000, 0.00000;
  (Japanese ATL) 0.99999, 0.00001, 0.00000, 0.00000;
  (Lymphoblastic) 0.99999, 0.00001, 0.00000, 0.00000;
  (Small noncleaved dif) 0.984, 0.010, 0.001, 0.005;
  (True histiocytic) 0.99999, 0.00001, 0.00000, 0.00000;
  (Ki-1 LC anaplas T) 0.99999, 0.00001, 0.00000, 0.00000;
  (Multiple myeloma) 0.99999, 0.00001, 0.00000, 0.00000;
  (Mycosis fungoides) 0.99999, 0.00001, 0.00000, 0.00000;
  (AML) 0.99999, 0.00001, 0.00000, 0.00000;
  (Hairy cell leukemia) 0.985, 0.010, 0.005, 0.000;
  (Carcinoma) 0.99999, 0.00001, 0.00000, 0.00000;
  (Melanoma) 0.99999, 0.00001, 0.00000, 0.00000;
  (EM plasmacytoma) 0.99999, 0.00001, 0.00000, 0.00000;
  (Kaposi's sarcoma) 0.99999, 0.00001, 0.00000, 0.00000;
  (Mast-cell disease) 0.985, 0.010, 0.005, 0.000;
  (AIDS involutionary) 0.75, 0.20, 0.05, 0.00;
  (T-immunob large) 0.99999, 0.00001, 0.00000, 0.00000;
  (Monocytoid B-cell) 0.00, 0.01, 0.15, 0.84;
  (Nasopharyngeal CA) 0.99999, 0.00001, 0.00000, 0.00000;
  (Seminoma) 0.99999, 0.00001, 0.00000, 0.00000;
  (SLE) 0.25, 0.70, 0.05, 0.00;
  (Mycobact histiocytos) 0.99999, 0.00001, 0.00000, 0.00000;
  (Mast-cell hyperplas) 0.985, 0.010, 0.005, 0.000;
  (LGV) 0.99999, 0.00001, 0.00000, 0.00000;
  (Histoplasmosis) 0.94, 0.05, 0.01, 0.00;
  (Coccidioidomycosis) 0.94, 0.05, 0.01, 0.00;
  (CMV) 0.94, 0.05, 0.01, 0.00;
  (Brucellosis) 0.0, 0.6, 0.4, 0.0;
  (Ki-1 LC anaplas B) 0.99999, 0.00001, 0.00000, 0.00000;
  (Intermed lymphocytic) 0.91, 0.04, 0.03, 0.02;
}
probability ( MONO | Fault, MUMMY ) {
  (AIDS early, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (AILD, Absent [0]) 0.969, 0.020, 0.010, 0.001;
  (ALIP, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Cat scratch disease, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Dermatopathic laden, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Florid follic hyperp, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (GLH hyaline vascular, Absent [0]) 0.98, 0.02, 0.00, 0.00;
  (GLH plasma cell, Absent [0]) 0.98, 0.02, 0.00, 0.00;
  (Granulomatous laden, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Histiocytosis x, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Infectious mono, Absent [0]) 0.969, 0.030, 0.001, 0.000;
  (Leprosy-lepromatous, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Lymphangiographic, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Mantle zone hyperpla, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Necrotizing Kikuchi, Absent [0]) 0.99, 0.01, 0.00, 0.00;
  (Necrotiz non-Kikuchi, Absent [0]) 0.99, 0.01, 0.00, 0.00;
  (Rheumatoid arthritis, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Sarcoidosis, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (SHML, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Sinus histiocytosis, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Syphilis, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Toxoplasmosis, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Tuberculosis, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Viral NOS, Absent [0]) 0.989, 0.010, 0.001, 0.000;
  (Whipple's disease, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (L&H nodular HD, Absent [0]) 0.01, 0.98, 0.01, 0.00;
  (L&H diffuse HD, Absent [0]) 0.01, 0.98, 0.01, 0.00;
  (Nodular sclerosis HD, Absent [0]) 0.00, 0.05, 0.85, 0.10;
  (Cellular phase NSHD, Absent [0]) 0.00, 0.05, 0.85, 0.10;
  (Syncytial NSHD, Absent [0]) 0.00, 0.05, 0.85, 0.10;
  (Mixed cellularity HD, Absent [0]) 0.000, 0.001, 0.849, 0.150;
  (Interfollicular HD, Absent [0]) 0.00, 0.20, 0.75, 0.05;
  (Diffuse fibrosis HD, Absent [0]) 0.00, 0.05, 0.15, 0.80;
  (Reticular-type HD, Absent [0]) 0.00, 0.01, 0.20, 0.79;
  (Small cleaved fol, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Mixed fol, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Large cell fol, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Small noncleaved fol, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Small lymphocytic, Absent [0]) 0.969, 0.020, 0.010, 0.001;
  (Plasmacytoid lyctic, Absent [0]) 0.969, 0.020, 0.010, 0.001;
  (Mantle zone lymphoma, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Small cleaved dif, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Mixed FCC dif, Absent [0]) 0.969, 0.020, 0.010, 0.001;
  (Large cell dif, Absent [0]) 0.969, 0.020, 0.010, 0.001;
  (B-immunoblastic, Absent [0]) 0.88, 0.07, 0.04, 0.01;
  (T-immunob mixed, Absent [0]) 0.969, 0.020, 0.010, 0.001;
  (AILD-like T-cell lym, Absent [0]) 0.969, 0.020, 0.010, 0.001;
  (Japanese ATL, Absent [0]) 0.969, 0.020, 0.010, 0.001;
  (Lymphoblastic, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Small noncleaved dif, Absent [0]) 0.969, 0.020, 0.010, 0.001;
  (True histiocytic, Absent [0]) 0.969, 0.020, 0.010, 0.001;
  (Ki-1 LC anaplas T, Absent [0]) 0.969, 0.020, 0.010, 0.001;
  (Multiple myeloma, Absent [0]) 0.45, 0.30, 0.20, 0.05;
  (Mycosis fungoides, Absent [0]) 0.969, 0.020, 0.010, 0.001;
  (AML, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Hairy cell leukemia, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Carcinoma, Absent [0]) 0.9499, 0.0400, 0.0100, 0.0001;
  (Melanoma, Absent [0]) 0.9499, 0.0400, 0.0100, 0.0001;
  (EM plasmacytoma, Absent [0]) 0.80, 0.15, 0.04, 0.01;
  (Kaposi's sarcoma, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Mast-cell disease, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (AIDS involutionary, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (T-immunob large, Absent [0]) 0.969, 0.020, 0.010, 0.001;
  (Monocytoid B-cell, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Nasopharyngeal CA, Absent [0]) 0.9499, 0.0400, 0.0100, 0.0001;
  (Seminoma, Absent [0]) 0.949, 0.040, 0.010, 0.001;
  (SLE, Absent [0]) 0.969, 0.030, 0.001, 0.000;
  (Mycobact histiocytos, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Mast-cell hyperplas, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (LGV, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Histoplasmosis, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Coccidioidomycosis, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (CMV, Absent [0]) 0.969, 0.020, 0.010, 0.001;
  (Brucellosis, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Ki-1 LC anaplas B, Absent [0]) 0.969, 0.020, 0.010, 0.001;
  (Intermed lymphocytic, Absent [0]) 0.9999, 0.0001, 0.0000, 0.0000;
  (AIDS early, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (AILD, Rare [1-2]) 0.969, 0.020, 0.010, 0.001;
  (ALIP, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (Cat scratch disease, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (Dermatopathic laden, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (Florid follic hyperp, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (GLH hyaline vascular, Rare [1-2]) 0.98, 0.02, 0.00, 0.00;
  (GLH plasma cell, Rare [1-2]) 0.98, 0.02, 0.00, 0.00;
  (Granulomatous laden, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (Histiocytosis x, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (Infectious mono, Rare [1-2]) 0.969, 0.030, 0.001, 0.000;
  (Leprosy-lepromatous, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (Lymphangiographic, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (Mantle zone hyperpla, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (Necrotizing Kikuchi, Rare [1-2]) 0.99, 0.01, 0.00, 0.00;
  (Necrotiz non-Kikuchi, Rare [1-2]) 0.99, 0.01, 0.00, 0.00;
  (Rheumatoid arthritis, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (Sarcoidosis, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (SHML, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (Sinus histiocytosis, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (Syphilis, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (Toxoplasmosis, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (Tuberculosis, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (Viral NOS, Rare [1-2]) 0.989, 0.010, 0.001, 0.000;
  (Whipple's disease, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (L&H nodular HD, Rare [1-2]) 0.01, 0.98, 0.01, 0.00;
  (L&H diffuse HD, Rare [1-2]) 0.01, 0.98, 0.01, 0.00;
  (Nodular sclerosis HD, Rare [1-2]) 0.00, 0.05, 0.85, 0.10;
  (Cellular phase NSHD, Rare [1-2]) 0.00, 0.05, 0.85, 0.10;
  (Syncytial NSHD, Rare [1-2]) 0.00, 0.05, 0.85, 0.10;
  (Mixed cellularity HD, Rare [1-2]) 0.000, 0.001, 0.849, 0.150;
  (Interfollicular HD, Rare [1-2]) 0.00, 0.20, 0.75, 0.05;
  (Diffuse fibrosis HD, Rare [1-2]) 0.00, 0.05, 0.15, 0.80;
  (Reticular-type HD, Rare [1-2]) 0.00, 0.01, 0.20, 0.79;
  (Small cleaved fol, Rare [1-2]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Mixed fol, Rare [1-2]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Large cell fol, Rare [1-2]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Small noncleaved fol, Rare [1-2]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Small lymphocytic, Rare [1-2]) 0.969, 0.020, 0.010, 0.001;
  (Plasmacytoid lyctic, Rare [1-2]) 0.969, 0.020, 0.010, 0.001;
  (Mantle zone lymphoma, Rare [1-2]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Small cleaved dif, Rare [1-2]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Mixed FCC dif, Rare [1-2]) 0.969, 0.020, 0.010, 0.001;
  (Large cell dif, Rare [1-2]) 0.969, 0.020, 0.010, 0.001;
  (B-immunoblastic, Rare [1-2]) 0.88, 0.07, 0.04, 0.01;
  (T-immunob mixed, Rare [1-2]) 0.969, 0.020, 0.010, 0.001;
  (AILD-like T-cell lym, Rare [1-2]) 0.969, 0.020, 0.010, 0.001;
  (Japanese ATL, Rare [1-2]) 0.969, 0.020, 0.010, 0.001;
  (Lymphoblastic, Rare [1-2]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Small noncleaved dif, Rare [1-2]) 0.969, 0.020, 0.010, 0.001;
  (True histiocytic, Rare [1-2]) 0.969, 0.020, 0.010, 0.001;
  (Ki-1 LC anaplas T, Rare [1-2]) 0.969, 0.020, 0.010, 0.001;
  (Multiple myeloma, Rare [1-2]) 0.45, 0.30, 0.20, 0.05;
  (Mycosis fungoides, Rare [1-2]) 0.969, 0.020, 0.010, 0.001;
  (AML, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (Hairy cell leukemia, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (Carcinoma, Rare [1-2]) 0.9499, 0.0400, 0.0100, 0.0001;
  (Melanoma, Rare [1-2]) 0.9499, 0.0400, 0.0100, 0.0001;
  (EM plasmacytoma, Rare [1-2]) 0.80, 0.15, 0.04, 0.01;
  (Kaposi's sarcoma, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (Mast-cell disease, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (AIDS involutionary, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (T-immunob large, Rare [1-2]) 0.969, 0.020, 0.010, 0.001;
  (Monocytoid B-cell, Rare [1-2]) 0.9999, 0.0001, 0.0000, 0.0000;
  (Nasopharyngeal CA, Rare [1-2]) 0.9499, 0.0400, 0.0100, 0.0001;
  (Seminoma, Rare [1-2]) 0.9499, 0.0400, 0.0100, 0.0001;
  (SLE, Rare [1-2]) 0.969, 0.030, 0.001, 0.000;
  (Mycobact histiocytos, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (Mast-cell hyperplas, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (LGV, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (Histoplasmosis, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (Coccidioidomycosis, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (CMV, Rare [1-2]) 0.969, 0.020, 0.010, 0.001;
  (Brucellosis, Rare [1-2]) 0.999, 0.001, 0.000, 0.000;
  (Ki-1 LC anaplas B, Rare [1-2]) 0.969, 0.020, 0.010, 0.001;
  (Intermed lymphocytic, Rare [1-2]) 0.9999, 0.0001, 0.0000, 0.0000;
  (AIDS early, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (AILD, Present [3-20]) 0.969, 0.020, 0.010, 0.001;
  (ALIP, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Cat scratch disease, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Dermatopathic laden, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Florid follic hyperp, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (GLH hyaline vascular, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (GLH plasma cell, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Granulomatous laden, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Histiocytosis x, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Infectious mono, Present [3-20]) 0.959, 0.030, 0.010, 0.001;
  (Leprosy-lepromatous, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Lymphangiographic, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Mantle zone hyperpla, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Necrotizing Kikuchi, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Necrotiz non-Kikuchi, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Rheumatoid arthritis, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Sarcoidosis, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (SHML, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Sinus histiocytosis, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Syphilis, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Toxoplasmosis, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Tuberculosis, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Viral NOS, Present [3-20]) 0.96, 0.03, 0.01, 0.00;
  (Whipple's disease, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (L&H nodular HD, Present [3-20]) 0.01, 0.98, 0.01, 0.00;
  (L&H diffuse HD, Present [3-20]) 0.01, 0.98, 0.01, 0.00;
  (Nodular sclerosis HD, Present [3-20]) 0.00, 0.02, 0.83, 0.15;
  (Cellular phase NSHD, Present [3-20]) 0.00, 0.02, 0.83, 0.15;
  (Syncytial NSHD, Present [3-20]) 0.00, 0.02, 0.83, 0.15;
  (Mixed cellularity HD, Present [3-20]) 0.00, 0.01, 0.84, 0.15;
  (Interfollicular HD, Present [3-20]) 0.00, 0.05, 0.83, 0.12;
  (Diffuse fibrosis HD, Present [3-20]) 0.00, 0.02, 0.15, 0.83;
  (Reticular-type HD, Present [3-20]) 0.00, 0.00, 0.15, 0.85;
  (Small cleaved fol, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Mixed fol, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Large cell fol, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Small noncleaved fol, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Small lymphocytic, Present [3-20]) 0.939, 0.040, 0.020, 0.001;
  (Plasmacytoid lyctic, Present [3-20]) 0.969, 0.020, 0.010, 0.001;
  (Mantle zone lymphoma, Present [3-20]) 0.969, 0.020, 0.010, 0.001;
  (Small cleaved dif, Present [3-20]) 0.969, 0.020, 0.010, 0.001;
  (Mixed FCC dif, Present [3-20]) 0.969, 0.020, 0.010, 0.001;
  (Large cell dif, Present [3-20]) 0.969, 0.020, 0.010, 0.001;
  (B-immunoblastic, Present [3-20]) 0.88, 0.07, 0.04, 0.01;
  (T-immunob mixed, Present [3-20]) 0.969, 0.020, 0.010, 0.001;
  (AILD-like T-cell lym, Present [3-20]) 0.969, 0.020, 0.010, 0.001;
  (Japanese ATL, Present [3-20]) 0.969, 0.020, 0.010, 0.001;
  (Lymphoblastic, Present [3-20]) 0.969, 0.020, 0.010, 0.001;
  (Small noncleaved dif, Present [3-20]) 0.969, 0.020, 0.010, 0.001;
  (True histiocytic, Present [3-20]) 0.969, 0.020, 0.010, 0.001;
  (Ki-1 LC anaplas T, Present [3-20]) 0.969, 0.020, 0.010, 0.001;
  (Multiple myeloma, Present [3-20]) 0.30, 0.35, 0.25, 0.10;
  (Mycosis fungoides, Present [3-20]) 0.969, 0.020, 0.010, 0.001;
  (AML, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Hairy cell leukemia, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Carcinoma, Present [3-20]) 0.59, 0.30, 0.10, 0.01;
  (Melanoma, Present [3-20]) 0.59, 0.30, 0.10, 0.01;
  (EM plasmacytoma, Present [3-20]) 0.60, 0.25, 0.10, 0.05;
  (Kaposi's sarcoma, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Mast-cell disease, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (AIDS involutionary, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (T-immunob large, Present [3-20]) 0.969, 0.020, 0.010, 0.001;
  (Monocytoid B-cell, Present [3-20]) 0.969, 0.020, 0.010, 0.001;
  (Nasopharyngeal CA, Present [3-20]) 0.59, 0.30, 0.10, 0.01;
  (Seminoma, Present [3-20]) 0.59, 0.30, 0.10, 0.01;
  (SLE, Present [3-20]) 0.96, 0.03, 0.01, 0.00;
  (Mycobact histiocytos, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Mast-cell hyperplas, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (LGV, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Histoplasmosis, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Coccidioidomycosis, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (CMV, Present [3-20]) 0.969, 0.020, 0.010, 0.001;
  (Brucellosis, Present [3-20]) 0.25, 0.25, 0.25, 0.25;
  (Ki-1 LC anaplas B, Present [3-20]) 0.969, 0.020, 0.010, 0.001;
  (Intermed lymphocytic, Present [3-20]) 0.969, 0.020, 0.010, 0.001;
  (AIDS early, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (AILD, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (ALIP, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Cat scratch disease, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Dermatopathic laden, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Florid follic hyperp, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (GLH hyaline vascular, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (GLH plasma cell, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Granulomatous laden, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Histiocytosis x, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Infectious mono, Many [>20]) 0.01, 0.93, 0.05, 0.01;
  (Leprosy-lepromatous, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Lymphangiographic, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Mantle zone hyperpla, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Necrotizing Kikuchi, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Necrotiz non-Kikuchi, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Rheumatoid arthritis, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Sarcoidosis, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (SHML, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Sinus histiocytosis, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Syphilis, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Toxoplasmosis, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Tuberculosis, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Viral NOS, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Whipple's disease, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (L&H nodular HD, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (L&H diffuse HD, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Nodular sclerosis HD, Many [>20]) 0.000000000, 0.000999001, 0.749250749, 0.249750250;
  (Cellular phase NSHD, Many [>20]) 0.000000000, 0.000999001, 0.749250749, 0.249750250;
  (Syncytial NSHD, Many [>20]) 0.000000000, 0.000999001, 0.749250749, 0.249750250;
  (Mixed cellularity HD, Many [>20]) 0.00, 0.00, 0.65, 0.35;
  (Interfollicular HD, Many [>20]) 0.00, 0.05, 0.80, 0.15;
  (Diffuse fibrosis HD, Many [>20]) 0.000000000, 0.000999001, 0.099900100, 0.899100899;
  (Reticular-type HD, Many [>20]) 0.00000000, 0.00009999, 0.04999500, 0.94990501;
  (Small cleaved fol, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Mixed fol, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Large cell fol, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Small noncleaved fol, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Small lymphocytic, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Plasmacytoid lyctic, Many [>20]) 0.80, 0.10, 0.09, 0.01;
  (Mantle zone lymphoma, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Small cleaved dif, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Mixed FCC dif, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Large cell dif, Many [>20]) 0.925, 0.050, 0.020, 0.005;
  (B-immunoblastic, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (T-immunob mixed, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (AILD-like T-cell lym, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Japanese ATL, Many [>20]) 0.969, 0.020, 0.010, 0.001;
  (Lymphoblastic, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Small noncleaved dif, Many [>20]) 0.925, 0.050, 0.020, 0.005;
  (True histiocytic, Many [>20]) 0.925, 0.050, 0.020, 0.005;
  (Ki-1 LC anaplas T, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Multiple myeloma, Many [>20]) 0.000000000, 0.000999001, 0.599400599, 0.399600400;
  (Mycosis fungoides, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (AML, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Hairy cell leukemia, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Carcinoma, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Melanoma, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (EM plasmacytoma, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Kaposi's sarcoma, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Mast-cell disease, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (AIDS involutionary, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (T-immunob large, Many [>20]) 0.969, 0.020, 0.010, 0.001;
  (Monocytoid B-cell, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Nasopharyngeal CA, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Seminoma, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (SLE, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Mycobact histiocytos, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Mast-cell hyperplas, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (LGV, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Histoplasmosis, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Coccidioidomycosis, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (CMV, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Brucellosis, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Ki-1 LC anaplas B, Many [>20]) 0.25, 0.25, 0.25, 0.25;
  (Intermed lymphocytic, Many [>20]) 0.25, 0.25, 0.25, 0.25;
}
probability ( MOT_HIST | Fault ) {
  (AIDS early) 0.64, 0.25, 0.10, 0.01;
  (AILD) 0.82, 0.10, 0.05, 0.03;
  (ALIP) 0.82, 0.10, 0.05, 0.03;
  (Cat scratch disease) 0.64, 0.25, 0.10, 0.01;
  (Dermatopathic laden) 0.05, 0.30, 0.55, 0.10;
  (Florid follic hyperp) 0.64, 0.25, 0.10, 0.01;
  (GLH hyaline vascular) 0.9699, 0.0200, 0.0100, 0.0001;
  (GLH plasma cell) 0.9699, 0.0200, 0.0100, 0.0001;
  (Granulomatous laden) 0.64, 0.25, 0.10, 0.01;
  (Histiocytosis x) 0.9699, 0.0200, 0.0100, 0.0001;
  (Infectious mono) 0.84, 0.10, 0.05, 0.01;
  (Leprosy-lepromatous) 0.64, 0.25, 0.10, 0.01;
  (Lymphangiographic) 0.9699, 0.0200, 0.0100, 0.0001;
  (Mantle zone hyperpla) 0.9699, 0.0200, 0.0100, 0.0001;
  (Necrotizing Kikuchi) 0.64, 0.25, 0.10, 0.01;
  (Necrotiz non-Kikuchi) 0.64, 0.25, 0.10, 0.01;
  (Rheumatoid arthritis) 0.9699, 0.0200, 0.0100, 0.0001;
  (Sarcoidosis) 0.9699, 0.0200, 0.0100, 0.0001;
  (SHML) 0.9699, 0.0200, 0.0100, 0.0001;
  (Sinus histiocytosis) 0.9699, 0.0200, 0.0100, 0.0001;
  (Syphilis) 0.64, 0.25, 0.10, 0.01;
  (Toxoplasmosis) 0.9699, 0.0200, 0.0100, 0.0001;
  (Tuberculosis) 0.9699, 0.0200, 0.0100, 0.0001;
  (Viral NOS) 0.84, 0.10, 0.05, 0.01;
  (Whipple's disease) 0.9699, 0.0200, 0.0100, 0.0001;
  (L&H nodular HD) 0.9699, 0.0200, 0.0100, 0.0001;
  (L&H diffuse HD) 0.9699, 0.0200, 0.0100, 0.0001;
  (Nodular sclerosis HD) 0.9699, 0.0200, 0.0100, 0.0001;
  (Cellular phase NSHD) 0.9699, 0.0200, 0.0100, 0.0001;
  (Syncytial NSHD) 0.9699, 0.0200, 0.0100, 0.0001;
  (Mixed cellularity HD) 0.9699, 0.0200, 0.0100, 0.0001;
  (Interfollicular HD) 0.9699, 0.0200, 0.0100, 0.0001;
  (Diffuse fibrosis HD) 0.9699, 0.0200, 0.0100, 0.0001;
  (Reticular-type HD) 0.9699, 0.0200, 0.0100, 0.0001;
  (Small cleaved fol) 0.9699, 0.0200, 0.0100, 0.0001;
  (Mixed fol) 0.9699, 0.0200, 0.0100, 0.0001;
  (Large cell fol) 0.9699, 0.0200, 0.0100, 0.0001;
  (Small noncleaved fol) 0.9699, 0.0200, 0.0100, 0.0001;
  (Small lymphocytic) 0.9699, 0.0200, 0.0100, 0.0001;
  (Plasmacytoid lyctic) 0.9699, 0.0200, 0.0100, 0.0001;
  (Mantle zone lymphoma) 0.9699, 0.0200, 0.0100, 0.0001;
  (Small cleaved dif) 0.9699, 0.0200, 0.0100, 0.0001;
  (Mixed FCC dif) 0.9699, 0.0200, 0.0100, 0.0001;
  (Large cell dif) 0.9699, 0.0200, 0.0100, 0.0001;
  (B-immunoblastic) 0.9699, 0.0200, 0.0100, 0.0001;
  (T-immunob mixed) 0.9699, 0.0200, 0.0100, 0.0001;
  (AILD-like T-cell lym) 0.82, 0.10, 0.05, 0.03;
  (Japanese ATL) 0.35, 0.20, 0.40, 0.05;
  (Lymphoblastic) 0.9699, 0.0200, 0.0100, 0.0001;
  (Small noncleaved dif) 0.9699, 0.0200, 0.0100, 0.0001;
  (True histiocytic) 0.9699, 0.0200, 0.0100, 0.0001;
  (Ki-1 LC anaplas T) 0.9699, 0.0200, 0.0100, 0.0001;
  (Multiple myeloma) 0.9699, 0.0200, 0.0100, 0.0001;
  (Mycosis fungoides) 0.15, 0.35, 0.45, 0.05;
  (AML) 0.9699, 0.0200, 0.0100, 0.0001;
  (Hairy cell leukemia) 0.9699, 0.0200, 0.0100, 0.0001;
  (Carcinoma) 0.9699, 0.0200, 0.0100, 0.0001;
  (Melanoma) 0.64, 0.25, 0.10, 0.01;
  (EM plasmacytoma) 0.9699, 0.0200, 0.0100, 0.0001;
  (Kaposi's sarcoma) 0.64, 0.25, 0.10, 0.01;
  (Mast-cell disease) 0.9699, 0.0200, 0.0100, 0.0001;
  (AIDS involutionary) 0.64, 0.25, 0.10, 0.01;
  (T-immunob large) 0.9699, 0.0200, 0.0100, 0.0001;
  (Monocytoid B-cell) 0.9699, 0.0200, 0.0100, 0.0001;
  (Nasopharyngeal CA) 0.9699, 0.0200, 0.0100, 0.0001;
  (Seminoma) 0.9699, 0.0200, 0.0100, 0.0001;
  (SLE) 0.84, 0.10, 0.05, 0.01;
  (Mycobact histiocytos) 0.9699, 0.0200, 0.0100, 0.0001;
  (Mast-cell hyperplas) 0.9699, 0.0200, 0.0100, 0.0001;
  (LGV) 0.64, 0.25, 0.10, 0.01;
  (Histoplasmosis) 0.64, 0.25, 0.10, 0.01;
  (Coccidioidomycosis) 0.64, 0.25, 0.10, 0.01;
  (CMV) 0.64, 0.25, 0.10, 0.01;
  (Brucellosis) 0.9699, 0.0200, 0.0100, 0.0001;
  (Ki-1 LC anaplas B) 0.9699, 0.0200, 0.0100, 0.0001;
  (Intermed lymphocytic) 0.9699, 0.0200, 0.0100, 0.0001;
}
probability ( MOT_LLC | Fault, LLC ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, Sparse [<10pc]) 0.885, 0.100, 0.010, 0.005;
  (AILD, Sparse [<10pc]) 0.939, 0.050, 0.010, 0.001;
  (ALIP, Sparse [<10pc]) 0.939, 0.050, 0.010, 0.001;
  (Cat scratch disease, Sparse [<10pc]) 0.42, 0.45, 0.08, 0.05;
  (Dermatopathic laden, Sparse [<10pc]) 0.939, 0.050, 0.010, 0.001;
  (Florid follic hyperp, Sparse [<10pc]) 0.885, 0.100, 0.010, 0.005;
  (GLH hyaline vascular, Sparse [<10pc]) 0.885, 0.100, 0.010, 0.005;
  (GLH plasma cell, Sparse [<10pc]) 0.885, 0.100, 0.010, 0.005;
  (Granulomatous laden, Sparse [<10pc]) 0.42, 0.45, 0.08, 0.05;
  (Histiocytosis x, Sparse [<10pc]) 0.939, 0.050, 0.010, 0.001;
  (Infectious mono, Sparse [<10pc]) 0.01, 0.20, 0.64, 0.15;
  (Leprosy-lepromatous, Sparse [<10pc]) 0.939, 0.050, 0.010, 0.001;
  (Lymphangiographic, Sparse [<10pc]) 0.939, 0.050, 0.010, 0.001;
  (Mantle zone hyperpla, Sparse [<10pc]) 0.939, 0.050, 0.010, 0.001;
  (Necrotizing Kikuchi, Sparse [<10pc]) 0.01, 0.20, 0.64, 0.15;
  (Necrotiz non-Kikuchi, Sparse [<10pc]) 0.42, 0.45, 0.08, 0.05;
  (Rheumatoid arthritis, Sparse [<10pc]) 0.885, 0.100, 0.010, 0.005;
  (Sarcoidosis, Sparse [<10pc]) 0.939, 0.050, 0.010, 0.001;
  (SHML, Sparse [<10pc]) 0.939, 0.050, 0.010, 0.001;
  (Sinus histiocytosis, Sparse [<10pc]) 0.939, 0.050, 0.010, 0.001;
  (Syphilis, Sparse [<10pc]) 0.939, 0.050, 0.010, 0.001;
  (Toxoplasmosis, Sparse [<10pc]) 0.885, 0.100, 0.010, 0.005;
  (Tuberculosis, Sparse [<10pc]) 0.939, 0.050, 0.010, 0.001;
  (Viral NOS, Sparse [<10pc]) 0.01, 0.20, 0.64, 0.15;
  (Whipple's disease, Sparse [<10pc]) 0.939, 0.050, 0.010, 0.001;
  (L&H nodular HD, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (L&H diffuse HD, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Nodular sclerosis HD, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Cellular phase NSHD, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Syncytial NSHD, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Mixed cellularity HD, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Interfollicular HD, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Diffuse fibrosis HD, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Reticular-type HD, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Small cleaved fol, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Mixed fol, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Large cell fol, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Small noncleaved fol, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Small lymphocytic, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Plasmacytoid lyctic, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Mantle zone lymphoma, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Small cleaved dif, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Mixed FCC dif, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Large cell dif, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (B-immunoblastic, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (T-immunob mixed, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (AILD-like T-cell lym, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Japanese ATL, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Lymphoblastic, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Small noncleaved dif, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (True histiocytic, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Ki-1 LC anaplas T, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Multiple myeloma, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Mycosis fungoides, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (AML, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Hairy cell leukemia, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Carcinoma, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Melanoma, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (EM plasmacytoma, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Kaposi's sarcoma, Sparse [<10pc]) 0.885, 0.100, 0.010, 0.005;
  (Mast-cell disease, Sparse [<10pc]) 0.989, 0.010, 0.001, 0.000;
  (AIDS involutionary, Sparse [<10pc]) 0.885, 0.100, 0.010, 0.005;
  (T-immunob large, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Monocytoid B-cell, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Nasopharyngeal CA, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Seminoma, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (SLE, Sparse [<10pc]) 0.01, 0.20, 0.64, 0.15;
  (Mycobact histiocytos, Sparse [<10pc]) 0.939, 0.050, 0.010, 0.001;
  (Mast-cell hyperplas, Sparse [<10pc]) 0.989, 0.010, 0.001, 0.000;
  (LGV, Sparse [<10pc]) 0.939, 0.050, 0.010, 0.001;
  (Histoplasmosis, Sparse [<10pc]) 0.939, 0.050, 0.010, 0.001;
  (Coccidioidomycosis, Sparse [<10pc]) 0.885, 0.100, 0.010, 0.005;
  (CMV, Sparse [<10pc]) 0.885, 0.100, 0.010, 0.005;
  (Brucellosis, Sparse [<10pc]) 0.885, 0.100, 0.010, 0.005;
  (Ki-1 LC anaplas B, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (Intermed lymphocytic, Sparse [<10pc]) 0.999, 0.001, 0.000, 0.000;
  (AIDS early, Moderate [11-50pc]) 0.885, 0.100, 0.010, 0.005;
  (AILD, Moderate [11-50pc]) 0.939, 0.050, 0.010, 0.001;
  (ALIP, Moderate [11-50pc]) 0.939, 0.050, 0.010, 0.001;
  (Cat scratch disease, Moderate [11-50pc]) 0.42, 0.45, 0.08, 0.05;
  (Dermatopathic laden, Moderate [11-50pc]) 0.939, 0.050, 0.010, 0.001;
  (Florid follic hyperp, Moderate [11-50pc]) 0.885, 0.100, 0.010, 0.005;
  (GLH hyaline vascular, Moderate [11-50pc]) 0.885, 0.100, 0.010, 0.005;
  (GLH plasma cell, Moderate [11-50pc]) 0.885, 0.100, 0.010, 0.005;
  (Granulomatous laden, Moderate [11-50pc]) 0.42, 0.45, 0.08, 0.05;
  (Histiocytosis x, Moderate [11-50pc]) 0.939, 0.050, 0.010, 0.001;
  (Infectious mono, Moderate [11-50pc]) 0.01, 0.20, 0.64, 0.15;
  (Leprosy-lepromatous, Moderate [11-50pc]) 0.939, 0.050, 0.010, 0.001;
  (Lymphangiographic, Moderate [11-50pc]) 0.939, 0.050, 0.010, 0.001;
  (Mantle zone hyperpla, Moderate [11-50pc]) 0.939, 0.050, 0.010, 0.001;
  (Necrotizing Kikuchi, Moderate [11-50pc]) 0.01, 0.20, 0.64, 0.15;
  (Necrotiz non-Kikuchi, Moderate [11-50pc]) 0.42, 0.45, 0.08, 0.05;
  (Rheumatoid arthritis, Moderate [11-50pc]) 0.885, 0.100, 0.010, 0.005;
  (Sarcoidosis, Moderate [11-50pc]) 0.939, 0.050, 0.010, 0.001;
  (SHML, Moderate [11-50pc]) 0.939, 0.050, 0.010, 0.001;
  (Sinus histiocytosis, Moderate [11-50pc]) 0.939, 0.050, 0.010, 0.001;
  (Syphilis, Moderate [11-50pc]) 0.939, 0.050, 0.010, 0.001;
  (Toxoplasmosis, Moderate [11-50pc]) 0.885, 0.100, 0.010, 0.005;
  (Tuberculosis, Moderate [11-50pc]) 0.939, 0.050, 0.010, 0.001;
  (Viral NOS, Moderate [11-50pc]) 0.01, 0.20, 0.64, 0.15;
  (Whipple's disease, Moderate [11-50pc]) 0.939, 0.050, 0.010, 0.001;
  (L&H nodular HD, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (L&H diffuse HD, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Nodular sclerosis HD, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Cellular phase NSHD, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Syncytial NSHD, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Mixed cellularity HD, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Interfollicular HD, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Diffuse fibrosis HD, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Reticular-type HD, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Small cleaved fol, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Mixed fol, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Large cell fol, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Small noncleaved fol, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Small lymphocytic, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Plasmacytoid lyctic, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Mantle zone lymphoma, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Small cleaved dif, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Mixed FCC dif, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Large cell dif, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (B-immunoblastic, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (T-immunob mixed, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (AILD-like T-cell lym, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Japanese ATL, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Lymphoblastic, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Small noncleaved dif, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (True histiocytic, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Ki-1 LC anaplas T, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Multiple myeloma, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Mycosis fungoides, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (AML, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Hairy cell leukemia, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Carcinoma, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Melanoma, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (EM plasmacytoma, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Kaposi's sarcoma, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Mast-cell disease, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (AIDS involutionary, Moderate [11-50pc]) 0.885, 0.100, 0.010, 0.005;
  (T-immunob large, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Monocytoid B-cell, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Nasopharyngeal CA, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Seminoma, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (SLE, Moderate [11-50pc]) 0.01, 0.20, 0.64, 0.15;
  (Mycobact histiocytos, Moderate [11-50pc]) 0.939, 0.050, 0.010, 0.001;
  (Mast-cell hyperplas, Moderate [11-50pc]) 0.939, 0.050, 0.010, 0.001;
  (LGV, Moderate [11-50pc]) 0.939, 0.050, 0.010, 0.001;
  (Histoplasmosis, Moderate [11-50pc]) 0.939, 0.050, 0.010, 0.001;
  (Coccidioidomycosis, Moderate [11-50pc]) 0.885, 0.100, 0.010, 0.005;
  (CMV, Moderate [11-50pc]) 0.885, 0.100, 0.010, 0.005;
  (Brucellosis, Moderate [11-50pc]) 0.885, 0.100, 0.010, 0.005;
  (Ki-1 LC anaplas B, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (Intermed lymphocytic, Moderate [11-50pc]) 0.999, 0.001, 0.000, 0.000;
  (AIDS early, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (AILD, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (ALIP, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Cat scratch disease, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Dermatopathic laden, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Florid follic hyperp, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Histiocytosis x, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, Numerous [51-90pc]) 0.879, 0.100, 0.020, 0.001;
  (Leprosy-lepromatous, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Numerous [51-90pc]) 0.879, 0.100, 0.020, 0.001;
  (Necrotiz non-Kikuchi, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Rheumatoid arthritis, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (SHML, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, Numerous [51-90pc]) 0.879, 0.100, 0.020, 0.001;
  (Whipple's disease, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (AML, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (T-immunob large, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (SLE, Numerous [51-90pc]) 0.879, 0.100, 0.020, 0.001;
  (Mycobact histiocytos, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (LGV, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (CMV, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Numerous [51-90pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (ALIP, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (SHML, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (AML, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (SLE, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (LGV, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (CMV, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Striking [>90pc]) 1.0, 0.0, 0.0, 0.0;
}
probability ( MUMMY | Fault ) {
  (AIDS early) 0.999, 0.001, 0.000, 0.000;
  (AILD) 0.985, 0.010, 0.005, 0.000;
  (ALIP) 0.999, 0.001, 0.000, 0.000;
  (Cat scratch disease) 0.999, 0.001, 0.000, 0.000;
  (Dermatopathic laden) 0.999, 0.001, 0.000, 0.000;
  (Florid follic hyperp) 0.999, 0.001, 0.000, 0.000;
  (GLH hyaline vascular) 0.999, 0.001, 0.000, 0.000;
  (GLH plasma cell) 0.999, 0.001, 0.000, 0.000;
  (Granulomatous laden) 0.999, 0.001, 0.000, 0.000;
  (Histiocytosis x) 0.999, 0.001, 0.000, 0.000;
  (Infectious mono) 0.959, 0.030, 0.010, 0.001;
  (Leprosy-lepromatous) 0.999, 0.001, 0.000, 0.000;
  (Lymphangiographic) 0.999, 0.001, 0.000, 0.000;
  (Mantle zone hyperpla) 0.999, 0.001, 0.000, 0.000;
  (Necrotizing Kikuchi) 0.999, 0.001, 0.000, 0.000;
  (Necrotiz non-Kikuchi) 0.999, 0.001, 0.000, 0.000;
  (Rheumatoid arthritis) 0.999, 0.001, 0.000, 0.000;
  (Sarcoidosis) 0.999, 0.001, 0.000, 0.000;
  (SHML) 0.999, 0.001, 0.000, 0.000;
  (Sinus histiocytosis) 0.999, 0.001, 0.000, 0.000;
  (Syphilis) 0.999, 0.001, 0.000, 0.000;
  (Toxoplasmosis) 0.999, 0.001, 0.000, 0.000;
  (Tuberculosis) 0.999, 0.001, 0.000, 0.000;
  (Viral NOS) 0.985, 0.010, 0.005, 0.000;
  (Whipple's disease) 0.999, 0.001, 0.000, 0.000;
  (L&H nodular HD) 0.80, 0.19, 0.01, 0.00;
  (L&H diffuse HD) 0.80, 0.19, 0.01, 0.00;
  (Nodular sclerosis HD) 0.25, 0.50, 0.20, 0.05;
  (Cellular phase NSHD) 0.25, 0.50, 0.20, 0.05;
  (Syncytial NSHD) 0.25, 0.50, 0.20, 0.05;
  (Mixed cellularity HD) 0.35, 0.50, 0.10, 0.05;
  (Interfollicular HD) 0.30, 0.60, 0.07, 0.03;
  (Diffuse fibrosis HD) 0.70, 0.15, 0.10, 0.05;
  (Reticular-type HD) 0.70, 0.15, 0.10, 0.05;
  (Small cleaved fol) 0.999, 0.001, 0.000, 0.000;
  (Mixed fol) 0.999, 0.001, 0.000, 0.000;
  (Large cell fol) 0.999, 0.001, 0.000, 0.000;
  (Small noncleaved fol) 0.999, 0.001, 0.000, 0.000;
  (Small lymphocytic) 0.985, 0.010, 0.005, 0.000;
  (Plasmacytoid lyctic) 0.985, 0.010, 0.005, 0.000;
  (Mantle zone lymphoma) 0.985, 0.010, 0.005, 0.000;
  (Small cleaved dif) 0.985, 0.010, 0.005, 0.000;
  (Mixed FCC dif) 0.985, 0.010, 0.005, 0.000;
  (Large cell dif) 0.985, 0.010, 0.005, 0.000;
  (B-immunoblastic) 0.98, 0.01, 0.01, 0.00;
  (T-immunob mixed) 0.98, 0.01, 0.01, 0.00;
  (AILD-like T-cell lym) 0.985, 0.010, 0.005, 0.000;
  (Japanese ATL) 0.949, 0.030, 0.020, 0.001;
  (Lymphoblastic) 0.985, 0.010, 0.005, 0.000;
  (Small noncleaved dif) 0.985, 0.010, 0.005, 0.000;
  (True histiocytic) 0.985, 0.010, 0.005, 0.000;
  (Ki-1 LC anaplas T) 0.98, 0.01, 0.01, 0.00;
  (Multiple myeloma) 0.79, 0.15, 0.05, 0.01;
  (Mycosis fungoides) 0.999, 0.001, 0.000, 0.000;
  (AML) 0.999, 0.001, 0.000, 0.000;
  (Hairy cell leukemia) 0.999, 0.001, 0.000, 0.000;
  (Carcinoma) 0.9985, 0.0010, 0.0005, 0.0000;
  (Melanoma) 0.9985, 0.0010, 0.0005, 0.0000;
  (EM plasmacytoma) 0.999, 0.001, 0.000, 0.000;
  (Kaposi's sarcoma) 0.999, 0.001, 0.000, 0.000;
  (Mast-cell disease) 0.999, 0.001, 0.000, 0.000;
  (AIDS involutionary) 0.999, 0.001, 0.000, 0.000;
  (T-immunob large) 0.949, 0.030, 0.020, 0.001;
  (Monocytoid B-cell) 0.985, 0.010, 0.005, 0.000;
  (Nasopharyngeal CA) 0.9985, 0.0010, 0.0005, 0.0000;
  (Seminoma) 0.9985, 0.0010, 0.0005, 0.0000;
  (SLE) 0.96, 0.03, 0.01, 0.00;
  (Mycobact histiocytos) 0.999, 0.001, 0.000, 0.000;
  (Mast-cell hyperplas) 0.999, 0.001, 0.000, 0.000;
  (LGV) 0.999, 0.001, 0.000, 0.000;
  (Histoplasmosis) 0.999, 0.001, 0.000, 0.000;
  (Coccidioidomycosis) 0.999, 0.001, 0.000, 0.000;
  (CMV) 0.97, 0.02, 0.01, 0.00;
  (Brucellosis) 0.999, 0.001, 0.000, 0.000;
  (Ki-1 LC anaplas B) 0.98, 0.01, 0.01, 0.00;
  (Intermed lymphocytic) 0.985, 0.010, 0.005, 0.000;
}
probability ( NECR | Fault ) {
  (AIDS early) 0.99, 0.01, 0.00, 0.00;
  (AILD) 0.99, 0.01, 0.00, 0.00;
  (ALIP) 0.99, 0.01, 0.00, 0.00;
  (Cat scratch disease) 0.05, 0.35, 0.55, 0.05;
  (Dermatopathic laden) 0.99, 0.01, 0.00, 0.00;
  (Florid follic hyperp) 0.99, 0.01, 0.00, 0.00;
  (GLH hyaline vascular) 0.99, 0.01, 0.00, 0.00;
  (GLH plasma cell) 0.99, 0.01, 0.00, 0.00;
  (Granulomatous laden) 0.4, 0.2, 0.2, 0.2;
  (Histiocytosis x) 0.25, 0.50, 0.20, 0.05;
  (Infectious mono) 0.91, 0.05, 0.03, 0.01;
  (Leprosy-lepromatous) 0.92, 0.05, 0.02, 0.01;
  (Lymphangiographic) 0.99, 0.01, 0.00, 0.00;
  (Mantle zone hyperpla) 0.99, 0.01, 0.00, 0.00;
  (Necrotizing Kikuchi) 0.3, 0.1, 0.4, 0.2;
  (Necrotiz non-Kikuchi) 0.0, 0.1, 0.3, 0.6;
  (Rheumatoid arthritis) 0.99, 0.01, 0.00, 0.00;
  (Sarcoidosis) 0.99, 0.01, 0.00, 0.00;
  (SHML) 0.99, 0.01, 0.00, 0.00;
  (Sinus histiocytosis) 0.99, 0.01, 0.00, 0.00;
  (Syphilis) 0.99, 0.01, 0.00, 0.00;
  (Toxoplasmosis) 0.99, 0.01, 0.00, 0.00;
  (Tuberculosis) 0.05, 0.30, 0.35, 0.30;
  (Viral NOS) 0.91, 0.05, 0.03, 0.01;
  (Whipple's disease) 0.92, 0.05, 0.02, 0.01;
  (L&H nodular HD) 0.989, 0.010, 0.001, 0.000;
  (L&H diffuse HD) 0.989, 0.010, 0.001, 0.000;
  (Nodular sclerosis HD) 0.49, 0.20, 0.30, 0.01;
  (Cellular phase NSHD) 0.49, 0.20, 0.30, 0.01;
  (Syncytial NSHD) 0.49, 0.20, 0.30, 0.01;
  (Mixed cellularity HD) 0.84158416, 0.12871287, 0.01980198, 0.00990099;
  (Interfollicular HD) 0.84158416, 0.12871287, 0.01980198, 0.00990099;
  (Diffuse fibrosis HD) 0.78, 0.10, 0.07, 0.05;
  (Reticular-type HD) 0.78, 0.10, 0.07, 0.05;
  (Small cleaved fol) 0.97, 0.01, 0.01, 0.01;
  (Mixed fol) 0.97, 0.01, 0.01, 0.01;
  (Large cell fol) 0.97, 0.01, 0.01, 0.01;
  (Small noncleaved fol) 0.97, 0.01, 0.01, 0.01;
  (Small lymphocytic) 0.94, 0.03, 0.02, 0.01;
  (Plasmacytoid lyctic) 0.94, 0.03, 0.02, 0.01;
  (Mantle zone lymphoma) 0.94, 0.03, 0.02, 0.01;
  (Small cleaved dif) 0.94, 0.03, 0.02, 0.01;
  (Mixed FCC dif) 0.94, 0.03, 0.02, 0.01;
  (Large cell dif) 0.88, 0.07, 0.03, 0.02;
  (B-immunoblastic) 0.88, 0.07, 0.03, 0.02;
  (T-immunob mixed) 0.88, 0.07, 0.03, 0.02;
  (AILD-like T-cell lym) 0.88, 0.07, 0.03, 0.02;
  (Japanese ATL) 0.88, 0.07, 0.03, 0.02;
  (Lymphoblastic) 0.88, 0.07, 0.03, 0.02;
  (Small noncleaved dif) 0.88, 0.07, 0.03, 0.02;
  (True histiocytic) 0.88, 0.07, 0.03, 0.02;
  (Ki-1 LC anaplas T) 0.88, 0.07, 0.03, 0.02;
  (Multiple myeloma) 0.88, 0.07, 0.03, 0.02;
  (Mycosis fungoides) 0.88, 0.07, 0.03, 0.02;
  (AML) 0.88, 0.07, 0.03, 0.02;
  (Hairy cell leukemia) 0.99, 0.01, 0.00, 0.00;
  (Carcinoma) 0.84, 0.10, 0.05, 0.01;
  (Melanoma) 0.84, 0.10, 0.05, 0.01;
  (EM plasmacytoma) 0.99, 0.01, 0.00, 0.00;
  (Kaposi's sarcoma) 0.99, 0.01, 0.00, 0.00;
  (Mast-cell disease) 0.94, 0.03, 0.02, 0.01;
  (AIDS involutionary) 0.99, 0.01, 0.00, 0.00;
  (T-immunob large) 0.88, 0.07, 0.03, 0.02;
  (Monocytoid B-cell) 0.97, 0.01, 0.01, 0.01;
  (Nasopharyngeal CA) 0.84, 0.10, 0.05, 0.01;
  (Seminoma) 0.84, 0.10, 0.05, 0.01;
  (SLE) 0.91, 0.05, 0.03, 0.01;
  (Mycobact histiocytos) 0.92, 0.05, 0.02, 0.01;
  (Mast-cell hyperplas) 0.99, 0.01, 0.00, 0.00;
  (LGV) 0.0, 0.1, 0.6, 0.3;
  (Histoplasmosis) 0.99, 0.01, 0.00, 0.00;
  (Coccidioidomycosis) 0.99, 0.01, 0.00, 0.00;
  (CMV) 0.99, 0.01, 0.00, 0.00;
  (Brucellosis) 0.99, 0.01, 0.00, 0.00;
  (Ki-1 LC anaplas B) 0.88, 0.07, 0.03, 0.02;
  (Intermed lymphocytic) 0.94, 0.03, 0.02, 0.01;
}
probability ( MA_NEUT | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 0.9, 0.1;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 0.95, 0.05;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 0.995, 0.005;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 0.9, 0.1;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 0.995, 0.005;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 0.995, 0.005;
  (Whipple's disease) 0.995, 0.005;
  (L&H nodular HD) 1.0, 0.0;
  (L&H diffuse HD) 1.0, 0.0;
  (Nodular sclerosis HD) 0.995, 0.005;
  (Cellular phase NSHD) 0.995, 0.005;
  (Syncytial NSHD) 0.995, 0.005;
  (Mixed cellularity HD) 0.995, 0.005;
  (Interfollicular HD) 0.995, 0.005;
  (Diffuse fibrosis HD) 1.0, 0.0;
  (Reticular-type HD) 1.0, 0.0;
  (Small cleaved fol) 1.0, 0.0;
  (Mixed fol) 1.0, 0.0;
  (Large cell fol) 1.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0;
  (Small lymphocytic) 1.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0;
  (Small cleaved dif) 1.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0;
  (Large cell dif) 1.0, 0.0;
  (B-immunoblastic) 1.0, 0.0;
  (T-immunob mixed) 1.0, 0.0;
  (AILD-like T-cell lym) 1.0, 0.0;
  (Japanese ATL) 1.0, 0.0;
  (Lymphoblastic) 1.0, 0.0;
  (Small noncleaved dif) 1.0, 0.0;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 1.0, 0.0;
  (Multiple myeloma) 1.0, 0.0;
  (Mycosis fungoides) 1.0, 0.0;
  (AML) 1.0, 0.0;
  (Hairy cell leukemia) 1.0, 0.0;
  (Carcinoma) 1.0, 0.0;
  (Melanoma) 1.0, 0.0;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0;
  (Mast-cell disease) 0.995, 0.005;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 1.0, 0.0;
  (Monocytoid B-cell) 0.97, 0.03;
  (Nasopharyngeal CA) 0.995, 0.005;
  (Seminoma) 1.0, 0.0;
  (SLE) 0.995, 0.005;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 0.995, 0.005;
  (LGV) 0.7, 0.3;
  (Histoplasmosis) 0.995, 0.005;
  (Coccidioidomycosis) 0.995, 0.005;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 1.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0;
}
probability ( NEUTRO | Fault ) {
  (AIDS early) 0.691, 0.300, 0.009;
  (AILD) 0.80, 0.19, 0.01;
  (ALIP) 0.691, 0.300, 0.009;
  (Cat scratch disease) 0.0, 0.6, 0.4;
  (Dermatopathic laden) 0.691, 0.300, 0.009;
  (Florid follic hyperp) 0.691, 0.300, 0.009;
  (GLH hyaline vascular) 0.691, 0.300, 0.009;
  (GLH plasma cell) 0.691, 0.300, 0.009;
  (Granulomatous laden) 0.1, 0.7, 0.2;
  (Histiocytosis x) 0.691, 0.300, 0.009;
  (Infectious mono) 0.37, 0.60, 0.03;
  (Leprosy-lepromatous) 0.691, 0.300, 0.009;
  (Lymphangiographic) 0.691, 0.300, 0.009;
  (Mantle zone hyperpla) 0.691, 0.300, 0.009;
  (Necrotizing Kikuchi) 0.89, 0.11, 0.00;
  (Necrotiz non-Kikuchi) 0.0, 0.6, 0.4;
  (Rheumatoid arthritis) 0.35, 0.60, 0.05;
  (Sarcoidosis) 0.691, 0.300, 0.009;
  (SHML) 0.691, 0.300, 0.009;
  (Sinus histiocytosis) 0.691, 0.300, 0.009;
  (Syphilis) 0.37, 0.60, 0.03;
  (Toxoplasmosis) 0.691, 0.300, 0.009;
  (Tuberculosis) 0.691, 0.300, 0.009;
  (Viral NOS) 0.37, 0.60, 0.03;
  (Whipple's disease) 0.691, 0.300, 0.009;
  (L&H nodular HD) 0.691, 0.300, 0.009;
  (L&H diffuse HD) 0.691, 0.300, 0.009;
  (Nodular sclerosis HD) 0.10, 0.85, 0.05;
  (Cellular phase NSHD) 0.10, 0.85, 0.05;
  (Syncytial NSHD) 0.10, 0.85, 0.05;
  (Mixed cellularity HD) 0.10, 0.85, 0.05;
  (Interfollicular HD) 0.10, 0.85, 0.05;
  (Diffuse fibrosis HD) 0.691, 0.300, 0.009;
  (Reticular-type HD) 0.691, 0.300, 0.009;
  (Small cleaved fol) 0.691, 0.300, 0.009;
  (Mixed fol) 0.691, 0.300, 0.009;
  (Large cell fol) 0.691, 0.300, 0.009;
  (Small noncleaved fol) 0.691, 0.300, 0.009;
  (Small lymphocytic) 0.691, 0.300, 0.009;
  (Plasmacytoid lyctic) 0.691, 0.300, 0.009;
  (Mantle zone lymphoma) 0.691, 0.300, 0.009;
  (Small cleaved dif) 0.691, 0.300, 0.009;
  (Mixed FCC dif) 0.691, 0.300, 0.009;
  (Large cell dif) 0.691, 0.300, 0.009;
  (B-immunoblastic) 0.691, 0.300, 0.009;
  (T-immunob mixed) 0.691, 0.300, 0.009;
  (AILD-like T-cell lym) 0.80, 0.19, 0.01;
  (Japanese ATL) 0.691, 0.300, 0.009;
  (Lymphoblastic) 0.691, 0.300, 0.009;
  (Small noncleaved dif) 0.691, 0.300, 0.009;
  (True histiocytic) 0.691, 0.300, 0.009;
  (Ki-1 LC anaplas T) 0.691, 0.300, 0.009;
  (Multiple myeloma) 0.691, 0.300, 0.009;
  (Mycosis fungoides) 0.691, 0.300, 0.009;
  (AML) 0.691, 0.300, 0.009;
  (Hairy cell leukemia) 0.691, 0.300, 0.009;
  (Carcinoma) 0.691, 0.300, 0.009;
  (Melanoma) 0.691, 0.300, 0.009;
  (EM plasmacytoma) 0.691, 0.300, 0.009;
  (Kaposi's sarcoma) 0.691, 0.300, 0.009;
  (Mast-cell disease) 0.05, 0.75, 0.20;
  (AIDS involutionary) 0.691, 0.300, 0.009;
  (T-immunob large) 0.691, 0.300, 0.009;
  (Monocytoid B-cell) 0.03, 0.77, 0.20;
  (Nasopharyngeal CA) 0.10, 0.85, 0.05;
  (Seminoma) 0.691, 0.300, 0.009;
  (SLE) 0.37, 0.60, 0.03;
  (Mycobact histiocytos) 0.60, 0.39, 0.01;
  (Mast-cell hyperplas) 0.05, 0.75, 0.20;
  (LGV) 0.0, 0.6, 0.4;
  (Histoplasmosis) 0.37, 0.60, 0.03;
  (Coccidioidomycosis) 0.37, 0.60, 0.03;
  (CMV) 0.37, 0.60, 0.03;
  (Brucellosis) 0.691, 0.300, 0.009;
  (Ki-1 LC anaplas B) 0.691, 0.300, 0.009;
  (Intermed lymphocytic) 0.691, 0.300, 0.009;
}
probability ( PAS | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 1.0, 0.0;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 1.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 0.0, 1.0;
  (L&H nodular HD) 1.0, 0.0;
  (L&H diffuse HD) 1.0, 0.0;
  (Nodular sclerosis HD) 1.0, 0.0;
  (Cellular phase NSHD) 1.0, 0.0;
  (Syncytial NSHD) 1.0, 0.0;
  (Mixed cellularity HD) 1.0, 0.0;
  (Interfollicular HD) 1.0, 0.0;
  (Diffuse fibrosis HD) 1.0, 0.0;
  (Reticular-type HD) 1.0, 0.0;
  (Small cleaved fol) 1.0, 0.0;
  (Mixed fol) 1.0, 0.0;
  (Large cell fol) 1.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0;
  (Small lymphocytic) 1.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0;
  (Small cleaved dif) 1.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0;
  (Large cell dif) 1.0, 0.0;
  (B-immunoblastic) 1.0, 0.0;
  (T-immunob mixed) 1.0, 0.0;
  (AILD-like T-cell lym) 1.0, 0.0;
  (Japanese ATL) 1.0, 0.0;
  (Lymphoblastic) 1.0, 0.0;
  (Small noncleaved dif) 1.0, 0.0;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 1.0, 0.0;
  (Multiple myeloma) 1.0, 0.0;
  (Mycosis fungoides) 1.0, 0.0;
  (AML) 1.0, 0.0;
  (Hairy cell leukemia) 1.0, 0.0;
  (Carcinoma) 1.0, 0.0;
  (Melanoma) 1.0, 0.0;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0;
  (Mast-cell disease) 1.0, 0.0;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 1.0, 0.0;
  (Monocytoid B-cell) 1.0, 0.0;
  (Nasopharyngeal CA) 1.0, 0.0;
  (Seminoma) 1.0, 0.0;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 1.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0;
}
probability ( PI | Fault ) {
  (AIDS early) 0.95, 0.04, 0.01;
  (AILD) 0.65, 0.30, 0.05;
  (ALIP) 0.95, 0.04, 0.01;
  (Cat scratch disease) 0.4, 0.5, 0.1;
  (Dermatopathic laden) 0.95, 0.04, 0.01;
  (Florid follic hyperp) 0.95, 0.04, 0.01;
  (GLH hyaline vascular) 0.95, 0.04, 0.01;
  (GLH plasma cell) 0.95, 0.04, 0.01;
  (Granulomatous laden) 0.85, 0.13, 0.02;
  (Histiocytosis x) 0.95, 0.04, 0.01;
  (Infectious mono) 0.55, 0.35, 0.10;
  (Leprosy-lepromatous) 0.95, 0.04, 0.01;
  (Lymphangiographic) 0.95, 0.04, 0.01;
  (Mantle zone hyperpla) 0.95, 0.04, 0.01;
  (Necrotizing Kikuchi) 0.4, 0.5, 0.1;
  (Necrotiz non-Kikuchi) 0.4, 0.5, 0.1;
  (Rheumatoid arthritis) 0.95, 0.04, 0.01;
  (Sarcoidosis) 0.95, 0.04, 0.01;
  (SHML) 0.95, 0.04, 0.01;
  (Sinus histiocytosis) 0.95, 0.04, 0.01;
  (Syphilis) 0.85, 0.13, 0.02;
  (Toxoplasmosis) 0.95, 0.04, 0.01;
  (Tuberculosis) 0.95, 0.04, 0.01;
  (Viral NOS) 0.70, 0.25, 0.05;
  (Whipple's disease) 0.95, 0.04, 0.01;
  (L&H nodular HD) 0.93, 0.05, 0.02;
  (L&H diffuse HD) 0.93, 0.05, 0.02;
  (Nodular sclerosis HD) 0.35, 0.45, 0.20;
  (Cellular phase NSHD) 0.35, 0.45, 0.20;
  (Syncytial NSHD) 0.35, 0.45, 0.20;
  (Mixed cellularity HD) 0.93, 0.05, 0.02;
  (Interfollicular HD) 0.93, 0.05, 0.02;
  (Diffuse fibrosis HD) 0.75, 0.20, 0.05;
  (Reticular-type HD) 0.75, 0.20, 0.05;
  (Small cleaved fol) 0.5, 0.4, 0.1;
  (Mixed fol) 0.5, 0.4, 0.1;
  (Large cell fol) 0.30, 0.55, 0.15;
  (Small noncleaved fol) 0.30, 0.55, 0.15;
  (Small lymphocytic) 0.60, 0.25, 0.15;
  (Plasmacytoid lyctic) 0.7, 0.2, 0.1;
  (Mantle zone lymphoma) 0.7, 0.2, 0.1;
  (Small cleaved dif) 0.6, 0.3, 0.1;
  (Mixed FCC dif) 0.6, 0.3, 0.1;
  (Large cell dif) 0.2, 0.6, 0.2;
  (B-immunoblastic) 0.2, 0.6, 0.2;
  (T-immunob mixed) 0.2, 0.6, 0.2;
  (AILD-like T-cell lym) 0.2, 0.6, 0.2;
  (Japanese ATL) 0.2, 0.6, 0.2;
  (Lymphoblastic) 0.2, 0.6, 0.2;
  (Small noncleaved dif) 0.2, 0.6, 0.2;
  (True histiocytic) 0.2, 0.6, 0.2;
  (Ki-1 LC anaplas T) 0.2, 0.6, 0.2;
  (Multiple myeloma) 0.2, 0.6, 0.2;
  (Mycosis fungoides) 0.2, 0.6, 0.2;
  (AML) 0.2, 0.6, 0.2;
  (Hairy cell leukemia) 0.90, 0.09, 0.01;
  (Carcinoma) 0.90, 0.09, 0.01;
  (Melanoma) 0.90, 0.09, 0.01;
  (EM plasmacytoma) 0.80, 0.15, 0.05;
  (Kaposi's sarcoma) 0.3, 0.4, 0.3;
  (Mast-cell disease) 0.80, 0.15, 0.05;
  (AIDS involutionary) 0.95, 0.04, 0.01;
  (T-immunob large) 0.2, 0.6, 0.2;
  (Monocytoid B-cell) 0.5, 0.4, 0.1;
  (Nasopharyngeal CA) 0.90, 0.09, 0.01;
  (Seminoma) 0.90, 0.09, 0.01;
  (SLE) 0.55, 0.35, 0.10;
  (Mycobact histiocytos) 0.95, 0.04, 0.01;
  (Mast-cell hyperplas) 0.80, 0.15, 0.05;
  (LGV) 0.4, 0.5, 0.1;
  (Histoplasmosis) 0.95, 0.04, 0.01;
  (Coccidioidomycosis) 0.95, 0.04, 0.01;
  (CMV) 0.95, 0.04, 0.01;
  (Brucellosis) 0.95, 0.04, 0.01;
  (Ki-1 LC anaplas B) 0.2, 0.6, 0.2;
  (Intermed lymphocytic) 0.7, 0.2, 0.1;
}
probability ( PLASMA | Fault, MOT_HIST ) {
  (AIDS early, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (AILD, Absent) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (ALIP, Absent) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (Cat scratch disease, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Dermatopathic laden, Absent) 0.005, 0.250, 0.695, 0.050, 0.000, 0.000;
  (Florid follic hyperp, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (GLH hyaline vascular, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (GLH plasma cell, Absent) 0.000, 0.000, 0.200, 0.799, 0.001, 0.000;
  (Granulomatous laden, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Histiocytosis x, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Infectious mono, Absent) 0.10, 0.74, 0.15, 0.01, 0.00, 0.00;
  (Leprosy-lepromatous, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Lymphangiographic, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Mantle zone hyperpla, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Necrotizing Kikuchi, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Necrotiz non-Kikuchi, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Rheumatoid arthritis, Absent) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (Sarcoidosis, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (SHML, Absent) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (Sinus histiocytosis, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Syphilis, Absent) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (Toxoplasmosis, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Tuberculosis, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Viral NOS, Absent) 0.10, 0.74, 0.15, 0.01, 0.00, 0.00;
  (Whipple's disease, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (L&H nodular HD, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (L&H diffuse HD, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Nodular sclerosis HD, Absent) 0.10, 0.80, 0.09, 0.01, 0.00, 0.00;
  (Cellular phase NSHD, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Syncytial NSHD, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Mixed cellularity HD, Absent) 0.10, 0.80, 0.09, 0.01, 0.00, 0.00;
  (Interfollicular HD, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Diffuse fibrosis HD, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Reticular-type HD, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Small cleaved fol, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Mixed fol, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Large cell fol, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Small noncleaved fol, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Small lymphocytic, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Plasmacytoid lyctic, Absent) 0.000, 0.149, 0.650, 0.200, 0.001, 0.000;
  (Mantle zone lymphoma, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Small cleaved dif, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Mixed FCC dif, Absent) 0.37, 0.46, 0.15, 0.02, 0.00, 0.00;
  (Large cell dif, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (B-immunoblastic, Absent) 0.15, 0.70, 0.10, 0.05, 0.00, 0.00;
  (T-immunob mixed, Absent) 0.37, 0.46, 0.15, 0.02, 0.00, 0.00;
  (AILD-like T-cell lym, Absent) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (Japanese ATL, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Lymphoblastic, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Small noncleaved dif, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (True histiocytic, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Ki-1 LC anaplas T, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Multiple myeloma, Absent) 0.00, 0.10, 0.65, 0.25, 0.00, 0.00;
  (Mycosis fungoides, Absent) 0.75, 0.20, 0.04, 0.01, 0.00, 0.00;
  (AML, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Hairy cell leukemia, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Carcinoma, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Melanoma, Absent) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (EM plasmacytoma, Absent) 0.00, 0.00, 0.00, 0.10, 0.55, 0.35;
  (Kaposi's sarcoma, Absent) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (Mast-cell disease, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (AIDS involutionary, Absent) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (T-immunob large, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Monocytoid B-cell, Absent) 0.10, 0.70, 0.19, 0.01, 0.00, 0.00;
  (Nasopharyngeal CA, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Seminoma, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (SLE, Absent) 0.10, 0.74, 0.15, 0.01, 0.00, 0.00;
  (Mycobact histiocytos, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Mast-cell hyperplas, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (LGV, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Histoplasmosis, Absent) 0.10, 0.74, 0.15, 0.01, 0.00, 0.00;
  (Coccidioidomycosis, Absent) 0.10, 0.74, 0.15, 0.01, 0.00, 0.00;
  (CMV, Absent) 0.10, 0.74, 0.15, 0.01, 0.00, 0.00;
  (Brucellosis, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Ki-1 LC anaplas B, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Intermed lymphocytic, Absent) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (AIDS early, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (AILD, Focal [nonextensive]) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (ALIP, Focal [nonextensive]) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (Cat scratch disease, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Dermatopathic laden, Focal [nonextensive]) 0.005, 0.250, 0.695, 0.050, 0.000, 0.000;
  (Florid follic hyperp, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (GLH hyaline vascular, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (GLH plasma cell, Focal [nonextensive]) 0.000, 0.000, 0.200, 0.799, 0.001, 0.000;
  (Granulomatous laden, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Histiocytosis x, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Infectious mono, Focal [nonextensive]) 0.10, 0.74, 0.15, 0.01, 0.00, 0.00;
  (Leprosy-lepromatous, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Lymphangiographic, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Mantle zone hyperpla, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Necrotizing Kikuchi, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Necrotiz non-Kikuchi, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Rheumatoid arthritis, Focal [nonextensive]) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (Sarcoidosis, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (SHML, Focal [nonextensive]) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (Sinus histiocytosis, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Syphilis, Focal [nonextensive]) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (Toxoplasmosis, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Tuberculosis, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Viral NOS, Focal [nonextensive]) 0.10, 0.74, 0.15, 0.01, 0.00, 0.00;
  (Whipple's disease, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (L&H nodular HD, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (L&H diffuse HD, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Nodular sclerosis HD, Focal [nonextensive]) 0.10, 0.80, 0.09, 0.01, 0.00, 0.00;
  (Cellular phase NSHD, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Syncytial NSHD, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Mixed cellularity HD, Focal [nonextensive]) 0.10, 0.80, 0.09, 0.01, 0.00, 0.00;
  (Interfollicular HD, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Diffuse fibrosis HD, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Reticular-type HD, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Small cleaved fol, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Mixed fol, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Large cell fol, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Small noncleaved fol, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Small lymphocytic, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Plasmacytoid lyctic, Focal [nonextensive]) 0.000, 0.149, 0.650, 0.200, 0.001, 0.000;
  (Mantle zone lymphoma, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Small cleaved dif, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Mixed FCC dif, Focal [nonextensive]) 0.37, 0.46, 0.15, 0.02, 0.00, 0.00;
  (Large cell dif, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (B-immunoblastic, Focal [nonextensive]) 0.15, 0.70, 0.10, 0.05, 0.00, 0.00;
  (T-immunob mixed, Focal [nonextensive]) 0.37, 0.46, 0.15, 0.02, 0.00, 0.00;
  (AILD-like T-cell lym, Focal [nonextensive]) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (Japanese ATL, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Lymphoblastic, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Small noncleaved dif, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (True histiocytic, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Ki-1 LC anaplas T, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Multiple myeloma, Focal [nonextensive]) 0.00, 0.10, 0.65, 0.25, 0.00, 0.00;
  (Mycosis fungoides, Focal [nonextensive]) 0.75, 0.20, 0.04, 0.01, 0.00, 0.00;
  (AML, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Hairy cell leukemia, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Carcinoma, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Melanoma, Focal [nonextensive]) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (EM plasmacytoma, Focal [nonextensive]) 0.00, 0.00, 0.00, 0.10, 0.55, 0.35;
  (Kaposi's sarcoma, Focal [nonextensive]) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (Mast-cell disease, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (AIDS involutionary, Focal [nonextensive]) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (T-immunob large, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Monocytoid B-cell, Focal [nonextensive]) 0.10, 0.70, 0.19, 0.01, 0.00, 0.00;
  (Nasopharyngeal CA, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Seminoma, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (SLE, Focal [nonextensive]) 0.10, 0.74, 0.15, 0.01, 0.00, 0.00;
  (Mycobact histiocytos, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Mast-cell hyperplas, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (LGV, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Histoplasmosis, Focal [nonextensive]) 0.10, 0.74, 0.15, 0.01, 0.00, 0.00;
  (Coccidioidomycosis, Focal [nonextensive]) 0.10, 0.74, 0.15, 0.01, 0.00, 0.00;
  (CMV, Focal [nonextensive]) 0.10, 0.74, 0.15, 0.01, 0.00, 0.00;
  (Brucellosis, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Ki-1 LC anaplas B, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Intermed lymphocytic, Focal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (AIDS early, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (AILD, Multifocal [nonextensive]) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (ALIP, Multifocal [nonextensive]) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (Cat scratch disease, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Dermatopathic laden, Multifocal [nonextensive]) 0.005, 0.250, 0.695, 0.050, 0.000, 0.000;
  (Florid follic hyperp, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (GLH hyaline vascular, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (GLH plasma cell, Multifocal [nonextensive]) 0.000, 0.000, 0.200, 0.799, 0.001, 0.000;
  (Granulomatous laden, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Histiocytosis x, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Infectious mono, Multifocal [nonextensive]) 0.10, 0.74, 0.15, 0.01, 0.00, 0.00;
  (Leprosy-lepromatous, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Lymphangiographic, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Mantle zone hyperpla, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Necrotizing Kikuchi, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Necrotiz non-Kikuchi, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Rheumatoid arthritis, Multifocal [nonextensive]) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (Sarcoidosis, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (SHML, Multifocal [nonextensive]) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (Sinus histiocytosis, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Syphilis, Multifocal [nonextensive]) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (Toxoplasmosis, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Tuberculosis, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Viral NOS, Multifocal [nonextensive]) 0.10, 0.74, 0.15, 0.01, 0.00, 0.00;
  (Whipple's disease, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (L&H nodular HD, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (L&H diffuse HD, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Nodular sclerosis HD, Multifocal [nonextensive]) 0.10, 0.80, 0.09, 0.01, 0.00, 0.00;
  (Cellular phase NSHD, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Syncytial NSHD, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Mixed cellularity HD, Multifocal [nonextensive]) 0.10, 0.80, 0.09, 0.01, 0.00, 0.00;
  (Interfollicular HD, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Diffuse fibrosis HD, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Reticular-type HD, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Small cleaved fol, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Mixed fol, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Large cell fol, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Small noncleaved fol, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Small lymphocytic, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Plasmacytoid lyctic, Multifocal [nonextensive]) 0.000, 0.149, 0.650, 0.200, 0.001, 0.000;
  (Mantle zone lymphoma, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Small cleaved dif, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Mixed FCC dif, Multifocal [nonextensive]) 0.37, 0.46, 0.15, 0.02, 0.00, 0.00;
  (Large cell dif, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (B-immunoblastic, Multifocal [nonextensive]) 0.15, 0.70, 0.10, 0.05, 0.00, 0.00;
  (T-immunob mixed, Multifocal [nonextensive]) 0.37, 0.46, 0.15, 0.02, 0.00, 0.00;
  (AILD-like T-cell lym, Multifocal [nonextensive]) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (Japanese ATL, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Lymphoblastic, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Small noncleaved dif, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (True histiocytic, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Ki-1 LC anaplas T, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Multiple myeloma, Multifocal [nonextensive]) 0.00, 0.10, 0.65, 0.25, 0.00, 0.00;
  (Mycosis fungoides, Multifocal [nonextensive]) 0.75, 0.20, 0.04, 0.01, 0.00, 0.00;
  (AML, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Hairy cell leukemia, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Carcinoma, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Melanoma, Multifocal [nonextensive]) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (EM plasmacytoma, Multifocal [nonextensive]) 0.00, 0.00, 0.00, 0.10, 0.55, 0.35;
  (Kaposi's sarcoma, Multifocal [nonextensive]) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (Mast-cell disease, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (AIDS involutionary, Multifocal [nonextensive]) 0.00, 0.01, 0.79, 0.20, 0.00, 0.00;
  (T-immunob large, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Monocytoid B-cell, Multifocal [nonextensive]) 0.10, 0.70, 0.19, 0.01, 0.00, 0.00;
  (Nasopharyngeal CA, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Seminoma, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (SLE, Multifocal [nonextensive]) 0.10, 0.74, 0.15, 0.01, 0.00, 0.00;
  (Mycobact histiocytos, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Mast-cell hyperplas, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (LGV, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Histoplasmosis, Multifocal [nonextensive]) 0.10, 0.74, 0.15, 0.01, 0.00, 0.00;
  (Coccidioidomycosis, Multifocal [nonextensive]) 0.10, 0.74, 0.15, 0.01, 0.00, 0.00;
  (CMV, Multifocal [nonextensive]) 0.10, 0.74, 0.15, 0.01, 0.00, 0.00;
  (Brucellosis, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Ki-1 LC anaplas B, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (Intermed lymphocytic, Multifocal [nonextensive]) 0.500, 0.480, 0.015, 0.005, 0.000, 0.000;
  (AIDS early, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (AILD, Extensive) 0.00, 0.01, 0.70, 0.29, 0.00, 0.00;
  (ALIP, Extensive) 0.00, 0.01, 0.70, 0.29, 0.00, 0.00;
  (Cat scratch disease, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Dermatopathic laden, Extensive) 0.005, 0.250, 0.605, 0.140, 0.000, 0.000;
  (Florid follic hyperp, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (GLH hyaline vascular, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (GLH plasma cell, Extensive) 0.000, 0.000, 0.200, 0.799, 0.001, 0.000;
  (Granulomatous laden, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Histiocytosis x, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Infectious mono, Extensive) 0.10, 0.62, 0.18, 0.10, 0.00, 0.00;
  (Leprosy-lepromatous, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Lymphangiographic, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Mantle zone hyperpla, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Necrotizing Kikuchi, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Necrotiz non-Kikuchi, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Rheumatoid arthritis, Extensive) 0.00, 0.01, 0.70, 0.29, 0.00, 0.00;
  (Sarcoidosis, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (SHML, Extensive) 0.00, 0.01, 0.70, 0.29, 0.00, 0.00;
  (Sinus histiocytosis, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Syphilis, Extensive) 0.00, 0.01, 0.70, 0.29, 0.00, 0.00;
  (Toxoplasmosis, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Tuberculosis, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Viral NOS, Extensive) 0.10, 0.62, 0.18, 0.10, 0.00, 0.00;
  (Whipple's disease, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (L&H nodular HD, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (L&H diffuse HD, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Nodular sclerosis HD, Extensive) 0.10, 0.68, 0.12, 0.10, 0.00, 0.00;
  (Cellular phase NSHD, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Syncytial NSHD, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Mixed cellularity HD, Extensive) 0.10, 0.68, 0.12, 0.10, 0.00, 0.00;
  (Interfollicular HD, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Diffuse fibrosis HD, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Reticular-type HD, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Small cleaved fol, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Mixed fol, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Large cell fol, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Small noncleaved fol, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Small lymphocytic, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Plasmacytoid lyctic, Extensive) 0.000, 0.149, 0.650, 0.200, 0.001, 0.000;
  (Mantle zone lymphoma, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Small cleaved dif, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Mixed FCC dif, Extensive) 0.27, 0.46, 0.17, 0.10, 0.00, 0.00;
  (Large cell dif, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (B-immunoblastic, Extensive) 0.25, 0.58, 0.07, 0.10, 0.00, 0.00;
  (T-immunob mixed, Extensive) 0.27, 0.46, 0.17, 0.10, 0.00, 0.00;
  (AILD-like T-cell lym, Extensive) 0.00, 0.01, 0.70, 0.29, 0.00, 0.00;
  (Japanese ATL, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Lymphoblastic, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Small noncleaved dif, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (True histiocytic, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Ki-1 LC anaplas T, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Multiple myeloma, Extensive) 0.00, 0.10, 0.56, 0.34, 0.00, 0.00;
  (Mycosis fungoides, Extensive) 0.59, 0.24, 0.07, 0.10, 0.00, 0.00;
  (AML, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Hairy cell leukemia, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Carcinoma, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Melanoma, Extensive) 0.00, 0.01, 0.70, 0.29, 0.00, 0.00;
  (EM plasmacytoma, Extensive) 0.00, 0.00, 0.05, 0.05, 0.60, 0.30;
  (Kaposi's sarcoma, Extensive) 0.00, 0.01, 0.70, 0.29, 0.00, 0.00;
  (Mast-cell disease, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (AIDS involutionary, Extensive) 0.00, 0.01, 0.70, 0.29, 0.00, 0.00;
  (T-immunob large, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Monocytoid B-cell, Extensive) 0.100, 0.778, 0.022, 0.050, 0.050, 0.000;
  (Nasopharyngeal CA, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Seminoma, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (SLE, Extensive) 0.10, 0.62, 0.18, 0.10, 0.00, 0.00;
  (Mycobact histiocytos, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Mast-cell hyperplas, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (LGV, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Histoplasmosis, Extensive) 0.10, 0.62, 0.18, 0.10, 0.00, 0.00;
  (Coccidioidomycosis, Extensive) 0.10, 0.62, 0.18, 0.10, 0.00, 0.00;
  (CMV, Extensive) 0.10, 0.62, 0.18, 0.10, 0.00, 0.00;
  (Brucellosis, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Ki-1 LC anaplas B, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
  (Intermed lymphocytic, Extensive) 0.500, 0.370, 0.035, 0.095, 0.000, 0.000;
}
probability ( PC_TP | Fault, PLASMA ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS early, Few [<5pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (AILD, Few [<5pc]) 0.000, 0.948, 0.001, 0.000, 0.001, 0.050;
  (ALIP, Few [<5pc]) 0.000, 0.948, 0.001, 0.000, 0.001, 0.050;
  (Cat scratch disease, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Dermatopathic laden, Few [<5pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Florid follic hyperp, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (GLH hyaline vascular, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (GLH plasma cell, Few [<5pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Granulomatous laden, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Histiocytosis x, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Infectious mono, Few [<5pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Leprosy-lepromatous, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Lymphangiographic, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mantle zone hyperpla, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Necrotizing Kikuchi, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Necrotiz non-Kikuchi, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Rheumatoid arthritis, Few [<5pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Sarcoidosis, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (SHML, Few [<5pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Sinus histiocytosis, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Syphilis, Few [<5pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Toxoplasmosis, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Tuberculosis, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Viral NOS, Few [<5pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Whipple's disease, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (L&H nodular HD, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (L&H diffuse HD, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Nodular sclerosis HD, Few [<5pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Cellular phase NSHD, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Syncytial NSHD, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mixed cellularity HD, Few [<5pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Interfollicular HD, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Diffuse fibrosis HD, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Reticular-type HD, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small cleaved fol, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mixed fol, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Large cell fol, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small noncleaved fol, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small lymphocytic, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Plasmacytoid lyctic, Few [<5pc]) 0.000, 0.928, 0.020, 0.001, 0.001, 0.050;
  (Mantle zone lymphoma, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small cleaved dif, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mixed FCC dif, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Large cell dif, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (B-immunoblastic, Few [<5pc]) 0.00, 0.92, 0.01, 0.01, 0.01, 0.05;
  (T-immunob mixed, Few [<5pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (AILD-like T-cell lym, Few [<5pc]) 0.000, 0.948, 0.001, 0.000, 0.001, 0.050;
  (Japanese ATL, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Lymphoblastic, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small noncleaved dif, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (True histiocytic, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Ki-1 LC anaplas T, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Multiple myeloma, Few [<5pc]) 0.00, 0.02, 0.30, 0.05, 0.15, 0.48;
  (Mycosis fungoides, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (AML, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Hairy cell leukemia, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Carcinoma, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Melanoma, Few [<5pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (EM plasmacytoma, Few [<5pc]) 0.1666667, 0.1666667, 0.1666667, 0.1666667, 0.1666667, 0.1666667;
  (Kaposi's sarcoma, Few [<5pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Mast-cell disease, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (AIDS involutionary, Few [<5pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (T-immunob large, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Monocytoid B-cell, Few [<5pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Nasopharyngeal CA, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Seminoma, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (SLE, Few [<5pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Mycobact histiocytos, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mast-cell hyperplas, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (LGV, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Histoplasmosis, Few [<5pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Coccidioidomycosis, Few [<5pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (CMV, Few [<5pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Brucellosis, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Ki-1 LC anaplas B, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Intermed lymphocytic, Few [<5pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (AIDS early, Moderate [6-20pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (AILD, Moderate [6-20pc]) 0.000, 0.948, 0.001, 0.000, 0.001, 0.050;
  (ALIP, Moderate [6-20pc]) 0.000, 0.948, 0.001, 0.000, 0.001, 0.050;
  (Cat scratch disease, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Dermatopathic laden, Moderate [6-20pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Florid follic hyperp, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (GLH hyaline vascular, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (GLH plasma cell, Moderate [6-20pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Granulomatous laden, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Histiocytosis x, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Infectious mono, Moderate [6-20pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Leprosy-lepromatous, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Lymphangiographic, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mantle zone hyperpla, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Necrotizing Kikuchi, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Necrotiz non-Kikuchi, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Rheumatoid arthritis, Moderate [6-20pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Sarcoidosis, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (SHML, Moderate [6-20pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Sinus histiocytosis, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Syphilis, Moderate [6-20pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Toxoplasmosis, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Tuberculosis, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Viral NOS, Moderate [6-20pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Whipple's disease, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (L&H nodular HD, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (L&H diffuse HD, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Nodular sclerosis HD, Moderate [6-20pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Cellular phase NSHD, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Syncytial NSHD, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mixed cellularity HD, Moderate [6-20pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Interfollicular HD, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Diffuse fibrosis HD, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Reticular-type HD, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small cleaved fol, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mixed fol, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Large cell fol, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small noncleaved fol, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small lymphocytic, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Plasmacytoid lyctic, Moderate [6-20pc]) 0.000, 0.928, 0.020, 0.001, 0.001, 0.050;
  (Mantle zone lymphoma, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small cleaved dif, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mixed FCC dif, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Large cell dif, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (B-immunoblastic, Moderate [6-20pc]) 0.00, 0.92, 0.01, 0.01, 0.01, 0.05;
  (T-immunob mixed, Moderate [6-20pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (AILD-like T-cell lym, Moderate [6-20pc]) 0.000, 0.948, 0.001, 0.000, 0.001, 0.050;
  (Japanese ATL, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Lymphoblastic, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small noncleaved dif, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (True histiocytic, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Ki-1 LC anaplas T, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Multiple myeloma, Moderate [6-20pc]) 0.00, 0.02, 0.30, 0.05, 0.15, 0.48;
  (Mycosis fungoides, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (AML, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Hairy cell leukemia, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Carcinoma, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Melanoma, Moderate [6-20pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (EM plasmacytoma, Moderate [6-20pc]) 0.00, 0.65, 0.10, 0.03, 0.02, 0.20;
  (Kaposi's sarcoma, Moderate [6-20pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Mast-cell disease, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (AIDS involutionary, Moderate [6-20pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (T-immunob large, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Monocytoid B-cell, Moderate [6-20pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Nasopharyngeal CA, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Seminoma, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (SLE, Moderate [6-20pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Mycobact histiocytos, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mast-cell hyperplas, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (LGV, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Histoplasmosis, Moderate [6-20pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Coccidioidomycosis, Moderate [6-20pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (CMV, Moderate [6-20pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Brucellosis, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Ki-1 LC anaplas B, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Intermed lymphocytic, Moderate [6-20pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (AIDS early, Marked [21-50pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (AILD, Marked [21-50pc]) 0.000, 0.948, 0.001, 0.000, 0.001, 0.050;
  (ALIP, Marked [21-50pc]) 0.000, 0.948, 0.001, 0.000, 0.001, 0.050;
  (Cat scratch disease, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Dermatopathic laden, Marked [21-50pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Florid follic hyperp, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (GLH hyaline vascular, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (GLH plasma cell, Marked [21-50pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Granulomatous laden, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Histiocytosis x, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Infectious mono, Marked [21-50pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Leprosy-lepromatous, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Lymphangiographic, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mantle zone hyperpla, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Necrotizing Kikuchi, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Necrotiz non-Kikuchi, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Rheumatoid arthritis, Marked [21-50pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Sarcoidosis, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (SHML, Marked [21-50pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Sinus histiocytosis, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Syphilis, Marked [21-50pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Toxoplasmosis, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Tuberculosis, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Viral NOS, Marked [21-50pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Whipple's disease, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (L&H nodular HD, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (L&H diffuse HD, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Nodular sclerosis HD, Marked [21-50pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Cellular phase NSHD, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Syncytial NSHD, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mixed cellularity HD, Marked [21-50pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Interfollicular HD, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Diffuse fibrosis HD, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Reticular-type HD, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small cleaved fol, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mixed fol, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Large cell fol, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small noncleaved fol, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small lymphocytic, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Plasmacytoid lyctic, Marked [21-50pc]) 0.000, 0.928, 0.020, 0.001, 0.001, 0.050;
  (Mantle zone lymphoma, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small cleaved dif, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mixed FCC dif, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Large cell dif, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (B-immunoblastic, Marked [21-50pc]) 0.00, 0.92, 0.01, 0.01, 0.01, 0.05;
  (T-immunob mixed, Marked [21-50pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (AILD-like T-cell lym, Marked [21-50pc]) 0.000, 0.948, 0.001, 0.000, 0.001, 0.050;
  (Japanese ATL, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Lymphoblastic, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small noncleaved dif, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (True histiocytic, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Ki-1 LC anaplas T, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Multiple myeloma, Marked [21-50pc]) 0.00, 0.02, 0.30, 0.05, 0.15, 0.48;
  (Mycosis fungoides, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (AML, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Hairy cell leukemia, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Carcinoma, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Melanoma, Marked [21-50pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (EM plasmacytoma, Marked [21-50pc]) 0.00, 0.65, 0.10, 0.03, 0.02, 0.20;
  (Kaposi's sarcoma, Marked [21-50pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Mast-cell disease, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (AIDS involutionary, Marked [21-50pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (T-immunob large, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Monocytoid B-cell, Marked [21-50pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Nasopharyngeal CA, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Seminoma, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (SLE, Marked [21-50pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Mycobact histiocytos, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mast-cell hyperplas, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (LGV, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Histoplasmosis, Marked [21-50pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Coccidioidomycosis, Marked [21-50pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (CMV, Marked [21-50pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Brucellosis, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Ki-1 LC anaplas B, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Intermed lymphocytic, Marked [21-50pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (AIDS early, Striking [51-90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (AILD, Striking [51-90pc]) 0.000, 0.948, 0.001, 0.000, 0.001, 0.050;
  (ALIP, Striking [51-90pc]) 0.000, 0.948, 0.001, 0.000, 0.001, 0.050;
  (Cat scratch disease, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Dermatopathic laden, Striking [51-90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Florid follic hyperp, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (GLH hyaline vascular, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (GLH plasma cell, Striking [51-90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Granulomatous laden, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Histiocytosis x, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Infectious mono, Striking [51-90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Leprosy-lepromatous, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Lymphangiographic, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mantle zone hyperpla, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Necrotizing Kikuchi, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Necrotiz non-Kikuchi, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Rheumatoid arthritis, Striking [51-90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Sarcoidosis, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (SHML, Striking [51-90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Sinus histiocytosis, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Syphilis, Striking [51-90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Toxoplasmosis, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Tuberculosis, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Viral NOS, Striking [51-90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Whipple's disease, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (L&H nodular HD, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (L&H diffuse HD, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Nodular sclerosis HD, Striking [51-90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Cellular phase NSHD, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Syncytial NSHD, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mixed cellularity HD, Striking [51-90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Interfollicular HD, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Diffuse fibrosis HD, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Reticular-type HD, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small cleaved fol, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mixed fol, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Large cell fol, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small noncleaved fol, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small lymphocytic, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Plasmacytoid lyctic, Striking [51-90pc]) 0.000, 0.928, 0.020, 0.001, 0.001, 0.050;
  (Mantle zone lymphoma, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small cleaved dif, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mixed FCC dif, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Large cell dif, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (B-immunoblastic, Striking [51-90pc]) 0.00, 0.92, 0.01, 0.01, 0.01, 0.05;
  (T-immunob mixed, Striking [51-90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (AILD-like T-cell lym, Striking [51-90pc]) 0.000, 0.948, 0.001, 0.000, 0.001, 0.050;
  (Japanese ATL, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Lymphoblastic, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small noncleaved dif, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (True histiocytic, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Ki-1 LC anaplas T, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Multiple myeloma, Striking [51-90pc]) 0.00, 0.02, 0.30, 0.05, 0.15, 0.48;
  (Mycosis fungoides, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (AML, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Hairy cell leukemia, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Carcinoma, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Melanoma, Striking [51-90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (EM plasmacytoma, Striking [51-90pc]) 0.00, 0.65, 0.10, 0.03, 0.02, 0.20;
  (Kaposi's sarcoma, Striking [51-90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Mast-cell disease, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (AIDS involutionary, Striking [51-90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (T-immunob large, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Monocytoid B-cell, Striking [51-90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Nasopharyngeal CA, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Seminoma, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (SLE, Striking [51-90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Mycobact histiocytos, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mast-cell hyperplas, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (LGV, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Histoplasmosis, Striking [51-90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Coccidioidomycosis, Striking [51-90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (CMV, Striking [51-90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Brucellosis, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Ki-1 LC anaplas B, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Intermed lymphocytic, Striking [51-90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (AIDS early, Sheets [>90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (AILD, Sheets [>90pc]) 0.000, 0.948, 0.001, 0.000, 0.001, 0.050;
  (ALIP, Sheets [>90pc]) 0.000, 0.948, 0.001, 0.000, 0.001, 0.050;
  (Cat scratch disease, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Dermatopathic laden, Sheets [>90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Florid follic hyperp, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (GLH hyaline vascular, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (GLH plasma cell, Sheets [>90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Granulomatous laden, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Histiocytosis x, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Infectious mono, Sheets [>90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Leprosy-lepromatous, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Lymphangiographic, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mantle zone hyperpla, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Necrotizing Kikuchi, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Necrotiz non-Kikuchi, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Rheumatoid arthritis, Sheets [>90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Sarcoidosis, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (SHML, Sheets [>90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Sinus histiocytosis, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Syphilis, Sheets [>90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Toxoplasmosis, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Tuberculosis, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Viral NOS, Sheets [>90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Whipple's disease, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (L&H nodular HD, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (L&H diffuse HD, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Nodular sclerosis HD, Sheets [>90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Cellular phase NSHD, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Syncytial NSHD, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mixed cellularity HD, Sheets [>90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Interfollicular HD, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Diffuse fibrosis HD, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Reticular-type HD, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small cleaved fol, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mixed fol, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Large cell fol, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small noncleaved fol, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small lymphocytic, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Plasmacytoid lyctic, Sheets [>90pc]) 0.000, 0.928, 0.020, 0.001, 0.001, 0.050;
  (Mantle zone lymphoma, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small cleaved dif, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mixed FCC dif, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Large cell dif, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (B-immunoblastic, Sheets [>90pc]) 0.00, 0.92, 0.01, 0.01, 0.01, 0.05;
  (T-immunob mixed, Sheets [>90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (AILD-like T-cell lym, Sheets [>90pc]) 0.000, 0.948, 0.001, 0.000, 0.001, 0.050;
  (Japanese ATL, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Lymphoblastic, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Small noncleaved dif, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (True histiocytic, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Ki-1 LC anaplas T, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Multiple myeloma, Sheets [>90pc]) 0.00, 0.02, 0.30, 0.05, 0.15, 0.48;
  (Mycosis fungoides, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (AML, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Hairy cell leukemia, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Carcinoma, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Melanoma, Sheets [>90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (EM plasmacytoma, Sheets [>90pc]) 0.00, 0.65, 0.10, 0.03, 0.02, 0.20;
  (Kaposi's sarcoma, Sheets [>90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Mast-cell disease, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (AIDS involutionary, Sheets [>90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (T-immunob large, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Monocytoid B-cell, Sheets [>90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Nasopharyngeal CA, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Seminoma, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (SLE, Sheets [>90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Mycobact histiocytos, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Mast-cell hyperplas, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (LGV, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Histoplasmosis, Sheets [>90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Coccidioidomycosis, Sheets [>90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (CMV, Sheets [>90pc]) 0.000, 0.929, 0.020, 0.000, 0.001, 0.050;
  (Brucellosis, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Ki-1 LC anaplas B, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
  (Intermed lymphocytic, Sheets [>90pc]) 0.000, 0.978, 0.001, 0.000, 0.001, 0.020;
}
probability ( PLEO | Fault ) {
  (AIDS early) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD) 1.0, 0.0, 0.0, 0.0, 0.0;
  (ALIP) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cat scratch disease) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH plasma cell) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Granulomatous laden) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histiocytosis x) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Infectious mono) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphangiographic) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sarcoidosis) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SHML) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syphilis) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Tuberculosis) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Viral NOS) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Whipple's disease) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H nodular HD) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD) 0.74, 0.20, 0.05, 0.01, 0.00;
  (Cellular phase NSHD) 0.74, 0.20, 0.05, 0.01, 0.00;
  (Syncytial NSHD) 0.74, 0.20, 0.05, 0.01, 0.00;
  (Mixed cellularity HD) 0.98990101, 0.00999900, 0.00009999, 0.00000000, 0.00000000;
  (Interfollicular HD) 0.98990101, 0.00999900, 0.00009999, 0.00000000, 0.00000000;
  (Diffuse fibrosis HD) 0.01, 0.60, 0.38, 0.01, 0.00;
  (Reticular-type HD) 0.0, 0.0, 0.2, 0.2, 0.6;
  (Small cleaved fol) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed fol) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell fol) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small lymphocytic) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved dif) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell dif) 1.0, 0.0, 0.0, 0.0, 0.0;
  (B-immunoblastic) 0.97, 0.02, 0.01, 0.00, 0.00;
  (T-immunob mixed) 0.97, 0.02, 0.01, 0.00, 0.00;
  (AILD-like T-cell lym) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Japanese ATL) 0.9589, 0.0300, 0.0100, 0.0010, 0.0001;
  (Lymphoblastic) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif) 1.0, 0.0, 0.0, 0.0, 0.0;
  (True histiocytic) 0.9299, 0.0500, 0.0200, 0.0001, 0.0000;
  (Ki-1 LC anaplas T) 0.9299, 0.0500, 0.0200, 0.0001, 0.0000;
  (Multiple myeloma) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AML) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Carcinoma) 0.96, 0.02, 0.01, 0.01, 0.00;
  (Melanoma) 1.0, 0.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell disease) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS involutionary) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob large) 0.97, 0.02, 0.01, 0.00, 0.00;
  (Monocytoid B-cell) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA) 0.96, 0.02, 0.01, 0.01, 0.00;
  (Seminoma) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SLE) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0, 0.0, 0.0, 0.0;
  (LGV) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histoplasmosis) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0, 0.0, 0.0, 0.0;
  (CMV) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Brucellosis) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B) 0.9299, 0.0500, 0.0200, 0.0001, 0.0000;
  (Intermed lymphocytic) 1.0, 0.0, 0.0, 0.0, 0.0;
}
probability ( PFP | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 1.0, 0.0;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 1.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 1.0, 0.0;
  (L&H diffuse HD) 1.0, 0.0;
  (Nodular sclerosis HD) 1.0, 0.0;
  (Cellular phase NSHD) 1.0, 0.0;
  (Syncytial NSHD) 1.0, 0.0;
  (Mixed cellularity HD) 1.0, 0.0;
  (Interfollicular HD) 1.0, 0.0;
  (Diffuse fibrosis HD) 1.0, 0.0;
  (Reticular-type HD) 1.0, 0.0;
  (Small cleaved fol) 1.0, 0.0;
  (Mixed fol) 1.0, 0.0;
  (Large cell fol) 1.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0;
  (Small lymphocytic) 0.1, 0.9;
  (Plasmacytoid lyctic) 0.98, 0.02;
  (Mantle zone lymphoma) 1.0, 0.0;
  (Small cleaved dif) 1.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0;
  (Large cell dif) 1.0, 0.0;
  (B-immunoblastic) 1.0, 0.0;
  (T-immunob mixed) 1.0, 0.0;
  (AILD-like T-cell lym) 1.0, 0.0;
  (Japanese ATL) 1.0, 0.0;
  (Lymphoblastic) 1.0, 0.0;
  (Small noncleaved dif) 1.0, 0.0;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 1.0, 0.0;
  (Multiple myeloma) 1.0, 0.0;
  (Mycosis fungoides) 1.0, 0.0;
  (AML) 1.0, 0.0;
  (Hairy cell leukemia) 1.0, 0.0;
  (Carcinoma) 1.0, 0.0;
  (Melanoma) 1.0, 0.0;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0;
  (Mast-cell disease) 1.0, 0.0;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 1.0, 0.0;
  (Monocytoid B-cell) 1.0, 0.0;
  (Nasopharyngeal CA) 1.0, 0.0;
  (Seminoma) 1.0, 0.0;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 1.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0;
}
probability ( PTGC_NOD | Fault ) {
  (AIDS early) 0.98, 0.02;
  (AILD) 0.995, 0.005;
  (ALIP) 0.99, 0.01;
  (Cat scratch disease) 0.99, 0.01;
  (Dermatopathic laden) 0.99, 0.01;
  (Florid follic hyperp) 0.93, 0.07;
  (GLH hyaline vascular) 0.99, 0.01;
  (GLH plasma cell) 0.99, 0.01;
  (Granulomatous laden) 0.99, 0.01;
  (Histiocytosis x) 0.99, 0.01;
  (Infectious mono) 0.99, 0.01;
  (Leprosy-lepromatous) 0.99, 0.01;
  (Lymphangiographic) 0.99, 0.01;
  (Mantle zone hyperpla) 0.99, 0.01;
  (Necrotizing Kikuchi) 0.99, 0.01;
  (Necrotiz non-Kikuchi) 0.99, 0.01;
  (Rheumatoid arthritis) 0.98, 0.02;
  (Sarcoidosis) 0.99, 0.01;
  (SHML) 0.99, 0.01;
  (Sinus histiocytosis) 0.99, 0.01;
  (Syphilis) 0.98, 0.02;
  (Toxoplasmosis) 0.98, 0.02;
  (Tuberculosis) 0.99, 0.01;
  (Viral NOS) 0.99, 0.01;
  (Whipple's disease) 0.99, 0.01;
  (L&H nodular HD) 0.75, 0.25;
  (L&H diffuse HD) 0.995, 0.005;
  (Nodular sclerosis HD) 0.995, 0.005;
  (Cellular phase NSHD) 0.995, 0.005;
  (Syncytial NSHD) 0.995, 0.005;
  (Mixed cellularity HD) 0.995, 0.005;
  (Interfollicular HD) 0.995, 0.005;
  (Diffuse fibrosis HD) 0.995, 0.005;
  (Reticular-type HD) 0.995, 0.005;
  (Small cleaved fol) 0.995, 0.005;
  (Mixed fol) 0.995, 0.005;
  (Large cell fol) 0.995, 0.005;
  (Small noncleaved fol) 0.995, 0.005;
  (Small lymphocytic) 0.995, 0.005;
  (Plasmacytoid lyctic) 0.995, 0.005;
  (Mantle zone lymphoma) 0.995, 0.005;
  (Small cleaved dif) 0.995, 0.005;
  (Mixed FCC dif) 0.995, 0.005;
  (Large cell dif) 0.995, 0.005;
  (B-immunoblastic) 0.995, 0.005;
  (T-immunob mixed) 0.995, 0.005;
  (AILD-like T-cell lym) 0.995, 0.005;
  (Japanese ATL) 0.995, 0.005;
  (Lymphoblastic) 0.995, 0.005;
  (Small noncleaved dif) 0.995, 0.005;
  (True histiocytic) 0.995, 0.005;
  (Ki-1 LC anaplas T) 0.995, 0.005;
  (Multiple myeloma) 0.995, 0.005;
  (Mycosis fungoides) 0.995, 0.005;
  (AML) 0.995, 0.005;
  (Hairy cell leukemia) 0.995, 0.005;
  (Carcinoma) 0.995, 0.005;
  (Melanoma) 0.995, 0.005;
  (EM plasmacytoma) 0.995, 0.005;
  (Kaposi's sarcoma) 0.995, 0.005;
  (Mast-cell disease) 0.995, 0.005;
  (AIDS involutionary) 0.995, 0.005;
  (T-immunob large) 0.995, 0.005;
  (Monocytoid B-cell) 0.995, 0.005;
  (Nasopharyngeal CA) 0.995, 0.005;
  (Seminoma) 0.995, 0.005;
  (SLE) 0.99, 0.01;
  (Mycobact histiocytos) 0.995, 0.005;
  (Mast-cell hyperplas) 0.99, 0.01;
  (LGV) 0.99, 0.01;
  (Histoplasmosis) 0.995, 0.005;
  (Coccidioidomycosis) 0.995, 0.005;
  (CMV) 0.995, 0.005;
  (Brucellosis) 0.98, 0.02;
  (Ki-1 LC anaplas B) 0.995, 0.005;
  (Intermed lymphocytic) 0.995, 0.005;
}
probability ( RD_BOD | Fault, PLASMA ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0;
  (AIDS early, Few [<5pc]) 0.9999, 0.0001;
  (AILD, Few [<5pc]) 0.99999, 0.00001;
  (ALIP, Few [<5pc]) 0.999999, 0.000001;
  (Cat scratch disease, Few [<5pc]) 0.999999, 0.000001;
  (Dermatopathic laden, Few [<5pc]) 0.9999, 0.0001;
  (Florid follic hyperp, Few [<5pc]) 0.999999, 0.000001;
  (GLH hyaline vascular, Few [<5pc]) 0.999999, 0.000001;
  (GLH plasma cell, Few [<5pc]) 0.9999, 0.0001;
  (Granulomatous laden, Few [<5pc]) 0.999999, 0.000001;
  (Histiocytosis x, Few [<5pc]) 0.999999, 0.000001;
  (Infectious mono, Few [<5pc]) 0.99999, 0.00001;
  (Leprosy-lepromatous, Few [<5pc]) 0.999999, 0.000001;
  (Lymphangiographic, Few [<5pc]) 0.999999, 0.000001;
  (Mantle zone hyperpla, Few [<5pc]) 0.999999, 0.000001;
  (Necrotizing Kikuchi, Few [<5pc]) 0.999999, 0.000001;
  (Necrotiz non-Kikuchi, Few [<5pc]) 0.999999, 0.000001;
  (Rheumatoid arthritis, Few [<5pc]) 0.9999, 0.0001;
  (Sarcoidosis, Few [<5pc]) 0.999999, 0.000001;
  (SHML, Few [<5pc]) 0.9999, 0.0001;
  (Sinus histiocytosis, Few [<5pc]) 0.999999, 0.000001;
  (Syphilis, Few [<5pc]) 0.9999, 0.0001;
  (Toxoplasmosis, Few [<5pc]) 0.999999, 0.000001;
  (Tuberculosis, Few [<5pc]) 0.999999, 0.000001;
  (Viral NOS, Few [<5pc]) 0.99999, 0.00001;
  (Whipple's disease, Few [<5pc]) 0.999999, 0.000001;
  (L&H nodular HD, Few [<5pc]) 0.999999, 0.000001;
  (L&H diffuse HD, Few [<5pc]) 0.999999, 0.000001;
  (Nodular sclerosis HD, Few [<5pc]) 0.99999, 0.00001;
  (Cellular phase NSHD, Few [<5pc]) 0.999999, 0.000001;
  (Syncytial NSHD, Few [<5pc]) 0.999999, 0.000001;
  (Mixed cellularity HD, Few [<5pc]) 0.99999, 0.00001;
  (Interfollicular HD, Few [<5pc]) 0.999999, 0.000001;
  (Diffuse fibrosis HD, Few [<5pc]) 0.999999, 0.000001;
  (Reticular-type HD, Few [<5pc]) 0.999999, 0.000001;
  (Small cleaved fol, Few [<5pc]) 0.999999, 0.000001;
  (Mixed fol, Few [<5pc]) 0.999999, 0.000001;
  (Large cell fol, Few [<5pc]) 0.999999, 0.000001;
  (Small noncleaved fol, Few [<5pc]) 0.999999, 0.000001;
  (Small lymphocytic, Few [<5pc]) 0.999999, 0.000001;
  (Plasmacytoid lyctic, Few [<5pc]) 0.5, 0.5;
  (Mantle zone lymphoma, Few [<5pc]) 0.999999, 0.000001;
  (Small cleaved dif, Few [<5pc]) 0.999999, 0.000001;
  (Mixed FCC dif, Few [<5pc]) 0.999999, 0.000001;
  (Large cell dif, Few [<5pc]) 0.999999, 0.000001;
  (B-immunoblastic, Few [<5pc]) 0.99999, 0.00001;
  (T-immunob mixed, Few [<5pc]) 0.99999, 0.00001;
  (AILD-like T-cell lym, Few [<5pc]) 0.99999, 0.00001;
  (Japanese ATL, Few [<5pc]) 0.999999, 0.000001;
  (Lymphoblastic, Few [<5pc]) 0.999999, 0.000001;
  (Small noncleaved dif, Few [<5pc]) 0.999999, 0.000001;
  (True histiocytic, Few [<5pc]) 0.999999, 0.000001;
  (Ki-1 LC anaplas T, Few [<5pc]) 0.999999, 0.000001;
  (Multiple myeloma, Few [<5pc]) 0.99, 0.01;
  (Mycosis fungoides, Few [<5pc]) 0.99999, 0.00001;
  (AML, Few [<5pc]) 0.999999, 0.000001;
  (Hairy cell leukemia, Few [<5pc]) 0.999999, 0.000001;
  (Carcinoma, Few [<5pc]) 0.999999, 0.000001;
  (Melanoma, Few [<5pc]) 0.9999, 0.0001;
  (EM plasmacytoma, Few [<5pc]) 0.5, 0.5;
  (Kaposi's sarcoma, Few [<5pc]) 0.9999, 0.0001;
  (Mast-cell disease, Few [<5pc]) 0.999999, 0.000001;
  (AIDS involutionary, Few [<5pc]) 0.9999, 0.0001;
  (T-immunob large, Few [<5pc]) 0.999999, 0.000001;
  (Monocytoid B-cell, Few [<5pc]) 0.999, 0.001;
  (Nasopharyngeal CA, Few [<5pc]) 0.999999, 0.000001;
  (Seminoma, Few [<5pc]) 0.999999, 0.000001;
  (SLE, Few [<5pc]) 0.99999, 0.00001;
  (Mycobact histiocytos, Few [<5pc]) 0.999999, 0.000001;
  (Mast-cell hyperplas, Few [<5pc]) 0.999999, 0.000001;
  (LGV, Few [<5pc]) 0.999999, 0.000001;
  (Histoplasmosis, Few [<5pc]) 0.999999, 0.000001;
  (Coccidioidomycosis, Few [<5pc]) 0.999999, 0.000001;
  (CMV, Few [<5pc]) 0.999999, 0.000001;
  (Brucellosis, Few [<5pc]) 0.999999, 0.000001;
  (Ki-1 LC anaplas B, Few [<5pc]) 0.999999, 0.000001;
  (Intermed lymphocytic, Few [<5pc]) 0.999999, 0.000001;
  (AIDS early, Moderate [6-20pc]) 0.999, 0.001;
  (AILD, Moderate [6-20pc]) 0.9999, 0.0001;
  (ALIP, Moderate [6-20pc]) 0.99999, 0.00001;
  (Cat scratch disease, Moderate [6-20pc]) 0.99999, 0.00001;
  (Dermatopathic laden, Moderate [6-20pc]) 0.999, 0.001;
  (Florid follic hyperp, Moderate [6-20pc]) 0.99999, 0.00001;
  (GLH hyaline vascular, Moderate [6-20pc]) 0.99999, 0.00001;
  (GLH plasma cell, Moderate [6-20pc]) 0.999, 0.001;
  (Granulomatous laden, Moderate [6-20pc]) 0.99999, 0.00001;
  (Histiocytosis x, Moderate [6-20pc]) 0.99999, 0.00001;
  (Infectious mono, Moderate [6-20pc]) 0.9999, 0.0001;
  (Leprosy-lepromatous, Moderate [6-20pc]) 0.99999, 0.00001;
  (Lymphangiographic, Moderate [6-20pc]) 0.99999, 0.00001;
  (Mantle zone hyperpla, Moderate [6-20pc]) 0.99999, 0.00001;
  (Necrotizing Kikuchi, Moderate [6-20pc]) 0.99999, 0.00001;
  (Necrotiz non-Kikuchi, Moderate [6-20pc]) 0.99999, 0.00001;
  (Rheumatoid arthritis, Moderate [6-20pc]) 0.999, 0.001;
  (Sarcoidosis, Moderate [6-20pc]) 0.99999, 0.00001;
  (SHML, Moderate [6-20pc]) 0.999, 0.001;
  (Sinus histiocytosis, Moderate [6-20pc]) 0.99999, 0.00001;
  (Syphilis, Moderate [6-20pc]) 0.999, 0.001;
  (Toxoplasmosis, Moderate [6-20pc]) 0.99999, 0.00001;
  (Tuberculosis, Moderate [6-20pc]) 0.99999, 0.00001;
  (Viral NOS, Moderate [6-20pc]) 0.9999, 0.0001;
  (Whipple's disease, Moderate [6-20pc]) 0.99999, 0.00001;
  (L&H nodular HD, Moderate [6-20pc]) 0.99999, 0.00001;
  (L&H diffuse HD, Moderate [6-20pc]) 0.99999, 0.00001;
  (Nodular sclerosis HD, Moderate [6-20pc]) 0.9999, 0.0001;
  (Cellular phase NSHD, Moderate [6-20pc]) 0.99999, 0.00001;
  (Syncytial NSHD, Moderate [6-20pc]) 0.99999, 0.00001;
  (Mixed cellularity HD, Moderate [6-20pc]) 0.9999, 0.0001;
  (Interfollicular HD, Moderate [6-20pc]) 0.99999, 0.00001;
  (Diffuse fibrosis HD, Moderate [6-20pc]) 0.99999, 0.00001;
  (Reticular-type HD, Moderate [6-20pc]) 0.99999, 0.00001;
  (Small cleaved fol, Moderate [6-20pc]) 0.99999, 0.00001;
  (Mixed fol, Moderate [6-20pc]) 0.99999, 0.00001;
  (Large cell fol, Moderate [6-20pc]) 0.99999, 0.00001;
  (Small noncleaved fol, Moderate [6-20pc]) 0.99999, 0.00001;
  (Small lymphocytic, Moderate [6-20pc]) 0.99999, 0.00001;
  (Plasmacytoid lyctic, Moderate [6-20pc]) 0.4, 0.6;
  (Mantle zone lymphoma, Moderate [6-20pc]) 0.99999, 0.00001;
  (Small cleaved dif, Moderate [6-20pc]) 0.99999, 0.00001;
  (Mixed FCC dif, Moderate [6-20pc]) 0.99999, 0.00001;
  (Large cell dif, Moderate [6-20pc]) 0.99999, 0.00001;
  (B-immunoblastic, Moderate [6-20pc]) 0.9999, 0.0001;
  (T-immunob mixed, Moderate [6-20pc]) 0.9999, 0.0001;
  (AILD-like T-cell lym, Moderate [6-20pc]) 0.9999, 0.0001;
  (Japanese ATL, Moderate [6-20pc]) 0.99999, 0.00001;
  (Lymphoblastic, Moderate [6-20pc]) 0.99999, 0.00001;
  (Small noncleaved dif, Moderate [6-20pc]) 0.99999, 0.00001;
  (True histiocytic, Moderate [6-20pc]) 0.99999, 0.00001;
  (Ki-1 LC anaplas T, Moderate [6-20pc]) 0.99999, 0.00001;
  (Multiple myeloma, Moderate [6-20pc]) 0.98, 0.02;
  (Mycosis fungoides, Moderate [6-20pc]) 0.9999, 0.0001;
  (AML, Moderate [6-20pc]) 0.99999, 0.00001;
  (Hairy cell leukemia, Moderate [6-20pc]) 0.99999, 0.00001;
  (Carcinoma, Moderate [6-20pc]) 0.99999, 0.00001;
  (Melanoma, Moderate [6-20pc]) 0.999, 0.001;
  (EM plasmacytoma, Moderate [6-20pc]) 0.9, 0.1;
  (Kaposi's sarcoma, Moderate [6-20pc]) 0.999, 0.001;
  (Mast-cell disease, Moderate [6-20pc]) 0.99999, 0.00001;
  (AIDS involutionary, Moderate [6-20pc]) 0.999, 0.001;
  (T-immunob large, Moderate [6-20pc]) 0.99999, 0.00001;
  (Monocytoid B-cell, Moderate [6-20pc]) 0.9, 0.1;
  (Nasopharyngeal CA, Moderate [6-20pc]) 0.99999, 0.00001;
  (Seminoma, Moderate [6-20pc]) 0.99999, 0.00001;
  (SLE, Moderate [6-20pc]) 0.9999, 0.0001;
  (Mycobact histiocytos, Moderate [6-20pc]) 0.99999, 0.00001;
  (Mast-cell hyperplas, Moderate [6-20pc]) 0.99999, 0.00001;
  (LGV, Moderate [6-20pc]) 0.99999, 0.00001;
  (Histoplasmosis, Moderate [6-20pc]) 0.99999, 0.00001;
  (Coccidioidomycosis, Moderate [6-20pc]) 0.99999, 0.00001;
  (CMV, Moderate [6-20pc]) 0.99999, 0.00001;
  (Brucellosis, Moderate [6-20pc]) 0.99999, 0.00001;
  (Ki-1 LC anaplas B, Moderate [6-20pc]) 0.99999, 0.00001;
  (Intermed lymphocytic, Moderate [6-20pc]) 0.99999, 0.00001;
  (AIDS early, Marked [21-50pc]) 0.99, 0.01;
  (AILD, Marked [21-50pc]) 0.999, 0.001;
  (ALIP, Marked [21-50pc]) 0.9999, 0.0001;
  (Cat scratch disease, Marked [21-50pc]) 0.9999, 0.0001;
  (Dermatopathic laden, Marked [21-50pc]) 0.99, 0.01;
  (Florid follic hyperp, Marked [21-50pc]) 0.9999, 0.0001;
  (GLH hyaline vascular, Marked [21-50pc]) 0.9999, 0.0001;
  (GLH plasma cell, Marked [21-50pc]) 0.99, 0.01;
  (Granulomatous laden, Marked [21-50pc]) 0.9999, 0.0001;
  (Histiocytosis x, Marked [21-50pc]) 0.9999, 0.0001;
  (Infectious mono, Marked [21-50pc]) 0.999, 0.001;
  (Leprosy-lepromatous, Marked [21-50pc]) 0.9999, 0.0001;
  (Lymphangiographic, Marked [21-50pc]) 0.9999, 0.0001;
  (Mantle zone hyperpla, Marked [21-50pc]) 0.9999, 0.0001;
  (Necrotizing Kikuchi, Marked [21-50pc]) 0.9999, 0.0001;
  (Necrotiz non-Kikuchi, Marked [21-50pc]) 0.9999, 0.0001;
  (Rheumatoid arthritis, Marked [21-50pc]) 0.99, 0.01;
  (Sarcoidosis, Marked [21-50pc]) 0.9999, 0.0001;
  (SHML, Marked [21-50pc]) 0.99, 0.01;
  (Sinus histiocytosis, Marked [21-50pc]) 0.9999, 0.0001;
  (Syphilis, Marked [21-50pc]) 0.99, 0.01;
  (Toxoplasmosis, Marked [21-50pc]) 0.9999, 0.0001;
  (Tuberculosis, Marked [21-50pc]) 0.9999, 0.0001;
  (Viral NOS, Marked [21-50pc]) 0.999, 0.001;
  (Whipple's disease, Marked [21-50pc]) 0.9999, 0.0001;
  (L&H nodular HD, Marked [21-50pc]) 0.9999, 0.0001;
  (L&H diffuse HD, Marked [21-50pc]) 0.9999, 0.0001;
  (Nodular sclerosis HD, Marked [21-50pc]) 0.999, 0.001;
  (Cellular phase NSHD, Marked [21-50pc]) 0.9999, 0.0001;
  (Syncytial NSHD, Marked [21-50pc]) 0.9999, 0.0001;
  (Mixed cellularity HD, Marked [21-50pc]) 0.999, 0.001;
  (Interfollicular HD, Marked [21-50pc]) 0.9999, 0.0001;
  (Diffuse fibrosis HD, Marked [21-50pc]) 0.9999, 0.0001;
  (Reticular-type HD, Marked [21-50pc]) 0.9999, 0.0001;
  (Small cleaved fol, Marked [21-50pc]) 0.9999, 0.0001;
  (Mixed fol, Marked [21-50pc]) 0.9999, 0.0001;
  (Large cell fol, Marked [21-50pc]) 0.9999, 0.0001;
  (Small noncleaved fol, Marked [21-50pc]) 0.9999, 0.0001;
  (Small lymphocytic, Marked [21-50pc]) 0.9999, 0.0001;
  (Plasmacytoid lyctic, Marked [21-50pc]) 0.3, 0.7;
  (Mantle zone lymphoma, Marked [21-50pc]) 0.9999, 0.0001;
  (Small cleaved dif, Marked [21-50pc]) 0.9999, 0.0001;
  (Mixed FCC dif, Marked [21-50pc]) 0.9999, 0.0001;
  (Large cell dif, Marked [21-50pc]) 0.9999, 0.0001;
  (B-immunoblastic, Marked [21-50pc]) 0.999, 0.001;
  (T-immunob mixed, Marked [21-50pc]) 0.999, 0.001;
  (AILD-like T-cell lym, Marked [21-50pc]) 0.999, 0.001;
  (Japanese ATL, Marked [21-50pc]) 0.9999, 0.0001;
  (Lymphoblastic, Marked [21-50pc]) 0.9999, 0.0001;
  (Small noncleaved dif, Marked [21-50pc]) 0.9999, 0.0001;
  (True histiocytic, Marked [21-50pc]) 0.9999, 0.0001;
  (Ki-1 LC anaplas T, Marked [21-50pc]) 0.9999, 0.0001;
  (Multiple myeloma, Marked [21-50pc]) 0.97, 0.03;
  (Mycosis fungoides, Marked [21-50pc]) 0.999, 0.001;
  (AML, Marked [21-50pc]) 0.9999, 0.0001;
  (Hairy cell leukemia, Marked [21-50pc]) 0.9999, 0.0001;
  (Carcinoma, Marked [21-50pc]) 0.9999, 0.0001;
  (Melanoma, Marked [21-50pc]) 0.99, 0.01;
  (EM plasmacytoma, Marked [21-50pc]) 0.99, 0.01;
  (Kaposi's sarcoma, Marked [21-50pc]) 0.99, 0.01;
  (Mast-cell disease, Marked [21-50pc]) 0.9999, 0.0001;
  (AIDS involutionary, Marked [21-50pc]) 0.99, 0.01;
  (T-immunob large, Marked [21-50pc]) 0.9999, 0.0001;
  (Monocytoid B-cell, Marked [21-50pc]) 0.9, 0.1;
  (Nasopharyngeal CA, Marked [21-50pc]) 0.9999, 0.0001;
  (Seminoma, Marked [21-50pc]) 0.9999, 0.0001;
  (SLE, Marked [21-50pc]) 0.999, 0.001;
  (Mycobact histiocytos, Marked [21-50pc]) 0.9999, 0.0001;
  (Mast-cell hyperplas, Marked [21-50pc]) 0.9999, 0.0001;
  (LGV, Marked [21-50pc]) 0.9999, 0.0001;
  (Histoplasmosis, Marked [21-50pc]) 0.9999, 0.0001;
  (Coccidioidomycosis, Marked [21-50pc]) 0.9999, 0.0001;
  (CMV, Marked [21-50pc]) 0.9999, 0.0001;
  (Brucellosis, Marked [21-50pc]) 0.9999, 0.0001;
  (Ki-1 LC anaplas B, Marked [21-50pc]) 0.9999, 0.0001;
  (Intermed lymphocytic, Marked [21-50pc]) 0.9999, 0.0001;
  (AIDS early, Striking [51-90pc]) 0.98, 0.02;
  (AILD, Striking [51-90pc]) 0.99, 0.01;
  (ALIP, Striking [51-90pc]) 0.9999, 0.0001;
  (Cat scratch disease, Striking [51-90pc]) 0.9999, 0.0001;
  (Dermatopathic laden, Striking [51-90pc]) 0.98, 0.02;
  (Florid follic hyperp, Striking [51-90pc]) 0.9999, 0.0001;
  (GLH hyaline vascular, Striking [51-90pc]) 0.9999, 0.0001;
  (GLH plasma cell, Striking [51-90pc]) 0.98, 0.02;
  (Granulomatous laden, Striking [51-90pc]) 0.9999, 0.0001;
  (Histiocytosis x, Striking [51-90pc]) 0.9999, 0.0001;
  (Infectious mono, Striking [51-90pc]) 0.99, 0.01;
  (Leprosy-lepromatous, Striking [51-90pc]) 0.9999, 0.0001;
  (Lymphangiographic, Striking [51-90pc]) 0.9999, 0.0001;
  (Mantle zone hyperpla, Striking [51-90pc]) 0.9999, 0.0001;
  (Necrotizing Kikuchi, Striking [51-90pc]) 0.9999, 0.0001;
  (Necrotiz non-Kikuchi, Striking [51-90pc]) 0.9999, 0.0001;
  (Rheumatoid arthritis, Striking [51-90pc]) 0.98, 0.02;
  (Sarcoidosis, Striking [51-90pc]) 0.9999, 0.0001;
  (SHML, Striking [51-90pc]) 0.98, 0.02;
  (Sinus histiocytosis, Striking [51-90pc]) 0.9999, 0.0001;
  (Syphilis, Striking [51-90pc]) 0.98, 0.02;
  (Toxoplasmosis, Striking [51-90pc]) 0.9999, 0.0001;
  (Tuberculosis, Striking [51-90pc]) 0.9999, 0.0001;
  (Viral NOS, Striking [51-90pc]) 0.99, 0.01;
  (Whipple's disease, Striking [51-90pc]) 0.9999, 0.0001;
  (L&H nodular HD, Striking [51-90pc]) 0.9999, 0.0001;
  (L&H diffuse HD, Striking [51-90pc]) 0.9999, 0.0001;
  (Nodular sclerosis HD, Striking [51-90pc]) 0.99, 0.01;
  (Cellular phase NSHD, Striking [51-90pc]) 0.9999, 0.0001;
  (Syncytial NSHD, Striking [51-90pc]) 0.9999, 0.0001;
  (Mixed cellularity HD, Striking [51-90pc]) 0.99, 0.01;
  (Interfollicular HD, Striking [51-90pc]) 0.9999, 0.0001;
  (Diffuse fibrosis HD, Striking [51-90pc]) 0.9999, 0.0001;
  (Reticular-type HD, Striking [51-90pc]) 0.9999, 0.0001;
  (Small cleaved fol, Striking [51-90pc]) 0.9999, 0.0001;
  (Mixed fol, Striking [51-90pc]) 0.9999, 0.0001;
  (Large cell fol, Striking [51-90pc]) 0.9999, 0.0001;
  (Small noncleaved fol, Striking [51-90pc]) 0.9999, 0.0001;
  (Small lymphocytic, Striking [51-90pc]) 0.9999, 0.0001;
  (Plasmacytoid lyctic, Striking [51-90pc]) 0.2, 0.8;
  (Mantle zone lymphoma, Striking [51-90pc]) 0.9999, 0.0001;
  (Small cleaved dif, Striking [51-90pc]) 0.9999, 0.0001;
  (Mixed FCC dif, Striking [51-90pc]) 0.9999, 0.0001;
  (Large cell dif, Striking [51-90pc]) 0.9999, 0.0001;
  (B-immunoblastic, Striking [51-90pc]) 0.99, 0.01;
  (T-immunob mixed, Striking [51-90pc]) 0.99, 0.01;
  (AILD-like T-cell lym, Striking [51-90pc]) 0.99, 0.01;
  (Japanese ATL, Striking [51-90pc]) 0.9999, 0.0001;
  (Lymphoblastic, Striking [51-90pc]) 0.9999, 0.0001;
  (Small noncleaved dif, Striking [51-90pc]) 0.9999, 0.0001;
  (True histiocytic, Striking [51-90pc]) 0.9999, 0.0001;
  (Ki-1 LC anaplas T, Striking [51-90pc]) 0.9999, 0.0001;
  (Multiple myeloma, Striking [51-90pc]) 0.96, 0.04;
  (Mycosis fungoides, Striking [51-90pc]) 0.99, 0.01;
  (AML, Striking [51-90pc]) 0.9999, 0.0001;
  (Hairy cell leukemia, Striking [51-90pc]) 0.9999, 0.0001;
  (Carcinoma, Striking [51-90pc]) 0.9999, 0.0001;
  (Melanoma, Striking [51-90pc]) 0.98, 0.02;
  (EM plasmacytoma, Striking [51-90pc]) 0.98, 0.02;
  (Kaposi's sarcoma, Striking [51-90pc]) 0.98, 0.02;
  (Mast-cell disease, Striking [51-90pc]) 0.9999, 0.0001;
  (AIDS involutionary, Striking [51-90pc]) 0.98, 0.02;
  (T-immunob large, Striking [51-90pc]) 0.9999, 0.0001;
  (Monocytoid B-cell, Striking [51-90pc]) 0.9, 0.1;
  (Nasopharyngeal CA, Striking [51-90pc]) 0.9999, 0.0001;
  (Seminoma, Striking [51-90pc]) 0.9999, 0.0001;
  (SLE, Striking [51-90pc]) 0.99, 0.01;
  (Mycobact histiocytos, Striking [51-90pc]) 0.9999, 0.0001;
  (Mast-cell hyperplas, Striking [51-90pc]) 0.9999, 0.0001;
  (LGV, Striking [51-90pc]) 0.9999, 0.0001;
  (Histoplasmosis, Striking [51-90pc]) 0.9999, 0.0001;
  (Coccidioidomycosis, Striking [51-90pc]) 0.9999, 0.0001;
  (CMV, Striking [51-90pc]) 0.9999, 0.0001;
  (Brucellosis, Striking [51-90pc]) 0.9999, 0.0001;
  (Ki-1 LC anaplas B, Striking [51-90pc]) 0.9999, 0.0001;
  (Intermed lymphocytic, Striking [51-90pc]) 0.9999, 0.0001;
  (AIDS early, Sheets [>90pc]) 0.5, 0.5;
  (AILD, Sheets [>90pc]) 0.5, 0.5;
  (ALIP, Sheets [>90pc]) 0.5, 0.5;
  (Cat scratch disease, Sheets [>90pc]) 0.5, 0.5;
  (Dermatopathic laden, Sheets [>90pc]) 0.5, 0.5;
  (Florid follic hyperp, Sheets [>90pc]) 0.5, 0.5;
  (GLH hyaline vascular, Sheets [>90pc]) 0.5, 0.5;
  (GLH plasma cell, Sheets [>90pc]) 0.5, 0.5;
  (Granulomatous laden, Sheets [>90pc]) 0.5, 0.5;
  (Histiocytosis x, Sheets [>90pc]) 0.5, 0.5;
  (Infectious mono, Sheets [>90pc]) 0.5, 0.5;
  (Leprosy-lepromatous, Sheets [>90pc]) 0.5, 0.5;
  (Lymphangiographic, Sheets [>90pc]) 0.5, 0.5;
  (Mantle zone hyperpla, Sheets [>90pc]) 0.5, 0.5;
  (Necrotizing Kikuchi, Sheets [>90pc]) 0.5, 0.5;
  (Necrotiz non-Kikuchi, Sheets [>90pc]) 0.5, 0.5;
  (Rheumatoid arthritis, Sheets [>90pc]) 0.5, 0.5;
  (Sarcoidosis, Sheets [>90pc]) 0.5, 0.5;
  (SHML, Sheets [>90pc]) 0.5, 0.5;
  (Sinus histiocytosis, Sheets [>90pc]) 0.5, 0.5;
  (Syphilis, Sheets [>90pc]) 0.5, 0.5;
  (Toxoplasmosis, Sheets [>90pc]) 0.5, 0.5;
  (Tuberculosis, Sheets [>90pc]) 0.5, 0.5;
  (Viral NOS, Sheets [>90pc]) 0.5, 0.5;
  (Whipple's disease, Sheets [>90pc]) 0.5, 0.5;
  (L&H nodular HD, Sheets [>90pc]) 0.5, 0.5;
  (L&H diffuse HD, Sheets [>90pc]) 0.5, 0.5;
  (Nodular sclerosis HD, Sheets [>90pc]) 0.5, 0.5;
  (Cellular phase NSHD, Sheets [>90pc]) 0.5, 0.5;
  (Syncytial NSHD, Sheets [>90pc]) 0.5, 0.5;
  (Mixed cellularity HD, Sheets [>90pc]) 0.5, 0.5;
  (Interfollicular HD, Sheets [>90pc]) 0.5, 0.5;
  (Diffuse fibrosis HD, Sheets [>90pc]) 0.5, 0.5;
  (Reticular-type HD, Sheets [>90pc]) 0.5, 0.5;
  (Small cleaved fol, Sheets [>90pc]) 0.5, 0.5;
  (Mixed fol, Sheets [>90pc]) 0.5, 0.5;
  (Large cell fol, Sheets [>90pc]) 0.5, 0.5;
  (Small noncleaved fol, Sheets [>90pc]) 0.5, 0.5;
  (Small lymphocytic, Sheets [>90pc]) 0.5, 0.5;
  (Plasmacytoid lyctic, Sheets [>90pc]) 0.5, 0.5;
  (Mantle zone lymphoma, Sheets [>90pc]) 0.5, 0.5;
  (Small cleaved dif, Sheets [>90pc]) 0.5, 0.5;
  (Mixed FCC dif, Sheets [>90pc]) 0.5, 0.5;
  (Large cell dif, Sheets [>90pc]) 0.5, 0.5;
  (B-immunoblastic, Sheets [>90pc]) 0.5, 0.5;
  (T-immunob mixed, Sheets [>90pc]) 0.5, 0.5;
  (AILD-like T-cell lym, Sheets [>90pc]) 0.5, 0.5;
  (Japanese ATL, Sheets [>90pc]) 0.5, 0.5;
  (Lymphoblastic, Sheets [>90pc]) 0.5, 0.5;
  (Small noncleaved dif, Sheets [>90pc]) 0.5, 0.5;
  (True histiocytic, Sheets [>90pc]) 0.5, 0.5;
  (Ki-1 LC anaplas T, Sheets [>90pc]) 0.5, 0.5;
  (Multiple myeloma, Sheets [>90pc]) 0.95, 0.05;
  (Mycosis fungoides, Sheets [>90pc]) 0.5, 0.5;
  (AML, Sheets [>90pc]) 0.5, 0.5;
  (Hairy cell leukemia, Sheets [>90pc]) 0.5, 0.5;
  (Carcinoma, Sheets [>90pc]) 0.5, 0.5;
  (Melanoma, Sheets [>90pc]) 0.5, 0.5;
  (EM plasmacytoma, Sheets [>90pc]) 0.95, 0.05;
  (Kaposi's sarcoma, Sheets [>90pc]) 0.5, 0.5;
  (Mast-cell disease, Sheets [>90pc]) 0.5, 0.5;
  (AIDS involutionary, Sheets [>90pc]) 0.5, 0.5;
  (T-immunob large, Sheets [>90pc]) 0.5, 0.5;
  (Monocytoid B-cell, Sheets [>90pc]) 0.5, 0.5;
  (Nasopharyngeal CA, Sheets [>90pc]) 0.5, 0.5;
  (Seminoma, Sheets [>90pc]) 0.5, 0.5;
  (SLE, Sheets [>90pc]) 0.5, 0.5;
  (Mycobact histiocytos, Sheets [>90pc]) 0.5, 0.5;
  (Mast-cell hyperplas, Sheets [>90pc]) 0.5, 0.5;
  (LGV, Sheets [>90pc]) 0.5, 0.5;
  (Histoplasmosis, Sheets [>90pc]) 0.5, 0.5;
  (Coccidioidomycosis, Sheets [>90pc]) 0.5, 0.5;
  (CMV, Sheets [>90pc]) 0.5, 0.5;
  (Brucellosis, Sheets [>90pc]) 0.5, 0.5;
  (Ki-1 LC anaplas B, Sheets [>90pc]) 0.5, 0.5;
  (Intermed lymphocytic, Sheets [>90pc]) 0.5, 0.5;
}
probability ( SARCOMA | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 1.0, 0.0;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 1.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 1.0, 0.0;
  (L&H diffuse HD) 1.0, 0.0;
  (Nodular sclerosis HD) 1.0, 0.0;
  (Cellular phase NSHD) 1.0, 0.0;
  (Syncytial NSHD) 1.0, 0.0;
  (Mixed cellularity HD) 1.0, 0.0;
  (Interfollicular HD) 1.0, 0.0;
  (Diffuse fibrosis HD) 1.0, 0.0;
  (Reticular-type HD) 1.0, 0.0;
  (Small cleaved fol) 1.0, 0.0;
  (Mixed fol) 1.0, 0.0;
  (Large cell fol) 1.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0;
  (Small lymphocytic) 1.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0;
  (Small cleaved dif) 1.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0;
  (Large cell dif) 1.0, 0.0;
  (B-immunoblastic) 1.0, 0.0;
  (T-immunob mixed) 1.0, 0.0;
  (AILD-like T-cell lym) 1.0, 0.0;
  (Japanese ATL) 1.0, 0.0;
  (Lymphoblastic) 1.0, 0.0;
  (Small noncleaved dif) 1.0, 0.0;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 1.0, 0.0;
  (Multiple myeloma) 1.0, 0.0;
  (Mycosis fungoides) 1.0, 0.0;
  (AML) 1.0, 0.0;
  (Hairy cell leukemia) 1.0, 0.0;
  (Carcinoma) 1.0, 0.0;
  (Melanoma) 1.0, 0.0;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 0.01, 0.99;
  (Mast-cell disease) 1.0, 0.0;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 1.0, 0.0;
  (Monocytoid B-cell) 1.0, 0.0;
  (Nasopharyngeal CA) 1.0, 0.0;
  (Seminoma) 1.0, 0.0;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 1.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0;
}
probability ( SCHAUM | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 1.0, 0.0;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 0.6, 0.4;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 1.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 1.0, 0.0;
  (L&H diffuse HD) 1.0, 0.0;
  (Nodular sclerosis HD) 1.0, 0.0;
  (Cellular phase NSHD) 1.0, 0.0;
  (Syncytial NSHD) 1.0, 0.0;
  (Mixed cellularity HD) 1.0, 0.0;
  (Interfollicular HD) 1.0, 0.0;
  (Diffuse fibrosis HD) 1.0, 0.0;
  (Reticular-type HD) 1.0, 0.0;
  (Small cleaved fol) 1.0, 0.0;
  (Mixed fol) 1.0, 0.0;
  (Large cell fol) 1.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0;
  (Small lymphocytic) 1.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0;
  (Small cleaved dif) 1.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0;
  (Large cell dif) 1.0, 0.0;
  (B-immunoblastic) 1.0, 0.0;
  (T-immunob mixed) 1.0, 0.0;
  (AILD-like T-cell lym) 1.0, 0.0;
  (Japanese ATL) 1.0, 0.0;
  (Lymphoblastic) 1.0, 0.0;
  (Small noncleaved dif) 1.0, 0.0;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 1.0, 0.0;
  (Multiple myeloma) 1.0, 0.0;
  (Mycosis fungoides) 1.0, 0.0;
  (AML) 1.0, 0.0;
  (Hairy cell leukemia) 1.0, 0.0;
  (Carcinoma) 1.0, 0.0;
  (Melanoma) 1.0, 0.0;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0;
  (Mast-cell disease) 1.0, 0.0;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 1.0, 0.0;
  (Monocytoid B-cell) 1.0, 0.0;
  (Nasopharyngeal CA) 1.0, 0.0;
  (Seminoma) 1.0, 0.0;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 1.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0;
}
probability ( S_RING | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 1.0, 0.0;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 1.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 1.0, 0.0;
  (L&H diffuse HD) 1.0, 0.0;
  (Nodular sclerosis HD) 1.0, 0.0;
  (Cellular phase NSHD) 1.0, 0.0;
  (Syncytial NSHD) 1.0, 0.0;
  (Mixed cellularity HD) 1.0, 0.0;
  (Interfollicular HD) 1.0, 0.0;
  (Diffuse fibrosis HD) 1.0, 0.0;
  (Reticular-type HD) 1.0, 0.0;
  (Small cleaved fol) 0.999, 0.001;
  (Mixed fol) 0.999, 0.001;
  (Large cell fol) 0.999, 0.001;
  (Small noncleaved fol) 1.0, 0.0;
  (Small lymphocytic) 1.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0;
  (Small cleaved dif) 0.999, 0.001;
  (Mixed FCC dif) 0.999, 0.001;
  (Large cell dif) 0.999, 0.001;
  (B-immunoblastic) 1.0, 0.0;
  (T-immunob mixed) 1.0, 0.0;
  (AILD-like T-cell lym) 1.0, 0.0;
  (Japanese ATL) 1.0, 0.0;
  (Lymphoblastic) 1.0, 0.0;
  (Small noncleaved dif) 1.0, 0.0;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 1.0, 0.0;
  (Multiple myeloma) 1.0, 0.0;
  (Mycosis fungoides) 1.0, 0.0;
  (AML) 1.0, 0.0;
  (Hairy cell leukemia) 1.0, 0.0;
  (Carcinoma) 0.9999, 0.0001;
  (Melanoma) 0.9999, 0.0001;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0;
  (Mast-cell disease) 1.0, 0.0;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 1.0, 0.0;
  (Monocytoid B-cell) 0.999, 0.001;
  (Nasopharyngeal CA) 0.9999, 0.0001;
  (Seminoma) 1.0, 0.0;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 1.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0;
}
probability ( SLC_CY | Fault, SLC ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (AILD, Sparse [1-10pc]) 0.000, 0.999, 0.001, 0.000;
  (ALIP, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Cat scratch disease, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Dermatopathic laden, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Florid follic hyperp, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (GLH hyaline vascular, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (GLH plasma cell, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Granulomatous laden, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Histiocytosis x, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Infectious mono, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Leprosy-lepromatous, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Lymphangiographic, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Mantle zone hyperpla, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Necrotizing Kikuchi, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Necrotiz non-Kikuchi, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Rheumatoid arthritis, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Sarcoidosis, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (SHML, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Sinus histiocytosis, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Syphilis, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Toxoplasmosis, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Tuberculosis, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Viral NOS, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Whipple's disease, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (L&H nodular HD, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (L&H diffuse HD, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Nodular sclerosis HD, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Cellular phase NSHD, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Syncytial NSHD, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Mixed cellularity HD, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Interfollicular HD, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Diffuse fibrosis HD, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Reticular-type HD, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Small cleaved fol, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Mixed fol, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Large cell fol, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Small noncleaved fol, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Small lymphocytic, Sparse [1-10pc]) 0.00, 0.95, 0.05, 0.00;
  (Plasmacytoid lyctic, Sparse [1-10pc]) 0.00, 0.85, 0.00, 0.15;
  (Mantle zone lymphoma, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Small cleaved dif, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Mixed FCC dif, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Large cell dif, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (B-immunoblastic, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (T-immunob mixed, Sparse [1-10pc]) 0.00, 0.91, 0.09, 0.00;
  (AILD-like T-cell lym, Sparse [1-10pc]) 0.0, 0.7, 0.3, 0.0;
  (Japanese ATL, Sparse [1-10pc]) 0.00, 0.98, 0.02, 0.00;
  (Lymphoblastic, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Small noncleaved dif, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (True histiocytic, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Ki-1 LC anaplas T, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Multiple myeloma, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Mycosis fungoides, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (AML, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Hairy cell leukemia, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Carcinoma, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Melanoma, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (EM plasmacytoma, Sparse [1-10pc]) 0.00, 0.99, 0.00, 0.01;
  (Kaposi's sarcoma, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Mast-cell disease, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (AIDS involutionary, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (T-immunob large, Sparse [1-10pc]) 0.00, 0.91, 0.09, 0.00;
  (Monocytoid B-cell, Sparse [1-10pc]) 0.00, 0.98, 0.01, 0.01;
  (Nasopharyngeal CA, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Seminoma, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (SLE, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Mycobact histiocytos, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Mast-cell hyperplas, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (LGV, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Histoplasmosis, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Coccidioidomycosis, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (CMV, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Brucellosis, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Ki-1 LC anaplas B, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (Intermed lymphocytic, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00;
  (AIDS early, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (AILD, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (ALIP, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Cat scratch disease, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Dermatopathic laden, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Florid follic hyperp, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (GLH hyaline vascular, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (GLH plasma cell, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Granulomatous laden, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Histiocytosis x, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Infectious mono, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Leprosy-lepromatous, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Lymphangiographic, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Mantle zone hyperpla, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Necrotizing Kikuchi, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Necrotiz non-Kikuchi, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Rheumatoid arthritis, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Sarcoidosis, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (SHML, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Sinus histiocytosis, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Syphilis, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Toxoplasmosis, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Tuberculosis, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Viral NOS, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Whipple's disease, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (L&H nodular HD, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (L&H diffuse HD, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Nodular sclerosis HD, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Cellular phase NSHD, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Syncytial NSHD, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Mixed cellularity HD, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Interfollicular HD, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Diffuse fibrosis HD, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Reticular-type HD, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Small cleaved fol, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Mixed fol, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Large cell fol, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Small noncleaved fol, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Small lymphocytic, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00;
  (Plasmacytoid lyctic, Moderate [11-50pc]) 0.00, 0.85, 0.00, 0.15;
  (Mantle zone lymphoma, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Small cleaved dif, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Mixed FCC dif, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Large cell dif, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (B-immunoblastic, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (T-immunob mixed, Moderate [11-50pc]) 0.00, 0.91, 0.09, 0.00;
  (AILD-like T-cell lym, Moderate [11-50pc]) 0.0, 0.7, 0.3, 0.0;
  (Japanese ATL, Moderate [11-50pc]) 0.00, 0.98, 0.02, 0.00;
  (Lymphoblastic, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Small noncleaved dif, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (True histiocytic, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Ki-1 LC anaplas T, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Multiple myeloma, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Mycosis fungoides, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (AML, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Hairy cell leukemia, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Carcinoma, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Melanoma, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (EM plasmacytoma, Moderate [11-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Kaposi's sarcoma, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Mast-cell disease, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (AIDS involutionary, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (T-immunob large, Moderate [11-50pc]) 0.00, 0.91, 0.09, 0.00;
  (Monocytoid B-cell, Moderate [11-50pc]) 0.00, 0.79, 0.20, 0.01;
  (Nasopharyngeal CA, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Seminoma, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (SLE, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Mycobact histiocytos, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Mast-cell hyperplas, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (LGV, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Histoplasmosis, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Coccidioidomycosis, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (CMV, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Brucellosis, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Ki-1 LC anaplas B, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (Intermed lymphocytic, Moderate [11-50pc]) 0.000, 0.999, 0.001, 0.000;
  (AIDS early, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (AILD, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (ALIP, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Cat scratch disease, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Dermatopathic laden, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Florid follic hyperp, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (GLH hyaline vascular, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (GLH plasma cell, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Granulomatous laden, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Histiocytosis x, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Infectious mono, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Leprosy-lepromatous, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Lymphangiographic, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Mantle zone hyperpla, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Necrotizing Kikuchi, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Necrotiz non-Kikuchi, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Rheumatoid arthritis, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Sarcoidosis, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (SHML, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Sinus histiocytosis, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Syphilis, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Toxoplasmosis, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Tuberculosis, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Viral NOS, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Whipple's disease, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (L&H nodular HD, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (L&H diffuse HD, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Nodular sclerosis HD, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Cellular phase NSHD, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Syncytial NSHD, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Mixed cellularity HD, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Interfollicular HD, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Diffuse fibrosis HD, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Reticular-type HD, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Small cleaved fol, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Mixed fol, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Large cell fol, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Small noncleaved fol, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Small lymphocytic, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00;
  (Plasmacytoid lyctic, Numerous [51-90pc]) 0.00, 0.85, 0.00, 0.15;
  (Mantle zone lymphoma, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Small cleaved dif, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Mixed FCC dif, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Large cell dif, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (B-immunoblastic, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (T-immunob mixed, Numerous [51-90pc]) 0.00, 0.91, 0.09, 0.00;
  (AILD-like T-cell lym, Numerous [51-90pc]) 0.0, 0.7, 0.3, 0.0;
  (Japanese ATL, Numerous [51-90pc]) 0.00, 0.98, 0.02, 0.00;
  (Lymphoblastic, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Small noncleaved dif, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (True histiocytic, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Ki-1 LC anaplas T, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Multiple myeloma, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Mycosis fungoides, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (AML, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Hairy cell leukemia, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Carcinoma, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Melanoma, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (EM plasmacytoma, Numerous [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Kaposi's sarcoma, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Mast-cell disease, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (AIDS involutionary, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (T-immunob large, Numerous [51-90pc]) 0.00, 0.91, 0.09, 0.00;
  (Monocytoid B-cell, Numerous [51-90pc]) 0.00, 0.79, 0.20, 0.01;
  (Nasopharyngeal CA, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Seminoma, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (SLE, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Mycobact histiocytos, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Mast-cell hyperplas, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (LGV, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Histoplasmosis, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Coccidioidomycosis, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (CMV, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Brucellosis, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Ki-1 LC anaplas B, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (Intermed lymphocytic, Numerous [51-90pc]) 0.000, 0.999, 0.001, 0.000;
  (AIDS early, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (AILD, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (ALIP, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Cat scratch disease, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Dermatopathic laden, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Florid follic hyperp, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (GLH hyaline vascular, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (GLH plasma cell, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Granulomatous laden, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Histiocytosis x, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Infectious mono, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Leprosy-lepromatous, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Lymphangiographic, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Mantle zone hyperpla, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Necrotizing Kikuchi, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Necrotiz non-Kikuchi, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Rheumatoid arthritis, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Sarcoidosis, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (SHML, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Sinus histiocytosis, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Syphilis, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Toxoplasmosis, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Tuberculosis, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Viral NOS, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Whipple's disease, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (L&H nodular HD, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (L&H diffuse HD, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Nodular sclerosis HD, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Cellular phase NSHD, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Syncytial NSHD, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Mixed cellularity HD, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Interfollicular HD, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Diffuse fibrosis HD, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Reticular-type HD, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Small cleaved fol, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Mixed fol, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Large cell fol, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Small noncleaved fol, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Small lymphocytic, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00;
  (Plasmacytoid lyctic, Striking [>90pc]) 0.00, 0.85, 0.00, 0.15;
  (Mantle zone lymphoma, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Small cleaved dif, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Mixed FCC dif, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Large cell dif, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (B-immunoblastic, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (T-immunob mixed, Striking [>90pc]) 0.00, 0.91, 0.09, 0.00;
  (AILD-like T-cell lym, Striking [>90pc]) 0.0, 0.7, 0.3, 0.0;
  (Japanese ATL, Striking [>90pc]) 0.00, 0.98, 0.02, 0.00;
  (Lymphoblastic, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Small noncleaved dif, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (True histiocytic, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Ki-1 LC anaplas T, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Multiple myeloma, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Mycosis fungoides, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (AML, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Hairy cell leukemia, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Carcinoma, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Melanoma, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (EM plasmacytoma, Striking [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Kaposi's sarcoma, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Mast-cell disease, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (AIDS involutionary, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (T-immunob large, Striking [>90pc]) 0.00, 0.91, 0.09, 0.00;
  (Monocytoid B-cell, Striking [>90pc]) 0.00, 0.79, 0.20, 0.01;
  (Nasopharyngeal CA, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Seminoma, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (SLE, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Mycobact histiocytos, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Mast-cell hyperplas, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (LGV, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Histoplasmosis, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Coccidioidomycosis, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (CMV, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Brucellosis, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Ki-1 LC anaplas B, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
  (Intermed lymphocytic, Striking [>90pc]) 0.000, 0.999, 0.001, 0.000;
}
probability ( SLC_NS | Fault, SLC ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS early, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (AILD, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (ALIP, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Cat scratch disease, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Dermatopathic laden, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Florid follic hyperp, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (GLH hyaline vascular, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (GLH plasma cell, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Granulomatous laden, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Histiocytosis x, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Infectious mono, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Leprosy-lepromatous, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Lymphangiographic, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mantle zone hyperpla, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Necrotizing Kikuchi, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Necrotiz non-Kikuchi, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Rheumatoid arthritis, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Sarcoidosis, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (SHML, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Sinus histiocytosis, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Syphilis, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Toxoplasmosis, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Tuberculosis, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Viral NOS, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Whipple's disease, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (L&H nodular HD, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (L&H diffuse HD, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Nodular sclerosis HD, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Cellular phase NSHD, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Syncytial NSHD, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mixed cellularity HD, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Interfollicular HD, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Diffuse fibrosis HD, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Reticular-type HD, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Small cleaved fol, Sparse [1-10pc]) 0.00000, 0.00000, 0.00001, 0.20000, 0.79999;
  (Mixed fol, Sparse [1-10pc]) 0.00000, 0.00000, 0.00001, 0.20000, 0.79999;
  (Large cell fol, Sparse [1-10pc]) 0.00, 0.00, 0.00, 0.03, 0.97;
  (Small noncleaved fol, Sparse [1-10pc]) 0.00, 0.00, 0.00, 0.03, 0.97;
  (Small lymphocytic, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Plasmacytoid lyctic, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mantle zone lymphoma, Sparse [1-10pc]) 0.000, 0.000, 0.001, 0.099, 0.900;
  (Small cleaved dif, Sparse [1-10pc]) 0.000, 0.000, 0.001, 0.998, 0.001;
  (Mixed FCC dif, Sparse [1-10pc]) 0.000, 0.000, 0.001, 0.998, 0.001;
  (Large cell dif, Sparse [1-10pc]) 0.00, 0.00, 0.00, 0.04, 0.96;
  (B-immunoblastic, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (T-immunob mixed, Sparse [1-10pc]) 0.000, 0.000, 0.005, 0.795, 0.200;
  (AILD-like T-cell lym, Sparse [1-10pc]) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Japanese ATL, Sparse [1-10pc]) 0.000, 0.100, 0.100, 0.799, 0.001;
  (Lymphoblastic, Sparse [1-10pc]) 0.00, 0.00, 0.01, 0.05, 0.94;
  (Small noncleaved dif, Sparse [1-10pc]) 0.00, 0.00, 0.00, 0.04, 0.96;
  (True histiocytic, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Ki-1 LC anaplas T, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Multiple myeloma, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mycosis fungoides, Sparse [1-10pc]) 0.000, 0.599, 0.300, 0.100, 0.001;
  (AML, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Hairy cell leukemia, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Carcinoma, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Melanoma, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (EM plasmacytoma, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Kaposi's sarcoma, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mast-cell disease, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (AIDS involutionary, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (T-immunob large, Sparse [1-10pc]) 0.000, 0.000, 0.005, 0.795, 0.200;
  (Monocytoid B-cell, Sparse [1-10pc]) 0.00, 0.00, 0.00, 0.02, 0.98;
  (Nasopharyngeal CA, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Seminoma, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (SLE, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mycobact histiocytos, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mast-cell hyperplas, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (LGV, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Histoplasmosis, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Coccidioidomycosis, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (CMV, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Brucellosis, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Ki-1 LC anaplas B, Sparse [1-10pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Intermed lymphocytic, Sparse [1-10pc]) 0.000, 0.000, 0.001, 0.099, 0.900;
  (AIDS early, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (AILD, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (ALIP, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Cat scratch disease, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Dermatopathic laden, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Florid follic hyperp, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (GLH hyaline vascular, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (GLH plasma cell, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Granulomatous laden, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Histiocytosis x, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Infectious mono, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Leprosy-lepromatous, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Lymphangiographic, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mantle zone hyperpla, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Necrotizing Kikuchi, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Necrotiz non-Kikuchi, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Rheumatoid arthritis, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Sarcoidosis, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (SHML, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Sinus histiocytosis, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Syphilis, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Toxoplasmosis, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Tuberculosis, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Viral NOS, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Whipple's disease, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (L&H nodular HD, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (L&H diffuse HD, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Nodular sclerosis HD, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Cellular phase NSHD, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Syncytial NSHD, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mixed cellularity HD, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Interfollicular HD, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Diffuse fibrosis HD, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Reticular-type HD, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Small cleaved fol, Moderate [11-50pc]) 0.00000, 0.00000, 0.00001, 0.20000, 0.79999;
  (Mixed fol, Moderate [11-50pc]) 0.00000, 0.00000, 0.00001, 0.20000, 0.79999;
  (Large cell fol, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.03, 0.97;
  (Small noncleaved fol, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.03, 0.97;
  (Small lymphocytic, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Plasmacytoid lyctic, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mantle zone lymphoma, Moderate [11-50pc]) 0.000, 0.000, 0.001, 0.099, 0.900;
  (Small cleaved dif, Moderate [11-50pc]) 0.000, 0.000, 0.001, 0.979, 0.020;
  (Mixed FCC dif, Moderate [11-50pc]) 0.000, 0.000, 0.001, 0.979, 0.020;
  (Large cell dif, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.04, 0.96;
  (B-immunoblastic, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (T-immunob mixed, Moderate [11-50pc]) 0.000, 0.000, 0.005, 0.795, 0.200;
  (AILD-like T-cell lym, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Japanese ATL, Moderate [11-50pc]) 0.000, 0.100, 0.100, 0.799, 0.001;
  (Lymphoblastic, Moderate [11-50pc]) 0.00, 0.00, 0.01, 0.05, 0.94;
  (Small noncleaved dif, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.04, 0.96;
  (True histiocytic, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Ki-1 LC anaplas T, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Multiple myeloma, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mycosis fungoides, Moderate [11-50pc]) 0.000, 0.599, 0.300, 0.100, 0.001;
  (AML, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Hairy cell leukemia, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Carcinoma, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Melanoma, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (EM plasmacytoma, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Kaposi's sarcoma, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mast-cell disease, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (AIDS involutionary, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (T-immunob large, Moderate [11-50pc]) 0.000, 0.000, 0.005, 0.795, 0.200;
  (Monocytoid B-cell, Moderate [11-50pc]) 0.00, 0.00, 0.00, 0.02, 0.98;
  (Nasopharyngeal CA, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Seminoma, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (SLE, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mycobact histiocytos, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mast-cell hyperplas, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (LGV, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Histoplasmosis, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Coccidioidomycosis, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (CMV, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Brucellosis, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Ki-1 LC anaplas B, Moderate [11-50pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Intermed lymphocytic, Moderate [11-50pc]) 0.000, 0.000, 0.001, 0.099, 0.900;
  (AIDS early, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (AILD, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (ALIP, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Cat scratch disease, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Dermatopathic laden, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Florid follic hyperp, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (GLH hyaline vascular, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (GLH plasma cell, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Granulomatous laden, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Histiocytosis x, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Infectious mono, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Leprosy-lepromatous, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Lymphangiographic, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mantle zone hyperpla, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Necrotizing Kikuchi, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Necrotiz non-Kikuchi, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Rheumatoid arthritis, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Sarcoidosis, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (SHML, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Sinus histiocytosis, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Syphilis, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Toxoplasmosis, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Tuberculosis, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Viral NOS, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Whipple's disease, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (L&H nodular HD, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (L&H diffuse HD, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Nodular sclerosis HD, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Cellular phase NSHD, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Syncytial NSHD, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mixed cellularity HD, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Interfollicular HD, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Diffuse fibrosis HD, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Reticular-type HD, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Small cleaved fol, Numerous [51-90pc]) 0.00000, 0.00000, 0.00001, 0.20000, 0.79999;
  (Mixed fol, Numerous [51-90pc]) 0.00000, 0.00000, 0.00001, 0.20000, 0.79999;
  (Large cell fol, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.03, 0.97;
  (Small noncleaved fol, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.03, 0.97;
  (Small lymphocytic, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Plasmacytoid lyctic, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mantle zone lymphoma, Numerous [51-90pc]) 0.000, 0.000, 0.001, 0.099, 0.900;
  (Small cleaved dif, Numerous [51-90pc]) 0.0000, 0.0000, 0.0001, 0.9799, 0.0200;
  (Mixed FCC dif, Numerous [51-90pc]) 0.0000, 0.0000, 0.0001, 0.9799, 0.0200;
  (Large cell dif, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.04, 0.96;
  (B-immunoblastic, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (T-immunob mixed, Numerous [51-90pc]) 0.000, 0.000, 0.005, 0.795, 0.200;
  (AILD-like T-cell lym, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Japanese ATL, Numerous [51-90pc]) 0.000, 0.100, 0.100, 0.799, 0.001;
  (Lymphoblastic, Numerous [51-90pc]) 0.00, 0.00, 0.01, 0.05, 0.94;
  (Small noncleaved dif, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.04, 0.96;
  (True histiocytic, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Ki-1 LC anaplas T, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Multiple myeloma, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mycosis fungoides, Numerous [51-90pc]) 0.000, 0.599, 0.300, 0.100, 0.001;
  (AML, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Hairy cell leukemia, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Carcinoma, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Melanoma, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (EM plasmacytoma, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Kaposi's sarcoma, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mast-cell disease, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (AIDS involutionary, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (T-immunob large, Numerous [51-90pc]) 0.000, 0.000, 0.005, 0.795, 0.200;
  (Monocytoid B-cell, Numerous [51-90pc]) 0.00, 0.00, 0.00, 0.02, 0.98;
  (Nasopharyngeal CA, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Seminoma, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (SLE, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mycobact histiocytos, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mast-cell hyperplas, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (LGV, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Histoplasmosis, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Coccidioidomycosis, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (CMV, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Brucellosis, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Ki-1 LC anaplas B, Numerous [51-90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Intermed lymphocytic, Numerous [51-90pc]) 0.000, 0.000, 0.001, 0.099, 0.900;
  (AIDS early, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (AILD, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (ALIP, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Cat scratch disease, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Dermatopathic laden, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Florid follic hyperp, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (GLH hyaline vascular, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (GLH plasma cell, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Granulomatous laden, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Histiocytosis x, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Infectious mono, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Leprosy-lepromatous, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Lymphangiographic, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mantle zone hyperpla, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Necrotizing Kikuchi, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Necrotiz non-Kikuchi, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Rheumatoid arthritis, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Sarcoidosis, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (SHML, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Sinus histiocytosis, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Syphilis, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Toxoplasmosis, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Tuberculosis, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Viral NOS, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Whipple's disease, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (L&H nodular HD, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (L&H diffuse HD, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Nodular sclerosis HD, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Cellular phase NSHD, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Syncytial NSHD, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mixed cellularity HD, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Interfollicular HD, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Diffuse fibrosis HD, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Reticular-type HD, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Small cleaved fol, Striking [>90pc]) 0.00000, 0.00000, 0.00001, 0.20000, 0.79999;
  (Mixed fol, Striking [>90pc]) 0.00000, 0.00000, 0.00001, 0.20000, 0.79999;
  (Large cell fol, Striking [>90pc]) 0.00, 0.00, 0.00, 0.03, 0.97;
  (Small noncleaved fol, Striking [>90pc]) 0.00, 0.00, 0.00, 0.03, 0.97;
  (Small lymphocytic, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Plasmacytoid lyctic, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mantle zone lymphoma, Striking [>90pc]) 0.000, 0.000, 0.001, 0.099, 0.900;
  (Small cleaved dif, Striking [>90pc]) 0.000, 0.000, 0.001, 0.979, 0.020;
  (Mixed FCC dif, Striking [>90pc]) 0.000, 0.000, 0.001, 0.979, 0.020;
  (Large cell dif, Striking [>90pc]) 0.00, 0.00, 0.00, 0.04, 0.96;
  (B-immunoblastic, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (T-immunob mixed, Striking [>90pc]) 0.000, 0.000, 0.005, 0.795, 0.200;
  (AILD-like T-cell lym, Striking [>90pc]) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Japanese ATL, Striking [>90pc]) 0.000, 0.100, 0.100, 0.799, 0.001;
  (Lymphoblastic, Striking [>90pc]) 0.00, 0.00, 0.01, 0.05, 0.94;
  (Small noncleaved dif, Striking [>90pc]) 0.00, 0.00, 0.00, 0.04, 0.96;
  (True histiocytic, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Ki-1 LC anaplas T, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Multiple myeloma, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mycosis fungoides, Striking [>90pc]) 0.000, 0.599, 0.300, 0.100, 0.001;
  (AML, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Hairy cell leukemia, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Carcinoma, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Melanoma, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (EM plasmacytoma, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Kaposi's sarcoma, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mast-cell disease, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (AIDS involutionary, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (T-immunob large, Striking [>90pc]) 0.000, 0.000, 0.005, 0.795, 0.200;
  (Monocytoid B-cell, Striking [>90pc]) 0.00, 0.00, 0.00, 0.02, 0.98;
  (Nasopharyngeal CA, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Seminoma, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (SLE, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mycobact histiocytos, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Mast-cell hyperplas, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (LGV, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Histoplasmosis, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Coccidioidomycosis, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (CMV, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Brucellosis, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Ki-1 LC anaplas B, Striking [>90pc]) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Intermed lymphocytic, Striking [>90pc]) 0.000, 0.000, 0.001, 0.099, 0.900;
}
probability ( SLC | Fault ) {
  (AIDS early) 0.00, 0.00, 0.01, 0.29, 0.70;
  (AILD) 0.00, 0.00, 0.00, 0.99, 0.01;
  (ALIP) 0.00, 0.00, 0.00, 0.99, 0.01;
  (Cat scratch disease) 0.000, 0.001, 0.050, 0.850, 0.099;
  (Dermatopathic laden) 0.000, 0.001, 0.300, 0.680, 0.019;
  (Florid follic hyperp) 0.00, 0.00, 0.01, 0.29, 0.70;
  (GLH hyaline vascular) 0.000, 0.001, 0.050, 0.850, 0.099;
  (GLH plasma cell) 0.000, 0.001, 0.489, 0.500, 0.010;
  (Granulomatous laden) 0.000, 0.001, 0.449, 0.500, 0.050;
  (Histiocytosis x) 0.000, 0.001, 0.050, 0.850, 0.099;
  (Infectious mono) 0.000, 0.001, 0.050, 0.849, 0.100;
  (Leprosy-lepromatous) 0.01, 0.30, 0.68, 0.01, 0.00;
  (Lymphangiographic) 0.00, 0.01, 0.37, 0.60, 0.02;
  (Mantle zone hyperpla) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Necrotizing Kikuchi) 0.00, 0.01, 0.25, 0.64, 0.10;
  (Necrotiz non-Kikuchi) 0.00, 0.01, 0.25, 0.64, 0.10;
  (Rheumatoid arthritis) 0.000, 0.001, 0.300, 0.680, 0.019;
  (Sarcoidosis) 0.000, 0.001, 0.300, 0.680, 0.019;
  (SHML) 0.000, 0.001, 0.300, 0.680, 0.019;
  (Sinus histiocytosis) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Syphilis) 0.000, 0.001, 0.300, 0.680, 0.019;
  (Toxoplasmosis) 0.000, 0.001, 0.050, 0.850, 0.099;
  (Tuberculosis) 0.01, 0.20, 0.69, 0.10, 0.00;
  (Viral NOS) 0.00, 0.00, 0.01, 0.89, 0.10;
  (Whipple's disease) 0.00, 0.01, 0.37, 0.60, 0.02;
  (L&H nodular HD) 0.00, 0.00, 0.01, 0.69, 0.30;
  (L&H diffuse HD) 0.00, 0.00, 0.01, 0.69, 0.30;
  (Nodular sclerosis HD) 0.00, 0.00, 0.10, 0.85, 0.05;
  (Cellular phase NSHD) 0.00, 0.00, 0.10, 0.85, 0.05;
  (Syncytial NSHD) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Mixed cellularity HD) 0.00, 0.00, 0.25, 0.70, 0.05;
  (Interfollicular HD) 0.00, 0.00, 0.02, 0.88, 0.10;
  (Diffuse fibrosis HD) 0.0, 0.6, 0.4, 0.0, 0.0;
  (Reticular-type HD) 0.0, 0.8, 0.2, 0.0, 0.0;
  (Small cleaved fol) 0.0, 0.0, 0.0, 0.1, 0.9;
  (Mixed fol) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Large cell fol) 0.01, 0.36, 0.50, 0.10, 0.03;
  (Small noncleaved fol) 0.01, 0.36, 0.50, 0.10, 0.03;
  (Small lymphocytic) 0.00, 0.00, 0.00, 0.25, 0.75;
  (Plasmacytoid lyctic) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Mantle zone lymphoma) 0.000, 0.000, 0.000, 0.001, 0.999;
  (Small cleaved dif) 0.000, 0.000, 0.000, 0.001, 0.999;
  (Mixed FCC dif) 0.000, 0.000, 0.010, 0.989, 0.001;
  (Large cell dif) 0.01, 0.94, 0.05, 0.00, 0.00;
  (B-immunoblastic) 0.01, 0.94, 0.05, 0.00, 0.00;
  (T-immunob mixed) 0.000, 0.000, 0.010, 0.989, 0.001;
  (AILD-like T-cell lym) 0.00, 0.01, 0.84, 0.15, 0.00;
  (Japanese ATL) 0.02, 0.88, 0.05, 0.05, 0.00;
  (Lymphoblastic) 0.01, 0.97, 0.02, 0.00, 0.00;
  (Small noncleaved dif) 0.01, 0.94, 0.05, 0.00, 0.00;
  (True histiocytic) 0.01, 0.98, 0.01, 0.00, 0.00;
  (Ki-1 LC anaplas T) 0.01, 0.98, 0.01, 0.00, 0.00;
  (Multiple myeloma) 0.01, 0.98, 0.01, 0.00, 0.00;
  (Mycosis fungoides) 0.005, 0.050, 0.295, 0.350, 0.300;
  (AML) 0.01, 0.98, 0.01, 0.00, 0.00;
  (Hairy cell leukemia) 0.20, 0.60, 0.10, 0.05, 0.05;
  (Carcinoma) 0.01, 0.05, 0.83, 0.10, 0.01;
  (Melanoma) 0.01, 0.05, 0.83, 0.10, 0.01;
  (EM plasmacytoma) 0.01, 0.68, 0.30, 0.01, 0.00;
  (Kaposi's sarcoma) 0.01, 0.05, 0.83, 0.10, 0.01;
  (Mast-cell disease) 0.02, 0.37, 0.60, 0.01, 0.00;
  (AIDS involutionary) 0.000, 0.001, 0.300, 0.680, 0.019;
  (T-immunob large) 0.01, 0.98, 0.01, 0.00, 0.00;
  (Monocytoid B-cell) 0.01, 0.05, 0.83, 0.10, 0.01;
  (Nasopharyngeal CA) 0.01, 0.05, 0.83, 0.10, 0.01;
  (Seminoma) 0.01, 0.05, 0.83, 0.10, 0.01;
  (SLE) 0.000, 0.001, 0.050, 0.849, 0.100;
  (Mycobact histiocytos) 0.01, 0.40, 0.58, 0.01, 0.00;
  (Mast-cell hyperplas) 0.00, 0.10, 0.85, 0.05, 0.00;
  (LGV) 0.000, 0.001, 0.050, 0.850, 0.099;
  (Histoplasmosis) 0.000, 0.001, 0.050, 0.850, 0.099;
  (Coccidioidomycosis) 0.000, 0.001, 0.050, 0.850, 0.099;
  (CMV) 0.000, 0.001, 0.050, 0.850, 0.099;
  (Brucellosis) 0.000, 0.001, 0.050, 0.850, 0.099;
  (Ki-1 LC anaplas B) 0.01, 0.98, 0.01, 0.00, 0.00;
  (Intermed lymphocytic) 0.000, 0.000, 0.000, 0.001, 0.999;
}
probability ( SINUSES | Fault, INTFOL, FOLLICLE ) {
  (AIDS early, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (AILD, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (ALIP, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Cat scratch disease, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Dermatopathic laden, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Florid follic hyperp, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (GLH hyaline vascular, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (GLH plasma cell, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Granulomatous laden, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Histiocytosis x, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Infectious mono, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Leprosy-lepromatous, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Lymphangiographic, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Mantle zone hyperpla, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Necrotizing Kikuchi, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Necrotiz non-Kikuchi, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Rheumatoid arthritis, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Sarcoidosis, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (SHML, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Sinus histiocytosis, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Syphilis, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Toxoplasmosis, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Tuberculosis, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Viral NOS, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Whipple's disease, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (L&H nodular HD, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (L&H diffuse HD, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Nodular sclerosis HD, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Cellular phase NSHD, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Syncytial NSHD, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Mixed cellularity HD, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Interfollicular HD, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Diffuse fibrosis HD, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Reticular-type HD, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Small cleaved fol, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Mixed fol, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Large cell fol, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Small noncleaved fol, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Small lymphocytic, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Plasmacytoid lyctic, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Mantle zone lymphoma, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Small cleaved dif, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Mixed FCC dif, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Large cell dif, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (B-immunoblastic, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (T-immunob mixed, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (AILD-like T-cell lym, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Japanese ATL, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Lymphoblastic, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Small noncleaved dif, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (True histiocytic, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Ki-1 LC anaplas T, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Multiple myeloma, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Mycosis fungoides, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (AML, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Hairy cell leukemia, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Carcinoma, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Melanoma, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (EM plasmacytoma, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Kaposi's sarcoma, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Mast-cell disease, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (AIDS involutionary, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (T-immunob large, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Monocytoid B-cell, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Nasopharyngeal CA, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Seminoma, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (SLE, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Mycobact histiocytos, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Mast-cell hyperplas, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (LGV, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Histoplasmosis, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Coccidioidomycosis, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (CMV, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Brucellosis, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Ki-1 LC anaplas B, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Intermed lymphocytic, No expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (AIDS early, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (AILD, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (ALIP, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Cat scratch disease, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Dermatopathic laden, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Florid follic hyperp, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (GLH hyaline vascular, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (GLH plasma cell, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Granulomatous laden, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Histiocytosis x, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Infectious mono, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Leprosy-lepromatous, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Lymphangiographic, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Mantle zone hyperpla, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Necrotizing Kikuchi, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Necrotiz non-Kikuchi, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Rheumatoid arthritis, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Sarcoidosis, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (SHML, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Sinus histiocytosis, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Syphilis, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Toxoplasmosis, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Tuberculosis, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Viral NOS, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Whipple's disease, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (L&H nodular HD, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (L&H diffuse HD, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Nodular sclerosis HD, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Cellular phase NSHD, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Syncytial NSHD, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Mixed cellularity HD, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Interfollicular HD, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Diffuse fibrosis HD, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Reticular-type HD, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Small cleaved fol, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Mixed fol, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Large cell fol, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Small noncleaved fol, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Small lymphocytic, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Plasmacytoid lyctic, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Mantle zone lymphoma, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Small cleaved dif, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Mixed FCC dif, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Large cell dif, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (B-immunoblastic, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (T-immunob mixed, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (AILD-like T-cell lym, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Japanese ATL, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Lymphoblastic, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Small noncleaved dif, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (True histiocytic, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Ki-1 LC anaplas T, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Multiple myeloma, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Mycosis fungoides, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (AML, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Hairy cell leukemia, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Carcinoma, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Melanoma, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (EM plasmacytoma, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Kaposi's sarcoma, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Mast-cell disease, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (AIDS involutionary, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (T-immunob large, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Monocytoid B-cell, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Nasopharyngeal CA, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Seminoma, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (SLE, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Mycobact histiocytos, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Mast-cell hyperplas, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (LGV, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Histoplasmosis, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Coccidioidomycosis, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (CMV, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Brucellosis, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Ki-1 LC anaplas B, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Intermed lymphocytic, Mild-moderate expansion, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (AIDS early, Unif mrkd expan/no follicles, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (AILD, Unif mrkd expan/no follicles, Absent [0pc]) 0.000, 0.001, 0.200, 0.799;
  (ALIP, Unif mrkd expan/no follicles, Absent [0pc]) 0.000, 0.001, 0.200, 0.799;
  (Cat scratch disease, Unif mrkd expan/no follicles, Absent [0pc]) 0.01, 0.10, 0.50, 0.39;
  (Dermatopathic laden, Unif mrkd expan/no follicles, Absent [0pc]) 0.01, 0.15, 0.45, 0.39;
  (Florid follic hyperp, Unif mrkd expan/no follicles, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (GLH hyaline vascular, Unif mrkd expan/no follicles, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (GLH plasma cell, Unif mrkd expan/no follicles, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Granulomatous laden, Unif mrkd expan/no follicles, Absent [0pc]) 0.01, 0.15, 0.45, 0.39;
  (Histiocytosis x, Unif mrkd expan/no follicles, Absent [0pc]) 0.01, 0.00, 0.19, 0.80;
  (Infectious mono, Unif mrkd expan/no follicles, Absent [0pc]) 0.01, 0.10, 0.48, 0.41;
  (Leprosy-lepromatous, Unif mrkd expan/no follicles, Absent [0pc]) 0.01, 0.15, 0.45, 0.39;
  (Lymphangiographic, Unif mrkd expan/no follicles, Absent [0pc]) 0.40, 0.05, 0.10, 0.45;
  (Mantle zone hyperpla, Unif mrkd expan/no follicles, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Necrotizing Kikuchi, Unif mrkd expan/no follicles, Absent [0pc]) 0.01, 0.10, 0.50, 0.39;
  (Necrotiz non-Kikuchi, Unif mrkd expan/no follicles, Absent [0pc]) 0.01, 0.10, 0.50, 0.39;
  (Rheumatoid arthritis, Unif mrkd expan/no follicles, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Sarcoidosis, Unif mrkd expan/no follicles, Absent [0pc]) 0.01, 0.15, 0.45, 0.39;
  (SHML, Unif mrkd expan/no follicles, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Sinus histiocytosis, Unif mrkd expan/no follicles, Absent [0pc]) 0.9, 0.1, 0.0, 0.0;
  (Syphilis, Unif mrkd expan/no follicles, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Toxoplasmosis, Unif mrkd expan/no follicles, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Tuberculosis, Unif mrkd expan/no follicles, Absent [0pc]) 0.01, 0.15, 0.45, 0.39;
  (Viral NOS, Unif mrkd expan/no follicles, Absent [0pc]) 0.01, 0.10, 0.48, 0.41;
  (Whipple's disease, Unif mrkd expan/no follicles, Absent [0pc]) 0.3, 0.1, 0.1, 0.5;
  (L&H nodular HD, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.1, 0.9;
  (L&H diffuse HD, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.1, 0.9;
  (Nodular sclerosis HD, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.1, 0.9;
  (Cellular phase NSHD, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.1, 0.9;
  (Syncytial NSHD, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.1, 0.9;
  (Mixed cellularity HD, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.1, 0.9;
  (Interfollicular HD, Unif mrkd expan/no follicles, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Diffuse fibrosis HD, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.1, 0.9;
  (Reticular-type HD, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.1, 0.9;
  (Small cleaved fol, Unif mrkd expan/no follicles, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Mixed fol, Unif mrkd expan/no follicles, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Large cell fol, Unif mrkd expan/no follicles, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Small noncleaved fol, Unif mrkd expan/no follicles, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Small lymphocytic, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.1, 0.9;
  (Plasmacytoid lyctic, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.1, 0.9;
  (Mantle zone lymphoma, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.2, 0.8;
  (Small cleaved dif, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.1, 0.9;
  (Mixed FCC dif, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.1, 0.9;
  (Large cell dif, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.1, 0.9;
  (B-immunoblastic, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.1, 0.9;
  (T-immunob mixed, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.1, 0.9;
  (AILD-like T-cell lym, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.1, 0.9;
  (Japanese ATL, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.1, 0.9;
  (Lymphoblastic, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.1, 0.9;
  (Small noncleaved dif, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.1, 0.9;
  (True histiocytic, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.1, 0.9;
  (Ki-1 LC anaplas T, Unif mrkd expan/no follicles, Absent [0pc]) 0.30, 0.05, 0.40, 0.25;
  (Multiple myeloma, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.1, 0.9;
  (Mycosis fungoides, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.2, 0.8;
  (AML, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.4, 0.6;
  (Hairy cell leukemia, Unif mrkd expan/no follicles, Absent [0pc]) 0.05, 0.01, 0.10, 0.84;
  (Carcinoma, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.3, 0.7;
  (Melanoma, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.3, 0.7;
  (EM plasmacytoma, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.1, 0.9;
  (Kaposi's sarcoma, Unif mrkd expan/no follicles, Absent [0pc]) 0.00, 0.01, 0.30, 0.69;
  (Mast-cell disease, Unif mrkd expan/no follicles, Absent [0pc]) 0.001, 0.010, 0.200, 0.789;
  (AIDS involutionary, Unif mrkd expan/no follicles, Absent [0pc]) 0.01, 0.15, 0.45, 0.39;
  (T-immunob large, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.1, 0.9;
  (Monocytoid B-cell, Unif mrkd expan/no follicles, Absent [0pc]) 0.01, 0.00, 0.20, 0.79;
  (Nasopharyngeal CA, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.1, 0.9;
  (Seminoma, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.3, 0.7;
  (SLE, Unif mrkd expan/no follicles, Absent [0pc]) 0.01, 0.10, 0.48, 0.41;
  (Mycobact histiocytos, Unif mrkd expan/no follicles, Absent [0pc]) 0.01, 0.15, 0.45, 0.39;
  (Mast-cell hyperplas, Unif mrkd expan/no follicles, Absent [0pc]) 0.001, 0.010, 0.789, 0.200;
  (LGV, Unif mrkd expan/no follicles, Absent [0pc]) 0.01, 0.10, 0.50, 0.39;
  (Histoplasmosis, Unif mrkd expan/no follicles, Absent [0pc]) 0.01, 0.15, 0.45, 0.39;
  (Coccidioidomycosis, Unif mrkd expan/no follicles, Absent [0pc]) 0.01, 0.15, 0.45, 0.39;
  (CMV, Unif mrkd expan/no follicles, Absent [0pc]) 0.01, 0.15, 0.45, 0.39;
  (Brucellosis, Unif mrkd expan/no follicles, Absent [0pc]) 0.25, 0.25, 0.25, 0.25;
  (Ki-1 LC anaplas B, Unif mrkd expan/no follicles, Absent [0pc]) 0.30, 0.05, 0.40, 0.25;
  (Intermed lymphocytic, Unif mrkd expan/no follicles, Absent [0pc]) 0.0, 0.0, 0.2, 0.8;
  (AIDS early, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (AILD, No expansion, 1-25pc) 0.25, 0.25, 0.25, 0.25;
  (ALIP, No expansion, 1-25pc) 0.25, 0.25, 0.25, 0.25;
  (Cat scratch disease, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Dermatopathic laden, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Florid follic hyperp, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (GLH hyaline vascular, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (GLH plasma cell, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Granulomatous laden, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Histiocytosis x, No expansion, 1-25pc) 0.6, 0.4, 0.0, 0.0;
  (Infectious mono, No expansion, 1-25pc) 0.2, 0.8, 0.0, 0.0;
  (Leprosy-lepromatous, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Lymphangiographic, No expansion, 1-25pc) 0.99, 0.01, 0.00, 0.00;
  (Mantle zone hyperpla, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Necrotizing Kikuchi, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Necrotiz non-Kikuchi, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Rheumatoid arthritis, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Sarcoidosis, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (SHML, No expansion, 1-25pc) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, No expansion, 1-25pc) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Toxoplasmosis, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Tuberculosis, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Viral NOS, No expansion, 1-25pc) 0.2, 0.8, 0.0, 0.0;
  (Whipple's disease, No expansion, 1-25pc) 0.99, 0.01, 0.00, 0.00;
  (L&H nodular HD, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (L&H diffuse HD, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Nodular sclerosis HD, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Cellular phase NSHD, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Syncytial NSHD, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Mixed cellularity HD, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Interfollicular HD, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Diffuse fibrosis HD, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Reticular-type HD, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Small cleaved fol, No expansion, 1-25pc) 0.01, 0.89, 0.10, 0.00;
  (Mixed fol, No expansion, 1-25pc) 0.01, 0.89, 0.10, 0.00;
  (Large cell fol, No expansion, 1-25pc) 0.01, 0.89, 0.10, 0.00;
  (Small noncleaved fol, No expansion, 1-25pc) 0.01, 0.89, 0.10, 0.00;
  (Small lymphocytic, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Plasmacytoid lyctic, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Mantle zone lymphoma, No expansion, 1-25pc) 0.01, 0.89, 0.10, 0.00;
  (Small cleaved dif, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Mixed FCC dif, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Large cell dif, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (B-immunoblastic, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (T-immunob mixed, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (AILD-like T-cell lym, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Japanese ATL, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Lymphoblastic, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Small noncleaved dif, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (True histiocytic, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Ki-1 LC anaplas T, No expansion, 1-25pc) 0.95, 0.05, 0.00, 0.00;
  (Multiple myeloma, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Mycosis fungoides, No expansion, 1-25pc) 0.1, 0.9, 0.0, 0.0;
  (AML, No expansion, 1-25pc) 0.6, 0.4, 0.0, 0.0;
  (Hairy cell leukemia, No expansion, 1-25pc) 0.6, 0.4, 0.0, 0.0;
  (Carcinoma, No expansion, 1-25pc) 0.05, 0.95, 0.00, 0.00;
  (Melanoma, No expansion, 1-25pc) 0.05, 0.95, 0.00, 0.00;
  (EM plasmacytoma, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Kaposi's sarcoma, No expansion, 1-25pc) 0.3, 0.7, 0.0, 0.0;
  (Mast-cell disease, No expansion, 1-25pc) 0.1, 0.9, 0.0, 0.0;
  (AIDS involutionary, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (T-immunob large, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Monocytoid B-cell, No expansion, 1-25pc) 0.99, 0.01, 0.00, 0.00;
  (Nasopharyngeal CA, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Seminoma, No expansion, 1-25pc) 0.05, 0.95, 0.00, 0.00;
  (SLE, No expansion, 1-25pc) 0.2, 0.8, 0.0, 0.0;
  (Mycobact histiocytos, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Mast-cell hyperplas, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (LGV, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Histoplasmosis, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Coccidioidomycosis, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (CMV, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Brucellosis, No expansion, 1-25pc) 0.01, 0.99, 0.00, 0.00;
  (Ki-1 LC anaplas B, No expansion, 1-25pc) 0.95, 0.05, 0.00, 0.00;
  (Intermed lymphocytic, No expansion, 1-25pc) 0.01, 0.89, 0.10, 0.00;
  (AIDS early, Mild-moderate expansion, 1-25pc) 0.001, 0.050, 0.919, 0.030;
  (AILD, Mild-moderate expansion, 1-25pc) 0.25, 0.25, 0.25, 0.25;
  (ALIP, Mild-moderate expansion, 1-25pc) 0.25, 0.25, 0.25, 0.25;
  (Cat scratch disease, Mild-moderate expansion, 1-25pc) 0.01, 0.50, 0.42, 0.07;
  (Dermatopathic laden, Mild-moderate expansion, 1-25pc) 0.001, 0.050, 0.919, 0.030;
  (Florid follic hyperp, Mild-moderate expansion, 1-25pc) 0.001, 0.050, 0.919, 0.030;
  (GLH hyaline vascular, Mild-moderate expansion, 1-25pc) 0.001, 0.050, 0.919, 0.030;
  (GLH plasma cell, Mild-moderate expansion, 1-25pc) 0.001, 0.050, 0.919, 0.030;
  (Granulomatous laden, Mild-moderate expansion, 1-25pc) 0.001, 0.050, 0.919, 0.030;
  (Histiocytosis x, Mild-moderate expansion, 1-25pc) 0.3, 0.3, 0.2, 0.2;
  (Infectious mono, Mild-moderate expansion, 1-25pc) 0.05, 0.20, 0.65, 0.10;
  (Leprosy-lepromatous, Mild-moderate expansion, 1-25pc) 0.001, 0.050, 0.919, 0.030;
  (Lymphangiographic, Mild-moderate expansion, 1-25pc) 0.70, 0.05, 0.20, 0.05;
  (Mantle zone hyperpla, Mild-moderate expansion, 1-25pc) 0.001, 0.050, 0.919, 0.030;
  (Necrotizing Kikuchi, Mild-moderate expansion, 1-25pc) 0.01, 0.50, 0.42, 0.07;
  (Necrotiz non-Kikuchi, Mild-moderate expansion, 1-25pc) 0.01, 0.50, 0.42, 0.07;
  (Rheumatoid arthritis, Mild-moderate expansion, 1-25pc) 0.001, 0.050, 0.919, 0.030;
  (Sarcoidosis, Mild-moderate expansion, 1-25pc) 0.001, 0.050, 0.919, 0.030;
  (SHML, Mild-moderate expansion, 1-25pc) 0.949050949, 0.049950050, 0.000999001, 0.000000000;
  (Sinus histiocytosis, Mild-moderate expansion, 1-25pc) 0.949050949, 0.049950050, 0.000999001, 0.000000000;
  (Syphilis, Mild-moderate expansion, 1-25pc) 0.001, 0.050, 0.919, 0.030;
  (Toxoplasmosis, Mild-moderate expansion, 1-25pc) 0.001, 0.050, 0.919, 0.030;
  (Tuberculosis, Mild-moderate expansion, 1-25pc) 0.001, 0.050, 0.919, 0.030;
  (Viral NOS, Mild-moderate expansion, 1-25pc) 0.05, 0.20, 0.65, 0.10;
  (Whipple's disease, Mild-moderate expansion, 1-25pc) 0.70, 0.05, 0.20, 0.05;
  (L&H nodular HD, Mild-moderate expansion, 1-25pc) 0.00, 0.01, 0.59, 0.40;
  (L&H diffuse HD, Mild-moderate expansion, 1-25pc) 0.00, 0.01, 0.59, 0.40;
  (Nodular sclerosis HD, Mild-moderate expansion, 1-25pc) 0.00, 0.01, 0.59, 0.40;
  (Cellular phase NSHD, Mild-moderate expansion, 1-25pc) 0.00, 0.01, 0.59, 0.40;
  (Syncytial NSHD, Mild-moderate expansion, 1-25pc) 0.00, 0.01, 0.59, 0.40;
  (Mixed cellularity HD, Mild-moderate expansion, 1-25pc) 0.00, 0.01, 0.59, 0.40;
  (Interfollicular HD, Mild-moderate expansion, 1-25pc) 0.00, 0.01, 0.59, 0.40;
  (Diffuse fibrosis HD, Mild-moderate expansion, 1-25pc) 0.00, 0.01, 0.39, 0.60;
  (Reticular-type HD, Mild-moderate expansion, 1-25pc) 0.00, 0.01, 0.39, 0.60;
  (Small cleaved fol, Mild-moderate expansion, 1-25pc) 0.000, 0.001, 0.399, 0.600;
  (Mixed fol, Mild-moderate expansion, 1-25pc) 0.000, 0.001, 0.399, 0.600;
  (Large cell fol, Mild-moderate expansion, 1-25pc) 0.000, 0.001, 0.399, 0.600;
  (Small noncleaved fol, Mild-moderate expansion, 1-25pc) 0.000, 0.001, 0.399, 0.600;
  (Small lymphocytic, Mild-moderate expansion, 1-25pc) 0.000, 0.001, 0.549, 0.450;
  (Plasmacytoid lyctic, Mild-moderate expansion, 1-25pc) 0.000, 0.001, 0.549, 0.450;
  (Mantle zone lymphoma, Mild-moderate expansion, 1-25pc) 0.000, 0.001, 0.399, 0.600;
  (Small cleaved dif, Mild-moderate expansion, 1-25pc) 0.000, 0.001, 0.549, 0.450;
  (Mixed FCC dif, Mild-moderate expansion, 1-25pc) 0.000, 0.001, 0.549, 0.450;
  (Large cell dif, Mild-moderate expansion, 1-25pc) 0.000, 0.001, 0.549, 0.450;
  (B-immunoblastic, Mild-moderate expansion, 1-25pc) 0.000, 0.001, 0.549, 0.450;
  (T-immunob mixed, Mild-moderate expansion, 1-25pc) 0.000, 0.001, 0.549, 0.450;
  (AILD-like T-cell lym, Mild-moderate expansion, 1-25pc) 0.000, 0.001, 0.549, 0.450;
  (Japanese ATL, Mild-moderate expansion, 1-25pc) 0.000, 0.001, 0.549, 0.450;
  (Lymphoblastic, Mild-moderate expansion, 1-25pc) 0.000, 0.001, 0.549, 0.450;
  (Small noncleaved dif, Mild-moderate expansion, 1-25pc) 0.000, 0.001, 0.549, 0.450;
  (True histiocytic, Mild-moderate expansion, 1-25pc) 0.000, 0.001, 0.549, 0.450;
  (Ki-1 LC anaplas T, Mild-moderate expansion, 1-25pc) 0.75, 0.10, 0.05, 0.10;
  (Multiple myeloma, Mild-moderate expansion, 1-25pc) 0.000, 0.001, 0.549, 0.450;
  (Mycosis fungoides, Mild-moderate expansion, 1-25pc) 0.02, 0.10, 0.58, 0.30;
  (AML, Mild-moderate expansion, 1-25pc) 0.01, 0.02, 0.72, 0.25;
  (Hairy cell leukemia, Mild-moderate expansion, 1-25pc) 0.3, 0.3, 0.2, 0.2;
  (Carcinoma, Mild-moderate expansion, 1-25pc) 0.15, 0.55, 0.05, 0.25;
  (Melanoma, Mild-moderate expansion, 1-25pc) 0.15, 0.55, 0.05, 0.25;
  (EM plasmacytoma, Mild-moderate expansion, 1-25pc) 0.000, 0.001, 0.549, 0.450;
  (Kaposi's sarcoma, Mild-moderate expansion, 1-25pc) 0.01, 0.01, 0.58, 0.40;
  (Mast-cell disease, Mild-moderate expansion, 1-25pc) 0.02, 0.10, 0.58, 0.30;
  (AIDS involutionary, Mild-moderate expansion, 1-25pc) 0.001, 0.050, 0.919, 0.030;
  (T-immunob large, Mild-moderate expansion, 1-25pc) 0.000, 0.001, 0.549, 0.450;
  (Monocytoid B-cell, Mild-moderate expansion, 1-25pc) 0.100, 0.005, 0.495, 0.400;
  (Nasopharyngeal CA, Mild-moderate expansion, 1-25pc) 0.00, 0.01, 0.59, 0.40;
  (Seminoma, Mild-moderate expansion, 1-25pc) 0.15, 0.55, 0.05, 0.25;
  (SLE, Mild-moderate expansion, 1-25pc) 0.05, 0.20, 0.65, 0.10;
  (Mycobact histiocytos, Mild-moderate expansion, 1-25pc) 0.001, 0.050, 0.919, 0.030;
  (Mast-cell hyperplas, Mild-moderate expansion, 1-25pc) 0.001, 0.050, 0.919, 0.030;
  (LGV, Mild-moderate expansion, 1-25pc) 0.01, 0.50, 0.42, 0.07;
  (Histoplasmosis, Mild-moderate expansion, 1-25pc) 0.001, 0.050, 0.919, 0.030;
  (Coccidioidomycosis, Mild-moderate expansion, 1-25pc) 0.001, 0.050, 0.919, 0.030;
  (CMV, Mild-moderate expansion, 1-25pc) 0.001, 0.050, 0.919, 0.030;
  (Brucellosis, Mild-moderate expansion, 1-25pc) 0.001, 0.050, 0.919, 0.030;
  (Ki-1 LC anaplas B, Mild-moderate expansion, 1-25pc) 0.75, 0.10, 0.05, 0.10;
  (Intermed lymphocytic, Mild-moderate expansion, 1-25pc) 0.000, 0.001, 0.399, 0.600;
  (AIDS early, Unif mrkd expan/no follicles, 1-25pc) 0.25, 0.25, 0.25, 0.25;
  (AILD, Unif mrkd expan/no follicles, 1-25pc) 0.00000000, 0.00000000, 0.02097902, 0.97902098;
  (ALIP, Unif mrkd expan/no follicles, 1-25pc) 0.00000000, 0.00000000, 0.02097902, 0.97902098;
  (Cat scratch disease, Unif mrkd expan/no follicles, 1-25pc) 0.01, 0.10, 0.79, 0.10;
  (Dermatopathic laden, Unif mrkd expan/no follicles, 1-25pc) 0.0, 0.0, 0.9, 0.1;
  (Florid follic hyperp, Unif mrkd expan/no follicles, 1-25pc) 0.25, 0.25, 0.25, 0.25;
  (GLH hyaline vascular, Unif mrkd expan/no follicles, 1-25pc) 0.0, 0.0, 0.9, 0.1;
  (GLH plasma cell, Unif mrkd expan/no follicles, 1-25pc) 0.0, 0.0, 0.9, 0.1;
  (Granulomatous laden, Unif mrkd expan/no follicles, 1-25pc) 0.0, 0.0, 0.9, 0.1;
  (Histiocytosis x, Unif mrkd expan/no follicles, 1-25pc) 0.05, 0.15, 0.75, 0.05;
  (Infectious mono, Unif mrkd expan/no follicles, 1-25pc) 0.03, 0.05, 0.32, 0.60;
  (Leprosy-lepromatous, Unif mrkd expan/no follicles, 1-25pc) 0.0, 0.0, 0.9, 0.1;
  (Lymphangiographic, Unif mrkd expan/no follicles, 1-25pc) 0.20, 0.01, 0.64, 0.15;
  (Mantle zone hyperpla, Unif mrkd expan/no follicles, 1-25pc) 0.25, 0.25, 0.25, 0.25;
  (Necrotizing Kikuchi, Unif mrkd expan/no follicles, 1-25pc) 0.01, 0.10, 0.79, 0.10;
  (Necrotiz non-Kikuchi, Unif mrkd expan/no follicles, 1-25pc) 0.01, 0.10, 0.79, 0.10;
  (Rheumatoid arthritis, Unif mrkd expan/no follicles, 1-25pc) 0.0, 0.0, 0.9, 0.1;
  (Sarcoidosis, Unif mrkd expan/no follicles, 1-25pc) 0.0, 0.0, 0.9, 0.1;
  (SHML, Unif mrkd expan/no follicles, 1-25pc) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Unif mrkd expan/no follicles, 1-25pc) 0.95, 0.05, 0.00, 0.00;
  (Syphilis, Unif mrkd expan/no follicles, 1-25pc) 0.0, 0.0, 0.9, 0.1;
  (Toxoplasmosis, Unif mrkd expan/no follicles, 1-25pc) 0.0, 0.0, 0.9, 0.1;
  (Tuberculosis, Unif mrkd expan/no follicles, 1-25pc) 0.0, 0.0, 0.9, 0.1;
  (Viral NOS, Unif mrkd expan/no follicles, 1-25pc) 0.03, 0.05, 0.72, 0.20;
  (Whipple's disease, Unif mrkd expan/no follicles, 1-25pc) 0.20, 0.01, 0.64, 0.15;
  (L&H nodular HD, Unif mrkd expan/no follicles, 1-25pc) 0.000000000, 0.004975124, 0.029850746, 0.965174129;
  (L&H diffuse HD, Unif mrkd expan/no follicles, 1-25pc) 0.000000000, 0.004975124, 0.029850746, 0.965174129;
  (Nodular sclerosis HD, Unif mrkd expan/no follicles, 1-25pc) 0.000000000, 0.004975124, 0.029850746, 0.965174129;
  (Cellular phase NSHD, Unif mrkd expan/no follicles, 1-25pc) 0.000000000, 0.004975124, 0.029850746, 0.965174129;
  (Syncytial NSHD, Unif mrkd expan/no follicles, 1-25pc) 0.000000000, 0.004975124, 0.029850746, 0.965174129;
  (Mixed cellularity HD, Unif mrkd expan/no follicles, 1-25pc) 0.000000000, 0.004975124, 0.029850746, 0.965174129;
  (Interfollicular HD, Unif mrkd expan/no follicles, 1-25pc) 0.000000000, 0.004975124, 0.029850746, 0.965174129;
  (Diffuse fibrosis HD, Unif mrkd expan/no follicles, 1-25pc) 0.000000000, 0.004975124, 0.029850746, 0.965174129;
  (Reticular-type HD, Unif mrkd expan/no follicles, 1-25pc) 0.000000000, 0.004975124, 0.029850746, 0.965174129;
  (Small cleaved fol, Unif mrkd expan/no follicles, 1-25pc) 0.000, 0.001, 0.019, 0.980;
  (Mixed fol, Unif mrkd expan/no follicles, 1-25pc) 0.000, 0.001, 0.019, 0.980;
  (Large cell fol, Unif mrkd expan/no follicles, 1-25pc) 0.000, 0.001, 0.019, 0.980;
  (Small noncleaved fol, Unif mrkd expan/no follicles, 1-25pc) 0.000, 0.001, 0.019, 0.980;
  (Small lymphocytic, Unif mrkd expan/no follicles, 1-25pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (Plasmacytoid lyctic, Unif mrkd expan/no follicles, 1-25pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (Mantle zone lymphoma, Unif mrkd expan/no follicles, 1-25pc) 0.000, 0.001, 0.019, 0.980;
  (Small cleaved dif, Unif mrkd expan/no follicles, 1-25pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (Mixed FCC dif, Unif mrkd expan/no follicles, 1-25pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (Large cell dif, Unif mrkd expan/no follicles, 1-25pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (B-immunoblastic, Unif mrkd expan/no follicles, 1-25pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (T-immunob mixed, Unif mrkd expan/no follicles, 1-25pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (AILD-like T-cell lym, Unif mrkd expan/no follicles, 1-25pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (Japanese ATL, Unif mrkd expan/no follicles, 1-25pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (Lymphoblastic, Unif mrkd expan/no follicles, 1-25pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (Small noncleaved dif, Unif mrkd expan/no follicles, 1-25pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (True histiocytic, Unif mrkd expan/no follicles, 1-25pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (Ki-1 LC anaplas T, Unif mrkd expan/no follicles, 1-25pc) 0.59, 0.20, 0.10, 0.11;
  (Multiple myeloma, Unif mrkd expan/no follicles, 1-25pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (Mycosis fungoides, Unif mrkd expan/no follicles, 1-25pc) 0.00, 0.01, 0.15, 0.84;
  (AML, Unif mrkd expan/no follicles, 1-25pc) 0.00, 0.01, 0.15, 0.84;
  (Hairy cell leukemia, Unif mrkd expan/no follicles, 1-25pc) 0.05, 0.15, 0.60, 0.20;
  (Carcinoma, Unif mrkd expan/no follicles, 1-25pc) 0.05, 0.15, 0.05, 0.75;
  (Melanoma, Unif mrkd expan/no follicles, 1-25pc) 0.05, 0.15, 0.05, 0.75;
  (EM plasmacytoma, Unif mrkd expan/no follicles, 1-25pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (Kaposi's sarcoma, Unif mrkd expan/no follicles, 1-25pc) 0.00, 0.04, 0.02, 0.94;
  (Mast-cell disease, Unif mrkd expan/no follicles, 1-25pc) 0.00, 0.01, 0.15, 0.84;
  (AIDS involutionary, Unif mrkd expan/no follicles, 1-25pc) 0.0, 0.0, 0.9, 0.1;
  (T-immunob large, Unif mrkd expan/no follicles, 1-25pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (Monocytoid B-cell, Unif mrkd expan/no follicles, 1-25pc) 0.050, 0.001, 0.100, 0.849;
  (Nasopharyngeal CA, Unif mrkd expan/no follicles, 1-25pc) 0.000000000, 0.004975124, 0.029850746, 0.965174129;
  (Seminoma, Unif mrkd expan/no follicles, 1-25pc) 0.05, 0.15, 0.05, 0.75;
  (SLE, Unif mrkd expan/no follicles, 1-25pc) 0.03, 0.05, 0.42, 0.50;
  (Mycobact histiocytos, Unif mrkd expan/no follicles, 1-25pc) 0.0, 0.0, 0.9, 0.1;
  (Mast-cell hyperplas, Unif mrkd expan/no follicles, 1-25pc) 0.0, 0.0, 0.9, 0.1;
  (LGV, Unif mrkd expan/no follicles, 1-25pc) 0.01, 0.10, 0.79, 0.10;
  (Histoplasmosis, Unif mrkd expan/no follicles, 1-25pc) 0.0, 0.0, 0.9, 0.1;
  (Coccidioidomycosis, Unif mrkd expan/no follicles, 1-25pc) 0.0, 0.0, 0.9, 0.1;
  (CMV, Unif mrkd expan/no follicles, 1-25pc) 0.0, 0.0, 0.9, 0.1;
  (Brucellosis, Unif mrkd expan/no follicles, 1-25pc) 0.0, 0.0, 0.9, 0.1;
  (Ki-1 LC anaplas B, Unif mrkd expan/no follicles, 1-25pc) 0.59, 0.20, 0.10, 0.11;
  (Intermed lymphocytic, Unif mrkd expan/no follicles, 1-25pc) 0.000, 0.001, 0.019, 0.980;
  (AIDS early, No expansion, 25-75pc) 0.01, 0.95, 0.04, 0.00;
  (AILD, No expansion, 25-75pc) 0.25, 0.25, 0.25, 0.25;
  (ALIP, No expansion, 25-75pc) 0.25, 0.25, 0.25, 0.25;
  (Cat scratch disease, No expansion, 25-75pc) 0.01, 0.98, 0.01, 0.00;
  (Dermatopathic laden, No expansion, 25-75pc) 0.01, 0.95, 0.04, 0.00;
  (Florid follic hyperp, No expansion, 25-75pc) 0.01, 0.95, 0.04, 0.00;
  (GLH hyaline vascular, No expansion, 25-75pc) 0.01, 0.95, 0.04, 0.00;
  (GLH plasma cell, No expansion, 25-75pc) 0.01, 0.95, 0.04, 0.00;
  (Granulomatous laden, No expansion, 25-75pc) 0.01, 0.95, 0.04, 0.00;
  (Histiocytosis x, No expansion, 25-75pc) 0.60, 0.34, 0.06, 0.00;
  (Infectious mono, No expansion, 25-75pc) 0.2, 0.7, 0.1, 0.0;
  (Leprosy-lepromatous, No expansion, 25-75pc) 0.01, 0.95, 0.04, 0.00;
  (Lymphangiographic, No expansion, 25-75pc) 0.99, 0.01, 0.00, 0.00;
  (Mantle zone hyperpla, No expansion, 25-75pc) 0.01, 0.95, 0.04, 0.00;
  (Necrotizing Kikuchi, No expansion, 25-75pc) 0.01, 0.98, 0.01, 0.00;
  (Necrotiz non-Kikuchi, No expansion, 25-75pc) 0.01, 0.98, 0.01, 0.00;
  (Rheumatoid arthritis, No expansion, 25-75pc) 0.01, 0.95, 0.04, 0.00;
  (Sarcoidosis, No expansion, 25-75pc) 0.01, 0.95, 0.04, 0.00;
  (SHML, No expansion, 25-75pc) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, No expansion, 25-75pc) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, No expansion, 25-75pc) 0.01, 0.95, 0.04, 0.00;
  (Toxoplasmosis, No expansion, 25-75pc) 0.01, 0.95, 0.04, 0.00;
  (Tuberculosis, No expansion, 25-75pc) 0.01, 0.95, 0.04, 0.00;
  (Viral NOS, No expansion, 25-75pc) 0.2, 0.7, 0.1, 0.0;
  (Whipple's disease, No expansion, 25-75pc) 0.99, 0.01, 0.00, 0.00;
  (L&H nodular HD, No expansion, 25-75pc) 0.01, 0.90, 0.09, 0.00;
  (L&H diffuse HD, No expansion, 25-75pc) 0.01, 0.90, 0.09, 0.00;
  (Nodular sclerosis HD, No expansion, 25-75pc) 0.01, 0.90, 0.09, 0.00;
  (Cellular phase NSHD, No expansion, 25-75pc) 0.01, 0.90, 0.09, 0.00;
  (Syncytial NSHD, No expansion, 25-75pc) 0.01, 0.90, 0.09, 0.00;
  (Mixed cellularity HD, No expansion, 25-75pc) 0.01, 0.90, 0.09, 0.00;
  (Interfollicular HD, No expansion, 25-75pc) 0.01, 0.90, 0.09, 0.00;
  (Diffuse fibrosis HD, No expansion, 25-75pc) 0.01, 0.90, 0.09, 0.00;
  (Reticular-type HD, No expansion, 25-75pc) 0.01, 0.90, 0.09, 0.00;
  (Small cleaved fol, No expansion, 25-75pc) 0.01, 0.54, 0.40, 0.05;
  (Mixed fol, No expansion, 25-75pc) 0.01, 0.54, 0.40, 0.05;
  (Large cell fol, No expansion, 25-75pc) 0.01, 0.54, 0.40, 0.05;
  (Small noncleaved fol, No expansion, 25-75pc) 0.01, 0.54, 0.40, 0.05;
  (Small lymphocytic, No expansion, 25-75pc) 0.01, 0.59, 0.40, 0.00;
  (Plasmacytoid lyctic, No expansion, 25-75pc) 0.01, 0.59, 0.40, 0.00;
  (Mantle zone lymphoma, No expansion, 25-75pc) 0.01, 0.59, 0.40, 0.00;
  (Small cleaved dif, No expansion, 25-75pc) 0.01, 0.59, 0.40, 0.00;
  (Mixed FCC dif, No expansion, 25-75pc) 0.01, 0.59, 0.40, 0.00;
  (Large cell dif, No expansion, 25-75pc) 0.01, 0.59, 0.40, 0.00;
  (B-immunoblastic, No expansion, 25-75pc) 0.01, 0.59, 0.40, 0.00;
  (T-immunob mixed, No expansion, 25-75pc) 0.01, 0.59, 0.40, 0.00;
  (AILD-like T-cell lym, No expansion, 25-75pc) 0.01, 0.59, 0.40, 0.00;
  (Japanese ATL, No expansion, 25-75pc) 0.01, 0.59, 0.40, 0.00;
  (Lymphoblastic, No expansion, 25-75pc) 0.01, 0.59, 0.40, 0.00;
  (Small noncleaved dif, No expansion, 25-75pc) 0.01, 0.59, 0.40, 0.00;
  (True histiocytic, No expansion, 25-75pc) 0.01, 0.59, 0.40, 0.00;
  (Ki-1 LC anaplas T, No expansion, 25-75pc) 0.95, 0.03, 0.02, 0.00;
  (Multiple myeloma, No expansion, 25-75pc) 0.01, 0.59, 0.40, 0.00;
  (Mycosis fungoides, No expansion, 25-75pc) 0.1, 0.8, 0.1, 0.0;
  (AML, No expansion, 25-75pc) 0.60, 0.39, 0.01, 0.00;
  (Hairy cell leukemia, No expansion, 25-75pc) 0.60, 0.34, 0.06, 0.00;
  (Carcinoma, No expansion, 25-75pc) 0.05, 0.92, 0.03, 0.00;
  (Melanoma, No expansion, 25-75pc) 0.05, 0.92, 0.03, 0.00;
  (EM plasmacytoma, No expansion, 25-75pc) 0.01, 0.59, 0.40, 0.00;
  (Kaposi's sarcoma, No expansion, 25-75pc) 0.3, 0.6, 0.1, 0.0;
  (Mast-cell disease, No expansion, 25-75pc) 0.1, 0.8, 0.1, 0.0;
  (AIDS involutionary, No expansion, 25-75pc) 0.01, 0.95, 0.04, 0.00;
  (T-immunob large, No expansion, 25-75pc) 0.01, 0.59, 0.40, 0.00;
  (Monocytoid B-cell, No expansion, 25-75pc) 0.95, 0.03, 0.02, 0.00;
  (Nasopharyngeal CA, No expansion, 25-75pc) 0.01, 0.90, 0.09, 0.00;
  (Seminoma, No expansion, 25-75pc) 0.05, 0.92, 0.03, 0.00;
  (SLE, No expansion, 25-75pc) 0.2, 0.7, 0.1, 0.0;
  (Mycobact histiocytos, No expansion, 25-75pc) 0.01, 0.95, 0.04, 0.00;
  (Mast-cell hyperplas, No expansion, 25-75pc) 0.01, 0.95, 0.04, 0.00;
  (LGV, No expansion, 25-75pc) 0.01, 0.98, 0.01, 0.00;
  (Histoplasmosis, No expansion, 25-75pc) 0.01, 0.95, 0.04, 0.00;
  (Coccidioidomycosis, No expansion, 25-75pc) 0.01, 0.95, 0.04, 0.00;
  (CMV, No expansion, 25-75pc) 0.01, 0.95, 0.04, 0.00;
  (Brucellosis, No expansion, 25-75pc) 0.01, 0.95, 0.04, 0.00;
  (Ki-1 LC anaplas B, No expansion, 25-75pc) 0.95, 0.03, 0.02, 0.00;
  (Intermed lymphocytic, No expansion, 25-75pc) 0.01, 0.59, 0.40, 0.00;
  (AIDS early, Mild-moderate expansion, 25-75pc) 0.000999001, 0.049950050, 0.899100899, 0.049950050;
  (AILD, Mild-moderate expansion, 25-75pc) 0.25, 0.25, 0.25, 0.25;
  (ALIP, Mild-moderate expansion, 25-75pc) 0.25, 0.25, 0.25, 0.25;
  (Cat scratch disease, Mild-moderate expansion, 25-75pc) 0.01, 0.50, 0.44, 0.05;
  (Dermatopathic laden, Mild-moderate expansion, 25-75pc) 0.000999001, 0.049950050, 0.899100899, 0.049950050;
  (Florid follic hyperp, Mild-moderate expansion, 25-75pc) 0.000999001, 0.049950050, 0.899100899, 0.049950050;
  (GLH hyaline vascular, Mild-moderate expansion, 25-75pc) 0.000999001, 0.049950050, 0.899100899, 0.049950050;
  (GLH plasma cell, Mild-moderate expansion, 25-75pc) 0.000999001, 0.049950050, 0.899100899, 0.049950050;
  (Granulomatous laden, Mild-moderate expansion, 25-75pc) 0.000999001, 0.049950050, 0.899100899, 0.049950050;
  (Histiocytosis x, Mild-moderate expansion, 25-75pc) 0.30, 0.30, 0.37, 0.03;
  (Infectious mono, Mild-moderate expansion, 25-75pc) 0.05, 0.20, 0.68, 0.07;
  (Leprosy-lepromatous, Mild-moderate expansion, 25-75pc) 0.000999001, 0.049950050, 0.899100899, 0.049950050;
  (Lymphangiographic, Mild-moderate expansion, 25-75pc) 0.70, 0.05, 0.22, 0.03;
  (Mantle zone hyperpla, Mild-moderate expansion, 25-75pc) 0.000999001, 0.049950050, 0.899100899, 0.049950050;
  (Necrotizing Kikuchi, Mild-moderate expansion, 25-75pc) 0.01, 0.50, 0.44, 0.05;
  (Necrotiz non-Kikuchi, Mild-moderate expansion, 25-75pc) 0.01, 0.50, 0.44, 0.05;
  (Rheumatoid arthritis, Mild-moderate expansion, 25-75pc) 0.000999001, 0.049950050, 0.899100899, 0.049950050;
  (Sarcoidosis, Mild-moderate expansion, 25-75pc) 0.000999001, 0.049950050, 0.899100899, 0.049950050;
  (SHML, Mild-moderate expansion, 25-75pc) 0.949050949, 0.049950050, 0.000999001, 0.000000000;
  (Sinus histiocytosis, Mild-moderate expansion, 25-75pc) 0.949050949, 0.049950050, 0.000999001, 0.000000000;
  (Syphilis, Mild-moderate expansion, 25-75pc) 0.000999001, 0.049950050, 0.899100899, 0.049950050;
  (Toxoplasmosis, Mild-moderate expansion, 25-75pc) 0.000999001, 0.049950050, 0.899100899, 0.049950050;
  (Tuberculosis, Mild-moderate expansion, 25-75pc) 0.000999001, 0.049950050, 0.899100899, 0.049950050;
  (Viral NOS, Mild-moderate expansion, 25-75pc) 0.05, 0.20, 0.71, 0.04;
  (Whipple's disease, Mild-moderate expansion, 25-75pc) 0.70, 0.05, 0.22, 0.03;
  (L&H nodular HD, Mild-moderate expansion, 25-75pc) 0.00, 0.01, 0.84, 0.15;
  (L&H diffuse HD, Mild-moderate expansion, 25-75pc) 0.00, 0.01, 0.84, 0.15;
  (Nodular sclerosis HD, Mild-moderate expansion, 25-75pc) 0.00, 0.01, 0.84, 0.15;
  (Cellular phase NSHD, Mild-moderate expansion, 25-75pc) 0.00, 0.01, 0.84, 0.15;
  (Syncytial NSHD, Mild-moderate expansion, 25-75pc) 0.00, 0.01, 0.84, 0.15;
  (Mixed cellularity HD, Mild-moderate expansion, 25-75pc) 0.00, 0.01, 0.84, 0.15;
  (Interfollicular HD, Mild-moderate expansion, 25-75pc) 0.00, 0.01, 0.84, 0.15;
  (Diffuse fibrosis HD, Mild-moderate expansion, 25-75pc) 0.25, 0.25, 0.25, 0.25;
  (Reticular-type HD, Mild-moderate expansion, 25-75pc) 0.25, 0.25, 0.25, 0.25;
  (Small cleaved fol, Mild-moderate expansion, 25-75pc) 0.000000000, 0.000999001, 0.099900100, 0.899100899;
  (Mixed fol, Mild-moderate expansion, 25-75pc) 0.000000000, 0.000999001, 0.099900100, 0.899100899;
  (Large cell fol, Mild-moderate expansion, 25-75pc) 0.000000000, 0.000999001, 0.099900100, 0.899100899;
  (Small noncleaved fol, Mild-moderate expansion, 25-75pc) 0.000000000, 0.000999001, 0.099900100, 0.899100899;
  (Small lymphocytic, Mild-moderate expansion, 25-75pc) 0.000, 0.001, 0.849, 0.150;
  (Plasmacytoid lyctic, Mild-moderate expansion, 25-75pc) 0.000, 0.001, 0.849, 0.150;
  (Mantle zone lymphoma, Mild-moderate expansion, 25-75pc) 0.000000000, 0.000999001, 0.099900100, 0.899100899;
  (Small cleaved dif, Mild-moderate expansion, 25-75pc) 0.000, 0.001, 0.849, 0.150;
  (Mixed FCC dif, Mild-moderate expansion, 25-75pc) 0.000, 0.001, 0.849, 0.150;
  (Large cell dif, Mild-moderate expansion, 25-75pc) 0.000, 0.001, 0.849, 0.150;
  (B-immunoblastic, Mild-moderate expansion, 25-75pc) 0.000, 0.001, 0.849, 0.150;
  (T-immunob mixed, Mild-moderate expansion, 25-75pc) 0.000, 0.001, 0.849, 0.150;
  (AILD-like T-cell lym, Mild-moderate expansion, 25-75pc) 0.000, 0.001, 0.849, 0.150;
  (Japanese ATL, Mild-moderate expansion, 25-75pc) 0.000, 0.001, 0.849, 0.150;
  (Lymphoblastic, Mild-moderate expansion, 25-75pc) 0.000, 0.001, 0.849, 0.150;
  (Small noncleaved dif, Mild-moderate expansion, 25-75pc) 0.000, 0.001, 0.849, 0.150;
  (True histiocytic, Mild-moderate expansion, 25-75pc) 0.000, 0.001, 0.849, 0.150;
  (Ki-1 LC anaplas T, Mild-moderate expansion, 25-75pc) 0.81, 0.10, 0.05, 0.04;
  (Multiple myeloma, Mild-moderate expansion, 25-75pc) 0.000, 0.001, 0.849, 0.150;
  (Mycosis fungoides, Mild-moderate expansion, 25-75pc) 0.02, 0.10, 0.78, 0.10;
  (AML, Mild-moderate expansion, 25-75pc) 0.01, 0.02, 0.82, 0.15;
  (Hairy cell leukemia, Mild-moderate expansion, 25-75pc) 0.30, 0.30, 0.36, 0.04;
  (Carcinoma, Mild-moderate expansion, 25-75pc) 0.15, 0.55, 0.26, 0.04;
  (Melanoma, Mild-moderate expansion, 25-75pc) 0.15, 0.55, 0.26, 0.04;
  (EM plasmacytoma, Mild-moderate expansion, 25-75pc) 0.000, 0.001, 0.849, 0.150;
  (Kaposi's sarcoma, Mild-moderate expansion, 25-75pc) 0.01, 0.01, 0.83, 0.15;
  (Mast-cell disease, Mild-moderate expansion, 25-75pc) 0.02, 0.10, 0.78, 0.10;
  (AIDS involutionary, Mild-moderate expansion, 25-75pc) 0.000999001, 0.049950050, 0.899100899, 0.049950050;
  (T-immunob large, Mild-moderate expansion, 25-75pc) 0.000, 0.001, 0.849, 0.150;
  (Monocytoid B-cell, Mild-moderate expansion, 25-75pc) 0.10, 0.02, 0.48, 0.40;
  (Nasopharyngeal CA, Mild-moderate expansion, 25-75pc) 0.00, 0.01, 0.84, 0.15;
  (Seminoma, Mild-moderate expansion, 25-75pc) 0.15, 0.55, 0.26, 0.04;
  (SLE, Mild-moderate expansion, 25-75pc) 0.05, 0.20, 0.69, 0.06;
  (Mycobact histiocytos, Mild-moderate expansion, 25-75pc) 0.000999001, 0.049950050, 0.899100899, 0.049950050;
  (Mast-cell hyperplas, Mild-moderate expansion, 25-75pc) 0.000999001, 0.049950050, 0.899100899, 0.049950050;
  (LGV, Mild-moderate expansion, 25-75pc) 0.01, 0.50, 0.44, 0.05;
  (Histoplasmosis, Mild-moderate expansion, 25-75pc) 0.000999001, 0.049950050, 0.899100899, 0.049950050;
  (Coccidioidomycosis, Mild-moderate expansion, 25-75pc) 0.000999001, 0.049950050, 0.899100899, 0.049950050;
  (CMV, Mild-moderate expansion, 25-75pc) 0.000999001, 0.049950050, 0.899100899, 0.049950050;
  (Brucellosis, Mild-moderate expansion, 25-75pc) 0.000999001, 0.049950050, 0.899100899, 0.049950050;
  (Ki-1 LC anaplas B, Mild-moderate expansion, 25-75pc) 0.81, 0.10, 0.05, 0.04;
  (Intermed lymphocytic, Mild-moderate expansion, 25-75pc) 0.000000000, 0.000999001, 0.099900100, 0.899100899;
  (AIDS early, Unif mrkd expan/no follicles, 25-75pc) 0.0, 0.0, 0.9, 0.1;
  (AILD, Unif mrkd expan/no follicles, 25-75pc) 0.25, 0.25, 0.25, 0.25;
  (ALIP, Unif mrkd expan/no follicles, 25-75pc) 0.25, 0.25, 0.25, 0.25;
  (Cat scratch disease, Unif mrkd expan/no follicles, 25-75pc) 0.01, 0.10, 0.79, 0.10;
  (Dermatopathic laden, Unif mrkd expan/no follicles, 25-75pc) 0.0, 0.0, 0.9, 0.1;
  (Florid follic hyperp, Unif mrkd expan/no follicles, 25-75pc) 0.0, 0.0, 0.9, 0.1;
  (GLH hyaline vascular, Unif mrkd expan/no follicles, 25-75pc) 0.0, 0.0, 0.9, 0.1;
  (GLH plasma cell, Unif mrkd expan/no follicles, 25-75pc) 0.0, 0.0, 0.9, 0.1;
  (Granulomatous laden, Unif mrkd expan/no follicles, 25-75pc) 0.0, 0.0, 0.9, 0.1;
  (Histiocytosis x, Unif mrkd expan/no follicles, 25-75pc) 0.05, 0.15, 0.75, 0.05;
  (Infectious mono, Unif mrkd expan/no follicles, 25-75pc) 0.03, 0.05, 0.32, 0.60;
  (Leprosy-lepromatous, Unif mrkd expan/no follicles, 25-75pc) 0.0, 0.0, 0.9, 0.1;
  (Lymphangiographic, Unif mrkd expan/no follicles, 25-75pc) 0.20, 0.01, 0.64, 0.15;
  (Mantle zone hyperpla, Unif mrkd expan/no follicles, 25-75pc) 0.0, 0.0, 0.9, 0.1;
  (Necrotizing Kikuchi, Unif mrkd expan/no follicles, 25-75pc) 0.01, 0.10, 0.79, 0.10;
  (Necrotiz non-Kikuchi, Unif mrkd expan/no follicles, 25-75pc) 0.01, 0.10, 0.79, 0.10;
  (Rheumatoid arthritis, Unif mrkd expan/no follicles, 25-75pc) 0.0, 0.0, 0.9, 0.1;
  (Sarcoidosis, Unif mrkd expan/no follicles, 25-75pc) 0.0, 0.0, 0.9, 0.1;
  (SHML, Unif mrkd expan/no follicles, 25-75pc) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Unif mrkd expan/no follicles, 25-75pc) 0.95, 0.05, 0.00, 0.00;
  (Syphilis, Unif mrkd expan/no follicles, 25-75pc) 0.0, 0.0, 0.9, 0.1;
  (Toxoplasmosis, Unif mrkd expan/no follicles, 25-75pc) 0.0, 0.0, 0.9, 0.1;
  (Tuberculosis, Unif mrkd expan/no follicles, 25-75pc) 0.0, 0.0, 0.9, 0.1;
  (Viral NOS, Unif mrkd expan/no follicles, 25-75pc) 0.03, 0.05, 0.72, 0.20;
  (Whipple's disease, Unif mrkd expan/no follicles, 25-75pc) 0.20, 0.01, 0.64, 0.15;
  (L&H nodular HD, Unif mrkd expan/no follicles, 25-75pc) 0.000000000, 0.004975124, 0.029850746, 0.965174129;
  (L&H diffuse HD, Unif mrkd expan/no follicles, 25-75pc) 0.000000000, 0.004975124, 0.029850746, 0.965174129;
  (Nodular sclerosis HD, Unif mrkd expan/no follicles, 25-75pc) 0.000000000, 0.004975124, 0.029850746, 0.965174129;
  (Cellular phase NSHD, Unif mrkd expan/no follicles, 25-75pc) 0.000000000, 0.004975124, 0.029850746, 0.965174129;
  (Syncytial NSHD, Unif mrkd expan/no follicles, 25-75pc) 0.000000000, 0.004975124, 0.029850746, 0.965174129;
  (Mixed cellularity HD, Unif mrkd expan/no follicles, 25-75pc) 0.000000000, 0.004975124, 0.029850746, 0.965174129;
  (Interfollicular HD, Unif mrkd expan/no follicles, 25-75pc) 0.000000000, 0.004975124, 0.029850746, 0.965174129;
  (Diffuse fibrosis HD, Unif mrkd expan/no follicles, 25-75pc) 0.000000000, 0.004975124, 0.029850746, 0.965174129;
  (Reticular-type HD, Unif mrkd expan/no follicles, 25-75pc) 0.000000000, 0.004975124, 0.029850746, 0.965174129;
  (Small cleaved fol, Unif mrkd expan/no follicles, 25-75pc) 0.000, 0.001, 0.019, 0.980;
  (Mixed fol, Unif mrkd expan/no follicles, 25-75pc) 0.000, 0.001, 0.019, 0.980;
  (Large cell fol, Unif mrkd expan/no follicles, 25-75pc) 0.000, 0.001, 0.019, 0.980;
  (Small noncleaved fol, Unif mrkd expan/no follicles, 25-75pc) 0.000, 0.001, 0.019, 0.980;
  (Small lymphocytic, Unif mrkd expan/no follicles, 25-75pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (Plasmacytoid lyctic, Unif mrkd expan/no follicles, 25-75pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (Mantle zone lymphoma, Unif mrkd expan/no follicles, 25-75pc) 0.000, 0.001, 0.019, 0.980;
  (Small cleaved dif, Unif mrkd expan/no follicles, 25-75pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (Mixed FCC dif, Unif mrkd expan/no follicles, 25-75pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (Large cell dif, Unif mrkd expan/no follicles, 25-75pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (B-immunoblastic, Unif mrkd expan/no follicles, 25-75pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (T-immunob mixed, Unif mrkd expan/no follicles, 25-75pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (AILD-like T-cell lym, Unif mrkd expan/no follicles, 25-75pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (Japanese ATL, Unif mrkd expan/no follicles, 25-75pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (Lymphoblastic, Unif mrkd expan/no follicles, 25-75pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (Small noncleaved dif, Unif mrkd expan/no follicles, 25-75pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (True histiocytic, Unif mrkd expan/no follicles, 25-75pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (Ki-1 LC anaplas T, Unif mrkd expan/no follicles, 25-75pc) 0.59, 0.20, 0.10, 0.11;
  (Multiple myeloma, Unif mrkd expan/no follicles, 25-75pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (Mycosis fungoides, Unif mrkd expan/no follicles, 25-75pc) 0.00, 0.01, 0.15, 0.84;
  (AML, Unif mrkd expan/no follicles, 25-75pc) 0.00, 0.01, 0.15, 0.84;
  (Hairy cell leukemia, Unif mrkd expan/no follicles, 25-75pc) 0.05, 0.15, 0.60, 0.20;
  (Carcinoma, Unif mrkd expan/no follicles, 25-75pc) 0.05, 0.15, 0.05, 0.75;
  (Melanoma, Unif mrkd expan/no follicles, 25-75pc) 0.05, 0.15, 0.05, 0.75;
  (EM plasmacytoma, Unif mrkd expan/no follicles, 25-75pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (Kaposi's sarcoma, Unif mrkd expan/no follicles, 25-75pc) 0.01, 0.01, 0.25, 0.73;
  (Mast-cell disease, Unif mrkd expan/no follicles, 25-75pc) 0.00, 0.01, 0.15, 0.84;
  (AIDS involutionary, Unif mrkd expan/no follicles, 25-75pc) 0.0, 0.0, 0.9, 0.1;
  (T-immunob large, Unif mrkd expan/no follicles, 25-75pc) 0.0000000000, 0.0009940358, 0.0248508946, 0.9741550696;
  (Monocytoid B-cell, Unif mrkd expan/no follicles, 25-75pc) 0.050, 0.001, 0.100, 0.849;
  (Nasopharyngeal CA, Unif mrkd expan/no follicles, 25-75pc) 0.000000000, 0.004975124, 0.029850746, 0.965174129;
  (Seminoma, Unif mrkd expan/no follicles, 25-75pc) 0.05, 0.15, 0.05, 0.75;
  (SLE, Unif mrkd expan/no follicles, 25-75pc) 0.03, 0.05, 0.42, 0.50;
  (Mycobact histiocytos, Unif mrkd expan/no follicles, 25-75pc) 0.0, 0.0, 0.9, 0.1;
  (Mast-cell hyperplas, Unif mrkd expan/no follicles, 25-75pc) 0.0, 0.0, 0.9, 0.1;
  (LGV, Unif mrkd expan/no follicles, 25-75pc) 0.01, 0.10, 0.79, 0.10;
  (Histoplasmosis, Unif mrkd expan/no follicles, 25-75pc) 0.0, 0.0, 0.9, 0.1;
  (Coccidioidomycosis, Unif mrkd expan/no follicles, 25-75pc) 0.0, 0.0, 0.9, 0.1;
  (CMV, Unif mrkd expan/no follicles, 25-75pc) 0.0, 0.0, 0.9, 0.1;
  (Brucellosis, Unif mrkd expan/no follicles, 25-75pc) 0.0, 0.0, 0.9, 0.1;
  (Ki-1 LC anaplas B, Unif mrkd expan/no follicles, 25-75pc) 0.59, 0.20, 0.10, 0.11;
  (Intermed lymphocytic, Unif mrkd expan/no follicles, 25-75pc) 0.000, 0.001, 0.019, 0.980;
  (AIDS early, No expansion, 75-90pc) 0.02, 0.96, 0.02, 0.00;
  (AILD, No expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (ALIP, No expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Cat scratch disease, No expansion, 75-90pc) 0.01, 0.98, 0.01, 0.00;
  (Dermatopathic laden, No expansion, 75-90pc) 0.02, 0.96, 0.02, 0.00;
  (Florid follic hyperp, No expansion, 75-90pc) 0.02, 0.96, 0.02, 0.00;
  (GLH hyaline vascular, No expansion, 75-90pc) 0.02, 0.96, 0.02, 0.00;
  (GLH plasma cell, No expansion, 75-90pc) 0.02, 0.96, 0.02, 0.00;
  (Granulomatous laden, No expansion, 75-90pc) 0.02, 0.96, 0.02, 0.00;
  (Histiocytosis x, No expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Infectious mono, No expansion, 75-90pc) 0.2020202, 0.6969697, 0.1010101, 0.0000000;
  (Leprosy-lepromatous, No expansion, 75-90pc) 0.02, 0.96, 0.02, 0.00;
  (Lymphangiographic, No expansion, 75-90pc) 0.99, 0.01, 0.00, 0.00;
  (Mantle zone hyperpla, No expansion, 75-90pc) 0.02, 0.96, 0.02, 0.00;
  (Necrotizing Kikuchi, No expansion, 75-90pc) 0.01, 0.98, 0.01, 0.00;
  (Necrotiz non-Kikuchi, No expansion, 75-90pc) 0.01, 0.98, 0.01, 0.00;
  (Rheumatoid arthritis, No expansion, 75-90pc) 0.02, 0.96, 0.02, 0.00;
  (Sarcoidosis, No expansion, 75-90pc) 0.02, 0.96, 0.02, 0.00;
  (SHML, No expansion, 75-90pc) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, No expansion, 75-90pc) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, No expansion, 75-90pc) 0.02, 0.96, 0.02, 0.00;
  (Toxoplasmosis, No expansion, 75-90pc) 0.02, 0.96, 0.02, 0.00;
  (Tuberculosis, No expansion, 75-90pc) 0.02, 0.96, 0.02, 0.00;
  (Viral NOS, No expansion, 75-90pc) 0.2020202, 0.6969697, 0.1010101, 0.0000000;
  (Whipple's disease, No expansion, 75-90pc) 0.99, 0.01, 0.00, 0.00;
  (L&H nodular HD, No expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (L&H diffuse HD, No expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Nodular sclerosis HD, No expansion, 75-90pc) 0.000999001, 0.799200799, 0.199800200, 0.000000000;
  (Cellular phase NSHD, No expansion, 75-90pc) 0.000999001, 0.799200799, 0.199800200, 0.000000000;
  (Syncytial NSHD, No expansion, 75-90pc) 0.000999001, 0.799200799, 0.199800200, 0.000000000;
  (Mixed cellularity HD, No expansion, 75-90pc) 0.000999001, 0.799200799, 0.199800200, 0.000000000;
  (Interfollicular HD, No expansion, 75-90pc) 0.000999001, 0.799200799, 0.199800200, 0.000000000;
  (Diffuse fibrosis HD, No expansion, 75-90pc) 0.000999001, 0.799200799, 0.199800200, 0.000000000;
  (Reticular-type HD, No expansion, 75-90pc) 0.000999001, 0.799200799, 0.199800200, 0.000000000;
  (Small cleaved fol, No expansion, 75-90pc) 0.000998004, 0.000998004, 0.109780439, 0.888223553;
  (Mixed fol, No expansion, 75-90pc) 0.000998004, 0.000998004, 0.109780439, 0.888223553;
  (Large cell fol, No expansion, 75-90pc) 0.000998004, 0.000998004, 0.109780439, 0.888223553;
  (Small noncleaved fol, No expansion, 75-90pc) 0.000998004, 0.000998004, 0.109780439, 0.888223553;
  (Small lymphocytic, No expansion, 75-90pc) 0.02, 0.93, 0.05, 0.00;
  (Plasmacytoid lyctic, No expansion, 75-90pc) 0.02, 0.93, 0.05, 0.00;
  (Mantle zone lymphoma, No expansion, 75-90pc) 0.000998004, 0.000998004, 0.109780439, 0.888223553;
  (Small cleaved dif, No expansion, 75-90pc) 0.02, 0.93, 0.05, 0.00;
  (Mixed FCC dif, No expansion, 75-90pc) 0.02, 0.93, 0.05, 0.00;
  (Large cell dif, No expansion, 75-90pc) 0.02, 0.93, 0.05, 0.00;
  (B-immunoblastic, No expansion, 75-90pc) 0.02, 0.93, 0.05, 0.00;
  (T-immunob mixed, No expansion, 75-90pc) 0.02, 0.93, 0.05, 0.00;
  (AILD-like T-cell lym, No expansion, 75-90pc) 0.02, 0.93, 0.05, 0.00;
  (Japanese ATL, No expansion, 75-90pc) 0.02, 0.93, 0.05, 0.00;
  (Lymphoblastic, No expansion, 75-90pc) 0.02, 0.93, 0.05, 0.00;
  (Small noncleaved dif, No expansion, 75-90pc) 0.02, 0.93, 0.05, 0.00;
  (True histiocytic, No expansion, 75-90pc) 0.02, 0.93, 0.05, 0.00;
  (Ki-1 LC anaplas T, No expansion, 75-90pc) 0.70, 0.25, 0.05, 0.00;
  (Multiple myeloma, No expansion, 75-90pc) 0.02, 0.93, 0.05, 0.00;
  (Mycosis fungoides, No expansion, 75-90pc) 0.10, 0.89, 0.01, 0.00;
  (AML, No expansion, 75-90pc) 0.05, 0.75, 0.20, 0.00;
  (Hairy cell leukemia, No expansion, 75-90pc) 0.60606061, 0.34343434, 0.05050505, 0.00000000;
  (Carcinoma, No expansion, 75-90pc) 0.28, 0.70, 0.02, 0.00;
  (Melanoma, No expansion, 75-90pc) 0.28, 0.70, 0.02, 0.00;
  (EM plasmacytoma, No expansion, 75-90pc) 0.02, 0.93, 0.05, 0.00;
  (Kaposi's sarcoma, No expansion, 75-90pc) 0.20, 0.65, 0.10, 0.05;
  (Mast-cell disease, No expansion, 75-90pc) 0.10, 0.89, 0.01, 0.00;
  (AIDS involutionary, No expansion, 75-90pc) 0.02, 0.96, 0.02, 0.00;
  (T-immunob large, No expansion, 75-90pc) 0.02, 0.93, 0.05, 0.00;
  (Monocytoid B-cell, No expansion, 75-90pc) 0.050, 0.001, 0.479, 0.470;
  (Nasopharyngeal CA, No expansion, 75-90pc) 0.000999001, 0.799200799, 0.199800200, 0.000000000;
  (Seminoma, No expansion, 75-90pc) 0.28, 0.70, 0.02, 0.00;
  (SLE, No expansion, 75-90pc) 0.2020202, 0.6969697, 0.1010101, 0.0000000;
  (Mycobact histiocytos, No expansion, 75-90pc) 0.02, 0.96, 0.02, 0.00;
  (Mast-cell hyperplas, No expansion, 75-90pc) 0.02, 0.96, 0.02, 0.00;
  (LGV, No expansion, 75-90pc) 0.01, 0.98, 0.01, 0.00;
  (Histoplasmosis, No expansion, 75-90pc) 0.02, 0.96, 0.02, 0.00;
  (Coccidioidomycosis, No expansion, 75-90pc) 0.02, 0.96, 0.02, 0.00;
  (CMV, No expansion, 75-90pc) 0.02, 0.96, 0.02, 0.00;
  (Brucellosis, No expansion, 75-90pc) 0.02, 0.96, 0.02, 0.00;
  (Ki-1 LC anaplas B, No expansion, 75-90pc) 0.70, 0.25, 0.05, 0.00;
  (Intermed lymphocytic, No expansion, 75-90pc) 0.000998004, 0.000998004, 0.109780439, 0.888223553;
  (AIDS early, Mild-moderate expansion, 75-90pc) 0.00, 0.25, 0.72, 0.03;
  (AILD, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (ALIP, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Cat scratch disease, Mild-moderate expansion, 75-90pc) 0.55, 0.10, 0.33, 0.02;
  (Dermatopathic laden, Mild-moderate expansion, 75-90pc) 0.00, 0.25, 0.72, 0.03;
  (Florid follic hyperp, Mild-moderate expansion, 75-90pc) 0.00, 0.25, 0.72, 0.03;
  (GLH hyaline vascular, Mild-moderate expansion, 75-90pc) 0.00, 0.25, 0.72, 0.03;
  (GLH plasma cell, Mild-moderate expansion, 75-90pc) 0.00, 0.25, 0.72, 0.03;
  (Granulomatous laden, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Histiocytosis x, Mild-moderate expansion, 75-90pc) 0.15, 0.45, 0.38, 0.02;
  (Infectious mono, Mild-moderate expansion, 75-90pc) 0.05, 0.25, 0.67, 0.03;
  (Leprosy-lepromatous, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Lymphangiographic, Mild-moderate expansion, 75-90pc) 0.55, 0.10, 0.35, 0.00;
  (Mantle zone hyperpla, Mild-moderate expansion, 75-90pc) 0.00, 0.25, 0.72, 0.03;
  (Necrotizing Kikuchi, Mild-moderate expansion, 75-90pc) 0.55, 0.10, 0.33, 0.02;
  (Necrotiz non-Kikuchi, Mild-moderate expansion, 75-90pc) 0.55, 0.10, 0.33, 0.02;
  (Rheumatoid arthritis, Mild-moderate expansion, 75-90pc) 0.00, 0.25, 0.72, 0.03;
  (Sarcoidosis, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (SHML, Mild-moderate expansion, 75-90pc) 0.55, 0.10, 0.35, 0.00;
  (Sinus histiocytosis, Mild-moderate expansion, 75-90pc) 0.55, 0.10, 0.35, 0.00;
  (Syphilis, Mild-moderate expansion, 75-90pc) 0.00, 0.25, 0.72, 0.03;
  (Toxoplasmosis, Mild-moderate expansion, 75-90pc) 0.00, 0.25, 0.72, 0.03;
  (Tuberculosis, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Viral NOS, Mild-moderate expansion, 75-90pc) 0.05, 0.25, 0.67, 0.03;
  (Whipple's disease, Mild-moderate expansion, 75-90pc) 0.55, 0.10, 0.35, 0.00;
  (L&H nodular HD, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (L&H diffuse HD, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Nodular sclerosis HD, Mild-moderate expansion, 75-90pc) 0.000999001, 0.049950050, 0.799200799, 0.149850150;
  (Cellular phase NSHD, Mild-moderate expansion, 75-90pc) 0.000999001, 0.049950050, 0.799200799, 0.149850150;
  (Syncytial NSHD, Mild-moderate expansion, 75-90pc) 0.000999001, 0.049950050, 0.799200799, 0.149850150;
  (Mixed cellularity HD, Mild-moderate expansion, 75-90pc) 0.000999001, 0.049950050, 0.799200799, 0.149850150;
  (Interfollicular HD, Mild-moderate expansion, 75-90pc) 0.001, 0.050, 0.849, 0.100;
  (Diffuse fibrosis HD, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Reticular-type HD, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Small cleaved fol, Mild-moderate expansion, 75-90pc) 0.00, 0.01, 0.05, 0.94;
  (Mixed fol, Mild-moderate expansion, 75-90pc) 0.00, 0.01, 0.05, 0.94;
  (Large cell fol, Mild-moderate expansion, 75-90pc) 0.00, 0.01, 0.05, 0.94;
  (Small noncleaved fol, Mild-moderate expansion, 75-90pc) 0.00, 0.01, 0.05, 0.94;
  (Small lymphocytic, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Plasmacytoid lyctic, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Mantle zone lymphoma, Mild-moderate expansion, 75-90pc) 0.001, 0.030, 0.300, 0.669;
  (Small cleaved dif, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Mixed FCC dif, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Large cell dif, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (B-immunoblastic, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (T-immunob mixed, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (AILD-like T-cell lym, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Japanese ATL, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Lymphoblastic, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Small noncleaved dif, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (True histiocytic, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Ki-1 LC anaplas T, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Multiple myeloma, Mild-moderate expansion, 75-90pc) 0.01, 0.10, 0.80, 0.09;
  (Mycosis fungoides, Mild-moderate expansion, 75-90pc) 0.01, 0.05, 0.91, 0.03;
  (AML, Mild-moderate expansion, 75-90pc) 0.01, 0.05, 0.89, 0.05;
  (Hairy cell leukemia, Mild-moderate expansion, 75-90pc) 0.60, 0.35, 0.05, 0.00;
  (Carcinoma, Mild-moderate expansion, 75-90pc) 0.01, 0.05, 0.89, 0.05;
  (Melanoma, Mild-moderate expansion, 75-90pc) 0.01, 0.05, 0.89, 0.05;
  (EM plasmacytoma, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Kaposi's sarcoma, Mild-moderate expansion, 75-90pc) 0.05, 0.30, 0.63, 0.02;
  (Mast-cell disease, Mild-moderate expansion, 75-90pc) 0.01, 0.05, 0.91, 0.03;
  (AIDS involutionary, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (T-immunob large, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Monocytoid B-cell, Mild-moderate expansion, 75-90pc) 0.05, 0.01, 0.24, 0.70;
  (Nasopharyngeal CA, Mild-moderate expansion, 75-90pc) 0.000999001, 0.049950050, 0.799200799, 0.149850150;
  (Seminoma, Mild-moderate expansion, 75-90pc) 0.01, 0.05, 0.89, 0.05;
  (SLE, Mild-moderate expansion, 75-90pc) 0.05, 0.25, 0.67, 0.03;
  (Mycobact histiocytos, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Mast-cell hyperplas, Mild-moderate expansion, 75-90pc) 0.00, 0.25, 0.72, 0.03;
  (LGV, Mild-moderate expansion, 75-90pc) 0.55, 0.10, 0.33, 0.02;
  (Histoplasmosis, Mild-moderate expansion, 75-90pc) 0.00, 0.25, 0.72, 0.03;
  (Coccidioidomycosis, Mild-moderate expansion, 75-90pc) 0.00, 0.25, 0.72, 0.03;
  (CMV, Mild-moderate expansion, 75-90pc) 0.00, 0.25, 0.72, 0.03;
  (Brucellosis, Mild-moderate expansion, 75-90pc) 0.00, 0.25, 0.72, 0.03;
  (Ki-1 LC anaplas B, Mild-moderate expansion, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Intermed lymphocytic, Mild-moderate expansion, 75-90pc) 0.001, 0.030, 0.300, 0.669;
  (AIDS early, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (AILD, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (ALIP, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Cat scratch disease, Unif mrkd expan/no follicles, 75-90pc) 0.01, 0.01, 0.93, 0.05;
  (Dermatopathic laden, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Florid follic hyperp, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (GLH hyaline vascular, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (GLH plasma cell, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Granulomatous laden, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Histiocytosis x, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Infectious mono, Unif mrkd expan/no follicles, 75-90pc) 0.000, 0.001, 0.899, 0.100;
  (Leprosy-lepromatous, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Lymphangiographic, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Mantle zone hyperpla, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Necrotizing Kikuchi, Unif mrkd expan/no follicles, 75-90pc) 0.01, 0.01, 0.93, 0.05;
  (Necrotiz non-Kikuchi, Unif mrkd expan/no follicles, 75-90pc) 0.01, 0.01, 0.93, 0.05;
  (Rheumatoid arthritis, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Sarcoidosis, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (SHML, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Sinus histiocytosis, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Syphilis, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Toxoplasmosis, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Tuberculosis, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Viral NOS, Unif mrkd expan/no follicles, 75-90pc) 0.000, 0.001, 0.899, 0.100;
  (Whipple's disease, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (L&H nodular HD, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (L&H diffuse HD, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Nodular sclerosis HD, Unif mrkd expan/no follicles, 75-90pc) 0.00, 0.00, 0.85, 0.15;
  (Cellular phase NSHD, Unif mrkd expan/no follicles, 75-90pc) 0.00, 0.00, 0.85, 0.15;
  (Syncytial NSHD, Unif mrkd expan/no follicles, 75-90pc) 0.00, 0.00, 0.85, 0.15;
  (Mixed cellularity HD, Unif mrkd expan/no follicles, 75-90pc) 0.00, 0.00, 0.85, 0.15;
  (Interfollicular HD, Unif mrkd expan/no follicles, 75-90pc) 0.00, 0.00, 0.85, 0.15;
  (Diffuse fibrosis HD, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Reticular-type HD, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Small cleaved fol, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Mixed fol, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Large cell fol, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Small noncleaved fol, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Small lymphocytic, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Plasmacytoid lyctic, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Mantle zone lymphoma, Unif mrkd expan/no follicles, 75-90pc) 0.00, 0.01, 0.10, 0.89;
  (Small cleaved dif, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Mixed FCC dif, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Large cell dif, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (B-immunoblastic, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (T-immunob mixed, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (AILD-like T-cell lym, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Japanese ATL, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Lymphoblastic, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Small noncleaved dif, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (True histiocytic, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Ki-1 LC anaplas T, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Multiple myeloma, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Mycosis fungoides, Unif mrkd expan/no follicles, 75-90pc) 0.0, 0.0, 0.9, 0.1;
  (AML, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Hairy cell leukemia, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Carcinoma, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Melanoma, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (EM plasmacytoma, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Kaposi's sarcoma, Unif mrkd expan/no follicles, 75-90pc) 0.0, 0.0, 0.9, 0.1;
  (Mast-cell disease, Unif mrkd expan/no follicles, 75-90pc) 0.0, 0.0, 0.9, 0.1;
  (AIDS involutionary, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (T-immunob large, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Monocytoid B-cell, Unif mrkd expan/no follicles, 75-90pc) 0.001, 0.001, 0.248, 0.750;
  (Nasopharyngeal CA, Unif mrkd expan/no follicles, 75-90pc) 0.00, 0.00, 0.85, 0.15;
  (Seminoma, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (SLE, Unif mrkd expan/no follicles, 75-90pc) 0.000, 0.001, 0.899, 0.100;
  (Mycobact histiocytos, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Mast-cell hyperplas, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (LGV, Unif mrkd expan/no follicles, 75-90pc) 0.01, 0.01, 0.93, 0.05;
  (Histoplasmosis, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Coccidioidomycosis, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (CMV, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Brucellosis, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Ki-1 LC anaplas B, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (Intermed lymphocytic, Unif mrkd expan/no follicles, 75-90pc) 0.25, 0.25, 0.25, 0.25;
  (AIDS early, No expansion, >90pc) 0.01, 0.01, 0.40, 0.58;
  (AILD, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (ALIP, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Cat scratch disease, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Dermatopathic laden, No expansion, >90pc) 0.01, 0.01, 0.40, 0.58;
  (Florid follic hyperp, No expansion, >90pc) 0.01, 0.01, 0.40, 0.58;
  (GLH hyaline vascular, No expansion, >90pc) 0.01, 0.01, 0.40, 0.58;
  (GLH plasma cell, No expansion, >90pc) 0.01, 0.01, 0.40, 0.58;
  (Granulomatous laden, No expansion, >90pc) 0.01, 0.01, 0.40, 0.58;
  (Histiocytosis x, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Infectious mono, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Leprosy-lepromatous, No expansion, >90pc) 0.01, 0.01, 0.40, 0.58;
  (Lymphangiographic, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Mantle zone hyperpla, No expansion, >90pc) 0.01, 0.01, 0.40, 0.58;
  (Necrotizing Kikuchi, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Necrotiz non-Kikuchi, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Rheumatoid arthritis, No expansion, >90pc) 0.01, 0.01, 0.40, 0.58;
  (Sarcoidosis, No expansion, >90pc) 0.01, 0.01, 0.40, 0.58;
  (SHML, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Sinus histiocytosis, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Syphilis, No expansion, >90pc) 0.01, 0.01, 0.40, 0.58;
  (Toxoplasmosis, No expansion, >90pc) 0.01, 0.01, 0.40, 0.58;
  (Tuberculosis, No expansion, >90pc) 0.01, 0.01, 0.40, 0.58;
  (Viral NOS, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Whipple's disease, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (L&H nodular HD, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (L&H diffuse HD, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Nodular sclerosis HD, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Cellular phase NSHD, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Syncytial NSHD, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Mixed cellularity HD, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Interfollicular HD, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Diffuse fibrosis HD, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Reticular-type HD, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Small cleaved fol, No expansion, >90pc) 0.000998004, 0.000998004, 0.049900200, 0.948103792;
  (Mixed fol, No expansion, >90pc) 0.000998004, 0.000998004, 0.049900200, 0.948103792;
  (Large cell fol, No expansion, >90pc) 0.000998004, 0.000998004, 0.049900200, 0.948103792;
  (Small noncleaved fol, No expansion, >90pc) 0.000998004, 0.000998004, 0.049900200, 0.948103792;
  (Small lymphocytic, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Plasmacytoid lyctic, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Mantle zone lymphoma, No expansion, >90pc) 0.000998004, 0.000998004, 0.049900200, 0.948103792;
  (Small cleaved dif, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Mixed FCC dif, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Large cell dif, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (B-immunoblastic, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (T-immunob mixed, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (AILD-like T-cell lym, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Japanese ATL, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Lymphoblastic, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Small noncleaved dif, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (True histiocytic, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Ki-1 LC anaplas T, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Multiple myeloma, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Mycosis fungoides, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (AML, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Hairy cell leukemia, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Carcinoma, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Melanoma, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (EM plasmacytoma, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Kaposi's sarcoma, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Mast-cell disease, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (AIDS involutionary, No expansion, >90pc) 0.01, 0.01, 0.40, 0.58;
  (T-immunob large, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Monocytoid B-cell, No expansion, >90pc) 0.000998004, 0.000998004, 0.199600798, 0.798403194;
  (Nasopharyngeal CA, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Seminoma, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (SLE, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Mycobact histiocytos, No expansion, >90pc) 0.01, 0.01, 0.40, 0.58;
  (Mast-cell hyperplas, No expansion, >90pc) 0.01, 0.01, 0.40, 0.58;
  (LGV, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Histoplasmosis, No expansion, >90pc) 0.01, 0.01, 0.40, 0.58;
  (Coccidioidomycosis, No expansion, >90pc) 0.01, 0.01, 0.40, 0.58;
  (CMV, No expansion, >90pc) 0.01, 0.01, 0.40, 0.58;
  (Brucellosis, No expansion, >90pc) 0.01, 0.01, 0.40, 0.58;
  (Ki-1 LC anaplas B, No expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Intermed lymphocytic, No expansion, >90pc) 0.000998004, 0.000998004, 0.049900200, 0.948103792;
  (AIDS early, Mild-moderate expansion, >90pc) 0.00, 0.01, 0.10, 0.89;
  (AILD, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (ALIP, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Cat scratch disease, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Dermatopathic laden, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Florid follic hyperp, Mild-moderate expansion, >90pc) 0.00, 0.01, 0.10, 0.89;
  (GLH hyaline vascular, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (GLH plasma cell, Mild-moderate expansion, >90pc) 0.00, 0.01, 0.10, 0.89;
  (Granulomatous laden, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Histiocytosis x, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Infectious mono, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Leprosy-lepromatous, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Lymphangiographic, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Mantle zone hyperpla, Mild-moderate expansion, >90pc) 0.00, 0.01, 0.10, 0.89;
  (Necrotizing Kikuchi, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Necrotiz non-Kikuchi, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Rheumatoid arthritis, Mild-moderate expansion, >90pc) 0.00, 0.01, 0.10, 0.89;
  (Sarcoidosis, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (SHML, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Sinus histiocytosis, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Syphilis, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Toxoplasmosis, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Tuberculosis, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Viral NOS, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Whipple's disease, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (L&H nodular HD, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (L&H diffuse HD, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Nodular sclerosis HD, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Cellular phase NSHD, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Syncytial NSHD, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Mixed cellularity HD, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Interfollicular HD, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Diffuse fibrosis HD, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Reticular-type HD, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Small cleaved fol, Mild-moderate expansion, >90pc) 0.000, 0.005, 0.050, 0.945;
  (Mixed fol, Mild-moderate expansion, >90pc) 0.000, 0.005, 0.050, 0.945;
  (Large cell fol, Mild-moderate expansion, >90pc) 0.000, 0.005, 0.050, 0.945;
  (Small noncleaved fol, Mild-moderate expansion, >90pc) 0.000, 0.005, 0.050, 0.945;
  (Small lymphocytic, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Plasmacytoid lyctic, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Mantle zone lymphoma, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Small cleaved dif, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Mixed FCC dif, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Large cell dif, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (B-immunoblastic, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (T-immunob mixed, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (AILD-like T-cell lym, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Japanese ATL, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Lymphoblastic, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Small noncleaved dif, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (True histiocytic, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Ki-1 LC anaplas T, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Multiple myeloma, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Mycosis fungoides, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (AML, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Hairy cell leukemia, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Carcinoma, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Melanoma, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (EM plasmacytoma, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Kaposi's sarcoma, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Mast-cell disease, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (AIDS involutionary, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (T-immunob large, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Monocytoid B-cell, Mild-moderate expansion, >90pc) 0.000, 0.005, 0.050, 0.945;
  (Nasopharyngeal CA, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Seminoma, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (SLE, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Mycobact histiocytos, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Mast-cell hyperplas, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (LGV, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Histoplasmosis, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Coccidioidomycosis, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (CMV, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Brucellosis, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Ki-1 LC anaplas B, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Intermed lymphocytic, Mild-moderate expansion, >90pc) 0.25, 0.25, 0.25, 0.25;
  (AIDS early, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (AILD, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (ALIP, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Cat scratch disease, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Dermatopathic laden, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Florid follic hyperp, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (GLH hyaline vascular, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (GLH plasma cell, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Granulomatous laden, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Histiocytosis x, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Infectious mono, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Leprosy-lepromatous, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Lymphangiographic, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Mantle zone hyperpla, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Necrotizing Kikuchi, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Necrotiz non-Kikuchi, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Rheumatoid arthritis, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Sarcoidosis, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (SHML, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Sinus histiocytosis, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Syphilis, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Toxoplasmosis, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Tuberculosis, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Viral NOS, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Whipple's disease, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (L&H nodular HD, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (L&H diffuse HD, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Nodular sclerosis HD, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Cellular phase NSHD, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Syncytial NSHD, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Mixed cellularity HD, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Interfollicular HD, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Diffuse fibrosis HD, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Reticular-type HD, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Small cleaved fol, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Mixed fol, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Large cell fol, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Small noncleaved fol, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Small lymphocytic, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Plasmacytoid lyctic, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Mantle zone lymphoma, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Small cleaved dif, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Mixed FCC dif, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Large cell dif, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (B-immunoblastic, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (T-immunob mixed, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (AILD-like T-cell lym, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Japanese ATL, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Lymphoblastic, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Small noncleaved dif, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (True histiocytic, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Ki-1 LC anaplas T, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Multiple myeloma, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Mycosis fungoides, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (AML, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Hairy cell leukemia, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Carcinoma, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Melanoma, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (EM plasmacytoma, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Kaposi's sarcoma, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Mast-cell disease, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (AIDS involutionary, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (T-immunob large, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Monocytoid B-cell, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Nasopharyngeal CA, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Seminoma, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (SLE, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Mycobact histiocytos, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Mast-cell hyperplas, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (LGV, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Histoplasmosis, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Coccidioidomycosis, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (CMV, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Brucellosis, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Ki-1 LC anaplas B, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
  (Intermed lymphocytic, Unif mrkd expan/no follicles, >90pc) 0.25, 0.25, 0.25, 0.25;
}
probability ( VASC_C | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 1.0, 0.0;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 0.4, 0.6;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 1.0, 0.0;
  (L&H diffuse HD) 1.0, 0.0;
  (Nodular sclerosis HD) 1.0, 0.0;
  (Cellular phase NSHD) 1.0, 0.0;
  (Syncytial NSHD) 1.0, 0.0;
  (Mixed cellularity HD) 1.0, 0.0;
  (Interfollicular HD) 1.0, 0.0;
  (Diffuse fibrosis HD) 1.0, 0.0;
  (Reticular-type HD) 1.0, 0.0;
  (Small cleaved fol) 1.0, 0.0;
  (Mixed fol) 1.0, 0.0;
  (Large cell fol) 1.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0;
  (Small lymphocytic) 1.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0;
  (Small cleaved dif) 1.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0;
  (Large cell dif) 1.0, 0.0;
  (B-immunoblastic) 1.0, 0.0;
  (T-immunob mixed) 1.0, 0.0;
  (AILD-like T-cell lym) 1.0, 0.0;
  (Japanese ATL) 1.0, 0.0;
  (Lymphoblastic) 1.0, 0.0;
  (Small noncleaved dif) 1.0, 0.0;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 1.0, 0.0;
  (Multiple myeloma) 1.0, 0.0;
  (Mycosis fungoides) 1.0, 0.0;
  (AML) 1.0, 0.0;
  (Hairy cell leukemia) 1.0, 0.0;
  (Carcinoma) 1.0, 0.0;
  (Melanoma) 1.0, 0.0;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0;
  (Mast-cell disease) 1.0, 0.0;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 1.0, 0.0;
  (Monocytoid B-cell) 1.0, 0.0;
  (Nasopharyngeal CA) 1.0, 0.0;
  (Seminoma) 1.0, 0.0;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 1.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0;
}
probability ( VASC_NS | Fault ) {
  (AIDS early) 0.05, 0.73, 0.20, 0.02, 0.00;
  (AILD) 0.00, 0.00, 0.01, 0.79, 0.20;
  (ALIP) 0.01, 0.35, 0.50, 0.13, 0.01;
  (Cat scratch disease) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Dermatopathic laden) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Florid follic hyperp) 0.05, 0.73, 0.20, 0.02, 0.00;
  (GLH hyaline vascular) 0.00, 0.00, 0.01, 0.89, 0.10;
  (GLH plasma cell) 0.100, 0.449, 0.300, 0.150, 0.001;
  (Granulomatous laden) 0.10, 0.60, 0.25, 0.05, 0.00;
  (Histiocytosis x) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Infectious mono) 0.01, 0.56, 0.35, 0.08, 0.00;
  (Leprosy-lepromatous) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Lymphangiographic) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Mantle zone hyperpla) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Necrotizing Kikuchi) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Necrotiz non-Kikuchi) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Rheumatoid arthritis) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Sarcoidosis) 0.05, 0.73, 0.20, 0.02, 0.00;
  (SHML) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Sinus histiocytosis) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Syphilis) 0.01, 0.56, 0.35, 0.08, 0.00;
  (Toxoplasmosis) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Tuberculosis) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Viral NOS) 0.01, 0.56, 0.35, 0.08, 0.00;
  (Whipple's disease) 0.05, 0.73, 0.20, 0.02, 0.00;
  (L&H nodular HD) 0.05, 0.73, 0.20, 0.02, 0.00;
  (L&H diffuse HD) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Nodular sclerosis HD) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Cellular phase NSHD) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Syncytial NSHD) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Mixed cellularity HD) 0.01, 0.56, 0.35, 0.08, 0.00;
  (Interfollicular HD) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Diffuse fibrosis HD) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Reticular-type HD) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Small cleaved fol) 0.01, 0.65, 0.32, 0.02, 0.00;
  (Mixed fol) 0.01, 0.65, 0.32, 0.02, 0.00;
  (Large cell fol) 0.01, 0.65, 0.32, 0.02, 0.00;
  (Small noncleaved fol) 0.01, 0.65, 0.32, 0.02, 0.00;
  (Small lymphocytic) 0.05, 0.65, 0.29, 0.01, 0.00;
  (Plasmacytoid lyctic) 0.05, 0.65, 0.29, 0.01, 0.00;
  (Mantle zone lymphoma) 0.05, 0.65, 0.29, 0.01, 0.00;
  (Small cleaved dif) 0.05, 0.65, 0.29, 0.01, 0.00;
  (Mixed FCC dif) 0.01, 0.60, 0.31, 0.08, 0.00;
  (Large cell dif) 0.01, 0.66, 0.31, 0.02, 0.00;
  (B-immunoblastic) 0.01, 0.66, 0.31, 0.02, 0.00;
  (T-immunob mixed) 0.01, 0.60, 0.31, 0.08, 0.00;
  (AILD-like T-cell lym) 0.00, 0.00, 0.01, 0.79, 0.20;
  (Japanese ATL) 0.01, 0.66, 0.31, 0.02, 0.00;
  (Lymphoblastic) 0.01, 0.66, 0.31, 0.02, 0.00;
  (Small noncleaved dif) 0.01, 0.66, 0.31, 0.02, 0.00;
  (True histiocytic) 0.01, 0.66, 0.31, 0.02, 0.00;
  (Ki-1 LC anaplas T) 0.01, 0.66, 0.31, 0.02, 0.00;
  (Multiple myeloma) 0.05, 0.74, 0.20, 0.01, 0.00;
  (Mycosis fungoides) 0.05, 0.65, 0.29, 0.01, 0.00;
  (AML) 0.05, 0.65, 0.29, 0.01, 0.00;
  (Hairy cell leukemia) 0.01, 0.70, 0.28, 0.01, 0.00;
  (Carcinoma) 0.05, 0.65, 0.29, 0.01, 0.00;
  (Melanoma) 0.05, 0.65, 0.29, 0.01, 0.00;
  (EM plasmacytoma) 0.05, 0.74, 0.20, 0.01, 0.00;
  (Kaposi's sarcoma) 0.01, 0.68, 0.30, 0.01, 0.00;
  (Mast-cell disease) 0.05, 0.73, 0.20, 0.02, 0.00;
  (AIDS involutionary) 0.01, 0.49, 0.40, 0.10, 0.00;
  (T-immunob large) 0.01, 0.66, 0.31, 0.02, 0.00;
  (Monocytoid B-cell) 0.01, 0.65, 0.32, 0.02, 0.00;
  (Nasopharyngeal CA) 0.05, 0.65, 0.29, 0.01, 0.00;
  (Seminoma) 0.05, 0.65, 0.29, 0.01, 0.00;
  (SLE) 0.01, 0.56, 0.35, 0.08, 0.00;
  (Mycobact histiocytos) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Mast-cell hyperplas) 0.05, 0.73, 0.20, 0.02, 0.00;
  (LGV) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Histoplasmosis) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Coccidioidomycosis) 0.05, 0.73, 0.20, 0.02, 0.00;
  (CMV) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Brucellosis) 0.05, 0.73, 0.20, 0.02, 0.00;
  (Ki-1 LC anaplas B) 0.01, 0.66, 0.31, 0.02, 0.00;
  (Intermed lymphocytic) 0.05, 0.65, 0.29, 0.01, 0.00;
}
probability ( VASC_S | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 1.0, 0.0;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 1.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 1.0, 0.0;
  (L&H diffuse HD) 1.0, 0.0;
  (Nodular sclerosis HD) 1.0, 0.0;
  (Cellular phase NSHD) 1.0, 0.0;
  (Syncytial NSHD) 1.0, 0.0;
  (Mixed cellularity HD) 1.0, 0.0;
  (Interfollicular HD) 1.0, 0.0;
  (Diffuse fibrosis HD) 1.0, 0.0;
  (Reticular-type HD) 1.0, 0.0;
  (Small cleaved fol) 1.0, 0.0;
  (Mixed fol) 1.0, 0.0;
  (Large cell fol) 1.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0;
  (Small lymphocytic) 1.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0;
  (Small cleaved dif) 1.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0;
  (Large cell dif) 1.0, 0.0;
  (B-immunoblastic) 1.0, 0.0;
  (T-immunob mixed) 1.0, 0.0;
  (AILD-like T-cell lym) 1.0, 0.0;
  (Japanese ATL) 1.0, 0.0;
  (Lymphoblastic) 1.0, 0.0;
  (Small noncleaved dif) 1.0, 0.0;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 1.0, 0.0;
  (Multiple myeloma) 1.0, 0.0;
  (Mycosis fungoides) 1.0, 0.0;
  (AML) 1.0, 0.0;
  (Hairy cell leukemia) 1.0, 0.0;
  (Carcinoma) 1.0, 0.0;
  (Melanoma) 1.0, 0.0;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 0.01, 0.99;
  (Mast-cell disease) 1.0, 0.0;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 1.0, 0.0;
  (Monocytoid B-cell) 1.0, 0.0;
  (Nasopharyngeal CA) 1.0, 0.0;
  (Seminoma) 1.0, 0.0;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 1.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0;
}
probability ( F_HEM | Fault, FOLLICLE ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0;
  (AIDS early, 1-25pc) 0.00, 0.55, 0.45;
  (AILD, 1-25pc) 0.00, 0.99, 0.01;
  (ALIP, 1-25pc) 0.00, 0.99, 0.01;
  (Cat scratch disease, 1-25pc) 0.00, 0.99, 0.01;
  (Dermatopathic laden, 1-25pc) 0.00, 0.99, 0.01;
  (Florid follic hyperp, 1-25pc) 0.00, 0.95, 0.05;
  (GLH hyaline vascular, 1-25pc) 0.00, 0.99, 0.01;
  (GLH plasma cell, 1-25pc) 0.00, 0.99, 0.01;
  (Granulomatous laden, 1-25pc) 0.00, 0.99, 0.01;
  (Histiocytosis x, 1-25pc) 0.00, 0.99, 0.01;
  (Infectious mono, 1-25pc) 0.00, 0.99, 0.01;
  (Leprosy-lepromatous, 1-25pc) 0.00, 0.99, 0.01;
  (Lymphangiographic, 1-25pc) 0.00, 0.99, 0.01;
  (Mantle zone hyperpla, 1-25pc) 0.00, 0.99, 0.01;
  (Necrotizing Kikuchi, 1-25pc) 0.00, 0.99, 0.01;
  (Necrotiz non-Kikuchi, 1-25pc) 0.00, 0.99, 0.01;
  (Rheumatoid arthritis, 1-25pc) 0.00, 0.99, 0.01;
  (Sarcoidosis, 1-25pc) 0.00, 0.99, 0.01;
  (SHML, 1-25pc) 0.00, 0.99, 0.01;
  (Sinus histiocytosis, 1-25pc) 0.00, 0.99, 0.01;
  (Syphilis, 1-25pc) 0.00, 0.99, 0.01;
  (Toxoplasmosis, 1-25pc) 0.00, 0.99, 0.01;
  (Tuberculosis, 1-25pc) 0.00, 0.99, 0.01;
  (Viral NOS, 1-25pc) 0.00, 0.99, 0.01;
  (Whipple's disease, 1-25pc) 0.00, 0.99, 0.01;
  (L&H nodular HD, 1-25pc) 0.00, 0.99, 0.01;
  (L&H diffuse HD, 1-25pc) 0.00, 0.99, 0.01;
  (Nodular sclerosis HD, 1-25pc) 0.00, 0.99, 0.01;
  (Cellular phase NSHD, 1-25pc) 0.00, 0.99, 0.01;
  (Syncytial NSHD, 1-25pc) 0.00, 0.99, 0.01;
  (Mixed cellularity HD, 1-25pc) 0.00, 0.99, 0.01;
  (Interfollicular HD, 1-25pc) 0.00, 0.99, 0.01;
  (Diffuse fibrosis HD, 1-25pc) 0.00, 0.99, 0.01;
  (Reticular-type HD, 1-25pc) 0.00, 0.99, 0.01;
  (Small cleaved fol, 1-25pc) 0.00, 0.99, 0.01;
  (Mixed fol, 1-25pc) 0.00, 0.99, 0.01;
  (Large cell fol, 1-25pc) 0.00, 0.99, 0.01;
  (Small noncleaved fol, 1-25pc) 0.00, 0.99, 0.01;
  (Small lymphocytic, 1-25pc) 0.00, 0.99, 0.01;
  (Plasmacytoid lyctic, 1-25pc) 0.00, 0.99, 0.01;
  (Mantle zone lymphoma, 1-25pc) 0.00, 0.99, 0.01;
  (Small cleaved dif, 1-25pc) 0.00, 0.99, 0.01;
  (Mixed FCC dif, 1-25pc) 0.00, 0.99, 0.01;
  (Large cell dif, 1-25pc) 0.00, 0.99, 0.01;
  (B-immunoblastic, 1-25pc) 0.00, 0.99, 0.01;
  (T-immunob mixed, 1-25pc) 0.00, 0.99, 0.01;
  (AILD-like T-cell lym, 1-25pc) 0.00, 0.99, 0.01;
  (Japanese ATL, 1-25pc) 0.00, 0.99, 0.01;
  (Lymphoblastic, 1-25pc) 0.00, 0.99, 0.01;
  (Small noncleaved dif, 1-25pc) 0.00, 0.99, 0.01;
  (True histiocytic, 1-25pc) 0.00, 0.99, 0.01;
  (Ki-1 LC anaplas T, 1-25pc) 0.00, 0.99, 0.01;
  (Multiple myeloma, 1-25pc) 0.00, 0.99, 0.01;
  (Mycosis fungoides, 1-25pc) 0.00, 0.99, 0.01;
  (AML, 1-25pc) 0.00, 0.99, 0.01;
  (Hairy cell leukemia, 1-25pc) 0.00, 0.99, 0.01;
  (Carcinoma, 1-25pc) 0.00, 0.99, 0.01;
  (Melanoma, 1-25pc) 0.00, 0.99, 0.01;
  (EM plasmacytoma, 1-25pc) 0.00, 0.99, 0.01;
  (Kaposi's sarcoma, 1-25pc) 0.00, 0.99, 0.01;
  (Mast-cell disease, 1-25pc) 0.00, 0.99, 0.01;
  (AIDS involutionary, 1-25pc) 0.0, 0.5, 0.5;
  (T-immunob large, 1-25pc) 0.00, 0.99, 0.01;
  (Monocytoid B-cell, 1-25pc) 0.00, 0.99, 0.01;
  (Nasopharyngeal CA, 1-25pc) 0.00, 0.99, 0.01;
  (Seminoma, 1-25pc) 0.00, 0.99, 0.01;
  (SLE, 1-25pc) 0.00, 0.99, 0.01;
  (Mycobact histiocytos, 1-25pc) 0.0, 0.9, 0.1;
  (Mast-cell hyperplas, 1-25pc) 0.00, 0.99, 0.01;
  (LGV, 1-25pc) 0.00, 0.99, 0.01;
  (Histoplasmosis, 1-25pc) 0.0, 0.9, 0.1;
  (Coccidioidomycosis, 1-25pc) 0.0, 0.9, 0.1;
  (CMV, 1-25pc) 0.0, 0.9, 0.1;
  (Brucellosis, 1-25pc) 0.00, 0.99, 0.01;
  (Ki-1 LC anaplas B, 1-25pc) 0.00, 0.99, 0.01;
  (Intermed lymphocytic, 1-25pc) 0.00, 0.99, 0.01;
  (AIDS early, 25-75pc) 0.00, 0.55, 0.45;
  (AILD, 25-75pc) 0.00, 0.99, 0.01;
  (ALIP, 25-75pc) 0.00, 0.99, 0.01;
  (Cat scratch disease, 25-75pc) 0.00, 0.99, 0.01;
  (Dermatopathic laden, 25-75pc) 0.00, 0.99, 0.01;
  (Florid follic hyperp, 25-75pc) 0.00, 0.95, 0.05;
  (GLH hyaline vascular, 25-75pc) 0.00, 0.99, 0.01;
  (GLH plasma cell, 25-75pc) 0.00, 0.99, 0.01;
  (Granulomatous laden, 25-75pc) 0.00, 0.99, 0.01;
  (Histiocytosis x, 25-75pc) 0.00, 0.99, 0.01;
  (Infectious mono, 25-75pc) 0.00, 0.99, 0.01;
  (Leprosy-lepromatous, 25-75pc) 0.00, 0.99, 0.01;
  (Lymphangiographic, 25-75pc) 0.00, 0.99, 0.01;
  (Mantle zone hyperpla, 25-75pc) 0.00, 0.99, 0.01;
  (Necrotizing Kikuchi, 25-75pc) 0.00, 0.99, 0.01;
  (Necrotiz non-Kikuchi, 25-75pc) 0.00, 0.99, 0.01;
  (Rheumatoid arthritis, 25-75pc) 0.00, 0.99, 0.01;
  (Sarcoidosis, 25-75pc) 0.00, 0.99, 0.01;
  (SHML, 25-75pc) 0.00, 0.99, 0.01;
  (Sinus histiocytosis, 25-75pc) 0.00, 0.99, 0.01;
  (Syphilis, 25-75pc) 0.00, 0.99, 0.01;
  (Toxoplasmosis, 25-75pc) 0.00, 0.99, 0.01;
  (Tuberculosis, 25-75pc) 0.00, 0.99, 0.01;
  (Viral NOS, 25-75pc) 0.00, 0.99, 0.01;
  (Whipple's disease, 25-75pc) 0.00, 0.99, 0.01;
  (L&H nodular HD, 25-75pc) 0.00, 0.99, 0.01;
  (L&H diffuse HD, 25-75pc) 0.00, 0.99, 0.01;
  (Nodular sclerosis HD, 25-75pc) 0.00, 0.99, 0.01;
  (Cellular phase NSHD, 25-75pc) 0.00, 0.99, 0.01;
  (Syncytial NSHD, 25-75pc) 0.00, 0.99, 0.01;
  (Mixed cellularity HD, 25-75pc) 0.00, 0.99, 0.01;
  (Interfollicular HD, 25-75pc) 0.00, 0.99, 0.01;
  (Diffuse fibrosis HD, 25-75pc) 0.00, 0.99, 0.01;
  (Reticular-type HD, 25-75pc) 0.00, 0.99, 0.01;
  (Small cleaved fol, 25-75pc) 0.00, 0.99, 0.01;
  (Mixed fol, 25-75pc) 0.00, 0.99, 0.01;
  (Large cell fol, 25-75pc) 0.00, 0.99, 0.01;
  (Small noncleaved fol, 25-75pc) 0.00, 0.99, 0.01;
  (Small lymphocytic, 25-75pc) 0.00, 0.99, 0.01;
  (Plasmacytoid lyctic, 25-75pc) 0.00, 0.99, 0.01;
  (Mantle zone lymphoma, 25-75pc) 0.00, 0.99, 0.01;
  (Small cleaved dif, 25-75pc) 0.00, 0.99, 0.01;
  (Mixed FCC dif, 25-75pc) 0.00, 0.99, 0.01;
  (Large cell dif, 25-75pc) 0.00, 0.99, 0.01;
  (B-immunoblastic, 25-75pc) 0.00, 0.99, 0.01;
  (T-immunob mixed, 25-75pc) 0.00, 0.99, 0.01;
  (AILD-like T-cell lym, 25-75pc) 0.00, 0.99, 0.01;
  (Japanese ATL, 25-75pc) 0.00, 0.99, 0.01;
  (Lymphoblastic, 25-75pc) 0.00, 0.99, 0.01;
  (Small noncleaved dif, 25-75pc) 0.00, 0.99, 0.01;
  (True histiocytic, 25-75pc) 0.00, 0.99, 0.01;
  (Ki-1 LC anaplas T, 25-75pc) 0.00, 0.99, 0.01;
  (Multiple myeloma, 25-75pc) 0.00, 0.99, 0.01;
  (Mycosis fungoides, 25-75pc) 0.00, 0.99, 0.01;
  (AML, 25-75pc) 0.00, 0.99, 0.01;
  (Hairy cell leukemia, 25-75pc) 0.00, 0.99, 0.01;
  (Carcinoma, 25-75pc) 0.00, 0.99, 0.01;
  (Melanoma, 25-75pc) 0.00, 0.99, 0.01;
  (EM plasmacytoma, 25-75pc) 0.00, 0.99, 0.01;
  (Kaposi's sarcoma, 25-75pc) 0.00, 0.99, 0.01;
  (Mast-cell disease, 25-75pc) 0.00, 0.99, 0.01;
  (AIDS involutionary, 25-75pc) 0.0, 0.5, 0.5;
  (T-immunob large, 25-75pc) 0.00, 0.99, 0.01;
  (Monocytoid B-cell, 25-75pc) 0.00, 0.99, 0.01;
  (Nasopharyngeal CA, 25-75pc) 0.00, 0.99, 0.01;
  (Seminoma, 25-75pc) 0.00, 0.99, 0.01;
  (SLE, 25-75pc) 0.00, 0.99, 0.01;
  (Mycobact histiocytos, 25-75pc) 0.0, 0.9, 0.1;
  (Mast-cell hyperplas, 25-75pc) 0.00, 0.99, 0.01;
  (LGV, 25-75pc) 0.00, 0.99, 0.01;
  (Histoplasmosis, 25-75pc) 0.0, 0.9, 0.1;
  (Coccidioidomycosis, 25-75pc) 0.0, 0.9, 0.1;
  (CMV, 25-75pc) 0.0, 0.9, 0.1;
  (Brucellosis, 25-75pc) 0.00, 0.99, 0.01;
  (Ki-1 LC anaplas B, 25-75pc) 0.00, 0.99, 0.01;
  (Intermed lymphocytic, 25-75pc) 0.00, 0.99, 0.01;
  (AIDS early, 75-90pc) 0.00, 0.55, 0.45;
  (AILD, 75-90pc) 0.00, 0.99, 0.01;
  (ALIP, 75-90pc) 0.00, 0.99, 0.01;
  (Cat scratch disease, 75-90pc) 0.00, 0.99, 0.01;
  (Dermatopathic laden, 75-90pc) 0.00, 0.99, 0.01;
  (Florid follic hyperp, 75-90pc) 0.00, 0.95, 0.05;
  (GLH hyaline vascular, 75-90pc) 0.00, 0.99, 0.01;
  (GLH plasma cell, 75-90pc) 0.00, 0.99, 0.01;
  (Granulomatous laden, 75-90pc) 0.00, 0.99, 0.01;
  (Histiocytosis x, 75-90pc) 0.00, 0.99, 0.01;
  (Infectious mono, 75-90pc) 0.00, 0.99, 0.01;
  (Leprosy-lepromatous, 75-90pc) 0.00, 0.99, 0.01;
  (Lymphangiographic, 75-90pc) 0.00, 0.99, 0.01;
  (Mantle zone hyperpla, 75-90pc) 0.00, 0.99, 0.01;
  (Necrotizing Kikuchi, 75-90pc) 0.00, 0.99, 0.01;
  (Necrotiz non-Kikuchi, 75-90pc) 0.00, 0.99, 0.01;
  (Rheumatoid arthritis, 75-90pc) 0.00, 0.99, 0.01;
  (Sarcoidosis, 75-90pc) 0.00, 0.99, 0.01;
  (SHML, 75-90pc) 0.00, 0.99, 0.01;
  (Sinus histiocytosis, 75-90pc) 0.00, 0.99, 0.01;
  (Syphilis, 75-90pc) 0.00, 0.99, 0.01;
  (Toxoplasmosis, 75-90pc) 0.00, 0.99, 0.01;
  (Tuberculosis, 75-90pc) 0.00, 0.99, 0.01;
  (Viral NOS, 75-90pc) 0.00, 0.99, 0.01;
  (Whipple's disease, 75-90pc) 0.00, 0.99, 0.01;
  (L&H nodular HD, 75-90pc) 0.00, 0.99, 0.01;
  (L&H diffuse HD, 75-90pc) 0.00, 0.99, 0.01;
  (Nodular sclerosis HD, 75-90pc) 0.00, 0.99, 0.01;
  (Cellular phase NSHD, 75-90pc) 0.00, 0.99, 0.01;
  (Syncytial NSHD, 75-90pc) 0.00, 0.99, 0.01;
  (Mixed cellularity HD, 75-90pc) 0.00, 0.99, 0.01;
  (Interfollicular HD, 75-90pc) 0.00, 0.99, 0.01;
  (Diffuse fibrosis HD, 75-90pc) 0.00, 0.99, 0.01;
  (Reticular-type HD, 75-90pc) 0.00, 0.99, 0.01;
  (Small cleaved fol, 75-90pc) 0.00, 0.99, 0.01;
  (Mixed fol, 75-90pc) 0.00, 0.99, 0.01;
  (Large cell fol, 75-90pc) 0.00, 0.99, 0.01;
  (Small noncleaved fol, 75-90pc) 0.00, 0.99, 0.01;
  (Small lymphocytic, 75-90pc) 0.00, 0.99, 0.01;
  (Plasmacytoid lyctic, 75-90pc) 0.00, 0.99, 0.01;
  (Mantle zone lymphoma, 75-90pc) 0.00, 0.99, 0.01;
  (Small cleaved dif, 75-90pc) 0.00, 0.99, 0.01;
  (Mixed FCC dif, 75-90pc) 0.00, 0.99, 0.01;
  (Large cell dif, 75-90pc) 0.00, 0.99, 0.01;
  (B-immunoblastic, 75-90pc) 0.00, 0.99, 0.01;
  (T-immunob mixed, 75-90pc) 0.00, 0.99, 0.01;
  (AILD-like T-cell lym, 75-90pc) 0.00, 0.99, 0.01;
  (Japanese ATL, 75-90pc) 0.00, 0.99, 0.01;
  (Lymphoblastic, 75-90pc) 0.00, 0.99, 0.01;
  (Small noncleaved dif, 75-90pc) 0.00, 0.99, 0.01;
  (True histiocytic, 75-90pc) 0.00, 0.99, 0.01;
  (Ki-1 LC anaplas T, 75-90pc) 0.00, 0.99, 0.01;
  (Multiple myeloma, 75-90pc) 0.00, 0.99, 0.01;
  (Mycosis fungoides, 75-90pc) 0.00, 0.99, 0.01;
  (AML, 75-90pc) 0.00, 0.99, 0.01;
  (Hairy cell leukemia, 75-90pc) 0.00, 0.99, 0.01;
  (Carcinoma, 75-90pc) 0.00, 0.99, 0.01;
  (Melanoma, 75-90pc) 0.00, 0.99, 0.01;
  (EM plasmacytoma, 75-90pc) 0.00, 0.99, 0.01;
  (Kaposi's sarcoma, 75-90pc) 0.00, 0.99, 0.01;
  (Mast-cell disease, 75-90pc) 0.00, 0.99, 0.01;
  (AIDS involutionary, 75-90pc) 0.0, 0.5, 0.5;
  (T-immunob large, 75-90pc) 0.00, 0.99, 0.01;
  (Monocytoid B-cell, 75-90pc) 0.00, 0.99, 0.01;
  (Nasopharyngeal CA, 75-90pc) 0.00, 0.99, 0.01;
  (Seminoma, 75-90pc) 0.00, 0.99, 0.01;
  (SLE, 75-90pc) 0.00, 0.99, 0.01;
  (Mycobact histiocytos, 75-90pc) 0.0, 0.9, 0.1;
  (Mast-cell hyperplas, 75-90pc) 0.00, 0.99, 0.01;
  (LGV, 75-90pc) 0.00, 0.99, 0.01;
  (Histoplasmosis, 75-90pc) 0.0, 0.9, 0.1;
  (Coccidioidomycosis, 75-90pc) 0.0, 0.9, 0.1;
  (CMV, 75-90pc) 0.0, 0.9, 0.1;
  (Brucellosis, 75-90pc) 0.00, 0.99, 0.01;
  (Ki-1 LC anaplas B, 75-90pc) 0.00, 0.99, 0.01;
  (Intermed lymphocytic, 75-90pc) 0.00, 0.99, 0.01;
  (AIDS early, >90pc) 0.00, 0.55, 0.45;
  (AILD, >90pc) 0.00, 0.99, 0.01;
  (ALIP, >90pc) 0.00, 0.99, 0.01;
  (Cat scratch disease, >90pc) 0.00, 0.99, 0.01;
  (Dermatopathic laden, >90pc) 0.00, 0.99, 0.01;
  (Florid follic hyperp, >90pc) 0.00, 0.95, 0.05;
  (GLH hyaline vascular, >90pc) 0.00, 0.99, 0.01;
  (GLH plasma cell, >90pc) 0.00, 0.99, 0.01;
  (Granulomatous laden, >90pc) 0.00, 0.99, 0.01;
  (Histiocytosis x, >90pc) 0.00, 0.99, 0.01;
  (Infectious mono, >90pc) 0.00, 0.99, 0.01;
  (Leprosy-lepromatous, >90pc) 0.00, 0.99, 0.01;
  (Lymphangiographic, >90pc) 0.00, 0.99, 0.01;
  (Mantle zone hyperpla, >90pc) 0.00, 0.99, 0.01;
  (Necrotizing Kikuchi, >90pc) 0.00, 0.99, 0.01;
  (Necrotiz non-Kikuchi, >90pc) 0.00, 0.99, 0.01;
  (Rheumatoid arthritis, >90pc) 0.00, 0.99, 0.01;
  (Sarcoidosis, >90pc) 0.00, 0.99, 0.01;
  (SHML, >90pc) 0.00, 0.99, 0.01;
  (Sinus histiocytosis, >90pc) 0.00, 0.99, 0.01;
  (Syphilis, >90pc) 0.00, 0.99, 0.01;
  (Toxoplasmosis, >90pc) 0.00, 0.99, 0.01;
  (Tuberculosis, >90pc) 0.00, 0.99, 0.01;
  (Viral NOS, >90pc) 0.00, 0.99, 0.01;
  (Whipple's disease, >90pc) 0.00, 0.99, 0.01;
  (L&H nodular HD, >90pc) 0.00, 0.99, 0.01;
  (L&H diffuse HD, >90pc) 0.00, 0.99, 0.01;
  (Nodular sclerosis HD, >90pc) 0.00, 0.99, 0.01;
  (Cellular phase NSHD, >90pc) 0.00, 0.99, 0.01;
  (Syncytial NSHD, >90pc) 0.00, 0.99, 0.01;
  (Mixed cellularity HD, >90pc) 0.00, 0.99, 0.01;
  (Interfollicular HD, >90pc) 0.00, 0.99, 0.01;
  (Diffuse fibrosis HD, >90pc) 0.00, 0.99, 0.01;
  (Reticular-type HD, >90pc) 0.00, 0.99, 0.01;
  (Small cleaved fol, >90pc) 0.00, 0.99, 0.01;
  (Mixed fol, >90pc) 0.00, 0.99, 0.01;
  (Large cell fol, >90pc) 0.00, 0.99, 0.01;
  (Small noncleaved fol, >90pc) 0.00, 0.99, 0.01;
  (Small lymphocytic, >90pc) 0.00, 0.99, 0.01;
  (Plasmacytoid lyctic, >90pc) 0.00, 0.99, 0.01;
  (Mantle zone lymphoma, >90pc) 0.00, 0.99, 0.01;
  (Small cleaved dif, >90pc) 0.00, 0.99, 0.01;
  (Mixed FCC dif, >90pc) 0.00, 0.99, 0.01;
  (Large cell dif, >90pc) 0.00, 0.99, 0.01;
  (B-immunoblastic, >90pc) 0.00, 0.99, 0.01;
  (T-immunob mixed, >90pc) 0.00, 0.99, 0.01;
  (AILD-like T-cell lym, >90pc) 0.00, 0.99, 0.01;
  (Japanese ATL, >90pc) 0.00, 0.99, 0.01;
  (Lymphoblastic, >90pc) 0.00, 0.99, 0.01;
  (Small noncleaved dif, >90pc) 0.00, 0.99, 0.01;
  (True histiocytic, >90pc) 0.00, 0.99, 0.01;
  (Ki-1 LC anaplas T, >90pc) 0.00, 0.99, 0.01;
  (Multiple myeloma, >90pc) 0.00, 0.99, 0.01;
  (Mycosis fungoides, >90pc) 0.00, 0.99, 0.01;
  (AML, >90pc) 0.00, 0.99, 0.01;
  (Hairy cell leukemia, >90pc) 0.00, 0.99, 0.01;
  (Carcinoma, >90pc) 0.00, 0.99, 0.01;
  (Melanoma, >90pc) 0.00, 0.99, 0.01;
  (EM plasmacytoma, >90pc) 0.00, 0.99, 0.01;
  (Kaposi's sarcoma, >90pc) 0.00, 0.99, 0.01;
  (Mast-cell disease, >90pc) 0.00, 0.99, 0.01;
  (AIDS involutionary, >90pc) 0.0, 0.5, 0.5;
  (T-immunob large, >90pc) 0.00, 0.99, 0.01;
  (Monocytoid B-cell, >90pc) 0.00, 0.99, 0.01;
  (Nasopharyngeal CA, >90pc) 0.00, 0.99, 0.01;
  (Seminoma, >90pc) 0.00, 0.99, 0.01;
  (SLE, >90pc) 0.00, 0.99, 0.01;
  (Mycobact histiocytos, >90pc) 0.0, 0.9, 0.1;
  (Mast-cell hyperplas, >90pc) 0.00, 0.99, 0.01;
  (LGV, >90pc) 0.00, 0.99, 0.01;
  (Histoplasmosis, >90pc) 0.0, 0.9, 0.1;
  (Coccidioidomycosis, >90pc) 0.0, 0.9, 0.1;
  (CMV, >90pc) 0.0, 0.9, 0.1;
  (Brucellosis, >90pc) 0.00, 0.99, 0.01;
  (Ki-1 LC anaplas B, >90pc) 0.00, 0.99, 0.01;
  (Intermed lymphocytic, >90pc) 0.00, 0.99, 0.01;
}
probability ( TAB | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 1.0, 0.0;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 1.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 1.0, 0.0;
  (L&H diffuse HD) 0.95, 0.05;
  (Nodular sclerosis HD) 0.95, 0.05;
  (Cellular phase NSHD) 0.95, 0.05;
  (Syncytial NSHD) 0.95, 0.05;
  (Mixed cellularity HD) 0.95, 0.05;
  (Interfollicular HD) 0.95, 0.05;
  (Diffuse fibrosis HD) 0.95, 0.05;
  (Reticular-type HD) 0.95, 0.05;
  (Small cleaved fol) 1.0, 0.0;
  (Mixed fol) 1.0, 0.0;
  (Large cell fol) 1.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0;
  (Small lymphocytic) 1.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0;
  (Small cleaved dif) 1.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0;
  (Large cell dif) 1.0, 0.0;
  (B-immunoblastic) 1.0, 0.0;
  (T-immunob mixed) 0.2, 0.8;
  (AILD-like T-cell lym) 0.2, 0.8;
  (Japanese ATL) 0.2, 0.8;
  (Lymphoblastic) 0.2, 0.8;
  (Small noncleaved dif) 1.0, 0.0;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 0.2, 0.8;
  (Multiple myeloma) 1.0, 0.0;
  (Mycosis fungoides) 0.2, 0.8;
  (AML) 1.0, 0.0;
  (Hairy cell leukemia) 1.0, 0.0;
  (Carcinoma) 1.0, 0.0;
  (Melanoma) 1.0, 0.0;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0;
  (Mast-cell disease) 1.0, 0.0;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 0.2, 0.8;
  (Monocytoid B-cell) 1.0, 0.0;
  (Nasopharyngeal CA) 1.0, 0.0;
  (Seminoma) 1.0, 0.0;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 1.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0;
}
probability ( CT | Fault ) {
  (AIDS early) 0.775, 0.200, 0.020, 0.005;
  (AILD) 0.775, 0.200, 0.020, 0.005;
  (ALIP) 0.775, 0.200, 0.020, 0.005;
  (Cat scratch disease) 0.75, 0.20, 0.04, 0.01;
  (Dermatopathic laden) 0.775, 0.200, 0.020, 0.005;
  (Florid follic hyperp) 0.775, 0.200, 0.020, 0.005;
  (GLH hyaline vascular) 0.01, 0.25, 0.65, 0.09;
  (GLH plasma cell) 0.775, 0.200, 0.020, 0.005;
  (Granulomatous laden) 0.01, 0.25, 0.65, 0.09;
  (Histiocytosis x) 0.775, 0.200, 0.020, 0.005;
  (Infectious mono) 0.775, 0.200, 0.020, 0.005;
  (Leprosy-lepromatous) 0.20, 0.60, 0.15, 0.05;
  (Lymphangiographic) 0.775, 0.200, 0.020, 0.005;
  (Mantle zone hyperpla) 0.775, 0.200, 0.020, 0.005;
  (Necrotizing Kikuchi) 0.775, 0.200, 0.020, 0.005;
  (Necrotiz non-Kikuchi) 0.775, 0.200, 0.020, 0.005;
  (Rheumatoid arthritis) 0.01, 0.25, 0.65, 0.09;
  (Sarcoidosis) 0.01, 0.25, 0.65, 0.09;
  (SHML) 0.01, 0.25, 0.65, 0.09;
  (Sinus histiocytosis) 0.775, 0.200, 0.020, 0.005;
  (Syphilis) 0.01, 0.25, 0.65, 0.09;
  (Toxoplasmosis) 0.01, 0.25, 0.65, 0.09;
  (Tuberculosis) 0.20, 0.60, 0.15, 0.05;
  (Viral NOS) 0.775, 0.200, 0.020, 0.005;
  (Whipple's disease) 0.775, 0.200, 0.020, 0.005;
  (L&H nodular HD) 0.70, 0.20, 0.09, 0.01;
  (L&H diffuse HD) 0.70, 0.20, 0.09, 0.01;
  (Nodular sclerosis HD) 0.01, 0.10, 0.40, 0.49;
  (Cellular phase NSHD) 0.01, 0.30, 0.40, 0.29;
  (Syncytial NSHD) 0.01, 0.20, 0.39, 0.40;
  (Mixed cellularity HD) 0.70, 0.20, 0.09, 0.01;
  (Interfollicular HD) 0.70, 0.20, 0.09, 0.01;
  (Diffuse fibrosis HD) 0.70, 0.20, 0.09, 0.01;
  (Reticular-type HD) 0.70, 0.20, 0.09, 0.01;
  (Small cleaved fol) 0.775, 0.200, 0.020, 0.005;
  (Mixed fol) 0.775, 0.200, 0.020, 0.005;
  (Large cell fol) 0.775, 0.200, 0.020, 0.005;
  (Small noncleaved fol) 0.775, 0.200, 0.020, 0.005;
  (Small lymphocytic) 0.775, 0.200, 0.020, 0.005;
  (Plasmacytoid lyctic) 0.775, 0.200, 0.020, 0.005;
  (Mantle zone lymphoma) 0.775, 0.200, 0.020, 0.005;
  (Small cleaved dif) 0.775, 0.200, 0.020, 0.005;
  (Mixed FCC dif) 0.775, 0.200, 0.020, 0.005;
  (Large cell dif) 0.775, 0.200, 0.020, 0.005;
  (B-immunoblastic) 0.775, 0.200, 0.020, 0.005;
  (T-immunob mixed) 0.775, 0.200, 0.020, 0.005;
  (AILD-like T-cell lym) 0.775, 0.200, 0.020, 0.005;
  (Japanese ATL) 0.775, 0.200, 0.020, 0.005;
  (Lymphoblastic) 0.775, 0.200, 0.020, 0.005;
  (Small noncleaved dif) 0.775, 0.200, 0.020, 0.005;
  (True histiocytic) 0.775, 0.200, 0.020, 0.005;
  (Ki-1 LC anaplas T) 0.775, 0.200, 0.020, 0.005;
  (Multiple myeloma) 0.775, 0.200, 0.020, 0.005;
  (Mycosis fungoides) 0.775, 0.200, 0.020, 0.005;
  (AML) 0.775, 0.200, 0.020, 0.005;
  (Hairy cell leukemia) 0.775, 0.200, 0.020, 0.005;
  (Carcinoma) 0.775, 0.200, 0.020, 0.005;
  (Melanoma) 0.775, 0.200, 0.020, 0.005;
  (EM plasmacytoma) 0.775, 0.200, 0.020, 0.005;
  (Kaposi's sarcoma) 0.55, 0.20, 0.15, 0.10;
  (Mast-cell disease) 0.70, 0.20, 0.09, 0.01;
  (AIDS involutionary) 0.775, 0.200, 0.020, 0.005;
  (T-immunob large) 0.775, 0.200, 0.020, 0.005;
  (Monocytoid B-cell) 0.750, 0.230, 0.017, 0.003;
  (Nasopharyngeal CA) 0.01, 0.10, 0.40, 0.49;
  (Seminoma) 0.775, 0.200, 0.020, 0.005;
  (SLE) 0.775, 0.200, 0.020, 0.005;
  (Mycobact histiocytos) 0.775, 0.200, 0.020, 0.005;
  (Mast-cell hyperplas) 0.64, 0.30, 0.05, 0.01;
  (LGV) 0.75, 0.20, 0.04, 0.01;
  (Histoplasmosis) 0.775, 0.200, 0.020, 0.005;
  (Coccidioidomycosis) 0.775, 0.200, 0.020, 0.005;
  (CMV) 0.775, 0.200, 0.020, 0.005;
  (Brucellosis) 0.01, 0.25, 0.65, 0.09;
  (Ki-1 LC anaplas B) 0.775, 0.200, 0.020, 0.005;
  (Intermed lymphocytic) 0.775, 0.200, 0.020, 0.005;
}
probability ( GENE_IG | Fault ) {
  (AIDS early) 0.99, 0.01;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 1.0, 0.0;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 1.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 0.55, 0.45;
  (L&H diffuse HD) 0.9, 0.1;
  (Nodular sclerosis HD) 0.9, 0.1;
  (Cellular phase NSHD) 0.9, 0.1;
  (Syncytial NSHD) 0.9, 0.1;
  (Mixed cellularity HD) 0.9, 0.1;
  (Interfollicular HD) 0.9, 0.1;
  (Diffuse fibrosis HD) 0.9, 0.1;
  (Reticular-type HD) 0.9, 0.1;
  (Small cleaved fol) 0.001, 0.999;
  (Mixed fol) 0.001, 0.999;
  (Large cell fol) 0.001, 0.999;
  (Small noncleaved fol) 0.001, 0.999;
  (Small lymphocytic) 0.001, 0.999;
  (Plasmacytoid lyctic) 0.001, 0.999;
  (Mantle zone lymphoma) 0.001, 0.999;
  (Small cleaved dif) 0.001, 0.999;
  (Mixed FCC dif) 0.001, 0.999;
  (Large cell dif) 0.001, 0.999;
  (B-immunoblastic) 0.001, 0.999;
  (T-immunob mixed) 0.999, 0.001;
  (AILD-like T-cell lym) 0.999, 0.001;
  (Japanese ATL) 0.999, 0.001;
  (Lymphoblastic) 0.999, 0.001;
  (Small noncleaved dif) 0.001, 0.999;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 0.999, 0.001;
  (Multiple myeloma) 0.001, 0.999;
  (Mycosis fungoides) 0.999, 0.001;
  (AML) 1.0, 0.0;
  (Hairy cell leukemia) 1.0, 0.0;
  (Carcinoma) 1.0, 0.0;
  (Melanoma) 1.0, 0.0;
  (EM plasmacytoma) 0.001, 0.999;
  (Kaposi's sarcoma) 1.0, 0.0;
  (Mast-cell disease) 1.0, 0.0;
  (AIDS involutionary) 0.99, 0.01;
  (T-immunob large) 0.999, 0.001;
  (Monocytoid B-cell) 0.001, 0.999;
  (Nasopharyngeal CA) 1.0, 0.0;
  (Seminoma) 1.0, 0.0;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 0.001, 0.999;
  (Intermed lymphocytic) 0.001, 0.999;
}
probability ( HIV_ST | Fault ) {
  (AIDS early) 0.00, 0.03, 0.97;
  (AILD) 0.9989, 0.0010, 0.0001;
  (ALIP) 0.9989, 0.0010, 0.0001;
  (Cat scratch disease) 0.9989, 0.0010, 0.0001;
  (Dermatopathic laden) 0.9989, 0.0010, 0.0001;
  (Florid follic hyperp) 0.9989, 0.0010, 0.0001;
  (GLH hyaline vascular) 0.975, 0.005, 0.020;
  (GLH plasma cell) 0.975, 0.005, 0.020;
  (Granulomatous laden) 0.9989, 0.0010, 0.0001;
  (Histiocytosis x) 0.9989, 0.0010, 0.0001;
  (Infectious mono) 0.9989, 0.0010, 0.0001;
  (Leprosy-lepromatous) 0.9989, 0.0010, 0.0001;
  (Lymphangiographic) 0.9989, 0.0010, 0.0001;
  (Mantle zone hyperpla) 0.9989, 0.0010, 0.0001;
  (Necrotizing Kikuchi) 0.9989, 0.0010, 0.0001;
  (Necrotiz non-Kikuchi) 0.9989, 0.0010, 0.0001;
  (Rheumatoid arthritis) 0.9989, 0.0010, 0.0001;
  (Sarcoidosis) 0.9989, 0.0010, 0.0001;
  (SHML) 0.9989, 0.0010, 0.0001;
  (Sinus histiocytosis) 0.9989, 0.0010, 0.0001;
  (Syphilis) 0.65, 0.05, 0.30;
  (Toxoplasmosis) 0.75, 0.05, 0.20;
  (Tuberculosis) 0.4, 0.1, 0.5;
  (Viral NOS) 0.9989, 0.0010, 0.0001;
  (Whipple's disease) 0.9989, 0.0010, 0.0001;
  (L&H nodular HD) 0.93, 0.05, 0.02;
  (L&H diffuse HD) 0.93, 0.05, 0.02;
  (Nodular sclerosis HD) 0.93, 0.05, 0.02;
  (Cellular phase NSHD) 0.93, 0.05, 0.02;
  (Syncytial NSHD) 0.93, 0.05, 0.02;
  (Mixed cellularity HD) 0.93, 0.05, 0.02;
  (Interfollicular HD) 0.93, 0.05, 0.02;
  (Diffuse fibrosis HD) 0.93, 0.05, 0.02;
  (Reticular-type HD) 0.93, 0.05, 0.02;
  (Small cleaved fol) 0.9875, 0.0025, 0.0100;
  (Mixed fol) 0.9875, 0.0025, 0.0100;
  (Large cell fol) 0.9875, 0.0025, 0.0100;
  (Small noncleaved fol) 0.9875, 0.0025, 0.0100;
  (Small lymphocytic) 0.975, 0.005, 0.020;
  (Plasmacytoid lyctic) 0.975, 0.005, 0.020;
  (Mantle zone lymphoma) 0.9875, 0.0025, 0.0100;
  (Small cleaved dif) 0.975, 0.005, 0.020;
  (Mixed FCC dif) 0.975, 0.005, 0.020;
  (Large cell dif) 0.78, 0.02, 0.20;
  (B-immunoblastic) 0.78, 0.02, 0.20;
  (T-immunob mixed) 0.975, 0.005, 0.020;
  (AILD-like T-cell lym) 0.975, 0.005, 0.020;
  (Japanese ATL) 0.975, 0.005, 0.020;
  (Lymphoblastic) 0.975, 0.005, 0.020;
  (Small noncleaved dif) 0.78, 0.02, 0.20;
  (True histiocytic) 0.975, 0.005, 0.020;
  (Ki-1 LC anaplas T) 0.975, 0.005, 0.020;
  (Multiple myeloma) 0.9989, 0.0010, 0.0001;
  (Mycosis fungoides) 0.9989, 0.0010, 0.0001;
  (AML) 0.9989, 0.0010, 0.0001;
  (Hairy cell leukemia) 0.9989, 0.0010, 0.0001;
  (Carcinoma) 0.9989, 0.0010, 0.0001;
  (Melanoma) 0.9989, 0.0010, 0.0001;
  (EM plasmacytoma) 0.9989, 0.0010, 0.0001;
  (Kaposi's sarcoma) 0.15, 0.20, 0.65;
  (Mast-cell disease) 0.9989, 0.0010, 0.0001;
  (AIDS involutionary) 0.00, 0.03, 0.97;
  (T-immunob large) 0.975, 0.005, 0.020;
  (Monocytoid B-cell) 0.975, 0.005, 0.020;
  (Nasopharyngeal CA) 0.9989, 0.0010, 0.0001;
  (Seminoma) 0.9989, 0.0010, 0.0001;
  (SLE) 0.9989, 0.0010, 0.0001;
  (Mycobact histiocytos) 0.01, 0.04, 0.95;
  (Mast-cell hyperplas) 0.9989, 0.0010, 0.0001;
  (LGV) 0.65, 0.05, 0.30;
  (Histoplasmosis) 0.5, 0.2, 0.3;
  (Coccidioidomycosis) 0.5, 0.2, 0.3;
  (CMV) 0.5, 0.2, 0.3;
  (Brucellosis) 0.9989, 0.0010, 0.0001;
  (Ki-1 LC anaplas B) 0.975, 0.005, 0.020;
  (Intermed lymphocytic) 0.9875, 0.0025, 0.0100;
}
probability ( MLC_LLC | Fault, LLC, MLC ) {
  (AIDS early, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (AILD, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (ALIP, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Cat scratch disease, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Dermatopathic laden, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Florid follic hyperp, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (GLH hyaline vascular, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (GLH plasma cell, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Granulomatous laden, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Histiocytosis x, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Infectious mono, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Lymphangiographic, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Sarcoidosis, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (SHML, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Sinus histiocytosis, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Syphilis, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Toxoplasmosis, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Tuberculosis, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Viral NOS, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Whipple's disease, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (L&H nodular HD, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (L&H diffuse HD, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Cellular phase NSHD, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Syncytial NSHD, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Mixed cellularity HD, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Interfollicular HD, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Reticular-type HD, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Small cleaved fol, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Mixed fol, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Large cell fol, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Small noncleaved fol, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Small lymphocytic, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Small cleaved dif, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Mixed FCC dif, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Large cell dif, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (B-immunoblastic, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (T-immunob mixed, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Japanese ATL, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Lymphoblastic, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Small noncleaved dif, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (True histiocytic, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Multiple myeloma, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Mycosis fungoides, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (AML, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Hairy cell leukemia, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Carcinoma, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Melanoma, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (EM plasmacytoma, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Mast-cell disease, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (AIDS involutionary, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (T-immunob large, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Monocytoid B-cell, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Seminoma, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (SLE, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Mycobact histiocytos, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (LGV, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Histoplasmosis, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Coccidioidomycosis, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (CMV, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Brucellosis, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (Intermed lymphocytic, Absent [0pc], Absent [0pc]) 1.0, 0.0;
  (AIDS early, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (AILD, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (ALIP, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Cat scratch disease, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Dermatopathic laden, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Florid follic hyperp, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (GLH hyaline vascular, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (GLH plasma cell, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Granulomatous laden, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Histiocytosis x, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Infectious mono, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Leprosy-lepromatous, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Lymphangiographic, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Mantle zone hyperpla, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Necrotizing Kikuchi, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Necrotiz non-Kikuchi, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Rheumatoid arthritis, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Sarcoidosis, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (SHML, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Sinus histiocytosis, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Syphilis, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Toxoplasmosis, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Tuberculosis, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Viral NOS, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Whipple's disease, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (L&H nodular HD, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (L&H diffuse HD, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Nodular sclerosis HD, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Cellular phase NSHD, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Syncytial NSHD, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Mixed cellularity HD, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Interfollicular HD, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Diffuse fibrosis HD, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Reticular-type HD, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Small cleaved fol, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Mixed fol, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Large cell fol, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Small noncleaved fol, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Small lymphocytic, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Plasmacytoid lyctic, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Mantle zone lymphoma, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Small cleaved dif, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Mixed FCC dif, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Large cell dif, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (B-immunoblastic, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (T-immunob mixed, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (AILD-like T-cell lym, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Japanese ATL, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Lymphoblastic, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Small noncleaved dif, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (True histiocytic, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Ki-1 LC anaplas T, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Multiple myeloma, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Mycosis fungoides, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (AML, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Hairy cell leukemia, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Carcinoma, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Melanoma, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (EM plasmacytoma, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Kaposi's sarcoma, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Mast-cell disease, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (AIDS involutionary, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (T-immunob large, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Monocytoid B-cell, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Nasopharyngeal CA, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Seminoma, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (SLE, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Mycobact histiocytos, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Mast-cell hyperplas, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (LGV, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Histoplasmosis, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Coccidioidomycosis, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (CMV, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Brucellosis, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Ki-1 LC anaplas B, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (Intermed lymphocytic, Sparse [<10pc], Absent [0pc]) 1.0, 0.0;
  (AIDS early, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (AILD, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (ALIP, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Cat scratch disease, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Dermatopathic laden, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Florid follic hyperp, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (GLH hyaline vascular, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (GLH plasma cell, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Granulomatous laden, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Histiocytosis x, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Infectious mono, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Leprosy-lepromatous, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Lymphangiographic, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Mantle zone hyperpla, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Necrotizing Kikuchi, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Necrotiz non-Kikuchi, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Rheumatoid arthritis, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Sarcoidosis, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (SHML, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Sinus histiocytosis, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Syphilis, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Toxoplasmosis, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Tuberculosis, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Viral NOS, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Whipple's disease, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (L&H nodular HD, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (L&H diffuse HD, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Nodular sclerosis HD, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Cellular phase NSHD, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Syncytial NSHD, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Mixed cellularity HD, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Interfollicular HD, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Diffuse fibrosis HD, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Reticular-type HD, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Small cleaved fol, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Mixed fol, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Large cell fol, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Small noncleaved fol, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Small lymphocytic, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Plasmacytoid lyctic, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Mantle zone lymphoma, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Small cleaved dif, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Mixed FCC dif, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Large cell dif, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (B-immunoblastic, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (T-immunob mixed, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (AILD-like T-cell lym, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Japanese ATL, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Lymphoblastic, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Small noncleaved dif, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (True histiocytic, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Ki-1 LC anaplas T, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Multiple myeloma, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Mycosis fungoides, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (AML, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Hairy cell leukemia, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Carcinoma, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Melanoma, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (EM plasmacytoma, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Kaposi's sarcoma, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Mast-cell disease, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (AIDS involutionary, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (T-immunob large, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Monocytoid B-cell, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Nasopharyngeal CA, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Seminoma, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (SLE, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Mycobact histiocytos, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Mast-cell hyperplas, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (LGV, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Histoplasmosis, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Coccidioidomycosis, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (CMV, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Brucellosis, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Ki-1 LC anaplas B, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (Intermed lymphocytic, Moderate [11-50pc], Absent [0pc]) 1.0, 0.0;
  (AIDS early, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (AILD, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (ALIP, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Cat scratch disease, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Dermatopathic laden, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Florid follic hyperp, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (GLH hyaline vascular, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (GLH plasma cell, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Granulomatous laden, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Histiocytosis x, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Infectious mono, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Leprosy-lepromatous, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Lymphangiographic, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Mantle zone hyperpla, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Necrotizing Kikuchi, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Necrotiz non-Kikuchi, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Rheumatoid arthritis, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Sarcoidosis, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (SHML, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Sinus histiocytosis, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Syphilis, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Toxoplasmosis, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Tuberculosis, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Viral NOS, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Whipple's disease, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (L&H nodular HD, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (L&H diffuse HD, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Nodular sclerosis HD, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Cellular phase NSHD, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Syncytial NSHD, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Mixed cellularity HD, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Interfollicular HD, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Diffuse fibrosis HD, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Reticular-type HD, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Small cleaved fol, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Mixed fol, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Large cell fol, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Small noncleaved fol, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Small lymphocytic, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Plasmacytoid lyctic, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Mantle zone lymphoma, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Small cleaved dif, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Mixed FCC dif, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Large cell dif, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (B-immunoblastic, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (T-immunob mixed, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (AILD-like T-cell lym, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Japanese ATL, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Lymphoblastic, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Small noncleaved dif, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (True histiocytic, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Ki-1 LC anaplas T, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Multiple myeloma, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Mycosis fungoides, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (AML, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Hairy cell leukemia, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Carcinoma, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Melanoma, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (EM plasmacytoma, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Kaposi's sarcoma, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Mast-cell disease, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (AIDS involutionary, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (T-immunob large, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Monocytoid B-cell, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Nasopharyngeal CA, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Seminoma, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (SLE, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Mycobact histiocytos, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Mast-cell hyperplas, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (LGV, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Histoplasmosis, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Coccidioidomycosis, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (CMV, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Brucellosis, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Ki-1 LC anaplas B, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (Intermed lymphocytic, Numerous [51-90pc], Absent [0pc]) 0.0, 1.0;
  (AIDS early, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (AILD, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (ALIP, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Cat scratch disease, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Dermatopathic laden, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Florid follic hyperp, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (GLH hyaline vascular, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (GLH plasma cell, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Granulomatous laden, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Histiocytosis x, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Infectious mono, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Leprosy-lepromatous, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Lymphangiographic, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Mantle zone hyperpla, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Necrotizing Kikuchi, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Necrotiz non-Kikuchi, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Rheumatoid arthritis, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Sarcoidosis, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (SHML, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Sinus histiocytosis, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Syphilis, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Toxoplasmosis, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Tuberculosis, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Viral NOS, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Whipple's disease, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (L&H nodular HD, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (L&H diffuse HD, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Nodular sclerosis HD, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Cellular phase NSHD, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Syncytial NSHD, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Mixed cellularity HD, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Interfollicular HD, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Diffuse fibrosis HD, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Reticular-type HD, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Small cleaved fol, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Mixed fol, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Large cell fol, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Small noncleaved fol, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Small lymphocytic, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Plasmacytoid lyctic, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Mantle zone lymphoma, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Small cleaved dif, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Mixed FCC dif, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Large cell dif, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (B-immunoblastic, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (T-immunob mixed, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (AILD-like T-cell lym, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Japanese ATL, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Lymphoblastic, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Small noncleaved dif, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (True histiocytic, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Ki-1 LC anaplas T, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Multiple myeloma, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Mycosis fungoides, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (AML, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Hairy cell leukemia, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Carcinoma, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Melanoma, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (EM plasmacytoma, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Kaposi's sarcoma, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Mast-cell disease, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (AIDS involutionary, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (T-immunob large, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Monocytoid B-cell, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Nasopharyngeal CA, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Seminoma, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (SLE, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Mycobact histiocytos, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Mast-cell hyperplas, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (LGV, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Histoplasmosis, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Coccidioidomycosis, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (CMV, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Brucellosis, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Ki-1 LC anaplas B, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (Intermed lymphocytic, Striking [>90pc], Absent [0pc]) 0.0, 1.0;
  (AIDS early, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (AILD, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (ALIP, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Cat scratch disease, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Dermatopathic laden, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Florid follic hyperp, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (GLH hyaline vascular, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (GLH plasma cell, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Granulomatous laden, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Histiocytosis x, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Infectious mono, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Lymphangiographic, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Sarcoidosis, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (SHML, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Sinus histiocytosis, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Syphilis, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Toxoplasmosis, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Tuberculosis, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Viral NOS, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Whipple's disease, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (L&H nodular HD, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (L&H diffuse HD, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Cellular phase NSHD, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Syncytial NSHD, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Mixed cellularity HD, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Interfollicular HD, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Reticular-type HD, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Small cleaved fol, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Mixed fol, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Large cell fol, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Small noncleaved fol, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Small lymphocytic, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Small cleaved dif, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Mixed FCC dif, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Large cell dif, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (B-immunoblastic, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (T-immunob mixed, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Japanese ATL, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Lymphoblastic, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Small noncleaved dif, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (True histiocytic, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Multiple myeloma, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Mycosis fungoides, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (AML, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Hairy cell leukemia, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Carcinoma, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Melanoma, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (EM plasmacytoma, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Mast-cell disease, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (AIDS involutionary, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (T-immunob large, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Monocytoid B-cell, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Seminoma, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (SLE, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Mycobact histiocytos, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (LGV, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Histoplasmosis, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Coccidioidomycosis, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (CMV, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Brucellosis, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (Intermed lymphocytic, Absent [0pc], Sparse [<10pc]) 1.0, 0.0;
  (AIDS early, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (AILD, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (ALIP, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Cat scratch disease, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Dermatopathic laden, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Florid follic hyperp, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (GLH hyaline vascular, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (GLH plasma cell, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Granulomatous laden, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Histiocytosis x, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Infectious mono, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Leprosy-lepromatous, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Lymphangiographic, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Mantle zone hyperpla, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Necrotizing Kikuchi, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Necrotiz non-Kikuchi, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Rheumatoid arthritis, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Sarcoidosis, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (SHML, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Sinus histiocytosis, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Syphilis, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Toxoplasmosis, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Tuberculosis, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Viral NOS, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Whipple's disease, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (L&H nodular HD, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (L&H diffuse HD, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Nodular sclerosis HD, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Cellular phase NSHD, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Syncytial NSHD, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Mixed cellularity HD, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Interfollicular HD, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Diffuse fibrosis HD, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Reticular-type HD, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Small cleaved fol, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Mixed fol, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Large cell fol, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Small noncleaved fol, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Small lymphocytic, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Plasmacytoid lyctic, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Mantle zone lymphoma, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Small cleaved dif, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Mixed FCC dif, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Large cell dif, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (B-immunoblastic, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (T-immunob mixed, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (AILD-like T-cell lym, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Japanese ATL, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Lymphoblastic, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Small noncleaved dif, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (True histiocytic, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Ki-1 LC anaplas T, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Multiple myeloma, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Mycosis fungoides, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (AML, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Hairy cell leukemia, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Carcinoma, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Melanoma, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (EM plasmacytoma, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Kaposi's sarcoma, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Mast-cell disease, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (AIDS involutionary, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (T-immunob large, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Monocytoid B-cell, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Nasopharyngeal CA, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Seminoma, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (SLE, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Mycobact histiocytos, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Mast-cell hyperplas, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (LGV, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Histoplasmosis, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Coccidioidomycosis, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (CMV, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Brucellosis, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Ki-1 LC anaplas B, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (Intermed lymphocytic, Sparse [<10pc], Sparse [<10pc]) 1.0, 0.0;
  (AIDS early, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (AILD, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (ALIP, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Cat scratch disease, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Dermatopathic laden, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Florid follic hyperp, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (GLH hyaline vascular, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (GLH plasma cell, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Granulomatous laden, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Histiocytosis x, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Infectious mono, Moderate [11-50pc], Sparse [<10pc]) 0.98, 0.02;
  (Leprosy-lepromatous, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Lymphangiographic, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Mantle zone hyperpla, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Necrotizing Kikuchi, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Necrotiz non-Kikuchi, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Rheumatoid arthritis, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Sarcoidosis, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (SHML, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Sinus histiocytosis, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Syphilis, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Toxoplasmosis, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Tuberculosis, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Viral NOS, Moderate [11-50pc], Sparse [<10pc]) 0.999, 0.001;
  (Whipple's disease, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (L&H nodular HD, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (L&H diffuse HD, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Nodular sclerosis HD, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Cellular phase NSHD, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Syncytial NSHD, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Mixed cellularity HD, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Interfollicular HD, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Diffuse fibrosis HD, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Reticular-type HD, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Small cleaved fol, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Mixed fol, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Large cell fol, Moderate [11-50pc], Sparse [<10pc]) 0.7, 0.3;
  (Small noncleaved fol, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Small lymphocytic, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Plasmacytoid lyctic, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Mantle zone lymphoma, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Small cleaved dif, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Mixed FCC dif, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Large cell dif, Moderate [11-50pc], Sparse [<10pc]) 0.0, 1.0;
  (B-immunoblastic, Moderate [11-50pc], Sparse [<10pc]) 0.0, 1.0;
  (T-immunob mixed, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (AILD-like T-cell lym, Moderate [11-50pc], Sparse [<10pc]) 0.8, 0.2;
  (Japanese ATL, Moderate [11-50pc], Sparse [<10pc]) 0.8, 0.2;
  (Lymphoblastic, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Small noncleaved dif, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (True histiocytic, Moderate [11-50pc], Sparse [<10pc]) 0.0, 1.0;
  (Ki-1 LC anaplas T, Moderate [11-50pc], Sparse [<10pc]) 0.0, 1.0;
  (Multiple myeloma, Moderate [11-50pc], Sparse [<10pc]) 0.75, 0.25;
  (Mycosis fungoides, Moderate [11-50pc], Sparse [<10pc]) 0.8, 0.2;
  (AML, Moderate [11-50pc], Sparse [<10pc]) 0.99, 0.01;
  (Hairy cell leukemia, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Carcinoma, Moderate [11-50pc], Sparse [<10pc]) 0.99, 0.01;
  (Melanoma, Moderate [11-50pc], Sparse [<10pc]) 0.99, 0.01;
  (EM plasmacytoma, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Kaposi's sarcoma, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Mast-cell disease, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (AIDS involutionary, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (T-immunob large, Moderate [11-50pc], Sparse [<10pc]) 0.0, 1.0;
  (Monocytoid B-cell, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Nasopharyngeal CA, Moderate [11-50pc], Sparse [<10pc]) 0.99, 0.01;
  (Seminoma, Moderate [11-50pc], Sparse [<10pc]) 0.99, 0.01;
  (SLE, Moderate [11-50pc], Sparse [<10pc]) 0.98, 0.02;
  (Mycobact histiocytos, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Mast-cell hyperplas, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (LGV, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Histoplasmosis, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Coccidioidomycosis, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (CMV, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Brucellosis, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (Ki-1 LC anaplas B, Moderate [11-50pc], Sparse [<10pc]) 0.0, 1.0;
  (Intermed lymphocytic, Moderate [11-50pc], Sparse [<10pc]) 1.0, 0.0;
  (AIDS early, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (AILD, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (ALIP, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Cat scratch disease, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Dermatopathic laden, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Florid follic hyperp, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (GLH hyaline vascular, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (GLH plasma cell, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Granulomatous laden, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Histiocytosis x, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Infectious mono, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Leprosy-lepromatous, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Lymphangiographic, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Mantle zone hyperpla, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Necrotizing Kikuchi, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Necrotiz non-Kikuchi, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Rheumatoid arthritis, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Sarcoidosis, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (SHML, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Sinus histiocytosis, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Syphilis, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Toxoplasmosis, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Tuberculosis, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Viral NOS, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Whipple's disease, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (L&H nodular HD, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (L&H diffuse HD, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Nodular sclerosis HD, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Cellular phase NSHD, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Syncytial NSHD, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Mixed cellularity HD, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Interfollicular HD, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Diffuse fibrosis HD, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Reticular-type HD, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Small cleaved fol, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Mixed fol, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Large cell fol, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Small noncleaved fol, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Small lymphocytic, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Plasmacytoid lyctic, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Mantle zone lymphoma, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Small cleaved dif, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Mixed FCC dif, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Large cell dif, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (B-immunoblastic, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (T-immunob mixed, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (AILD-like T-cell lym, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Japanese ATL, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Lymphoblastic, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Small noncleaved dif, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (True histiocytic, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Ki-1 LC anaplas T, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Multiple myeloma, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Mycosis fungoides, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (AML, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Hairy cell leukemia, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Carcinoma, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Melanoma, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (EM plasmacytoma, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Kaposi's sarcoma, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Mast-cell disease, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (AIDS involutionary, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (T-immunob large, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Monocytoid B-cell, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Nasopharyngeal CA, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Seminoma, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (SLE, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Mycobact histiocytos, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Mast-cell hyperplas, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (LGV, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Histoplasmosis, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Coccidioidomycosis, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (CMV, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Brucellosis, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Ki-1 LC anaplas B, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (Intermed lymphocytic, Numerous [51-90pc], Sparse [<10pc]) 0.0, 1.0;
  (AIDS early, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (AILD, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (ALIP, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Cat scratch disease, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Dermatopathic laden, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Florid follic hyperp, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (GLH hyaline vascular, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (GLH plasma cell, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Granulomatous laden, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Histiocytosis x, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Infectious mono, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Leprosy-lepromatous, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Lymphangiographic, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Mantle zone hyperpla, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Necrotizing Kikuchi, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Necrotiz non-Kikuchi, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Rheumatoid arthritis, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Sarcoidosis, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (SHML, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Sinus histiocytosis, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Syphilis, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Toxoplasmosis, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Tuberculosis, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Viral NOS, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Whipple's disease, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (L&H nodular HD, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (L&H diffuse HD, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Nodular sclerosis HD, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Cellular phase NSHD, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Syncytial NSHD, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Mixed cellularity HD, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Interfollicular HD, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Diffuse fibrosis HD, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Reticular-type HD, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Small cleaved fol, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Mixed fol, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Large cell fol, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Small noncleaved fol, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Small lymphocytic, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Plasmacytoid lyctic, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Mantle zone lymphoma, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Small cleaved dif, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Mixed FCC dif, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Large cell dif, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (B-immunoblastic, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (T-immunob mixed, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (AILD-like T-cell lym, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Japanese ATL, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Lymphoblastic, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Small noncleaved dif, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (True histiocytic, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Ki-1 LC anaplas T, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Multiple myeloma, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Mycosis fungoides, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (AML, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Hairy cell leukemia, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Carcinoma, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Melanoma, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (EM plasmacytoma, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Kaposi's sarcoma, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Mast-cell disease, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (AIDS involutionary, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (T-immunob large, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Monocytoid B-cell, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Nasopharyngeal CA, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Seminoma, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (SLE, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Mycobact histiocytos, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Mast-cell hyperplas, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (LGV, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Histoplasmosis, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Coccidioidomycosis, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (CMV, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Brucellosis, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Ki-1 LC anaplas B, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (Intermed lymphocytic, Striking [>90pc], Sparse [<10pc]) 0.0, 1.0;
  (AIDS early, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (AILD, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (ALIP, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Cat scratch disease, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Dermatopathic laden, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Florid follic hyperp, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (GLH hyaline vascular, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (GLH plasma cell, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Granulomatous laden, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Histiocytosis x, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Infectious mono, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Lymphangiographic, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Sarcoidosis, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (SHML, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Sinus histiocytosis, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Syphilis, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Toxoplasmosis, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Tuberculosis, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Viral NOS, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Whipple's disease, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (L&H nodular HD, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (L&H diffuse HD, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Cellular phase NSHD, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Syncytial NSHD, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Mixed cellularity HD, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Interfollicular HD, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Reticular-type HD, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Small cleaved fol, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Mixed fol, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Large cell fol, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Small noncleaved fol, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Small lymphocytic, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Small cleaved dif, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Mixed FCC dif, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Large cell dif, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (B-immunoblastic, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (T-immunob mixed, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Japanese ATL, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Lymphoblastic, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Small noncleaved dif, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (True histiocytic, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Multiple myeloma, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Mycosis fungoides, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (AML, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Hairy cell leukemia, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Carcinoma, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Melanoma, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (EM plasmacytoma, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Mast-cell disease, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (AIDS involutionary, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (T-immunob large, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Monocytoid B-cell, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Seminoma, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (SLE, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Mycobact histiocytos, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (LGV, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Histoplasmosis, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Coccidioidomycosis, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (CMV, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Brucellosis, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (Intermed lymphocytic, Absent [0pc], Moderate [11-50pc]) 1.0, 0.0;
  (AIDS early, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (AILD, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (ALIP, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Cat scratch disease, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Dermatopathic laden, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Florid follic hyperp, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (GLH hyaline vascular, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (GLH plasma cell, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Granulomatous laden, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Histiocytosis x, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Infectious mono, Sparse [<10pc], Moderate [11-50pc]) 0.98, 0.02;
  (Leprosy-lepromatous, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Lymphangiographic, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Mantle zone hyperpla, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Necrotizing Kikuchi, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Necrotiz non-Kikuchi, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Rheumatoid arthritis, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Sarcoidosis, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (SHML, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Sinus histiocytosis, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Syphilis, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Toxoplasmosis, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Tuberculosis, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Viral NOS, Sparse [<10pc], Moderate [11-50pc]) 0.999, 0.001;
  (Whipple's disease, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (L&H nodular HD, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (L&H diffuse HD, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Nodular sclerosis HD, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Cellular phase NSHD, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Syncytial NSHD, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Mixed cellularity HD, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Interfollicular HD, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Diffuse fibrosis HD, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Reticular-type HD, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Small cleaved fol, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Mixed fol, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Large cell fol, Sparse [<10pc], Moderate [11-50pc]) 0.95, 0.05;
  (Small noncleaved fol, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Small lymphocytic, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Plasmacytoid lyctic, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Mantle zone lymphoma, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Small cleaved dif, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Mixed FCC dif, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Large cell dif, Sparse [<10pc], Moderate [11-50pc]) 0.0, 1.0;
  (B-immunoblastic, Sparse [<10pc], Moderate [11-50pc]) 0.0, 1.0;
  (T-immunob mixed, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (AILD-like T-cell lym, Sparse [<10pc], Moderate [11-50pc]) 0.9, 0.1;
  (Japanese ATL, Sparse [<10pc], Moderate [11-50pc]) 0.92, 0.08;
  (Lymphoblastic, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Small noncleaved dif, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (True histiocytic, Sparse [<10pc], Moderate [11-50pc]) 0.0, 1.0;
  (Ki-1 LC anaplas T, Sparse [<10pc], Moderate [11-50pc]) 0.0, 1.0;
  (Multiple myeloma, Sparse [<10pc], Moderate [11-50pc]) 0.9, 0.1;
  (Mycosis fungoides, Sparse [<10pc], Moderate [11-50pc]) 0.9, 0.1;
  (AML, Sparse [<10pc], Moderate [11-50pc]) 0.99, 0.01;
  (Hairy cell leukemia, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Carcinoma, Sparse [<10pc], Moderate [11-50pc]) 0.99, 0.01;
  (Melanoma, Sparse [<10pc], Moderate [11-50pc]) 0.99, 0.01;
  (EM plasmacytoma, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Kaposi's sarcoma, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Mast-cell disease, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (AIDS involutionary, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (T-immunob large, Sparse [<10pc], Moderate [11-50pc]) 0.0, 1.0;
  (Monocytoid B-cell, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Nasopharyngeal CA, Sparse [<10pc], Moderate [11-50pc]) 0.99, 0.01;
  (Seminoma, Sparse [<10pc], Moderate [11-50pc]) 0.99, 0.01;
  (SLE, Sparse [<10pc], Moderate [11-50pc]) 0.98, 0.02;
  (Mycobact histiocytos, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Mast-cell hyperplas, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (LGV, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Histoplasmosis, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Coccidioidomycosis, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (CMV, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Brucellosis, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (Ki-1 LC anaplas B, Sparse [<10pc], Moderate [11-50pc]) 0.0, 1.0;
  (Intermed lymphocytic, Sparse [<10pc], Moderate [11-50pc]) 1.0, 0.0;
  (AIDS early, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (AILD, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (ALIP, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Cat scratch disease, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Dermatopathic laden, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Florid follic hyperp, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (GLH hyaline vascular, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (GLH plasma cell, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Granulomatous laden, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Histiocytosis x, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Infectious mono, Moderate [11-50pc], Moderate [11-50pc]) 0.98, 0.02;
  (Leprosy-lepromatous, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Lymphangiographic, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Mantle zone hyperpla, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Necrotizing Kikuchi, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Necrotiz non-Kikuchi, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Rheumatoid arthritis, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Sarcoidosis, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (SHML, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Sinus histiocytosis, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Syphilis, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Toxoplasmosis, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Tuberculosis, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Viral NOS, Moderate [11-50pc], Moderate [11-50pc]) 0.999, 0.001;
  (Whipple's disease, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (L&H nodular HD, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (L&H diffuse HD, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Nodular sclerosis HD, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Cellular phase NSHD, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Syncytial NSHD, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Mixed cellularity HD, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Interfollicular HD, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Diffuse fibrosis HD, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Reticular-type HD, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Small cleaved fol, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Mixed fol, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Large cell fol, Moderate [11-50pc], Moderate [11-50pc]) 0.5, 0.5;
  (Small noncleaved fol, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Small lymphocytic, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Plasmacytoid lyctic, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Mantle zone lymphoma, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Small cleaved dif, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Mixed FCC dif, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Large cell dif, Moderate [11-50pc], Moderate [11-50pc]) 0.0, 1.0;
  (B-immunoblastic, Moderate [11-50pc], Moderate [11-50pc]) 0.0, 1.0;
  (T-immunob mixed, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (AILD-like T-cell lym, Moderate [11-50pc], Moderate [11-50pc]) 0.7, 0.3;
  (Japanese ATL, Moderate [11-50pc], Moderate [11-50pc]) 0.5, 0.5;
  (Lymphoblastic, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Small noncleaved dif, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (True histiocytic, Moderate [11-50pc], Moderate [11-50pc]) 0.0, 1.0;
  (Ki-1 LC anaplas T, Moderate [11-50pc], Moderate [11-50pc]) 0.0, 1.0;
  (Multiple myeloma, Moderate [11-50pc], Moderate [11-50pc]) 0.7, 0.3;
  (Mycosis fungoides, Moderate [11-50pc], Moderate [11-50pc]) 0.8, 0.2;
  (AML, Moderate [11-50pc], Moderate [11-50pc]) 0.99, 0.01;
  (Hairy cell leukemia, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Carcinoma, Moderate [11-50pc], Moderate [11-50pc]) 0.99, 0.01;
  (Melanoma, Moderate [11-50pc], Moderate [11-50pc]) 0.99, 0.01;
  (EM plasmacytoma, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Kaposi's sarcoma, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Mast-cell disease, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (AIDS involutionary, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (T-immunob large, Moderate [11-50pc], Moderate [11-50pc]) 0.0, 1.0;
  (Monocytoid B-cell, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Nasopharyngeal CA, Moderate [11-50pc], Moderate [11-50pc]) 0.99, 0.01;
  (Seminoma, Moderate [11-50pc], Moderate [11-50pc]) 0.99, 0.01;
  (SLE, Moderate [11-50pc], Moderate [11-50pc]) 0.98, 0.02;
  (Mycobact histiocytos, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Mast-cell hyperplas, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (LGV, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Histoplasmosis, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Coccidioidomycosis, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (CMV, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Brucellosis, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (Ki-1 LC anaplas B, Moderate [11-50pc], Moderate [11-50pc]) 0.0, 1.0;
  (Intermed lymphocytic, Moderate [11-50pc], Moderate [11-50pc]) 1.0, 0.0;
  (AIDS early, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (AILD, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (ALIP, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Cat scratch disease, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Dermatopathic laden, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Florid follic hyperp, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (GLH hyaline vascular, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (GLH plasma cell, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Granulomatous laden, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Histiocytosis x, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Infectious mono, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Leprosy-lepromatous, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Lymphangiographic, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Mantle zone hyperpla, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Necrotizing Kikuchi, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Necrotiz non-Kikuchi, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Rheumatoid arthritis, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Sarcoidosis, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (SHML, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Sinus histiocytosis, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Syphilis, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Toxoplasmosis, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Tuberculosis, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Viral NOS, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Whipple's disease, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (L&H nodular HD, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (L&H diffuse HD, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Nodular sclerosis HD, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Cellular phase NSHD, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Syncytial NSHD, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Mixed cellularity HD, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Interfollicular HD, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Diffuse fibrosis HD, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Reticular-type HD, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Small cleaved fol, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Mixed fol, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Large cell fol, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Small noncleaved fol, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Small lymphocytic, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Plasmacytoid lyctic, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Mantle zone lymphoma, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Small cleaved dif, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Mixed FCC dif, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Large cell dif, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (B-immunoblastic, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (T-immunob mixed, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (AILD-like T-cell lym, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Japanese ATL, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Lymphoblastic, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Small noncleaved dif, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (True histiocytic, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Ki-1 LC anaplas T, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Multiple myeloma, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Mycosis fungoides, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (AML, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Hairy cell leukemia, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Carcinoma, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Melanoma, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (EM plasmacytoma, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Kaposi's sarcoma, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Mast-cell disease, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (AIDS involutionary, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (T-immunob large, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Monocytoid B-cell, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Nasopharyngeal CA, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Seminoma, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (SLE, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Mycobact histiocytos, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Mast-cell hyperplas, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (LGV, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Histoplasmosis, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Coccidioidomycosis, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (CMV, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Brucellosis, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Ki-1 LC anaplas B, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Intermed lymphocytic, Numerous [51-90pc], Moderate [11-50pc]) 0.0, 1.0;
  (AIDS early, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (AILD, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (ALIP, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Cat scratch disease, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Dermatopathic laden, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Florid follic hyperp, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (GLH hyaline vascular, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (GLH plasma cell, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Granulomatous laden, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Histiocytosis x, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Infectious mono, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Leprosy-lepromatous, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Lymphangiographic, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Mantle zone hyperpla, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Necrotizing Kikuchi, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Necrotiz non-Kikuchi, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Rheumatoid arthritis, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Sarcoidosis, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (SHML, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Sinus histiocytosis, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Syphilis, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Toxoplasmosis, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Tuberculosis, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Viral NOS, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Whipple's disease, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (L&H nodular HD, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (L&H diffuse HD, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Nodular sclerosis HD, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Cellular phase NSHD, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Syncytial NSHD, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Mixed cellularity HD, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Interfollicular HD, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Diffuse fibrosis HD, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Reticular-type HD, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Small cleaved fol, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Mixed fol, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Large cell fol, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Small noncleaved fol, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Small lymphocytic, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Plasmacytoid lyctic, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Mantle zone lymphoma, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Small cleaved dif, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Mixed FCC dif, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Large cell dif, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (B-immunoblastic, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (T-immunob mixed, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (AILD-like T-cell lym, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Japanese ATL, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Lymphoblastic, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Small noncleaved dif, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (True histiocytic, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Ki-1 LC anaplas T, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Multiple myeloma, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Mycosis fungoides, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (AML, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Hairy cell leukemia, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Carcinoma, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Melanoma, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (EM plasmacytoma, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Kaposi's sarcoma, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Mast-cell disease, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (AIDS involutionary, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (T-immunob large, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Monocytoid B-cell, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Nasopharyngeal CA, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Seminoma, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (SLE, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Mycobact histiocytos, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Mast-cell hyperplas, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (LGV, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Histoplasmosis, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Coccidioidomycosis, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (CMV, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Brucellosis, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Ki-1 LC anaplas B, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (Intermed lymphocytic, Striking [>90pc], Moderate [11-50pc]) 0.0, 1.0;
  (AIDS early, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (AILD, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (ALIP, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Cat scratch disease, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Dermatopathic laden, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Florid follic hyperp, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (GLH hyaline vascular, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (GLH plasma cell, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Granulomatous laden, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Histiocytosis x, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Infectious mono, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Leprosy-lepromatous, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Lymphangiographic, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mantle zone hyperpla, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Necrotizing Kikuchi, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Necrotiz non-Kikuchi, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Rheumatoid arthritis, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Sarcoidosis, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (SHML, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Sinus histiocytosis, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Syphilis, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Toxoplasmosis, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Tuberculosis, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Viral NOS, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Whipple's disease, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (L&H nodular HD, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (L&H diffuse HD, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Nodular sclerosis HD, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Cellular phase NSHD, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Syncytial NSHD, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mixed cellularity HD, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Interfollicular HD, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Diffuse fibrosis HD, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Reticular-type HD, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small cleaved fol, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mixed fol, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Large cell fol, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small noncleaved fol, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small lymphocytic, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Plasmacytoid lyctic, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mantle zone lymphoma, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small cleaved dif, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mixed FCC dif, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Large cell dif, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (B-immunoblastic, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (T-immunob mixed, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (AILD-like T-cell lym, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Japanese ATL, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Lymphoblastic, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small noncleaved dif, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (True histiocytic, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Ki-1 LC anaplas T, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Multiple myeloma, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mycosis fungoides, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (AML, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Hairy cell leukemia, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Carcinoma, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Melanoma, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (EM plasmacytoma, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Kaposi's sarcoma, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mast-cell disease, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (AIDS involutionary, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (T-immunob large, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Monocytoid B-cell, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Nasopharyngeal CA, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Seminoma, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (SLE, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mycobact histiocytos, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mast-cell hyperplas, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (LGV, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Histoplasmosis, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Coccidioidomycosis, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (CMV, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Brucellosis, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Ki-1 LC anaplas B, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (Intermed lymphocytic, Absent [0pc], Numerous [51-90pc]) 0.0, 1.0;
  (AIDS early, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (AILD, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (ALIP, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Cat scratch disease, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Dermatopathic laden, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Florid follic hyperp, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (GLH hyaline vascular, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (GLH plasma cell, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Granulomatous laden, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Histiocytosis x, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Infectious mono, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Leprosy-lepromatous, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Lymphangiographic, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mantle zone hyperpla, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Necrotizing Kikuchi, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Necrotiz non-Kikuchi, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Rheumatoid arthritis, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Sarcoidosis, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (SHML, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Sinus histiocytosis, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Syphilis, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Toxoplasmosis, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Tuberculosis, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Viral NOS, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Whipple's disease, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (L&H nodular HD, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (L&H diffuse HD, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Nodular sclerosis HD, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Cellular phase NSHD, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Syncytial NSHD, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mixed cellularity HD, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Interfollicular HD, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Diffuse fibrosis HD, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Reticular-type HD, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small cleaved fol, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mixed fol, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Large cell fol, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small noncleaved fol, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small lymphocytic, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Plasmacytoid lyctic, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mantle zone lymphoma, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small cleaved dif, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mixed FCC dif, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Large cell dif, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (B-immunoblastic, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (T-immunob mixed, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (AILD-like T-cell lym, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Japanese ATL, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Lymphoblastic, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small noncleaved dif, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (True histiocytic, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Ki-1 LC anaplas T, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Multiple myeloma, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mycosis fungoides, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (AML, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Hairy cell leukemia, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Carcinoma, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Melanoma, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (EM plasmacytoma, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Kaposi's sarcoma, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mast-cell disease, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (AIDS involutionary, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (T-immunob large, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Monocytoid B-cell, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Nasopharyngeal CA, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Seminoma, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (SLE, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mycobact histiocytos, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mast-cell hyperplas, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (LGV, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Histoplasmosis, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Coccidioidomycosis, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (CMV, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Brucellosis, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Ki-1 LC anaplas B, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (Intermed lymphocytic, Sparse [<10pc], Numerous [51-90pc]) 0.0, 1.0;
  (AIDS early, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (AILD, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (ALIP, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Cat scratch disease, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Dermatopathic laden, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Florid follic hyperp, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (GLH hyaline vascular, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (GLH plasma cell, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Granulomatous laden, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Histiocytosis x, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Infectious mono, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Leprosy-lepromatous, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Lymphangiographic, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mantle zone hyperpla, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Necrotizing Kikuchi, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Necrotiz non-Kikuchi, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Rheumatoid arthritis, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Sarcoidosis, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (SHML, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Sinus histiocytosis, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Syphilis, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Toxoplasmosis, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Tuberculosis, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Viral NOS, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Whipple's disease, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (L&H nodular HD, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (L&H diffuse HD, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Nodular sclerosis HD, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Cellular phase NSHD, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Syncytial NSHD, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mixed cellularity HD, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Interfollicular HD, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Diffuse fibrosis HD, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Reticular-type HD, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small cleaved fol, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mixed fol, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Large cell fol, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small noncleaved fol, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small lymphocytic, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Plasmacytoid lyctic, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mantle zone lymphoma, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small cleaved dif, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mixed FCC dif, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Large cell dif, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (B-immunoblastic, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (T-immunob mixed, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (AILD-like T-cell lym, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Japanese ATL, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Lymphoblastic, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small noncleaved dif, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (True histiocytic, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Ki-1 LC anaplas T, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Multiple myeloma, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mycosis fungoides, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (AML, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Hairy cell leukemia, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Carcinoma, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Melanoma, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (EM plasmacytoma, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Kaposi's sarcoma, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mast-cell disease, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (AIDS involutionary, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (T-immunob large, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Monocytoid B-cell, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Nasopharyngeal CA, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Seminoma, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (SLE, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mycobact histiocytos, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mast-cell hyperplas, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (LGV, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Histoplasmosis, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Coccidioidomycosis, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (CMV, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Brucellosis, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Ki-1 LC anaplas B, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (Intermed lymphocytic, Moderate [11-50pc], Numerous [51-90pc]) 0.0, 1.0;
  (AIDS early, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (AILD, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (ALIP, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Cat scratch disease, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Dermatopathic laden, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Florid follic hyperp, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (GLH hyaline vascular, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (GLH plasma cell, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Granulomatous laden, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Histiocytosis x, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Infectious mono, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Leprosy-lepromatous, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Lymphangiographic, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mantle zone hyperpla, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Necrotizing Kikuchi, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Necrotiz non-Kikuchi, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Rheumatoid arthritis, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Sarcoidosis, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (SHML, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Sinus histiocytosis, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Syphilis, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Toxoplasmosis, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Tuberculosis, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Viral NOS, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Whipple's disease, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (L&H nodular HD, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (L&H diffuse HD, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Nodular sclerosis HD, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Cellular phase NSHD, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Syncytial NSHD, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mixed cellularity HD, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Interfollicular HD, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Diffuse fibrosis HD, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Reticular-type HD, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small cleaved fol, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mixed fol, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Large cell fol, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small noncleaved fol, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small lymphocytic, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Plasmacytoid lyctic, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mantle zone lymphoma, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small cleaved dif, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mixed FCC dif, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Large cell dif, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (B-immunoblastic, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (T-immunob mixed, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (AILD-like T-cell lym, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Japanese ATL, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Lymphoblastic, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small noncleaved dif, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (True histiocytic, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Ki-1 LC anaplas T, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Multiple myeloma, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mycosis fungoides, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (AML, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Hairy cell leukemia, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Carcinoma, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Melanoma, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (EM plasmacytoma, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Kaposi's sarcoma, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mast-cell disease, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (AIDS involutionary, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (T-immunob large, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Monocytoid B-cell, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Nasopharyngeal CA, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Seminoma, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (SLE, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mycobact histiocytos, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mast-cell hyperplas, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (LGV, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Histoplasmosis, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Coccidioidomycosis, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (CMV, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Brucellosis, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Ki-1 LC anaplas B, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Intermed lymphocytic, Numerous [51-90pc], Numerous [51-90pc]) 0.0, 1.0;
  (AIDS early, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (AILD, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (ALIP, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Cat scratch disease, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Dermatopathic laden, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Florid follic hyperp, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (GLH hyaline vascular, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (GLH plasma cell, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Granulomatous laden, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Histiocytosis x, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Infectious mono, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Leprosy-lepromatous, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Lymphangiographic, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mantle zone hyperpla, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Necrotizing Kikuchi, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Necrotiz non-Kikuchi, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Rheumatoid arthritis, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Sarcoidosis, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (SHML, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Sinus histiocytosis, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Syphilis, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Toxoplasmosis, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Tuberculosis, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Viral NOS, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Whipple's disease, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (L&H nodular HD, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (L&H diffuse HD, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Nodular sclerosis HD, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Cellular phase NSHD, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Syncytial NSHD, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mixed cellularity HD, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Interfollicular HD, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Diffuse fibrosis HD, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Reticular-type HD, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small cleaved fol, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mixed fol, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Large cell fol, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small noncleaved fol, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small lymphocytic, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Plasmacytoid lyctic, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mantle zone lymphoma, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small cleaved dif, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mixed FCC dif, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Large cell dif, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (B-immunoblastic, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (T-immunob mixed, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (AILD-like T-cell lym, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Japanese ATL, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Lymphoblastic, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Small noncleaved dif, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (True histiocytic, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Ki-1 LC anaplas T, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Multiple myeloma, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mycosis fungoides, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (AML, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Hairy cell leukemia, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Carcinoma, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Melanoma, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (EM plasmacytoma, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Kaposi's sarcoma, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mast-cell disease, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (AIDS involutionary, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (T-immunob large, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Monocytoid B-cell, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Nasopharyngeal CA, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Seminoma, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (SLE, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mycobact histiocytos, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Mast-cell hyperplas, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (LGV, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Histoplasmosis, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Coccidioidomycosis, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (CMV, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Brucellosis, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Ki-1 LC anaplas B, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (Intermed lymphocytic, Striking [>90pc], Numerous [51-90pc]) 0.0, 1.0;
  (AIDS early, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (AILD, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (ALIP, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Cat scratch disease, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Dermatopathic laden, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Florid follic hyperp, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (GLH hyaline vascular, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (GLH plasma cell, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Granulomatous laden, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Histiocytosis x, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Infectious mono, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Leprosy-lepromatous, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Lymphangiographic, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Mantle zone hyperpla, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Necrotizing Kikuchi, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Necrotiz non-Kikuchi, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Rheumatoid arthritis, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Sarcoidosis, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (SHML, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Sinus histiocytosis, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Syphilis, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Toxoplasmosis, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Tuberculosis, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Viral NOS, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Whipple's disease, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (L&H nodular HD, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (L&H diffuse HD, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Nodular sclerosis HD, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Cellular phase NSHD, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Syncytial NSHD, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Mixed cellularity HD, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Interfollicular HD, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Diffuse fibrosis HD, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Reticular-type HD, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Small cleaved fol, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Mixed fol, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Large cell fol, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Small noncleaved fol, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Small lymphocytic, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Plasmacytoid lyctic, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Mantle zone lymphoma, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Small cleaved dif, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Mixed FCC dif, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Large cell dif, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (B-immunoblastic, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (T-immunob mixed, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (AILD-like T-cell lym, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Japanese ATL, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Lymphoblastic, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Small noncleaved dif, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (True histiocytic, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Ki-1 LC anaplas T, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Multiple myeloma, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Mycosis fungoides, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (AML, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Hairy cell leukemia, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Carcinoma, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Melanoma, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (EM plasmacytoma, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Kaposi's sarcoma, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Mast-cell disease, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (AIDS involutionary, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (T-immunob large, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Monocytoid B-cell, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Nasopharyngeal CA, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Seminoma, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (SLE, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Mycobact histiocytos, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Mast-cell hyperplas, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (LGV, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Histoplasmosis, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Coccidioidomycosis, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (CMV, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Brucellosis, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Ki-1 LC anaplas B, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (Intermed lymphocytic, Absent [0pc], Striking [>90pc]) 0.0, 1.0;
  (AIDS early, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (AILD, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (ALIP, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Cat scratch disease, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Dermatopathic laden, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Florid follic hyperp, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (GLH hyaline vascular, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (GLH plasma cell, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Granulomatous laden, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Histiocytosis x, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Infectious mono, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Leprosy-lepromatous, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Lymphangiographic, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Mantle zone hyperpla, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Necrotizing Kikuchi, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Necrotiz non-Kikuchi, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Rheumatoid arthritis, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Sarcoidosis, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (SHML, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Sinus histiocytosis, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Syphilis, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Toxoplasmosis, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Tuberculosis, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Viral NOS, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Whipple's disease, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (L&H nodular HD, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (L&H diffuse HD, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Nodular sclerosis HD, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Cellular phase NSHD, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Syncytial NSHD, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Mixed cellularity HD, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Interfollicular HD, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Diffuse fibrosis HD, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Reticular-type HD, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Small cleaved fol, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Mixed fol, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Large cell fol, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Small noncleaved fol, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Small lymphocytic, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Plasmacytoid lyctic, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Mantle zone lymphoma, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Small cleaved dif, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Mixed FCC dif, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Large cell dif, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (B-immunoblastic, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (T-immunob mixed, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (AILD-like T-cell lym, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Japanese ATL, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Lymphoblastic, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Small noncleaved dif, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (True histiocytic, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Ki-1 LC anaplas T, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Multiple myeloma, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Mycosis fungoides, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (AML, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Hairy cell leukemia, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Carcinoma, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Melanoma, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (EM plasmacytoma, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Kaposi's sarcoma, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Mast-cell disease, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (AIDS involutionary, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (T-immunob large, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Monocytoid B-cell, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Nasopharyngeal CA, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Seminoma, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (SLE, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Mycobact histiocytos, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Mast-cell hyperplas, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (LGV, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Histoplasmosis, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Coccidioidomycosis, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (CMV, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Brucellosis, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Ki-1 LC anaplas B, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (Intermed lymphocytic, Sparse [<10pc], Striking [>90pc]) 0.0, 1.0;
  (AIDS early, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (AILD, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (ALIP, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Cat scratch disease, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Dermatopathic laden, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Florid follic hyperp, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (GLH hyaline vascular, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (GLH plasma cell, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Granulomatous laden, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Histiocytosis x, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Infectious mono, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Leprosy-lepromatous, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Lymphangiographic, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Mantle zone hyperpla, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Necrotizing Kikuchi, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Necrotiz non-Kikuchi, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Rheumatoid arthritis, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Sarcoidosis, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (SHML, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Sinus histiocytosis, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Syphilis, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Toxoplasmosis, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Tuberculosis, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Viral NOS, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Whipple's disease, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (L&H nodular HD, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (L&H diffuse HD, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Nodular sclerosis HD, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Cellular phase NSHD, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Syncytial NSHD, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Mixed cellularity HD, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Interfollicular HD, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Diffuse fibrosis HD, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Reticular-type HD, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Small cleaved fol, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Mixed fol, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Large cell fol, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Small noncleaved fol, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Small lymphocytic, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Plasmacytoid lyctic, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Mantle zone lymphoma, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Small cleaved dif, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Mixed FCC dif, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Large cell dif, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (B-immunoblastic, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (T-immunob mixed, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (AILD-like T-cell lym, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Japanese ATL, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Lymphoblastic, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Small noncleaved dif, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (True histiocytic, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Ki-1 LC anaplas T, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Multiple myeloma, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Mycosis fungoides, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (AML, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Hairy cell leukemia, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Carcinoma, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Melanoma, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (EM plasmacytoma, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Kaposi's sarcoma, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Mast-cell disease, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (AIDS involutionary, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (T-immunob large, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Monocytoid B-cell, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Nasopharyngeal CA, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Seminoma, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (SLE, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Mycobact histiocytos, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Mast-cell hyperplas, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (LGV, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Histoplasmosis, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Coccidioidomycosis, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (CMV, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Brucellosis, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Ki-1 LC anaplas B, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (Intermed lymphocytic, Moderate [11-50pc], Striking [>90pc]) 0.0, 1.0;
  (AIDS early, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (AILD, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (ALIP, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Cat scratch disease, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Dermatopathic laden, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Florid follic hyperp, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (GLH hyaline vascular, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (GLH plasma cell, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Granulomatous laden, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Histiocytosis x, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Infectious mono, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Leprosy-lepromatous, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Lymphangiographic, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Mantle zone hyperpla, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Necrotizing Kikuchi, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Necrotiz non-Kikuchi, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Rheumatoid arthritis, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Sarcoidosis, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (SHML, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Sinus histiocytosis, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Syphilis, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Toxoplasmosis, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Tuberculosis, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Viral NOS, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Whipple's disease, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (L&H nodular HD, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (L&H diffuse HD, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Nodular sclerosis HD, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Cellular phase NSHD, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Syncytial NSHD, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Mixed cellularity HD, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Interfollicular HD, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Diffuse fibrosis HD, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Reticular-type HD, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Small cleaved fol, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Mixed fol, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Large cell fol, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Small noncleaved fol, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Small lymphocytic, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Plasmacytoid lyctic, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Mantle zone lymphoma, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Small cleaved dif, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Mixed FCC dif, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Large cell dif, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (B-immunoblastic, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (T-immunob mixed, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (AILD-like T-cell lym, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Japanese ATL, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Lymphoblastic, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Small noncleaved dif, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (True histiocytic, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Ki-1 LC anaplas T, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Multiple myeloma, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Mycosis fungoides, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (AML, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Hairy cell leukemia, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Carcinoma, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Melanoma, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (EM plasmacytoma, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Kaposi's sarcoma, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Mast-cell disease, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (AIDS involutionary, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (T-immunob large, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Monocytoid B-cell, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Nasopharyngeal CA, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Seminoma, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (SLE, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Mycobact histiocytos, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Mast-cell hyperplas, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (LGV, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Histoplasmosis, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Coccidioidomycosis, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (CMV, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Brucellosis, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Ki-1 LC anaplas B, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (Intermed lymphocytic, Numerous [51-90pc], Striking [>90pc]) 0.0, 1.0;
  (AIDS early, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (AILD, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (ALIP, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Cat scratch disease, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Dermatopathic laden, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Florid follic hyperp, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (GLH hyaline vascular, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (GLH plasma cell, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Granulomatous laden, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Histiocytosis x, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Infectious mono, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Leprosy-lepromatous, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Lymphangiographic, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Mantle zone hyperpla, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Necrotizing Kikuchi, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Necrotiz non-Kikuchi, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Rheumatoid arthritis, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Sarcoidosis, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (SHML, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Sinus histiocytosis, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Syphilis, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Toxoplasmosis, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Tuberculosis, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Viral NOS, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Whipple's disease, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (L&H nodular HD, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (L&H diffuse HD, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Nodular sclerosis HD, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Cellular phase NSHD, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Syncytial NSHD, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Mixed cellularity HD, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Interfollicular HD, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Diffuse fibrosis HD, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Reticular-type HD, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Small cleaved fol, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Mixed fol, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Large cell fol, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Small noncleaved fol, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Small lymphocytic, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Plasmacytoid lyctic, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Mantle zone lymphoma, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Small cleaved dif, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Mixed FCC dif, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Large cell dif, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (B-immunoblastic, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (T-immunob mixed, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (AILD-like T-cell lym, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Japanese ATL, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Lymphoblastic, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Small noncleaved dif, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (True histiocytic, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Ki-1 LC anaplas T, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Multiple myeloma, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Mycosis fungoides, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (AML, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Hairy cell leukemia, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Carcinoma, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Melanoma, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (EM plasmacytoma, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Kaposi's sarcoma, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Mast-cell disease, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (AIDS involutionary, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (T-immunob large, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Monocytoid B-cell, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Nasopharyngeal CA, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Seminoma, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (SLE, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Mycobact histiocytos, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Mast-cell hyperplas, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (LGV, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Histoplasmosis, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Coccidioidomycosis, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (CMV, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Brucellosis, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Ki-1 LC anaplas B, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
  (Intermed lymphocytic, Striking [>90pc], Striking [>90pc]) 0.0, 1.0;
}
probability ( LLC_NI | Fault, LLC_ID ) {
  (AIDS early, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (ALIP, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Infectious mono, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SHML, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syphilis, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Tuberculosis, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Viral NOS, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Whipple's disease, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed fol, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell fol, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell dif, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Japanese ATL, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (True histiocytic, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AML, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Carcinoma, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Melanoma, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob large, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Seminoma, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SLE, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (LGV, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (CMV, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Brucellosis, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, No LLCs) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS early, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (AILD, Other) 0.00, 0.03, 0.76, 0.20, 0.01;
  (ALIP, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Cat scratch disease, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Dermatopathic laden, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Florid follic hyperp, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (GLH hyaline vascular, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (GLH plasma cell, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Granulomatous laden, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Histiocytosis x, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Infectious mono, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Leprosy-lepromatous, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Lymphangiographic, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Mantle zone hyperpla, Other) 0.00, 0.30, 0.30, 0.39, 0.01;
  (Necrotizing Kikuchi, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Necrotiz non-Kikuchi, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Rheumatoid arthritis, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Sarcoidosis, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (SHML, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Sinus histiocytosis, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Syphilis, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Toxoplasmosis, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Tuberculosis, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Viral NOS, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Whipple's disease, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (L&H nodular HD, Other) 0.00, 0.10, 0.15, 0.74, 0.01;
  (L&H diffuse HD, Other) 0.00, 0.10, 0.15, 0.74, 0.01;
  (Nodular sclerosis HD, Other) 0.00, 0.10, 0.15, 0.74, 0.01;
  (Cellular phase NSHD, Other) 0.00, 0.10, 0.15, 0.74, 0.01;
  (Syncytial NSHD, Other) 0.00, 0.10, 0.15, 0.74, 0.01;
  (Mixed cellularity HD, Other) 0.00, 0.10, 0.15, 0.74, 0.01;
  (Interfollicular HD, Other) 0.00, 0.10, 0.15, 0.74, 0.01;
  (Diffuse fibrosis HD, Other) 0.00, 0.10, 0.15, 0.74, 0.01;
  (Reticular-type HD, Other) 0.00, 0.10, 0.15, 0.74, 0.01;
  (Small cleaved fol, Other) 0.00, 0.05, 0.03, 0.91, 0.01;
  (Mixed fol, Other) 0.00, 0.05, 0.03, 0.91, 0.01;
  (Large cell fol, Other) 0.00, 0.05, 0.03, 0.91, 0.01;
  (Small noncleaved fol, Other) 0.00, 0.05, 0.03, 0.91, 0.01;
  (Small lymphocytic, Other) 0.00, 0.00, 0.94, 0.05, 0.01;
  (Plasmacytoid lyctic, Other) 0.00, 0.00, 0.98, 0.01, 0.01;
  (Mantle zone lymphoma, Other) 0.00, 0.30, 0.30, 0.39, 0.01;
  (Small cleaved dif, Other) 0.00, 0.05, 0.03, 0.91, 0.01;
  (Mixed FCC dif, Other) 0.00, 0.05, 0.03, 0.91, 0.01;
  (Large cell dif, Other) 0.00, 0.05, 0.03, 0.91, 0.01;
  (B-immunoblastic, Other) 0.00, 0.00, 0.97, 0.02, 0.01;
  (T-immunob mixed, Other) 0.00, 0.03, 0.76, 0.20, 0.01;
  (AILD-like T-cell lym, Other) 0.00, 0.03, 0.76, 0.20, 0.01;
  (Japanese ATL, Other) 0.00, 0.10, 0.64, 0.25, 0.01;
  (Lymphoblastic, Other) 0.00, 0.97, 0.00, 0.02, 0.01;
  (Small noncleaved dif, Other) 0.00, 0.05, 0.03, 0.91, 0.01;
  (True histiocytic, Other) 0.00, 0.03, 0.76, 0.20, 0.01;
  (Ki-1 LC anaplas T, Other) 0.00, 0.03, 0.76, 0.20, 0.01;
  (Multiple myeloma, Other) 0.00, 0.00, 0.97, 0.02, 0.01;
  (Mycosis fungoides, Other) 0.00, 0.59, 0.15, 0.25, 0.01;
  (AML, Other) 0.00, 0.01, 0.97, 0.01, 0.01;
  (Hairy cell leukemia, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Carcinoma, Other) 0.00, 0.03, 0.91, 0.05, 0.01;
  (Melanoma, Other) 0.00, 0.01, 0.97, 0.01, 0.01;
  (EM plasmacytoma, Other) 0.00, 0.00, 0.97, 0.02, 0.01;
  (Kaposi's sarcoma, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Mast-cell disease, Other) 0.00, 0.30, 0.30, 0.39, 0.01;
  (AIDS involutionary, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (T-immunob large, Other) 0.00, 0.03, 0.76, 0.20, 0.01;
  (Monocytoid B-cell, Other) 0.00, 0.44, 0.30, 0.25, 0.01;
  (Nasopharyngeal CA, Other) 0.00, 0.01, 0.97, 0.01, 0.01;
  (Seminoma, Other) 0.00, 0.01, 0.93, 0.05, 0.01;
  (SLE, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Mycobact histiocytos, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Mast-cell hyperplas, Other) 0.00, 0.30, 0.30, 0.39, 0.01;
  (LGV, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Histoplasmosis, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Coccidioidomycosis, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (CMV, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Brucellosis, Other) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Ki-1 LC anaplas B, Other) 0.00, 0.03, 0.76, 0.20, 0.01;
  (Intermed lymphocytic, Other) 0.00, 0.30, 0.30, 0.39, 0.01;
  (AIDS early, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (AILD, Large cleaved) 0.00, 0.03, 0.76, 0.20, 0.01;
  (ALIP, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Cat scratch disease, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Dermatopathic laden, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Florid follic hyperp, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (GLH hyaline vascular, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (GLH plasma cell, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Granulomatous laden, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Histiocytosis x, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Infectious mono, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Leprosy-lepromatous, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Lymphangiographic, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Mantle zone hyperpla, Large cleaved) 0.00, 0.30, 0.30, 0.39, 0.01;
  (Necrotizing Kikuchi, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Necrotiz non-Kikuchi, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Rheumatoid arthritis, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Sarcoidosis, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (SHML, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Sinus histiocytosis, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Syphilis, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Toxoplasmosis, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Tuberculosis, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Viral NOS, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Whipple's disease, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (L&H nodular HD, Large cleaved) 0.00, 0.10, 0.15, 0.74, 0.01;
  (L&H diffuse HD, Large cleaved) 0.00, 0.10, 0.15, 0.74, 0.01;
  (Nodular sclerosis HD, Large cleaved) 0.00, 0.10, 0.15, 0.74, 0.01;
  (Cellular phase NSHD, Large cleaved) 0.00, 0.10, 0.15, 0.74, 0.01;
  (Syncytial NSHD, Large cleaved) 0.00, 0.10, 0.15, 0.74, 0.01;
  (Mixed cellularity HD, Large cleaved) 0.00, 0.10, 0.15, 0.74, 0.01;
  (Interfollicular HD, Large cleaved) 0.00, 0.10, 0.15, 0.74, 0.01;
  (Diffuse fibrosis HD, Large cleaved) 0.00, 0.10, 0.15, 0.74, 0.01;
  (Reticular-type HD, Large cleaved) 0.00, 0.10, 0.15, 0.74, 0.01;
  (Small cleaved fol, Large cleaved) 0.00, 0.05, 0.03, 0.91, 0.01;
  (Mixed fol, Large cleaved) 0.00, 0.05, 0.03, 0.91, 0.01;
  (Large cell fol, Large cleaved) 0.00, 0.05, 0.03, 0.91, 0.01;
  (Small noncleaved fol, Large cleaved) 0.00, 0.05, 0.03, 0.91, 0.01;
  (Small lymphocytic, Large cleaved) 0.00, 0.00, 0.94, 0.05, 0.01;
  (Plasmacytoid lyctic, Large cleaved) 0.00, 0.00, 0.98, 0.01, 0.01;
  (Mantle zone lymphoma, Large cleaved) 0.00, 0.30, 0.30, 0.39, 0.01;
  (Small cleaved dif, Large cleaved) 0.00, 0.05, 0.03, 0.91, 0.01;
  (Mixed FCC dif, Large cleaved) 0.00, 0.05, 0.03, 0.91, 0.01;
  (Large cell dif, Large cleaved) 0.00, 0.05, 0.03, 0.91, 0.01;
  (B-immunoblastic, Large cleaved) 0.00, 0.00, 0.97, 0.02, 0.01;
  (T-immunob mixed, Large cleaved) 0.00, 0.03, 0.76, 0.20, 0.01;
  (AILD-like T-cell lym, Large cleaved) 0.00, 0.03, 0.76, 0.20, 0.01;
  (Japanese ATL, Large cleaved) 0.00, 0.10, 0.64, 0.25, 0.01;
  (Lymphoblastic, Large cleaved) 0.00, 0.97, 0.00, 0.02, 0.01;
  (Small noncleaved dif, Large cleaved) 0.00, 0.05, 0.03, 0.91, 0.01;
  (True histiocytic, Large cleaved) 0.00, 0.03, 0.76, 0.20, 0.01;
  (Ki-1 LC anaplas T, Large cleaved) 0.00, 0.03, 0.76, 0.20, 0.01;
  (Multiple myeloma, Large cleaved) 0.00, 0.00, 0.97, 0.02, 0.01;
  (Mycosis fungoides, Large cleaved) 0.00, 0.59, 0.15, 0.25, 0.01;
  (AML, Large cleaved) 0.00, 0.01, 0.97, 0.01, 0.01;
  (Hairy cell leukemia, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Carcinoma, Large cleaved) 0.00, 0.03, 0.91, 0.05, 0.01;
  (Melanoma, Large cleaved) 0.00, 0.01, 0.97, 0.01, 0.01;
  (EM plasmacytoma, Large cleaved) 0.00, 0.00, 0.97, 0.02, 0.01;
  (Kaposi's sarcoma, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Mast-cell disease, Large cleaved) 0.00, 0.30, 0.30, 0.39, 0.01;
  (AIDS involutionary, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (T-immunob large, Large cleaved) 0.00, 0.03, 0.76, 0.20, 0.01;
  (Monocytoid B-cell, Large cleaved) 0.00, 0.44, 0.30, 0.25, 0.01;
  (Nasopharyngeal CA, Large cleaved) 0.00, 0.01, 0.97, 0.01, 0.01;
  (Seminoma, Large cleaved) 0.00, 0.01, 0.93, 0.05, 0.01;
  (SLE, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Mycobact histiocytos, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Mast-cell hyperplas, Large cleaved) 0.00, 0.30, 0.30, 0.39, 0.01;
  (LGV, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Histoplasmosis, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Coccidioidomycosis, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (CMV, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Brucellosis, Large cleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Ki-1 LC anaplas B, Large cleaved) 0.00, 0.03, 0.76, 0.20, 0.01;
  (Intermed lymphocytic, Large cleaved) 0.00, 0.30, 0.30, 0.39, 0.01;
  (AIDS early, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (AILD, Large noncleaved) 0.00, 0.03, 0.76, 0.20, 0.01;
  (ALIP, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Cat scratch disease, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Dermatopathic laden, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Florid follic hyperp, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (GLH hyaline vascular, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (GLH plasma cell, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Granulomatous laden, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Histiocytosis x, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Infectious mono, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Leprosy-lepromatous, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Lymphangiographic, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Mantle zone hyperpla, Large noncleaved) 0.00, 0.30, 0.30, 0.39, 0.01;
  (Necrotizing Kikuchi, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Necrotiz non-Kikuchi, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Rheumatoid arthritis, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Sarcoidosis, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (SHML, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Sinus histiocytosis, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Syphilis, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Toxoplasmosis, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Tuberculosis, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Viral NOS, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Whipple's disease, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (L&H nodular HD, Large noncleaved) 0.00, 0.10, 0.15, 0.74, 0.01;
  (L&H diffuse HD, Large noncleaved) 0.00, 0.10, 0.15, 0.74, 0.01;
  (Nodular sclerosis HD, Large noncleaved) 0.00, 0.10, 0.15, 0.74, 0.01;
  (Cellular phase NSHD, Large noncleaved) 0.00, 0.10, 0.15, 0.74, 0.01;
  (Syncytial NSHD, Large noncleaved) 0.00, 0.10, 0.15, 0.74, 0.01;
  (Mixed cellularity HD, Large noncleaved) 0.00, 0.10, 0.15, 0.74, 0.01;
  (Interfollicular HD, Large noncleaved) 0.00, 0.10, 0.15, 0.74, 0.01;
  (Diffuse fibrosis HD, Large noncleaved) 0.00, 0.10, 0.15, 0.74, 0.01;
  (Reticular-type HD, Large noncleaved) 0.00, 0.10, 0.15, 0.74, 0.01;
  (Small cleaved fol, Large noncleaved) 0.00, 0.05, 0.03, 0.91, 0.01;
  (Mixed fol, Large noncleaved) 0.00, 0.05, 0.03, 0.91, 0.01;
  (Large cell fol, Large noncleaved) 0.00, 0.05, 0.03, 0.91, 0.01;
  (Small noncleaved fol, Large noncleaved) 0.00, 0.05, 0.03, 0.91, 0.01;
  (Small lymphocytic, Large noncleaved) 0.00, 0.00, 0.94, 0.05, 0.01;
  (Plasmacytoid lyctic, Large noncleaved) 0.00, 0.00, 0.98, 0.01, 0.01;
  (Mantle zone lymphoma, Large noncleaved) 0.00, 0.30, 0.30, 0.39, 0.01;
  (Small cleaved dif, Large noncleaved) 0.00, 0.05, 0.03, 0.91, 0.01;
  (Mixed FCC dif, Large noncleaved) 0.00, 0.05, 0.03, 0.91, 0.01;
  (Large cell dif, Large noncleaved) 0.00, 0.05, 0.03, 0.91, 0.01;
  (B-immunoblastic, Large noncleaved) 0.00, 0.00, 0.97, 0.02, 0.01;
  (T-immunob mixed, Large noncleaved) 0.00, 0.03, 0.76, 0.20, 0.01;
  (AILD-like T-cell lym, Large noncleaved) 0.00, 0.03, 0.76, 0.20, 0.01;
  (Japanese ATL, Large noncleaved) 0.00, 0.10, 0.64, 0.25, 0.01;
  (Lymphoblastic, Large noncleaved) 0.00, 0.97, 0.00, 0.02, 0.01;
  (Small noncleaved dif, Large noncleaved) 0.00, 0.05, 0.03, 0.91, 0.01;
  (True histiocytic, Large noncleaved) 0.00, 0.03, 0.76, 0.20, 0.01;
  (Ki-1 LC anaplas T, Large noncleaved) 0.00, 0.03, 0.76, 0.20, 0.01;
  (Multiple myeloma, Large noncleaved) 0.00, 0.00, 0.97, 0.02, 0.01;
  (Mycosis fungoides, Large noncleaved) 0.00, 0.59, 0.15, 0.25, 0.01;
  (AML, Large noncleaved) 0.00, 0.01, 0.97, 0.01, 0.01;
  (Hairy cell leukemia, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Carcinoma, Large noncleaved) 0.00, 0.03, 0.91, 0.05, 0.01;
  (Melanoma, Large noncleaved) 0.00, 0.01, 0.97, 0.01, 0.01;
  (EM plasmacytoma, Large noncleaved) 0.00, 0.00, 0.97, 0.02, 0.01;
  (Kaposi's sarcoma, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Mast-cell disease, Large noncleaved) 0.00, 0.30, 0.30, 0.39, 0.01;
  (AIDS involutionary, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (T-immunob large, Large noncleaved) 0.00, 0.03, 0.76, 0.20, 0.01;
  (Monocytoid B-cell, Large noncleaved) 0.00, 0.44, 0.30, 0.25, 0.01;
  (Nasopharyngeal CA, Large noncleaved) 0.00, 0.01, 0.97, 0.01, 0.01;
  (Seminoma, Large noncleaved) 0.00, 0.01, 0.93, 0.05, 0.01;
  (SLE, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Mycobact histiocytos, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Mast-cell hyperplas, Large noncleaved) 0.00, 0.30, 0.30, 0.39, 0.01;
  (LGV, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Histoplasmosis, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Coccidioidomycosis, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (CMV, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Brucellosis, Large noncleaved) 0.00, 0.05, 0.59, 0.35, 0.01;
  (Ki-1 LC anaplas B, Large noncleaved) 0.00, 0.03, 0.76, 0.20, 0.01;
  (Intermed lymphocytic, Large noncleaved) 0.00, 0.30, 0.30, 0.39, 0.01;
}
probability ( SLC_CS | Fault, SLC ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS early, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (AILD, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (ALIP, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Cat scratch disease, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Dermatopathic laden, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Florid follic hyperp, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (GLH hyaline vascular, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (GLH plasma cell, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Granulomatous laden, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Histiocytosis x, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Infectious mono, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Leprosy-lepromatous, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Lymphangiographic, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mantle zone hyperpla, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Necrotizing Kikuchi, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Necrotiz non-Kikuchi, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Rheumatoid arthritis, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Sarcoidosis, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (SHML, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Sinus histiocytosis, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Syphilis, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Toxoplasmosis, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Tuberculosis, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Viral NOS, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Whipple's disease, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (L&H nodular HD, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (L&H diffuse HD, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Nodular sclerosis HD, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Cellular phase NSHD, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Syncytial NSHD, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mixed cellularity HD, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Interfollicular HD, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Diffuse fibrosis HD, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Reticular-type HD, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Small cleaved fol, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mixed fol, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Large cell fol, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Small noncleaved fol, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Small lymphocytic, Sparse [1-10pc]) 0.00, 0.98, 0.01, 0.00, 0.01;
  (Plasmacytoid lyctic, Sparse [1-10pc]) 0.00, 0.69, 0.01, 0.00, 0.30;
  (Mantle zone lymphoma, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Small cleaved dif, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mixed FCC dif, Sparse [1-10pc]) 0.00, 0.98, 0.01, 0.00, 0.01;
  (Large cell dif, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (B-immunoblastic, Sparse [1-10pc]) 0.00, 0.98, 0.01, 0.00, 0.01;
  (T-immunob mixed, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (AILD-like T-cell lym, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Japanese ATL, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Lymphoblastic, Sparse [1-10pc]) 0.00, 0.79, 0.01, 0.20, 0.00;
  (Small noncleaved dif, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (True histiocytic, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Ki-1 LC anaplas T, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Multiple myeloma, Sparse [1-10pc]) 0.00, 0.98, 0.01, 0.00, 0.01;
  (Mycosis fungoides, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (AML, Sparse [1-10pc]) 0.00, 0.90, 0.01, 0.09, 0.00;
  (Hairy cell leukemia, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Carcinoma, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Melanoma, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (EM plasmacytoma, Sparse [1-10pc]) 0.00, 0.98, 0.01, 0.00, 0.01;
  (Kaposi's sarcoma, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mast-cell disease, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (AIDS involutionary, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (T-immunob large, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Monocytoid B-cell, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.00, 0.02;
  (Nasopharyngeal CA, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Seminoma, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (SLE, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mycobact histiocytos, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mast-cell hyperplas, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (LGV, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Histoplasmosis, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Coccidioidomycosis, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (CMV, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Brucellosis, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Ki-1 LC anaplas B, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Intermed lymphocytic, Sparse [1-10pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (AIDS early, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (AILD, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (ALIP, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Cat scratch disease, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Dermatopathic laden, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Florid follic hyperp, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (GLH hyaline vascular, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (GLH plasma cell, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Granulomatous laden, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Histiocytosis x, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Infectious mono, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Leprosy-lepromatous, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Lymphangiographic, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mantle zone hyperpla, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Necrotizing Kikuchi, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Necrotiz non-Kikuchi, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Rheumatoid arthritis, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Sarcoidosis, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (SHML, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Sinus histiocytosis, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Syphilis, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Toxoplasmosis, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Tuberculosis, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Viral NOS, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Whipple's disease, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (L&H nodular HD, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (L&H diffuse HD, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Nodular sclerosis HD, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Cellular phase NSHD, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Syncytial NSHD, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mixed cellularity HD, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Interfollicular HD, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Diffuse fibrosis HD, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Reticular-type HD, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Small cleaved fol, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mixed fol, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Large cell fol, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Small noncleaved fol, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Small lymphocytic, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.00, 0.01;
  (Plasmacytoid lyctic, Moderate [11-50pc]) 0.00, 0.69, 0.01, 0.00, 0.30;
  (Mantle zone lymphoma, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Small cleaved dif, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mixed FCC dif, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.00, 0.01;
  (Large cell dif, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (B-immunoblastic, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.00, 0.01;
  (T-immunob mixed, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (AILD-like T-cell lym, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Japanese ATL, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Lymphoblastic, Moderate [11-50pc]) 0.00, 0.79, 0.01, 0.20, 0.00;
  (Small noncleaved dif, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (True histiocytic, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Ki-1 LC anaplas T, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Multiple myeloma, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.00, 0.01;
  (Mycosis fungoides, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (AML, Moderate [11-50pc]) 0.00, 0.90, 0.01, 0.09, 0.00;
  (Hairy cell leukemia, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Carcinoma, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Melanoma, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (EM plasmacytoma, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.00, 0.01;
  (Kaposi's sarcoma, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mast-cell disease, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (AIDS involutionary, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (T-immunob large, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Monocytoid B-cell, Moderate [11-50pc]) 0.00, 0.97, 0.01, 0.00, 0.02;
  (Nasopharyngeal CA, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Seminoma, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (SLE, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mycobact histiocytos, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mast-cell hyperplas, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (LGV, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Histoplasmosis, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Coccidioidomycosis, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (CMV, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Brucellosis, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Ki-1 LC anaplas B, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Intermed lymphocytic, Moderate [11-50pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (AIDS early, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (AILD, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (ALIP, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Cat scratch disease, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Dermatopathic laden, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Florid follic hyperp, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (GLH hyaline vascular, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (GLH plasma cell, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Granulomatous laden, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Histiocytosis x, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Infectious mono, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Leprosy-lepromatous, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Lymphangiographic, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mantle zone hyperpla, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Necrotizing Kikuchi, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Necrotiz non-Kikuchi, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Rheumatoid arthritis, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Sarcoidosis, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (SHML, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Sinus histiocytosis, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Syphilis, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Toxoplasmosis, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Tuberculosis, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Viral NOS, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Whipple's disease, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (L&H nodular HD, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (L&H diffuse HD, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Nodular sclerosis HD, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Cellular phase NSHD, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Syncytial NSHD, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mixed cellularity HD, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Interfollicular HD, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Diffuse fibrosis HD, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Reticular-type HD, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Small cleaved fol, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mixed fol, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Large cell fol, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Small noncleaved fol, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Small lymphocytic, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.00, 0.01;
  (Plasmacytoid lyctic, Numerous [51-90pc]) 0.00, 0.69, 0.01, 0.00, 0.30;
  (Mantle zone lymphoma, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Small cleaved dif, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mixed FCC dif, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.00, 0.01;
  (Large cell dif, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (B-immunoblastic, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.00, 0.01;
  (T-immunob mixed, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (AILD-like T-cell lym, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Japanese ATL, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Lymphoblastic, Numerous [51-90pc]) 0.00, 0.79, 0.01, 0.20, 0.00;
  (Small noncleaved dif, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (True histiocytic, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Ki-1 LC anaplas T, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Multiple myeloma, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.00, 0.01;
  (Mycosis fungoides, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (AML, Numerous [51-90pc]) 0.00, 0.90, 0.01, 0.09, 0.00;
  (Hairy cell leukemia, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Carcinoma, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Melanoma, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (EM plasmacytoma, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.00, 0.01;
  (Kaposi's sarcoma, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mast-cell disease, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (AIDS involutionary, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (T-immunob large, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Monocytoid B-cell, Numerous [51-90pc]) 0.00, 0.97, 0.01, 0.00, 0.02;
  (Nasopharyngeal CA, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Seminoma, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (SLE, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mycobact histiocytos, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mast-cell hyperplas, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (LGV, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Histoplasmosis, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Coccidioidomycosis, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (CMV, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Brucellosis, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Ki-1 LC anaplas B, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Intermed lymphocytic, Numerous [51-90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (AIDS early, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (AILD, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (ALIP, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Cat scratch disease, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Dermatopathic laden, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Florid follic hyperp, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (GLH hyaline vascular, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (GLH plasma cell, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Granulomatous laden, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Histiocytosis x, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Infectious mono, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Leprosy-lepromatous, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Lymphangiographic, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mantle zone hyperpla, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Necrotizing Kikuchi, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Necrotiz non-Kikuchi, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Rheumatoid arthritis, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Sarcoidosis, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (SHML, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Sinus histiocytosis, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Syphilis, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Toxoplasmosis, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Tuberculosis, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Viral NOS, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Whipple's disease, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (L&H nodular HD, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (L&H diffuse HD, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Nodular sclerosis HD, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Cellular phase NSHD, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Syncytial NSHD, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mixed cellularity HD, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Interfollicular HD, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Diffuse fibrosis HD, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Reticular-type HD, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Small cleaved fol, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mixed fol, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Large cell fol, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Small noncleaved fol, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Small lymphocytic, Striking [>90pc]) 0.00, 0.98, 0.01, 0.00, 0.01;
  (Plasmacytoid lyctic, Striking [>90pc]) 0.00, 0.69, 0.01, 0.00, 0.30;
  (Mantle zone lymphoma, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Small cleaved dif, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mixed FCC dif, Striking [>90pc]) 0.00, 0.98, 0.01, 0.00, 0.01;
  (Large cell dif, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (B-immunoblastic, Striking [>90pc]) 0.00, 0.98, 0.01, 0.00, 0.01;
  (T-immunob mixed, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (AILD-like T-cell lym, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Japanese ATL, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Lymphoblastic, Striking [>90pc]) 0.00, 0.79, 0.01, 0.20, 0.00;
  (Small noncleaved dif, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (True histiocytic, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Ki-1 LC anaplas T, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Multiple myeloma, Striking [>90pc]) 0.00, 0.98, 0.01, 0.00, 0.01;
  (Mycosis fungoides, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (AML, Striking [>90pc]) 0.00, 0.90, 0.01, 0.09, 0.00;
  (Hairy cell leukemia, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Carcinoma, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Melanoma, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (EM plasmacytoma, Striking [>90pc]) 0.00, 0.98, 0.01, 0.00, 0.01;
  (Kaposi's sarcoma, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mast-cell disease, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (AIDS involutionary, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (T-immunob large, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Monocytoid B-cell, Striking [>90pc]) 0.00, 0.97, 0.01, 0.00, 0.02;
  (Nasopharyngeal CA, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Seminoma, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (SLE, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mycobact histiocytos, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mast-cell hyperplas, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (LGV, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Histoplasmosis, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Coccidioidomycosis, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (CMV, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Brucellosis, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Ki-1 LC anaplas B, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Intermed lymphocytic, Striking [>90pc]) 0.00, 0.99, 0.01, 0.00, 0.00;
}
probability ( LLC_ID | Fault, LLC ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (AILD, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (ALIP, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Cat scratch disease, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Dermatopathic laden, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Florid follic hyperp, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (GLH hyaline vascular, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (GLH plasma cell, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Granulomatous laden, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Histiocytosis x, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Infectious mono, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Leprosy-lepromatous, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Lymphangiographic, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Mantle zone hyperpla, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Necrotizing Kikuchi, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Necrotiz non-Kikuchi, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Rheumatoid arthritis, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Sarcoidosis, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (SHML, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Sinus histiocytosis, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Syphilis, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Toxoplasmosis, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Tuberculosis, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Viral NOS, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Whipple's disease, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (L&H nodular HD, Sparse [<10pc]) 0.0, 0.7, 0.1, 0.2;
  (L&H diffuse HD, Sparse [<10pc]) 0.0, 0.7, 0.1, 0.2;
  (Nodular sclerosis HD, Sparse [<10pc]) 0.0, 0.7, 0.1, 0.2;
  (Cellular phase NSHD, Sparse [<10pc]) 0.0, 0.7, 0.1, 0.2;
  (Syncytial NSHD, Sparse [<10pc]) 0.0, 0.7, 0.1, 0.2;
  (Mixed cellularity HD, Sparse [<10pc]) 0.0, 0.7, 0.1, 0.2;
  (Interfollicular HD, Sparse [<10pc]) 0.0, 0.7, 0.1, 0.2;
  (Diffuse fibrosis HD, Sparse [<10pc]) 0.0, 0.7, 0.1, 0.2;
  (Reticular-type HD, Sparse [<10pc]) 0.0, 0.7, 0.1, 0.2;
  (Small cleaved fol, Sparse [<10pc]) 0.00, 0.01, 0.05, 0.94;
  (Mixed fol, Sparse [<10pc]) 0.00, 0.01, 0.15, 0.84;
  (Large cell fol, Sparse [<10pc]) 0.00, 0.01, 0.05, 0.94;
  (Small noncleaved fol, Sparse [<10pc]) 0.00, 0.01, 0.05, 0.94;
  (Small lymphocytic, Sparse [<10pc]) 0.00, 0.89, 0.01, 0.10;
  (Plasmacytoid lyctic, Sparse [<10pc]) 0.00, 0.89, 0.01, 0.10;
  (Mantle zone lymphoma, Sparse [<10pc]) 0.00, 0.01, 0.05, 0.94;
  (Small cleaved dif, Sparse [<10pc]) 0.00, 0.01, 0.05, 0.94;
  (Mixed FCC dif, Sparse [<10pc]) 0.00, 0.01, 0.15, 0.84;
  (Large cell dif, Sparse [<10pc]) 0.25, 0.25, 0.25, 0.25;
  (B-immunoblastic, Sparse [<10pc]) 0.25, 0.25, 0.25, 0.25;
  (T-immunob mixed, Sparse [<10pc]) 0.00, 0.91, 0.02, 0.07;
  (AILD-like T-cell lym, Sparse [<10pc]) 0.00, 0.69, 0.01, 0.30;
  (Japanese ATL, Sparse [<10pc]) 0.00, 0.97, 0.01, 0.02;
  (Lymphoblastic, Sparse [<10pc]) 0.00, 0.84, 0.15, 0.01;
  (Small noncleaved dif, Sparse [<10pc]) 0.00, 0.01, 0.05, 0.94;
  (True histiocytic, Sparse [<10pc]) 0.25, 0.25, 0.25, 0.25;
  (Ki-1 LC anaplas T, Sparse [<10pc]) 0.25, 0.25, 0.25, 0.25;
  (Multiple myeloma, Sparse [<10pc]) 0.25, 0.25, 0.25, 0.25;
  (Mycosis fungoides, Sparse [<10pc]) 0.00, 0.64, 0.35, 0.01;
  (AML, Sparse [<10pc]) 0.00, 0.67, 0.03, 0.30;
  (Hairy cell leukemia, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Carcinoma, Sparse [<10pc]) 0.00, 0.99, 0.00, 0.01;
  (Melanoma, Sparse [<10pc]) 0.00, 0.99, 0.00, 0.01;
  (EM plasmacytoma, Sparse [<10pc]) 0.0, 0.9, 0.0, 0.1;
  (Kaposi's sarcoma, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Mast-cell disease, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (AIDS involutionary, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (T-immunob large, Sparse [<10pc]) 0.25, 0.25, 0.25, 0.25;
  (Monocytoid B-cell, Sparse [<10pc]) 0.00, 0.39, 0.01, 0.60;
  (Nasopharyngeal CA, Sparse [<10pc]) 0.00, 0.99, 0.00, 0.01;
  (Seminoma, Sparse [<10pc]) 0.00, 0.99, 0.00, 0.01;
  (SLE, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Mycobact histiocytos, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Mast-cell hyperplas, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (LGV, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Histoplasmosis, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Coccidioidomycosis, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (CMV, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Brucellosis, Sparse [<10pc]) 0.00, 0.50, 0.05, 0.45;
  (Ki-1 LC anaplas B, Sparse [<10pc]) 0.25, 0.25, 0.25, 0.25;
  (Intermed lymphocytic, Sparse [<10pc]) 0.00, 0.01, 0.05, 0.94;
  (AIDS early, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (AILD, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (ALIP, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Cat scratch disease, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Dermatopathic laden, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Florid follic hyperp, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (GLH hyaline vascular, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (GLH plasma cell, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Granulomatous laden, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Histiocytosis x, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Infectious mono, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Leprosy-lepromatous, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Lymphangiographic, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Mantle zone hyperpla, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Necrotizing Kikuchi, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Necrotiz non-Kikuchi, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Rheumatoid arthritis, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Sarcoidosis, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (SHML, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Sinus histiocytosis, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Syphilis, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Toxoplasmosis, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Tuberculosis, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Viral NOS, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Whipple's disease, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (L&H nodular HD, Moderate [11-50pc]) 0.0, 0.7, 0.1, 0.2;
  (L&H diffuse HD, Moderate [11-50pc]) 0.0, 0.7, 0.1, 0.2;
  (Nodular sclerosis HD, Moderate [11-50pc]) 0.0, 0.7, 0.1, 0.2;
  (Cellular phase NSHD, Moderate [11-50pc]) 0.0, 0.7, 0.1, 0.2;
  (Syncytial NSHD, Moderate [11-50pc]) 0.0, 0.7, 0.1, 0.2;
  (Mixed cellularity HD, Moderate [11-50pc]) 0.0, 0.7, 0.1, 0.2;
  (Interfollicular HD, Moderate [11-50pc]) 0.0, 0.7, 0.1, 0.2;
  (Diffuse fibrosis HD, Moderate [11-50pc]) 0.0, 0.7, 0.1, 0.2;
  (Reticular-type HD, Moderate [11-50pc]) 0.0, 0.7, 0.1, 0.2;
  (Small cleaved fol, Moderate [11-50pc]) 0.25, 0.25, 0.25, 0.25;
  (Mixed fol, Moderate [11-50pc]) 0.00, 0.01, 0.15, 0.84;
  (Large cell fol, Moderate [11-50pc]) 0.00, 0.01, 0.05, 0.94;
  (Small noncleaved fol, Moderate [11-50pc]) 0.00, 0.02, 0.05, 0.93;
  (Small lymphocytic, Moderate [11-50pc]) 0.00, 0.90, 0.01, 0.09;
  (Plasmacytoid lyctic, Moderate [11-50pc]) 0.00, 0.90, 0.01, 0.09;
  (Mantle zone lymphoma, Moderate [11-50pc]) 0.25, 0.25, 0.25, 0.25;
  (Small cleaved dif, Moderate [11-50pc]) 0.25, 0.25, 0.25, 0.25;
  (Mixed FCC dif, Moderate [11-50pc]) 0.00, 0.01, 0.15, 0.84;
  (Large cell dif, Moderate [11-50pc]) 0.00, 0.05, 0.05, 0.90;
  (B-immunoblastic, Moderate [11-50pc]) 0.00, 0.97, 0.00, 0.03;
  (T-immunob mixed, Moderate [11-50pc]) 0.00, 0.91, 0.02, 0.07;
  (AILD-like T-cell lym, Moderate [11-50pc]) 0.00, 0.69, 0.01, 0.30;
  (Japanese ATL, Moderate [11-50pc]) 0.00, 0.97, 0.01, 0.02;
  (Lymphoblastic, Moderate [11-50pc]) 0.25, 0.25, 0.25, 0.25;
  (Small noncleaved dif, Moderate [11-50pc]) 0.00, 0.02, 0.05, 0.93;
  (True histiocytic, Moderate [11-50pc]) 0.00, 0.97, 0.01, 0.02;
  (Ki-1 LC anaplas T, Moderate [11-50pc]) 0.00, 0.95, 0.00, 0.05;
  (Multiple myeloma, Moderate [11-50pc]) 0.00, 0.97, 0.00, 0.03;
  (Mycosis fungoides, Moderate [11-50pc]) 0.00, 0.64, 0.35, 0.01;
  (AML, Moderate [11-50pc]) 0.00, 0.67, 0.03, 0.30;
  (Hairy cell leukemia, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Carcinoma, Moderate [11-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Melanoma, Moderate [11-50pc]) 0.00, 0.99, 0.00, 0.01;
  (EM plasmacytoma, Moderate [11-50pc]) 0.0, 0.9, 0.0, 0.1;
  (Kaposi's sarcoma, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Mast-cell disease, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (AIDS involutionary, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (T-immunob large, Moderate [11-50pc]) 0.00, 0.91, 0.02, 0.07;
  (Monocytoid B-cell, Moderate [11-50pc]) 0.00, 0.39, 0.01, 0.60;
  (Nasopharyngeal CA, Moderate [11-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Seminoma, Moderate [11-50pc]) 0.00, 0.99, 0.00, 0.01;
  (SLE, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Mycobact histiocytos, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Mast-cell hyperplas, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (LGV, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Histoplasmosis, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Coccidioidomycosis, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (CMV, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Brucellosis, Moderate [11-50pc]) 0.00, 0.50, 0.05, 0.45;
  (Ki-1 LC anaplas B, Moderate [11-50pc]) 0.00, 0.95, 0.00, 0.05;
  (Intermed lymphocytic, Moderate [11-50pc]) 0.25, 0.25, 0.25, 0.25;
  (AIDS early, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (AILD, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (ALIP, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Cat scratch disease, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Dermatopathic laden, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Florid follic hyperp, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (GLH hyaline vascular, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (GLH plasma cell, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Granulomatous laden, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Histiocytosis x, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Infectious mono, Numerous [51-90pc]) 0.00, 0.50, 0.05, 0.45;
  (Leprosy-lepromatous, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Lymphangiographic, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Mantle zone hyperpla, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Necrotizing Kikuchi, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Necrotiz non-Kikuchi, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Rheumatoid arthritis, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Sarcoidosis, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (SHML, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Sinus histiocytosis, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Syphilis, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Toxoplasmosis, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Tuberculosis, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Viral NOS, Numerous [51-90pc]) 0.00, 0.50, 0.05, 0.45;
  (Whipple's disease, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (L&H nodular HD, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (L&H diffuse HD, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Nodular sclerosis HD, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Cellular phase NSHD, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Syncytial NSHD, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Mixed cellularity HD, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Interfollicular HD, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Diffuse fibrosis HD, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Reticular-type HD, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Small cleaved fol, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Mixed fol, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Large cell fol, Numerous [51-90pc]) 0.00, 0.05, 0.05, 0.90;
  (Small noncleaved fol, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Small lymphocytic, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Plasmacytoid lyctic, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Mantle zone lymphoma, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Small cleaved dif, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Mixed FCC dif, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Large cell dif, Numerous [51-90pc]) 0.00, 0.05, 0.05, 0.90;
  (B-immunoblastic, Numerous [51-90pc]) 0.00, 0.97, 0.00, 0.03;
  (T-immunob mixed, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (AILD-like T-cell lym, Numerous [51-90pc]) 0.00, 0.69, 0.01, 0.30;
  (Japanese ATL, Numerous [51-90pc]) 0.00, 0.97, 0.01, 0.02;
  (Lymphoblastic, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Small noncleaved dif, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (True histiocytic, Numerous [51-90pc]) 0.00, 0.97, 0.01, 0.02;
  (Ki-1 LC anaplas T, Numerous [51-90pc]) 0.00, 0.95, 0.00, 0.05;
  (Multiple myeloma, Numerous [51-90pc]) 0.00, 0.97, 0.00, 0.03;
  (Mycosis fungoides, Numerous [51-90pc]) 0.00, 0.64, 0.35, 0.01;
  (AML, Numerous [51-90pc]) 0.00, 0.67, 0.03, 0.30;
  (Hairy cell leukemia, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Carcinoma, Numerous [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Melanoma, Numerous [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (EM plasmacytoma, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Kaposi's sarcoma, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Mast-cell disease, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (AIDS involutionary, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (T-immunob large, Numerous [51-90pc]) 0.00, 0.91, 0.02, 0.07;
  (Monocytoid B-cell, Numerous [51-90pc]) 0.00, 0.39, 0.01, 0.60;
  (Nasopharyngeal CA, Numerous [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Seminoma, Numerous [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (SLE, Numerous [51-90pc]) 0.00, 0.50, 0.05, 0.45;
  (Mycobact histiocytos, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Mast-cell hyperplas, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (LGV, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Histoplasmosis, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Coccidioidomycosis, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (CMV, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Brucellosis, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (Ki-1 LC anaplas B, Numerous [51-90pc]) 0.00, 0.95, 0.00, 0.05;
  (Intermed lymphocytic, Numerous [51-90pc]) 0.25, 0.25, 0.25, 0.25;
  (AIDS early, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (AILD, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (ALIP, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Cat scratch disease, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Dermatopathic laden, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Florid follic hyperp, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (GLH hyaline vascular, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (GLH plasma cell, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Granulomatous laden, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Histiocytosis x, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Infectious mono, Striking [>90pc]) 0.00, 0.50, 0.05, 0.45;
  (Leprosy-lepromatous, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Lymphangiographic, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Mantle zone hyperpla, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Necrotizing Kikuchi, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Necrotiz non-Kikuchi, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Rheumatoid arthritis, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Sarcoidosis, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (SHML, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Sinus histiocytosis, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Syphilis, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Toxoplasmosis, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Tuberculosis, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Viral NOS, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Whipple's disease, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (L&H nodular HD, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (L&H diffuse HD, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Nodular sclerosis HD, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Cellular phase NSHD, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Syncytial NSHD, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Mixed cellularity HD, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Interfollicular HD, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Diffuse fibrosis HD, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Reticular-type HD, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Small cleaved fol, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Mixed fol, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Large cell fol, Striking [>90pc]) 0.00, 0.05, 0.05, 0.90;
  (Small noncleaved fol, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Small lymphocytic, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Plasmacytoid lyctic, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Mantle zone lymphoma, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Small cleaved dif, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Mixed FCC dif, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Large cell dif, Striking [>90pc]) 0.00, 0.05, 0.05, 0.90;
  (B-immunoblastic, Striking [>90pc]) 0.00, 0.97, 0.00, 0.03;
  (T-immunob mixed, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (AILD-like T-cell lym, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Japanese ATL, Striking [>90pc]) 0.00, 0.97, 0.01, 0.02;
  (Lymphoblastic, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Small noncleaved dif, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (True histiocytic, Striking [>90pc]) 0.00, 0.97, 0.01, 0.02;
  (Ki-1 LC anaplas T, Striking [>90pc]) 0.00, 0.95, 0.00, 0.05;
  (Multiple myeloma, Striking [>90pc]) 0.00, 0.97, 0.00, 0.03;
  (Mycosis fungoides, Striking [>90pc]) 0.00, 0.64, 0.35, 0.01;
  (AML, Striking [>90pc]) 0.00, 0.67, 0.03, 0.30;
  (Hairy cell leukemia, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Carcinoma, Striking [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Melanoma, Striking [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (EM plasmacytoma, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Kaposi's sarcoma, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Mast-cell disease, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (AIDS involutionary, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (T-immunob large, Striking [>90pc]) 0.00, 0.91, 0.02, 0.07;
  (Monocytoid B-cell, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Nasopharyngeal CA, Striking [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Seminoma, Striking [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (SLE, Striking [>90pc]) 0.00, 0.50, 0.05, 0.45;
  (Mycobact histiocytos, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Mast-cell hyperplas, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (LGV, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Histoplasmosis, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Coccidioidomycosis, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (CMV, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Brucellosis, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
  (Ki-1 LC anaplas B, Striking [>90pc]) 0.00, 0.95, 0.00, 0.05;
  (Intermed lymphocytic, Striking [>90pc]) 0.25, 0.25, 0.25, 0.25;
}
probability ( FOLLICLE | Fault ) {
  (AIDS early) 0.00, 0.00, 0.21, 0.74, 0.05;
  (AILD) 0.95, 0.05, 0.00, 0.00, 0.00;
  (ALIP) 0.98, 0.02, 0.00, 0.00, 0.00;
  (Cat scratch disease) 0.01, 0.59, 0.40, 0.00, 0.00;
  (Dermatopathic laden) 0.01, 0.58, 0.40, 0.01, 0.00;
  (Florid follic hyperp) 0.00, 0.00, 0.21, 0.74, 0.05;
  (GLH hyaline vascular) 0.00, 0.79, 0.20, 0.01, 0.00;
  (GLH plasma cell) 0.00, 0.34, 0.60, 0.05, 0.01;
  (Granulomatous laden) 0.01, 0.59, 0.40, 0.00, 0.00;
  (Histiocytosis x) 0.01, 0.59, 0.40, 0.00, 0.00;
  (Infectious mono) 0.0099901098, 0.6923146085, 0.2967062608, 0.0009890209, 0.0000000000;
  (Leprosy-lepromatous) 0.200, 0.799, 0.001, 0.000, 0.000;
  (Lymphangiographic) 0.010, 0.979, 0.010, 0.001, 0.000;
  (Mantle zone hyperpla) 0.00000000, 0.09999000, 0.88991101, 0.00999900, 0.00009999;
  (Necrotizing Kikuchi) 0.01, 0.59, 0.40, 0.00, 0.00;
  (Necrotiz non-Kikuchi) 0.01, 0.59, 0.40, 0.00, 0.00;
  (Rheumatoid arthritis) 0.00, 0.34, 0.60, 0.05, 0.01;
  (Sarcoidosis) 0.200, 0.799, 0.001, 0.000, 0.000;
  (SHML) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Sinus histiocytosis) 0.02, 0.96, 0.02, 0.00, 0.00;
  (Syphilis) 0.0, 0.3, 0.7, 0.0, 0.0;
  (Toxoplasmosis) 0.0, 0.3, 0.7, 0.0, 0.0;
  (Tuberculosis) 0.200, 0.799, 0.001, 0.000, 0.000;
  (Viral NOS) 0.01, 0.59, 0.40, 0.00, 0.00;
  (Whipple's disease) 0.01, 0.98, 0.01, 0.00, 0.00;
  (L&H nodular HD) 0.85, 0.15, 0.00, 0.00, 0.00;
  (L&H diffuse HD) 0.95, 0.05, 0.00, 0.00, 0.00;
  (Nodular sclerosis HD) 0.800, 0.198, 0.002, 0.000, 0.000;
  (Cellular phase NSHD) 0.800, 0.198, 0.002, 0.000, 0.000;
  (Syncytial NSHD) 0.800, 0.198, 0.002, 0.000, 0.000;
  (Mixed cellularity HD) 0.7, 0.3, 0.0, 0.0, 0.0;
  (Interfollicular HD) 0.000, 0.399, 0.600, 0.001, 0.000;
  (Diffuse fibrosis HD) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Reticular-type HD) 0.999, 0.001, 0.000, 0.000, 0.000;
  (Small cleaved fol) 0.00, 0.05, 0.10, 0.15, 0.70;
  (Mixed fol) 0.00, 0.06, 0.15, 0.20, 0.59;
  (Large cell fol) 0.0, 0.5, 0.2, 0.2, 0.1;
  (Small noncleaved fol) 0.00, 0.65, 0.20, 0.10, 0.05;
  (Small lymphocytic) 0.9, 0.1, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic) 0.98, 0.02, 0.00, 0.00, 0.00;
  (Mantle zone lymphoma) 0.0000, 0.6999, 0.3000, 0.0001, 0.0000;
  (Small cleaved dif) 0.98, 0.02, 0.00, 0.00, 0.00;
  (Mixed FCC dif) 0.98, 0.02, 0.00, 0.00, 0.00;
  (Large cell dif) 0.98, 0.02, 0.00, 0.00, 0.00;
  (B-immunoblastic) 0.98, 0.02, 0.00, 0.00, 0.00;
  (T-immunob mixed) 0.9, 0.1, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym) 0.95, 0.05, 0.00, 0.00, 0.00;
  (Japanese ATL) 0.98, 0.02, 0.00, 0.00, 0.00;
  (Lymphoblastic) 0.94049524, 0.04950396, 0.01000080, 0.00000000, 0.00000000;
  (Small noncleaved dif) 0.98, 0.02, 0.00, 0.00, 0.00;
  (True histiocytic) 0.98, 0.02, 0.00, 0.00, 0.00;
  (Ki-1 LC anaplas T) 0.25, 0.70, 0.05, 0.00, 0.00;
  (Multiple myeloma) 0.1999840013, 0.7599392049, 0.0399968003, 0.0000799936, 0.0000000000;
  (Mycosis fungoides) 0.1999840013, 0.7599392049, 0.0399968003, 0.0000799936, 0.0000000000;
  (AML) 0.1999840013, 0.7599392049, 0.0399968003, 0.0000799936, 0.0000000000;
  (Hairy cell leukemia) 0.1999840013, 0.7599392049, 0.0399968003, 0.0000799936, 0.0000000000;
  (Carcinoma) 0.1999840013, 0.7599392049, 0.0399968003, 0.0000799936, 0.0000000000;
  (Melanoma) 0.1999840013, 0.7599392049, 0.0399968003, 0.0000799936, 0.0000000000;
  (EM plasmacytoma) 0.500, 0.475, 0.025, 0.000, 0.000;
  (Kaposi's sarcoma) 0.0500, 0.8550, 0.0855, 0.0095, 0.0000;
  (Mast-cell disease) 0.500, 0.475, 0.025, 0.000, 0.000;
  (AIDS involutionary) 0.0500, 0.9025, 0.0475, 0.0000, 0.0000;
  (T-immunob large) 0.98, 0.02, 0.00, 0.00, 0.00;
  (Monocytoid B-cell) 0.01, 0.71, 0.25, 0.02, 0.01;
  (Nasopharyngeal CA) 0.200, 0.792, 0.008, 0.000, 0.000;
  (Seminoma) 0.1999840013, 0.7599392049, 0.0399968003, 0.0000799936, 0.0000000000;
  (SLE) 0.01, 0.59, 0.40, 0.00, 0.00;
  (Mycobact histiocytos) 0.0500, 0.9025, 0.0475, 0.0000, 0.0000;
  (Mast-cell hyperplas) 0.049529470, 0.564635958, 0.376423972, 0.009410599, 0.000000000;
  (LGV) 0.01, 0.59, 0.40, 0.00, 0.00;
  (Histoplasmosis) 0.049529470, 0.564635958, 0.376423972, 0.009410599, 0.000000000;
  (Coccidioidomycosis) 0.049529470, 0.564635958, 0.376423972, 0.009410599, 0.000000000;
  (CMV) 0.049529470, 0.564635958, 0.376423972, 0.009410599, 0.000000000;
  (Brucellosis) 0.0, 0.3, 0.7, 0.0, 0.0;
  (Ki-1 LC anaplas B) 0.25, 0.70, 0.05, 0.00, 0.00;
  (Intermed lymphocytic) 0.8, 0.2, 0.0, 0.0, 0.0;
}
probability ( F_DEN | Fault, FOLLICLE ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS early, 1-25pc) 0.00, 0.00, 0.01, 0.50, 0.49;
  (AILD, 1-25pc) 0.0, 0.0, 0.0, 0.0, 1.0;
  (ALIP, 1-25pc) 0.00, 0.00, 0.00, 0.02, 0.98;
  (Cat scratch disease, 1-25pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Dermatopathic laden, 1-25pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Florid follic hyperp, 1-25pc) 0.00, 0.00, 0.01, 0.50, 0.49;
  (GLH hyaline vascular, 1-25pc) 0.00, 0.00, 0.00, 0.15, 0.85;
  (GLH plasma cell, 1-25pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Granulomatous laden, 1-25pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Histiocytosis x, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Infectious mono, 1-25pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Leprosy-lepromatous, 1-25pc) 0.00, 0.00, 0.00, 0.02, 0.98;
  (Lymphangiographic, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Mantle zone hyperpla, 1-25pc) 0.00, 0.00, 0.01, 0.80, 0.19;
  (Necrotizing Kikuchi, 1-25pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Necrotiz non-Kikuchi, 1-25pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Rheumatoid arthritis, 1-25pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Sarcoidosis, 1-25pc) 0.00, 0.00, 0.00, 0.02, 0.98;
  (SHML, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Sinus histiocytosis, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Syphilis, 1-25pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Toxoplasmosis, 1-25pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Tuberculosis, 1-25pc) 0.00, 0.00, 0.00, 0.02, 0.98;
  (Viral NOS, 1-25pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Whipple's disease, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (L&H nodular HD, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (L&H diffuse HD, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Nodular sclerosis HD, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Cellular phase NSHD, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Syncytial NSHD, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Mixed cellularity HD, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Interfollicular HD, 1-25pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Diffuse fibrosis HD, 1-25pc) 0.0, 0.0, 0.0, 0.1, 0.9;
  (Reticular-type HD, 1-25pc) 0.0, 0.0, 0.0, 0.1, 0.9;
  (Small cleaved fol, 1-25pc) 0.0000, 0.7799, 0.2000, 0.0200, 0.0001;
  (Mixed fol, 1-25pc) 0.0000, 0.7799, 0.2000, 0.0200, 0.0001;
  (Large cell fol, 1-25pc) 0.0000, 0.7799, 0.2000, 0.0200, 0.0001;
  (Small noncleaved fol, 1-25pc) 0.0000, 0.7799, 0.2000, 0.0200, 0.0001;
  (Small lymphocytic, 1-25pc) 0.0, 0.0, 0.0, 0.1, 0.9;
  (Plasmacytoid lyctic, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Mantle zone lymphoma, 1-25pc) 0.00, 0.00, 0.01, 0.30, 0.69;
  (Small cleaved dif, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Mixed FCC dif, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Large cell dif, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (B-immunoblastic, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (T-immunob mixed, 1-25pc) 0.0, 0.0, 0.0, 0.1, 0.9;
  (AILD-like T-cell lym, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Japanese ATL, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Lymphoblastic, 1-25pc) 0.0, 0.0, 0.0, 0.1, 0.9;
  (Small noncleaved dif, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (True histiocytic, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Ki-1 LC anaplas T, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Multiple myeloma, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Mycosis fungoides, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (AML, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Hairy cell leukemia, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Carcinoma, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Melanoma, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (EM plasmacytoma, 1-25pc) 0.0, 0.0, 0.0, 0.1, 0.9;
  (Kaposi's sarcoma, 1-25pc) 0.00, 0.00, 0.00, 0.15, 0.85;
  (Mast-cell disease, 1-25pc) 0.0, 0.0, 0.0, 0.1, 0.9;
  (AIDS involutionary, 1-25pc) 0.00, 0.00, 0.00, 0.15, 0.85;
  (T-immunob large, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Monocytoid B-cell, 1-25pc) 0.0, 0.0, 0.0, 0.1, 0.9;
  (Nasopharyngeal CA, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Seminoma, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (SLE, 1-25pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Mycobact histiocytos, 1-25pc) 0.00, 0.00, 0.00, 0.15, 0.85;
  (Mast-cell hyperplas, 1-25pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (LGV, 1-25pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Histoplasmosis, 1-25pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Coccidioidomycosis, 1-25pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (CMV, 1-25pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Brucellosis, 1-25pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Ki-1 LC anaplas B, 1-25pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Intermed lymphocytic, 1-25pc) 0.000, 0.000, 0.005, 0.150, 0.845;
  (AIDS early, 25-75pc) 0.00, 0.00, 0.01, 0.50, 0.49;
  (AILD, 25-75pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (ALIP, 25-75pc) 0.00, 0.00, 0.00, 0.02, 0.98;
  (Cat scratch disease, 25-75pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Dermatopathic laden, 25-75pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Florid follic hyperp, 25-75pc) 0.00, 0.00, 0.01, 0.50, 0.49;
  (GLH hyaline vascular, 25-75pc) 0.00, 0.00, 0.00, 0.15, 0.85;
  (GLH plasma cell, 25-75pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Granulomatous laden, 25-75pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Histiocytosis x, 25-75pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Infectious mono, 25-75pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Leprosy-lepromatous, 25-75pc) 0.00, 0.00, 0.00, 0.02, 0.98;
  (Lymphangiographic, 25-75pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Mantle zone hyperpla, 25-75pc) 0.00, 0.00, 0.01, 0.80, 0.19;
  (Necrotizing Kikuchi, 25-75pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Necrotiz non-Kikuchi, 25-75pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Rheumatoid arthritis, 25-75pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Sarcoidosis, 25-75pc) 0.00, 0.00, 0.00, 0.02, 0.98;
  (SHML, 25-75pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Sinus histiocytosis, 25-75pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Syphilis, 25-75pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Toxoplasmosis, 25-75pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Tuberculosis, 25-75pc) 0.00, 0.00, 0.00, 0.02, 0.98;
  (Viral NOS, 25-75pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Whipple's disease, 25-75pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (L&H nodular HD, 25-75pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (L&H diffuse HD, 25-75pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Nodular sclerosis HD, 25-75pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Cellular phase NSHD, 25-75pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Syncytial NSHD, 25-75pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Mixed cellularity HD, 25-75pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Interfollicular HD, 25-75pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Diffuse fibrosis HD, 25-75pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Reticular-type HD, 25-75pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small cleaved fol, 25-75pc) 0.0000, 0.7799, 0.2000, 0.0200, 0.0001;
  (Mixed fol, 25-75pc) 0.0000, 0.7799, 0.2000, 0.0200, 0.0001;
  (Large cell fol, 25-75pc) 0.0000, 0.7799, 0.2000, 0.0200, 0.0001;
  (Small noncleaved fol, 25-75pc) 0.0000, 0.7799, 0.2000, 0.0200, 0.0001;
  (Small lymphocytic, 25-75pc) 0.00, 0.00, 0.01, 0.01, 0.98;
  (Plasmacytoid lyctic, 25-75pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mantle zone lymphoma, 25-75pc) 0.0000, 0.0001, 0.0300, 0.5000, 0.4699;
  (Small cleaved dif, 25-75pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mixed FCC dif, 25-75pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Large cell dif, 25-75pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (B-immunoblastic, 25-75pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (T-immunob mixed, 25-75pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (AILD-like T-cell lym, 25-75pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Japanese ATL, 25-75pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Lymphoblastic, 25-75pc) 0.00, 0.00, 0.01, 0.01, 0.98;
  (Small noncleaved dif, 25-75pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (True histiocytic, 25-75pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Ki-1 LC anaplas T, 25-75pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Multiple myeloma, 25-75pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Mycosis fungoides, 25-75pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (AML, 25-75pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Hairy cell leukemia, 25-75pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Carcinoma, 25-75pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Melanoma, 25-75pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (EM plasmacytoma, 25-75pc) 0.0, 0.0, 0.0, 0.1, 0.9;
  (Kaposi's sarcoma, 25-75pc) 0.00, 0.00, 0.00, 0.15, 0.85;
  (Mast-cell disease, 25-75pc) 0.0, 0.0, 0.0, 0.1, 0.9;
  (AIDS involutionary, 25-75pc) 0.00, 0.00, 0.00, 0.15, 0.85;
  (T-immunob large, 25-75pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Monocytoid B-cell, 25-75pc) 0.0, 0.0, 0.0, 0.1, 0.9;
  (Nasopharyngeal CA, 25-75pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (Seminoma, 25-75pc) 0.00, 0.00, 0.00, 0.05, 0.95;
  (SLE, 25-75pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Mycobact histiocytos, 25-75pc) 0.00, 0.00, 0.00, 0.15, 0.85;
  (Mast-cell hyperplas, 25-75pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (LGV, 25-75pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Histoplasmosis, 25-75pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Coccidioidomycosis, 25-75pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (CMV, 25-75pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Brucellosis, 25-75pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Ki-1 LC anaplas B, 25-75pc) 0.0, 0.0, 0.0, 0.2, 0.8;
  (Intermed lymphocytic, 25-75pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (AIDS early, 75-90pc) 0.000, 0.200, 0.795, 0.005, 0.000;
  (AILD, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (ALIP, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Cat scratch disease, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Dermatopathic laden, 75-90pc) 0.00, 0.20, 0.79, 0.01, 0.00;
  (Florid follic hyperp, 75-90pc) 0.000, 0.200, 0.795, 0.005, 0.000;
  (GLH hyaline vascular, 75-90pc) 0.000, 0.200, 0.795, 0.005, 0.000;
  (GLH plasma cell, 75-90pc) 0.000, 0.200, 0.795, 0.005, 0.000;
  (Granulomatous laden, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Histiocytosis x, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Infectious mono, 75-90pc) 0.000, 0.200, 0.795, 0.005, 0.000;
  (Leprosy-lepromatous, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Lymphangiographic, 75-90pc) 0.00, 0.20, 0.79, 0.01, 0.00;
  (Mantle zone hyperpla, 75-90pc) 0.000, 0.200, 0.795, 0.005, 0.000;
  (Necrotizing Kikuchi, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Necrotiz non-Kikuchi, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Rheumatoid arthritis, 75-90pc) 0.000, 0.200, 0.795, 0.005, 0.000;
  (Sarcoidosis, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (SHML, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Sinus histiocytosis, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Syphilis, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Toxoplasmosis, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Tuberculosis, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Viral NOS, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Whipple's disease, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (L&H nodular HD, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (L&H diffuse HD, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Nodular sclerosis HD, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Cellular phase NSHD, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Syncytial NSHD, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mixed cellularity HD, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Interfollicular HD, 75-90pc) 0.00, 0.20, 0.79, 0.01, 0.00;
  (Diffuse fibrosis HD, 75-90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, 75-90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, 75-90pc) 0.000, 0.300, 0.699, 0.001, 0.000;
  (Mixed fol, 75-90pc) 0.000, 0.300, 0.699, 0.001, 0.000;
  (Large cell fol, 75-90pc) 0.000, 0.300, 0.699, 0.001, 0.000;
  (Small noncleaved fol, 75-90pc) 0.000, 0.300, 0.699, 0.001, 0.000;
  (Small lymphocytic, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Plasmacytoid lyctic, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mantle zone lymphoma, 75-90pc) 0.000, 0.300, 0.699, 0.001, 0.000;
  (Small cleaved dif, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mixed FCC dif, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Large cell dif, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (B-immunoblastic, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (T-immunob mixed, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (AILD-like T-cell lym, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Japanese ATL, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Lymphoblastic, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small noncleaved dif, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (True histiocytic, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Ki-1 LC anaplas T, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Multiple myeloma, 75-90pc) 0.00, 0.20, 0.79, 0.01, 0.00;
  (Mycosis fungoides, 75-90pc) 0.00, 0.20, 0.79, 0.01, 0.00;
  (AML, 75-90pc) 0.00, 0.20, 0.79, 0.01, 0.00;
  (Hairy cell leukemia, 75-90pc) 0.00, 0.20, 0.79, 0.01, 0.00;
  (Carcinoma, 75-90pc) 0.00, 0.20, 0.79, 0.01, 0.00;
  (Melanoma, 75-90pc) 0.00, 0.20, 0.79, 0.01, 0.00;
  (EM plasmacytoma, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Kaposi's sarcoma, 75-90pc) 0.00, 0.20, 0.79, 0.01, 0.00;
  (Mast-cell disease, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (AIDS involutionary, 75-90pc) 0.000, 0.200, 0.795, 0.005, 0.000;
  (T-immunob large, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Monocytoid B-cell, 75-90pc) 0.000, 0.300, 0.699, 0.001, 0.000;
  (Nasopharyngeal CA, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Seminoma, 75-90pc) 0.00, 0.20, 0.79, 0.01, 0.00;
  (SLE, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mycobact histiocytos, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mast-cell hyperplas, 75-90pc) 0.00, 0.20, 0.79, 0.01, 0.00;
  (LGV, 75-90pc) 0.00, 0.20, 0.79, 0.01, 0.00;
  (Histoplasmosis, 75-90pc) 0.00, 0.20, 0.79, 0.01, 0.00;
  (Coccidioidomycosis, 75-90pc) 0.00, 0.20, 0.79, 0.01, 0.00;
  (CMV, 75-90pc) 0.00, 0.20, 0.79, 0.01, 0.00;
  (Brucellosis, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Ki-1 LC anaplas B, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Intermed lymphocytic, 75-90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
  (AIDS early, >90pc) 0.0, 0.9, 0.1, 0.0, 0.0;
  (AILD, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (ALIP, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, >90pc) 0.0, 0.9, 0.1, 0.0, 0.0;
  (GLH hyaline vascular, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, >90pc) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Granulomatous laden, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Infectious mono, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, >90pc) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Necrotizing Kikuchi, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, >90pc) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Sarcoidosis, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SHML, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syphilis, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Tuberculosis, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Viral NOS, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Whipple's disease, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, >90pc) 0.00, 0.95, 0.05, 0.00, 0.00;
  (Mixed fol, >90pc) 0.00, 0.95, 0.05, 0.00, 0.00;
  (Large cell fol, >90pc) 0.00, 0.95, 0.05, 0.00, 0.00;
  (Small noncleaved fol, >90pc) 0.00, 0.95, 0.05, 0.00, 0.00;
  (Small lymphocytic, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell dif, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Japanese ATL, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (True histiocytic, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AML, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Carcinoma, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Melanoma, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, >90pc) 0.0, 0.9, 0.1, 0.0, 0.0;
  (T-immunob large, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, >90pc) 0.00, 0.95, 0.05, 0.00, 0.00;
  (Nasopharyngeal CA, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Seminoma, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SLE, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (LGV, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (CMV, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Brucellosis, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, >90pc) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, >90pc) 0.2, 0.2, 0.2, 0.2, 0.2;
}
probability ( F_SS | Fault, F_POL ) {
  (AIDS early, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (ALIP, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Infectious mono, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SHML, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syphilis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Tuberculosis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Viral NOS, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Whipple's disease, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed fol, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell fol, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell dif, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Japanese ATL, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (True histiocytic, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AML, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Carcinoma, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Melanoma, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob large, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Seminoma, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SLE, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (LGV, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (CMV, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Brucellosis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS early, Absent) 0.00, 0.94, 0.03, 0.02, 0.01;
  (AILD, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (ALIP, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Cat scratch disease, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Dermatopathic laden, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Florid follic hyperp, Absent) 0.00, 0.70, 0.15, 0.10, 0.05;
  (GLH hyaline vascular, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (GLH plasma cell, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Granulomatous laden, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Histiocytosis x, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Infectious mono, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Leprosy-lepromatous, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Lymphangiographic, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Mantle zone hyperpla, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Necrotizing Kikuchi, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Necrotiz non-Kikuchi, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Rheumatoid arthritis, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Sarcoidosis, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (SHML, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Sinus histiocytosis, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Syphilis, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Toxoplasmosis, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Tuberculosis, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Viral NOS, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Whipple's disease, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (L&H nodular HD, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (L&H diffuse HD, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Nodular sclerosis HD, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Cellular phase NSHD, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Syncytial NSHD, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Mixed cellularity HD, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Interfollicular HD, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Diffuse fibrosis HD, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Reticular-type HD, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Small cleaved fol, Absent) 0.0000, 0.9889, 0.0100, 0.0010, 0.0001;
  (Mixed fol, Absent) 0.0000, 0.9889, 0.0100, 0.0010, 0.0001;
  (Large cell fol, Absent) 0.000, 0.969, 0.020, 0.010, 0.001;
  (Small noncleaved fol, Absent) 0.000, 0.929, 0.050, 0.020, 0.001;
  (Small lymphocytic, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Plasmacytoid lyctic, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Mantle zone lymphoma, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Small cleaved dif, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Mixed FCC dif, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Large cell dif, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (B-immunoblastic, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (T-immunob mixed, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (AILD-like T-cell lym, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Japanese ATL, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Lymphoblastic, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Small noncleaved dif, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (True histiocytic, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Ki-1 LC anaplas T, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Multiple myeloma, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Mycosis fungoides, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (AML, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Hairy cell leukemia, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Carcinoma, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Melanoma, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (EM plasmacytoma, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Kaposi's sarcoma, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Mast-cell disease, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (AIDS involutionary, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (T-immunob large, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Monocytoid B-cell, Absent) 0.000, 0.969, 0.020, 0.010, 0.001;
  (Nasopharyngeal CA, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Seminoma, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (SLE, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Mycobact histiocytos, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Mast-cell hyperplas, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (LGV, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Histoplasmosis, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Coccidioidomycosis, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (CMV, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Brucellosis, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Ki-1 LC anaplas B, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (Intermed lymphocytic, Absent) 0.000, 0.965, 0.020, 0.010, 0.005;
  (AIDS early, Present) 0.00, 0.00, 0.01, 0.15, 0.84;
  (AILD, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (ALIP, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Cat scratch disease, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Dermatopathic laden, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Florid follic hyperp, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (GLH hyaline vascular, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (GLH plasma cell, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Granulomatous laden, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Histiocytosis x, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Infectious mono, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Leprosy-lepromatous, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Lymphangiographic, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Mantle zone hyperpla, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Necrotizing Kikuchi, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Necrotiz non-Kikuchi, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Rheumatoid arthritis, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Sarcoidosis, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (SHML, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Sinus histiocytosis, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Syphilis, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Toxoplasmosis, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Tuberculosis, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Viral NOS, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Whipple's disease, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (L&H nodular HD, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (L&H diffuse HD, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Nodular sclerosis HD, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Cellular phase NSHD, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Syncytial NSHD, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Mixed cellularity HD, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Interfollicular HD, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Diffuse fibrosis HD, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Reticular-type HD, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Small cleaved fol, Present) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mixed fol, Present) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Large cell fol, Present) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small noncleaved fol, Present) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small lymphocytic, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Plasmacytoid lyctic, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Mantle zone lymphoma, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Small cleaved dif, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Mixed FCC dif, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Large cell dif, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (B-immunoblastic, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (T-immunob mixed, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (AILD-like T-cell lym, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Japanese ATL, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Lymphoblastic, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Small noncleaved dif, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (True histiocytic, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Ki-1 LC anaplas T, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Multiple myeloma, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Mycosis fungoides, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (AML, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Hairy cell leukemia, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Carcinoma, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Melanoma, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (EM plasmacytoma, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Kaposi's sarcoma, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Mast-cell disease, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (AIDS involutionary, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (T-immunob large, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Monocytoid B-cell, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Nasopharyngeal CA, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Seminoma, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (SLE, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Mycobact histiocytos, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Mast-cell hyperplas, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (LGV, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Histoplasmosis, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Coccidioidomycosis, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (CMV, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Brucellosis, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Ki-1 LC anaplas B, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
  (Intermed lymphocytic, Present) 0.00, 0.00, 0.01, 0.24, 0.75;
}
probability ( F_MZSTAT | Fault, F_MZ ) {
  (AIDS early, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (ALIP, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Infectious mono, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SHML, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syphilis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Tuberculosis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Viral NOS, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Whipple's disease, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed fol, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell fol, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell dif, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Japanese ATL, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (True histiocytic, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AML, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Carcinoma, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Melanoma, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob large, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Seminoma, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SLE, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (LGV, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (CMV, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Brucellosis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS early, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (ALIP, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SHML, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AML, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SLE, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (LGV, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (CMV, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS early, Present) 0.0000, 0.9399, 0.0500, 0.0100, 0.0001;
  (AILD, Present) 0.00, 0.25, 0.20, 0.25, 0.30;
  (ALIP, Present) 0.00, 0.25, 0.20, 0.25, 0.30;
  (Cat scratch disease, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Dermatopathic laden, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Florid follic hyperp, Present) 0.000, 0.879, 0.100, 0.020, 0.001;
  (GLH hyaline vascular, Present) 0.0, 0.0, 0.0, 0.0, 1.0;
  (GLH plasma cell, Present) 0.00, 0.10, 0.15, 0.55, 0.20;
  (Granulomatous laden, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Histiocytosis x, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Infectious mono, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Leprosy-lepromatous, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Lymphangiographic, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Mantle zone hyperpla, Present) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Necrotizing Kikuchi, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Necrotiz non-Kikuchi, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Rheumatoid arthritis, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Sarcoidosis, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (SHML, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Sinus histiocytosis, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Syphilis, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Toxoplasmosis, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Tuberculosis, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Viral NOS, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Whipple's disease, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (L&H nodular HD, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (L&H diffuse HD, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Nodular sclerosis HD, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Cellular phase NSHD, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Syncytial NSHD, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Mixed cellularity HD, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Interfollicular HD, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Diffuse fibrosis HD, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Reticular-type HD, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Small cleaved fol, Present) 0.00, 0.79, 0.20, 0.01, 0.00;
  (Mixed fol, Present) 0.00, 0.79, 0.20, 0.01, 0.00;
  (Large cell fol, Present) 0.00, 0.79, 0.20, 0.01, 0.00;
  (Small noncleaved fol, Present) 0.00, 0.79, 0.20, 0.01, 0.00;
  (Small lymphocytic, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Plasmacytoid lyctic, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Mantle zone lymphoma, Present) 0.0, 0.0, 0.0, 0.0, 1.0;
  (Small cleaved dif, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Mixed FCC dif, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Large cell dif, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (B-immunoblastic, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (T-immunob mixed, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (AILD-like T-cell lym, Present) 0.00, 0.25, 0.20, 0.25, 0.30;
  (Japanese ATL, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Lymphoblastic, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Small noncleaved dif, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (True histiocytic, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Ki-1 LC anaplas T, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Multiple myeloma, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Mycosis fungoides, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (AML, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Hairy cell leukemia, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Carcinoma, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Melanoma, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (EM plasmacytoma, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Kaposi's sarcoma, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Mast-cell disease, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (AIDS involutionary, Present) 0.000, 0.650, 0.299, 0.050, 0.001;
  (T-immunob large, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Monocytoid B-cell, Present) 0.00, 0.55, 0.10, 0.30, 0.05;
  (Nasopharyngeal CA, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Seminoma, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (SLE, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Mycobact histiocytos, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Mast-cell hyperplas, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (LGV, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Histoplasmosis, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Coccidioidomycosis, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (CMV, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Brucellosis, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Ki-1 LC anaplas B, Present) 0.00, 0.05, 0.07, 0.30, 0.58;
  (Intermed lymphocytic, Present) 0.0, 0.0, 0.0, 0.0, 1.0;
}
probability ( F_MZCM | Fault, F_MZ ) {
  (AIDS early, No follicles) 1.0, 0.0, 0.0;
  (AILD, No follicles) 1.0, 0.0, 0.0;
  (ALIP, No follicles) 1.0, 0.0, 0.0;
  (Cat scratch disease, No follicles) 1.0, 0.0, 0.0;
  (Dermatopathic laden, No follicles) 1.0, 0.0, 0.0;
  (Florid follic hyperp, No follicles) 1.0, 0.0, 0.0;
  (GLH hyaline vascular, No follicles) 1.0, 0.0, 0.0;
  (GLH plasma cell, No follicles) 1.0, 0.0, 0.0;
  (Granulomatous laden, No follicles) 1.0, 0.0, 0.0;
  (Histiocytosis x, No follicles) 1.0, 0.0, 0.0;
  (Infectious mono, No follicles) 1.0, 0.0, 0.0;
  (Leprosy-lepromatous, No follicles) 1.0, 0.0, 0.0;
  (Lymphangiographic, No follicles) 1.0, 0.0, 0.0;
  (Mantle zone hyperpla, No follicles) 1.0, 0.0, 0.0;
  (Necrotizing Kikuchi, No follicles) 1.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, No follicles) 1.0, 0.0, 0.0;
  (Rheumatoid arthritis, No follicles) 1.0, 0.0, 0.0;
  (Sarcoidosis, No follicles) 1.0, 0.0, 0.0;
  (SHML, No follicles) 1.0, 0.0, 0.0;
  (Sinus histiocytosis, No follicles) 1.0, 0.0, 0.0;
  (Syphilis, No follicles) 1.0, 0.0, 0.0;
  (Toxoplasmosis, No follicles) 1.0, 0.0, 0.0;
  (Tuberculosis, No follicles) 1.0, 0.0, 0.0;
  (Viral NOS, No follicles) 1.0, 0.0, 0.0;
  (Whipple's disease, No follicles) 1.0, 0.0, 0.0;
  (L&H nodular HD, No follicles) 1.0, 0.0, 0.0;
  (L&H diffuse HD, No follicles) 1.0, 0.0, 0.0;
  (Nodular sclerosis HD, No follicles) 1.0, 0.0, 0.0;
  (Cellular phase NSHD, No follicles) 1.0, 0.0, 0.0;
  (Syncytial NSHD, No follicles) 1.0, 0.0, 0.0;
  (Mixed cellularity HD, No follicles) 1.0, 0.0, 0.0;
  (Interfollicular HD, No follicles) 1.0, 0.0, 0.0;
  (Diffuse fibrosis HD, No follicles) 1.0, 0.0, 0.0;
  (Reticular-type HD, No follicles) 1.0, 0.0, 0.0;
  (Small cleaved fol, No follicles) 1.0, 0.0, 0.0;
  (Mixed fol, No follicles) 1.0, 0.0, 0.0;
  (Large cell fol, No follicles) 1.0, 0.0, 0.0;
  (Small noncleaved fol, No follicles) 1.0, 0.0, 0.0;
  (Small lymphocytic, No follicles) 1.0, 0.0, 0.0;
  (Plasmacytoid lyctic, No follicles) 1.0, 0.0, 0.0;
  (Mantle zone lymphoma, No follicles) 1.0, 0.0, 0.0;
  (Small cleaved dif, No follicles) 1.0, 0.0, 0.0;
  (Mixed FCC dif, No follicles) 1.0, 0.0, 0.0;
  (Large cell dif, No follicles) 1.0, 0.0, 0.0;
  (B-immunoblastic, No follicles) 1.0, 0.0, 0.0;
  (T-immunob mixed, No follicles) 1.0, 0.0, 0.0;
  (AILD-like T-cell lym, No follicles) 1.0, 0.0, 0.0;
  (Japanese ATL, No follicles) 1.0, 0.0, 0.0;
  (Lymphoblastic, No follicles) 1.0, 0.0, 0.0;
  (Small noncleaved dif, No follicles) 1.0, 0.0, 0.0;
  (True histiocytic, No follicles) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, No follicles) 1.0, 0.0, 0.0;
  (Multiple myeloma, No follicles) 1.0, 0.0, 0.0;
  (Mycosis fungoides, No follicles) 1.0, 0.0, 0.0;
  (AML, No follicles) 1.0, 0.0, 0.0;
  (Hairy cell leukemia, No follicles) 1.0, 0.0, 0.0;
  (Carcinoma, No follicles) 1.0, 0.0, 0.0;
  (Melanoma, No follicles) 1.0, 0.0, 0.0;
  (EM plasmacytoma, No follicles) 1.0, 0.0, 0.0;
  (Kaposi's sarcoma, No follicles) 1.0, 0.0, 0.0;
  (Mast-cell disease, No follicles) 1.0, 0.0, 0.0;
  (AIDS involutionary, No follicles) 1.0, 0.0, 0.0;
  (T-immunob large, No follicles) 1.0, 0.0, 0.0;
  (Monocytoid B-cell, No follicles) 1.0, 0.0, 0.0;
  (Nasopharyngeal CA, No follicles) 1.0, 0.0, 0.0;
  (Seminoma, No follicles) 1.0, 0.0, 0.0;
  (SLE, No follicles) 1.0, 0.0, 0.0;
  (Mycobact histiocytos, No follicles) 1.0, 0.0, 0.0;
  (Mast-cell hyperplas, No follicles) 1.0, 0.0, 0.0;
  (LGV, No follicles) 1.0, 0.0, 0.0;
  (Histoplasmosis, No follicles) 1.0, 0.0, 0.0;
  (Coccidioidomycosis, No follicles) 1.0, 0.0, 0.0;
  (CMV, No follicles) 1.0, 0.0, 0.0;
  (Brucellosis, No follicles) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, No follicles) 1.0, 0.0, 0.0;
  (Intermed lymphocytic, No follicles) 1.0, 0.0, 0.0;
  (AIDS early, Absent) 1.0, 0.0, 0.0;
  (AILD, Absent) 1.0, 0.0, 0.0;
  (ALIP, Absent) 1.0, 0.0, 0.0;
  (Cat scratch disease, Absent) 1.0, 0.0, 0.0;
  (Dermatopathic laden, Absent) 1.0, 0.0, 0.0;
  (Florid follic hyperp, Absent) 1.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent) 1.0, 0.0, 0.0;
  (GLH plasma cell, Absent) 1.0, 0.0, 0.0;
  (Granulomatous laden, Absent) 1.0, 0.0, 0.0;
  (Histiocytosis x, Absent) 1.0, 0.0, 0.0;
  (Infectious mono, Absent) 1.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent) 1.0, 0.0, 0.0;
  (Lymphangiographic, Absent) 1.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent) 1.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent) 1.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent) 1.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent) 1.0, 0.0, 0.0;
  (Sarcoidosis, Absent) 1.0, 0.0, 0.0;
  (SHML, Absent) 1.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent) 1.0, 0.0, 0.0;
  (Syphilis, Absent) 1.0, 0.0, 0.0;
  (Toxoplasmosis, Absent) 1.0, 0.0, 0.0;
  (Tuberculosis, Absent) 1.0, 0.0, 0.0;
  (Viral NOS, Absent) 1.0, 0.0, 0.0;
  (Whipple's disease, Absent) 1.0, 0.0, 0.0;
  (L&H nodular HD, Absent) 1.0, 0.0, 0.0;
  (L&H diffuse HD, Absent) 1.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent) 1.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent) 1.0, 0.0, 0.0;
  (Syncytial NSHD, Absent) 1.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent) 1.0, 0.0, 0.0;
  (Interfollicular HD, Absent) 1.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent) 1.0, 0.0, 0.0;
  (Reticular-type HD, Absent) 1.0, 0.0, 0.0;
  (Small cleaved fol, Absent) 1.0, 0.0, 0.0;
  (Mixed fol, Absent) 1.0, 0.0, 0.0;
  (Large cell fol, Absent) 1.0, 0.0, 0.0;
  (Small noncleaved fol, Absent) 1.0, 0.0, 0.0;
  (Small lymphocytic, Absent) 1.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent) 1.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent) 1.0, 0.0, 0.0;
  (Small cleaved dif, Absent) 1.0, 0.0, 0.0;
  (Mixed FCC dif, Absent) 1.0, 0.0, 0.0;
  (Large cell dif, Absent) 1.0, 0.0, 0.0;
  (B-immunoblastic, Absent) 1.0, 0.0, 0.0;
  (T-immunob mixed, Absent) 1.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent) 1.0, 0.0, 0.0;
  (Japanese ATL, Absent) 1.0, 0.0, 0.0;
  (Lymphoblastic, Absent) 1.0, 0.0, 0.0;
  (Small noncleaved dif, Absent) 1.0, 0.0, 0.0;
  (True histiocytic, Absent) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent) 1.0, 0.0, 0.0;
  (Multiple myeloma, Absent) 1.0, 0.0, 0.0;
  (Mycosis fungoides, Absent) 1.0, 0.0, 0.0;
  (AML, Absent) 1.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent) 1.0, 0.0, 0.0;
  (Carcinoma, Absent) 1.0, 0.0, 0.0;
  (Melanoma, Absent) 1.0, 0.0, 0.0;
  (EM plasmacytoma, Absent) 1.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent) 1.0, 0.0, 0.0;
  (Mast-cell disease, Absent) 1.0, 0.0, 0.0;
  (AIDS involutionary, Absent) 1.0, 0.0, 0.0;
  (T-immunob large, Absent) 1.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent) 1.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent) 1.0, 0.0, 0.0;
  (Seminoma, Absent) 1.0, 0.0, 0.0;
  (SLE, Absent) 1.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent) 1.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent) 1.0, 0.0, 0.0;
  (LGV, Absent) 1.0, 0.0, 0.0;
  (Histoplasmosis, Absent) 1.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent) 1.0, 0.0, 0.0;
  (CMV, Absent) 1.0, 0.0, 0.0;
  (Brucellosis, Absent) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent) 1.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent) 1.0, 0.0, 0.0;
  (AIDS early, Present) 0.00, 0.99, 0.01;
  (AILD, Present) 0.00, 0.99, 0.01;
  (ALIP, Present) 0.00, 0.99, 0.01;
  (Cat scratch disease, Present) 0.00, 0.99, 0.01;
  (Dermatopathic laden, Present) 0.00, 0.99, 0.01;
  (Florid follic hyperp, Present) 0.00, 0.99, 0.01;
  (GLH hyaline vascular, Present) 0.00, 0.01, 0.99;
  (GLH plasma cell, Present) 0.00, 0.99, 0.01;
  (Granulomatous laden, Present) 0.00, 0.99, 0.01;
  (Histiocytosis x, Present) 0.00, 0.99, 0.01;
  (Infectious mono, Present) 0.00, 0.99, 0.01;
  (Leprosy-lepromatous, Present) 0.00, 0.99, 0.01;
  (Lymphangiographic, Present) 0.00, 0.99, 0.01;
  (Mantle zone hyperpla, Present) 0.0, 0.9, 0.1;
  (Necrotizing Kikuchi, Present) 0.00, 0.99, 0.01;
  (Necrotiz non-Kikuchi, Present) 0.00, 0.99, 0.01;
  (Rheumatoid arthritis, Present) 0.00, 0.99, 0.01;
  (Sarcoidosis, Present) 0.00, 0.99, 0.01;
  (SHML, Present) 0.00, 0.99, 0.01;
  (Sinus histiocytosis, Present) 0.00, 0.99, 0.01;
  (Syphilis, Present) 0.00, 0.99, 0.01;
  (Toxoplasmosis, Present) 0.00, 0.99, 0.01;
  (Tuberculosis, Present) 0.00, 0.99, 0.01;
  (Viral NOS, Present) 0.00, 0.99, 0.01;
  (Whipple's disease, Present) 0.00, 0.99, 0.01;
  (L&H nodular HD, Present) 0.00, 0.99, 0.01;
  (L&H diffuse HD, Present) 0.00, 0.99, 0.01;
  (Nodular sclerosis HD, Present) 0.00, 0.99, 0.01;
  (Cellular phase NSHD, Present) 0.00, 0.99, 0.01;
  (Syncytial NSHD, Present) 0.00, 0.99, 0.01;
  (Mixed cellularity HD, Present) 0.00, 0.99, 0.01;
  (Interfollicular HD, Present) 0.00, 0.99, 0.01;
  (Diffuse fibrosis HD, Present) 0.00, 0.99, 0.01;
  (Reticular-type HD, Present) 0.00, 0.99, 0.01;
  (Small cleaved fol, Present) 0.000, 0.999, 0.001;
  (Mixed fol, Present) 0.000, 0.999, 0.001;
  (Large cell fol, Present) 0.000, 0.999, 0.001;
  (Small noncleaved fol, Present) 0.000, 0.999, 0.001;
  (Small lymphocytic, Present) 0.00, 0.99, 0.01;
  (Plasmacytoid lyctic, Present) 0.00, 0.99, 0.01;
  (Mantle zone lymphoma, Present) 0.0, 1.0, 0.0;
  (Small cleaved dif, Present) 0.00, 0.99, 0.01;
  (Mixed FCC dif, Present) 0.00, 0.99, 0.01;
  (Large cell dif, Present) 0.00, 0.99, 0.01;
  (B-immunoblastic, Present) 0.00, 0.99, 0.01;
  (T-immunob mixed, Present) 0.00, 0.99, 0.01;
  (AILD-like T-cell lym, Present) 0.00, 0.99, 0.01;
  (Japanese ATL, Present) 0.00, 0.99, 0.01;
  (Lymphoblastic, Present) 0.00, 0.99, 0.01;
  (Small noncleaved dif, Present) 0.00, 0.99, 0.01;
  (True histiocytic, Present) 0.00, 0.99, 0.01;
  (Ki-1 LC anaplas T, Present) 0.00, 0.99, 0.01;
  (Multiple myeloma, Present) 0.00, 0.99, 0.01;
  (Mycosis fungoides, Present) 0.00, 0.99, 0.01;
  (AML, Present) 0.00, 0.99, 0.01;
  (Hairy cell leukemia, Present) 0.00, 0.99, 0.01;
  (Carcinoma, Present) 0.00, 0.99, 0.01;
  (Melanoma, Present) 0.00, 0.99, 0.01;
  (EM plasmacytoma, Present) 0.00, 0.99, 0.01;
  (Kaposi's sarcoma, Present) 0.00, 0.99, 0.01;
  (Mast-cell disease, Present) 0.00, 0.99, 0.01;
  (AIDS involutionary, Present) 0.00, 0.99, 0.01;
  (T-immunob large, Present) 0.00, 0.99, 0.01;
  (Monocytoid B-cell, Present) 0.000, 0.999, 0.001;
  (Nasopharyngeal CA, Present) 0.00, 0.99, 0.01;
  (Seminoma, Present) 0.00, 0.99, 0.01;
  (SLE, Present) 0.00, 0.99, 0.01;
  (Mycobact histiocytos, Present) 0.00, 0.99, 0.01;
  (Mast-cell hyperplas, Present) 0.00, 0.99, 0.01;
  (LGV, Present) 0.00, 0.99, 0.01;
  (Histoplasmosis, Present) 0.00, 0.99, 0.01;
  (Coccidioidomycosis, Present) 0.00, 0.99, 0.01;
  (CMV, Present) 0.00, 0.99, 0.01;
  (Brucellosis, Present) 0.00, 0.99, 0.01;
  (Ki-1 LC anaplas B, Present) 0.00, 0.99, 0.01;
  (Intermed lymphocytic, Present) 0.0, 1.0, 0.0;
}
probability ( F_DEF | Fault, FOLLICLE ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, 1-25pc) 0.00, 0.83, 0.15, 0.02;
  (AILD, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (ALIP, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Cat scratch disease, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Dermatopathic laden, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Florid follic hyperp, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (GLH hyaline vascular, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (GLH plasma cell, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Granulomatous laden, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Histiocytosis x, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Infectious mono, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Leprosy-lepromatous, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Lymphangiographic, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Mantle zone hyperpla, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Necrotizing Kikuchi, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Necrotiz non-Kikuchi, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Rheumatoid arthritis, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Sarcoidosis, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (SHML, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Sinus histiocytosis, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Syphilis, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Toxoplasmosis, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Tuberculosis, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Viral NOS, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Whipple's disease, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (L&H nodular HD, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (L&H diffuse HD, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Nodular sclerosis HD, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Cellular phase NSHD, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Syncytial NSHD, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Mixed cellularity HD, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Interfollicular HD, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Diffuse fibrosis HD, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Reticular-type HD, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Small cleaved fol, 1-25pc) 0.00, 0.05, 0.25, 0.70;
  (Mixed fol, 1-25pc) 0.00, 0.05, 0.25, 0.70;
  (Large cell fol, 1-25pc) 0.00, 0.05, 0.25, 0.70;
  (Small noncleaved fol, 1-25pc) 0.00, 0.05, 0.25, 0.70;
  (Small lymphocytic, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Plasmacytoid lyctic, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Mantle zone lymphoma, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Small cleaved dif, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Mixed FCC dif, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Large cell dif, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (B-immunoblastic, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (T-immunob mixed, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (AILD-like T-cell lym, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Japanese ATL, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Lymphoblastic, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Small noncleaved dif, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (True histiocytic, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Ki-1 LC anaplas T, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Multiple myeloma, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Mycosis fungoides, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (AML, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Hairy cell leukemia, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Carcinoma, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Melanoma, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (EM plasmacytoma, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Kaposi's sarcoma, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Mast-cell disease, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (AIDS involutionary, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (T-immunob large, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Monocytoid B-cell, 1-25pc) 0.00, 0.35, 0.45, 0.20;
  (Nasopharyngeal CA, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Seminoma, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (SLE, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Mycobact histiocytos, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Mast-cell hyperplas, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (LGV, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Histoplasmosis, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Coccidioidomycosis, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (CMV, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Brucellosis, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Ki-1 LC anaplas B, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Intermed lymphocytic, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (AIDS early, 25-75pc) 0.00, 0.83, 0.15, 0.02;
  (AILD, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (ALIP, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Cat scratch disease, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Dermatopathic laden, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Florid follic hyperp, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (GLH hyaline vascular, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (GLH plasma cell, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Granulomatous laden, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Histiocytosis x, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Infectious mono, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Leprosy-lepromatous, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Lymphangiographic, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Mantle zone hyperpla, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Necrotizing Kikuchi, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Necrotiz non-Kikuchi, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Rheumatoid arthritis, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Sarcoidosis, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (SHML, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Sinus histiocytosis, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Syphilis, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Toxoplasmosis, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Tuberculosis, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Viral NOS, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Whipple's disease, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (L&H nodular HD, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (L&H diffuse HD, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Nodular sclerosis HD, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Cellular phase NSHD, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Syncytial NSHD, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Mixed cellularity HD, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Interfollicular HD, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Diffuse fibrosis HD, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Reticular-type HD, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Small cleaved fol, 25-75pc) 0.00, 0.05, 0.25, 0.70;
  (Mixed fol, 25-75pc) 0.00, 0.05, 0.25, 0.70;
  (Large cell fol, 25-75pc) 0.00, 0.05, 0.25, 0.70;
  (Small noncleaved fol, 25-75pc) 0.00, 0.05, 0.25, 0.70;
  (Small lymphocytic, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Plasmacytoid lyctic, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Mantle zone lymphoma, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Small cleaved dif, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Mixed FCC dif, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Large cell dif, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (B-immunoblastic, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (T-immunob mixed, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (AILD-like T-cell lym, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Japanese ATL, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Lymphoblastic, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Small noncleaved dif, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (True histiocytic, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Ki-1 LC anaplas T, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Multiple myeloma, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Mycosis fungoides, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (AML, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Hairy cell leukemia, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Carcinoma, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Melanoma, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (EM plasmacytoma, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Kaposi's sarcoma, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Mast-cell disease, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (AIDS involutionary, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (T-immunob large, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Monocytoid B-cell, 25-75pc) 0.00, 0.35, 0.45, 0.20;
  (Nasopharyngeal CA, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Seminoma, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (SLE, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Mycobact histiocytos, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Mast-cell hyperplas, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (LGV, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Histoplasmosis, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Coccidioidomycosis, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (CMV, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Brucellosis, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Ki-1 LC anaplas B, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Intermed lymphocytic, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (AIDS early, 75-90pc) 0.00, 0.83, 0.15, 0.02;
  (AILD, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (ALIP, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Cat scratch disease, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Dermatopathic laden, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Florid follic hyperp, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (GLH hyaline vascular, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (GLH plasma cell, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Granulomatous laden, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Histiocytosis x, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Infectious mono, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Leprosy-lepromatous, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Lymphangiographic, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Mantle zone hyperpla, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Necrotizing Kikuchi, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Necrotiz non-Kikuchi, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Rheumatoid arthritis, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Sarcoidosis, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (SHML, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Sinus histiocytosis, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Syphilis, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Toxoplasmosis, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Tuberculosis, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Viral NOS, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Whipple's disease, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (L&H nodular HD, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (L&H diffuse HD, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Nodular sclerosis HD, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Cellular phase NSHD, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Syncytial NSHD, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Mixed cellularity HD, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Interfollicular HD, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Diffuse fibrosis HD, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Reticular-type HD, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Small cleaved fol, 75-90pc) 0.00, 0.05, 0.25, 0.70;
  (Mixed fol, 75-90pc) 0.00, 0.05, 0.25, 0.70;
  (Large cell fol, 75-90pc) 0.00, 0.05, 0.25, 0.70;
  (Small noncleaved fol, 75-90pc) 0.00, 0.05, 0.25, 0.70;
  (Small lymphocytic, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Plasmacytoid lyctic, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Mantle zone lymphoma, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Small cleaved dif, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Mixed FCC dif, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Large cell dif, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (B-immunoblastic, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (T-immunob mixed, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (AILD-like T-cell lym, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Japanese ATL, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Lymphoblastic, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Small noncleaved dif, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (True histiocytic, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Ki-1 LC anaplas T, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Multiple myeloma, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Mycosis fungoides, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (AML, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Hairy cell leukemia, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Carcinoma, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Melanoma, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (EM plasmacytoma, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Kaposi's sarcoma, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Mast-cell disease, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (AIDS involutionary, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (T-immunob large, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Monocytoid B-cell, 75-90pc) 0.00, 0.35, 0.45, 0.20;
  (Nasopharyngeal CA, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Seminoma, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (SLE, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Mycobact histiocytos, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Mast-cell hyperplas, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (LGV, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Histoplasmosis, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Coccidioidomycosis, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (CMV, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Brucellosis, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Ki-1 LC anaplas B, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Intermed lymphocytic, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (AIDS early, >90pc) 0.00, 0.83, 0.15, 0.02;
  (AILD, >90pc) 0.00, 0.75, 0.20, 0.05;
  (ALIP, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Cat scratch disease, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Dermatopathic laden, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Florid follic hyperp, >90pc) 0.00, 0.75, 0.20, 0.05;
  (GLH hyaline vascular, >90pc) 0.00, 0.75, 0.20, 0.05;
  (GLH plasma cell, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Granulomatous laden, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Histiocytosis x, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Infectious mono, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Leprosy-lepromatous, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Lymphangiographic, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Mantle zone hyperpla, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Necrotizing Kikuchi, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Necrotiz non-Kikuchi, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Rheumatoid arthritis, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Sarcoidosis, >90pc) 0.00, 0.75, 0.20, 0.05;
  (SHML, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Sinus histiocytosis, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Syphilis, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Toxoplasmosis, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Tuberculosis, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Viral NOS, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Whipple's disease, >90pc) 0.00, 0.75, 0.20, 0.05;
  (L&H nodular HD, >90pc) 0.00, 0.75, 0.20, 0.05;
  (L&H diffuse HD, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Nodular sclerosis HD, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Cellular phase NSHD, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Syncytial NSHD, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Mixed cellularity HD, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Interfollicular HD, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Diffuse fibrosis HD, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Reticular-type HD, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Small cleaved fol, >90pc) 0.00, 0.05, 0.25, 0.70;
  (Mixed fol, >90pc) 0.00, 0.05, 0.25, 0.70;
  (Large cell fol, >90pc) 0.00, 0.05, 0.25, 0.70;
  (Small noncleaved fol, >90pc) 0.00, 0.05, 0.25, 0.70;
  (Small lymphocytic, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Plasmacytoid lyctic, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Mantle zone lymphoma, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Small cleaved dif, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Mixed FCC dif, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Large cell dif, >90pc) 0.00, 0.75, 0.20, 0.05;
  (B-immunoblastic, >90pc) 0.00, 0.75, 0.20, 0.05;
  (T-immunob mixed, >90pc) 0.00, 0.75, 0.20, 0.05;
  (AILD-like T-cell lym, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Japanese ATL, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Lymphoblastic, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Small noncleaved dif, >90pc) 0.00, 0.75, 0.20, 0.05;
  (True histiocytic, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Ki-1 LC anaplas T, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Multiple myeloma, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Mycosis fungoides, >90pc) 0.00, 0.75, 0.20, 0.05;
  (AML, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Hairy cell leukemia, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Carcinoma, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Melanoma, >90pc) 0.00, 0.75, 0.20, 0.05;
  (EM plasmacytoma, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Kaposi's sarcoma, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Mast-cell disease, >90pc) 0.00, 0.75, 0.20, 0.05;
  (AIDS involutionary, >90pc) 0.00, 0.75, 0.20, 0.05;
  (T-immunob large, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Monocytoid B-cell, >90pc) 0.00, 0.35, 0.45, 0.20;
  (Nasopharyngeal CA, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Seminoma, >90pc) 0.00, 0.75, 0.20, 0.05;
  (SLE, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Mycobact histiocytos, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Mast-cell hyperplas, >90pc) 0.00, 0.75, 0.20, 0.05;
  (LGV, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Histoplasmosis, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Coccidioidomycosis, >90pc) 0.00, 0.75, 0.20, 0.05;
  (CMV, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Brucellosis, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Ki-1 LC anaplas B, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Intermed lymphocytic, >90pc) 0.00, 0.75, 0.20, 0.05;
}
probability ( F_MITO | Fault, FOLLICLE ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, 1-25pc) 0.00, 0.05, 0.15, 0.80;
  (AILD, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (ALIP, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Cat scratch disease, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Dermatopathic laden, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Florid follic hyperp, 1-25pc) 0.00, 0.05, 0.15, 0.80;
  (GLH hyaline vascular, 1-25pc) 0.00, 0.95, 0.04, 0.01;
  (GLH plasma cell, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Granulomatous laden, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Histiocytosis x, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Infectious mono, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Leprosy-lepromatous, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Lymphangiographic, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Mantle zone hyperpla, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Necrotizing Kikuchi, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Necrotiz non-Kikuchi, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Rheumatoid arthritis, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Sarcoidosis, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (SHML, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Sinus histiocytosis, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Syphilis, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Toxoplasmosis, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Tuberculosis, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Viral NOS, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Whipple's disease, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (L&H nodular HD, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (L&H diffuse HD, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Nodular sclerosis HD, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Cellular phase NSHD, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Syncytial NSHD, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Mixed cellularity HD, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Interfollicular HD, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Diffuse fibrosis HD, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Reticular-type HD, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Small cleaved fol, 1-25pc) 0.00, 0.75, 0.20, 0.05;
  (Mixed fol, 1-25pc) 0.00, 0.70, 0.25, 0.05;
  (Large cell fol, 1-25pc) 0.0, 0.3, 0.5, 0.2;
  (Small noncleaved fol, 1-25pc) 0.00, 0.10, 0.55, 0.35;
  (Small lymphocytic, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Plasmacytoid lyctic, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Mantle zone lymphoma, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Small cleaved dif, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Mixed FCC dif, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Large cell dif, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (B-immunoblastic, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (T-immunob mixed, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (AILD-like T-cell lym, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Japanese ATL, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Lymphoblastic, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Small noncleaved dif, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (True histiocytic, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Ki-1 LC anaplas T, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Multiple myeloma, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Mycosis fungoides, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (AML, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Hairy cell leukemia, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Carcinoma, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Melanoma, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (EM plasmacytoma, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Kaposi's sarcoma, 1-25pc) 0.00, 0.15, 0.20, 0.65;
  (Mast-cell disease, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (AIDS involutionary, 1-25pc) 0.00, 0.65, 0.20, 0.15;
  (T-immunob large, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Monocytoid B-cell, 1-25pc) 0.0, 0.3, 0.4, 0.3;
  (Nasopharyngeal CA, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Seminoma, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (SLE, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Mycobact histiocytos, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Mast-cell hyperplas, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (LGV, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Histoplasmosis, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Coccidioidomycosis, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (CMV, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Brucellosis, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Ki-1 LC anaplas B, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (Intermed lymphocytic, 1-25pc) 0.0, 0.2, 0.4, 0.4;
  (AIDS early, 25-75pc) 0.00, 0.05, 0.15, 0.80;
  (AILD, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (ALIP, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Cat scratch disease, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Dermatopathic laden, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Florid follic hyperp, 25-75pc) 0.00, 0.05, 0.15, 0.80;
  (GLH hyaline vascular, 25-75pc) 0.00, 0.95, 0.04, 0.01;
  (GLH plasma cell, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Granulomatous laden, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Histiocytosis x, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Infectious mono, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Leprosy-lepromatous, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Lymphangiographic, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Mantle zone hyperpla, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Necrotizing Kikuchi, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Necrotiz non-Kikuchi, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Rheumatoid arthritis, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Sarcoidosis, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (SHML, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Sinus histiocytosis, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Syphilis, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Toxoplasmosis, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Tuberculosis, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Viral NOS, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Whipple's disease, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (L&H nodular HD, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (L&H diffuse HD, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Nodular sclerosis HD, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Cellular phase NSHD, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Syncytial NSHD, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Mixed cellularity HD, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Interfollicular HD, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Diffuse fibrosis HD, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Reticular-type HD, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Small cleaved fol, 25-75pc) 0.00, 0.75, 0.20, 0.05;
  (Mixed fol, 25-75pc) 0.00, 0.70, 0.25, 0.05;
  (Large cell fol, 25-75pc) 0.0, 0.3, 0.5, 0.2;
  (Small noncleaved fol, 25-75pc) 0.00, 0.10, 0.55, 0.35;
  (Small lymphocytic, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Plasmacytoid lyctic, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Mantle zone lymphoma, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Small cleaved dif, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Mixed FCC dif, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Large cell dif, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (B-immunoblastic, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (T-immunob mixed, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (AILD-like T-cell lym, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Japanese ATL, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Lymphoblastic, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Small noncleaved dif, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (True histiocytic, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Ki-1 LC anaplas T, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Multiple myeloma, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Mycosis fungoides, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (AML, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Hairy cell leukemia, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Carcinoma, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Melanoma, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (EM plasmacytoma, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Kaposi's sarcoma, 25-75pc) 0.00, 0.15, 0.20, 0.65;
  (Mast-cell disease, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (AIDS involutionary, 25-75pc) 0.00, 0.65, 0.20, 0.15;
  (T-immunob large, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Monocytoid B-cell, 25-75pc) 0.0, 0.3, 0.4, 0.3;
  (Nasopharyngeal CA, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Seminoma, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (SLE, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Mycobact histiocytos, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Mast-cell hyperplas, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (LGV, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Histoplasmosis, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Coccidioidomycosis, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (CMV, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Brucellosis, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Ki-1 LC anaplas B, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (Intermed lymphocytic, 25-75pc) 0.0, 0.2, 0.4, 0.4;
  (AIDS early, 75-90pc) 0.00, 0.05, 0.15, 0.80;
  (AILD, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (ALIP, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Cat scratch disease, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Dermatopathic laden, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Florid follic hyperp, 75-90pc) 0.00, 0.05, 0.15, 0.80;
  (GLH hyaline vascular, 75-90pc) 0.00, 0.95, 0.04, 0.01;
  (GLH plasma cell, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Granulomatous laden, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Histiocytosis x, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Infectious mono, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Leprosy-lepromatous, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Lymphangiographic, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Mantle zone hyperpla, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Necrotizing Kikuchi, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Necrotiz non-Kikuchi, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Rheumatoid arthritis, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Sarcoidosis, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (SHML, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Sinus histiocytosis, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Syphilis, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Toxoplasmosis, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Tuberculosis, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Viral NOS, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Whipple's disease, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (L&H nodular HD, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (L&H diffuse HD, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Nodular sclerosis HD, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Cellular phase NSHD, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Syncytial NSHD, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Mixed cellularity HD, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Interfollicular HD, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Diffuse fibrosis HD, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Reticular-type HD, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Small cleaved fol, 75-90pc) 0.00, 0.75, 0.20, 0.05;
  (Mixed fol, 75-90pc) 0.00, 0.70, 0.25, 0.05;
  (Large cell fol, 75-90pc) 0.0, 0.3, 0.5, 0.2;
  (Small noncleaved fol, 75-90pc) 0.00, 0.10, 0.55, 0.35;
  (Small lymphocytic, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Plasmacytoid lyctic, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Mantle zone lymphoma, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Small cleaved dif, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Mixed FCC dif, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Large cell dif, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (B-immunoblastic, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (T-immunob mixed, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (AILD-like T-cell lym, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Japanese ATL, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Lymphoblastic, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Small noncleaved dif, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (True histiocytic, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Ki-1 LC anaplas T, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Multiple myeloma, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Mycosis fungoides, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (AML, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Hairy cell leukemia, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Carcinoma, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Melanoma, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (EM plasmacytoma, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Kaposi's sarcoma, 75-90pc) 0.00, 0.15, 0.20, 0.65;
  (Mast-cell disease, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (AIDS involutionary, 75-90pc) 0.00, 0.65, 0.20, 0.15;
  (T-immunob large, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Monocytoid B-cell, 75-90pc) 0.0, 0.3, 0.4, 0.3;
  (Nasopharyngeal CA, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Seminoma, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (SLE, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Mycobact histiocytos, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Mast-cell hyperplas, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (LGV, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Histoplasmosis, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Coccidioidomycosis, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (CMV, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Brucellosis, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Ki-1 LC anaplas B, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (Intermed lymphocytic, 75-90pc) 0.0, 0.2, 0.4, 0.4;
  (AIDS early, >90pc) 0.00, 0.05, 0.15, 0.80;
  (AILD, >90pc) 0.0, 0.2, 0.4, 0.4;
  (ALIP, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Cat scratch disease, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Dermatopathic laden, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Florid follic hyperp, >90pc) 0.00, 0.05, 0.15, 0.80;
  (GLH hyaline vascular, >90pc) 0.00, 0.95, 0.04, 0.01;
  (GLH plasma cell, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Granulomatous laden, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Histiocytosis x, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Infectious mono, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Leprosy-lepromatous, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Lymphangiographic, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Mantle zone hyperpla, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Necrotizing Kikuchi, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Necrotiz non-Kikuchi, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Rheumatoid arthritis, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Sarcoidosis, >90pc) 0.0, 0.2, 0.4, 0.4;
  (SHML, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Sinus histiocytosis, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Syphilis, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Toxoplasmosis, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Tuberculosis, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Viral NOS, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Whipple's disease, >90pc) 0.0, 0.2, 0.4, 0.4;
  (L&H nodular HD, >90pc) 0.0, 0.2, 0.4, 0.4;
  (L&H diffuse HD, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Nodular sclerosis HD, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Cellular phase NSHD, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Syncytial NSHD, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Mixed cellularity HD, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Interfollicular HD, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Diffuse fibrosis HD, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Reticular-type HD, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Small cleaved fol, >90pc) 0.00, 0.75, 0.20, 0.05;
  (Mixed fol, >90pc) 0.00, 0.70, 0.25, 0.05;
  (Large cell fol, >90pc) 0.0, 0.3, 0.5, 0.2;
  (Small noncleaved fol, >90pc) 0.00, 0.10, 0.55, 0.35;
  (Small lymphocytic, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Plasmacytoid lyctic, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Mantle zone lymphoma, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Small cleaved dif, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Mixed FCC dif, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Large cell dif, >90pc) 0.0, 0.2, 0.4, 0.4;
  (B-immunoblastic, >90pc) 0.0, 0.2, 0.4, 0.4;
  (T-immunob mixed, >90pc) 0.0, 0.2, 0.4, 0.4;
  (AILD-like T-cell lym, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Japanese ATL, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Lymphoblastic, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Small noncleaved dif, >90pc) 0.0, 0.2, 0.4, 0.4;
  (True histiocytic, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Ki-1 LC anaplas T, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Multiple myeloma, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Mycosis fungoides, >90pc) 0.0, 0.2, 0.4, 0.4;
  (AML, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Hairy cell leukemia, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Carcinoma, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Melanoma, >90pc) 0.0, 0.2, 0.4, 0.4;
  (EM plasmacytoma, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Kaposi's sarcoma, >90pc) 0.00, 0.15, 0.20, 0.65;
  (Mast-cell disease, >90pc) 0.0, 0.2, 0.4, 0.4;
  (AIDS involutionary, >90pc) 0.00, 0.65, 0.20, 0.15;
  (T-immunob large, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Monocytoid B-cell, >90pc) 0.0, 0.3, 0.4, 0.3;
  (Nasopharyngeal CA, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Seminoma, >90pc) 0.0, 0.2, 0.4, 0.4;
  (SLE, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Mycobact histiocytos, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Mast-cell hyperplas, >90pc) 0.0, 0.2, 0.4, 0.4;
  (LGV, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Histoplasmosis, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Coccidioidomycosis, >90pc) 0.0, 0.2, 0.4, 0.4;
  (CMV, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Brucellosis, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Ki-1 LC anaplas B, >90pc) 0.0, 0.2, 0.4, 0.4;
  (Intermed lymphocytic, >90pc) 0.0, 0.2, 0.4, 0.4;
}
probability ( F_MZ | Fault, FOLLICLE ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0;
  (AIDS early, 1-25pc) 0.00, 0.95, 0.05;
  (AILD, 1-25pc) 0.0, 0.1, 0.9;
  (ALIP, 1-25pc) 0.0, 0.1, 0.9;
  (Cat scratch disease, 1-25pc) 0.0, 0.1, 0.9;
  (Dermatopathic laden, 1-25pc) 0.0, 0.1, 0.9;
  (Florid follic hyperp, 1-25pc) 0.0, 0.9, 0.1;
  (GLH hyaline vascular, 1-25pc) 0.0, 0.0, 1.0;
  (GLH plasma cell, 1-25pc) 0.0, 0.1, 0.9;
  (Granulomatous laden, 1-25pc) 0.0, 0.1, 0.9;
  (Histiocytosis x, 1-25pc) 0.0, 0.1, 0.9;
  (Infectious mono, 1-25pc) 0.0, 0.1, 0.9;
  (Leprosy-lepromatous, 1-25pc) 0.0, 0.1, 0.9;
  (Lymphangiographic, 1-25pc) 0.0, 0.1, 0.9;
  (Mantle zone hyperpla, 1-25pc) 0.0, 0.0, 1.0;
  (Necrotizing Kikuchi, 1-25pc) 0.0, 0.1, 0.9;
  (Necrotiz non-Kikuchi, 1-25pc) 0.0, 0.1, 0.9;
  (Rheumatoid arthritis, 1-25pc) 0.0, 0.1, 0.9;
  (Sarcoidosis, 1-25pc) 0.0, 0.1, 0.9;
  (SHML, 1-25pc) 0.0, 0.1, 0.9;
  (Sinus histiocytosis, 1-25pc) 0.0, 0.1, 0.9;
  (Syphilis, 1-25pc) 0.0, 0.1, 0.9;
  (Toxoplasmosis, 1-25pc) 0.0, 0.1, 0.9;
  (Tuberculosis, 1-25pc) 0.0, 0.1, 0.9;
  (Viral NOS, 1-25pc) 0.0, 0.1, 0.9;
  (Whipple's disease, 1-25pc) 0.0, 0.1, 0.9;
  (L&H nodular HD, 1-25pc) 0.0, 0.1, 0.9;
  (L&H diffuse HD, 1-25pc) 0.0, 0.1, 0.9;
  (Nodular sclerosis HD, 1-25pc) 0.0, 0.1, 0.9;
  (Cellular phase NSHD, 1-25pc) 0.0, 0.1, 0.9;
  (Syncytial NSHD, 1-25pc) 0.0, 0.1, 0.9;
  (Mixed cellularity HD, 1-25pc) 0.0, 0.1, 0.9;
  (Interfollicular HD, 1-25pc) 0.0, 0.1, 0.9;
  (Diffuse fibrosis HD, 1-25pc) 0.0, 0.1, 0.9;
  (Reticular-type HD, 1-25pc) 0.0, 0.1, 0.9;
  (Small cleaved fol, 1-25pc) 0.0, 0.8, 0.2;
  (Mixed fol, 1-25pc) 0.0, 0.8, 0.2;
  (Large cell fol, 1-25pc) 0.0, 0.9, 0.1;
  (Small noncleaved fol, 1-25pc) 0.00, 0.95, 0.05;
  (Small lymphocytic, 1-25pc) 0.0, 0.1, 0.9;
  (Plasmacytoid lyctic, 1-25pc) 0.0, 0.1, 0.9;
  (Mantle zone lymphoma, 1-25pc) 0.0, 0.0, 1.0;
  (Small cleaved dif, 1-25pc) 0.0, 0.1, 0.9;
  (Mixed FCC dif, 1-25pc) 0.0, 0.1, 0.9;
  (Large cell dif, 1-25pc) 0.0, 0.1, 0.9;
  (B-immunoblastic, 1-25pc) 0.0, 0.1, 0.9;
  (T-immunob mixed, 1-25pc) 0.0, 0.1, 0.9;
  (AILD-like T-cell lym, 1-25pc) 0.0, 0.1, 0.9;
  (Japanese ATL, 1-25pc) 0.0, 0.1, 0.9;
  (Lymphoblastic, 1-25pc) 0.0, 0.1, 0.9;
  (Small noncleaved dif, 1-25pc) 0.0, 0.1, 0.9;
  (True histiocytic, 1-25pc) 0.0, 0.1, 0.9;
  (Ki-1 LC anaplas T, 1-25pc) 0.0, 0.1, 0.9;
  (Multiple myeloma, 1-25pc) 0.0, 0.1, 0.9;
  (Mycosis fungoides, 1-25pc) 0.0, 0.1, 0.9;
  (AML, 1-25pc) 0.0, 0.1, 0.9;
  (Hairy cell leukemia, 1-25pc) 0.0, 0.1, 0.9;
  (Carcinoma, 1-25pc) 0.0, 0.1, 0.9;
  (Melanoma, 1-25pc) 0.0, 0.1, 0.9;
  (EM plasmacytoma, 1-25pc) 0.0, 0.1, 0.9;
  (Kaposi's sarcoma, 1-25pc) 0.0, 0.1, 0.9;
  (Mast-cell disease, 1-25pc) 0.0, 0.1, 0.9;
  (AIDS involutionary, 1-25pc) 0.0, 0.9, 0.1;
  (T-immunob large, 1-25pc) 0.0, 0.1, 0.9;
  (Monocytoid B-cell, 1-25pc) 0.00, 0.25, 0.75;
  (Nasopharyngeal CA, 1-25pc) 0.0, 0.1, 0.9;
  (Seminoma, 1-25pc) 0.0, 0.1, 0.9;
  (SLE, 1-25pc) 0.0, 0.1, 0.9;
  (Mycobact histiocytos, 1-25pc) 0.0, 0.9, 0.1;
  (Mast-cell hyperplas, 1-25pc) 0.0, 0.1, 0.9;
  (LGV, 1-25pc) 0.0, 0.1, 0.9;
  (Histoplasmosis, 1-25pc) 0.0, 0.9, 0.1;
  (Coccidioidomycosis, 1-25pc) 0.0, 0.9, 0.1;
  (CMV, 1-25pc) 0.0, 0.9, 0.1;
  (Brucellosis, 1-25pc) 0.0, 0.1, 0.9;
  (Ki-1 LC anaplas B, 1-25pc) 0.0, 0.1, 0.9;
  (Intermed lymphocytic, 1-25pc) 0.0, 0.0, 1.0;
  (AIDS early, 25-75pc) 0.00, 0.95, 0.05;
  (AILD, 25-75pc) 0.0, 0.1, 0.9;
  (ALIP, 25-75pc) 0.0, 0.1, 0.9;
  (Cat scratch disease, 25-75pc) 0.0, 0.1, 0.9;
  (Dermatopathic laden, 25-75pc) 0.0, 0.1, 0.9;
  (Florid follic hyperp, 25-75pc) 0.0, 0.9, 0.1;
  (GLH hyaline vascular, 25-75pc) 0.0, 0.0, 1.0;
  (GLH plasma cell, 25-75pc) 0.0, 0.1, 0.9;
  (Granulomatous laden, 25-75pc) 0.0, 0.1, 0.9;
  (Histiocytosis x, 25-75pc) 0.0, 0.1, 0.9;
  (Infectious mono, 25-75pc) 0.0, 0.1, 0.9;
  (Leprosy-lepromatous, 25-75pc) 0.0, 0.1, 0.9;
  (Lymphangiographic, 25-75pc) 0.0, 0.1, 0.9;
  (Mantle zone hyperpla, 25-75pc) 0.0, 0.0, 1.0;
  (Necrotizing Kikuchi, 25-75pc) 0.0, 0.1, 0.9;
  (Necrotiz non-Kikuchi, 25-75pc) 0.0, 0.1, 0.9;
  (Rheumatoid arthritis, 25-75pc) 0.0, 0.1, 0.9;
  (Sarcoidosis, 25-75pc) 0.0, 0.1, 0.9;
  (SHML, 25-75pc) 0.0, 0.1, 0.9;
  (Sinus histiocytosis, 25-75pc) 0.0, 0.1, 0.9;
  (Syphilis, 25-75pc) 0.0, 0.1, 0.9;
  (Toxoplasmosis, 25-75pc) 0.0, 0.1, 0.9;
  (Tuberculosis, 25-75pc) 0.0, 0.1, 0.9;
  (Viral NOS, 25-75pc) 0.0, 0.1, 0.9;
  (Whipple's disease, 25-75pc) 0.0, 0.1, 0.9;
  (L&H nodular HD, 25-75pc) 0.0, 0.1, 0.9;
  (L&H diffuse HD, 25-75pc) 0.0, 0.1, 0.9;
  (Nodular sclerosis HD, 25-75pc) 0.0, 0.1, 0.9;
  (Cellular phase NSHD, 25-75pc) 0.0, 0.1, 0.9;
  (Syncytial NSHD, 25-75pc) 0.0, 0.1, 0.9;
  (Mixed cellularity HD, 25-75pc) 0.0, 0.1, 0.9;
  (Interfollicular HD, 25-75pc) 0.0, 0.1, 0.9;
  (Diffuse fibrosis HD, 25-75pc) 0.0, 0.1, 0.9;
  (Reticular-type HD, 25-75pc) 0.0, 0.1, 0.9;
  (Small cleaved fol, 25-75pc) 0.0, 0.8, 0.2;
  (Mixed fol, 25-75pc) 0.0, 0.8, 0.2;
  (Large cell fol, 25-75pc) 0.0, 0.9, 0.1;
  (Small noncleaved fol, 25-75pc) 0.00, 0.95, 0.05;
  (Small lymphocytic, 25-75pc) 0.0, 0.1, 0.9;
  (Plasmacytoid lyctic, 25-75pc) 0.0, 0.1, 0.9;
  (Mantle zone lymphoma, 25-75pc) 0.0, 0.0, 1.0;
  (Small cleaved dif, 25-75pc) 0.0, 0.1, 0.9;
  (Mixed FCC dif, 25-75pc) 0.0, 0.1, 0.9;
  (Large cell dif, 25-75pc) 0.0, 0.1, 0.9;
  (B-immunoblastic, 25-75pc) 0.0, 0.1, 0.9;
  (T-immunob mixed, 25-75pc) 0.0, 0.1, 0.9;
  (AILD-like T-cell lym, 25-75pc) 0.0, 0.1, 0.9;
  (Japanese ATL, 25-75pc) 0.0, 0.1, 0.9;
  (Lymphoblastic, 25-75pc) 0.0, 0.1, 0.9;
  (Small noncleaved dif, 25-75pc) 0.0, 0.1, 0.9;
  (True histiocytic, 25-75pc) 0.0, 0.1, 0.9;
  (Ki-1 LC anaplas T, 25-75pc) 0.0, 0.1, 0.9;
  (Multiple myeloma, 25-75pc) 0.0, 0.1, 0.9;
  (Mycosis fungoides, 25-75pc) 0.0, 0.1, 0.9;
  (AML, 25-75pc) 0.0, 0.1, 0.9;
  (Hairy cell leukemia, 25-75pc) 0.0, 0.1, 0.9;
  (Carcinoma, 25-75pc) 0.0, 0.1, 0.9;
  (Melanoma, 25-75pc) 0.0, 0.1, 0.9;
  (EM plasmacytoma, 25-75pc) 0.0, 0.1, 0.9;
  (Kaposi's sarcoma, 25-75pc) 0.0, 0.1, 0.9;
  (Mast-cell disease, 25-75pc) 0.0, 0.1, 0.9;
  (AIDS involutionary, 25-75pc) 0.0, 0.9, 0.1;
  (T-immunob large, 25-75pc) 0.0, 0.1, 0.9;
  (Monocytoid B-cell, 25-75pc) 0.00, 0.25, 0.75;
  (Nasopharyngeal CA, 25-75pc) 0.0, 0.1, 0.9;
  (Seminoma, 25-75pc) 0.0, 0.1, 0.9;
  (SLE, 25-75pc) 0.0, 0.1, 0.9;
  (Mycobact histiocytos, 25-75pc) 0.0, 0.9, 0.1;
  (Mast-cell hyperplas, 25-75pc) 0.0, 0.1, 0.9;
  (LGV, 25-75pc) 0.0, 0.1, 0.9;
  (Histoplasmosis, 25-75pc) 0.0, 0.9, 0.1;
  (Coccidioidomycosis, 25-75pc) 0.0, 0.9, 0.1;
  (CMV, 25-75pc) 0.0, 0.9, 0.1;
  (Brucellosis, 25-75pc) 0.0, 0.1, 0.9;
  (Ki-1 LC anaplas B, 25-75pc) 0.0, 0.1, 0.9;
  (Intermed lymphocytic, 25-75pc) 0.3333333, 0.3333333, 0.3333333;
  (AIDS early, 75-90pc) 0.00, 0.95, 0.05;
  (AILD, 75-90pc) 0.0, 0.1, 0.9;
  (ALIP, 75-90pc) 0.0, 0.1, 0.9;
  (Cat scratch disease, 75-90pc) 0.0, 0.1, 0.9;
  (Dermatopathic laden, 75-90pc) 0.0, 0.1, 0.9;
  (Florid follic hyperp, 75-90pc) 0.0, 0.9, 0.1;
  (GLH hyaline vascular, 75-90pc) 0.0, 0.0, 1.0;
  (GLH plasma cell, 75-90pc) 0.0, 0.1, 0.9;
  (Granulomatous laden, 75-90pc) 0.0, 0.1, 0.9;
  (Histiocytosis x, 75-90pc) 0.0, 0.1, 0.9;
  (Infectious mono, 75-90pc) 0.0, 0.1, 0.9;
  (Leprosy-lepromatous, 75-90pc) 0.0, 0.1, 0.9;
  (Lymphangiographic, 75-90pc) 0.0, 0.1, 0.9;
  (Mantle zone hyperpla, 75-90pc) 0.0, 0.0, 1.0;
  (Necrotizing Kikuchi, 75-90pc) 0.0, 0.1, 0.9;
  (Necrotiz non-Kikuchi, 75-90pc) 0.0, 0.1, 0.9;
  (Rheumatoid arthritis, 75-90pc) 0.0, 0.1, 0.9;
  (Sarcoidosis, 75-90pc) 0.0, 0.1, 0.9;
  (SHML, 75-90pc) 0.0, 0.1, 0.9;
  (Sinus histiocytosis, 75-90pc) 0.0, 0.1, 0.9;
  (Syphilis, 75-90pc) 0.0, 0.1, 0.9;
  (Toxoplasmosis, 75-90pc) 0.0, 0.1, 0.9;
  (Tuberculosis, 75-90pc) 0.0, 0.1, 0.9;
  (Viral NOS, 75-90pc) 0.0, 0.1, 0.9;
  (Whipple's disease, 75-90pc) 0.0, 0.1, 0.9;
  (L&H nodular HD, 75-90pc) 0.0, 0.1, 0.9;
  (L&H diffuse HD, 75-90pc) 0.0, 0.1, 0.9;
  (Nodular sclerosis HD, 75-90pc) 0.0, 0.1, 0.9;
  (Cellular phase NSHD, 75-90pc) 0.0, 0.1, 0.9;
  (Syncytial NSHD, 75-90pc) 0.0, 0.1, 0.9;
  (Mixed cellularity HD, 75-90pc) 0.0, 0.1, 0.9;
  (Interfollicular HD, 75-90pc) 0.0, 0.1, 0.9;
  (Diffuse fibrosis HD, 75-90pc) 0.0, 0.1, 0.9;
  (Reticular-type HD, 75-90pc) 0.0, 0.1, 0.9;
  (Small cleaved fol, 75-90pc) 0.0, 0.8, 0.2;
  (Mixed fol, 75-90pc) 0.0, 0.8, 0.2;
  (Large cell fol, 75-90pc) 0.0, 0.9, 0.1;
  (Small noncleaved fol, 75-90pc) 0.00, 0.95, 0.05;
  (Small lymphocytic, 75-90pc) 0.0, 0.1, 0.9;
  (Plasmacytoid lyctic, 75-90pc) 0.0, 0.1, 0.9;
  (Mantle zone lymphoma, 75-90pc) 0.0, 0.0, 1.0;
  (Small cleaved dif, 75-90pc) 0.0, 0.1, 0.9;
  (Mixed FCC dif, 75-90pc) 0.0, 0.1, 0.9;
  (Large cell dif, 75-90pc) 0.0, 0.1, 0.9;
  (B-immunoblastic, 75-90pc) 0.0, 0.1, 0.9;
  (T-immunob mixed, 75-90pc) 0.0, 0.1, 0.9;
  (AILD-like T-cell lym, 75-90pc) 0.0, 0.1, 0.9;
  (Japanese ATL, 75-90pc) 0.0, 0.1, 0.9;
  (Lymphoblastic, 75-90pc) 0.0, 0.1, 0.9;
  (Small noncleaved dif, 75-90pc) 0.0, 0.1, 0.9;
  (True histiocytic, 75-90pc) 0.0, 0.1, 0.9;
  (Ki-1 LC anaplas T, 75-90pc) 0.0, 0.1, 0.9;
  (Multiple myeloma, 75-90pc) 0.0, 0.1, 0.9;
  (Mycosis fungoides, 75-90pc) 0.0, 0.1, 0.9;
  (AML, 75-90pc) 0.0, 0.1, 0.9;
  (Hairy cell leukemia, 75-90pc) 0.0, 0.1, 0.9;
  (Carcinoma, 75-90pc) 0.0, 0.1, 0.9;
  (Melanoma, 75-90pc) 0.0, 0.1, 0.9;
  (EM plasmacytoma, 75-90pc) 0.0, 0.1, 0.9;
  (Kaposi's sarcoma, 75-90pc) 0.0, 0.1, 0.9;
  (Mast-cell disease, 75-90pc) 0.0, 0.1, 0.9;
  (AIDS involutionary, 75-90pc) 0.0, 0.9, 0.1;
  (T-immunob large, 75-90pc) 0.0, 0.1, 0.9;
  (Monocytoid B-cell, 75-90pc) 0.00, 0.25, 0.75;
  (Nasopharyngeal CA, 75-90pc) 0.0, 0.1, 0.9;
  (Seminoma, 75-90pc) 0.0, 0.1, 0.9;
  (SLE, 75-90pc) 0.0, 0.1, 0.9;
  (Mycobact histiocytos, 75-90pc) 0.0, 0.9, 0.1;
  (Mast-cell hyperplas, 75-90pc) 0.0, 0.1, 0.9;
  (LGV, 75-90pc) 0.0, 0.1, 0.9;
  (Histoplasmosis, 75-90pc) 0.0, 0.9, 0.1;
  (Coccidioidomycosis, 75-90pc) 0.0, 0.9, 0.1;
  (CMV, 75-90pc) 0.0, 0.9, 0.1;
  (Brucellosis, 75-90pc) 0.0, 0.1, 0.9;
  (Ki-1 LC anaplas B, 75-90pc) 0.0, 0.1, 0.9;
  (Intermed lymphocytic, 75-90pc) 0.3333333, 0.3333333, 0.3333333;
  (AIDS early, >90pc) 0.00, 0.95, 0.05;
  (AILD, >90pc) 0.0, 0.1, 0.9;
  (ALIP, >90pc) 0.0, 0.1, 0.9;
  (Cat scratch disease, >90pc) 0.0, 0.1, 0.9;
  (Dermatopathic laden, >90pc) 0.0, 0.1, 0.9;
  (Florid follic hyperp, >90pc) 0.0, 0.9, 0.1;
  (GLH hyaline vascular, >90pc) 0.0, 0.0, 1.0;
  (GLH plasma cell, >90pc) 0.0, 0.1, 0.9;
  (Granulomatous laden, >90pc) 0.0, 0.1, 0.9;
  (Histiocytosis x, >90pc) 0.0, 0.1, 0.9;
  (Infectious mono, >90pc) 0.0, 0.1, 0.9;
  (Leprosy-lepromatous, >90pc) 0.0, 0.1, 0.9;
  (Lymphangiographic, >90pc) 0.0, 0.1, 0.9;
  (Mantle zone hyperpla, >90pc) 0.0, 0.0, 1.0;
  (Necrotizing Kikuchi, >90pc) 0.0, 0.1, 0.9;
  (Necrotiz non-Kikuchi, >90pc) 0.0, 0.1, 0.9;
  (Rheumatoid arthritis, >90pc) 0.0, 0.1, 0.9;
  (Sarcoidosis, >90pc) 0.0, 0.1, 0.9;
  (SHML, >90pc) 0.0, 0.1, 0.9;
  (Sinus histiocytosis, >90pc) 0.0, 0.1, 0.9;
  (Syphilis, >90pc) 0.0, 0.1, 0.9;
  (Toxoplasmosis, >90pc) 0.0, 0.1, 0.9;
  (Tuberculosis, >90pc) 0.0, 0.1, 0.9;
  (Viral NOS, >90pc) 0.0, 0.1, 0.9;
  (Whipple's disease, >90pc) 0.0, 0.1, 0.9;
  (L&H nodular HD, >90pc) 0.0, 0.1, 0.9;
  (L&H diffuse HD, >90pc) 0.0, 0.1, 0.9;
  (Nodular sclerosis HD, >90pc) 0.0, 0.1, 0.9;
  (Cellular phase NSHD, >90pc) 0.0, 0.1, 0.9;
  (Syncytial NSHD, >90pc) 0.0, 0.1, 0.9;
  (Mixed cellularity HD, >90pc) 0.0, 0.1, 0.9;
  (Interfollicular HD, >90pc) 0.0, 0.1, 0.9;
  (Diffuse fibrosis HD, >90pc) 0.0, 0.1, 0.9;
  (Reticular-type HD, >90pc) 0.0, 0.1, 0.9;
  (Small cleaved fol, >90pc) 0.0, 0.8, 0.2;
  (Mixed fol, >90pc) 0.0, 0.8, 0.2;
  (Large cell fol, >90pc) 0.0, 0.9, 0.1;
  (Small noncleaved fol, >90pc) 0.00, 0.95, 0.05;
  (Small lymphocytic, >90pc) 0.0, 0.1, 0.9;
  (Plasmacytoid lyctic, >90pc) 0.0, 0.1, 0.9;
  (Mantle zone lymphoma, >90pc) 0.3333333, 0.3333333, 0.3333333;
  (Small cleaved dif, >90pc) 0.0, 0.1, 0.9;
  (Mixed FCC dif, >90pc) 0.0, 0.1, 0.9;
  (Large cell dif, >90pc) 0.0, 0.1, 0.9;
  (B-immunoblastic, >90pc) 0.0, 0.1, 0.9;
  (T-immunob mixed, >90pc) 0.0, 0.1, 0.9;
  (AILD-like T-cell lym, >90pc) 0.0, 0.1, 0.9;
  (Japanese ATL, >90pc) 0.0, 0.1, 0.9;
  (Lymphoblastic, >90pc) 0.0, 0.1, 0.9;
  (Small noncleaved dif, >90pc) 0.0, 0.1, 0.9;
  (True histiocytic, >90pc) 0.0, 0.1, 0.9;
  (Ki-1 LC anaplas T, >90pc) 0.0, 0.1, 0.9;
  (Multiple myeloma, >90pc) 0.0, 0.1, 0.9;
  (Mycosis fungoides, >90pc) 0.0, 0.1, 0.9;
  (AML, >90pc) 0.0, 0.1, 0.9;
  (Hairy cell leukemia, >90pc) 0.0, 0.1, 0.9;
  (Carcinoma, >90pc) 0.0, 0.1, 0.9;
  (Melanoma, >90pc) 0.0, 0.1, 0.9;
  (EM plasmacytoma, >90pc) 0.0, 0.1, 0.9;
  (Kaposi's sarcoma, >90pc) 0.0, 0.1, 0.9;
  (Mast-cell disease, >90pc) 0.0, 0.1, 0.9;
  (AIDS involutionary, >90pc) 0.0, 0.9, 0.1;
  (T-immunob large, >90pc) 0.0, 0.1, 0.9;
  (Monocytoid B-cell, >90pc) 0.00, 0.25, 0.75;
  (Nasopharyngeal CA, >90pc) 0.0, 0.1, 0.9;
  (Seminoma, >90pc) 0.0, 0.1, 0.9;
  (SLE, >90pc) 0.0, 0.1, 0.9;
  (Mycobact histiocytos, >90pc) 0.0, 0.9, 0.1;
  (Mast-cell hyperplas, >90pc) 0.0, 0.1, 0.9;
  (LGV, >90pc) 0.0, 0.1, 0.9;
  (Histoplasmosis, >90pc) 0.0, 0.9, 0.1;
  (Coccidioidomycosis, >90pc) 0.0, 0.9, 0.1;
  (CMV, >90pc) 0.0, 0.9, 0.1;
  (Brucellosis, >90pc) 0.0, 0.1, 0.9;
  (Ki-1 LC anaplas B, >90pc) 0.0, 0.1, 0.9;
  (Intermed lymphocytic, >90pc) 0.3333333, 0.3333333, 0.3333333;
}
probability ( F_CIO | Fault, FOLLICLE ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (AILD, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (ALIP, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Cat scratch disease, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Dermatopathic laden, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Florid follic hyperp, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (GLH hyaline vascular, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (GLH plasma cell, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Granulomatous laden, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Histiocytosis x, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Infectious mono, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Leprosy-lepromatous, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Lymphangiographic, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Mantle zone hyperpla, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Necrotizing Kikuchi, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Necrotiz non-Kikuchi, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Rheumatoid arthritis, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Sarcoidosis, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (SHML, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Sinus histiocytosis, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Syphilis, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Toxoplasmosis, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Tuberculosis, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Viral NOS, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Whipple's disease, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (L&H nodular HD, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (L&H diffuse HD, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Nodular sclerosis HD, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Cellular phase NSHD, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Syncytial NSHD, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Mixed cellularity HD, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Interfollicular HD, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Diffuse fibrosis HD, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Reticular-type HD, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Small cleaved fol, 1-25pc) 0.0, 0.5, 0.4, 0.1;
  (Mixed fol, 1-25pc) 0.0, 0.5, 0.4, 0.1;
  (Large cell fol, 1-25pc) 0.00, 0.80, 0.15, 0.05;
  (Small noncleaved fol, 1-25pc) 0.00, 0.90, 0.08, 0.02;
  (Small lymphocytic, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Plasmacytoid lyctic, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Mantle zone lymphoma, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Small cleaved dif, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Mixed FCC dif, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Large cell dif, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (B-immunoblastic, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (T-immunob mixed, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (AILD-like T-cell lym, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Japanese ATL, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Lymphoblastic, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Small noncleaved dif, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (True histiocytic, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Ki-1 LC anaplas T, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Multiple myeloma, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Mycosis fungoides, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (AML, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Hairy cell leukemia, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Carcinoma, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Melanoma, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (EM plasmacytoma, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Kaposi's sarcoma, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Mast-cell disease, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (AIDS involutionary, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (T-immunob large, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Monocytoid B-cell, 1-25pc) 0.00, 0.05, 0.03, 0.92;
  (Nasopharyngeal CA, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Seminoma, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (SLE, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Mycobact histiocytos, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Mast-cell hyperplas, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (LGV, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Histoplasmosis, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Coccidioidomycosis, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (CMV, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Brucellosis, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Ki-1 LC anaplas B, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (Intermed lymphocytic, 1-25pc) 0.0, 0.0, 0.1, 0.9;
  (AIDS early, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (AILD, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (ALIP, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Cat scratch disease, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Dermatopathic laden, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Florid follic hyperp, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (GLH hyaline vascular, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (GLH plasma cell, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Granulomatous laden, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Histiocytosis x, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Infectious mono, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Leprosy-lepromatous, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Lymphangiographic, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Mantle zone hyperpla, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Necrotizing Kikuchi, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Necrotiz non-Kikuchi, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Rheumatoid arthritis, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Sarcoidosis, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (SHML, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Sinus histiocytosis, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Syphilis, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Toxoplasmosis, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Tuberculosis, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Viral NOS, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Whipple's disease, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (L&H nodular HD, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (L&H diffuse HD, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Nodular sclerosis HD, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Cellular phase NSHD, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Syncytial NSHD, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Mixed cellularity HD, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Interfollicular HD, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Diffuse fibrosis HD, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Reticular-type HD, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Small cleaved fol, 25-75pc) 0.0, 0.5, 0.4, 0.1;
  (Mixed fol, 25-75pc) 0.0, 0.5, 0.4, 0.1;
  (Large cell fol, 25-75pc) 0.00, 0.80, 0.15, 0.05;
  (Small noncleaved fol, 25-75pc) 0.00, 0.90, 0.08, 0.02;
  (Small lymphocytic, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Plasmacytoid lyctic, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Mantle zone lymphoma, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Small cleaved dif, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Mixed FCC dif, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Large cell dif, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (B-immunoblastic, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (T-immunob mixed, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (AILD-like T-cell lym, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Japanese ATL, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Lymphoblastic, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Small noncleaved dif, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (True histiocytic, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Ki-1 LC anaplas T, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Multiple myeloma, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Mycosis fungoides, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (AML, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Hairy cell leukemia, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Carcinoma, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Melanoma, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (EM plasmacytoma, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Kaposi's sarcoma, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Mast-cell disease, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (AIDS involutionary, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (T-immunob large, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Monocytoid B-cell, 25-75pc) 0.00, 0.05, 0.03, 0.92;
  (Nasopharyngeal CA, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Seminoma, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (SLE, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Mycobact histiocytos, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Mast-cell hyperplas, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (LGV, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Histoplasmosis, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Coccidioidomycosis, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (CMV, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Brucellosis, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Ki-1 LC anaplas B, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (Intermed lymphocytic, 25-75pc) 0.0, 0.0, 0.1, 0.9;
  (AIDS early, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (AILD, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (ALIP, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Cat scratch disease, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Dermatopathic laden, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Florid follic hyperp, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (GLH hyaline vascular, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (GLH plasma cell, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Granulomatous laden, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Histiocytosis x, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Infectious mono, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Leprosy-lepromatous, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Lymphangiographic, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Mantle zone hyperpla, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Necrotizing Kikuchi, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Necrotiz non-Kikuchi, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Rheumatoid arthritis, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Sarcoidosis, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (SHML, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Sinus histiocytosis, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Syphilis, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Toxoplasmosis, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Tuberculosis, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Viral NOS, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Whipple's disease, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (L&H nodular HD, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (L&H diffuse HD, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Nodular sclerosis HD, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Cellular phase NSHD, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Syncytial NSHD, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Mixed cellularity HD, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Interfollicular HD, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Diffuse fibrosis HD, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Reticular-type HD, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Small cleaved fol, 75-90pc) 0.0, 0.5, 0.4, 0.1;
  (Mixed fol, 75-90pc) 0.0, 0.5, 0.4, 0.1;
  (Large cell fol, 75-90pc) 0.00, 0.80, 0.13, 0.07;
  (Small noncleaved fol, 75-90pc) 0.00, 0.85, 0.10, 0.05;
  (Small lymphocytic, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Plasmacytoid lyctic, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Mantle zone lymphoma, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Small cleaved dif, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Mixed FCC dif, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Large cell dif, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (B-immunoblastic, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (T-immunob mixed, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (AILD-like T-cell lym, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Japanese ATL, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Lymphoblastic, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Small noncleaved dif, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (True histiocytic, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Ki-1 LC anaplas T, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Multiple myeloma, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Mycosis fungoides, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (AML, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Hairy cell leukemia, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Carcinoma, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Melanoma, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (EM plasmacytoma, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Kaposi's sarcoma, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Mast-cell disease, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (AIDS involutionary, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (T-immunob large, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Monocytoid B-cell, 75-90pc) 0.00, 0.05, 0.03, 0.92;
  (Nasopharyngeal CA, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Seminoma, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (SLE, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Mycobact histiocytos, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Mast-cell hyperplas, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (LGV, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Histoplasmosis, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Coccidioidomycosis, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (CMV, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Brucellosis, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Ki-1 LC anaplas B, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (Intermed lymphocytic, 75-90pc) 0.0, 0.0, 0.1, 0.9;
  (AIDS early, >90pc) 0.0, 0.0, 0.1, 0.9;
  (AILD, >90pc) 0.0, 0.0, 0.1, 0.9;
  (ALIP, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Cat scratch disease, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Dermatopathic laden, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Florid follic hyperp, >90pc) 0.0, 0.0, 0.1, 0.9;
  (GLH hyaline vascular, >90pc) 0.0, 0.0, 0.1, 0.9;
  (GLH plasma cell, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Granulomatous laden, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Histiocytosis x, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Infectious mono, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Leprosy-lepromatous, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Lymphangiographic, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Mantle zone hyperpla, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Necrotizing Kikuchi, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Necrotiz non-Kikuchi, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Rheumatoid arthritis, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Sarcoidosis, >90pc) 0.0, 0.0, 0.1, 0.9;
  (SHML, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Sinus histiocytosis, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Syphilis, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Toxoplasmosis, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Tuberculosis, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Viral NOS, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Whipple's disease, >90pc) 0.0, 0.0, 0.1, 0.9;
  (L&H nodular HD, >90pc) 0.0, 0.0, 0.1, 0.9;
  (L&H diffuse HD, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Nodular sclerosis HD, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Cellular phase NSHD, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Syncytial NSHD, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Mixed cellularity HD, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Interfollicular HD, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Diffuse fibrosis HD, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Reticular-type HD, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Small cleaved fol, >90pc) 0.0, 0.5, 0.4, 0.1;
  (Mixed fol, >90pc) 0.0, 0.5, 0.4, 0.1;
  (Large cell fol, >90pc) 0.0, 0.7, 0.2, 0.1;
  (Small noncleaved fol, >90pc) 0.00, 0.85, 0.10, 0.05;
  (Small lymphocytic, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Plasmacytoid lyctic, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Mantle zone lymphoma, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Small cleaved dif, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Mixed FCC dif, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Large cell dif, >90pc) 0.0, 0.0, 0.1, 0.9;
  (B-immunoblastic, >90pc) 0.0, 0.0, 0.1, 0.9;
  (T-immunob mixed, >90pc) 0.0, 0.0, 0.1, 0.9;
  (AILD-like T-cell lym, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Japanese ATL, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Lymphoblastic, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Small noncleaved dif, >90pc) 0.0, 0.0, 0.1, 0.9;
  (True histiocytic, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Ki-1 LC anaplas T, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Multiple myeloma, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Mycosis fungoides, >90pc) 0.0, 0.0, 0.1, 0.9;
  (AML, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Hairy cell leukemia, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Carcinoma, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Melanoma, >90pc) 0.0, 0.0, 0.1, 0.9;
  (EM plasmacytoma, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Kaposi's sarcoma, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Mast-cell disease, >90pc) 0.0, 0.0, 0.1, 0.9;
  (AIDS involutionary, >90pc) 0.0, 0.0, 0.1, 0.9;
  (T-immunob large, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Monocytoid B-cell, >90pc) 0.00, 0.07, 0.03, 0.90;
  (Nasopharyngeal CA, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Seminoma, >90pc) 0.0, 0.0, 0.1, 0.9;
  (SLE, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Mycobact histiocytos, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Mast-cell hyperplas, >90pc) 0.0, 0.0, 0.1, 0.9;
  (LGV, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Histoplasmosis, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Coccidioidomycosis, >90pc) 0.0, 0.0, 0.1, 0.9;
  (CMV, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Brucellosis, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Ki-1 LC anaplas B, >90pc) 0.0, 0.0, 0.1, 0.9;
  (Intermed lymphocytic, >90pc) 0.0, 0.0, 0.1, 0.9;
}
probability ( LLC_KL | Fault, LLC_ID ) {
  (AIDS early, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (AILD, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (ALIP, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (SHML, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (AML, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (SLE, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (LGV, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (CMV, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, No LLCs) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, Other) 0.0, 0.1, 0.0, 0.9;
  (AILD, Other) 0.0, 0.1, 0.0, 0.9;
  (ALIP, Other) 0.0, 0.1, 0.0, 0.9;
  (Cat scratch disease, Other) 0.0, 0.1, 0.0, 0.9;
  (Dermatopathic laden, Other) 0.0, 0.1, 0.0, 0.9;
  (Florid follic hyperp, Other) 0.0, 0.1, 0.0, 0.9;
  (GLH hyaline vascular, Other) 0.0, 0.1, 0.0, 0.9;
  (GLH plasma cell, Other) 0.0, 0.1, 0.0, 0.9;
  (Granulomatous laden, Other) 0.0, 0.1, 0.0, 0.9;
  (Histiocytosis x, Other) 0.0, 0.1, 0.0, 0.9;
  (Infectious mono, Other) 0.0, 0.1, 0.0, 0.9;
  (Leprosy-lepromatous, Other) 0.0, 0.1, 0.0, 0.9;
  (Lymphangiographic, Other) 0.0, 0.1, 0.0, 0.9;
  (Mantle zone hyperpla, Other) 0.0, 0.1, 0.0, 0.9;
  (Necrotizing Kikuchi, Other) 0.0, 0.1, 0.0, 0.9;
  (Necrotiz non-Kikuchi, Other) 0.0, 0.1, 0.0, 0.9;
  (Rheumatoid arthritis, Other) 0.0, 0.1, 0.0, 0.9;
  (Sarcoidosis, Other) 0.0, 0.1, 0.0, 0.9;
  (SHML, Other) 0.0, 0.1, 0.0, 0.9;
  (Sinus histiocytosis, Other) 0.0, 0.1, 0.0, 0.9;
  (Syphilis, Other) 0.0, 0.1, 0.0, 0.9;
  (Toxoplasmosis, Other) 0.0, 0.1, 0.0, 0.9;
  (Tuberculosis, Other) 0.0, 0.1, 0.0, 0.9;
  (Viral NOS, Other) 0.0, 0.1, 0.0, 0.9;
  (Whipple's disease, Other) 0.0, 0.1, 0.0, 0.9;
  (L&H nodular HD, Other) 0.0, 0.1, 0.0, 0.9;
  (L&H diffuse HD, Other) 0.0, 0.1, 0.0, 0.9;
  (Nodular sclerosis HD, Other) 0.0, 0.1, 0.0, 0.9;
  (Cellular phase NSHD, Other) 0.0, 0.1, 0.0, 0.9;
  (Syncytial NSHD, Other) 0.0, 0.1, 0.0, 0.9;
  (Mixed cellularity HD, Other) 0.0, 0.1, 0.0, 0.9;
  (Interfollicular HD, Other) 0.0, 0.1, 0.0, 0.9;
  (Diffuse fibrosis HD, Other) 0.0, 0.1, 0.0, 0.9;
  (Reticular-type HD, Other) 0.0, 0.1, 0.0, 0.9;
  (Small cleaved fol, Other) 0.000, 0.050, 0.094, 0.856;
  (Mixed fol, Other) 0.000, 0.050, 0.094, 0.856;
  (Large cell fol, Other) 0.000, 0.050, 0.094, 0.856;
  (Small noncleaved fol, Other) 0.000, 0.050, 0.094, 0.856;
  (Small lymphocytic, Other) 0.00, 0.15, 0.84, 0.01;
  (Plasmacytoid lyctic, Other) 0.00, 0.15, 0.84, 0.01;
  (Mantle zone lymphoma, Other) 0.00, 0.05, 0.94, 0.01;
  (Small cleaved dif, Other) 0.00, 0.15, 0.84, 0.01;
  (Mixed FCC dif, Other) 0.00, 0.15, 0.84, 0.01;
  (Large cell dif, Other) 0.00, 0.15, 0.84, 0.01;
  (B-immunoblastic, Other) 0.00, 0.15, 0.84, 0.01;
  (T-immunob mixed, Other) 0.00, 0.99, 0.00, 0.01;
  (AILD-like T-cell lym, Other) 0.00, 0.99, 0.00, 0.01;
  (Japanese ATL, Other) 0.00, 0.99, 0.00, 0.01;
  (Lymphoblastic, Other) 0.00, 0.99, 0.00, 0.01;
  (Small noncleaved dif, Other) 0.00, 0.15, 0.84, 0.01;
  (True histiocytic, Other) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas T, Other) 0.00, 0.99, 0.00, 0.01;
  (Multiple myeloma, Other) 0.00, 0.15, 0.84, 0.01;
  (Mycosis fungoides, Other) 0.0, 0.1, 0.0, 0.9;
  (AML, Other) 0.0, 0.1, 0.0, 0.9;
  (Hairy cell leukemia, Other) 0.0, 0.1, 0.0, 0.9;
  (Carcinoma, Other) 0.0, 0.1, 0.0, 0.9;
  (Melanoma, Other) 0.0, 0.1, 0.0, 0.9;
  (EM plasmacytoma, Other) 0.00, 0.04, 0.95, 0.01;
  (Kaposi's sarcoma, Other) 0.0, 0.1, 0.0, 0.9;
  (Mast-cell disease, Other) 0.0, 0.1, 0.0, 0.9;
  (AIDS involutionary, Other) 0.0, 0.1, 0.0, 0.9;
  (T-immunob large, Other) 0.00, 0.99, 0.00, 0.01;
  (Monocytoid B-cell, Other) 0.00, 0.15, 0.84, 0.01;
  (Nasopharyngeal CA, Other) 0.0, 0.1, 0.0, 0.9;
  (Seminoma, Other) 0.0, 0.1, 0.0, 0.9;
  (SLE, Other) 0.0, 0.1, 0.0, 0.9;
  (Mycobact histiocytos, Other) 0.0, 0.1, 0.0, 0.9;
  (Mast-cell hyperplas, Other) 0.0, 0.1, 0.0, 0.9;
  (LGV, Other) 0.0, 0.1, 0.0, 0.9;
  (Histoplasmosis, Other) 0.0, 0.1, 0.0, 0.9;
  (Coccidioidomycosis, Other) 0.0, 0.1, 0.0, 0.9;
  (CMV, Other) 0.0, 0.1, 0.0, 0.9;
  (Brucellosis, Other) 0.0, 0.1, 0.0, 0.9;
  (Ki-1 LC anaplas B, Other) 0.00, 0.15, 0.84, 0.01;
  (Intermed lymphocytic, Other) 0.00, 0.05, 0.94, 0.01;
  (AIDS early, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (AILD, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (ALIP, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Cat scratch disease, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Dermatopathic laden, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Florid follic hyperp, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (GLH hyaline vascular, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (GLH plasma cell, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Granulomatous laden, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Histiocytosis x, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Infectious mono, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Leprosy-lepromatous, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Lymphangiographic, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Mantle zone hyperpla, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Necrotizing Kikuchi, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Necrotiz non-Kikuchi, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Rheumatoid arthritis, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Sarcoidosis, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (SHML, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Sinus histiocytosis, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Syphilis, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Toxoplasmosis, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Tuberculosis, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Viral NOS, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Whipple's disease, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (L&H nodular HD, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (L&H diffuse HD, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Nodular sclerosis HD, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Cellular phase NSHD, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Syncytial NSHD, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Mixed cellularity HD, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Interfollicular HD, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Diffuse fibrosis HD, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Reticular-type HD, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Small cleaved fol, Large cleaved) 0.0, 0.3, 0.7, 0.0;
  (Mixed fol, Large cleaved) 0.0, 0.3, 0.7, 0.0;
  (Large cell fol, Large cleaved) 0.0, 0.3, 0.7, 0.0;
  (Small noncleaved fol, Large cleaved) 0.0, 0.3, 0.7, 0.0;
  (Small lymphocytic, Large cleaved) 0.0, 0.3, 0.7, 0.0;
  (Plasmacytoid lyctic, Large cleaved) 0.0, 0.3, 0.7, 0.0;
  (Mantle zone lymphoma, Large cleaved) 0.0, 0.3, 0.7, 0.0;
  (Small cleaved dif, Large cleaved) 0.0, 0.3, 0.7, 0.0;
  (Mixed FCC dif, Large cleaved) 0.0, 0.3, 0.7, 0.0;
  (Large cell dif, Large cleaved) 0.0, 0.3, 0.7, 0.0;
  (B-immunoblastic, Large cleaved) 0.0, 0.3, 0.7, 0.0;
  (T-immunob mixed, Large cleaved) 0.000, 0.995, 0.000, 0.005;
  (AILD-like T-cell lym, Large cleaved) 0.000, 0.995, 0.000, 0.005;
  (Japanese ATL, Large cleaved) 0.000, 0.995, 0.000, 0.005;
  (Lymphoblastic, Large cleaved) 0.000, 0.995, 0.000, 0.005;
  (Small noncleaved dif, Large cleaved) 0.0, 0.3, 0.7, 0.0;
  (True histiocytic, Large cleaved) 0.000, 0.995, 0.000, 0.005;
  (Ki-1 LC anaplas T, Large cleaved) 0.000, 0.995, 0.000, 0.005;
  (Multiple myeloma, Large cleaved) 0.0, 0.3, 0.7, 0.0;
  (Mycosis fungoides, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (AML, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Hairy cell leukemia, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Carcinoma, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Melanoma, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (EM plasmacytoma, Large cleaved) 0.00, 0.04, 0.95, 0.01;
  (Kaposi's sarcoma, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Mast-cell disease, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (AIDS involutionary, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (T-immunob large, Large cleaved) 0.000, 0.995, 0.000, 0.005;
  (Monocytoid B-cell, Large cleaved) 0.0, 0.3, 0.7, 0.0;
  (Nasopharyngeal CA, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Seminoma, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (SLE, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Mycobact histiocytos, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Mast-cell hyperplas, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (LGV, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Histoplasmosis, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Coccidioidomycosis, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (CMV, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Brucellosis, Large cleaved) 0.0, 0.1, 0.0, 0.9;
  (Ki-1 LC anaplas B, Large cleaved) 0.0, 0.3, 0.7, 0.0;
  (Intermed lymphocytic, Large cleaved) 0.0, 0.3, 0.7, 0.0;
  (AIDS early, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (AILD, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (ALIP, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Cat scratch disease, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Dermatopathic laden, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Florid follic hyperp, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (GLH hyaline vascular, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (GLH plasma cell, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Granulomatous laden, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Histiocytosis x, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Infectious mono, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Leprosy-lepromatous, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Lymphangiographic, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Mantle zone hyperpla, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Necrotizing Kikuchi, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Necrotiz non-Kikuchi, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Rheumatoid arthritis, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Sarcoidosis, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (SHML, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Sinus histiocytosis, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Syphilis, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Toxoplasmosis, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Tuberculosis, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Viral NOS, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Whipple's disease, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (L&H nodular HD, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (L&H diffuse HD, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Nodular sclerosis HD, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Cellular phase NSHD, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Syncytial NSHD, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Mixed cellularity HD, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Interfollicular HD, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Diffuse fibrosis HD, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Reticular-type HD, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Small cleaved fol, Large noncleaved) 0.0, 0.3, 0.7, 0.0;
  (Mixed fol, Large noncleaved) 0.0, 0.3, 0.7, 0.0;
  (Large cell fol, Large noncleaved) 0.0, 0.3, 0.7, 0.0;
  (Small noncleaved fol, Large noncleaved) 0.0, 0.3, 0.7, 0.0;
  (Small lymphocytic, Large noncleaved) 0.0, 0.3, 0.7, 0.0;
  (Plasmacytoid lyctic, Large noncleaved) 0.0, 0.3, 0.7, 0.0;
  (Mantle zone lymphoma, Large noncleaved) 0.0, 0.3, 0.7, 0.0;
  (Small cleaved dif, Large noncleaved) 0.0, 0.3, 0.7, 0.0;
  (Mixed FCC dif, Large noncleaved) 0.0, 0.3, 0.7, 0.0;
  (Large cell dif, Large noncleaved) 0.0, 0.3, 0.7, 0.0;
  (B-immunoblastic, Large noncleaved) 0.0, 0.3, 0.7, 0.0;
  (T-immunob mixed, Large noncleaved) 0.000, 0.995, 0.000, 0.005;
  (AILD-like T-cell lym, Large noncleaved) 0.000, 0.995, 0.000, 0.005;
  (Japanese ATL, Large noncleaved) 0.000, 0.995, 0.000, 0.005;
  (Lymphoblastic, Large noncleaved) 0.000, 0.995, 0.000, 0.005;
  (Small noncleaved dif, Large noncleaved) 0.0, 0.3, 0.7, 0.0;
  (True histiocytic, Large noncleaved) 0.000, 0.995, 0.000, 0.005;
  (Ki-1 LC anaplas T, Large noncleaved) 0.000, 0.995, 0.000, 0.005;
  (Multiple myeloma, Large noncleaved) 0.0, 0.3, 0.7, 0.0;
  (Mycosis fungoides, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (AML, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Hairy cell leukemia, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Carcinoma, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Melanoma, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (EM plasmacytoma, Large noncleaved) 0.00, 0.04, 0.95, 0.01;
  (Kaposi's sarcoma, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Mast-cell disease, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (AIDS involutionary, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (T-immunob large, Large noncleaved) 0.000, 0.995, 0.000, 0.005;
  (Monocytoid B-cell, Large noncleaved) 0.0, 0.3, 0.7, 0.0;
  (Nasopharyngeal CA, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Seminoma, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (SLE, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Mycobact histiocytos, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Mast-cell hyperplas, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (LGV, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Histoplasmosis, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Coccidioidomycosis, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (CMV, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Brucellosis, Large noncleaved) 0.0, 0.1, 0.0, 0.9;
  (Ki-1 LC anaplas B, Large noncleaved) 0.0, 0.3, 0.7, 0.0;
  (Intermed lymphocytic, Large noncleaved) 0.0, 0.3, 0.7, 0.0;
}
probability ( PLAS_KL | Fault, PLASMA ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (AILD, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (ALIP, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Cat scratch disease, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Dermatopathic laden, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Florid follic hyperp, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (GLH hyaline vascular, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (GLH plasma cell, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Granulomatous laden, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Histiocytosis x, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Infectious mono, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Leprosy-lepromatous, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Lymphangiographic, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Mantle zone hyperpla, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Necrotizing Kikuchi, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Necrotiz non-Kikuchi, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Rheumatoid arthritis, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Sarcoidosis, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (SHML, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Sinus histiocytosis, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Syphilis, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Toxoplasmosis, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Tuberculosis, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Viral NOS, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Whipple's disease, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (L&H nodular HD, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (L&H diffuse HD, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Nodular sclerosis HD, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Cellular phase NSHD, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Syncytial NSHD, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Mixed cellularity HD, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Interfollicular HD, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Diffuse fibrosis HD, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Reticular-type HD, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Small cleaved fol, Few [<5pc]) 0.00, 0.97, 0.02, 0.01;
  (Mixed fol, Few [<5pc]) 0.00, 0.97, 0.02, 0.01;
  (Large cell fol, Few [<5pc]) 0.00, 0.97, 0.02, 0.01;
  (Small noncleaved fol, Few [<5pc]) 0.00, 0.97, 0.02, 0.01;
  (Small lymphocytic, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Plasmacytoid lyctic, Few [<5pc]) 0.0, 0.0, 1.0, 0.0;
  (Mantle zone lymphoma, Few [<5pc]) 0.00, 0.98, 0.01, 0.01;
  (Small cleaved dif, Few [<5pc]) 0.00, 0.97, 0.02, 0.01;
  (Mixed FCC dif, Few [<5pc]) 0.00, 0.89, 0.10, 0.01;
  (Large cell dif, Few [<5pc]) 0.00, 0.97, 0.02, 0.01;
  (B-immunoblastic, Few [<5pc]) 0.00, 0.88, 0.10, 0.02;
  (T-immunob mixed, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (AILD-like T-cell lym, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Japanese ATL, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Lymphoblastic, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Small noncleaved dif, Few [<5pc]) 0.00, 0.97, 0.02, 0.01;
  (True histiocytic, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas T, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Multiple myeloma, Few [<5pc]) 0.00, 0.01, 0.95, 0.04;
  (Mycosis fungoides, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (AML, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Hairy cell leukemia, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Carcinoma, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Melanoma, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (EM plasmacytoma, Few [<5pc]) 0.0, 0.0, 1.0, 0.0;
  (Kaposi's sarcoma, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Mast-cell disease, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (AIDS involutionary, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (T-immunob large, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Monocytoid B-cell, Few [<5pc]) 0.00, 0.35, 0.64, 0.01;
  (Nasopharyngeal CA, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Seminoma, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (SLE, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Mycobact histiocytos, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Mast-cell hyperplas, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (LGV, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Histoplasmosis, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Coccidioidomycosis, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (CMV, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Brucellosis, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas B, Few [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Intermed lymphocytic, Few [<5pc]) 0.00, 0.98, 0.01, 0.01;
  (AIDS early, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (AILD, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (ALIP, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Cat scratch disease, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Dermatopathic laden, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Florid follic hyperp, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (GLH hyaline vascular, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (GLH plasma cell, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Granulomatous laden, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Histiocytosis x, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Infectious mono, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Leprosy-lepromatous, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Lymphangiographic, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Mantle zone hyperpla, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Necrotizing Kikuchi, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Necrotiz non-Kikuchi, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Rheumatoid arthritis, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Sarcoidosis, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (SHML, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Sinus histiocytosis, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Syphilis, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Toxoplasmosis, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Tuberculosis, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Viral NOS, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Whipple's disease, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (L&H nodular HD, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (L&H diffuse HD, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Nodular sclerosis HD, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Cellular phase NSHD, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Syncytial NSHD, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Mixed cellularity HD, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Interfollicular HD, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Diffuse fibrosis HD, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Reticular-type HD, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Small cleaved fol, Moderate [6-20pc]) 0.00, 0.97, 0.02, 0.01;
  (Mixed fol, Moderate [6-20pc]) 0.00, 0.97, 0.02, 0.01;
  (Large cell fol, Moderate [6-20pc]) 0.00, 0.97, 0.02, 0.01;
  (Small noncleaved fol, Moderate [6-20pc]) 0.00, 0.97, 0.02, 0.01;
  (Small lymphocytic, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Plasmacytoid lyctic, Moderate [6-20pc]) 0.0, 0.0, 1.0, 0.0;
  (Mantle zone lymphoma, Moderate [6-20pc]) 0.00, 0.98, 0.01, 0.01;
  (Small cleaved dif, Moderate [6-20pc]) 0.00, 0.97, 0.02, 0.01;
  (Mixed FCC dif, Moderate [6-20pc]) 0.00, 0.89, 0.10, 0.01;
  (Large cell dif, Moderate [6-20pc]) 0.00, 0.97, 0.02, 0.01;
  (B-immunoblastic, Moderate [6-20pc]) 0.00, 0.88, 0.10, 0.02;
  (T-immunob mixed, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (AILD-like T-cell lym, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Japanese ATL, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Lymphoblastic, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Small noncleaved dif, Moderate [6-20pc]) 0.00, 0.97, 0.02, 0.01;
  (True histiocytic, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas T, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Multiple myeloma, Moderate [6-20pc]) 0.00, 0.01, 0.95, 0.04;
  (Mycosis fungoides, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (AML, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Hairy cell leukemia, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Carcinoma, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Melanoma, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (EM plasmacytoma, Moderate [6-20pc]) 0.0, 0.0, 1.0, 0.0;
  (Kaposi's sarcoma, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Mast-cell disease, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (AIDS involutionary, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (T-immunob large, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Monocytoid B-cell, Moderate [6-20pc]) 0.00, 0.35, 0.64, 0.01;
  (Nasopharyngeal CA, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Seminoma, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (SLE, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Mycobact histiocytos, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Mast-cell hyperplas, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (LGV, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Histoplasmosis, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Coccidioidomycosis, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (CMV, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Brucellosis, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas B, Moderate [6-20pc]) 0.00, 0.99, 0.00, 0.01;
  (Intermed lymphocytic, Moderate [6-20pc]) 0.00, 0.98, 0.01, 0.01;
  (AIDS early, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (AILD, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (ALIP, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Cat scratch disease, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Dermatopathic laden, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Florid follic hyperp, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (GLH hyaline vascular, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (GLH plasma cell, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Granulomatous laden, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Histiocytosis x, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Infectious mono, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Leprosy-lepromatous, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Lymphangiographic, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Mantle zone hyperpla, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Necrotizing Kikuchi, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Necrotiz non-Kikuchi, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Rheumatoid arthritis, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Sarcoidosis, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (SHML, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Sinus histiocytosis, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Syphilis, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Toxoplasmosis, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Tuberculosis, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Viral NOS, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Whipple's disease, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (L&H nodular HD, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (L&H diffuse HD, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Nodular sclerosis HD, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Cellular phase NSHD, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Syncytial NSHD, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Mixed cellularity HD, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Interfollicular HD, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Diffuse fibrosis HD, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Reticular-type HD, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Small cleaved fol, Marked [21-50pc]) 0.00, 0.97, 0.02, 0.01;
  (Mixed fol, Marked [21-50pc]) 0.00, 0.97, 0.02, 0.01;
  (Large cell fol, Marked [21-50pc]) 0.00, 0.97, 0.02, 0.01;
  (Small noncleaved fol, Marked [21-50pc]) 0.00, 0.97, 0.02, 0.01;
  (Small lymphocytic, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Plasmacytoid lyctic, Marked [21-50pc]) 0.0, 0.0, 1.0, 0.0;
  (Mantle zone lymphoma, Marked [21-50pc]) 0.00, 0.98, 0.01, 0.01;
  (Small cleaved dif, Marked [21-50pc]) 0.00, 0.97, 0.02, 0.01;
  (Mixed FCC dif, Marked [21-50pc]) 0.00, 0.89, 0.10, 0.01;
  (Large cell dif, Marked [21-50pc]) 0.00, 0.97, 0.02, 0.01;
  (B-immunoblastic, Marked [21-50pc]) 0.00, 0.88, 0.10, 0.02;
  (T-immunob mixed, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (AILD-like T-cell lym, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Japanese ATL, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Lymphoblastic, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Small noncleaved dif, Marked [21-50pc]) 0.00, 0.97, 0.02, 0.01;
  (True histiocytic, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas T, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Multiple myeloma, Marked [21-50pc]) 0.00, 0.01, 0.95, 0.04;
  (Mycosis fungoides, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (AML, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Hairy cell leukemia, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Carcinoma, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Melanoma, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (EM plasmacytoma, Marked [21-50pc]) 0.0, 0.0, 1.0, 0.0;
  (Kaposi's sarcoma, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Mast-cell disease, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (AIDS involutionary, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (T-immunob large, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Monocytoid B-cell, Marked [21-50pc]) 0.00, 0.35, 0.64, 0.01;
  (Nasopharyngeal CA, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Seminoma, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (SLE, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Mycobact histiocytos, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Mast-cell hyperplas, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (LGV, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Histoplasmosis, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Coccidioidomycosis, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (CMV, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Brucellosis, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas B, Marked [21-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Intermed lymphocytic, Marked [21-50pc]) 0.00, 0.98, 0.01, 0.01;
  (AIDS early, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (AILD, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (ALIP, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Cat scratch disease, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Dermatopathic laden, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Florid follic hyperp, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (GLH hyaline vascular, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (GLH plasma cell, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Granulomatous laden, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Histiocytosis x, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Infectious mono, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Leprosy-lepromatous, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Lymphangiographic, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Mantle zone hyperpla, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Necrotizing Kikuchi, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Necrotiz non-Kikuchi, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Rheumatoid arthritis, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Sarcoidosis, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (SHML, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Sinus histiocytosis, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Syphilis, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Toxoplasmosis, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Tuberculosis, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Viral NOS, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Whipple's disease, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (L&H nodular HD, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (L&H diffuse HD, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Nodular sclerosis HD, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Cellular phase NSHD, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Syncytial NSHD, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Mixed cellularity HD, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Interfollicular HD, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Diffuse fibrosis HD, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Reticular-type HD, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Small cleaved fol, Striking [51-90pc]) 0.00, 0.97, 0.02, 0.01;
  (Mixed fol, Striking [51-90pc]) 0.00, 0.97, 0.02, 0.01;
  (Large cell fol, Striking [51-90pc]) 0.00, 0.97, 0.02, 0.01;
  (Small noncleaved fol, Striking [51-90pc]) 0.00, 0.97, 0.02, 0.01;
  (Small lymphocytic, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Plasmacytoid lyctic, Striking [51-90pc]) 0.0, 0.0, 1.0, 0.0;
  (Mantle zone lymphoma, Striking [51-90pc]) 0.00, 0.98, 0.01, 0.01;
  (Small cleaved dif, Striking [51-90pc]) 0.00, 0.97, 0.02, 0.01;
  (Mixed FCC dif, Striking [51-90pc]) 0.00, 0.89, 0.10, 0.01;
  (Large cell dif, Striking [51-90pc]) 0.00, 0.97, 0.02, 0.01;
  (B-immunoblastic, Striking [51-90pc]) 0.00, 0.88, 0.10, 0.02;
  (T-immunob mixed, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (AILD-like T-cell lym, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Japanese ATL, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Lymphoblastic, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Small noncleaved dif, Striking [51-90pc]) 0.00, 0.97, 0.02, 0.01;
  (True histiocytic, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas T, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Multiple myeloma, Striking [51-90pc]) 0.00, 0.01, 0.95, 0.04;
  (Mycosis fungoides, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (AML, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Hairy cell leukemia, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Carcinoma, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Melanoma, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (EM plasmacytoma, Striking [51-90pc]) 0.0, 0.0, 1.0, 0.0;
  (Kaposi's sarcoma, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Mast-cell disease, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (AIDS involutionary, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (T-immunob large, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Monocytoid B-cell, Striking [51-90pc]) 0.00, 0.35, 0.64, 0.01;
  (Nasopharyngeal CA, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Seminoma, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (SLE, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Mycobact histiocytos, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Mast-cell hyperplas, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (LGV, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Histoplasmosis, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Coccidioidomycosis, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (CMV, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Brucellosis, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas B, Striking [51-90pc]) 0.00, 0.99, 0.00, 0.01;
  (Intermed lymphocytic, Striking [51-90pc]) 0.00, 0.98, 0.01, 0.01;
  (AIDS early, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (AILD, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (ALIP, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Cat scratch disease, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Dermatopathic laden, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Florid follic hyperp, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (GLH hyaline vascular, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (GLH plasma cell, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Granulomatous laden, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Histiocytosis x, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Infectious mono, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Leprosy-lepromatous, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Lymphangiographic, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Mantle zone hyperpla, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Necrotizing Kikuchi, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Necrotiz non-Kikuchi, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Rheumatoid arthritis, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Sarcoidosis, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (SHML, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Sinus histiocytosis, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Syphilis, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Toxoplasmosis, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Tuberculosis, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Viral NOS, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Whipple's disease, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (L&H nodular HD, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (L&H diffuse HD, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Nodular sclerosis HD, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Cellular phase NSHD, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Syncytial NSHD, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Mixed cellularity HD, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Interfollicular HD, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Diffuse fibrosis HD, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Reticular-type HD, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Small cleaved fol, Sheets [>90pc]) 0.00, 0.97, 0.02, 0.01;
  (Mixed fol, Sheets [>90pc]) 0.00, 0.97, 0.02, 0.01;
  (Large cell fol, Sheets [>90pc]) 0.00, 0.97, 0.02, 0.01;
  (Small noncleaved fol, Sheets [>90pc]) 0.00, 0.97, 0.02, 0.01;
  (Small lymphocytic, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Plasmacytoid lyctic, Sheets [>90pc]) 0.0, 0.0, 1.0, 0.0;
  (Mantle zone lymphoma, Sheets [>90pc]) 0.00, 0.98, 0.01, 0.01;
  (Small cleaved dif, Sheets [>90pc]) 0.00, 0.97, 0.02, 0.01;
  (Mixed FCC dif, Sheets [>90pc]) 0.00, 0.94, 0.05, 0.01;
  (Large cell dif, Sheets [>90pc]) 0.00, 0.97, 0.02, 0.01;
  (B-immunoblastic, Sheets [>90pc]) 0.00, 0.88, 0.10, 0.02;
  (T-immunob mixed, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (AILD-like T-cell lym, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Japanese ATL, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Lymphoblastic, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Small noncleaved dif, Sheets [>90pc]) 0.00, 0.97, 0.02, 0.01;
  (True histiocytic, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas T, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Multiple myeloma, Sheets [>90pc]) 0.00, 0.01, 0.95, 0.04;
  (Mycosis fungoides, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (AML, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Hairy cell leukemia, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Carcinoma, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Melanoma, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (EM plasmacytoma, Sheets [>90pc]) 0.0, 0.0, 1.0, 0.0;
  (Kaposi's sarcoma, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Mast-cell disease, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (AIDS involutionary, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (T-immunob large, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Monocytoid B-cell, Sheets [>90pc]) 0.00, 0.35, 0.64, 0.01;
  (Nasopharyngeal CA, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Seminoma, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (SLE, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Mycobact histiocytos, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Mast-cell hyperplas, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (LGV, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Histoplasmosis, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Coccidioidomycosis, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (CMV, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Brucellosis, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas B, Sheets [>90pc]) 0.00, 0.99, 0.00, 0.01;
  (Intermed lymphocytic, Sheets [>90pc]) 0.00, 0.98, 0.01, 0.01;
}
probability ( FCC_KL | Fault, FOLLICLE ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (AILD, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (ALIP, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Cat scratch disease, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Dermatopathic laden, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Florid follic hyperp, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (GLH hyaline vascular, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (GLH plasma cell, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Granulomatous laden, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Histiocytosis x, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Infectious mono, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Leprosy-lepromatous, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Lymphangiographic, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Mantle zone hyperpla, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Necrotizing Kikuchi, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Necrotiz non-Kikuchi, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Rheumatoid arthritis, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Sarcoidosis, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (SHML, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Sinus histiocytosis, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Syphilis, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Toxoplasmosis, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Tuberculosis, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Viral NOS, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Whipple's disease, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (L&H nodular HD, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (L&H diffuse HD, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Nodular sclerosis HD, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Cellular phase NSHD, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Syncytial NSHD, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Mixed cellularity HD, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Interfollicular HD, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Diffuse fibrosis HD, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Reticular-type HD, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Small cleaved fol, 1-25pc) 0.00, 0.00, 0.98, 0.02;
  (Mixed fol, 1-25pc) 0.00, 0.00, 0.98, 0.02;
  (Large cell fol, 1-25pc) 0.00, 0.00, 0.98, 0.02;
  (Small noncleaved fol, 1-25pc) 0.00, 0.00, 0.98, 0.02;
  (Small lymphocytic, 1-25pc) 0.00, 0.95, 0.00, 0.05;
  (Plasmacytoid lyctic, 1-25pc) 0.00, 0.95, 0.00, 0.05;
  (Mantle zone lymphoma, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Small cleaved dif, 1-25pc) 0.00, 0.95, 0.00, 0.05;
  (Mixed FCC dif, 1-25pc) 0.00, 0.95, 0.00, 0.05;
  (Large cell dif, 1-25pc) 0.00, 0.95, 0.00, 0.05;
  (B-immunoblastic, 1-25pc) 0.00, 0.95, 0.00, 0.05;
  (T-immunob mixed, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (AILD-like T-cell lym, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Japanese ATL, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Lymphoblastic, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Small noncleaved dif, 1-25pc) 0.00, 0.95, 0.00, 0.05;
  (True histiocytic, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas T, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Multiple myeloma, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Mycosis fungoides, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (AML, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Hairy cell leukemia, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Carcinoma, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Melanoma, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (EM plasmacytoma, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Kaposi's sarcoma, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Mast-cell disease, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (AIDS involutionary, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (T-immunob large, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Monocytoid B-cell, 1-25pc) 0.00, 0.65, 0.30, 0.05;
  (Nasopharyngeal CA, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Seminoma, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (SLE, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Mycobact histiocytos, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Mast-cell hyperplas, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (LGV, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Histoplasmosis, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Coccidioidomycosis, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (CMV, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Brucellosis, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas B, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (Intermed lymphocytic, 1-25pc) 0.00, 0.99, 0.00, 0.01;
  (AIDS early, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (AILD, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (ALIP, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Cat scratch disease, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Dermatopathic laden, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Florid follic hyperp, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (GLH hyaline vascular, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (GLH plasma cell, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Granulomatous laden, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Histiocytosis x, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Infectious mono, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Leprosy-lepromatous, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Lymphangiographic, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Mantle zone hyperpla, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Necrotizing Kikuchi, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Necrotiz non-Kikuchi, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Rheumatoid arthritis, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Sarcoidosis, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (SHML, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Sinus histiocytosis, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Syphilis, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Toxoplasmosis, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Tuberculosis, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Viral NOS, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Whipple's disease, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (L&H nodular HD, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (L&H diffuse HD, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Nodular sclerosis HD, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Cellular phase NSHD, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Syncytial NSHD, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Mixed cellularity HD, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Interfollicular HD, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Diffuse fibrosis HD, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Reticular-type HD, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Small cleaved fol, 25-75pc) 0.00, 0.00, 0.98, 0.02;
  (Mixed fol, 25-75pc) 0.00, 0.00, 0.98, 0.02;
  (Large cell fol, 25-75pc) 0.00, 0.00, 0.98, 0.02;
  (Small noncleaved fol, 25-75pc) 0.00, 0.00, 0.98, 0.02;
  (Small lymphocytic, 25-75pc) 0.00, 0.95, 0.00, 0.05;
  (Plasmacytoid lyctic, 25-75pc) 0.00, 0.95, 0.00, 0.05;
  (Mantle zone lymphoma, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Small cleaved dif, 25-75pc) 0.00, 0.95, 0.00, 0.05;
  (Mixed FCC dif, 25-75pc) 0.00, 0.95, 0.00, 0.05;
  (Large cell dif, 25-75pc) 0.00, 0.95, 0.00, 0.05;
  (B-immunoblastic, 25-75pc) 0.00, 0.95, 0.00, 0.05;
  (T-immunob mixed, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (AILD-like T-cell lym, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Japanese ATL, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Lymphoblastic, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Small noncleaved dif, 25-75pc) 0.00, 0.95, 0.00, 0.05;
  (True histiocytic, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas T, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Multiple myeloma, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Mycosis fungoides, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (AML, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Hairy cell leukemia, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Carcinoma, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Melanoma, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (EM plasmacytoma, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Kaposi's sarcoma, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Mast-cell disease, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (AIDS involutionary, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (T-immunob large, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Monocytoid B-cell, 25-75pc) 0.00, 0.65, 0.30, 0.05;
  (Nasopharyngeal CA, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Seminoma, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (SLE, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Mycobact histiocytos, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Mast-cell hyperplas, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (LGV, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Histoplasmosis, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Coccidioidomycosis, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (CMV, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Brucellosis, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas B, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (Intermed lymphocytic, 25-75pc) 0.00, 0.99, 0.00, 0.01;
  (AIDS early, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (AILD, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (ALIP, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Cat scratch disease, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Dermatopathic laden, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Florid follic hyperp, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (GLH hyaline vascular, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (GLH plasma cell, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Granulomatous laden, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Histiocytosis x, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Infectious mono, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Leprosy-lepromatous, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Lymphangiographic, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Mantle zone hyperpla, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Necrotizing Kikuchi, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Necrotiz non-Kikuchi, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Rheumatoid arthritis, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Sarcoidosis, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (SHML, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Sinus histiocytosis, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Syphilis, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Toxoplasmosis, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Tuberculosis, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Viral NOS, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Whipple's disease, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (L&H nodular HD, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (L&H diffuse HD, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Nodular sclerosis HD, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Cellular phase NSHD, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Syncytial NSHD, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Mixed cellularity HD, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Interfollicular HD, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Diffuse fibrosis HD, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Reticular-type HD, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Small cleaved fol, 75-90pc) 0.00, 0.00, 0.98, 0.02;
  (Mixed fol, 75-90pc) 0.00, 0.00, 0.98, 0.02;
  (Large cell fol, 75-90pc) 0.00, 0.00, 0.98, 0.02;
  (Small noncleaved fol, 75-90pc) 0.00, 0.00, 0.98, 0.02;
  (Small lymphocytic, 75-90pc) 0.00, 0.95, 0.00, 0.05;
  (Plasmacytoid lyctic, 75-90pc) 0.00, 0.95, 0.00, 0.05;
  (Mantle zone lymphoma, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Small cleaved dif, 75-90pc) 0.00, 0.95, 0.00, 0.05;
  (Mixed FCC dif, 75-90pc) 0.00, 0.95, 0.00, 0.05;
  (Large cell dif, 75-90pc) 0.00, 0.95, 0.00, 0.05;
  (B-immunoblastic, 75-90pc) 0.00, 0.95, 0.00, 0.05;
  (T-immunob mixed, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (AILD-like T-cell lym, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Japanese ATL, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Lymphoblastic, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Small noncleaved dif, 75-90pc) 0.00, 0.95, 0.00, 0.05;
  (True histiocytic, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas T, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Multiple myeloma, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Mycosis fungoides, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (AML, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Hairy cell leukemia, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Carcinoma, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Melanoma, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (EM plasmacytoma, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Kaposi's sarcoma, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Mast-cell disease, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (AIDS involutionary, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (T-immunob large, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Monocytoid B-cell, 75-90pc) 0.00, 0.65, 0.30, 0.05;
  (Nasopharyngeal CA, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Seminoma, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (SLE, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Mycobact histiocytos, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Mast-cell hyperplas, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (LGV, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Histoplasmosis, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Coccidioidomycosis, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (CMV, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Brucellosis, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas B, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (Intermed lymphocytic, 75-90pc) 0.00, 0.99, 0.00, 0.01;
  (AIDS early, >90pc) 0.00, 0.99, 0.00, 0.01;
  (AILD, >90pc) 0.00, 0.99, 0.00, 0.01;
  (ALIP, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Cat scratch disease, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Dermatopathic laden, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Florid follic hyperp, >90pc) 0.00, 0.99, 0.00, 0.01;
  (GLH hyaline vascular, >90pc) 0.00, 0.99, 0.00, 0.01;
  (GLH plasma cell, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Granulomatous laden, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Histiocytosis x, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Infectious mono, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Leprosy-lepromatous, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Lymphangiographic, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Mantle zone hyperpla, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Necrotizing Kikuchi, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Necrotiz non-Kikuchi, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Rheumatoid arthritis, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Sarcoidosis, >90pc) 0.00, 0.99, 0.00, 0.01;
  (SHML, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Sinus histiocytosis, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Syphilis, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Toxoplasmosis, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Tuberculosis, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Viral NOS, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Whipple's disease, >90pc) 0.00, 0.99, 0.00, 0.01;
  (L&H nodular HD, >90pc) 0.00, 0.99, 0.00, 0.01;
  (L&H diffuse HD, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Nodular sclerosis HD, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Cellular phase NSHD, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Syncytial NSHD, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Mixed cellularity HD, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Interfollicular HD, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Diffuse fibrosis HD, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Reticular-type HD, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Small cleaved fol, >90pc) 0.00, 0.00, 0.98, 0.02;
  (Mixed fol, >90pc) 0.00, 0.00, 0.98, 0.02;
  (Large cell fol, >90pc) 0.00, 0.00, 0.98, 0.02;
  (Small noncleaved fol, >90pc) 0.00, 0.00, 0.98, 0.02;
  (Small lymphocytic, >90pc) 0.00, 0.95, 0.00, 0.05;
  (Plasmacytoid lyctic, >90pc) 0.00, 0.95, 0.00, 0.05;
  (Mantle zone lymphoma, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Small cleaved dif, >90pc) 0.00, 0.95, 0.00, 0.05;
  (Mixed FCC dif, >90pc) 0.00, 0.95, 0.00, 0.05;
  (Large cell dif, >90pc) 0.00, 0.95, 0.00, 0.05;
  (B-immunoblastic, >90pc) 0.00, 0.95, 0.00, 0.05;
  (T-immunob mixed, >90pc) 0.00, 0.99, 0.00, 0.01;
  (AILD-like T-cell lym, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Japanese ATL, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Lymphoblastic, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Small noncleaved dif, >90pc) 0.00, 0.95, 0.00, 0.05;
  (True histiocytic, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas T, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Multiple myeloma, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Mycosis fungoides, >90pc) 0.00, 0.99, 0.00, 0.01;
  (AML, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Hairy cell leukemia, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Carcinoma, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Melanoma, >90pc) 0.00, 0.99, 0.00, 0.01;
  (EM plasmacytoma, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Kaposi's sarcoma, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Mast-cell disease, >90pc) 0.00, 0.99, 0.00, 0.01;
  (AIDS involutionary, >90pc) 0.00, 0.99, 0.00, 0.01;
  (T-immunob large, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Monocytoid B-cell, >90pc) 0.00, 0.65, 0.30, 0.05;
  (Nasopharyngeal CA, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Seminoma, >90pc) 0.00, 0.99, 0.00, 0.01;
  (SLE, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Mycobact histiocytos, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Mast-cell hyperplas, >90pc) 0.00, 0.99, 0.00, 0.01;
  (LGV, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Histoplasmosis, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Coccidioidomycosis, >90pc) 0.00, 0.99, 0.00, 0.01;
  (CMV, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Brucellosis, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas B, >90pc) 0.00, 0.99, 0.00, 0.01;
  (Intermed lymphocytic, >90pc) 0.00, 0.99, 0.00, 0.01;
}
probability ( MZL_KL | Fault, F_MZ ) {
  (AIDS early, No follicles) 1.0, 0.0, 0.0, 0.0;
  (AILD, No follicles) 1.0, 0.0, 0.0, 0.0;
  (ALIP, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, No follicles) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, No follicles) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, No follicles) 1.0, 0.0, 0.0, 0.0;
  (SHML, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, No follicles) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, No follicles) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, No follicles) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, No follicles) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, No follicles) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, No follicles) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, No follicles) 1.0, 0.0, 0.0, 0.0;
  (AML, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, No follicles) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, No follicles) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, No follicles) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, No follicles) 1.0, 0.0, 0.0, 0.0;
  (SLE, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, No follicles) 1.0, 0.0, 0.0, 0.0;
  (LGV, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, No follicles) 1.0, 0.0, 0.0, 0.0;
  (CMV, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, No follicles) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, No follicles) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, Absent) 1.0, 0.0, 0.0, 0.0;
  (AILD, Absent) 1.0, 0.0, 0.0, 0.0;
  (ALIP, Absent) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent) 1.0, 0.0, 0.0, 0.0;
  (SHML, Absent) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent) 1.0, 0.0, 0.0, 0.0;
  (AML, Absent) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent) 1.0, 0.0, 0.0, 0.0;
  (SLE, Absent) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent) 1.0, 0.0, 0.0, 0.0;
  (LGV, Absent) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent) 1.0, 0.0, 0.0, 0.0;
  (CMV, Absent) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, Present) 0.0, 1.0, 0.0, 0.0;
  (AILD, Present) 0.0, 1.0, 0.0, 0.0;
  (ALIP, Present) 0.0, 1.0, 0.0, 0.0;
  (Cat scratch disease, Present) 0.0, 1.0, 0.0, 0.0;
  (Dermatopathic laden, Present) 0.0, 1.0, 0.0, 0.0;
  (Florid follic hyperp, Present) 0.0, 1.0, 0.0, 0.0;
  (GLH hyaline vascular, Present) 0.0, 1.0, 0.0, 0.0;
  (GLH plasma cell, Present) 0.0, 1.0, 0.0, 0.0;
  (Granulomatous laden, Present) 0.0, 1.0, 0.0, 0.0;
  (Histiocytosis x, Present) 0.0, 1.0, 0.0, 0.0;
  (Infectious mono, Present) 0.0, 1.0, 0.0, 0.0;
  (Leprosy-lepromatous, Present) 0.0, 1.0, 0.0, 0.0;
  (Lymphangiographic, Present) 0.0, 1.0, 0.0, 0.0;
  (Mantle zone hyperpla, Present) 0.0, 1.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Present) 0.0, 1.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Present) 0.0, 1.0, 0.0, 0.0;
  (Rheumatoid arthritis, Present) 0.0, 1.0, 0.0, 0.0;
  (Sarcoidosis, Present) 0.0, 1.0, 0.0, 0.0;
  (SHML, Present) 0.0, 1.0, 0.0, 0.0;
  (Sinus histiocytosis, Present) 0.0, 1.0, 0.0, 0.0;
  (Syphilis, Present) 0.0, 1.0, 0.0, 0.0;
  (Toxoplasmosis, Present) 0.0, 1.0, 0.0, 0.0;
  (Tuberculosis, Present) 0.0, 1.0, 0.0, 0.0;
  (Viral NOS, Present) 0.0, 1.0, 0.0, 0.0;
  (Whipple's disease, Present) 0.0, 1.0, 0.0, 0.0;
  (L&H nodular HD, Present) 0.0, 1.0, 0.0, 0.0;
  (L&H diffuse HD, Present) 0.0, 1.0, 0.0, 0.0;
  (Nodular sclerosis HD, Present) 0.0, 1.0, 0.0, 0.0;
  (Cellular phase NSHD, Present) 0.0, 1.0, 0.0, 0.0;
  (Syncytial NSHD, Present) 0.0, 1.0, 0.0, 0.0;
  (Mixed cellularity HD, Present) 0.0, 1.0, 0.0, 0.0;
  (Interfollicular HD, Present) 0.0, 1.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Present) 0.0, 1.0, 0.0, 0.0;
  (Reticular-type HD, Present) 0.0, 1.0, 0.0, 0.0;
  (Small cleaved fol, Present) 0.00, 0.98, 0.00, 0.02;
  (Mixed fol, Present) 0.00, 0.98, 0.00, 0.02;
  (Large cell fol, Present) 0.00, 0.98, 0.00, 0.02;
  (Small noncleaved fol, Present) 0.00, 0.98, 0.00, 0.02;
  (Small lymphocytic, Present) 0.00, 0.98, 0.00, 0.02;
  (Plasmacytoid lyctic, Present) 0.00, 0.98, 0.00, 0.02;
  (Mantle zone lymphoma, Present) 0.00, 0.00, 0.98, 0.02;
  (Small cleaved dif, Present) 0.00, 0.98, 0.00, 0.02;
  (Mixed FCC dif, Present) 0.00, 0.98, 0.00, 0.02;
  (Large cell dif, Present) 0.00, 0.98, 0.00, 0.02;
  (B-immunoblastic, Present) 0.00, 0.98, 0.00, 0.02;
  (T-immunob mixed, Present) 0.0, 1.0, 0.0, 0.0;
  (AILD-like T-cell lym, Present) 0.0, 1.0, 0.0, 0.0;
  (Japanese ATL, Present) 0.0, 1.0, 0.0, 0.0;
  (Lymphoblastic, Present) 0.0, 1.0, 0.0, 0.0;
  (Small noncleaved dif, Present) 0.00, 0.98, 0.00, 0.02;
  (True histiocytic, Present) 0.0, 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Present) 0.0, 1.0, 0.0, 0.0;
  (Multiple myeloma, Present) 0.0, 1.0, 0.0, 0.0;
  (Mycosis fungoides, Present) 0.0, 1.0, 0.0, 0.0;
  (AML, Present) 0.0, 1.0, 0.0, 0.0;
  (Hairy cell leukemia, Present) 0.0, 1.0, 0.0, 0.0;
  (Carcinoma, Present) 0.0, 1.0, 0.0, 0.0;
  (Melanoma, Present) 0.0, 1.0, 0.0, 0.0;
  (EM plasmacytoma, Present) 0.00, 0.98, 0.00, 0.02;
  (Kaposi's sarcoma, Present) 0.0, 1.0, 0.0, 0.0;
  (Mast-cell disease, Present) 0.0, 1.0, 0.0, 0.0;
  (AIDS involutionary, Present) 0.0, 1.0, 0.0, 0.0;
  (T-immunob large, Present) 0.0, 1.0, 0.0, 0.0;
  (Monocytoid B-cell, Present) 0.00, 0.75, 0.20, 0.05;
  (Nasopharyngeal CA, Present) 0.0, 1.0, 0.0, 0.0;
  (Seminoma, Present) 0.0, 1.0, 0.0, 0.0;
  (SLE, Present) 0.0, 1.0, 0.0, 0.0;
  (Mycobact histiocytos, Present) 0.0, 1.0, 0.0, 0.0;
  (Mast-cell hyperplas, Present) 0.0, 1.0, 0.0, 0.0;
  (LGV, Present) 0.0, 1.0, 0.0, 0.0;
  (Histoplasmosis, Present) 0.0, 1.0, 0.0, 0.0;
  (Coccidioidomycosis, Present) 0.0, 1.0, 0.0, 0.0;
  (CMV, Present) 0.0, 1.0, 0.0, 0.0;
  (Brucellosis, Present) 0.0, 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Present) 0.0, 1.0, 0.0, 0.0;
  (Intermed lymphocytic, Present) 0.00, 0.00, 0.98, 0.02;
}
probability ( SR_LEU | Fault, SR ) {
  (AIDS early, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AML, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS early, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AILD, Rare [1-3]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (ALIP, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Cat scratch disease, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Dermatopathic laden, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Florid follic hyperp, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (GLH hyaline vascular, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (GLH plasma cell, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Granulomatous laden, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Histiocytosis x, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Infectious mono, Rare [1-3]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Leprosy-lepromatous, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Lymphangiographic, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mantle zone hyperpla, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Necrotizing Kikuchi, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Necrotiz non-Kikuchi, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Rheumatoid arthritis, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Sarcoidosis, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (SHML, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Sinus histiocytosis, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Syphilis, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Toxoplasmosis, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Tuberculosis, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Viral NOS, Rare [1-3]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Whipple's disease, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (L&H nodular HD, Rare [1-3]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (L&H diffuse HD, Rare [1-3]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Nodular sclerosis HD, Rare [1-3]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Cellular phase NSHD, Rare [1-3]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Syncytial NSHD, Rare [1-3]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Mixed cellularity HD, Rare [1-3]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Interfollicular HD, Rare [1-3]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Diffuse fibrosis HD, Rare [1-3]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Reticular-type HD, Rare [1-3]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Small cleaved fol, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mixed fol, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Large cell fol, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Small noncleaved fol, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Small lymphocytic, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Plasmacytoid lyctic, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mantle zone lymphoma, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Small cleaved dif, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mixed FCC dif, Rare [1-3]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Large cell dif, Rare [1-3]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (B-immunoblastic, Rare [1-3]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (T-immunob mixed, Rare [1-3]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (AILD-like T-cell lym, Rare [1-3]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Japanese ATL, Rare [1-3]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Lymphoblastic, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Small noncleaved dif, Rare [1-3]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (True histiocytic, Rare [1-3]) 0.00, 0.99, 0.00, 0.01, 0.00;
  (Ki-1 LC anaplas T, Rare [1-3]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Multiple myeloma, Rare [1-3]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mycosis fungoides, Rare [1-3]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (AML, Rare [1-3]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Hairy cell leukemia, Rare [1-3]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Carcinoma, Rare [1-3]) 0.0, 0.8, 0.2, 0.0, 0.0;
  (Melanoma, Rare [1-3]) 0.0, 0.8, 0.2, 0.0, 0.0;
  (EM plasmacytoma, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Kaposi's sarcoma, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mast-cell disease, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AIDS involutionary, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (T-immunob large, Rare [1-3]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Monocytoid B-cell, Rare [1-3]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Nasopharyngeal CA, Rare [1-3]) 0.0, 0.8, 0.2, 0.0, 0.0;
  (Seminoma, Rare [1-3]) 0.0, 0.8, 0.2, 0.0, 0.0;
  (SLE, Rare [1-3]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mycobact histiocytos, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mast-cell hyperplas, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (LGV, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Histoplasmosis, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Coccidioidomycosis, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (CMV, Rare [1-3]) 0.00, 0.95, 0.05, 0.00, 0.00;
  (Brucellosis, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Ki-1 LC anaplas B, Rare [1-3]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Intermed lymphocytic, Rare [1-3]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AIDS early, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AILD, Present [4-15]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (ALIP, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Cat scratch disease, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Dermatopathic laden, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Florid follic hyperp, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (GLH hyaline vascular, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (GLH plasma cell, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Granulomatous laden, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Histiocytosis x, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Infectious mono, Present [4-15]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Leprosy-lepromatous, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Lymphangiographic, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mantle zone hyperpla, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Necrotizing Kikuchi, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Necrotiz non-Kikuchi, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Rheumatoid arthritis, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Sarcoidosis, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (SHML, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Sinus histiocytosis, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Syphilis, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Toxoplasmosis, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Tuberculosis, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Viral NOS, Present [4-15]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Whipple's disease, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (L&H nodular HD, Present [4-15]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (L&H diffuse HD, Present [4-15]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Nodular sclerosis HD, Present [4-15]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Cellular phase NSHD, Present [4-15]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Syncytial NSHD, Present [4-15]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Mixed cellularity HD, Present [4-15]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Interfollicular HD, Present [4-15]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Diffuse fibrosis HD, Present [4-15]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Reticular-type HD, Present [4-15]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Small cleaved fol, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mixed fol, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Large cell fol, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Small noncleaved fol, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Small lymphocytic, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Plasmacytoid lyctic, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mantle zone lymphoma, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Small cleaved dif, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mixed FCC dif, Present [4-15]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Large cell dif, Present [4-15]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (B-immunoblastic, Present [4-15]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (T-immunob mixed, Present [4-15]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (AILD-like T-cell lym, Present [4-15]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Japanese ATL, Present [4-15]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Lymphoblastic, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Small noncleaved dif, Present [4-15]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (True histiocytic, Present [4-15]) 0.00, 0.99, 0.00, 0.01, 0.00;
  (Ki-1 LC anaplas T, Present [4-15]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Multiple myeloma, Present [4-15]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mycosis fungoides, Present [4-15]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (AML, Present [4-15]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Hairy cell leukemia, Present [4-15]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Carcinoma, Present [4-15]) 0.0, 0.8, 0.2, 0.0, 0.0;
  (Melanoma, Present [4-15]) 0.0, 0.8, 0.2, 0.0, 0.0;
  (EM plasmacytoma, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Kaposi's sarcoma, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mast-cell disease, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AIDS involutionary, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (T-immunob large, Present [4-15]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Monocytoid B-cell, Present [4-15]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Nasopharyngeal CA, Present [4-15]) 0.0, 0.8, 0.2, 0.0, 0.0;
  (Seminoma, Present [4-15]) 0.0, 0.8, 0.2, 0.0, 0.0;
  (SLE, Present [4-15]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mycobact histiocytos, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mast-cell hyperplas, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (LGV, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Histoplasmosis, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Coccidioidomycosis, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (CMV, Present [4-15]) 0.00, 0.95, 0.05, 0.00, 0.00;
  (Brucellosis, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Ki-1 LC anaplas B, Present [4-15]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Intermed lymphocytic, Present [4-15]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AIDS early, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AILD, Many [16-50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (ALIP, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Cat scratch disease, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Dermatopathic laden, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Florid follic hyperp, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (GLH hyaline vascular, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (GLH plasma cell, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Granulomatous laden, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Histiocytosis x, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Infectious mono, Many [16-50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Leprosy-lepromatous, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Lymphangiographic, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mantle zone hyperpla, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Necrotizing Kikuchi, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Necrotiz non-Kikuchi, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Rheumatoid arthritis, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Sarcoidosis, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (SHML, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Sinus histiocytosis, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Syphilis, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Toxoplasmosis, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Tuberculosis, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Viral NOS, Many [16-50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Whipple's disease, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (L&H nodular HD, Many [16-50]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (L&H diffuse HD, Many [16-50]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Nodular sclerosis HD, Many [16-50]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Cellular phase NSHD, Many [16-50]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Syncytial NSHD, Many [16-50]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Mixed cellularity HD, Many [16-50]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Interfollicular HD, Many [16-50]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Diffuse fibrosis HD, Many [16-50]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Reticular-type HD, Many [16-50]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Small cleaved fol, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mixed fol, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Large cell fol, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Small noncleaved fol, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Small lymphocytic, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Plasmacytoid lyctic, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mantle zone lymphoma, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Small cleaved dif, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mixed FCC dif, Many [16-50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Large cell dif, Many [16-50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (B-immunoblastic, Many [16-50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (T-immunob mixed, Many [16-50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (AILD-like T-cell lym, Many [16-50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Japanese ATL, Many [16-50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Lymphoblastic, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Small noncleaved dif, Many [16-50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (True histiocytic, Many [16-50]) 0.00, 0.99, 0.00, 0.01, 0.00;
  (Ki-1 LC anaplas T, Many [16-50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Multiple myeloma, Many [16-50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mycosis fungoides, Many [16-50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (AML, Many [16-50]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Hairy cell leukemia, Many [16-50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Carcinoma, Many [16-50]) 0.0, 0.8, 0.2, 0.0, 0.0;
  (Melanoma, Many [16-50]) 0.0, 0.8, 0.2, 0.0, 0.0;
  (EM plasmacytoma, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Kaposi's sarcoma, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mast-cell disease, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AIDS involutionary, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (T-immunob large, Many [16-50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Monocytoid B-cell, Many [16-50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Nasopharyngeal CA, Many [16-50]) 0.0, 0.8, 0.2, 0.0, 0.0;
  (Seminoma, Many [16-50]) 0.0, 0.8, 0.2, 0.0, 0.0;
  (SLE, Many [16-50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mycobact histiocytos, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mast-cell hyperplas, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (LGV, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Histoplasmosis, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Coccidioidomycosis, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (CMV, Many [16-50]) 0.00, 0.95, 0.05, 0.00, 0.00;
  (Brucellosis, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Ki-1 LC anaplas B, Many [16-50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Intermed lymphocytic, Many [16-50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AIDS early, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AILD, Striking [>50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (ALIP, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Cat scratch disease, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Dermatopathic laden, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Florid follic hyperp, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (GLH hyaline vascular, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (GLH plasma cell, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Granulomatous laden, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Histiocytosis x, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Infectious mono, Striking [>50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Leprosy-lepromatous, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Lymphangiographic, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mantle zone hyperpla, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Necrotizing Kikuchi, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Necrotiz non-Kikuchi, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Rheumatoid arthritis, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Sarcoidosis, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (SHML, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Sinus histiocytosis, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Syphilis, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Toxoplasmosis, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Tuberculosis, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Viral NOS, Striking [>50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Whipple's disease, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (L&H nodular HD, Striking [>50]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (L&H diffuse HD, Striking [>50]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Nodular sclerosis HD, Striking [>50]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Cellular phase NSHD, Striking [>50]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Syncytial NSHD, Striking [>50]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Mixed cellularity HD, Striking [>50]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Interfollicular HD, Striking [>50]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Diffuse fibrosis HD, Striking [>50]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Reticular-type HD, Striking [>50]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Small cleaved fol, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mixed fol, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Large cell fol, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Small noncleaved fol, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Small lymphocytic, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Plasmacytoid lyctic, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mantle zone lymphoma, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Small cleaved dif, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mixed FCC dif, Striking [>50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Large cell dif, Striking [>50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (B-immunoblastic, Striking [>50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (T-immunob mixed, Striking [>50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (AILD-like T-cell lym, Striking [>50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Japanese ATL, Striking [>50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Lymphoblastic, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Small noncleaved dif, Striking [>50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (True histiocytic, Striking [>50]) 0.00, 0.99, 0.00, 0.01, 0.00;
  (Ki-1 LC anaplas T, Striking [>50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Multiple myeloma, Striking [>50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mycosis fungoides, Striking [>50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (AML, Striking [>50]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Hairy cell leukemia, Striking [>50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Carcinoma, Striking [>50]) 0.0, 0.8, 0.2, 0.0, 0.0;
  (Melanoma, Striking [>50]) 0.0, 0.8, 0.2, 0.0, 0.0;
  (EM plasmacytoma, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Kaposi's sarcoma, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mast-cell disease, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AIDS involutionary, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (T-immunob large, Striking [>50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Monocytoid B-cell, Striking [>50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Nasopharyngeal CA, Striking [>50]) 0.0, 0.8, 0.2, 0.0, 0.0;
  (Seminoma, Striking [>50]) 0.0, 0.8, 0.2, 0.0, 0.0;
  (SLE, Striking [>50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mycobact histiocytos, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mast-cell hyperplas, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (LGV, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Histoplasmosis, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Coccidioidomycosis, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (CMV, Striking [>50]) 0.00, 0.95, 0.05, 0.00, 0.00;
  (Brucellosis, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Ki-1 LC anaplas B, Striking [>50]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Intermed lymphocytic, Striking [>50]) 0.00, 0.01, 0.00, 0.99, 0.00;
}
probability ( LAC_LEU | Fault, LACUN ) {
  (AIDS early, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AML, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS early, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (AILD, Rare [1-5]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (ALIP, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Cat scratch disease, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Dermatopathic laden, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Florid follic hyperp, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (GLH hyaline vascular, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (GLH plasma cell, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Granulomatous laden, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Histiocytosis x, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Infectious mono, Rare [1-5]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Leprosy-lepromatous, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Lymphangiographic, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mantle zone hyperpla, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Necrotizing Kikuchi, Rare [1-5]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Necrotiz non-Kikuchi, Rare [1-5]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Rheumatoid arthritis, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Sarcoidosis, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (SHML, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Sinus histiocytosis, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Syphilis, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Toxoplasmosis, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Tuberculosis, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Viral NOS, Rare [1-5]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Whipple's disease, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (L&H nodular HD, Rare [1-5]) 0.0, 0.1, 0.1, 0.8, 0.0;
  (L&H diffuse HD, Rare [1-5]) 0.0, 0.1, 0.1, 0.8, 0.0;
  (Nodular sclerosis HD, Rare [1-5]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Cellular phase NSHD, Rare [1-5]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Syncytial NSHD, Rare [1-5]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Mixed cellularity HD, Rare [1-5]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Interfollicular HD, Rare [1-5]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Diffuse fibrosis HD, Rare [1-5]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Reticular-type HD, Rare [1-5]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Small cleaved fol, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mixed fol, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Large cell fol, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Small noncleaved fol, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Small lymphocytic, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Plasmacytoid lyctic, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mantle zone lymphoma, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Small cleaved dif, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mixed FCC dif, Rare [1-5]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Large cell dif, Rare [1-5]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (B-immunoblastic, Rare [1-5]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (T-immunob mixed, Rare [1-5]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (AILD-like T-cell lym, Rare [1-5]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Japanese ATL, Rare [1-5]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Lymphoblastic, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Small noncleaved dif, Rare [1-5]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (True histiocytic, Rare [1-5]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Ki-1 LC anaplas T, Rare [1-5]) 0.0, 0.1, 0.0, 0.8, 0.1;
  (Multiple myeloma, Rare [1-5]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Mycosis fungoides, Rare [1-5]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (AML, Rare [1-5]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Hairy cell leukemia, Rare [1-5]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Carcinoma, Rare [1-5]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Melanoma, Rare [1-5]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (EM plasmacytoma, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Kaposi's sarcoma, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mast-cell disease, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (AIDS involutionary, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (T-immunob large, Rare [1-5]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Monocytoid B-cell, Rare [1-5]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Nasopharyngeal CA, Rare [1-5]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Seminoma, Rare [1-5]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (SLE, Rare [1-5]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mycobact histiocytos, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mast-cell hyperplas, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (LGV, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Histoplasmosis, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Coccidioidomycosis, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (CMV, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Brucellosis, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Ki-1 LC anaplas B, Rare [1-5]) 0.0, 0.1, 0.0, 0.8, 0.1;
  (Intermed lymphocytic, Rare [1-5]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (AIDS early, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (AILD, Few [6-25]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (ALIP, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Cat scratch disease, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Dermatopathic laden, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Florid follic hyperp, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (GLH hyaline vascular, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (GLH plasma cell, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Granulomatous laden, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Histiocytosis x, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Infectious mono, Few [6-25]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Leprosy-lepromatous, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Lymphangiographic, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mantle zone hyperpla, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Necrotizing Kikuchi, Few [6-25]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Necrotiz non-Kikuchi, Few [6-25]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Rheumatoid arthritis, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Sarcoidosis, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (SHML, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Sinus histiocytosis, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Syphilis, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Toxoplasmosis, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Tuberculosis, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Viral NOS, Few [6-25]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Whipple's disease, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (L&H nodular HD, Few [6-25]) 0.0, 0.1, 0.1, 0.8, 0.0;
  (L&H diffuse HD, Few [6-25]) 0.0, 0.1, 0.1, 0.8, 0.0;
  (Nodular sclerosis HD, Few [6-25]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Cellular phase NSHD, Few [6-25]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Syncytial NSHD, Few [6-25]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Mixed cellularity HD, Few [6-25]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Interfollicular HD, Few [6-25]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Diffuse fibrosis HD, Few [6-25]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Reticular-type HD, Few [6-25]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Small cleaved fol, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mixed fol, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Large cell fol, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Small noncleaved fol, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Small lymphocytic, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Plasmacytoid lyctic, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mantle zone lymphoma, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Small cleaved dif, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mixed FCC dif, Few [6-25]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Large cell dif, Few [6-25]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (B-immunoblastic, Few [6-25]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (T-immunob mixed, Few [6-25]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (AILD-like T-cell lym, Few [6-25]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Japanese ATL, Few [6-25]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Lymphoblastic, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Small noncleaved dif, Few [6-25]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (True histiocytic, Few [6-25]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Ki-1 LC anaplas T, Few [6-25]) 0.0, 0.1, 0.0, 0.8, 0.1;
  (Multiple myeloma, Few [6-25]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Mycosis fungoides, Few [6-25]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (AML, Few [6-25]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Hairy cell leukemia, Few [6-25]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Carcinoma, Few [6-25]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Melanoma, Few [6-25]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (EM plasmacytoma, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Kaposi's sarcoma, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mast-cell disease, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (AIDS involutionary, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (T-immunob large, Few [6-25]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Monocytoid B-cell, Few [6-25]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Nasopharyngeal CA, Few [6-25]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Seminoma, Few [6-25]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (SLE, Few [6-25]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mycobact histiocytos, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mast-cell hyperplas, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (LGV, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Histoplasmosis, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Coccidioidomycosis, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (CMV, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Brucellosis, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Ki-1 LC anaplas B, Few [6-25]) 0.0, 0.1, 0.0, 0.8, 0.1;
  (Intermed lymphocytic, Few [6-25]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (AIDS early, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (AILD, Many [26 - 100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (ALIP, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Cat scratch disease, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Dermatopathic laden, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Florid follic hyperp, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (GLH hyaline vascular, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (GLH plasma cell, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Granulomatous laden, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Histiocytosis x, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Infectious mono, Many [26 - 100]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Leprosy-lepromatous, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Lymphangiographic, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mantle zone hyperpla, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Necrotizing Kikuchi, Many [26 - 100]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Necrotiz non-Kikuchi, Many [26 - 100]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Rheumatoid arthritis, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Sarcoidosis, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (SHML, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Sinus histiocytosis, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Syphilis, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Toxoplasmosis, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Tuberculosis, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Viral NOS, Many [26 - 100]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Whipple's disease, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (L&H nodular HD, Many [26 - 100]) 0.0, 0.1, 0.1, 0.8, 0.0;
  (L&H diffuse HD, Many [26 - 100]) 0.0, 0.1, 0.1, 0.8, 0.0;
  (Nodular sclerosis HD, Many [26 - 100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Cellular phase NSHD, Many [26 - 100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Syncytial NSHD, Many [26 - 100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Mixed cellularity HD, Many [26 - 100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Interfollicular HD, Many [26 - 100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Diffuse fibrosis HD, Many [26 - 100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Reticular-type HD, Many [26 - 100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Small cleaved fol, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mixed fol, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Large cell fol, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Small noncleaved fol, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Small lymphocytic, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Plasmacytoid lyctic, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mantle zone lymphoma, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Small cleaved dif, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mixed FCC dif, Many [26 - 100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Large cell dif, Many [26 - 100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (B-immunoblastic, Many [26 - 100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (T-immunob mixed, Many [26 - 100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (AILD-like T-cell lym, Many [26 - 100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Japanese ATL, Many [26 - 100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Lymphoblastic, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Small noncleaved dif, Many [26 - 100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (True histiocytic, Many [26 - 100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Ki-1 LC anaplas T, Many [26 - 100]) 0.0, 0.1, 0.0, 0.8, 0.1;
  (Multiple myeloma, Many [26 - 100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Mycosis fungoides, Many [26 - 100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (AML, Many [26 - 100]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Hairy cell leukemia, Many [26 - 100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Carcinoma, Many [26 - 100]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Melanoma, Many [26 - 100]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (EM plasmacytoma, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Kaposi's sarcoma, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mast-cell disease, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (AIDS involutionary, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (T-immunob large, Many [26 - 100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Monocytoid B-cell, Many [26 - 100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Nasopharyngeal CA, Many [26 - 100]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Seminoma, Many [26 - 100]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (SLE, Many [26 - 100]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mycobact histiocytos, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mast-cell hyperplas, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (LGV, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Histoplasmosis, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Coccidioidomycosis, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (CMV, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Brucellosis, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Ki-1 LC anaplas B, Many [26 - 100]) 0.0, 0.1, 0.0, 0.8, 0.1;
  (Intermed lymphocytic, Many [26 - 100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (AIDS early, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (AILD, Striking [>100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (ALIP, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Cat scratch disease, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Dermatopathic laden, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Florid follic hyperp, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (GLH hyaline vascular, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (GLH plasma cell, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Granulomatous laden, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Histiocytosis x, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Infectious mono, Striking [>100]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Leprosy-lepromatous, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Lymphangiographic, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mantle zone hyperpla, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Necrotizing Kikuchi, Striking [>100]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Necrotiz non-Kikuchi, Striking [>100]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Rheumatoid arthritis, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Sarcoidosis, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (SHML, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Sinus histiocytosis, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Syphilis, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Toxoplasmosis, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Tuberculosis, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Viral NOS, Striking [>100]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Whipple's disease, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (L&H nodular HD, Striking [>100]) 0.0, 0.1, 0.1, 0.8, 0.0;
  (L&H diffuse HD, Striking [>100]) 0.0, 0.1, 0.1, 0.8, 0.0;
  (Nodular sclerosis HD, Striking [>100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Cellular phase NSHD, Striking [>100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Syncytial NSHD, Striking [>100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Mixed cellularity HD, Striking [>100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Interfollicular HD, Striking [>100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Diffuse fibrosis HD, Striking [>100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Reticular-type HD, Striking [>100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Small cleaved fol, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mixed fol, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Large cell fol, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Small noncleaved fol, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Small lymphocytic, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Plasmacytoid lyctic, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mantle zone lymphoma, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Small cleaved dif, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mixed FCC dif, Striking [>100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Large cell dif, Striking [>100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (B-immunoblastic, Striking [>100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (T-immunob mixed, Striking [>100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (AILD-like T-cell lym, Striking [>100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Japanese ATL, Striking [>100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Lymphoblastic, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Small noncleaved dif, Striking [>100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (True histiocytic, Striking [>100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Ki-1 LC anaplas T, Striking [>100]) 0.0, 0.1, 0.0, 0.8, 0.1;
  (Multiple myeloma, Striking [>100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Mycosis fungoides, Striking [>100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (AML, Striking [>100]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Hairy cell leukemia, Striking [>100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Carcinoma, Striking [>100]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Melanoma, Striking [>100]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (EM plasmacytoma, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Kaposi's sarcoma, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mast-cell disease, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (AIDS involutionary, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (T-immunob large, Striking [>100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Monocytoid B-cell, Striking [>100]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Nasopharyngeal CA, Striking [>100]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Seminoma, Striking [>100]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (SLE, Striking [>100]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mycobact histiocytos, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mast-cell hyperplas, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (LGV, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Histoplasmosis, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Coccidioidomycosis, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (CMV, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Brucellosis, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Ki-1 LC anaplas B, Striking [>100]) 0.0, 0.1, 0.0, 0.8, 0.1;
  (Intermed lymphocytic, Striking [>100]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (AIDS early, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (AILD, Sheets [>50pc of section]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (ALIP, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Cat scratch disease, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Dermatopathic laden, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Florid follic hyperp, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (GLH hyaline vascular, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (GLH plasma cell, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Granulomatous laden, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Histiocytosis x, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Infectious mono, Sheets [>50pc of section]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Leprosy-lepromatous, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Lymphangiographic, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mantle zone hyperpla, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Necrotizing Kikuchi, Sheets [>50pc of section]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Necrotiz non-Kikuchi, Sheets [>50pc of section]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Rheumatoid arthritis, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Sarcoidosis, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (SHML, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Sinus histiocytosis, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Syphilis, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Toxoplasmosis, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Tuberculosis, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Viral NOS, Sheets [>50pc of section]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Whipple's disease, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (L&H nodular HD, Sheets [>50pc of section]) 0.0, 0.1, 0.1, 0.8, 0.0;
  (L&H diffuse HD, Sheets [>50pc of section]) 0.0, 0.1, 0.1, 0.8, 0.0;
  (Nodular sclerosis HD, Sheets [>50pc of section]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Cellular phase NSHD, Sheets [>50pc of section]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Syncytial NSHD, Sheets [>50pc of section]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Mixed cellularity HD, Sheets [>50pc of section]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Interfollicular HD, Sheets [>50pc of section]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Diffuse fibrosis HD, Sheets [>50pc of section]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Reticular-type HD, Sheets [>50pc of section]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Small cleaved fol, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mixed fol, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Large cell fol, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Small noncleaved fol, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Small lymphocytic, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Plasmacytoid lyctic, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mantle zone lymphoma, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Small cleaved dif, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mixed FCC dif, Sheets [>50pc of section]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Large cell dif, Sheets [>50pc of section]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (B-immunoblastic, Sheets [>50pc of section]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (T-immunob mixed, Sheets [>50pc of section]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (AILD-like T-cell lym, Sheets [>50pc of section]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Japanese ATL, Sheets [>50pc of section]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Lymphoblastic, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Small noncleaved dif, Sheets [>50pc of section]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (True histiocytic, Sheets [>50pc of section]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Ki-1 LC anaplas T, Sheets [>50pc of section]) 0.0, 0.1, 0.0, 0.8, 0.1;
  (Multiple myeloma, Sheets [>50pc of section]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Mycosis fungoides, Sheets [>50pc of section]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (AML, Sheets [>50pc of section]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Hairy cell leukemia, Sheets [>50pc of section]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Carcinoma, Sheets [>50pc of section]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Melanoma, Sheets [>50pc of section]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (EM plasmacytoma, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Kaposi's sarcoma, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mast-cell disease, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (AIDS involutionary, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (T-immunob large, Sheets [>50pc of section]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Monocytoid B-cell, Sheets [>50pc of section]) 0.00, 0.05, 0.00, 0.95, 0.00;
  (Nasopharyngeal CA, Sheets [>50pc of section]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Seminoma, Sheets [>50pc of section]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (SLE, Sheets [>50pc of section]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mycobact histiocytos, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Mast-cell hyperplas, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (LGV, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Histoplasmosis, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Coccidioidomycosis, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (CMV, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Brucellosis, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
  (Ki-1 LC anaplas B, Sheets [>50pc of section]) 0.0, 0.1, 0.0, 0.8, 0.1;
  (Intermed lymphocytic, Sheets [>50pc of section]) 0.00, 0.01, 0.01, 0.98, 0.00;
}
probability ( PLEO_LEU | Fault, PLEO ) {
  (AIDS early, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AML, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS early, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (AILD, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (ALIP, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Cat scratch disease, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Dermatopathic laden, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Florid follic hyperp, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (GLH hyaline vascular, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (GLH plasma cell, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Granulomatous laden, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Histiocytosis x, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Infectious mono, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Leprosy-lepromatous, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Lymphangiographic, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mantle zone hyperpla, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Necrotizing Kikuchi, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Necrotiz non-Kikuchi, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Rheumatoid arthritis, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Sarcoidosis, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (SHML, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Sinus histiocytosis, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Syphilis, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Toxoplasmosis, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Tuberculosis, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Viral NOS, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Whipple's disease, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (L&H nodular HD, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (L&H diffuse HD, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Nodular sclerosis HD, Rare [1-5]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Cellular phase NSHD, Rare [1-5]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Syncytial NSHD, Rare [1-5]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Mixed cellularity HD, Rare [1-5]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Interfollicular HD, Rare [1-5]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Diffuse fibrosis HD, Rare [1-5]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Reticular-type HD, Rare [1-5]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Small cleaved fol, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mixed fol, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Large cell fol, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small noncleaved fol, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small lymphocytic, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Plasmacytoid lyctic, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mantle zone lymphoma, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small cleaved dif, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mixed FCC dif, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Large cell dif, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (B-immunoblastic, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (T-immunob mixed, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AILD-like T-cell lym, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Japanese ATL, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Lymphoblastic, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small noncleaved dif, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (True histiocytic, Rare [1-5]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Ki-1 LC anaplas T, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Multiple myeloma, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mycosis fungoides, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AML, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Hairy cell leukemia, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Carcinoma, Rare [1-5]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Melanoma, Rare [1-5]) 0.0, 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Kaposi's sarcoma, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mast-cell disease, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (AIDS involutionary, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (T-immunob large, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Monocytoid B-cell, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Nasopharyngeal CA, Rare [1-5]) 0.0, 1.0, 0.0, 0.0, 0.0;
  (Seminoma, Rare [1-5]) 0.0, 1.0, 0.0, 0.0, 0.0;
  (SLE, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mycobact histiocytos, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mast-cell hyperplas, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (LGV, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Histoplasmosis, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Coccidioidomycosis, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (CMV, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Brucellosis, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Ki-1 LC anaplas B, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Intermed lymphocytic, Rare [1-5]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (AIDS early, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (AILD, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (ALIP, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Cat scratch disease, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Dermatopathic laden, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Florid follic hyperp, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (GLH hyaline vascular, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (GLH plasma cell, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Granulomatous laden, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Histiocytosis x, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Infectious mono, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Leprosy-lepromatous, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Lymphangiographic, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mantle zone hyperpla, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Necrotizing Kikuchi, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Necrotiz non-Kikuchi, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Rheumatoid arthritis, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Sarcoidosis, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (SHML, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Sinus histiocytosis, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Syphilis, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Toxoplasmosis, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Tuberculosis, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Viral NOS, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Whipple's disease, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (L&H nodular HD, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (L&H diffuse HD, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Nodular sclerosis HD, Few [6-25]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Cellular phase NSHD, Few [6-25]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Syncytial NSHD, Few [6-25]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Mixed cellularity HD, Few [6-25]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Interfollicular HD, Few [6-25]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Diffuse fibrosis HD, Few [6-25]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Reticular-type HD, Few [6-25]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Small cleaved fol, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mixed fol, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Large cell fol, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small noncleaved fol, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small lymphocytic, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Plasmacytoid lyctic, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mantle zone lymphoma, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small cleaved dif, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mixed FCC dif, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Large cell dif, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (B-immunoblastic, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (T-immunob mixed, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AILD-like T-cell lym, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Japanese ATL, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Lymphoblastic, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small noncleaved dif, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (True histiocytic, Few [6-25]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Ki-1 LC anaplas T, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Multiple myeloma, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mycosis fungoides, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AML, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Hairy cell leukemia, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Carcinoma, Few [6-25]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Melanoma, Few [6-25]) 0.0, 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Kaposi's sarcoma, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mast-cell disease, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (AIDS involutionary, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (T-immunob large, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Monocytoid B-cell, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Nasopharyngeal CA, Few [6-25]) 0.0, 1.0, 0.0, 0.0, 0.0;
  (Seminoma, Few [6-25]) 0.0, 1.0, 0.0, 0.0, 0.0;
  (SLE, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mycobact histiocytos, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mast-cell hyperplas, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (LGV, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Histoplasmosis, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Coccidioidomycosis, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (CMV, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Brucellosis, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Ki-1 LC anaplas B, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Intermed lymphocytic, Few [6-25]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (AIDS early, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (AILD, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (ALIP, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Cat scratch disease, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Dermatopathic laden, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Florid follic hyperp, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (GLH hyaline vascular, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (GLH plasma cell, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Granulomatous laden, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Histiocytosis x, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Infectious mono, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Leprosy-lepromatous, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Lymphangiographic, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mantle zone hyperpla, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Necrotizing Kikuchi, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Necrotiz non-Kikuchi, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Rheumatoid arthritis, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Sarcoidosis, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (SHML, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Sinus histiocytosis, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Syphilis, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Toxoplasmosis, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Tuberculosis, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Viral NOS, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Whipple's disease, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (L&H nodular HD, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (L&H diffuse HD, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Nodular sclerosis HD, Many [26-100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Cellular phase NSHD, Many [26-100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Syncytial NSHD, Many [26-100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Mixed cellularity HD, Many [26-100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Interfollicular HD, Many [26-100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Diffuse fibrosis HD, Many [26-100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Reticular-type HD, Many [26-100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Small cleaved fol, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mixed fol, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Large cell fol, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small noncleaved fol, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small lymphocytic, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Plasmacytoid lyctic, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mantle zone lymphoma, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small cleaved dif, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mixed FCC dif, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Large cell dif, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (B-immunoblastic, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (T-immunob mixed, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AILD-like T-cell lym, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Japanese ATL, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Lymphoblastic, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small noncleaved dif, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (True histiocytic, Many [26-100]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Ki-1 LC anaplas T, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Multiple myeloma, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mycosis fungoides, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AML, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Hairy cell leukemia, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Carcinoma, Many [26-100]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Melanoma, Many [26-100]) 0.0, 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Kaposi's sarcoma, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mast-cell disease, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (AIDS involutionary, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (T-immunob large, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Monocytoid B-cell, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Nasopharyngeal CA, Many [26-100]) 0.0, 1.0, 0.0, 0.0, 0.0;
  (Seminoma, Many [26-100]) 0.0, 1.0, 0.0, 0.0, 0.0;
  (SLE, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mycobact histiocytos, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mast-cell hyperplas, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (LGV, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Histoplasmosis, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Coccidioidomycosis, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (CMV, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Brucellosis, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Ki-1 LC anaplas B, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Intermed lymphocytic, Many [26-100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (AIDS early, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (AILD, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (ALIP, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Cat scratch disease, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Dermatopathic laden, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Florid follic hyperp, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (GLH hyaline vascular, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (GLH plasma cell, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Granulomatous laden, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Histiocytosis x, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Infectious mono, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Leprosy-lepromatous, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Lymphangiographic, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mantle zone hyperpla, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Necrotizing Kikuchi, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Necrotiz non-Kikuchi, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Rheumatoid arthritis, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Sarcoidosis, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (SHML, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Sinus histiocytosis, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Syphilis, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Toxoplasmosis, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Tuberculosis, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Viral NOS, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Whipple's disease, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (L&H nodular HD, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (L&H diffuse HD, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Nodular sclerosis HD, Striking [>100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Cellular phase NSHD, Striking [>100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Syncytial NSHD, Striking [>100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Mixed cellularity HD, Striking [>100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Interfollicular HD, Striking [>100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Diffuse fibrosis HD, Striking [>100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Reticular-type HD, Striking [>100]) 0.00, 0.05, 0.95, 0.00, 0.00;
  (Small cleaved fol, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mixed fol, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Large cell fol, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small noncleaved fol, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small lymphocytic, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Plasmacytoid lyctic, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mantle zone lymphoma, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small cleaved dif, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mixed FCC dif, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Large cell dif, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (B-immunoblastic, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (T-immunob mixed, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AILD-like T-cell lym, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Japanese ATL, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Lymphoblastic, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Small noncleaved dif, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (True histiocytic, Striking [>100]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Ki-1 LC anaplas T, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Multiple myeloma, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mycosis fungoides, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AML, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Hairy cell leukemia, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Carcinoma, Striking [>100]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Melanoma, Striking [>100]) 0.0, 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Kaposi's sarcoma, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mast-cell disease, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (AIDS involutionary, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (T-immunob large, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Monocytoid B-cell, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Nasopharyngeal CA, Striking [>100]) 0.0, 1.0, 0.0, 0.0, 0.0;
  (Seminoma, Striking [>100]) 0.0, 1.0, 0.0, 0.0, 0.0;
  (SLE, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mycobact histiocytos, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Mast-cell hyperplas, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (LGV, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Histoplasmosis, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Coccidioidomycosis, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (CMV, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Brucellosis, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
  (Ki-1 LC anaplas B, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Intermed lymphocytic, Striking [>100]) 0.2, 0.2, 0.2, 0.2, 0.2;
}
probability ( MONO_LEU | Fault, MONO ) {
  (AIDS early, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AML, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS early, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (AILD, Rare [1-2]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (ALIP, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Cat scratch disease, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Dermatopathic laden, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Florid follic hyperp, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (GLH hyaline vascular, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (GLH plasma cell, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Granulomatous laden, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Histiocytosis x, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Infectious mono, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Leprosy-lepromatous, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Lymphangiographic, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mantle zone hyperpla, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Necrotizing Kikuchi, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Necrotiz non-Kikuchi, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Rheumatoid arthritis, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Sarcoidosis, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (SHML, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Sinus histiocytosis, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Syphilis, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Toxoplasmosis, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Tuberculosis, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Viral NOS, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Whipple's disease, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (L&H nodular HD, Rare [1-2]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (L&H diffuse HD, Rare [1-2]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Nodular sclerosis HD, Rare [1-2]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Cellular phase NSHD, Rare [1-2]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Syncytial NSHD, Rare [1-2]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Mixed cellularity HD, Rare [1-2]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Interfollicular HD, Rare [1-2]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Diffuse fibrosis HD, Rare [1-2]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Reticular-type HD, Rare [1-2]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Small cleaved fol, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mixed fol, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Large cell fol, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Small noncleaved fol, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Small lymphocytic, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Plasmacytoid lyctic, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mantle zone lymphoma, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Small cleaved dif, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mixed FCC dif, Rare [1-2]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Large cell dif, Rare [1-2]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (B-immunoblastic, Rare [1-2]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (T-immunob mixed, Rare [1-2]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (AILD-like T-cell lym, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Japanese ATL, Rare [1-2]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Lymphoblastic, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Small noncleaved dif, Rare [1-2]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (True histiocytic, Rare [1-2]) 0.0, 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Rare [1-2]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Multiple myeloma, Rare [1-2]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Mycosis fungoides, Rare [1-2]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (AML, Rare [1-2]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Hairy cell leukemia, Rare [1-2]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Carcinoma, Rare [1-2]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Melanoma, Rare [1-2]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (EM plasmacytoma, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Kaposi's sarcoma, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mast-cell disease, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (AIDS involutionary, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (T-immunob large, Rare [1-2]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Monocytoid B-cell, Rare [1-2]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Nasopharyngeal CA, Rare [1-2]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Seminoma, Rare [1-2]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (SLE, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mycobact histiocytos, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mast-cell hyperplas, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (LGV, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Histoplasmosis, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Coccidioidomycosis, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (CMV, Rare [1-2]) 0.00, 0.95, 0.05, 0.00, 0.00;
  (Brucellosis, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Ki-1 LC anaplas B, Rare [1-2]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Intermed lymphocytic, Rare [1-2]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (AIDS early, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (AILD, Present [3-20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (ALIP, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Cat scratch disease, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Dermatopathic laden, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Florid follic hyperp, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (GLH hyaline vascular, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (GLH plasma cell, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Granulomatous laden, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Histiocytosis x, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Infectious mono, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Leprosy-lepromatous, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Lymphangiographic, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mantle zone hyperpla, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Necrotizing Kikuchi, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Necrotiz non-Kikuchi, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Rheumatoid arthritis, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Sarcoidosis, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (SHML, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Sinus histiocytosis, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Syphilis, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Toxoplasmosis, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Tuberculosis, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Viral NOS, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Whipple's disease, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (L&H nodular HD, Present [3-20]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (L&H diffuse HD, Present [3-20]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Nodular sclerosis HD, Present [3-20]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Cellular phase NSHD, Present [3-20]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Syncytial NSHD, Present [3-20]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Mixed cellularity HD, Present [3-20]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Interfollicular HD, Present [3-20]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Diffuse fibrosis HD, Present [3-20]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Reticular-type HD, Present [3-20]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Small cleaved fol, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mixed fol, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Large cell fol, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Small noncleaved fol, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Small lymphocytic, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Plasmacytoid lyctic, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mantle zone lymphoma, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Small cleaved dif, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mixed FCC dif, Present [3-20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Large cell dif, Present [3-20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (B-immunoblastic, Present [3-20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (T-immunob mixed, Present [3-20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (AILD-like T-cell lym, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Japanese ATL, Present [3-20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Lymphoblastic, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Small noncleaved dif, Present [3-20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (True histiocytic, Present [3-20]) 0.0, 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Present [3-20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Multiple myeloma, Present [3-20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Mycosis fungoides, Present [3-20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (AML, Present [3-20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Hairy cell leukemia, Present [3-20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Carcinoma, Present [3-20]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Melanoma, Present [3-20]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (EM plasmacytoma, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Kaposi's sarcoma, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mast-cell disease, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (AIDS involutionary, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (T-immunob large, Present [3-20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Monocytoid B-cell, Present [3-20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Nasopharyngeal CA, Present [3-20]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Seminoma, Present [3-20]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (SLE, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mycobact histiocytos, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mast-cell hyperplas, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (LGV, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Histoplasmosis, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Coccidioidomycosis, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (CMV, Present [3-20]) 0.00, 0.95, 0.05, 0.00, 0.00;
  (Brucellosis, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Ki-1 LC anaplas B, Present [3-20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Intermed lymphocytic, Present [3-20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (AIDS early, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (AILD, Many [>20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (ALIP, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Cat scratch disease, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Dermatopathic laden, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Florid follic hyperp, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (GLH hyaline vascular, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (GLH plasma cell, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Granulomatous laden, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Histiocytosis x, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Infectious mono, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Leprosy-lepromatous, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Lymphangiographic, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mantle zone hyperpla, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Necrotizing Kikuchi, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Necrotiz non-Kikuchi, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Rheumatoid arthritis, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Sarcoidosis, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (SHML, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Sinus histiocytosis, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Syphilis, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Toxoplasmosis, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Tuberculosis, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Viral NOS, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Whipple's disease, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (L&H nodular HD, Many [>20]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (L&H diffuse HD, Many [>20]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Nodular sclerosis HD, Many [>20]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Cellular phase NSHD, Many [>20]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Syncytial NSHD, Many [>20]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Mixed cellularity HD, Many [>20]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Interfollicular HD, Many [>20]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Diffuse fibrosis HD, Many [>20]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Reticular-type HD, Many [>20]) 0.0, 0.1, 0.9, 0.0, 0.0;
  (Small cleaved fol, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mixed fol, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Large cell fol, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Small noncleaved fol, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Small lymphocytic, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Plasmacytoid lyctic, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mantle zone lymphoma, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Small cleaved dif, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mixed FCC dif, Many [>20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Large cell dif, Many [>20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (B-immunoblastic, Many [>20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (T-immunob mixed, Many [>20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (AILD-like T-cell lym, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Japanese ATL, Many [>20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Lymphoblastic, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Small noncleaved dif, Many [>20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (True histiocytic, Many [>20]) 0.0, 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Many [>20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Multiple myeloma, Many [>20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Mycosis fungoides, Many [>20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (AML, Many [>20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Hairy cell leukemia, Many [>20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Carcinoma, Many [>20]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Melanoma, Many [>20]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (EM plasmacytoma, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Kaposi's sarcoma, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mast-cell disease, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (AIDS involutionary, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (T-immunob large, Many [>20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Monocytoid B-cell, Many [>20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Nasopharyngeal CA, Many [>20]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Seminoma, Many [>20]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (SLE, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mycobact histiocytos, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Mast-cell hyperplas, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (LGV, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Histoplasmosis, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Coccidioidomycosis, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (CMV, Many [>20]) 0.00, 0.95, 0.05, 0.00, 0.00;
  (Brucellosis, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
  (Ki-1 LC anaplas B, Many [>20]) 0.0, 0.2, 0.0, 0.8, 0.0;
  (Intermed lymphocytic, Many [>20]) 0.0, 0.1, 0.0, 0.9, 0.0;
}
probability ( LH_LEU | Fault, L_and_H ) {
  (AIDS early, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AML, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS early, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (AILD, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (ALIP, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Cat scratch disease, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Dermatopathic laden, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Florid follic hyperp, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (GLH hyaline vascular, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (GLH plasma cell, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Granulomatous laden, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Histiocytosis x, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Infectious mono, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Leprosy-lepromatous, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Lymphangiographic, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Mantle zone hyperpla, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Necrotizing Kikuchi, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Necrotiz non-Kikuchi, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Rheumatoid arthritis, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Sarcoidosis, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (SHML, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Sinus histiocytosis, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Syphilis, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Toxoplasmosis, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Tuberculosis, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Viral NOS, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Whipple's disease, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (L&H nodular HD, Rare [1-5]) 0.00, 0.02, 0.01, 0.97, 0.00;
  (L&H diffuse HD, Rare [1-5]) 0.00, 0.02, 0.01, 0.97, 0.00;
  (Nodular sclerosis HD, Rare [1-5]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Cellular phase NSHD, Rare [1-5]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Syncytial NSHD, Rare [1-5]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Mixed cellularity HD, Rare [1-5]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Interfollicular HD, Rare [1-5]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Diffuse fibrosis HD, Rare [1-5]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Reticular-type HD, Rare [1-5]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Small cleaved fol, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Mixed fol, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Large cell fol, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Small noncleaved fol, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Small lymphocytic, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Plasmacytoid lyctic, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Mantle zone lymphoma, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Small cleaved dif, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Mixed FCC dif, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Large cell dif, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (B-immunoblastic, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (T-immunob mixed, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AILD-like T-cell lym, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Japanese ATL, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Lymphoblastic, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Small noncleaved dif, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (True histiocytic, Rare [1-5]) 0.0, 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Multiple myeloma, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mycosis fungoides, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AML, Rare [1-5]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Hairy cell leukemia, Rare [1-5]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Carcinoma, Rare [1-5]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Melanoma, Rare [1-5]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (EM plasmacytoma, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Kaposi's sarcoma, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Mast-cell disease, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (AIDS involutionary, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (T-immunob large, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Monocytoid B-cell, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Nasopharyngeal CA, Rare [1-5]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Seminoma, Rare [1-5]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (SLE, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mycobact histiocytos, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Mast-cell hyperplas, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (LGV, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Histoplasmosis, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Coccidioidomycosis, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (CMV, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Brucellosis, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas B, Rare [1-5]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Intermed lymphocytic, Rare [1-5]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (AIDS early, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (AILD, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (ALIP, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Cat scratch disease, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Dermatopathic laden, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Florid follic hyperp, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (GLH hyaline vascular, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (GLH plasma cell, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Granulomatous laden, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Histiocytosis x, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Infectious mono, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Leprosy-lepromatous, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Lymphangiographic, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Mantle zone hyperpla, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Necrotizing Kikuchi, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Necrotiz non-Kikuchi, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Rheumatoid arthritis, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Sarcoidosis, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (SHML, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Sinus histiocytosis, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Syphilis, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Toxoplasmosis, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Tuberculosis, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Viral NOS, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Whipple's disease, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (L&H nodular HD, Few [6-25]) 0.00, 0.02, 0.01, 0.97, 0.00;
  (L&H diffuse HD, Few [6-25]) 0.00, 0.02, 0.01, 0.97, 0.00;
  (Nodular sclerosis HD, Few [6-25]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Cellular phase NSHD, Few [6-25]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Syncytial NSHD, Few [6-25]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Mixed cellularity HD, Few [6-25]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Interfollicular HD, Few [6-25]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Diffuse fibrosis HD, Few [6-25]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Reticular-type HD, Few [6-25]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Small cleaved fol, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Mixed fol, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Large cell fol, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Small noncleaved fol, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Small lymphocytic, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Plasmacytoid lyctic, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Mantle zone lymphoma, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Small cleaved dif, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Mixed FCC dif, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Large cell dif, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (B-immunoblastic, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (T-immunob mixed, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AILD-like T-cell lym, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Japanese ATL, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Lymphoblastic, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Small noncleaved dif, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (True histiocytic, Few [6-25]) 0.0, 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Multiple myeloma, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mycosis fungoides, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AML, Few [6-25]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Hairy cell leukemia, Few [6-25]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Carcinoma, Few [6-25]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Melanoma, Few [6-25]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (EM plasmacytoma, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Kaposi's sarcoma, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Mast-cell disease, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (AIDS involutionary, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (T-immunob large, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Monocytoid B-cell, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Nasopharyngeal CA, Few [6-25]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Seminoma, Few [6-25]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (SLE, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mycobact histiocytos, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Mast-cell hyperplas, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (LGV, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Histoplasmosis, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Coccidioidomycosis, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (CMV, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Brucellosis, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas B, Few [6-25]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Intermed lymphocytic, Few [6-25]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (AIDS early, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (AILD, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (ALIP, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Cat scratch disease, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Dermatopathic laden, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Florid follic hyperp, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (GLH hyaline vascular, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (GLH plasma cell, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Granulomatous laden, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Histiocytosis x, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Infectious mono, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Leprosy-lepromatous, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Lymphangiographic, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Mantle zone hyperpla, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Necrotizing Kikuchi, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Necrotiz non-Kikuchi, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Rheumatoid arthritis, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Sarcoidosis, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (SHML, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Sinus histiocytosis, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Syphilis, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Toxoplasmosis, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Tuberculosis, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Viral NOS, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Whipple's disease, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (L&H nodular HD, Many [26-100]) 0.00, 0.02, 0.01, 0.97, 0.00;
  (L&H diffuse HD, Many [26-100]) 0.00, 0.02, 0.01, 0.97, 0.00;
  (Nodular sclerosis HD, Many [26-100]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Cellular phase NSHD, Many [26-100]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Syncytial NSHD, Many [26-100]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Mixed cellularity HD, Many [26-100]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Interfollicular HD, Many [26-100]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Diffuse fibrosis HD, Many [26-100]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Reticular-type HD, Many [26-100]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Small cleaved fol, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Mixed fol, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Large cell fol, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Small noncleaved fol, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Small lymphocytic, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Plasmacytoid lyctic, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Mantle zone lymphoma, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Small cleaved dif, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Mixed FCC dif, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Large cell dif, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (B-immunoblastic, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (T-immunob mixed, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AILD-like T-cell lym, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Japanese ATL, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Lymphoblastic, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Small noncleaved dif, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (True histiocytic, Many [26-100]) 0.0, 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Multiple myeloma, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mycosis fungoides, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AML, Many [26-100]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Hairy cell leukemia, Many [26-100]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Carcinoma, Many [26-100]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Melanoma, Many [26-100]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (EM plasmacytoma, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Kaposi's sarcoma, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Mast-cell disease, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (AIDS involutionary, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (T-immunob large, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Monocytoid B-cell, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Nasopharyngeal CA, Many [26-100]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Seminoma, Many [26-100]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (SLE, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mycobact histiocytos, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Mast-cell hyperplas, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (LGV, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Histoplasmosis, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Coccidioidomycosis, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (CMV, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Brucellosis, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas B, Many [26-100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Intermed lymphocytic, Many [26-100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (AIDS early, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (AILD, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (ALIP, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Cat scratch disease, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Dermatopathic laden, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Florid follic hyperp, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (GLH hyaline vascular, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (GLH plasma cell, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Granulomatous laden, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Histiocytosis x, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Infectious mono, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Leprosy-lepromatous, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Lymphangiographic, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Mantle zone hyperpla, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Necrotizing Kikuchi, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Necrotiz non-Kikuchi, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Rheumatoid arthritis, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Sarcoidosis, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (SHML, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Sinus histiocytosis, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Syphilis, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Toxoplasmosis, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Tuberculosis, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Viral NOS, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Whipple's disease, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (L&H nodular HD, Striking [>100]) 0.00, 0.02, 0.01, 0.97, 0.00;
  (L&H diffuse HD, Striking [>100]) 0.00, 0.02, 0.01, 0.97, 0.00;
  (Nodular sclerosis HD, Striking [>100]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Cellular phase NSHD, Striking [>100]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Syncytial NSHD, Striking [>100]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Mixed cellularity HD, Striking [>100]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Interfollicular HD, Striking [>100]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Diffuse fibrosis HD, Striking [>100]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Reticular-type HD, Striking [>100]) 0.0, 0.1, 0.8, 0.1, 0.0;
  (Small cleaved fol, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Mixed fol, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Large cell fol, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Small noncleaved fol, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Small lymphocytic, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Plasmacytoid lyctic, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Mantle zone lymphoma, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Small cleaved dif, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Mixed FCC dif, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Large cell dif, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (B-immunoblastic, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (T-immunob mixed, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AILD-like T-cell lym, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Japanese ATL, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Lymphoblastic, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Small noncleaved dif, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (True histiocytic, Striking [>100]) 0.0, 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Multiple myeloma, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mycosis fungoides, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (AML, Striking [>100]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Hairy cell leukemia, Striking [>100]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Carcinoma, Striking [>100]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Melanoma, Striking [>100]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (EM plasmacytoma, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Kaposi's sarcoma, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Mast-cell disease, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (AIDS involutionary, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (T-immunob large, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Monocytoid B-cell, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Nasopharyngeal CA, Striking [>100]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Seminoma, Striking [>100]) 0.00, 0.99, 0.01, 0.00, 0.00;
  (SLE, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Mycobact histiocytos, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Mast-cell hyperplas, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (LGV, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Histoplasmosis, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Coccidioidomycosis, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (CMV, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Brucellosis, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas B, Striking [>100]) 0.00, 0.01, 0.00, 0.99, 0.00;
  (Intermed lymphocytic, Striking [>100]) 0.0, 0.0, 0.0, 1.0, 0.0;
}
probability ( CA_KER | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 1.0, 0.0;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 1.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 1.0, 0.0;
  (L&H diffuse HD) 1.0, 0.0;
  (Nodular sclerosis HD) 1.0, 0.0;
  (Cellular phase NSHD) 1.0, 0.0;
  (Syncytial NSHD) 1.0, 0.0;
  (Mixed cellularity HD) 1.0, 0.0;
  (Interfollicular HD) 1.0, 0.0;
  (Diffuse fibrosis HD) 1.0, 0.0;
  (Reticular-type HD) 1.0, 0.0;
  (Small cleaved fol) 1.0, 0.0;
  (Mixed fol) 1.0, 0.0;
  (Large cell fol) 1.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0;
  (Small lymphocytic) 1.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0;
  (Small cleaved dif) 1.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0;
  (Large cell dif) 1.0, 0.0;
  (B-immunoblastic) 1.0, 0.0;
  (T-immunob mixed) 1.0, 0.0;
  (AILD-like T-cell lym) 1.0, 0.0;
  (Japanese ATL) 1.0, 0.0;
  (Lymphoblastic) 1.0, 0.0;
  (Small noncleaved dif) 1.0, 0.0;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 1.0, 0.0;
  (Multiple myeloma) 1.0, 0.0;
  (Mycosis fungoides) 1.0, 0.0;
  (AML) 1.0, 0.0;
  (Hairy cell leukemia) 1.0, 0.0;
  (Carcinoma) 0.05, 0.95;
  (Melanoma) 1.0, 0.0;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0;
  (Mast-cell disease) 1.0, 0.0;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 1.0, 0.0;
  (Monocytoid B-cell) 1.0, 0.0;
  (Nasopharyngeal CA) 0.05, 0.95;
  (Seminoma) 1.0, 0.0;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 1.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0;
}
probability ( MLC_LEU9 | Fault, MLC ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0;
  (AIDS early, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (AILD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (ALIP, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Cat scratch disease, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Dermatopathic laden, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Florid follic hyperp, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (GLH hyaline vascular, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (GLH plasma cell, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Granulomatous laden, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Histiocytosis x, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Infectious mono, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Leprosy-lepromatous, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Lymphangiographic, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mantle zone hyperpla, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Necrotizing Kikuchi, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Necrotiz non-Kikuchi, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Rheumatoid arthritis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Sarcoidosis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (SHML, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Sinus histiocytosis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Syphilis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Toxoplasmosis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Tuberculosis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Viral NOS, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Whipple's disease, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (L&H nodular HD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (L&H diffuse HD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Nodular sclerosis HD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Cellular phase NSHD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Syncytial NSHD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mixed cellularity HD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Interfollicular HD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Diffuse fibrosis HD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Reticular-type HD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Small cleaved fol, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mixed fol, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Large cell fol, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Small noncleaved fol, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Small lymphocytic, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Plasmacytoid lyctic, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mantle zone lymphoma, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Small cleaved dif, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mixed FCC dif, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Large cell dif, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (B-immunoblastic, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (T-immunob mixed, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (AILD-like T-cell lym, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Japanese ATL, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Lymphoblastic, Sparse [<10pc]) 0.00, 0.05, 0.95;
  (Small noncleaved dif, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (True histiocytic, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas T, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Multiple myeloma, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mycosis fungoides, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (AML, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Hairy cell leukemia, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Carcinoma, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Melanoma, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (EM plasmacytoma, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Kaposi's sarcoma, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mast-cell disease, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (AIDS involutionary, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (T-immunob large, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Monocytoid B-cell, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Nasopharyngeal CA, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Seminoma, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (SLE, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mycobact histiocytos, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mast-cell hyperplas, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (LGV, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Histoplasmosis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Coccidioidomycosis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (CMV, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Brucellosis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas B, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Intermed lymphocytic, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (AIDS early, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (AILD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (ALIP, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Cat scratch disease, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Dermatopathic laden, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Florid follic hyperp, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (GLH hyaline vascular, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (GLH plasma cell, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Granulomatous laden, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Histiocytosis x, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Infectious mono, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Leprosy-lepromatous, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Lymphangiographic, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mantle zone hyperpla, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Necrotizing Kikuchi, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Necrotiz non-Kikuchi, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Rheumatoid arthritis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Sarcoidosis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (SHML, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Sinus histiocytosis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Syphilis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Toxoplasmosis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Tuberculosis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Viral NOS, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Whipple's disease, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (L&H nodular HD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (L&H diffuse HD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Nodular sclerosis HD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Cellular phase NSHD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Syncytial NSHD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mixed cellularity HD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Interfollicular HD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Diffuse fibrosis HD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Reticular-type HD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Small cleaved fol, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mixed fol, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Large cell fol, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Small noncleaved fol, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Small lymphocytic, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Plasmacytoid lyctic, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mantle zone lymphoma, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Small cleaved dif, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mixed FCC dif, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Large cell dif, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (B-immunoblastic, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (T-immunob mixed, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (AILD-like T-cell lym, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Japanese ATL, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Lymphoblastic, Moderate [11-50pc]) 0.00, 0.05, 0.95;
  (Small noncleaved dif, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (True histiocytic, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas T, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Multiple myeloma, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mycosis fungoides, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (AML, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Hairy cell leukemia, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Carcinoma, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Melanoma, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (EM plasmacytoma, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Kaposi's sarcoma, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mast-cell disease, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (AIDS involutionary, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (T-immunob large, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Monocytoid B-cell, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Nasopharyngeal CA, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Seminoma, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (SLE, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mycobact histiocytos, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mast-cell hyperplas, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (LGV, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Histoplasmosis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Coccidioidomycosis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (CMV, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Brucellosis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas B, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Intermed lymphocytic, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (AIDS early, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (AILD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (ALIP, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Cat scratch disease, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Dermatopathic laden, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Florid follic hyperp, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (GLH hyaline vascular, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (GLH plasma cell, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Granulomatous laden, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Histiocytosis x, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Infectious mono, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Leprosy-lepromatous, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Lymphangiographic, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mantle zone hyperpla, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Necrotizing Kikuchi, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Necrotiz non-Kikuchi, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Rheumatoid arthritis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Sarcoidosis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (SHML, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Sinus histiocytosis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Syphilis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Toxoplasmosis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Tuberculosis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Viral NOS, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Whipple's disease, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (L&H nodular HD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (L&H diffuse HD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Nodular sclerosis HD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Cellular phase NSHD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Syncytial NSHD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mixed cellularity HD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Interfollicular HD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Diffuse fibrosis HD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Reticular-type HD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Small cleaved fol, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mixed fol, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Large cell fol, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Small noncleaved fol, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Small lymphocytic, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Plasmacytoid lyctic, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mantle zone lymphoma, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Small cleaved dif, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mixed FCC dif, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Large cell dif, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (B-immunoblastic, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (T-immunob mixed, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (AILD-like T-cell lym, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Japanese ATL, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Lymphoblastic, Numerous [51-90pc]) 0.00, 0.05, 0.95;
  (Small noncleaved dif, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (True histiocytic, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas T, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Multiple myeloma, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mycosis fungoides, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (AML, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Hairy cell leukemia, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Carcinoma, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Melanoma, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (EM plasmacytoma, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Kaposi's sarcoma, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mast-cell disease, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (AIDS involutionary, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (T-immunob large, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Monocytoid B-cell, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Nasopharyngeal CA, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Seminoma, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (SLE, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mycobact histiocytos, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mast-cell hyperplas, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (LGV, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Histoplasmosis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Coccidioidomycosis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (CMV, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Brucellosis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas B, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Intermed lymphocytic, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (AIDS early, Striking [>90pc]) 0.0, 1.0, 0.0;
  (AILD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (ALIP, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Cat scratch disease, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Dermatopathic laden, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Florid follic hyperp, Striking [>90pc]) 0.0, 1.0, 0.0;
  (GLH hyaline vascular, Striking [>90pc]) 0.0, 1.0, 0.0;
  (GLH plasma cell, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Granulomatous laden, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Histiocytosis x, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Infectious mono, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Leprosy-lepromatous, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Lymphangiographic, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mantle zone hyperpla, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Necrotizing Kikuchi, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Necrotiz non-Kikuchi, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Rheumatoid arthritis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Sarcoidosis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (SHML, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Sinus histiocytosis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Syphilis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Toxoplasmosis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Tuberculosis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Viral NOS, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Whipple's disease, Striking [>90pc]) 0.0, 1.0, 0.0;
  (L&H nodular HD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (L&H diffuse HD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Nodular sclerosis HD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Cellular phase NSHD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Syncytial NSHD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mixed cellularity HD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Interfollicular HD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Diffuse fibrosis HD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Reticular-type HD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Small cleaved fol, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mixed fol, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Large cell fol, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Small noncleaved fol, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Small lymphocytic, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Plasmacytoid lyctic, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mantle zone lymphoma, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Small cleaved dif, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mixed FCC dif, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Large cell dif, Striking [>90pc]) 0.0, 1.0, 0.0;
  (B-immunoblastic, Striking [>90pc]) 0.0, 1.0, 0.0;
  (T-immunob mixed, Striking [>90pc]) 0.0, 1.0, 0.0;
  (AILD-like T-cell lym, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Japanese ATL, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Lymphoblastic, Striking [>90pc]) 0.00, 0.05, 0.95;
  (Small noncleaved dif, Striking [>90pc]) 0.0, 1.0, 0.0;
  (True histiocytic, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas T, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Multiple myeloma, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mycosis fungoides, Striking [>90pc]) 0.0, 1.0, 0.0;
  (AML, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Hairy cell leukemia, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Carcinoma, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Melanoma, Striking [>90pc]) 0.0, 1.0, 0.0;
  (EM plasmacytoma, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Kaposi's sarcoma, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mast-cell disease, Striking [>90pc]) 0.0, 1.0, 0.0;
  (AIDS involutionary, Striking [>90pc]) 0.0, 1.0, 0.0;
  (T-immunob large, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Monocytoid B-cell, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Nasopharyngeal CA, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Seminoma, Striking [>90pc]) 0.0, 1.0, 0.0;
  (SLE, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mycobact histiocytos, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mast-cell hyperplas, Striking [>90pc]) 0.0, 1.0, 0.0;
  (LGV, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Histoplasmosis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Coccidioidomycosis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (CMV, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Brucellosis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas B, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Intermed lymphocytic, Striking [>90pc]) 0.0, 1.0, 0.0;
}
probability ( MLC_TDT | Fault, MLC ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0;
  (AIDS early, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (AILD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (ALIP, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Cat scratch disease, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Dermatopathic laden, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Florid follic hyperp, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (GLH hyaline vascular, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (GLH plasma cell, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Granulomatous laden, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Histiocytosis x, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Infectious mono, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Leprosy-lepromatous, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Lymphangiographic, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mantle zone hyperpla, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Necrotizing Kikuchi, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Necrotiz non-Kikuchi, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Rheumatoid arthritis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Sarcoidosis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (SHML, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Sinus histiocytosis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Syphilis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Toxoplasmosis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Tuberculosis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Viral NOS, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Whipple's disease, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (L&H nodular HD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (L&H diffuse HD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Nodular sclerosis HD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Cellular phase NSHD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Syncytial NSHD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mixed cellularity HD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Interfollicular HD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Diffuse fibrosis HD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Reticular-type HD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Small cleaved fol, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mixed fol, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Large cell fol, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Small noncleaved fol, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Small lymphocytic, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Plasmacytoid lyctic, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mantle zone lymphoma, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Small cleaved dif, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mixed FCC dif, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Large cell dif, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (B-immunoblastic, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (T-immunob mixed, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (AILD-like T-cell lym, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Japanese ATL, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Lymphoblastic, Sparse [<10pc]) 0.00, 0.02, 0.98;
  (Small noncleaved dif, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (True histiocytic, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas T, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Multiple myeloma, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mycosis fungoides, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (AML, Sparse [<10pc]) 0.00, 0.95, 0.05;
  (Hairy cell leukemia, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Carcinoma, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Melanoma, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (EM plasmacytoma, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Kaposi's sarcoma, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mast-cell disease, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (AIDS involutionary, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (T-immunob large, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Monocytoid B-cell, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Nasopharyngeal CA, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Seminoma, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (SLE, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mycobact histiocytos, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mast-cell hyperplas, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (LGV, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Histoplasmosis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Coccidioidomycosis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (CMV, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Brucellosis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas B, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Intermed lymphocytic, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (AIDS early, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (AILD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (ALIP, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Cat scratch disease, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Dermatopathic laden, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Florid follic hyperp, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (GLH hyaline vascular, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (GLH plasma cell, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Granulomatous laden, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Histiocytosis x, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Infectious mono, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Leprosy-lepromatous, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Lymphangiographic, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mantle zone hyperpla, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Necrotizing Kikuchi, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Necrotiz non-Kikuchi, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Rheumatoid arthritis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Sarcoidosis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (SHML, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Sinus histiocytosis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Syphilis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Toxoplasmosis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Tuberculosis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Viral NOS, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Whipple's disease, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (L&H nodular HD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (L&H diffuse HD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Nodular sclerosis HD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Cellular phase NSHD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Syncytial NSHD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mixed cellularity HD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Interfollicular HD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Diffuse fibrosis HD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Reticular-type HD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Small cleaved fol, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mixed fol, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Large cell fol, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Small noncleaved fol, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Small lymphocytic, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Plasmacytoid lyctic, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mantle zone lymphoma, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Small cleaved dif, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mixed FCC dif, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Large cell dif, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (B-immunoblastic, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (T-immunob mixed, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (AILD-like T-cell lym, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Japanese ATL, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Lymphoblastic, Moderate [11-50pc]) 0.00, 0.02, 0.98;
  (Small noncleaved dif, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (True histiocytic, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas T, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Multiple myeloma, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mycosis fungoides, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (AML, Moderate [11-50pc]) 0.00, 0.95, 0.05;
  (Hairy cell leukemia, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Carcinoma, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Melanoma, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (EM plasmacytoma, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Kaposi's sarcoma, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mast-cell disease, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (AIDS involutionary, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (T-immunob large, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Monocytoid B-cell, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Nasopharyngeal CA, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Seminoma, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (SLE, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mycobact histiocytos, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mast-cell hyperplas, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (LGV, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Histoplasmosis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Coccidioidomycosis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (CMV, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Brucellosis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas B, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Intermed lymphocytic, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (AIDS early, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (AILD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (ALIP, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Cat scratch disease, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Dermatopathic laden, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Florid follic hyperp, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (GLH hyaline vascular, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (GLH plasma cell, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Granulomatous laden, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Histiocytosis x, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Infectious mono, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Leprosy-lepromatous, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Lymphangiographic, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mantle zone hyperpla, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Necrotizing Kikuchi, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Necrotiz non-Kikuchi, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Rheumatoid arthritis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Sarcoidosis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (SHML, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Sinus histiocytosis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Syphilis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Toxoplasmosis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Tuberculosis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Viral NOS, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Whipple's disease, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (L&H nodular HD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (L&H diffuse HD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Nodular sclerosis HD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Cellular phase NSHD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Syncytial NSHD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mixed cellularity HD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Interfollicular HD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Diffuse fibrosis HD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Reticular-type HD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Small cleaved fol, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mixed fol, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Large cell fol, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Small noncleaved fol, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Small lymphocytic, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Plasmacytoid lyctic, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mantle zone lymphoma, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Small cleaved dif, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mixed FCC dif, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Large cell dif, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (B-immunoblastic, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (T-immunob mixed, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (AILD-like T-cell lym, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Japanese ATL, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Lymphoblastic, Numerous [51-90pc]) 0.00, 0.02, 0.98;
  (Small noncleaved dif, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (True histiocytic, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas T, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Multiple myeloma, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mycosis fungoides, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (AML, Numerous [51-90pc]) 0.00, 0.95, 0.05;
  (Hairy cell leukemia, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Carcinoma, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Melanoma, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (EM plasmacytoma, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Kaposi's sarcoma, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mast-cell disease, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (AIDS involutionary, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (T-immunob large, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Monocytoid B-cell, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Nasopharyngeal CA, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Seminoma, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (SLE, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mycobact histiocytos, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mast-cell hyperplas, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (LGV, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Histoplasmosis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Coccidioidomycosis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (CMV, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Brucellosis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas B, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Intermed lymphocytic, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (AIDS early, Striking [>90pc]) 0.0, 1.0, 0.0;
  (AILD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (ALIP, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Cat scratch disease, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Dermatopathic laden, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Florid follic hyperp, Striking [>90pc]) 0.0, 1.0, 0.0;
  (GLH hyaline vascular, Striking [>90pc]) 0.0, 1.0, 0.0;
  (GLH plasma cell, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Granulomatous laden, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Histiocytosis x, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Infectious mono, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Leprosy-lepromatous, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Lymphangiographic, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mantle zone hyperpla, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Necrotizing Kikuchi, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Necrotiz non-Kikuchi, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Rheumatoid arthritis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Sarcoidosis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (SHML, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Sinus histiocytosis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Syphilis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Toxoplasmosis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Tuberculosis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Viral NOS, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Whipple's disease, Striking [>90pc]) 0.0, 1.0, 0.0;
  (L&H nodular HD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (L&H diffuse HD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Nodular sclerosis HD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Cellular phase NSHD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Syncytial NSHD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mixed cellularity HD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Interfollicular HD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Diffuse fibrosis HD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Reticular-type HD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Small cleaved fol, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mixed fol, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Large cell fol, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Small noncleaved fol, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Small lymphocytic, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Plasmacytoid lyctic, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mantle zone lymphoma, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Small cleaved dif, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mixed FCC dif, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Large cell dif, Striking [>90pc]) 0.0, 1.0, 0.0;
  (B-immunoblastic, Striking [>90pc]) 0.0, 1.0, 0.0;
  (T-immunob mixed, Striking [>90pc]) 0.0, 1.0, 0.0;
  (AILD-like T-cell lym, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Japanese ATL, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Lymphoblastic, Striking [>90pc]) 0.00, 0.02, 0.98;
  (Small noncleaved dif, Striking [>90pc]) 0.0, 1.0, 0.0;
  (True histiocytic, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas T, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Multiple myeloma, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mycosis fungoides, Striking [>90pc]) 0.0, 1.0, 0.0;
  (AML, Striking [>90pc]) 0.00, 0.95, 0.05;
  (Hairy cell leukemia, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Carcinoma, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Melanoma, Striking [>90pc]) 0.0, 1.0, 0.0;
  (EM plasmacytoma, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Kaposi's sarcoma, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mast-cell disease, Striking [>90pc]) 0.0, 1.0, 0.0;
  (AIDS involutionary, Striking [>90pc]) 0.0, 1.0, 0.0;
  (T-immunob large, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Monocytoid B-cell, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Nasopharyngeal CA, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Seminoma, Striking [>90pc]) 0.0, 1.0, 0.0;
  (SLE, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mycobact histiocytos, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mast-cell hyperplas, Striking [>90pc]) 0.0, 1.0, 0.0;
  (LGV, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Histoplasmosis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Coccidioidomycosis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (CMV, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Brucellosis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas B, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Intermed lymphocytic, Striking [>90pc]) 0.0, 1.0, 0.0;
}
probability ( CA_CHROM | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 1.0, 0.0;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 1.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 1.0, 0.0;
  (L&H diffuse HD) 1.0, 0.0;
  (Nodular sclerosis HD) 1.0, 0.0;
  (Cellular phase NSHD) 1.0, 0.0;
  (Syncytial NSHD) 1.0, 0.0;
  (Mixed cellularity HD) 1.0, 0.0;
  (Interfollicular HD) 1.0, 0.0;
  (Diffuse fibrosis HD) 1.0, 0.0;
  (Reticular-type HD) 1.0, 0.0;
  (Small cleaved fol) 1.0, 0.0;
  (Mixed fol) 1.0, 0.0;
  (Large cell fol) 1.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0;
  (Small lymphocytic) 1.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0;
  (Small cleaved dif) 1.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0;
  (Large cell dif) 1.0, 0.0;
  (B-immunoblastic) 1.0, 0.0;
  (T-immunob mixed) 1.0, 0.0;
  (AILD-like T-cell lym) 1.0, 0.0;
  (Japanese ATL) 1.0, 0.0;
  (Lymphoblastic) 1.0, 0.0;
  (Small noncleaved dif) 1.0, 0.0;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 1.0, 0.0;
  (Multiple myeloma) 1.0, 0.0;
  (Mycosis fungoides) 1.0, 0.0;
  (AML) 1.0, 0.0;
  (Hairy cell leukemia) 1.0, 0.0;
  (Carcinoma) 0.95, 0.05;
  (Melanoma) 1.0, 0.0;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0;
  (Mast-cell disease) 1.0, 0.0;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 1.0, 0.0;
  (Monocytoid B-cell) 1.0, 0.0;
  (Nasopharyngeal CA) 0.95, 0.05;
  (Seminoma) 1.0, 0.0;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 1.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0;
}
probability ( UCHL_1 | Fault ) {
  (AIDS early) 0.1, 0.9;
  (AILD) 0.5, 0.5;
  (ALIP) 0.1, 0.9;
  (Cat scratch disease) 0.1, 0.9;
  (Dermatopathic laden) 0.1, 0.9;
  (Florid follic hyperp) 0.1, 0.9;
  (GLH hyaline vascular) 0.1, 0.9;
  (GLH plasma cell) 0.1, 0.9;
  (Granulomatous laden) 0.1, 0.9;
  (Histiocytosis x) 0.1, 0.9;
  (Infectious mono) 0.1, 0.9;
  (Leprosy-lepromatous) 0.1, 0.9;
  (Lymphangiographic) 0.1, 0.9;
  (Mantle zone hyperpla) 0.1, 0.9;
  (Necrotizing Kikuchi) 0.1, 0.9;
  (Necrotiz non-Kikuchi) 0.1, 0.9;
  (Rheumatoid arthritis) 0.1, 0.9;
  (Sarcoidosis) 0.1, 0.9;
  (SHML) 0.1, 0.9;
  (Sinus histiocytosis) 0.1, 0.9;
  (Syphilis) 0.1, 0.9;
  (Toxoplasmosis) 0.1, 0.9;
  (Tuberculosis) 0.1, 0.9;
  (Viral NOS) 0.1, 0.9;
  (Whipple's disease) 0.1, 0.9;
  (L&H nodular HD) 0.9, 0.1;
  (L&H diffuse HD) 0.2, 0.8;
  (Nodular sclerosis HD) 0.2, 0.8;
  (Cellular phase NSHD) 0.2, 0.8;
  (Syncytial NSHD) 0.2, 0.8;
  (Mixed cellularity HD) 0.2, 0.8;
  (Interfollicular HD) 0.2, 0.8;
  (Diffuse fibrosis HD) 0.2, 0.8;
  (Reticular-type HD) 0.2, 0.8;
  (Small cleaved fol) 0.999, 0.001;
  (Mixed fol) 0.999, 0.001;
  (Large cell fol) 0.999, 0.001;
  (Small noncleaved fol) 0.999, 0.001;
  (Small lymphocytic) 0.999, 0.001;
  (Plasmacytoid lyctic) 0.999, 0.001;
  (Mantle zone lymphoma) 0.999, 0.001;
  (Small cleaved dif) 0.999, 0.001;
  (Mixed FCC dif) 0.999, 0.001;
  (Large cell dif) 0.999, 0.001;
  (B-immunoblastic) 0.999, 0.001;
  (T-immunob mixed) 0.5, 0.5;
  (AILD-like T-cell lym) 0.5, 0.5;
  (Japanese ATL) 0.5, 0.5;
  (Lymphoblastic) 0.5, 0.5;
  (Small noncleaved dif) 0.999, 0.001;
  (True histiocytic) 0.5, 0.5;
  (Ki-1 LC anaplas T) 0.5, 0.5;
  (Multiple myeloma) 0.1, 0.9;
  (Mycosis fungoides) 0.5, 0.5;
  (AML) 0.1, 0.9;
  (Hairy cell leukemia) 0.1, 0.9;
  (Carcinoma) 0.1, 0.9;
  (Melanoma) 0.1, 0.9;
  (EM plasmacytoma) 0.1, 0.9;
  (Kaposi's sarcoma) 0.1, 0.9;
  (Mast-cell disease) 0.1, 0.9;
  (AIDS involutionary) 0.1, 0.9;
  (T-immunob large) 0.5, 0.5;
  (Monocytoid B-cell) 0.999, 0.001;
  (Nasopharyngeal CA) 0.1, 0.9;
  (Seminoma) 0.1, 0.9;
  (SLE) 0.1, 0.9;
  (Mycobact histiocytos) 0.1, 0.9;
  (Mast-cell hyperplas) 0.1, 0.9;
  (LGV) 0.1, 0.9;
  (Histoplasmosis) 0.1, 0.9;
  (Coccidioidomycosis) 0.1, 0.9;
  (CMV) 0.1, 0.9;
  (Brucellosis) 0.1, 0.9;
  (Ki-1 LC anaplas B) 0.999, 0.001;
  (Intermed lymphocytic) 0.999, 0.001;
}
probability ( KI_AB | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 1.0, 0.0;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 1.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 0.99, 0.01;
  (L&H diffuse HD) 0.99, 0.01;
  (Nodular sclerosis HD) 0.05, 0.95;
  (Cellular phase NSHD) 0.05, 0.95;
  (Syncytial NSHD) 0.05, 0.95;
  (Mixed cellularity HD) 0.05, 0.95;
  (Interfollicular HD) 0.05, 0.95;
  (Diffuse fibrosis HD) 0.05, 0.95;
  (Reticular-type HD) 0.05, 0.95;
  (Small cleaved fol) 0.99, 0.01;
  (Mixed fol) 0.99, 0.01;
  (Large cell fol) 0.99, 0.01;
  (Small noncleaved fol) 0.99, 0.01;
  (Small lymphocytic) 0.99, 0.01;
  (Plasmacytoid lyctic) 0.99, 0.01;
  (Mantle zone lymphoma) 0.99, 0.01;
  (Small cleaved dif) 0.99, 0.01;
  (Mixed FCC dif) 0.99, 0.01;
  (Large cell dif) 0.99, 0.01;
  (B-immunoblastic) 0.99, 0.01;
  (T-immunob mixed) 0.99, 0.01;
  (AILD-like T-cell lym) 0.99, 0.01;
  (Japanese ATL) 0.99, 0.01;
  (Lymphoblastic) 0.99, 0.01;
  (Small noncleaved dif) 0.99, 0.01;
  (True histiocytic) 0.99, 0.01;
  (Ki-1 LC anaplas T) 0.0, 1.0;
  (Multiple myeloma) 0.98, 0.02;
  (Mycosis fungoides) 0.98, 0.02;
  (AML) 0.98, 0.02;
  (Hairy cell leukemia) 0.98, 0.02;
  (Carcinoma) 0.98, 0.02;
  (Melanoma) 0.98, 0.02;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0;
  (Mast-cell disease) 1.0, 0.0;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 0.99, 0.01;
  (Monocytoid B-cell) 0.99, 0.01;
  (Nasopharyngeal CA) 0.98, 0.02;
  (Seminoma) 0.98, 0.02;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 0.0, 1.0;
  (Intermed lymphocytic) 0.99, 0.01;
}
probability ( L_26 | Fault ) {
  (AIDS early) 0.5, 0.5;
  (AILD) 0.8, 0.2;
  (ALIP) 0.8, 0.2;
  (Cat scratch disease) 0.8, 0.2;
  (Dermatopathic laden) 0.8, 0.2;
  (Florid follic hyperp) 0.8, 0.2;
  (GLH hyaline vascular) 0.8, 0.2;
  (GLH plasma cell) 0.8, 0.2;
  (Granulomatous laden) 0.8, 0.2;
  (Histiocytosis x) 0.8, 0.2;
  (Infectious mono) 0.8, 0.2;
  (Leprosy-lepromatous) 0.8, 0.2;
  (Lymphangiographic) 0.8, 0.2;
  (Mantle zone hyperpla) 0.8, 0.2;
  (Necrotizing Kikuchi) 0.8, 0.2;
  (Necrotiz non-Kikuchi) 0.8, 0.2;
  (Rheumatoid arthritis) 0.8, 0.2;
  (Sarcoidosis) 0.8, 0.2;
  (SHML) 0.8, 0.2;
  (Sinus histiocytosis) 0.8, 0.2;
  (Syphilis) 0.8, 0.2;
  (Toxoplasmosis) 0.8, 0.2;
  (Tuberculosis) 0.8, 0.2;
  (Viral NOS) 0.8, 0.2;
  (Whipple's disease) 0.8, 0.2;
  (L&H nodular HD) 0.2, 0.8;
  (L&H diffuse HD) 0.5, 0.5;
  (Nodular sclerosis HD) 0.8, 0.2;
  (Cellular phase NSHD) 0.8, 0.2;
  (Syncytial NSHD) 0.8, 0.2;
  (Mixed cellularity HD) 0.8, 0.2;
  (Interfollicular HD) 0.8, 0.2;
  (Diffuse fibrosis HD) 0.8, 0.2;
  (Reticular-type HD) 0.8, 0.2;
  (Small cleaved fol) 0.01, 0.99;
  (Mixed fol) 0.01, 0.99;
  (Large cell fol) 0.01, 0.99;
  (Small noncleaved fol) 0.01, 0.99;
  (Small lymphocytic) 0.01, 0.99;
  (Plasmacytoid lyctic) 0.01, 0.99;
  (Mantle zone lymphoma) 0.01, 0.99;
  (Small cleaved dif) 0.01, 0.99;
  (Mixed FCC dif) 0.01, 0.99;
  (Large cell dif) 0.01, 0.99;
  (B-immunoblastic) 0.01, 0.99;
  (T-immunob mixed) 1.0, 0.0;
  (AILD-like T-cell lym) 1.0, 0.0;
  (Japanese ATL) 1.0, 0.0;
  (Lymphoblastic) 1.0, 0.0;
  (Small noncleaved dif) 0.01, 0.99;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 1.0, 0.0;
  (Multiple myeloma) 0.8, 0.2;
  (Mycosis fungoides) 1.0, 0.0;
  (AML) 0.8, 0.2;
  (Hairy cell leukemia) 0.8, 0.2;
  (Carcinoma) 0.8, 0.2;
  (Melanoma) 0.8, 0.2;
  (EM plasmacytoma) 0.01, 0.99;
  (Kaposi's sarcoma) 0.8, 0.2;
  (Mast-cell disease) 0.8, 0.2;
  (AIDS involutionary) 0.5, 0.5;
  (T-immunob large) 1.0, 0.0;
  (Monocytoid B-cell) 0.01, 0.99;
  (Nasopharyngeal CA) 0.8, 0.2;
  (Seminoma) 0.8, 0.2;
  (SLE) 0.8, 0.2;
  (Mycobact histiocytos) 0.8, 0.2;
  (Mast-cell hyperplas) 0.8, 0.2;
  (LGV) 0.8, 0.2;
  (Histoplasmosis) 0.8, 0.2;
  (Coccidioidomycosis) 0.8, 0.2;
  (CMV) 0.8, 0.2;
  (Brucellosis) 0.8, 0.2;
  (Ki-1 LC anaplas B) 0.01, 0.99;
  (Intermed lymphocytic) 0.01, 0.99;
}
probability ( BER_H2 | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 1.0, 0.0;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 1.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 0.99, 0.01;
  (L&H diffuse HD) 0.99, 0.01;
  (Nodular sclerosis HD) 0.05, 0.95;
  (Cellular phase NSHD) 0.05, 0.95;
  (Syncytial NSHD) 0.05, 0.95;
  (Mixed cellularity HD) 0.05, 0.95;
  (Interfollicular HD) 0.05, 0.95;
  (Diffuse fibrosis HD) 0.05, 0.95;
  (Reticular-type HD) 0.05, 0.95;
  (Small cleaved fol) 0.99, 0.01;
  (Mixed fol) 0.99, 0.01;
  (Large cell fol) 0.99, 0.01;
  (Small noncleaved fol) 0.99, 0.01;
  (Small lymphocytic) 0.99, 0.01;
  (Plasmacytoid lyctic) 0.99, 0.01;
  (Mantle zone lymphoma) 0.99, 0.01;
  (Small cleaved dif) 0.99, 0.01;
  (Mixed FCC dif) 0.99, 0.01;
  (Large cell dif) 0.99, 0.01;
  (B-immunoblastic) 0.99, 0.01;
  (T-immunob mixed) 0.99, 0.01;
  (AILD-like T-cell lym) 0.99, 0.01;
  (Japanese ATL) 0.99, 0.01;
  (Lymphoblastic) 0.99, 0.01;
  (Small noncleaved dif) 0.99, 0.01;
  (True histiocytic) 0.99, 0.01;
  (Ki-1 LC anaplas T) 0.0, 1.0;
  (Multiple myeloma) 0.98, 0.02;
  (Mycosis fungoides) 0.98, 0.02;
  (AML) 0.98, 0.02;
  (Hairy cell leukemia) 0.98, 0.02;
  (Carcinoma) 0.98, 0.02;
  (Melanoma) 0.98, 0.02;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0;
  (Mast-cell disease) 1.0, 0.0;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 0.99, 0.01;
  (Monocytoid B-cell) 0.99, 0.01;
  (Nasopharyngeal CA) 0.98, 0.02;
  (Seminoma) 0.98, 0.02;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 0.0, 1.0;
  (Intermed lymphocytic) 0.99, 0.01;
}
probability ( SEMINOMA | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 1.0, 0.0;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 1.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 1.0, 0.0;
  (L&H diffuse HD) 1.0, 0.0;
  (Nodular sclerosis HD) 1.0, 0.0;
  (Cellular phase NSHD) 1.0, 0.0;
  (Syncytial NSHD) 1.0, 0.0;
  (Mixed cellularity HD) 1.0, 0.0;
  (Interfollicular HD) 1.0, 0.0;
  (Diffuse fibrosis HD) 1.0, 0.0;
  (Reticular-type HD) 1.0, 0.0;
  (Small cleaved fol) 1.0, 0.0;
  (Mixed fol) 1.0, 0.0;
  (Large cell fol) 1.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0;
  (Small lymphocytic) 1.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0;
  (Small cleaved dif) 1.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0;
  (Large cell dif) 1.0, 0.0;
  (B-immunoblastic) 1.0, 0.0;
  (T-immunob mixed) 1.0, 0.0;
  (AILD-like T-cell lym) 1.0, 0.0;
  (Japanese ATL) 1.0, 0.0;
  (Lymphoblastic) 1.0, 0.0;
  (Small noncleaved dif) 1.0, 0.0;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 1.0, 0.0;
  (Multiple myeloma) 1.0, 0.0;
  (Mycosis fungoides) 1.0, 0.0;
  (AML) 1.0, 0.0;
  (Hairy cell leukemia) 1.0, 0.0;
  (Carcinoma) 1.0, 0.0;
  (Melanoma) 1.0, 0.0;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0;
  (Mast-cell disease) 1.0, 0.0;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 1.0, 0.0;
  (Monocytoid B-cell) 1.0, 0.0;
  (Nasopharyngeal CA) 1.0, 0.0;
  (Seminoma) 0.0, 1.0;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 1.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0;
}
probability ( AGE | Fault ) {
  (AIDS early) 0.05, 0.40, 0.54, 0.01;
  (AILD) 0.00001, 0.01000, 0.58999, 0.40000;
  (ALIP) 0.00001, 0.20000, 0.39999, 0.40000;
  (Cat scratch disease) 0.30, 0.20, 0.49, 0.01;
  (Dermatopathic laden) 0.01, 0.10, 0.69, 0.20;
  (Florid follic hyperp) 0.34, 0.40, 0.25, 0.01;
  (GLH hyaline vascular) 0.30, 0.30, 0.39, 0.01;
  (GLH plasma cell) 0.20, 0.20, 0.55, 0.05;
  (Granulomatous laden) 0.10, 0.15, 0.70, 0.05;
  (Histiocytosis x) 0.40, 0.20, 0.39, 0.01;
  (Infectious mono) 0.25, 0.45, 0.29, 0.01;
  (Leprosy-lepromatous) 0.1, 0.1, 0.7, 0.1;
  (Lymphangiographic) 0.05, 0.10, 0.65, 0.20;
  (Mantle zone hyperpla) 0.20, 0.30, 0.45, 0.05;
  (Necrotizing Kikuchi) 0.40, 0.40, 0.19, 0.01;
  (Necrotiz non-Kikuchi) 0.20, 0.25, 0.54, 0.01;
  (Rheumatoid arthritis) 0.01, 0.01, 0.35, 0.63;
  (Sarcoidosis) 0.10, 0.10, 0.65, 0.15;
  (SHML) 0.88, 0.10, 0.01, 0.01;
  (Sinus histiocytosis) 0.1, 0.1, 0.7, 0.1;
  (Syphilis) 0.01, 0.14, 0.84, 0.01;
  (Toxoplasmosis) 0.10, 0.64, 0.25, 0.01;
  (Tuberculosis) 0.10, 0.25, 0.64, 0.01;
  (Viral NOS) 0.10, 0.35, 0.54, 0.01;
  (Whipple's disease) 0.05, 0.10, 0.65, 0.20;
  (L&H nodular HD) 0.40, 0.39, 0.20, 0.01;
  (L&H diffuse HD) 0.40, 0.39, 0.20, 0.01;
  (Nodular sclerosis HD) 0.35, 0.40, 0.20, 0.05;
  (Cellular phase NSHD) 0.35, 0.40, 0.20, 0.05;
  (Syncytial NSHD) 0.35, 0.40, 0.20, 0.05;
  (Mixed cellularity HD) 0.20, 0.15, 0.60, 0.05;
  (Interfollicular HD) 0.20, 0.15, 0.60, 0.05;
  (Diffuse fibrosis HD) 0.01, 0.15, 0.54, 0.30;
  (Reticular-type HD) 0.01, 0.15, 0.54, 0.30;
  (Small cleaved fol) 0.001, 0.049, 0.650, 0.300;
  (Mixed fol) 0.001, 0.049, 0.650, 0.300;
  (Large cell fol) 0.01, 0.01, 0.60, 0.38;
  (Small noncleaved fol) 0.01, 0.01, 0.60, 0.38;
  (Small lymphocytic) 0.000001, 0.010000, 0.499999, 0.490000;
  (Plasmacytoid lyctic) 0.000001, 0.010000, 0.499999, 0.490000;
  (Mantle zone lymphoma) 0.000001, 0.010000, 0.499999, 0.490000;
  (Small cleaved dif) 0.001, 0.100, 0.500, 0.399;
  (Mixed FCC dif) 0.01, 0.05, 0.40, 0.54;
  (Large cell dif) 0.3, 0.1, 0.3, 0.3;
  (B-immunoblastic) 0.05, 0.10, 0.30, 0.55;
  (T-immunob mixed) 0.15, 0.20, 0.30, 0.35;
  (AILD-like T-cell lym) 0.00001, 0.01000, 0.58999, 0.40000;
  (Japanese ATL) 0.05, 0.10, 0.30, 0.55;
  (Lymphoblastic) 0.5, 0.2, 0.2, 0.1;
  (Small noncleaved dif) 0.5, 0.2, 0.2, 0.1;
  (True histiocytic) 0.05, 0.05, 0.40, 0.50;
  (Ki-1 LC anaplas T) 0.30, 0.25, 0.30, 0.15;
  (Multiple myeloma) 0.00, 0.01, 0.40, 0.59;
  (Mycosis fungoides) 0.00, 0.01, 0.60, 0.39;
  (AML) 0.02, 0.08, 0.73, 0.17;
  (Hairy cell leukemia) 0.001, 0.009, 0.600, 0.390;
  (Carcinoma) 0.01, 0.02, 0.60, 0.37;
  (Melanoma) 0.01, 0.10, 0.60, 0.29;
  (EM plasmacytoma) 9.999990e-07, 9.999990e-03, 4.999995e-01, 4.899995e-01;
  (Kaposi's sarcoma) 0.20, 0.25, 0.30, 0.25;
  (Mast-cell disease) 0.00, 0.01, 0.70, 0.29;
  (AIDS involutionary) 0.05, 0.40, 0.54, 0.01;
  (T-immunob large) 0.15, 0.20, 0.30, 0.35;
  (Monocytoid B-cell) 0.001, 0.049, 0.650, 0.300;
  (Nasopharyngeal CA) 0.15, 0.20, 0.60, 0.05;
  (Seminoma) 0.2, 0.3, 0.4, 0.1;
  (SLE) 0.25, 0.50, 0.20, 0.05;
  (Mycobact histiocytos) 0.10, 0.25, 0.64, 0.01;
  (Mast-cell hyperplas) 0.01, 0.05, 0.54, 0.40;
  (LGV) 0.01, 0.14, 0.84, 0.01;
  (Histoplasmosis) 0.15, 0.25, 0.40, 0.20;
  (Coccidioidomycosis) 0.15, 0.25, 0.40, 0.20;
  (CMV) 0.15, 0.25, 0.40, 0.20;
  (Brucellosis) 0.10, 0.64, 0.25, 0.01;
  (Ki-1 LC anaplas B) 0.30, 0.25, 0.30, 0.15;
  (Intermed lymphocytic) 0.000001, 0.010000, 0.499999, 0.490000;
}
probability ( LYMPHADE | Fault ) {
  (AIDS early) 0.15, 0.85;
  (AILD) 0.05, 0.95;
  (ALIP) 0.15, 0.85;
  (Cat scratch disease) 0.99, 0.01;
  (Dermatopathic laden) 0.99, 0.01;
  (Florid follic hyperp) 0.99, 0.01;
  (GLH hyaline vascular) 0.99, 0.01;
  (GLH plasma cell) 0.9, 0.1;
  (Granulomatous laden) 0.99, 0.01;
  (Histiocytosis x) 0.99, 0.01;
  (Infectious mono) 0.95, 0.05;
  (Leprosy-lepromatous) 0.9, 0.1;
  (Lymphangiographic) 0.9, 0.1;
  (Mantle zone hyperpla) 0.99, 0.01;
  (Necrotizing Kikuchi) 0.98, 0.02;
  (Necrotiz non-Kikuchi) 0.98, 0.02;
  (Rheumatoid arthritis) 0.95, 0.05;
  (Sarcoidosis) 0.95, 0.05;
  (SHML) 0.99, 0.01;
  (Sinus histiocytosis) 0.99, 0.01;
  (Syphilis) 0.95, 0.05;
  (Toxoplasmosis) 0.98, 0.02;
  (Tuberculosis) 0.95, 0.05;
  (Viral NOS) 0.95, 0.05;
  (Whipple's disease) 0.9, 0.1;
  (L&H nodular HD) 0.9, 0.1;
  (L&H diffuse HD) 0.9, 0.1;
  (Nodular sclerosis HD) 0.6, 0.4;
  (Cellular phase NSHD) 0.6, 0.4;
  (Syncytial NSHD) 0.6, 0.4;
  (Mixed cellularity HD) 0.5, 0.5;
  (Interfollicular HD) 0.5, 0.5;
  (Diffuse fibrosis HD) 0.15, 0.85;
  (Reticular-type HD) 0.15, 0.85;
  (Small cleaved fol) 0.15, 0.85;
  (Mixed fol) 0.15, 0.85;
  (Large cell fol) 0.4, 0.6;
  (Small noncleaved fol) 0.4, 0.6;
  (Small lymphocytic) 0.15, 0.85;
  (Plasmacytoid lyctic) 0.15, 0.85;
  (Mantle zone lymphoma) 0.4, 0.6;
  (Small cleaved dif) 0.4, 0.6;
  (Mixed FCC dif) 0.4, 0.6;
  (Large cell dif) 0.4, 0.6;
  (B-immunoblastic) 0.4, 0.6;
  (T-immunob mixed) 0.4, 0.6;
  (AILD-like T-cell lym) 0.05, 0.95;
  (Japanese ATL) 0.4, 0.6;
  (Lymphoblastic) 0.6, 0.4;
  (Small noncleaved dif) 0.4, 0.6;
  (True histiocytic) 0.4, 0.6;
  (Ki-1 LC anaplas T) 0.4, 0.6;
  (Multiple myeloma) 0.7, 0.3;
  (Mycosis fungoides) 0.7, 0.3;
  (AML) 0.7, 0.3;
  (Hairy cell leukemia) 0.95, 0.05;
  (Carcinoma) 0.98, 0.02;
  (Melanoma) 0.99, 0.01;
  (EM plasmacytoma) 0.98, 0.02;
  (Kaposi's sarcoma) 0.9, 0.1;
  (Mast-cell disease) 0.7, 0.3;
  (AIDS involutionary) 0.15, 0.85;
  (T-immunob large) 0.4, 0.6;
  (Monocytoid B-cell) 0.4, 0.6;
  (Nasopharyngeal CA) 0.98, 0.02;
  (Seminoma) 0.95, 0.05;
  (SLE) 0.95, 0.05;
  (Mycobact histiocytos) 0.95, 0.05;
  (Mast-cell hyperplas) 0.99, 0.01;
  (LGV) 0.99, 0.01;
  (Histoplasmosis) 0.99, 0.01;
  (Coccidioidomycosis) 0.99, 0.01;
  (CMV) 0.99, 0.01;
  (Brucellosis) 0.99, 0.01;
  (Ki-1 LC anaplas B) 0.4, 0.6;
  (Intermed lymphocytic) 0.4, 0.6;
}
probability ( MED_MASS | Fault ) {
  (AIDS early) 0.99, 0.01;
  (AILD) 0.97, 0.03;
  (ALIP) 0.995, 0.005;
  (Cat scratch disease) 0.995, 0.005;
  (Dermatopathic laden) 0.995, 0.005;
  (Florid follic hyperp) 0.995, 0.005;
  (GLH hyaline vascular) 0.1, 0.9;
  (GLH plasma cell) 0.9, 0.1;
  (Granulomatous laden) 0.995, 0.005;
  (Histiocytosis x) 0.995, 0.005;
  (Infectious mono) 0.995, 0.005;
  (Leprosy-lepromatous) 0.995, 0.005;
  (Lymphangiographic) 0.995, 0.005;
  (Mantle zone hyperpla) 0.995, 0.005;
  (Necrotizing Kikuchi) 0.995, 0.005;
  (Necrotiz non-Kikuchi) 0.995, 0.005;
  (Rheumatoid arthritis) 0.995, 0.005;
  (Sarcoidosis) 0.8, 0.2;
  (SHML) 0.97, 0.03;
  (Sinus histiocytosis) 0.995, 0.005;
  (Syphilis) 0.995, 0.005;
  (Toxoplasmosis) 0.995, 0.005;
  (Tuberculosis) 0.9, 0.1;
  (Viral NOS) 0.995, 0.005;
  (Whipple's disease) 0.995, 0.005;
  (L&H nodular HD) 0.99, 0.01;
  (L&H diffuse HD) 0.99, 0.01;
  (Nodular sclerosis HD) 0.4, 0.6;
  (Cellular phase NSHD) 0.4, 0.6;
  (Syncytial NSHD) 0.4, 0.6;
  (Mixed cellularity HD) 0.9, 0.1;
  (Interfollicular HD) 0.9, 0.1;
  (Diffuse fibrosis HD) 0.9, 0.1;
  (Reticular-type HD) 0.9, 0.1;
  (Small cleaved fol) 0.95, 0.05;
  (Mixed fol) 0.95, 0.05;
  (Large cell fol) 0.95, 0.05;
  (Small noncleaved fol) 0.95, 0.05;
  (Small lymphocytic) 0.97, 0.03;
  (Plasmacytoid lyctic) 0.97, 0.03;
  (Mantle zone lymphoma) 0.97, 0.03;
  (Small cleaved dif) 0.97, 0.03;
  (Mixed FCC dif) 0.97, 0.03;
  (Large cell dif) 0.85, 0.15;
  (B-immunoblastic) 0.9, 0.1;
  (T-immunob mixed) 0.9, 0.1;
  (AILD-like T-cell lym) 0.97, 0.03;
  (Japanese ATL) 0.9, 0.1;
  (Lymphoblastic) 0.6, 0.4;
  (Small noncleaved dif) 0.9, 0.1;
  (True histiocytic) 0.9, 0.1;
  (Ki-1 LC anaplas T) 0.9, 0.1;
  (Multiple myeloma) 0.993, 0.007;
  (Mycosis fungoides) 0.993, 0.007;
  (AML) 0.97, 0.03;
  (Hairy cell leukemia) 0.995, 0.005;
  (Carcinoma) 0.95, 0.05;
  (Melanoma) 0.993, 0.007;
  (EM plasmacytoma) 0.993, 0.007;
  (Kaposi's sarcoma) 0.993, 0.007;
  (Mast-cell disease) 0.993, 0.007;
  (AIDS involutionary) 0.99, 0.01;
  (T-immunob large) 0.9, 0.1;
  (Monocytoid B-cell) 0.97, 0.03;
  (Nasopharyngeal CA) 0.97, 0.03;
  (Seminoma) 0.95, 0.05;
  (SLE) 0.995, 0.005;
  (Mycobact histiocytos) 0.995, 0.005;
  (Mast-cell hyperplas) 0.995, 0.005;
  (LGV) 0.995, 0.005;
  (Histoplasmosis) 0.995, 0.005;
  (Coccidioidomycosis) 0.995, 0.005;
  (CMV) 0.995, 0.005;
  (Brucellosis) 0.995, 0.005;
  (Ki-1 LC anaplas B) 0.9, 0.1;
  (Intermed lymphocytic) 0.97, 0.03;
}
probability ( HMB45 | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 1.0, 0.0;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 1.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 1.0, 0.0;
  (L&H diffuse HD) 1.0, 0.0;
  (Nodular sclerosis HD) 1.0, 0.0;
  (Cellular phase NSHD) 1.0, 0.0;
  (Syncytial NSHD) 1.0, 0.0;
  (Mixed cellularity HD) 1.0, 0.0;
  (Interfollicular HD) 1.0, 0.0;
  (Diffuse fibrosis HD) 1.0, 0.0;
  (Reticular-type HD) 1.0, 0.0;
  (Small cleaved fol) 1.0, 0.0;
  (Mixed fol) 1.0, 0.0;
  (Large cell fol) 1.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0;
  (Small lymphocytic) 1.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0;
  (Small cleaved dif) 1.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0;
  (Large cell dif) 1.0, 0.0;
  (B-immunoblastic) 1.0, 0.0;
  (T-immunob mixed) 1.0, 0.0;
  (AILD-like T-cell lym) 1.0, 0.0;
  (Japanese ATL) 1.0, 0.0;
  (Lymphoblastic) 1.0, 0.0;
  (Small noncleaved dif) 1.0, 0.0;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 1.0, 0.0;
  (Multiple myeloma) 1.0, 0.0;
  (Mycosis fungoides) 1.0, 0.0;
  (AML) 1.0, 0.0;
  (Hairy cell leukemia) 1.0, 0.0;
  (Carcinoma) 1.0, 0.0;
  (Melanoma) 0.05, 0.95;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0;
  (Mast-cell disease) 1.0, 0.0;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 1.0, 0.0;
  (Monocytoid B-cell) 1.0, 0.0;
  (Nasopharyngeal CA) 1.0, 0.0;
  (Seminoma) 1.0, 0.0;
  (SLE) 1.0, 0.0;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 1.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0;
}
probability ( MLC_LYZ | Fault, MLC ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0;
  (AIDS early, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (AILD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (ALIP, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Cat scratch disease, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Dermatopathic laden, Sparse [<10pc]) 0.00, 0.98, 0.02;
  (Florid follic hyperp, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (GLH hyaline vascular, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (GLH plasma cell, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Granulomatous laden, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Histiocytosis x, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Infectious mono, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Leprosy-lepromatous, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Lymphangiographic, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mantle zone hyperpla, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Necrotizing Kikuchi, Sparse [<10pc]) 0.0, 0.9, 0.1;
  (Necrotiz non-Kikuchi, Sparse [<10pc]) 0.0, 0.9, 0.1;
  (Rheumatoid arthritis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Sarcoidosis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (SHML, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Sinus histiocytosis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Syphilis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Toxoplasmosis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Tuberculosis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Viral NOS, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Whipple's disease, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (L&H nodular HD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (L&H diffuse HD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Nodular sclerosis HD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Cellular phase NSHD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Syncytial NSHD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mixed cellularity HD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Interfollicular HD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Diffuse fibrosis HD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Reticular-type HD, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Small cleaved fol, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mixed fol, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Large cell fol, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Small noncleaved fol, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Small lymphocytic, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Plasmacytoid lyctic, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mantle zone lymphoma, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Small cleaved dif, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mixed FCC dif, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Large cell dif, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (B-immunoblastic, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (T-immunob mixed, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (AILD-like T-cell lym, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Japanese ATL, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Lymphoblastic, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Small noncleaved dif, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (True histiocytic, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas T, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Multiple myeloma, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mycosis fungoides, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (AML, Sparse [<10pc]) 0.0, 0.7, 0.3;
  (Hairy cell leukemia, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Carcinoma, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Melanoma, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (EM plasmacytoma, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Kaposi's sarcoma, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mast-cell disease, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (AIDS involutionary, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (T-immunob large, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Monocytoid B-cell, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Nasopharyngeal CA, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Seminoma, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (SLE, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mycobact histiocytos, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Mast-cell hyperplas, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (LGV, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Histoplasmosis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Coccidioidomycosis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (CMV, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Brucellosis, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas B, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (Intermed lymphocytic, Sparse [<10pc]) 0.0, 1.0, 0.0;
  (AIDS early, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (AILD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (ALIP, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Cat scratch disease, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Dermatopathic laden, Moderate [11-50pc]) 0.00, 0.98, 0.02;
  (Florid follic hyperp, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (GLH hyaline vascular, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (GLH plasma cell, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Granulomatous laden, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Histiocytosis x, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Infectious mono, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Leprosy-lepromatous, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Lymphangiographic, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mantle zone hyperpla, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Necrotizing Kikuchi, Moderate [11-50pc]) 0.0, 0.9, 0.1;
  (Necrotiz non-Kikuchi, Moderate [11-50pc]) 0.0, 0.9, 0.1;
  (Rheumatoid arthritis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Sarcoidosis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (SHML, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Sinus histiocytosis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Syphilis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Toxoplasmosis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Tuberculosis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Viral NOS, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Whipple's disease, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (L&H nodular HD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (L&H diffuse HD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Nodular sclerosis HD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Cellular phase NSHD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Syncytial NSHD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mixed cellularity HD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Interfollicular HD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Diffuse fibrosis HD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Reticular-type HD, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Small cleaved fol, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mixed fol, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Large cell fol, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Small noncleaved fol, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Small lymphocytic, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Plasmacytoid lyctic, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mantle zone lymphoma, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Small cleaved dif, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mixed FCC dif, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Large cell dif, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (B-immunoblastic, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (T-immunob mixed, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (AILD-like T-cell lym, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Japanese ATL, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Lymphoblastic, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Small noncleaved dif, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (True histiocytic, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas T, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Multiple myeloma, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mycosis fungoides, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (AML, Moderate [11-50pc]) 0.0, 0.7, 0.3;
  (Hairy cell leukemia, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Carcinoma, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Melanoma, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (EM plasmacytoma, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Kaposi's sarcoma, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mast-cell disease, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (AIDS involutionary, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (T-immunob large, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Monocytoid B-cell, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Nasopharyngeal CA, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Seminoma, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (SLE, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mycobact histiocytos, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Mast-cell hyperplas, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (LGV, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Histoplasmosis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Coccidioidomycosis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (CMV, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Brucellosis, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas B, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (Intermed lymphocytic, Moderate [11-50pc]) 0.0, 1.0, 0.0;
  (AIDS early, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (AILD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (ALIP, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Cat scratch disease, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Dermatopathic laden, Numerous [51-90pc]) 0.00, 0.98, 0.02;
  (Florid follic hyperp, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (GLH hyaline vascular, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (GLH plasma cell, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Granulomatous laden, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Histiocytosis x, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Infectious mono, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Leprosy-lepromatous, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Lymphangiographic, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mantle zone hyperpla, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Necrotizing Kikuchi, Numerous [51-90pc]) 0.0, 0.9, 0.1;
  (Necrotiz non-Kikuchi, Numerous [51-90pc]) 0.0, 0.9, 0.1;
  (Rheumatoid arthritis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Sarcoidosis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (SHML, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Sinus histiocytosis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Syphilis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Toxoplasmosis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Tuberculosis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Viral NOS, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Whipple's disease, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (L&H nodular HD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (L&H diffuse HD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Nodular sclerosis HD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Cellular phase NSHD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Syncytial NSHD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mixed cellularity HD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Interfollicular HD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Diffuse fibrosis HD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Reticular-type HD, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Small cleaved fol, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mixed fol, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Large cell fol, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Small noncleaved fol, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Small lymphocytic, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Plasmacytoid lyctic, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mantle zone lymphoma, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Small cleaved dif, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mixed FCC dif, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Large cell dif, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (B-immunoblastic, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (T-immunob mixed, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (AILD-like T-cell lym, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Japanese ATL, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Lymphoblastic, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Small noncleaved dif, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (True histiocytic, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas T, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Multiple myeloma, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mycosis fungoides, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (AML, Numerous [51-90pc]) 0.0, 0.7, 0.3;
  (Hairy cell leukemia, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Carcinoma, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Melanoma, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (EM plasmacytoma, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Kaposi's sarcoma, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mast-cell disease, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (AIDS involutionary, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (T-immunob large, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Monocytoid B-cell, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Nasopharyngeal CA, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Seminoma, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (SLE, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mycobact histiocytos, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Mast-cell hyperplas, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (LGV, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Histoplasmosis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Coccidioidomycosis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (CMV, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Brucellosis, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas B, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (Intermed lymphocytic, Numerous [51-90pc]) 0.0, 1.0, 0.0;
  (AIDS early, Striking [>90pc]) 0.0, 1.0, 0.0;
  (AILD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (ALIP, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Cat scratch disease, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Dermatopathic laden, Striking [>90pc]) 0.00, 0.98, 0.02;
  (Florid follic hyperp, Striking [>90pc]) 0.0, 1.0, 0.0;
  (GLH hyaline vascular, Striking [>90pc]) 0.0, 1.0, 0.0;
  (GLH plasma cell, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Granulomatous laden, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Histiocytosis x, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Infectious mono, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Leprosy-lepromatous, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Lymphangiographic, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mantle zone hyperpla, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Necrotizing Kikuchi, Striking [>90pc]) 0.0, 0.9, 0.1;
  (Necrotiz non-Kikuchi, Striking [>90pc]) 0.0, 0.9, 0.1;
  (Rheumatoid arthritis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Sarcoidosis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (SHML, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Sinus histiocytosis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Syphilis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Toxoplasmosis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Tuberculosis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Viral NOS, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Whipple's disease, Striking [>90pc]) 0.0, 1.0, 0.0;
  (L&H nodular HD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (L&H diffuse HD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Nodular sclerosis HD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Cellular phase NSHD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Syncytial NSHD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mixed cellularity HD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Interfollicular HD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Diffuse fibrosis HD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Reticular-type HD, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Small cleaved fol, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mixed fol, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Large cell fol, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Small noncleaved fol, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Small lymphocytic, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Plasmacytoid lyctic, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mantle zone lymphoma, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Small cleaved dif, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mixed FCC dif, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Large cell dif, Striking [>90pc]) 0.0, 1.0, 0.0;
  (B-immunoblastic, Striking [>90pc]) 0.0, 1.0, 0.0;
  (T-immunob mixed, Striking [>90pc]) 0.0, 1.0, 0.0;
  (AILD-like T-cell lym, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Japanese ATL, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Lymphoblastic, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Small noncleaved dif, Striking [>90pc]) 0.0, 1.0, 0.0;
  (True histiocytic, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas T, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Multiple myeloma, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mycosis fungoides, Striking [>90pc]) 0.0, 1.0, 0.0;
  (AML, Striking [>90pc]) 0.0, 0.7, 0.3;
  (Hairy cell leukemia, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Carcinoma, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Melanoma, Striking [>90pc]) 0.0, 1.0, 0.0;
  (EM plasmacytoma, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Kaposi's sarcoma, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mast-cell disease, Striking [>90pc]) 0.0, 1.0, 0.0;
  (AIDS involutionary, Striking [>90pc]) 0.0, 1.0, 0.0;
  (T-immunob large, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Monocytoid B-cell, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Nasopharyngeal CA, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Seminoma, Striking [>90pc]) 0.0, 1.0, 0.0;
  (SLE, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mycobact histiocytos, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Mast-cell hyperplas, Striking [>90pc]) 0.0, 1.0, 0.0;
  (LGV, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Histoplasmosis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Coccidioidomycosis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (CMV, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Brucellosis, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Ki-1 LC anaplas B, Striking [>90pc]) 0.0, 1.0, 0.0;
  (Intermed lymphocytic, Striking [>90pc]) 0.0, 1.0, 0.0;
}
probability ( MLC_I | MLC ) {
  (Absent [0pc]) 1.0, 0.0;
  (Sparse [<10pc]) 0.0, 1.0;
  (Moderate [11-50pc]) 0.0, 1.0;
  (Numerous [51-90pc]) 0.0, 1.0;
  (Striking [>90pc]) 0.0, 1.0;
}
probability ( LLC_I | LLC ) {
  (Absent [0pc]) 1.0, 0.0;
  (Sparse [<10pc]) 0.0, 1.0;
  (Moderate [11-50pc]) 0.0, 1.0;
  (Numerous [51-90pc]) 0.0, 1.0;
  (Striking [>90pc]) 0.0, 1.0;
}
probability ( LIPID | Fault ) {
  (AIDS early) 0.99, 0.01;
  (AILD) 0.99, 0.01;
  (ALIP) 0.99, 0.01;
  (Cat scratch disease) 0.99, 0.01;
  (Dermatopathic laden) 0.9, 0.1;
  (Florid follic hyperp) 0.99, 0.01;
  (GLH hyaline vascular) 0.99, 0.01;
  (GLH plasma cell) 0.99, 0.01;
  (Granulomatous laden) 0.99, 0.01;
  (Histiocytosis x) 0.99, 0.01;
  (Infectious mono) 0.99, 0.01;
  (Leprosy-lepromatous) 0.9, 0.1;
  (Lymphangiographic) 0.01, 0.99;
  (Mantle zone hyperpla) 0.99, 0.01;
  (Necrotizing Kikuchi) 0.99, 0.01;
  (Necrotiz non-Kikuchi) 0.99, 0.01;
  (Rheumatoid arthritis) 0.99, 0.01;
  (Sarcoidosis) 0.99, 0.01;
  (SHML) 0.99, 0.01;
  (Sinus histiocytosis) 0.99, 0.01;
  (Syphilis) 0.99, 0.01;
  (Toxoplasmosis) 0.99, 0.01;
  (Tuberculosis) 0.99, 0.01;
  (Viral NOS) 0.99, 0.01;
  (Whipple's disease) 0.01, 0.99;
  (L&H nodular HD) 0.95, 0.05;
  (L&H diffuse HD) 0.95, 0.05;
  (Nodular sclerosis HD) 0.95, 0.05;
  (Cellular phase NSHD) 0.95, 0.05;
  (Syncytial NSHD) 0.95, 0.05;
  (Mixed cellularity HD) 0.95, 0.05;
  (Interfollicular HD) 0.95, 0.05;
  (Diffuse fibrosis HD) 0.95, 0.05;
  (Reticular-type HD) 0.95, 0.05;
  (Small cleaved fol) 0.95, 0.05;
  (Mixed fol) 0.95, 0.05;
  (Large cell fol) 0.95, 0.05;
  (Small noncleaved fol) 0.95, 0.05;
  (Small lymphocytic) 0.95, 0.05;
  (Plasmacytoid lyctic) 0.95, 0.05;
  (Mantle zone lymphoma) 0.95, 0.05;
  (Small cleaved dif) 0.95, 0.05;
  (Mixed FCC dif) 0.95, 0.05;
  (Large cell dif) 0.95, 0.05;
  (B-immunoblastic) 0.95, 0.05;
  (T-immunob mixed) 0.95, 0.05;
  (AILD-like T-cell lym) 0.95, 0.05;
  (Japanese ATL) 0.95, 0.05;
  (Lymphoblastic) 0.95, 0.05;
  (Small noncleaved dif) 0.95, 0.05;
  (True histiocytic) 0.95, 0.05;
  (Ki-1 LC anaplas T) 0.95, 0.05;
  (Multiple myeloma) 0.95, 0.05;
  (Mycosis fungoides) 0.95, 0.05;
  (AML) 0.95, 0.05;
  (Hairy cell leukemia) 0.95, 0.05;
  (Carcinoma) 0.95, 0.05;
  (Melanoma) 0.95, 0.05;
  (EM plasmacytoma) 0.99, 0.01;
  (Kaposi's sarcoma) 0.99, 0.01;
  (Mast-cell disease) 0.99, 0.01;
  (AIDS involutionary) 0.99, 0.01;
  (T-immunob large) 0.95, 0.05;
  (Monocytoid B-cell) 0.95, 0.05;
  (Nasopharyngeal CA) 0.95, 0.05;
  (Seminoma) 0.95, 0.05;
  (SLE) 0.99, 0.01;
  (Mycobact histiocytos) 0.9, 0.1;
  (Mast-cell hyperplas) 0.99, 0.01;
  (LGV) 0.9, 0.1;
  (Histoplasmosis) 0.99, 0.01;
  (Coccidioidomycosis) 0.99, 0.01;
  (CMV) 0.99, 0.01;
  (Brucellosis) 0.99, 0.01;
  (Ki-1 LC anaplas B) 0.95, 0.05;
  (Intermed lymphocytic) 0.95, 0.05;
}
probability ( HX_LA | Fault ) {
  (AIDS early) 0.995, 0.005;
  (AILD) 0.9, 0.1;
  (ALIP) 0.995, 0.005;
  (Cat scratch disease) 0.995, 0.005;
  (Dermatopathic laden) 0.995, 0.005;
  (Florid follic hyperp) 0.995, 0.005;
  (GLH hyaline vascular) 0.995, 0.005;
  (GLH plasma cell) 0.995, 0.005;
  (Granulomatous laden) 0.995, 0.005;
  (Histiocytosis x) 0.995, 0.005;
  (Infectious mono) 0.995, 0.005;
  (Leprosy-lepromatous) 0.995, 0.005;
  (Lymphangiographic) 0.0, 1.0;
  (Mantle zone hyperpla) 0.995, 0.005;
  (Necrotizing Kikuchi) 0.995, 0.005;
  (Necrotiz non-Kikuchi) 0.995, 0.005;
  (Rheumatoid arthritis) 0.995, 0.005;
  (Sarcoidosis) 0.995, 0.005;
  (SHML) 0.995, 0.005;
  (Sinus histiocytosis) 0.995, 0.005;
  (Syphilis) 0.995, 0.005;
  (Toxoplasmosis) 0.995, 0.005;
  (Tuberculosis) 0.995, 0.005;
  (Viral NOS) 0.995, 0.005;
  (Whipple's disease) 0.995, 0.005;
  (L&H nodular HD) 0.4, 0.6;
  (L&H diffuse HD) 0.4, 0.6;
  (Nodular sclerosis HD) 0.4, 0.6;
  (Cellular phase NSHD) 0.4, 0.6;
  (Syncytial NSHD) 0.4, 0.6;
  (Mixed cellularity HD) 0.4, 0.6;
  (Interfollicular HD) 0.4, 0.6;
  (Diffuse fibrosis HD) 0.4, 0.6;
  (Reticular-type HD) 0.4, 0.6;
  (Small cleaved fol) 0.9, 0.1;
  (Mixed fol) 0.9, 0.1;
  (Large cell fol) 0.9, 0.1;
  (Small noncleaved fol) 0.9, 0.1;
  (Small lymphocytic) 0.9, 0.1;
  (Plasmacytoid lyctic) 0.9, 0.1;
  (Mantle zone lymphoma) 0.9, 0.1;
  (Small cleaved dif) 0.9, 0.1;
  (Mixed FCC dif) 0.9, 0.1;
  (Large cell dif) 0.9, 0.1;
  (B-immunoblastic) 0.9, 0.1;
  (T-immunob mixed) 0.9, 0.1;
  (AILD-like T-cell lym) 0.9, 0.1;
  (Japanese ATL) 0.9, 0.1;
  (Lymphoblastic) 0.9, 0.1;
  (Small noncleaved dif) 0.9, 0.1;
  (True histiocytic) 0.9, 0.1;
  (Ki-1 LC anaplas T) 0.9, 0.1;
  (Multiple myeloma) 0.98, 0.02;
  (Mycosis fungoides) 0.98, 0.02;
  (AML) 0.98, 0.02;
  (Hairy cell leukemia) 0.98, 0.02;
  (Carcinoma) 0.98, 0.02;
  (Melanoma) 0.98, 0.02;
  (EM plasmacytoma) 0.9, 0.1;
  (Kaposi's sarcoma) 0.98, 0.02;
  (Mast-cell disease) 0.9, 0.1;
  (AIDS involutionary) 0.995, 0.005;
  (T-immunob large) 0.9, 0.1;
  (Monocytoid B-cell) 0.9, 0.1;
  (Nasopharyngeal CA) 0.98, 0.02;
  (Seminoma) 0.98, 0.02;
  (SLE) 0.995, 0.005;
  (Mycobact histiocytos) 0.995, 0.005;
  (Mast-cell hyperplas) 0.995, 0.005;
  (LGV) 0.995, 0.005;
  (Histoplasmosis) 0.995, 0.005;
  (Coccidioidomycosis) 0.995, 0.005;
  (CMV) 0.995, 0.005;
  (Brucellosis) 0.995, 0.005;
  (Ki-1 LC anaplas B) 0.9, 0.1;
  (Intermed lymphocytic) 0.9, 0.1;
}
probability ( HEMATOX | Fault ) {
  (AIDS early) 1.0, 0.0;
  (AILD) 1.0, 0.0;
  (ALIP) 1.0, 0.0;
  (Cat scratch disease) 1.0, 0.0;
  (Dermatopathic laden) 1.0, 0.0;
  (Florid follic hyperp) 1.0, 0.0;
  (GLH hyaline vascular) 1.0, 0.0;
  (GLH plasma cell) 1.0, 0.0;
  (Granulomatous laden) 1.0, 0.0;
  (Histiocytosis x) 1.0, 0.0;
  (Infectious mono) 1.0, 0.0;
  (Leprosy-lepromatous) 1.0, 0.0;
  (Lymphangiographic) 1.0, 0.0;
  (Mantle zone hyperpla) 1.0, 0.0;
  (Necrotizing Kikuchi) 1.0, 0.0;
  (Necrotiz non-Kikuchi) 1.0, 0.0;
  (Rheumatoid arthritis) 1.0, 0.0;
  (Sarcoidosis) 1.0, 0.0;
  (SHML) 1.0, 0.0;
  (Sinus histiocytosis) 1.0, 0.0;
  (Syphilis) 1.0, 0.0;
  (Toxoplasmosis) 1.0, 0.0;
  (Tuberculosis) 1.0, 0.0;
  (Viral NOS) 1.0, 0.0;
  (Whipple's disease) 1.0, 0.0;
  (L&H nodular HD) 1.0, 0.0;
  (L&H diffuse HD) 1.0, 0.0;
  (Nodular sclerosis HD) 1.0, 0.0;
  (Cellular phase NSHD) 1.0, 0.0;
  (Syncytial NSHD) 1.0, 0.0;
  (Mixed cellularity HD) 1.0, 0.0;
  (Interfollicular HD) 1.0, 0.0;
  (Diffuse fibrosis HD) 1.0, 0.0;
  (Reticular-type HD) 1.0, 0.0;
  (Small cleaved fol) 1.0, 0.0;
  (Mixed fol) 1.0, 0.0;
  (Large cell fol) 1.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0;
  (Small lymphocytic) 1.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0;
  (Small cleaved dif) 1.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0;
  (Large cell dif) 1.0, 0.0;
  (B-immunoblastic) 1.0, 0.0;
  (T-immunob mixed) 1.0, 0.0;
  (AILD-like T-cell lym) 1.0, 0.0;
  (Japanese ATL) 1.0, 0.0;
  (Lymphoblastic) 1.0, 0.0;
  (Small noncleaved dif) 1.0, 0.0;
  (True histiocytic) 1.0, 0.0;
  (Ki-1 LC anaplas T) 1.0, 0.0;
  (Multiple myeloma) 1.0, 0.0;
  (Mycosis fungoides) 1.0, 0.0;
  (AML) 1.0, 0.0;
  (Hairy cell leukemia) 1.0, 0.0;
  (Carcinoma) 1.0, 0.0;
  (Melanoma) 1.0, 0.0;
  (EM plasmacytoma) 1.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0;
  (Mast-cell disease) 1.0, 0.0;
  (AIDS involutionary) 1.0, 0.0;
  (T-immunob large) 1.0, 0.0;
  (Monocytoid B-cell) 1.0, 0.0;
  (Nasopharyngeal CA) 1.0, 0.0;
  (Seminoma) 1.0, 0.0;
  (SLE) 0.15, 0.85;
  (Mycobact histiocytos) 1.0, 0.0;
  (Mast-cell hyperplas) 1.0, 0.0;
  (LGV) 1.0, 0.0;
  (Histoplasmosis) 1.0, 0.0;
  (Coccidioidomycosis) 1.0, 0.0;
  (CMV) 1.0, 0.0;
  (Brucellosis) 1.0, 0.0;
  (Ki-1 LC anaplas B) 1.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0;
}
probability ( CMV | Fault ) {
  (AIDS early) 0.98, 0.02;
  (AILD) 0.99, 0.01;
  (ALIP) 0.99999, 0.00001;
  (Cat scratch disease) 0.99999, 0.00001;
  (Dermatopathic laden) 0.99999, 0.00001;
  (Florid follic hyperp) 0.99999, 0.00001;
  (GLH hyaline vascular) 0.99999, 0.00001;
  (GLH plasma cell) 0.99999, 0.00001;
  (Granulomatous laden) 0.99999, 0.00001;
  (Histiocytosis x) 0.99999, 0.00001;
  (Infectious mono) 0.99999, 0.00001;
  (Leprosy-lepromatous) 0.99999, 0.00001;
  (Lymphangiographic) 0.99999, 0.00001;
  (Mantle zone hyperpla) 0.99999, 0.00001;
  (Necrotizing Kikuchi) 0.99999, 0.00001;
  (Necrotiz non-Kikuchi) 0.99999, 0.00001;
  (Rheumatoid arthritis) 0.99999, 0.00001;
  (Sarcoidosis) 0.99999, 0.00001;
  (SHML) 0.99999, 0.00001;
  (Sinus histiocytosis) 0.99999, 0.00001;
  (Syphilis) 0.99999, 0.00001;
  (Toxoplasmosis) 0.99999, 0.00001;
  (Tuberculosis) 0.99999, 0.00001;
  (Viral NOS) 0.99999, 0.00001;
  (Whipple's disease) 0.99999, 0.00001;
  (L&H nodular HD) 0.99, 0.01;
  (L&H diffuse HD) 0.99, 0.01;
  (Nodular sclerosis HD) 0.99, 0.01;
  (Cellular phase NSHD) 0.99, 0.01;
  (Syncytial NSHD) 0.99, 0.01;
  (Mixed cellularity HD) 0.99, 0.01;
  (Interfollicular HD) 0.99, 0.01;
  (Diffuse fibrosis HD) 0.99, 0.01;
  (Reticular-type HD) 0.99, 0.01;
  (Small cleaved fol) 0.99, 0.01;
  (Mixed fol) 0.99, 0.01;
  (Large cell fol) 0.99, 0.01;
  (Small noncleaved fol) 0.99, 0.01;
  (Small lymphocytic) 0.99, 0.01;
  (Plasmacytoid lyctic) 0.99, 0.01;
  (Mantle zone lymphoma) 0.99, 0.01;
  (Small cleaved dif) 0.99, 0.01;
  (Mixed FCC dif) 0.99, 0.01;
  (Large cell dif) 0.99, 0.01;
  (B-immunoblastic) 0.99, 0.01;
  (T-immunob mixed) 0.99, 0.01;
  (AILD-like T-cell lym) 0.99, 0.01;
  (Japanese ATL) 0.99, 0.01;
  (Lymphoblastic) 0.99, 0.01;
  (Small noncleaved dif) 0.99, 0.01;
  (True histiocytic) 0.99, 0.01;
  (Ki-1 LC anaplas T) 0.99, 0.01;
  (Multiple myeloma) 0.99, 0.01;
  (Mycosis fungoides) 0.99, 0.01;
  (AML) 0.99, 0.01;
  (Hairy cell leukemia) 0.99, 0.01;
  (Carcinoma) 0.99, 0.01;
  (Melanoma) 0.99, 0.01;
  (EM plasmacytoma) 0.99, 0.01;
  (Kaposi's sarcoma) 0.99, 0.01;
  (Mast-cell disease) 0.99, 0.01;
  (AIDS involutionary) 0.98, 0.02;
  (T-immunob large) 0.99, 0.01;
  (Monocytoid B-cell) 0.99, 0.01;
  (Nasopharyngeal CA) 0.99, 0.01;
  (Seminoma) 0.99, 0.01;
  (SLE) 0.99999, 0.00001;
  (Mycobact histiocytos) 0.99999, 0.00001;
  (Mast-cell hyperplas) 0.99999, 0.00001;
  (LGV) 0.99999, 0.00001;
  (Histoplasmosis) 0.99999, 0.00001;
  (Coccidioidomycosis) 0.99999, 0.00001;
  (CMV) 0.0, 1.0;
  (Brucellosis) 0.99999, 0.00001;
  (Ki-1 LC anaplas B) 0.99, 0.01;
  (Intermed lymphocytic) 0.99, 0.01;
}
probability ( BRUCELLA | Fault ) {
  (AIDS early) 0.999999, 0.000001;
  (AILD) 0.999999, 0.000001;
  (ALIP) 0.999999, 0.000001;
  (Cat scratch disease) 0.999999, 0.000001;
  (Dermatopathic laden) 0.999999, 0.000001;
  (Florid follic hyperp) 0.999999, 0.000001;
  (GLH hyaline vascular) 0.999999, 0.000001;
  (GLH plasma cell) 0.999999, 0.000001;
  (Granulomatous laden) 0.999999, 0.000001;
  (Histiocytosis x) 0.999999, 0.000001;
  (Infectious mono) 0.999999, 0.000001;
  (Leprosy-lepromatous) 0.999999, 0.000001;
  (Lymphangiographic) 0.999999, 0.000001;
  (Mantle zone hyperpla) 0.999999, 0.000001;
  (Necrotizing Kikuchi) 0.999999, 0.000001;
  (Necrotiz non-Kikuchi) 0.999999, 0.000001;
  (Rheumatoid arthritis) 0.999999, 0.000001;
  (Sarcoidosis) 0.999999, 0.000001;
  (SHML) 0.999999, 0.000001;
  (Sinus histiocytosis) 0.999999, 0.000001;
  (Syphilis) 0.999999, 0.000001;
  (Toxoplasmosis) 0.999999, 0.000001;
  (Tuberculosis) 0.999999, 0.000001;
  (Viral NOS) 0.999999, 0.000001;
  (Whipple's disease) 0.999999, 0.000001;
  (L&H nodular HD) 0.999999, 0.000001;
  (L&H diffuse HD) 0.999999, 0.000001;
  (Nodular sclerosis HD) 0.999999, 0.000001;
  (Cellular phase NSHD) 0.999999, 0.000001;
  (Syncytial NSHD) 0.999999, 0.000001;
  (Mixed cellularity HD) 0.999999, 0.000001;
  (Interfollicular HD) 0.999999, 0.000001;
  (Diffuse fibrosis HD) 0.999999, 0.000001;
  (Reticular-type HD) 0.999999, 0.000001;
  (Small cleaved fol) 0.999999, 0.000001;
  (Mixed fol) 0.999999, 0.000001;
  (Large cell fol) 0.999999, 0.000001;
  (Small noncleaved fol) 0.999999, 0.000001;
  (Small lymphocytic) 0.999999, 0.000001;
  (Plasmacytoid lyctic) 0.999999, 0.000001;
  (Mantle zone lymphoma) 0.999999, 0.000001;
  (Small cleaved dif) 0.999999, 0.000001;
  (Mixed FCC dif) 0.999999, 0.000001;
  (Large cell dif) 0.999999, 0.000001;
  (B-immunoblastic) 0.999999, 0.000001;
  (T-immunob mixed) 0.999999, 0.000001;
  (AILD-like T-cell lym) 0.999999, 0.000001;
  (Japanese ATL) 0.999999, 0.000001;
  (Lymphoblastic) 0.999999, 0.000001;
  (Small noncleaved dif) 0.999999, 0.000001;
  (True histiocytic) 0.999999, 0.000001;
  (Ki-1 LC anaplas T) 0.999999, 0.000001;
  (Multiple myeloma) 0.999999, 0.000001;
  (Mycosis fungoides) 0.999999, 0.000001;
  (AML) 0.999999, 0.000001;
  (Hairy cell leukemia) 0.999999, 0.000001;
  (Carcinoma) 0.999999, 0.000001;
  (Melanoma) 0.999999, 0.000001;
  (EM plasmacytoma) 0.999999, 0.000001;
  (Kaposi's sarcoma) 0.999999, 0.000001;
  (Mast-cell disease) 0.999999, 0.000001;
  (AIDS involutionary) 0.999999, 0.000001;
  (T-immunob large) 0.999999, 0.000001;
  (Monocytoid B-cell) 0.999999, 0.000001;
  (Nasopharyngeal CA) 0.999999, 0.000001;
  (Seminoma) 0.999999, 0.000001;
  (SLE) 0.999999, 0.000001;
  (Mycobact histiocytos) 0.999999, 0.000001;
  (Mast-cell hyperplas) 0.999999, 0.000001;
  (LGV) 0.999999, 0.000001;
  (Histoplasmosis) 0.999999, 0.000001;
  (Coccidioidomycosis) 0.999999, 0.000001;
  (CMV) 0.999999, 0.000001;
  (Brucellosis) 0.01, 0.99;
  (Ki-1 LC anaplas B) 0.999999, 0.000001;
  (Intermed lymphocytic) 0.999999, 0.000001;
}
probability ( COCCIDIA | Fault ) {
  (AIDS early) 0.95, 0.05;
  (AILD) 0.999, 0.001;
  (ALIP) 0.999999, 0.000001;
  (Cat scratch disease) 0.999999, 0.000001;
  (Dermatopathic laden) 0.999999, 0.000001;
  (Florid follic hyperp) 0.999999, 0.000001;
  (GLH hyaline vascular) 0.999999, 0.000001;
  (GLH plasma cell) 0.999999, 0.000001;
  (Granulomatous laden) 0.999999, 0.000001;
  (Histiocytosis x) 0.999999, 0.000001;
  (Infectious mono) 0.999999, 0.000001;
  (Leprosy-lepromatous) 0.999999, 0.000001;
  (Lymphangiographic) 0.999999, 0.000001;
  (Mantle zone hyperpla) 0.999999, 0.000001;
  (Necrotizing Kikuchi) 0.999999, 0.000001;
  (Necrotiz non-Kikuchi) 0.999999, 0.000001;
  (Rheumatoid arthritis) 0.999999, 0.000001;
  (Sarcoidosis) 0.999999, 0.000001;
  (SHML) 0.999999, 0.000001;
  (Sinus histiocytosis) 0.999999, 0.000001;
  (Syphilis) 0.999999, 0.000001;
  (Toxoplasmosis) 0.999999, 0.000001;
  (Tuberculosis) 0.999999, 0.000001;
  (Viral NOS) 0.999999, 0.000001;
  (Whipple's disease) 0.999999, 0.000001;
  (L&H nodular HD) 0.999, 0.001;
  (L&H diffuse HD) 0.999, 0.001;
  (Nodular sclerosis HD) 0.999, 0.001;
  (Cellular phase NSHD) 0.999, 0.001;
  (Syncytial NSHD) 0.999, 0.001;
  (Mixed cellularity HD) 0.999, 0.001;
  (Interfollicular HD) 0.999, 0.001;
  (Diffuse fibrosis HD) 0.999, 0.001;
  (Reticular-type HD) 0.999, 0.001;
  (Small cleaved fol) 0.999, 0.001;
  (Mixed fol) 0.999, 0.001;
  (Large cell fol) 0.999, 0.001;
  (Small noncleaved fol) 0.999, 0.001;
  (Small lymphocytic) 0.999, 0.001;
  (Plasmacytoid lyctic) 0.999, 0.001;
  (Mantle zone lymphoma) 0.999, 0.001;
  (Small cleaved dif) 0.999, 0.001;
  (Mixed FCC dif) 0.999, 0.001;
  (Large cell dif) 0.999, 0.001;
  (B-immunoblastic) 0.999, 0.001;
  (T-immunob mixed) 0.999, 0.001;
  (AILD-like T-cell lym) 0.999, 0.001;
  (Japanese ATL) 0.999, 0.001;
  (Lymphoblastic) 0.999, 0.001;
  (Small noncleaved dif) 0.999, 0.001;
  (True histiocytic) 0.999, 0.001;
  (Ki-1 LC anaplas T) 0.999, 0.001;
  (Multiple myeloma) 0.999, 0.001;
  (Mycosis fungoides) 0.999, 0.001;
  (AML) 0.999, 0.001;
  (Hairy cell leukemia) 0.999, 0.001;
  (Carcinoma) 0.999, 0.001;
  (Melanoma) 0.999, 0.001;
  (EM plasmacytoma) 0.999, 0.001;
  (Kaposi's sarcoma) 0.999, 0.001;
  (Mast-cell disease) 0.999, 0.001;
  (AIDS involutionary) 0.95, 0.05;
  (T-immunob large) 0.999, 0.001;
  (Monocytoid B-cell) 0.999, 0.001;
  (Nasopharyngeal CA) 0.999, 0.001;
  (Seminoma) 0.999, 0.001;
  (SLE) 0.999999, 0.000001;
  (Mycobact histiocytos) 0.999999, 0.000001;
  (Mast-cell hyperplas) 0.999999, 0.000001;
  (LGV) 0.999999, 0.000001;
  (Histoplasmosis) 0.999999, 0.000001;
  (Coccidioidomycosis) 0.0, 1.0;
  (CMV) 0.999999, 0.000001;
  (Brucellosis) 0.999999, 0.000001;
  (Ki-1 LC anaplas B) 0.999, 0.001;
  (Intermed lymphocytic) 0.999, 0.001;
}
probability ( HISTOPLA | Fault ) {
  (AIDS early) 0.95, 0.05;
  (AILD) 0.9999, 0.0001;
  (ALIP) 0.999999, 0.000001;
  (Cat scratch disease) 0.999999, 0.000001;
  (Dermatopathic laden) 0.999999, 0.000001;
  (Florid follic hyperp) 0.999999, 0.000001;
  (GLH hyaline vascular) 0.999999, 0.000001;
  (GLH plasma cell) 0.999999, 0.000001;
  (Granulomatous laden) 0.999999, 0.000001;
  (Histiocytosis x) 0.999999, 0.000001;
  (Infectious mono) 0.999999, 0.000001;
  (Leprosy-lepromatous) 0.999999, 0.000001;
  (Lymphangiographic) 0.999999, 0.000001;
  (Mantle zone hyperpla) 0.999999, 0.000001;
  (Necrotizing Kikuchi) 0.999999, 0.000001;
  (Necrotiz non-Kikuchi) 0.999999, 0.000001;
  (Rheumatoid arthritis) 0.999999, 0.000001;
  (Sarcoidosis) 0.999999, 0.000001;
  (SHML) 0.999999, 0.000001;
  (Sinus histiocytosis) 0.999999, 0.000001;
  (Syphilis) 0.999999, 0.000001;
  (Toxoplasmosis) 0.999999, 0.000001;
  (Tuberculosis) 0.999999, 0.000001;
  (Viral NOS) 0.999999, 0.000001;
  (Whipple's disease) 0.999999, 0.000001;
  (L&H nodular HD) 0.9999, 0.0001;
  (L&H diffuse HD) 0.9999, 0.0001;
  (Nodular sclerosis HD) 0.9999, 0.0001;
  (Cellular phase NSHD) 0.9999, 0.0001;
  (Syncytial NSHD) 0.9999, 0.0001;
  (Mixed cellularity HD) 0.9999, 0.0001;
  (Interfollicular HD) 0.9999, 0.0001;
  (Diffuse fibrosis HD) 0.9999, 0.0001;
  (Reticular-type HD) 0.9999, 0.0001;
  (Small cleaved fol) 0.9999, 0.0001;
  (Mixed fol) 0.9999, 0.0001;
  (Large cell fol) 0.9999, 0.0001;
  (Small noncleaved fol) 0.9999, 0.0001;
  (Small lymphocytic) 0.9999, 0.0001;
  (Plasmacytoid lyctic) 0.9999, 0.0001;
  (Mantle zone lymphoma) 0.9999, 0.0001;
  (Small cleaved dif) 0.9999, 0.0001;
  (Mixed FCC dif) 0.9999, 0.0001;
  (Large cell dif) 0.9999, 0.0001;
  (B-immunoblastic) 0.9999, 0.0001;
  (T-immunob mixed) 0.9999, 0.0001;
  (AILD-like T-cell lym) 0.9999, 0.0001;
  (Japanese ATL) 0.9999, 0.0001;
  (Lymphoblastic) 0.9999, 0.0001;
  (Small noncleaved dif) 0.9999, 0.0001;
  (True histiocytic) 0.9999, 0.0001;
  (Ki-1 LC anaplas T) 0.9999, 0.0001;
  (Multiple myeloma) 0.9999, 0.0001;
  (Mycosis fungoides) 0.9999, 0.0001;
  (AML) 0.9999, 0.0001;
  (Hairy cell leukemia) 0.9999, 0.0001;
  (Carcinoma) 0.9999, 0.0001;
  (Melanoma) 0.9999, 0.0001;
  (EM plasmacytoma) 0.9999, 0.0001;
  (Kaposi's sarcoma) 0.9999, 0.0001;
  (Mast-cell disease) 0.9999, 0.0001;
  (AIDS involutionary) 0.95, 0.05;
  (T-immunob large) 0.9999, 0.0001;
  (Monocytoid B-cell) 0.9999, 0.0001;
  (Nasopharyngeal CA) 0.9999, 0.0001;
  (Seminoma) 0.9999, 0.0001;
  (SLE) 0.999999, 0.000001;
  (Mycobact histiocytos) 0.999999, 0.000001;
  (Mast-cell hyperplas) 0.999999, 0.000001;
  (LGV) 0.999999, 0.000001;
  (Histoplasmosis) 0.0, 1.0;
  (Coccidioidomycosis) 0.999999, 0.000001;
  (CMV) 0.999999, 0.000001;
  (Brucellosis) 0.999999, 0.000001;
  (Ki-1 LC anaplas B) 0.9999, 0.0001;
  (Intermed lymphocytic) 0.9999, 0.0001;
}
probability ( LGV | Fault ) {
  (AIDS early) 0.97, 0.03;
  (AILD) 0.999999, 0.000001;
  (ALIP) 0.999999, 0.000001;
  (Cat scratch disease) 0.999999, 0.000001;
  (Dermatopathic laden) 0.999999, 0.000001;
  (Florid follic hyperp) 0.999999, 0.000001;
  (GLH hyaline vascular) 0.999999, 0.000001;
  (GLH plasma cell) 0.999999, 0.000001;
  (Granulomatous laden) 0.999999, 0.000001;
  (Histiocytosis x) 0.999999, 0.000001;
  (Infectious mono) 0.999999, 0.000001;
  (Leprosy-lepromatous) 0.999999, 0.000001;
  (Lymphangiographic) 0.999999, 0.000001;
  (Mantle zone hyperpla) 0.999999, 0.000001;
  (Necrotizing Kikuchi) 0.999999, 0.000001;
  (Necrotiz non-Kikuchi) 0.999999, 0.000001;
  (Rheumatoid arthritis) 0.999999, 0.000001;
  (Sarcoidosis) 0.999999, 0.000001;
  (SHML) 0.999999, 0.000001;
  (Sinus histiocytosis) 0.999999, 0.000001;
  (Syphilis) 0.999999, 0.000001;
  (Toxoplasmosis) 0.999999, 0.000001;
  (Tuberculosis) 0.999999, 0.000001;
  (Viral NOS) 0.999999, 0.000001;
  (Whipple's disease) 0.999999, 0.000001;
  (L&H nodular HD) 0.999999, 0.000001;
  (L&H diffuse HD) 0.999999, 0.000001;
  (Nodular sclerosis HD) 0.999999, 0.000001;
  (Cellular phase NSHD) 0.999999, 0.000001;
  (Syncytial NSHD) 0.999999, 0.000001;
  (Mixed cellularity HD) 0.999999, 0.000001;
  (Interfollicular HD) 0.999999, 0.000001;
  (Diffuse fibrosis HD) 0.999999, 0.000001;
  (Reticular-type HD) 0.999999, 0.000001;
  (Small cleaved fol) 0.999999, 0.000001;
  (Mixed fol) 0.999999, 0.000001;
  (Large cell fol) 0.999999, 0.000001;
  (Small noncleaved fol) 0.999999, 0.000001;
  (Small lymphocytic) 0.999999, 0.000001;
  (Plasmacytoid lyctic) 0.999999, 0.000001;
  (Mantle zone lymphoma) 0.999999, 0.000001;
  (Small cleaved dif) 0.999999, 0.000001;
  (Mixed FCC dif) 0.999999, 0.000001;
  (Large cell dif) 0.999999, 0.000001;
  (B-immunoblastic) 0.999999, 0.000001;
  (T-immunob mixed) 0.999999, 0.000001;
  (AILD-like T-cell lym) 0.999999, 0.000001;
  (Japanese ATL) 0.999999, 0.000001;
  (Lymphoblastic) 0.999999, 0.000001;
  (Small noncleaved dif) 0.999999, 0.000001;
  (True histiocytic) 0.999999, 0.000001;
  (Ki-1 LC anaplas T) 0.999999, 0.000001;
  (Multiple myeloma) 0.999999, 0.000001;
  (Mycosis fungoides) 0.999999, 0.000001;
  (AML) 0.999999, 0.000001;
  (Hairy cell leukemia) 0.999999, 0.000001;
  (Carcinoma) 0.999999, 0.000001;
  (Melanoma) 0.999999, 0.000001;
  (EM plasmacytoma) 0.999999, 0.000001;
  (Kaposi's sarcoma) 0.999999, 0.000001;
  (Mast-cell disease) 0.999999, 0.000001;
  (AIDS involutionary) 0.97, 0.03;
  (T-immunob large) 0.999999, 0.000001;
  (Monocytoid B-cell) 0.999999, 0.000001;
  (Nasopharyngeal CA) 0.999999, 0.000001;
  (Seminoma) 0.999999, 0.000001;
  (SLE) 0.999999, 0.000001;
  (Mycobact histiocytos) 0.999999, 0.000001;
  (Mast-cell hyperplas) 0.999999, 0.000001;
  (LGV) 0.01, 0.99;
  (Histoplasmosis) 0.999999, 0.000001;
  (Coccidioidomycosis) 0.999999, 0.000001;
  (CMV) 0.999999, 0.000001;
  (Brucellosis) 0.999999, 0.000001;
  (Ki-1 LC anaplas B) 0.999999, 0.000001;
  (Intermed lymphocytic) 0.999999, 0.000001;
}
probability ( VDRL | Fault ) {
  (AIDS early) 0.97, 0.03;
  (AILD) 0.9999, 0.0001;
  (ALIP) 0.9999, 0.0001;
  (Cat scratch disease) 0.9999, 0.0001;
  (Dermatopathic laden) 0.9999, 0.0001;
  (Florid follic hyperp) 0.9999, 0.0001;
  (GLH hyaline vascular) 0.9999, 0.0001;
  (GLH plasma cell) 0.9999, 0.0001;
  (Granulomatous laden) 0.9999, 0.0001;
  (Histiocytosis x) 0.9999, 0.0001;
  (Infectious mono) 0.9999, 0.0001;
  (Leprosy-lepromatous) 0.9999, 0.0001;
  (Lymphangiographic) 0.9999, 0.0001;
  (Mantle zone hyperpla) 0.9999, 0.0001;
  (Necrotizing Kikuchi) 0.9999, 0.0001;
  (Necrotiz non-Kikuchi) 0.9999, 0.0001;
  (Rheumatoid arthritis) 0.9999, 0.0001;
  (Sarcoidosis) 0.9999, 0.0001;
  (SHML) 0.9999, 0.0001;
  (Sinus histiocytosis) 0.9999, 0.0001;
  (Syphilis) 0.02, 0.98;
  (Toxoplasmosis) 0.9999, 0.0001;
  (Tuberculosis) 0.9999, 0.0001;
  (Viral NOS) 0.9999, 0.0001;
  (Whipple's disease) 0.9999, 0.0001;
  (L&H nodular HD) 0.9999, 0.0001;
  (L&H diffuse HD) 0.9999, 0.0001;
  (Nodular sclerosis HD) 0.9999, 0.0001;
  (Cellular phase NSHD) 0.9999, 0.0001;
  (Syncytial NSHD) 0.9999, 0.0001;
  (Mixed cellularity HD) 0.9999, 0.0001;
  (Interfollicular HD) 0.9999, 0.0001;
  (Diffuse fibrosis HD) 0.9999, 0.0001;
  (Reticular-type HD) 0.9999, 0.0001;
  (Small cleaved fol) 0.9999, 0.0001;
  (Mixed fol) 0.9999, 0.0001;
  (Large cell fol) 0.9999, 0.0001;
  (Small noncleaved fol) 0.9999, 0.0001;
  (Small lymphocytic) 0.9999, 0.0001;
  (Plasmacytoid lyctic) 0.9999, 0.0001;
  (Mantle zone lymphoma) 0.9999, 0.0001;
  (Small cleaved dif) 0.9999, 0.0001;
  (Mixed FCC dif) 0.9999, 0.0001;
  (Large cell dif) 0.9999, 0.0001;
  (B-immunoblastic) 0.9999, 0.0001;
  (T-immunob mixed) 0.9999, 0.0001;
  (AILD-like T-cell lym) 0.9999, 0.0001;
  (Japanese ATL) 0.9999, 0.0001;
  (Lymphoblastic) 0.9999, 0.0001;
  (Small noncleaved dif) 0.9999, 0.0001;
  (True histiocytic) 0.9999, 0.0001;
  (Ki-1 LC anaplas T) 0.9999, 0.0001;
  (Multiple myeloma) 0.9999, 0.0001;
  (Mycosis fungoides) 0.9999, 0.0001;
  (AML) 0.9999, 0.0001;
  (Hairy cell leukemia) 0.9999, 0.0001;
  (Carcinoma) 0.9999, 0.0001;
  (Melanoma) 0.9999, 0.0001;
  (EM plasmacytoma) 0.9999, 0.0001;
  (Kaposi's sarcoma) 0.9999, 0.0001;
  (Mast-cell disease) 0.9999, 0.0001;
  (AIDS involutionary) 0.97, 0.03;
  (T-immunob large) 0.9999, 0.0001;
  (Monocytoid B-cell) 0.9999, 0.0001;
  (Nasopharyngeal CA) 0.9999, 0.0001;
  (Seminoma) 0.9999, 0.0001;
  (SLE) 0.9999, 0.0001;
  (Mycobact histiocytos) 0.9999, 0.0001;
  (Mast-cell hyperplas) 0.9999, 0.0001;
  (LGV) 0.9999, 0.0001;
  (Histoplasmosis) 0.9999, 0.0001;
  (Coccidioidomycosis) 0.9999, 0.0001;
  (CMV) 0.9999, 0.0001;
  (Brucellosis) 0.9999, 0.0001;
  (Ki-1 LC anaplas B) 0.9999, 0.0001;
  (Intermed lymphocytic) 0.9999, 0.0001;
}
probability ( PLASCY_T | Fault ) {
  (AIDS early) 0.99999, 0.00001, 0.00000;
  (AILD) 1.0, 0.0, 0.0;
  (ALIP) 0.99999, 0.00001, 0.00000;
  (Cat scratch disease) 0.985, 0.010, 0.005;
  (Dermatopathic laden) 0.99999, 0.00001, 0.00000;
  (Florid follic hyperp) 0.99999, 0.00001, 0.00000;
  (GLH hyaline vascular) 0.94, 0.05, 0.01;
  (GLH plasma cell) 0.94, 0.05, 0.01;
  (Granulomatous laden) 0.99999, 0.00001, 0.00000;
  (Histiocytosis x) 0.99999, 0.00001, 0.00000;
  (Infectious mono) 0.985, 0.010, 0.005;
  (Leprosy-lepromatous) 0.99999, 0.00001, 0.00000;
  (Lymphangiographic) 0.99999, 0.00001, 0.00000;
  (Mantle zone hyperpla) 0.99999, 0.00001, 0.00000;
  (Necrotizing Kikuchi) 0.05, 0.45, 0.50;
  (Necrotiz non-Kikuchi) 0.94, 0.05, 0.01;
  (Rheumatoid arthritis) 0.99999, 0.00001, 0.00000;
  (Sarcoidosis) 0.99999, 0.00001, 0.00000;
  (SHML) 0.99999, 0.00001, 0.00000;
  (Sinus histiocytosis) 0.99999, 0.00001, 0.00000;
  (Syphilis) 0.99999, 0.00001, 0.00000;
  (Toxoplasmosis) 0.99999, 0.00001, 0.00000;
  (Tuberculosis) 0.99999, 0.00001, 0.00000;
  (Viral NOS) 0.985, 0.010, 0.005;
  (Whipple's disease) 0.99999, 0.00001, 0.00000;
  (L&H nodular HD) 1.0, 0.0, 0.0;
  (L&H diffuse HD) 1.0, 0.0, 0.0;
  (Nodular sclerosis HD) 1.0, 0.0, 0.0;
  (Cellular phase NSHD) 1.0, 0.0, 0.0;
  (Syncytial NSHD) 1.0, 0.0, 0.0;
  (Mixed cellularity HD) 1.0, 0.0, 0.0;
  (Interfollicular HD) 1.0, 0.0, 0.0;
  (Diffuse fibrosis HD) 1.0, 0.0, 0.0;
  (Reticular-type HD) 1.0, 0.0, 0.0;
  (Small cleaved fol) 1.0, 0.0, 0.0;
  (Mixed fol) 1.0, 0.0, 0.0;
  (Large cell fol) 1.0, 0.0, 0.0;
  (Small noncleaved fol) 1.0, 0.0, 0.0;
  (Small lymphocytic) 1.0, 0.0, 0.0;
  (Plasmacytoid lyctic) 1.0, 0.0, 0.0;
  (Mantle zone lymphoma) 1.0, 0.0, 0.0;
  (Small cleaved dif) 1.0, 0.0, 0.0;
  (Mixed FCC dif) 1.0, 0.0, 0.0;
  (Large cell dif) 1.0, 0.0, 0.0;
  (B-immunoblastic) 1.0, 0.0, 0.0;
  (T-immunob mixed) 1.0, 0.0, 0.0;
  (AILD-like T-cell lym) 1.0, 0.0, 0.0;
  (Japanese ATL) 1.0, 0.0, 0.0;
  (Lymphoblastic) 1.0, 0.0, 0.0;
  (Small noncleaved dif) 1.0, 0.0, 0.0;
  (True histiocytic) 1.0, 0.0, 0.0;
  (Ki-1 LC anaplas T) 1.0, 0.0, 0.0;
  (Multiple myeloma) 1.0, 0.0, 0.0;
  (Mycosis fungoides) 1.0, 0.0, 0.0;
  (AML) 1.0, 0.0, 0.0;
  (Hairy cell leukemia) 1.0, 0.0, 0.0;
  (Carcinoma) 1.0, 0.0, 0.0;
  (Melanoma) 1.0, 0.0, 0.0;
  (EM plasmacytoma) 1.0, 0.0, 0.0;
  (Kaposi's sarcoma) 1.0, 0.0, 0.0;
  (Mast-cell disease) 1.0, 0.0, 0.0;
  (AIDS involutionary) 0.99999, 0.00001, 0.00000;
  (T-immunob large) 1.0, 0.0, 0.0;
  (Monocytoid B-cell) 1.0, 0.0, 0.0;
  (Nasopharyngeal CA) 1.0, 0.0, 0.0;
  (Seminoma) 1.0, 0.0, 0.0;
  (SLE) 0.985, 0.010, 0.005;
  (Mycobact histiocytos) 0.99999, 0.00001, 0.00000;
  (Mast-cell hyperplas) 0.99999, 0.00001, 0.00000;
  (LGV) 0.985, 0.010, 0.005;
  (Histoplasmosis) 0.99999, 0.00001, 0.00000;
  (Coccidioidomycosis) 0.99999, 0.00001, 0.00000;
  (CMV) 0.99999, 0.00001, 0.00000;
  (Brucellosis) 0.99999, 0.00001, 0.00000;
  (Ki-1 LC anaplas B) 1.0, 0.0, 0.0;
  (Intermed lymphocytic) 1.0, 0.0, 0.0;
}
probability ( TB | Fault, HIV_ST ) {
  (AIDS early, Negative) 0.999999, 0.000001, 0.000000;
  (AILD, Negative) 0.999999, 0.000001, 0.000000;
  (ALIP, Negative) 0.999999, 0.000001, 0.000000;
  (Cat scratch disease, Negative) 0.999999, 0.000001, 0.000000;
  (Dermatopathic laden, Negative) 0.999999, 0.000001, 0.000000;
  (Florid follic hyperp, Negative) 0.999999, 0.000001, 0.000000;
  (GLH hyaline vascular, Negative) 0.999999, 0.000001, 0.000000;
  (GLH plasma cell, Negative) 0.999999, 0.000001, 0.000000;
  (Granulomatous laden, Negative) 0.999999, 0.000001, 0.000000;
  (Histiocytosis x, Negative) 0.999999, 0.000001, 0.000000;
  (Infectious mono, Negative) 0.999999, 0.000001, 0.000000;
  (Leprosy-lepromatous, Negative) 0.999999, 0.000001, 0.000000;
  (Lymphangiographic, Negative) 0.999999, 0.000001, 0.000000;
  (Mantle zone hyperpla, Negative) 0.999999, 0.000001, 0.000000;
  (Necrotizing Kikuchi, Negative) 0.999999, 0.000001, 0.000000;
  (Necrotiz non-Kikuchi, Negative) 0.999999, 0.000001, 0.000000;
  (Rheumatoid arthritis, Negative) 0.999999, 0.000001, 0.000000;
  (Sarcoidosis, Negative) 0.999999, 0.000001, 0.000000;
  (SHML, Negative) 0.999999, 0.000001, 0.000000;
  (Sinus histiocytosis, Negative) 0.999999, 0.000001, 0.000000;
  (Syphilis, Negative) 0.999999, 0.000001, 0.000000;
  (Toxoplasmosis, Negative) 0.999999, 0.000001, 0.000000;
  (Tuberculosis, Negative) 0.00, 0.98, 0.02;
  (Viral NOS, Negative) 0.999999, 0.000001, 0.000000;
  (Whipple's disease, Negative) 0.999999, 0.000001, 0.000000;
  (L&H nodular HD, Negative) 0.999999, 0.000001, 0.000000;
  (L&H diffuse HD, Negative) 0.999999, 0.000001, 0.000000;
  (Nodular sclerosis HD, Negative) 0.999999, 0.000001, 0.000000;
  (Cellular phase NSHD, Negative) 0.999999, 0.000001, 0.000000;
  (Syncytial NSHD, Negative) 0.999999, 0.000001, 0.000000;
  (Mixed cellularity HD, Negative) 0.999999, 0.000001, 0.000000;
  (Interfollicular HD, Negative) 0.999999, 0.000001, 0.000000;
  (Diffuse fibrosis HD, Negative) 0.999999, 0.000001, 0.000000;
  (Reticular-type HD, Negative) 0.999999, 0.000001, 0.000000;
  (Small cleaved fol, Negative) 0.999999, 0.000001, 0.000000;
  (Mixed fol, Negative) 0.999999, 0.000001, 0.000000;
  (Large cell fol, Negative) 0.999999, 0.000001, 0.000000;
  (Small noncleaved fol, Negative) 0.999999, 0.000001, 0.000000;
  (Small lymphocytic, Negative) 0.999999, 0.000001, 0.000000;
  (Plasmacytoid lyctic, Negative) 0.999999, 0.000001, 0.000000;
  (Mantle zone lymphoma, Negative) 0.999999, 0.000001, 0.000000;
  (Small cleaved dif, Negative) 0.999999, 0.000001, 0.000000;
  (Mixed FCC dif, Negative) 0.999999, 0.000001, 0.000000;
  (Large cell dif, Negative) 0.999999, 0.000001, 0.000000;
  (B-immunoblastic, Negative) 0.999999, 0.000001, 0.000000;
  (T-immunob mixed, Negative) 0.999999, 0.000001, 0.000000;
  (AILD-like T-cell lym, Negative) 0.999999, 0.000001, 0.000000;
  (Japanese ATL, Negative) 0.999999, 0.000001, 0.000000;
  (Lymphoblastic, Negative) 0.999999, 0.000001, 0.000000;
  (Small noncleaved dif, Negative) 0.999999, 0.000001, 0.000000;
  (True histiocytic, Negative) 0.999999, 0.000001, 0.000000;
  (Ki-1 LC anaplas T, Negative) 0.999999, 0.000001, 0.000000;
  (Multiple myeloma, Negative) 0.999999, 0.000001, 0.000000;
  (Mycosis fungoides, Negative) 0.999999, 0.000001, 0.000000;
  (AML, Negative) 0.999999, 0.000001, 0.000000;
  (Hairy cell leukemia, Negative) 0.999999, 0.000001, 0.000000;
  (Carcinoma, Negative) 0.999999, 0.000001, 0.000000;
  (Melanoma, Negative) 0.999999, 0.000001, 0.000000;
  (EM plasmacytoma, Negative) 0.999999, 0.000001, 0.000000;
  (Kaposi's sarcoma, Negative) 0.999999, 0.000001, 0.000000;
  (Mast-cell disease, Negative) 0.999999, 0.000001, 0.000000;
  (AIDS involutionary, Negative) 0.999999, 0.000001, 0.000000;
  (T-immunob large, Negative) 0.999999, 0.000001, 0.000000;
  (Monocytoid B-cell, Negative) 0.999999, 0.000001, 0.000000;
  (Nasopharyngeal CA, Negative) 0.999999, 0.000001, 0.000000;
  (Seminoma, Negative) 0.999999, 0.000001, 0.000000;
  (SLE, Negative) 0.999999, 0.000001, 0.000000;
  (Mycobact histiocytos, Negative) 0.0, 0.0, 1.0;
  (Mast-cell hyperplas, Negative) 0.999999, 0.000001, 0.000000;
  (LGV, Negative) 0.999999, 0.000001, 0.000000;
  (Histoplasmosis, Negative) 0.999999, 0.000001, 0.000000;
  (Coccidioidomycosis, Negative) 0.999999, 0.000001, 0.000000;
  (CMV, Negative) 0.999999, 0.000001, 0.000000;
  (Brucellosis, Negative) 0.999999, 0.000001, 0.000000;
  (Ki-1 LC anaplas B, Negative) 0.999999, 0.000001, 0.000000;
  (Intermed lymphocytic, Negative) 0.999999, 0.000001, 0.000000;
  (AIDS early, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (AILD, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (ALIP, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Cat scratch disease, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Dermatopathic laden, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Florid follic hyperp, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (GLH hyaline vascular, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (GLH plasma cell, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Granulomatous laden, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Histiocytosis x, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Infectious mono, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Leprosy-lepromatous, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Lymphangiographic, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Mantle zone hyperpla, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Necrotizing Kikuchi, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Necrotiz non-Kikuchi, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Rheumatoid arthritis, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Sarcoidosis, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (SHML, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Sinus histiocytosis, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Syphilis, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Toxoplasmosis, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Tuberculosis, Positive/Asymptomatic) 0.00, 0.98, 0.02;
  (Viral NOS, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Whipple's disease, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (L&H nodular HD, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (L&H diffuse HD, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Nodular sclerosis HD, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Cellular phase NSHD, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Syncytial NSHD, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Mixed cellularity HD, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Interfollicular HD, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Diffuse fibrosis HD, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Reticular-type HD, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Small cleaved fol, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Mixed fol, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Large cell fol, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Small noncleaved fol, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Small lymphocytic, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Plasmacytoid lyctic, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Mantle zone lymphoma, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Small cleaved dif, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Mixed FCC dif, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Large cell dif, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (B-immunoblastic, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (T-immunob mixed, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (AILD-like T-cell lym, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Japanese ATL, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Lymphoblastic, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Small noncleaved dif, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (True histiocytic, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Ki-1 LC anaplas T, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Multiple myeloma, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Mycosis fungoides, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (AML, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Hairy cell leukemia, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Carcinoma, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Melanoma, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (EM plasmacytoma, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Kaposi's sarcoma, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Mast-cell disease, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (AIDS involutionary, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (T-immunob large, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Monocytoid B-cell, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Nasopharyngeal CA, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Seminoma, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (SLE, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Mycobact histiocytos, Positive/Asymptomatic) 0.0, 0.0, 1.0;
  (Mast-cell hyperplas, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (LGV, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Histoplasmosis, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Coccidioidomycosis, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (CMV, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Brucellosis, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Ki-1 LC anaplas B, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (Intermed lymphocytic, Positive/Asymptomatic) 0.98, 0.02, 0.00;
  (AIDS early, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (AILD, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (ALIP, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Cat scratch disease, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Dermatopathic laden, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Florid follic hyperp, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (GLH hyaline vascular, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (GLH plasma cell, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Granulomatous laden, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Histiocytosis x, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Infectious mono, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Leprosy-lepromatous, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Lymphangiographic, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Mantle zone hyperpla, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Necrotizing Kikuchi, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Necrotiz non-Kikuchi, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Rheumatoid arthritis, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Sarcoidosis, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (SHML, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Sinus histiocytosis, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Syphilis, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Toxoplasmosis, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Tuberculosis, Positive/Symptomatic) 0.00, 0.98, 0.02;
  (Viral NOS, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Whipple's disease, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (L&H nodular HD, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (L&H diffuse HD, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Nodular sclerosis HD, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Cellular phase NSHD, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Syncytial NSHD, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Mixed cellularity HD, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Interfollicular HD, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Diffuse fibrosis HD, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Reticular-type HD, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Small cleaved fol, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Mixed fol, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Large cell fol, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Small noncleaved fol, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Small lymphocytic, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Plasmacytoid lyctic, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Mantle zone lymphoma, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Small cleaved dif, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Mixed FCC dif, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Large cell dif, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (B-immunoblastic, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (T-immunob mixed, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (AILD-like T-cell lym, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Japanese ATL, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Lymphoblastic, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Small noncleaved dif, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (True histiocytic, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Ki-1 LC anaplas T, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Multiple myeloma, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Mycosis fungoides, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (AML, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Hairy cell leukemia, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Carcinoma, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Melanoma, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (EM plasmacytoma, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Kaposi's sarcoma, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Mast-cell disease, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (AIDS involutionary, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (T-immunob large, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Monocytoid B-cell, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Nasopharyngeal CA, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Seminoma, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (SLE, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Mycobact histiocytos, Positive/Symptomatic) 0.0, 0.0, 1.0;
  (Mast-cell hyperplas, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (LGV, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Histoplasmosis, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Coccidioidomycosis, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (CMV, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Brucellosis, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Ki-1 LC anaplas B, Positive/Symptomatic) 0.8, 0.2, 0.0;
  (Intermed lymphocytic, Positive/Symptomatic) 0.8, 0.2, 0.0;
}
probability ( MELANIN | Fault ) {
  (AIDS early) 0.30, 0.65, 0.05;
  (AILD) 0.90, 0.09, 0.01;
  (ALIP) 0.99, 0.01, 0.00;
  (Cat scratch disease) 0.65, 0.20, 0.15;
  (Dermatopathic laden) 0.001, 0.600, 0.399;
  (Florid follic hyperp) 0.99, 0.01, 0.00;
  (GLH hyaline vascular) 0.99, 0.01, 0.00;
  (GLH plasma cell) 0.99, 0.01, 0.00;
  (Granulomatous laden) 0.65, 0.20, 0.15;
  (Histiocytosis x) 0.99, 0.01, 0.00;
  (Infectious mono) 0.99, 0.01, 0.00;
  (Leprosy-lepromatous) 0.65, 0.20, 0.15;
  (Lymphangiographic) 0.99, 0.01, 0.00;
  (Mantle zone hyperpla) 0.99, 0.01, 0.00;
  (Necrotizing Kikuchi) 0.99, 0.01, 0.00;
  (Necrotiz non-Kikuchi) 0.99, 0.01, 0.00;
  (Rheumatoid arthritis) 0.99, 0.01, 0.00;
  (Sarcoidosis) 0.99, 0.01, 0.00;
  (SHML) 0.99, 0.01, 0.00;
  (Sinus histiocytosis) 0.99, 0.01, 0.00;
  (Syphilis) 0.65, 0.20, 0.15;
  (Toxoplasmosis) 0.99, 0.01, 0.00;
  (Tuberculosis) 0.99, 0.01, 0.00;
  (Viral NOS) 0.99, 0.01, 0.00;
  (Whipple's disease) 0.99, 0.01, 0.00;
  (L&H nodular HD) 0.99, 0.01, 0.00;
  (L&H diffuse HD) 0.99, 0.01, 0.00;
  (Nodular sclerosis HD) 0.99, 0.01, 0.00;
  (Cellular phase NSHD) 0.99, 0.01, 0.00;
  (Syncytial NSHD) 0.99, 0.01, 0.00;
  (Mixed cellularity HD) 0.99, 0.01, 0.00;
  (Interfollicular HD) 0.99, 0.01, 0.00;
  (Diffuse fibrosis HD) 0.99, 0.01, 0.00;
  (Reticular-type HD) 0.99, 0.01, 0.00;
  (Small cleaved fol) 0.99, 0.01, 0.00;
  (Mixed fol) 0.99, 0.01, 0.00;
  (Large cell fol) 0.99, 0.01, 0.00;
  (Small noncleaved fol) 0.99, 0.01, 0.00;
  (Small lymphocytic) 0.99, 0.01, 0.00;
  (Plasmacytoid lyctic) 0.99, 0.01, 0.00;
  (Mantle zone lymphoma) 0.99, 0.01, 0.00;
  (Small cleaved dif) 0.99, 0.01, 0.00;
  (Mixed FCC dif) 0.99, 0.01, 0.00;
  (Large cell dif) 0.99, 0.01, 0.00;
  (B-immunoblastic) 0.99, 0.01, 0.00;
  (T-immunob mixed) 0.99, 0.01, 0.00;
  (AILD-like T-cell lym) 0.90, 0.09, 0.01;
  (Japanese ATL) 0.01, 0.10, 0.89;
  (Lymphoblastic) 0.99, 0.01, 0.00;
  (Small noncleaved dif) 0.99, 0.01, 0.00;
  (True histiocytic) 0.99, 0.01, 0.00;
  (Ki-1 LC anaplas T) 0.99, 0.01, 0.00;
  (Multiple myeloma) 0.99, 0.01, 0.00;
  (Mycosis fungoides) 0.01, 0.10, 0.89;
  (AML) 0.99, 0.01, 0.00;
  (Hairy cell leukemia) 0.99, 0.01, 0.00;
  (Carcinoma) 0.99, 0.01, 0.00;
  (Melanoma) 0.99, 0.01, 0.00;
  (EM plasmacytoma) 0.99, 0.01, 0.00;
  (Kaposi's sarcoma) 0.3, 0.6, 0.1;
  (Mast-cell disease) 0.6, 0.3, 0.1;
  (AIDS involutionary) 0.01, 0.50, 0.49;
  (T-immunob large) 0.99, 0.01, 0.00;
  (Monocytoid B-cell) 0.99, 0.01, 0.00;
  (Nasopharyngeal CA) 0.99, 0.01, 0.00;
  (Seminoma) 0.99, 0.01, 0.00;
  (SLE) 0.99, 0.01, 0.00;
  (Mycobact histiocytos) 0.99, 0.01, 0.00;
  (Mast-cell hyperplas) 0.6, 0.3, 0.1;
  (LGV) 0.99, 0.01, 0.00;
  (Histoplasmosis) 0.99, 0.01, 0.00;
  (Coccidioidomycosis) 0.99, 0.01, 0.00;
  (CMV) 0.99, 0.01, 0.00;
  (Brucellosis) 0.99, 0.01, 0.00;
  (Ki-1 LC anaplas B) 0.99, 0.01, 0.00;
  (Intermed lymphocytic) 0.99, 0.01, 0.00;
}
probability ( MC_SL_NS | Fault, F_MZ ) {
  (AIDS early, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (ALIP, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Infectious mono, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SHML, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syphilis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Tuberculosis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Viral NOS, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Whipple's disease, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed fol, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell fol, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell dif, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Japanese ATL, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (True histiocytic, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AML, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Carcinoma, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Melanoma, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob large, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Seminoma, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SLE, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (LGV, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (CMV, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Brucellosis, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, No follicles) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS early, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (ALIP, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SHML, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AML, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SLE, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (LGV, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (CMV, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS early, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (AILD, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (ALIP, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Cat scratch disease, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Dermatopathic laden, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Florid follic hyperp, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (GLH hyaline vascular, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (GLH plasma cell, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Granulomatous laden, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Histiocytosis x, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Infectious mono, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Leprosy-lepromatous, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Lymphangiographic, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mantle zone hyperpla, Present) 0.000, 0.949, 0.050, 0.001, 0.000;
  (Necrotizing Kikuchi, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Necrotiz non-Kikuchi, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Rheumatoid arthritis, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Sarcoidosis, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (SHML, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Sinus histiocytosis, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Syphilis, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Toxoplasmosis, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Tuberculosis, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Viral NOS, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Whipple's disease, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (L&H nodular HD, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (L&H diffuse HD, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Nodular sclerosis HD, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Cellular phase NSHD, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Syncytial NSHD, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mixed cellularity HD, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Interfollicular HD, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Diffuse fibrosis HD, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Reticular-type HD, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Small cleaved fol, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mixed fol, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Large cell fol, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Small noncleaved fol, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Small lymphocytic, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Plasmacytoid lyctic, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mantle zone lymphoma, Present) 0.000, 0.100, 0.499, 0.400, 0.001;
  (Small cleaved dif, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mixed FCC dif, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Large cell dif, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (B-immunoblastic, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (T-immunob mixed, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (AILD-like T-cell lym, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Japanese ATL, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Lymphoblastic, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Small noncleaved dif, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (True histiocytic, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Ki-1 LC anaplas T, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Multiple myeloma, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mycosis fungoides, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (AML, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Hairy cell leukemia, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Carcinoma, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Melanoma, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (EM plasmacytoma, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Kaposi's sarcoma, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mast-cell disease, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (AIDS involutionary, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (T-immunob large, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Monocytoid B-cell, Present) 0.00, 0.89, 0.10, 0.01, 0.00;
  (Nasopharyngeal CA, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Seminoma, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (SLE, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mycobact histiocytos, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Mast-cell hyperplas, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (LGV, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Histoplasmosis, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Coccidioidomycosis, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (CMV, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Brucellosis, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Ki-1 LC anaplas B, Present) 0.00, 0.99, 0.01, 0.00, 0.00;
  (Intermed lymphocytic, Present) 0.0, 0.0, 0.6, 0.4, 0.0;
}
probability ( FMZ_FUS | Fault, F_MZSTAT ) {
  (AIDS early, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (AILD, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (ALIP, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (SHML, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (AML, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (SLE, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (LGV, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (CMV, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, No follicles/no mantle zones) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (AILD, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (ALIP, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (SHML, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (AML, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (SLE, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (LGV, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (CMV, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Mantle zones absent in most follicles) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (AILD, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (ALIP, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (SHML, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (AML, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (SLE, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (LGV, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (CMV, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Most incompletely surround follicles) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (AILD, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (ALIP, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Infectious mono, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (SHML, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Viral NOS, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Large cell dif, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (True histiocytic, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (AML, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Carcinoma, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Melanoma, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (T-immunob large, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Seminoma, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (SLE, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (LGV, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (CMV, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Brucellosis, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Most completely surround fol not thick) 1.0, 0.0, 0.0, 0.0;
  (AIDS early, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (AILD, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (ALIP, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Cat scratch disease, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Dermatopathic laden, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Florid follic hyperp, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (GLH hyaline vascular, Most thick [>10 lymphocytes]) 0.0, 0.3, 0.6, 0.1;
  (GLH plasma cell, Most thick [>10 lymphocytes]) 0.00, 0.94, 0.05, 0.01;
  (Granulomatous laden, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Histiocytosis x, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Infectious mono, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Leprosy-lepromatous, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Lymphangiographic, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Mantle zone hyperpla, Most thick [>10 lymphocytes]) 0.00, 0.60, 0.35, 0.05;
  (Necrotizing Kikuchi, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Necrotiz non-Kikuchi, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Rheumatoid arthritis, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Sarcoidosis, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (SHML, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Sinus histiocytosis, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Syphilis, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Toxoplasmosis, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Tuberculosis, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Viral NOS, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Whipple's disease, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (L&H nodular HD, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (L&H diffuse HD, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Nodular sclerosis HD, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Cellular phase NSHD, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Syncytial NSHD, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Mixed cellularity HD, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Interfollicular HD, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Diffuse fibrosis HD, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Reticular-type HD, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Small cleaved fol, Most thick [>10 lymphocytes]) 1.0, 0.0, 0.0, 0.0;
  (Mixed fol, Most thick [>10 lymphocytes]) 1.0, 0.0, 0.0, 0.0;
  (Large cell fol, Most thick [>10 lymphocytes]) 1.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Most thick [>10 lymphocytes]) 1.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Plasmacytoid lyctic, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Mantle zone lymphoma, Most thick [>10 lymphocytes]) 0.00, 0.00, 0.01, 0.99;
  (Small cleaved dif, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Mixed FCC dif, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Large cell dif, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (B-immunoblastic, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (T-immunob mixed, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (AILD-like T-cell lym, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Japanese ATL, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Lymphoblastic, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Small noncleaved dif, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (True histiocytic, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Ki-1 LC anaplas T, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Multiple myeloma, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Mycosis fungoides, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (AML, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Hairy cell leukemia, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Carcinoma, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Melanoma, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (EM plasmacytoma, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Kaposi's sarcoma, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Mast-cell disease, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (AIDS involutionary, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (T-immunob large, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Monocytoid B-cell, Most thick [>10 lymphocytes]) 0.00, 0.85, 0.14, 0.01;
  (Nasopharyngeal CA, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Seminoma, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (SLE, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Mycobact histiocytos, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Mast-cell hyperplas, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (LGV, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Histoplasmosis, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Coccidioidomycosis, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (CMV, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Brucellosis, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Ki-1 LC anaplas B, Most thick [>10 lymphocytes]) 0.0, 0.9, 0.1, 0.0;
  (Intermed lymphocytic, Most thick [>10 lymphocytes]) 0.00, 0.00, 0.03, 0.97;
}
probability ( BH_NOS_L | Fault, BH_NOS ) {
  (AIDS early, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (AILD, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (ALIP, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Cat scratch disease, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Dermatopathic laden, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Florid follic hyperp, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (GLH hyaline vascular, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (GLH plasma cell, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Granulomatous laden, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Histiocytosis x, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Infectious mono, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Leprosy-lepromatous, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Lymphangiographic, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Mantle zone hyperpla, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Necrotizing Kikuchi, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Necrotiz non-Kikuchi, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Rheumatoid arthritis, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Sarcoidosis, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (SHML, Absent to slight [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent to slight [<5pc]) 1.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Toxoplasmosis, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Tuberculosis, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Viral NOS, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Whipple's disease, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (L&H nodular HD, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (L&H diffuse HD, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Nodular sclerosis HD, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Cellular phase NSHD, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Syncytial NSHD, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Mixed cellularity HD, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Interfollicular HD, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Diffuse fibrosis HD, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Reticular-type HD, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Small cleaved fol, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Mixed fol, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Large cell fol, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Small noncleaved fol, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Small lymphocytic, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Plasmacytoid lyctic, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Mantle zone lymphoma, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Small cleaved dif, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Mixed FCC dif, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Large cell dif, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (B-immunoblastic, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (T-immunob mixed, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (AILD-like T-cell lym, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Japanese ATL, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Lymphoblastic, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Small noncleaved dif, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (True histiocytic, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas T, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Multiple myeloma, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Mycosis fungoides, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (AML, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Hairy cell leukemia, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Carcinoma, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Melanoma, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (EM plasmacytoma, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Kaposi's sarcoma, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Mast-cell disease, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (AIDS involutionary, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (T-immunob large, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Monocytoid B-cell, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Nasopharyngeal CA, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Seminoma, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (SLE, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Mycobact histiocytos, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Mast-cell hyperplas, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (LGV, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Histoplasmosis, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Coccidioidomycosis, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (CMV, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Brucellosis, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas B, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (Intermed lymphocytic, Absent to slight [<5pc]) 0.00, 0.99, 0.00, 0.01;
  (AIDS early, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (AILD, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (ALIP, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Cat scratch disease, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Dermatopathic laden, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Florid follic hyperp, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (GLH hyaline vascular, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (GLH plasma cell, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Granulomatous laden, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Histiocytosis x, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Infectious mono, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Leprosy-lepromatous, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Lymphangiographic, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Mantle zone hyperpla, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Necrotizing Kikuchi, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Necrotiz non-Kikuchi, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Rheumatoid arthritis, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Sarcoidosis, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (SHML, Moderate [5-50pc]) 0.0, 0.0, 1.0, 0.0;
  (Sinus histiocytosis, Moderate [5-50pc]) 0.0, 0.0, 1.0, 0.0;
  (Syphilis, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Toxoplasmosis, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Tuberculosis, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Viral NOS, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Whipple's disease, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (L&H nodular HD, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (L&H diffuse HD, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Nodular sclerosis HD, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Cellular phase NSHD, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Syncytial NSHD, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Mixed cellularity HD, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Interfollicular HD, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Diffuse fibrosis HD, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Reticular-type HD, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Small cleaved fol, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Mixed fol, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Large cell fol, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Small noncleaved fol, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Small lymphocytic, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Plasmacytoid lyctic, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Mantle zone lymphoma, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Small cleaved dif, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Mixed FCC dif, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Large cell dif, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (B-immunoblastic, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (T-immunob mixed, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (AILD-like T-cell lym, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Japanese ATL, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Lymphoblastic, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Small noncleaved dif, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (True histiocytic, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas T, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Multiple myeloma, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Mycosis fungoides, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (AML, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Hairy cell leukemia, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Carcinoma, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Melanoma, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (EM plasmacytoma, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Kaposi's sarcoma, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Mast-cell disease, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (AIDS involutionary, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (T-immunob large, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Monocytoid B-cell, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Nasopharyngeal CA, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Seminoma, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (SLE, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Mycobact histiocytos, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Mast-cell hyperplas, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (LGV, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Histoplasmosis, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Coccidioidomycosis, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (CMV, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Brucellosis, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas B, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (Intermed lymphocytic, Moderate [5-50pc]) 0.00, 0.99, 0.00, 0.01;
  (AIDS early, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (AILD, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (ALIP, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Cat scratch disease, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Dermatopathic laden, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Florid follic hyperp, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (GLH hyaline vascular, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (GLH plasma cell, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Granulomatous laden, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Histiocytosis x, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Infectious mono, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Leprosy-lepromatous, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Lymphangiographic, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Mantle zone hyperpla, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Necrotizing Kikuchi, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Necrotiz non-Kikuchi, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Rheumatoid arthritis, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Sarcoidosis, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (SHML, Marked [>50pc]) 0.0, 0.0, 1.0, 0.0;
  (Sinus histiocytosis, Marked [>50pc]) 0.0, 0.0, 1.0, 0.0;
  (Syphilis, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Toxoplasmosis, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Tuberculosis, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Viral NOS, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Whipple's disease, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (L&H nodular HD, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (L&H diffuse HD, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Nodular sclerosis HD, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Cellular phase NSHD, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Syncytial NSHD, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Mixed cellularity HD, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Interfollicular HD, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Diffuse fibrosis HD, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Reticular-type HD, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Small cleaved fol, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Mixed fol, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Large cell fol, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Small noncleaved fol, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Small lymphocytic, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Plasmacytoid lyctic, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Mantle zone lymphoma, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Small cleaved dif, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Mixed FCC dif, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Large cell dif, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (B-immunoblastic, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (T-immunob mixed, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (AILD-like T-cell lym, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Japanese ATL, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Lymphoblastic, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Small noncleaved dif, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (True histiocytic, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas T, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Multiple myeloma, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Mycosis fungoides, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (AML, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Hairy cell leukemia, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Carcinoma, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Melanoma, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (EM plasmacytoma, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Kaposi's sarcoma, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Mast-cell disease, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (AIDS involutionary, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (T-immunob large, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Monocytoid B-cell, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Nasopharyngeal CA, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Seminoma, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (SLE, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Mycobact histiocytos, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Mast-cell hyperplas, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (LGV, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Histoplasmosis, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Coccidioidomycosis, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (CMV, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Brucellosis, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Ki-1 LC anaplas B, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
  (Intermed lymphocytic, Marked [>50pc]) 0.00, 0.99, 0.00, 0.01;
}
probability ( SLC_NI | Fault, SLC ) {
  (AIDS early, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (ALIP, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cat scratch disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Dermatopathic laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Florid follic hyperp, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH hyaline vascular, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (GLH plasma cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Granulomatous laden, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histiocytosis x, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Infectious mono, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Leprosy-lepromatous, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphangiographic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone hyperpla, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotizing Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Necrotiz non-Kikuchi, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Rheumatoid arthritis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sarcoidosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SHML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Sinus histiocytosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syphilis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Toxoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Tuberculosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Viral NOS, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Whipple's disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H nodular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (L&H diffuse HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nodular sclerosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Cellular phase NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Syncytial NSHD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed cellularity HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Interfollicular HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Diffuse fibrosis HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Reticular-type HD, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved fol, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Plasmacytoid lyctic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mantle zone lymphoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small cleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mixed FCC dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Large cell dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (B-immunoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob mixed, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AILD-like T-cell lym, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Japanese ATL, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Lymphoblastic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Small noncleaved dif, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (True histiocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas T, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Multiple myeloma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycosis fungoides, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AML, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Hairy cell leukemia, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Carcinoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Melanoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (EM plasmacytoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Kaposi's sarcoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell disease, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS involutionary, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (T-immunob large, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Monocytoid B-cell, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Nasopharyngeal CA, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Seminoma, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (SLE, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mycobact histiocytos, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Mast-cell hyperplas, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (LGV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Histoplasmosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Coccidioidomycosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (CMV, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Brucellosis, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Ki-1 LC anaplas B, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (Intermed lymphocytic, Absent [0pc]) 1.0, 0.0, 0.0, 0.0, 0.0;
  (AIDS early, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (AILD, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (ALIP, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Cat scratch disease, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Dermatopathic laden, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Florid follic hyperp, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (GLH hyaline vascular, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (GLH plasma cell, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Granulomatous laden, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Histiocytosis x, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Infectious mono, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Leprosy-lepromatous, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Lymphangiographic, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Mantle zone hyperpla, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Necrotizing Kikuchi, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Necrotiz non-Kikuchi, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Rheumatoid arthritis, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Sarcoidosis, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (SHML, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Sinus histiocytosis, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Syphilis, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Toxoplasmosis, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Tuberculosis, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Viral NOS, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Whipple's disease, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (L&H nodular HD, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (L&H diffuse HD, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Nodular sclerosis HD, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Cellular phase NSHD, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Syncytial NSHD, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Mixed cellularity HD, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Interfollicular HD, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Diffuse fibrosis HD, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Reticular-type HD, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Small cleaved fol, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Mixed fol, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Large cell fol, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Small noncleaved fol, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Small lymphocytic, Sparse [1-10pc]) 0.00, 0.83, 0.01, 0.15, 0.01;
  (Plasmacytoid lyctic, Sparse [1-10pc]) 0.00, 0.95, 0.01, 0.03, 0.01;
  (Mantle zone lymphoma, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Small cleaved dif, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Mixed FCC dif, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Large cell dif, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (B-immunoblastic, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (T-immunob mixed, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (AILD-like T-cell lym, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Japanese ATL, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Lymphoblastic, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Small noncleaved dif, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (True histiocytic, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Ki-1 LC anaplas T, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Multiple myeloma, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Mycosis fungoides, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (AML, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Hairy cell leukemia, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Carcinoma, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Melanoma, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (EM plasmacytoma, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Kaposi's sarcoma, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Mast-cell disease, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (AIDS involutionary, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (T-immunob large, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Monocytoid B-cell, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Nasopharyngeal CA, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Seminoma, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (SLE, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Mycobact histiocytos, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Mast-cell hyperplas, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (LGV, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Histoplasmosis, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Coccidioidomycosis, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (CMV, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Brucellosis, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Ki-1 LC anaplas B, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (Intermed lymphocytic, Sparse [1-10pc]) 0.00, 0.97, 0.01, 0.01, 0.01;
  (AIDS early, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (AILD, Moderate [11-50pc]) 0.00, 0.94, 0.03, 0.03, 0.00;
  (ALIP, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Cat scratch disease, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Dermatopathic laden, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Florid follic hyperp, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (GLH hyaline vascular, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (GLH plasma cell, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Granulomatous laden, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Histiocytosis x, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Infectious mono, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Leprosy-lepromatous, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Lymphangiographic, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Mantle zone hyperpla, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Necrotizing Kikuchi, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Necrotiz non-Kikuchi, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Rheumatoid arthritis, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Sarcoidosis, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (SHML, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Sinus histiocytosis, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Syphilis, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Toxoplasmosis, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Tuberculosis, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Viral NOS, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Whipple's disease, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (L&H nodular HD, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (L&H diffuse HD, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Nodular sclerosis HD, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Cellular phase NSHD, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Syncytial NSHD, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Mixed cellularity HD, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Interfollicular HD, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Diffuse fibrosis HD, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Reticular-type HD, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Small cleaved fol, Moderate [11-50pc]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Mixed fol, Moderate [11-50pc]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Large cell fol, Moderate [11-50pc]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Small noncleaved fol, Moderate [11-50pc]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Small lymphocytic, Moderate [11-50pc]) 0.00, 0.84, 0.01, 0.15, 0.00;
  (Plasmacytoid lyctic, Moderate [11-50pc]) 0.00, 0.96, 0.01, 0.03, 0.00;
  (Mantle zone lymphoma, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Small cleaved dif, Moderate [11-50pc]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Mixed FCC dif, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Large cell dif, Moderate [11-50pc]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (B-immunoblastic, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (T-immunob mixed, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (AILD-like T-cell lym, Moderate [11-50pc]) 0.00, 0.94, 0.03, 0.03, 0.00;
  (Japanese ATL, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Lymphoblastic, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Small noncleaved dif, Moderate [11-50pc]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (True histiocytic, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Ki-1 LC anaplas T, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Multiple myeloma, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Mycosis fungoides, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (AML, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Hairy cell leukemia, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Carcinoma, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Melanoma, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (EM plasmacytoma, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Kaposi's sarcoma, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Mast-cell disease, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (AIDS involutionary, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (T-immunob large, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Monocytoid B-cell, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Nasopharyngeal CA, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Seminoma, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (SLE, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Mycobact histiocytos, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Mast-cell hyperplas, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (LGV, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Histoplasmosis, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Coccidioidomycosis, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (CMV, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Brucellosis, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Ki-1 LC anaplas B, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Intermed lymphocytic, Moderate [11-50pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (AIDS early, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (AILD, Numerous [51-90pc]) 0.00, 0.94, 0.03, 0.03, 0.00;
  (ALIP, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Cat scratch disease, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Dermatopathic laden, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Florid follic hyperp, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (GLH hyaline vascular, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (GLH plasma cell, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Granulomatous laden, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Histiocytosis x, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Infectious mono, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Leprosy-lepromatous, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Lymphangiographic, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Mantle zone hyperpla, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Necrotizing Kikuchi, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Necrotiz non-Kikuchi, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Rheumatoid arthritis, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Sarcoidosis, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (SHML, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Sinus histiocytosis, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Syphilis, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Toxoplasmosis, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Tuberculosis, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Viral NOS, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Whipple's disease, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (L&H nodular HD, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (L&H diffuse HD, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Nodular sclerosis HD, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Cellular phase NSHD, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Syncytial NSHD, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Mixed cellularity HD, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Interfollicular HD, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Diffuse fibrosis HD, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Reticular-type HD, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Small cleaved fol, Numerous [51-90pc]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Mixed fol, Numerous [51-90pc]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Large cell fol, Numerous [51-90pc]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Small noncleaved fol, Numerous [51-90pc]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Small lymphocytic, Numerous [51-90pc]) 0.00, 0.84, 0.01, 0.15, 0.00;
  (Plasmacytoid lyctic, Numerous [51-90pc]) 0.00, 0.96, 0.01, 0.03, 0.00;
  (Mantle zone lymphoma, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Small cleaved dif, Numerous [51-90pc]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Mixed FCC dif, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Large cell dif, Numerous [51-90pc]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (B-immunoblastic, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (T-immunob mixed, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (AILD-like T-cell lym, Numerous [51-90pc]) 0.00, 0.94, 0.03, 0.03, 0.00;
  (Japanese ATL, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Lymphoblastic, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Small noncleaved dif, Numerous [51-90pc]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (True histiocytic, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Ki-1 LC anaplas T, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Multiple myeloma, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Mycosis fungoides, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (AML, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Hairy cell leukemia, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Carcinoma, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Melanoma, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (EM plasmacytoma, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Kaposi's sarcoma, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Mast-cell disease, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (AIDS involutionary, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (T-immunob large, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Monocytoid B-cell, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Nasopharyngeal CA, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Seminoma, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (SLE, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Mycobact histiocytos, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Mast-cell hyperplas, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (LGV, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Histoplasmosis, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Coccidioidomycosis, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (CMV, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Brucellosis, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Ki-1 LC anaplas B, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Intermed lymphocytic, Numerous [51-90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (AIDS early, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (AILD, Striking [>90pc]) 0.00, 0.94, 0.03, 0.03, 0.00;
  (ALIP, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Cat scratch disease, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Dermatopathic laden, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Florid follic hyperp, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (GLH hyaline vascular, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (GLH plasma cell, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Granulomatous laden, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Histiocytosis x, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Infectious mono, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Leprosy-lepromatous, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Lymphangiographic, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Mantle zone hyperpla, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Necrotizing Kikuchi, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Necrotiz non-Kikuchi, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Rheumatoid arthritis, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Sarcoidosis, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (SHML, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Sinus histiocytosis, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Syphilis, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Toxoplasmosis, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Tuberculosis, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Viral NOS, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Whipple's disease, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (L&H nodular HD, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (L&H diffuse HD, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Nodular sclerosis HD, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Cellular phase NSHD, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Syncytial NSHD, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Mixed cellularity HD, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Interfollicular HD, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Diffuse fibrosis HD, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Reticular-type HD, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Small cleaved fol, Striking [>90pc]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Mixed fol, Striking [>90pc]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Large cell fol, Striking [>90pc]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Small noncleaved fol, Striking [>90pc]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Small lymphocytic, Striking [>90pc]) 0.00, 0.84, 0.01, 0.15, 0.00;
  (Plasmacytoid lyctic, Striking [>90pc]) 0.00, 0.96, 0.01, 0.03, 0.00;
  (Mantle zone lymphoma, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Small cleaved dif, Striking [>90pc]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (Mixed FCC dif, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Large cell dif, Striking [>90pc]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (B-immunoblastic, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (T-immunob mixed, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (AILD-like T-cell lym, Striking [>90pc]) 0.00, 0.94, 0.03, 0.03, 0.00;
  (Japanese ATL, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Lymphoblastic, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Small noncleaved dif, Striking [>90pc]) 0.0, 0.9, 0.1, 0.0, 0.0;
  (True histiocytic, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Ki-1 LC anaplas T, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Multiple myeloma, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Mycosis fungoides, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (AML, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Hairy cell leukemia, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Carcinoma, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Melanoma, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (EM plasmacytoma, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Kaposi's sarcoma, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Mast-cell disease, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (AIDS involutionary, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (T-immunob large, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Monocytoid B-cell, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Nasopharyngeal CA, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Seminoma, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (SLE, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Mycobact histiocytos, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Mast-cell hyperplas, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (LGV, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Histoplasmosis, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Coccidioidomycosis, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (CMV, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Brucellosis, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Ki-1 LC anaplas B, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
  (Intermed lymphocytic, Striking [>90pc]) 0.00, 0.98, 0.01, 0.01, 0.00;
}
probability ( HYALIN | Fault ) {
  (AIDS early) 0.94, 0.05, 0.01;
  (AILD) 0.75, 0.20, 0.05;
  (ALIP) 0.75, 0.20, 0.05;
  (Cat scratch disease) 0.94, 0.05, 0.01;
  (Dermatopathic laden) 0.94, 0.05, 0.01;
  (Florid follic hyperp) 0.94, 0.05, 0.01;
  (GLH hyaline vascular) 0.00, 0.01, 0.99;
  (GLH plasma cell) 0.6, 0.3, 0.1;
  (Granulomatous laden) 0.94, 0.05, 0.01;
  (Histiocytosis x) 0.94, 0.05, 0.01;
  (Infectious mono) 0.94, 0.05, 0.01;
  (Leprosy-lepromatous) 0.94, 0.05, 0.01;
  (Lymphangiographic) 0.94, 0.05, 0.01;
  (Mantle zone hyperpla) 0.94, 0.05, 0.01;
  (Necrotizing Kikuchi) 0.94, 0.05, 0.01;
  (Necrotiz non-Kikuchi) 0.94, 0.05, 0.01;
  (Rheumatoid arthritis) 0.94, 0.05, 0.01;
  (Sarcoidosis) 0.94, 0.05, 0.01;
  (SHML) 0.94, 0.05, 0.01;
  (Sinus histiocytosis) 0.94, 0.05, 0.01;
  (Syphilis) 0.94, 0.05, 0.01;
  (Toxoplasmosis) 0.94, 0.05, 0.01;
  (Tuberculosis) 0.94, 0.05, 0.01;
  (Viral NOS) 0.94, 0.05, 0.01;
  (Whipple's disease) 0.94, 0.05, 0.01;
  (L&H nodular HD) 0.94, 0.05, 0.01;
  (L&H diffuse HD) 0.94, 0.05, 0.01;
  (Nodular sclerosis HD) 0.94, 0.05, 0.01;
  (Cellular phase NSHD) 0.94, 0.05, 0.01;
  (Syncytial NSHD) 0.94, 0.05, 0.01;
  (Mixed cellularity HD) 0.94, 0.05, 0.01;
  (Interfollicular HD) 0.94, 0.05, 0.01;
  (Diffuse fibrosis HD) 0.94, 0.05, 0.01;
  (Reticular-type HD) 0.94, 0.05, 0.01;
  (Small cleaved fol) 0.94, 0.05, 0.01;
  (Mixed fol) 0.94, 0.05, 0.01;
  (Large cell fol) 0.94, 0.05, 0.01;
  (Small noncleaved fol) 0.94, 0.05, 0.01;
  (Small lymphocytic) 0.94, 0.05, 0.01;
  (Plasmacytoid lyctic) 0.94, 0.05, 0.01;
  (Mantle zone lymphoma) 0.94, 0.05, 0.01;
  (Small cleaved dif) 0.94, 0.05, 0.01;
  (Mixed FCC dif) 0.94, 0.05, 0.01;
  (Large cell dif) 0.94, 0.05, 0.01;
  (B-immunoblastic) 0.94, 0.05, 0.01;
  (T-immunob mixed) 0.94, 0.05, 0.01;
  (AILD-like T-cell lym) 0.75, 0.20, 0.05;
  (Japanese ATL) 0.94, 0.05, 0.01;
  (Lymphoblastic) 0.94, 0.05, 0.01;
  (Small noncleaved dif) 0.94, 0.05, 0.01;
  (True histiocytic) 0.94, 0.05, 0.01;
  (Ki-1 LC anaplas T) 0.94, 0.05, 0.01;
  (Multiple myeloma) 0.94, 0.05, 0.01;
  (Mycosis fungoides) 0.94, 0.05, 0.01;
  (AML) 0.94, 0.05, 0.01;
  (Hairy cell leukemia) 0.94, 0.05, 0.01;
  (Carcinoma) 0.94, 0.05, 0.01;
  (Melanoma) 0.94, 0.05, 0.01;
  (EM plasmacytoma) 0.94, 0.05, 0.01;
  (Kaposi's sarcoma) 0.94, 0.05, 0.01;
  (Mast-cell disease) 0.94, 0.05, 0.01;
  (AIDS involutionary) 0.94, 0.05, 0.01;
  (T-immunob large) 0.94, 0.05, 0.01;
  (Monocytoid B-cell) 0.94, 0.05, 0.01;
  (Nasopharyngeal CA) 0.94, 0.05, 0.01;
  (Seminoma) 0.94, 0.05, 0.01;
  (SLE) 0.94, 0.05, 0.01;
  (Mycobact histiocytos) 0.94, 0.05, 0.01;
  (Mast-cell hyperplas) 0.94, 0.05, 0.01;
  (LGV) 0.94, 0.05, 0.01;
  (Histoplasmosis) 0.94, 0.05, 0.01;
  (Coccidioidomycosis) 0.94, 0.05, 0.01;
  (CMV) 0.94, 0.05, 0.01;
  (Brucellosis) 0.94, 0.05, 0.01;
  (Ki-1 LC anaplas B) 0.94, 0.05, 0.01;
  (Intermed lymphocytic) 0.94, 0.05, 0.01;
}
